<SEC-DOCUMENT>0001193125-13-425338.txt : 20131104
<SEC-HEADER>0001193125-13-425338.hdr.sgml : 20131104
<ACCEPTANCE-DATETIME>20131104165024
ACCESSION NUMBER:		0001193125-13-425338
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20130930
FILED AS OF DATE:		20131104
DATE AS OF CHANGE:		20131104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		131189699

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d595389d10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10-Q
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Mark One) </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934 </B><B> </B></TD></TR></TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the quarterly period ended September&nbsp;30, 2013 </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934 </B><B> </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission file number 000-30171 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SANGAMO BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>68-0359556</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>501 Canal Blvd </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Richmond, California 94804 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(510) 970-6000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by section 13 or 15(d) of the Securities Act
of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller
reporting company. See definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2013, 61,797,202 shares of the issuer&#146;s common stock, par value $0.01 per share, were outstanding. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>SANGAMO BIOSCIENCES, INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><B><A HREF="#tx595389_14">PART I. FINANCIAL INFORMATION</A></B> </P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;1.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx595389_1">Financial Statements (Unaudited)</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx595389_2">Condensed Consolidated Balance Sheets at September 30, 2013 and December&nbsp;31, 2012</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx595389_3">Condensed Consolidated Statements of Operations for the Three and Nine Months ended September 30, 2013 and 2012
</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx595389_4">Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2013 and
2012</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx595389_5">Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2013 and
2012</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx595389_6">Notes to Condensed Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;2.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx595389_7">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;3.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx595389_8">Quantitative and Qualitative Disclosures about Market Risk</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;4.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx595389_9">Controls and Procedures</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><A HREF="#tx595389_15"><B>PART II. OTHER INFORMATION </B></A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;1.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><A HREF="#tx595389_10">Legal Proceedings</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;1A</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><A HREF="#tx595389_11">Risk Factors</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;6.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><A HREF="#tx595389_12">Exhibits</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><A HREF="#tx595389_13"><B>SIGNATURES </B></A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; "><B>CERTIFICATIONS</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPECIAL NOTE&nbsp;REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some statements contained in this report are forward-looking with respect to our operations, research, development and commercialization
activities, clinical trials, operating results and financial condition. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from
any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product development and commercialization of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">revenues from existing and new collaborations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our research and development and other expenses; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sufficiency of our cash resources; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our operational and legal risks;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans, objectives, expectations and intentions and any other statements that are not historical facts. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as: &#147;anticipates,&#148; &#147;believes,&#148;
&#147;continues,&#148; &#147;could,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;seeks,&#148; &#147;should&#148; and &#147;will.&#148; These statements reflect our current views
with respect to future events and are based on assumptions and subject to risks and uncertainties. Many of these risks are discussed in greater detail under the headings &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of
Financial Conditions and Results of Operations&#148; in this Form 10-Q. Sangamo undertakes no obligation to publicly release any revisions to forward-looking statements to reflect events or circumstances arising after the date of this report.
Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report on Form&nbsp;10-Q. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZFP Therapeutic<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is a registered trademark of Sangamo BioSciences, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx595389_14"></A>PART I. FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx595389_1"></A>ITEM&nbsp;1. FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx595389_2"></A>SANGAMO BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities, non-current</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation and employee benefits</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenues</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenues, non-current</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.01 par value; 80,000,000 shares authorized, 61,420,655 and 53,058,525 shares issued and outstanding at
September&nbsp;30, 2013 and December&nbsp;31, 2012, respectively</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">419,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">339,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(293,989</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(275,509</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx595389_3"></A>SANGAMO BIOSCIENCES, INC. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except per share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three months ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine months ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,802</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,532</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,829</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other income, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,786</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx595389_4"></A>SANGAMO BIOSCIENCES, INC. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three months ended<BR>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine months ended<BR>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,786</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in unrealized loss on available-for-sale securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,783</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx595389_5"></A>SANGAMO BIOSCIENCES, INC. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine months ended<BR>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,786</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of premium / discount on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation and employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(434</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,630</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing Activities:</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of investments</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maturities of investments</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(363</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by investing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing Activities:</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from public offering, net of issuance costs</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase / (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,042</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx595389_6"></A>SANGAMO BIOSCIENCES, INC. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30, 2013 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 1&#151;BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed consolidated financial statements of Sangamo BioSciences, Inc. (&#147;Sangamo&#148; or the
&#147;Company&#148;) have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#147;SEC&#148;).
Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments)
considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September&nbsp;30, 2013 are not necessarily indicative of the results that may be expected for the year ending December&nbsp;31,
2013. The condensed consolidated balance sheet data at December&nbsp;31, 2012 were derived from the audited consolidated financial statements included in Sangamo&#146;s Form 10-K for the year ended December&nbsp;31, 2012, as filed with the SEC.
These financial statements should be read in conjunction with the financial statements and footnotes thereto for the year ended December&nbsp;31, 2012, included in Sangamo&#146;s Form 10-K, as filed with the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates and Classifications </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and
assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition,
clinical trial accruals, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results
of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided
when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront
signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#146;s product sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Multiple Element Arrangements prior to the adoption of ASU No.&nbsp;2009-13, Revenue Recognition&#151;Multiple Deliverable Revenue
Arrangements (ASU 2009-13)</I>. For revenue arrangements entered into before January&nbsp;1, 2011, that include multiple deliverables, the elements of such agreement were divided into separate units of accounting if the deliverables met certain
criteria, including whether the fair value of the delivered items could be determined and whether there was evidence of fair value of the undelivered items. In addition, the consideration was allocated among the separate units of accounting based on
their fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units of accounting. Prior to the adoption of ASU 2009-13, the Company recognized nonrefundable signing, license or non-exclusive
option fees as revenue when rights to use the intellectual property related to the license were delivered and over the period of performance obligations if the Company had continuing performance obligations. The Company estimated the performance
period at the inception of the arrangement and reevaluated it each reporting period. Changes to these estimates were recorded on a prospective basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Multiple Element Arrangements after the adoption of ASU 2009-13.</I> ASU 2009-13 amended the accounting standards for certain multiple
element revenue arrangements to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide updated guidance on whether multiple elements exist, how the elements in an arrangement should be separated, and how the arrangement consideration should be allocated to the separate elements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require an entity to allocate arrangement consideration to each element based on a selling price hierarchy where the selling price for an element is based on vendor-specific objective evidence (&#147;VSOE&#148;), if
available; third-party evidence (&#147;TPE&#148;), if available and VSOE is not available; or the best estimate of selling price (&#147;ESP&#148;), if neither VSOE nor TPE is available; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">eliminate the use of the residual method and require an entity to allocate arrangement consideration using the relative selling price method. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For revenue agreements with multiple element arrangements, such as license and development
agreements, entered into on or after January&nbsp;1, 2011, the Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the
selling price for each deliverable using VSOE of selling price or TPE of selling price. If neither exists the Company uses ESP for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for
each element. The collaboration and license agreement entered into with Shire AG (Shire) in January 2012 was evaluated under these amended accounting standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the Company may be entitled to receive certain milestone payments which are contingent upon reaching specified objectives. These
milestone payments are recognized as revenue in full upon achievement of the milestone if there is substantive uncertainty at the date the arrangement is entered into that objectives will be achieved and if the achievement is based on the
Company&#146;s performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due.
Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. The Company recognizes cost reimbursement revenue under collaborative agreements as the related research and development
costs for services are rendered. Deferred revenue represents the portion of research or license payments received which have not been earned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sangamo&#146;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and
development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2013, the FASB issued ASU No.&nbsp;2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated
Other Comprehensive Income (ASU 2013-02). This newly issued accounting standard requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. This ASU is effective for reporting
periods beginning after December&nbsp;15, 2012. We adopted this standard in the first quarter of 2013 and the adoption of this standard did not have an impact on our financial position or results of operations. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 2&#151;INVESTMENTS AND FAIR VALUE MEASUREMENT </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Investments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sangamo classifies its marketable securities as available-for-sale and records its investments at fair value. Available-for-sale securities are
carried at estimated fair value based on quoted market prices, with the unrealized holding gains and losses included in accumulated other comprehensive income. Marketable securities which have maturities beyond one year as of the end of the
reporting period are classified as non-current. The Company&#146;s investments are subject to a periodic impairment review and the Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is
judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#146;s cost basis, the
financial condition and near-term prospects of the investee, and the Company&#146;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below summarizes the Company&#146;s available-for-sale securities (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>(Losses)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>September&nbsp;30, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Available-for-sale securities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government sponsored entity debt securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents and available-for-sale securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2012</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government sponsored entity debt securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Available-for-sale securities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government sponsored entity debt securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents and available-for-sale securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2013, none of the available-for-sale securities held by the Company had material
unrealized losses and there were no realized losses for the three and nine months ended September&nbsp;30, 2013. The Company had no other-than-temporary impairments of available-for-sale securities for the three and nine months ended
September&nbsp;30, 2013 or the twelve months ended December&nbsp;31, 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures certain financial assets at fair value on a recurring basis, including cash equivalents and available-for
sale-securities.&nbsp;The fair value of these assets was determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical,
unrestricted assets or liabilities; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 2: Quoted prices in markets that are not active or inputs which are observable,
either directly or indirectly, for substantially the full term of the asset or liability; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 3: Prices or valuation
techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company generally classifies its available-for-sale debt instruments as Level 2. Instruments can be classified as Level 2
when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of
like securities, sector groupings, and matrix pricing as well as model processes. These models are proprietary to the pricing providers or brokers. These valuation models incorporate a number of inputs, including, listed in approximate order of
priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be
used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each
security evaluation on any given day. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value measurements of our cash equivalents and available-for-sale
marketable securities are identified at the following levels within the fair value hierarchy (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,&nbsp;2013<BR>Fair&nbsp;Value&nbsp;Measurements</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Available-for-sale securities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government sponsored entity debt securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents and available-for-sale securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2012<BR>Fair&nbsp;Value&nbsp;Measurements</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government sponsored entity debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Available-for-sale securities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government sponsored entity debt securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents and available-for-sale securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 3&#151;BASIC AND DILUTED NET LOSS PER SHARE </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share has been computed by dividing the net loss by the weighted-average number of shares of common stock
outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock and potential dilutive securities outstanding during the period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because Sangamo is in a net loss position, diluted net loss per share excludes the effects of common stock equivalents consisting of options,
which are anti-dilutive. The total stock options outstanding excluded from consideration in the calculation of diluted net loss per share for the nine months ended September&nbsp;30, 2013 and 2012 were 7,853,936 and 8,075,898, respectively. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 4&#151;MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration and License Agreement with Shire AG in Human Therapeutics and Diagnostics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2012, the Company entered into a collaboration and license agreement (the Agreement) with Shire AG (Shire), pursuant to which the
Company and Shire collaborate to research, develop and commercialize human therapeutics and diagnostics for monogenic diseases based on Sangamo&#146;s novel zinc finger DNA-binding proteins (ZFP) technology. Under the Agreement, the Company and
Shire may develop potential human therapeutic or diagnostic products for seven gene targets. The initial four gene targets selected were blood clotting Factors VII, VIII, IX and X, and products developed for such initial gene targets will be used
for treating or diagnosing hemophilia. In June 2012, Shire selected a fifth gene target for the development of a ZFP therapeutic for Huntington&#146;s disease, an inherited neurodegenerative disease for which there are currently no therapies
available to slow the disease progression. Shire has the right, subject to certain limitations, to designate two additional gene targets. Pursuant to the Agreement, the Company granted Shire an exclusive, world-wide, royalty-bearing license, with
the right to grant sublicenses, to use Sangamo&#146;s ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the gene targets. The initial research term of the Agreement is six years and is
subject to extensions upon mutual agreement and under other specified circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Agreement, the Company is responsible for all research activities through
the submission of an Investigative New Drug Application (IND) or European Clinical Trial Application (CTA), while Shire is responsible for clinical development and commercialization of products generated from the research program from and after the
acceptance of an IND or CTA for the product. Shire reimburses Sangamo for its internal and external research program-related costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company received an upfront license fee of $13.0 million. The Company will also be eligible to receive up to $213.5 million of contingent payments for each gene target if specified research, regulatory, clinical development, commercialization and
sales milestone events occur, including payments for each gene target through the acceptance of an IND or CTA submission totaling $8.5 million. The Company will also be eligible to receive royalty payments that are a tiered double-digit percentage
of net sales of licensed product sold by Shire or its sublicensees developed under the collaboration, if any. To date, no products have been approved and therefore no royalty fees have been earned under the Agreement with Shire. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All contingent payments under the Agreement, when earned, will be non-refundable and non-creditable. The Company has evaluated the contingent
payments under the Agreement with Shire based on the authoritative guidance for research and development milestones and determined that certain of these payments meet the definition of a milestone and that all such milestones are evaluated to
determine if they are considered substantive milestones. Milestones are considered substantive if they are related to events (i)&nbsp;that can be achieved based in whole or in part on either the Company&#146;s performance or on the occurrence of a
specific outcome resulting from the Company&#146;s performance, (ii)&nbsp;for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved and (iii)&nbsp;that would result in additional payments
being due to the Company. Accordingly, revenue for the achievement of milestones that are determined to be substantive will be recognized in its entirety in the period when the milestone is achieved and collectability is reasonably assured. Revenue
for the achievement of milestones that are not substantive will be recognized over the remaining period of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has
identified the deliverables within the arrangement as a license to the technology and on-going research services activities. The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to
Shire apart from the research services to be performed pursuant to the Agreement. As a result, the Company will recognize revenue from the upfront payment on a straight-line basis over a six-year initial research term during which the Company will
perform research services. As of September&nbsp;30, 2013, the Company has deferred revenue of $9.5 million related to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues recognized under the agreement with Shire for the three and nine months ended September&nbsp;30, 2013 and September&nbsp;30, 2012,
were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine months ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue related to Shire Collaboration:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of upfront fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Related costs and expenses incurred under the Shire agreement were $3.5 million and $2.2 million during the
three months ended September&nbsp;30, 2013 and September&nbsp;30, 2012, respectively and $10.3 million and $3.8 million during the nine months ended September&nbsp;30, 2013 and September&nbsp;30, 2012, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agreement with Sigma-Aldrich Corporation in Laboratory Research Reagents, Transgenic Animal and Commercial Protein Production Cell-line Engineering
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2007, Sangamo entered into a license agreement (the Agreement) with Sigma-Aldrich Corporation (Sigma). Under the
Agreement, Sangamo agreed to provide Sigma with access to our proprietary ZFP technology and the exclusive right to use the technology to develop and commercialize research reagent products and services in the research field, excluding certain
agricultural research uses that Sangamo previously licensed to Dow AgroSciences LLC (DAS), a wholly-owned subsidiary of Dow Chemical Corporation. Under the Agreement, Sangamo and Sigma agreed to conduct a three-year research program to develop
laboratory research reagents using Sangamo&#146;s ZFP technology during which time Sangamo agreed to assist Sigma in connection with its efforts to market and sell services employing the Company&#146;s ZFP technology in the research field. Sangamo
has transferred the ZFP manufacturing technology to Sigma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2009, Sangamo expanded its Agreement with Sigma. In addition to the
original terms of the Agreement, Sigma received exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and certain ZFP-engineered transgenic animals for commercial applications. Under
the terms of the Agreement, Sigma made upfront cash payment of $20.0 million consisting of a $4.9 million purchase of 636,133 shares of Sangamo common stock, valued at $4.9 million, and a $15.1 million upfront license fee. The upfront license fee
was recognized on a straight-line basis from the effective date of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expanded license through July 2010, which represents the period over which Sangamo was obligated to perform research services for Sigma. Sangamo is also eligible to receive commercial license
fees of $5.0 million based upon a percentage of net sales and sublicensing revenue and thereafter a reduced royalty rate of 10.5% of net sales and sublicensing revenue. In addition, upon the achievement of certain cumulative commercial milestones
Sigma will make milestone payments to Sangamo up to an aggregate of $25.0 million. In April 2013, the Company recognized $1.3 million in sublicense revenues under the agreement with Sigma. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues recognized under the agreement with Sigma for the three and nine months ended September&nbsp;30, 2013 and September&nbsp;30, 2012,
were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;months&nbsp;ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue related to Sigma Collaboration<B>:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License fee and milestone revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Related costs and expenses incurred under the Sigma agreement were $0.1 million during both the three months
ended September&nbsp;30, 2013 and 2012. Related costs and expenses incurred under the Sigma agreement were $0.1 million and $0.3 million during the nine months ended September&nbsp;30, 2013 and 2012, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agreement with Dow AgroSciences in Plant Agriculture </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2005, Sangamo entered into an exclusive commercial license agreement (the Agreement) with DAS. Under the Agreement, Sangamo provides
DAS with access to its proprietary ZFP technology and the exclusive right to use the technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Sangamo has retained rights to use
plants or plant-derived products to deliver ZFP transcription factors (ZFP TFs) or ZFP nucleases (ZFNs) into humans or animals for diagnostic, therapeutic, or prophylactic purposes. The Agreement with DAS provided for an initial three-year research
term. In June 2008, DAS exercised its option under the agreement to obtain a commercial license to sell products incorporating or derived from plant cells generated using the Company&#146;s ZFP technology, including agricultural crops, industrial
products and plant-derived biopharmaceuticals. The exercise of the option triggered a one-time commercial license fee of $6.0 million, payment of the remaining $2.3 million of the previously agreed $4.0 million in research milestones, development
and commercialization milestone payments for each product, and royalties on sales of products. Furthermore, DAS has the right to sublicense Sangamo&#146;s ZFP technology to third parties for use in plant cells, plants, or plant cell cultures.
Sangamo will be entitled to 25% of any cash consideration received by DAS under such sublicenses. In December 2010, the Company amended the Agreement with DAS to extend the period of reagent manufacturing services and research services through
December&nbsp;31, 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Agreement also provides for minimum sublicense fees each year due to Sangamo every October, provided the
Agreement is not terminated by DAS. Annual fees range from $250,000 to $3.0 million and total $25.3 million over 11 years. The Company does not have any performance obligations with respect to the sublicensing activities to be conducted by DAS. DAS
has the right to terminate the Agreement at any time; accordingly, the Company&#146;s actual sublicense fees over the term of the Agreement could be lower than $25.3 million. In addition, each party may terminate the Agreement upon an uncured
material breach by the other party. In the event of any termination of the Agreement, all rights to use the Company&#146;s ZFP technology will revert to Sangamo, and DAS will no longer be permitted access to Sangamo&#146;s ZFP technology or to
develop or, except in limited circumstances, commercialize any products derived from the Company&#146;s ZFP technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues under
the agreement were $0.4 million during the three months ended September&nbsp;30, 2012, and $1.3 million during the nine months ended September&nbsp;30, 2012. Related costs and expenses incurred under the agreement were $0.1 million during the three
months ended September&nbsp;30, 2012, and $0.4 million during the nine months ended September&nbsp;30, 2012. There were no such revenues or related expenses during the three and nine months ended September&nbsp;30, 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Funding from Research Foundations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>California
Institute for Regenerative Medicine </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2009, the California Institute for Regenerative Medicine (CIRM), a State of
California entity, granted a $14.5 million Disease Team Research Award to develop an AIDS-related lymphoma therapy based on the application of ZFN gene editing technology in stem cells. The four year grant supports an innovative research project
conducted by a multidisciplinary team of investigators, including investigators from the University of Southern California, City of Hope National Medical Center and Sangamo BioSciences. Sangamo expects to receive funding up to $5.2 million from the
total amount awarded based on expenses incurred for research and development efforts by Sangamo as prescribed in the agreement, and subject to its terms and conditions. The award is intended to substantially fund Sangamo&#146;s research and
development efforts related to the agreement. The State of California has the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
right to receive, subject to the terms and conditions of the agreement between Sangamo and CIRM, payments from Sangamo resulting from sales of a commercial product resulting from research and
development efforts supported by the grant, not to exceed two times the amount Sangamo receives in funding under the agreement with CIRM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues attributable to research and development performed under the CIRM grant agreement were $0.5 million and $0.3 million during the three
months ended September&nbsp;30, 2013 and 2012, respectively and $ 1.2&nbsp;million and $0.9 million during the nine months ended September&nbsp;30, 2013 and 2012, respectively. Related costs and expenses incurred under the CIRM agreement were $0.5
million and $0.3 million during the three months ended September&nbsp;30, 2013 and 2012, respectively, and $1.4 million and $0.9 million during the nine months ended September&nbsp;30, 2013 and 2012, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CHDI Foundation, Inc. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April
2011, Sangamo entered into an agreement with the CHDI Foundation, Inc. (CHDI) to develop a novel therapeutic for Huntington&#146;s disease based on Sangamo&#146;s proprietary ZFP technology. Under the agreement with CHDI, and subject to its terms
and conditions, CHDI paid the Company $1.3 million, the total funds due under the agreement, over a period of one year which is intended to substantially fund the Company&#146;s research efforts related to the agreement. During 2012, the agreement
was amended to extend the project through August 2012 and to increase total potential funding from $1.3 million to $2.1 million, plus reimbursement for certain direct expenses related to the project. The research grant from CHDI was completed in
August 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues attributable to research and development performed under the CHDI collaboration agreement were $0.3 million and
$1.1 million during the three and nine months ended September&nbsp;30, 2012, respectively. Related costs and expenses incurred under the CHDI agreement were $0.3 million and $1.1 million during the three and nine months ended September&nbsp;30,
2012, respectively. There were no revenues or related expenses during the three and nine months ended September&nbsp;30, 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Juvenile
Diabetes Research Foundation International </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2006, Sangamo entered into an agreement with the Juvenile Diabetes Research
Foundation International (JDRF) to provide financial support for one of Sangamo&#146;s Phase 2 human clinical studies of the Company&#146;s product candidate SB-509, a ZFP Therapeutic that was in development for the treatment of diabetic neuropathy.
In January 2010, JDRF and Sangamo amended the agreement and, subject to its terms and conditions, JDRF agreed to provide additional funding of up to $3.0 million for a Phase 2b trial in diabetic neuropathy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2011, the Company announced of the termination of its SB-509 program. In March 2012, the Company received a final payment of $0.8
million for work performed under the JDRF agreements. The Company does not expect to receive additional funding under these agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues attributable to research and development activities performed under the JDRF agreements were $0 for the three months ended
September&nbsp;30, 2012 and $0.8 million during the nine months ended September&nbsp;30, 2012. There were no such revenues during the three and nine months ended September&nbsp;30, 2013. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 5&#151;INCOME TAXES </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying
amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and capitalized research and development.
Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain based on the Company&#146;s history of losses. Accordingly, the net deferred tax assets have been fully offset by a valuation
allowance. Utilization of operating losses and credits may be subject to substantial annual limitation due to ownership change provisions of the Internal Revenue Code of 1986, as amended and similar state provisions. The annual limitation may result
in the expiration of net operating losses and credits before utilization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 6&#151;STOCK-BASED COMPENSATION </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows total stock-based compensation expense included in the condensed consolidated statement of
operations for the three month and nine months ended September&nbsp;30, 2013 and 2012 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;months&nbsp;ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs and expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 7&#151;STOCKHOLDERS&#146; EQUITY </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;23, 2013, Sangamo completed an underwritten public offering of its common stock, in which the Company
sold an aggregate of 7,015,000 shares of its common stock, including 915,000 issued to the Underwriters pursuant to a 30-day overallotment option, at a public offering price of $10.58 per share. The net proceeds to Sangamo from the sale of shares in
this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $69.5 million. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 8&#151;SUBSEQUENT EVENTS </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Acquisition of Ceregene </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;23, 2013, Sangamo and its wholly-owned subsidiary CG Acquisition Sub, Inc., a Delaware corporation (&#147;Merger Sub&#148;),
entered into an Agreement and Plan of Merger (the &#147;Merger Agreement&#148;) with Ceregene, Inc., (&#147;Ceregene&#148;) and a stockholders&#146; representative. Pursuant to the Merger Agreement, the Company acquired all outstanding shares of
Ceregene, a privately held biotechnology company focused on the development of adeno-associated virus (&#147;AAV&#148;) gene therapies. The acquired assets include all of Ceregene&#146;s therapeutic programs, including CERE-110, an AAV vector
delivery system for the treatment of Alzheimer&#146;s disease that is currently in a Phase 2 clinical trial, certain intellectual property rights relating to the manufacturing of AAV, and certain toxicology and safety data from Ceregene&#146;s human
clinical trials (the Acquisition). The Acquisition was closed on October&nbsp;1, 2013 (the Closing Date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the Closing Date, Merger Sub
merged with and into Ceregene, with Ceregene continuing as the surviving company and a wholly-owned subsidiaries of the Company. On the Closing Date, each share of Ceregene&#146;s issued and outstanding capital stock held by its stockholders
converted to the right to receive a portion of the merger consideration for the Acquisition, which consists initially of (i)&nbsp;100,000 shares of Sangamo common stock with a market value of approximately $1.2 million on the Closing Date, and
(ii)&nbsp;amount of cash and cash equivalent of Ceregene on the Closing Date less certain liabilities and expenses. In addition to such initial merger consideration, during the term of the Merger Agreement, the Company is required to make contingent
earn-out payments (the &#147;Earn-Out Payments&#148;) to the stockholders of Ceregene as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If the Company grants a third-party license to develop and commercialize Ceregene&#146;s CERE-110 for the treatment of Alzheimer&#146;s disease or CERE-120 for the treatment of Parkinson&#146;s diseases or
Huntington&#146;s disease (the &#147;Earn-Out Products&#148;), the Company is required to pay a double digit percentage of any upfront and milestone payments the Company receives for such license, subject to certain reductions based on expenses
incurred by the Company in the development of the Earn-Out Products; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If the Company commercializes any Earn-Out Product itself, the Company is required to pay, for each Earn-Out Product, royalty-like earnout payments as a percentage of net sales that range in the low double digits
depending upon the amount of net sales, subject to certain reductions by the Company. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also on the Closing Date, the
Company, Ceregene and certain of its stockholders entered into an indemnity escrow agreement, pursuant to which a portion of the purchase price was deposited in an escrow account for the benefit of the Company to satisfy indemnity obligations of the
stockholders under the Merger Agreement. Due to the relatively short time from the Closing Date of the Acquisition to the completion of the accompanying unaudited interim consolidated financial statements, the accounting for the initial purchase
price allocation as well as certain required supplemental disclosures with respect to the Acquisition have not been completed. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx595389_7"></A>ITEM&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; contains trend
analysis, estimates and other forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements
include, without limitation, statements containing the words &#147;believes,&#148; &#147;anticipates,&#148; &#147;expects,&#148; &#147;continue,&#148; and other words of similar import or the negative of those terms or expressions. Such
forward-looking statements are subject to known and unknown risks, uncertainties, estimates and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any
future results, performance or achievements expressed or implied by such forward-looking statements. You should read the following discussion and analysis along with the financial statements and notes attached to those statements included elsewhere
in this report and in our annual report on Form 10-K for the year ended December&nbsp;31, 2012 as filed with the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Overview
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered
DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. Our current mission is to develop ZFP Therapeutics, or human therapeutics based on our proprietary ZFP technology, through early stage clinical
testing, strategically partner with biopharmaceutical companies at points of value inflection and have the partner execute late-stage clinical trials and commercial development. In the long term, our goal is to integrate marketing and development
operations and to capture the value of late-stage and commercial ZFP Therapeutic products for ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, and our licensed partners,
are the leaders in the research, development and commercialization of zinc finger DNA-binding proteins (ZFPs), a naturally occurring class of proteins. We have used our knowledge and expertise to develop a proprietary technology platform. ZFPs can
be engineered to make ZFP nucleases (ZFNs), proteins that can be used to modify DNA sequences in a variety of ways and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. As ZFPs act at the DNA level, they have
broad potential applications in several areas including human therapeutics, plant agriculture and research reagents, as well as production of transgenic animals and cell-line engineering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The main focus for our company is the development of novel human therapeutics and we are building a pipeline of ZFP Therapeutics. Our lead ZFP
Therapeutic, SB-728-T, a ZFN-modified autologous T-cell product for the treatment of HIV/AIDS, is the first therapeutic application of our ZFN technology and is being evaluated in ongoing clinical trials, the most advanced of which are a Phase 2
study (SB-728-902 Cohort 5) and a Phase 1/2 study (SB-728-1102) in HIV-infected subjects. We expect to present data from these programs at appropriate scientific and medical meetings in 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2012, we established a collaborative partnership with Shire AG (Shire) to research, develop and commercialize some of our
preclinical ZFP Therapeutic development programs, including programs in hemophilia, Huntington&#146;s disease and other monogenic diseases. We also have several proprietary preclinical programs in monogenic diseases, including hemoglobinopathies
such as sickle cell disease and &szlig;-thalassemia and several lysosomal storage disorders. In addition, we have research stage programs in other monogenic diseases, including certain immunodeficiencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the potential commercial applications of ZFPs are broad-based and we have also licensed our ZFP platform in fields outside human
therapeutics as follows to facilitate the sale or license of ZFNs and ZFP TFs: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have a license agreement with the research reagent company Sigma-Aldrich Corporation (Sigma). Sigma has the exclusive rights to develop and market high value laboratory research reagents based upon our ZFP technology
as well as ZFP-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals. Sigma is marketing ZFN-derived gene editing tools under the trademark
CompoZr<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have a license agreement with Dow AgroSciences, LLC (DAS), a wholly owned subsidiary of Dow Chemical Corporation. Under the agreement, we have provided DAS with access to our ZFP technology and the exclusive rights
to use it to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. DAS markets our ZFN technology under the trademark EXZACT<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> Precision Technology. We
have retained rights to use plants or plant-derived products to deliver ZFP TFs or ZFNs into human or animals for diagnostic, therapeutic, or prophylactic purposes </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;1, 2013, we acquired Ceregene, Inc., (&#147;Ceregene&#148;) a privately held biotechnology company focused on the development
of adeno-associated virus (&#147;AAV&#148;) gene therapies. The acquired assets include all of Ceregene&#146;s therapeutic programs, including CERE-110, an AAV vector delivery system for the treatment of Alzheimer&#146;s disease that is currently in
a Phase 2 clinical trial, certain intellectual property rights relating to the manufacturing of AAV, and certain toxicology and safety data from Ceregene&#146;s human clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred net losses since inception and expect to incur losses in the future as we
continue our research and development activities. To date, we have funded our operations primarily through the issuance of equity securities, payments from corporate collaborations and research grants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended September&nbsp;30, 2013, we incurred a consolidated net loss of $6.1 million, or $0.11 per share, compared to a net
loss of $5.8 million, or $0.11 per share, for the same period in 2012. As of September&nbsp;30, 2013, we had cash, cash equivalents, marketable securities and interest receivable totaling $133.1 million compared to $76.3 million as of
December&nbsp;31, 2012. As of September&nbsp;30, 2013, we had an accumulated deficit of $294.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenues have consisted
primarily of revenues from our corporate partners for ZFNs and ZFP TFs, contractual payments from strategic partners for research programs and research milestones, and research grant funding. We expect revenues will continue to fluctuate from period
to period and there can be no assurance that new collaborations or partner funding will continue beyond their initial terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
development of our ZFP technology platform, we are focusing our resources on higher-value ZFP Therapeutic product development and less on our non-therapeutic applications. We are conducting a Phase 2 and two Phase 1/2 clinical trials to evaluate a
ZFP Therapeutic for the treatment of HIV/AIDS. Development of novel therapeutic products is costly and is subject to a lengthy and uncertain regulatory process by the FDA. Our future products will be gene-based therapeutics. Adverse events in both
our own clinical program and other programs may have a negative impact on regulatory approval, the willingness of potential commercial partners to enter into agreements and the perception of the public. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Critical Accounting Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying discussion and analysis of our financial condition and results of operations are based upon our consolidated financial
statements and the related disclosures, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make estimates, assumptions and judgments
that affect the reported amounts in our consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results
of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe
that there have been no significant changes in our critical accounting policies and estimates disclosed in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2012, as filed with the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Three months
and nine months ended September&nbsp;30, 2013 and 2012 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three months ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine months ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in&nbsp;thousands,&nbsp;except&nbsp;percentage&nbsp;values)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in&nbsp;thousands,&nbsp;except&nbsp;percentage&nbsp;values)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total revenues consist of revenues from collaboration agreements, strategic partnerships and research grants.
We anticipate revenues over the next several years will primarily be derived from our collaboration agreements with Shire, Sigma-Aldrich Corporation (Sigma) and Dow AgroSciences LLC (DAS), a wholly-owned subsidiary of Dow Chemical Corporation. In
May 2013, the California Institute for Regenerative Medicine (CIRM) granted us a $6.4 million Strategic Partnership Award to develop a potentially curative ZFP Therapeutic for beta-thalassemia based on the application of our ZFN gene-editing
technology in hematopoietic stem cells (HSCs). The four year grant provides matching funds to support a potential Investigational New Drug (IND) application and a Phase 1 clinical trial in transfusion-dependent beta-thalassemia patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues from our corporate collaboration and strategic partnering agreements were $4.8 million for the three months ended September&nbsp;30,
2013, compared to $4.2 million in the corresponding period in 2012. The $0.6 million increase in collaboration agreement revenues was primarily due to an increase of $1.3 million in research service revenues related to our collaboration and license
agreement with Shire. The revenues from Shire include amortization of an upfront payment of $13.0 million and revenues from research services. These increases were partially offset by a $0.5 million decrease in revenues related to research services
under the agreement with DAS and $0.2 million decrease in revenues related to other collaboration agreements. Research grant revenues were approximately $0.9 million for the three months ended September&nbsp;30, 2013, compared to $0.7 million in the
corresponding period in 2012. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues from our corporate collaboration and strategic partnering agreements were $15.1 million
for the nine months ended September&nbsp;30, 2013, compared to $9.7 million in the corresponding period in 2012. The increase of $5.4 million in collaboration agreement revenues was primarily attributable to an increase in revenues of $6.8 million
related to the agreement with Shire, partially offset by $1.3 million in lower revenues related to our agreement with DAS and $0.1 million decrease in revenues related to other collaboration agreements. Research grant revenues were $2.2 million for
the nine months ended September&nbsp;30, 2013, compared to $3.1 million in the corresponding period in 2012. The decrease of $0.9 million in research grant revenues was primarily due to the completion of our research grants with Juvenile Diabetes
Research Foundation International and the CHDI Foundation in 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three months ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine months ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in&nbsp;thousands,&nbsp;except&nbsp;percentage&nbsp;values)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in&nbsp;thousands,&nbsp;except&nbsp;percentage&nbsp;values)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of salaries and personnel related expenses, including stock-based compensation, laboratory
supplies, pre-clinical and clinical studies, manufacturing expenses, allocated facilities expenses, subcontracted research expenses and expenses for trademark registration and technology licenses. We expect to continue to devote substantial
resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in advancing our HIV/AIDS program in the clinic and if we are able to move our earlier stage
ZFP Therapeutic product candidates into clinical trials. We also expect that expenses related to research performed under our collaboration and license agreement with Shire will increase our research and development expenses during the term of the
agreement. Pursuant to the terms of the agreement with Shire, future expenses related to research activities related to the collaboration will be reimbursed by Shire, including employee and external research costs related to the programs. The
reimbursement funds received from Shire will be recognized as revenue as the costs are incurred and collection is assured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and
development expenses were $8.7 million for the three months ended September&nbsp;30, 2013, compared to $7.6 million in the corresponding period in 2012. The increase of $1.1 million in research and development expenses was primarily due to an
increase of $1.0 million in external expenses, lab supplies and other costs related to our hemophilia, hemoglobinopathies and Huntington&#146;s disease programs and $0.2 million in salaries and benefits, partially offset by a decrease of $0.1
million in clinical trial expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $26.2 million for the nine months ended September&nbsp;30,
2013, compared to $22.4 million in the corresponding period in 2012. The increase of $3.8 million in research and development expenses was primarily due to an increase of $4.2 million in external expenses, lab supplies and other costs related to our
hemophilia, hemoglobinopathies and Huntington&#146;s disease programs and $0.6 million in salaries and benefits, partially offset by a decrease of $1.0 million in clinical trial and manufacturing expenses, primarily attributable to our SB-728-T
HIV/AID programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General and administrative </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries and personnel related expenses for executive, finance and administrative
personnel, stock-based compensation expenses, professional fees, allocated facilities expenses, patent prosecution expenses and other general corporate expenses. As we pursue commercial development of our therapeutic programs, we expect the business
aspects of the Company to become more complex. We may be required in the future to add personnel and incur additional costs related to the maturity of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $3.2 million for the three month period ended September&nbsp;30, 2013 and $3.1 million for the
corresponding period in 2012. The increase was primarily related to higher corporate legal fees of $0.1 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and
administrative expenses were $9.6 million for the nine month period ended September&nbsp;30, 2013 and $9.1 million for the corresponding period in 2012. The increase was primarily related to higher patent related legal fees of $0.3 million, higher
professional fees of $0.1 million and higher employee related costs of $0.2 million, partially offset by lower allocated expenses of $0.1 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Liquidity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since
inception, we have incurred significant net losses and we have funded our operations primarily through the issuance of equity securities, payments from corporate collaborators and strategic partners and research grants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2013, we had cash, cash equivalents, marketable securities and interest receivable totaling $133.1&nbsp;million
compared to $76.3 million as of December&nbsp;31, 2012 with the increase primarily attributable to the completion of an underwritten public offering of the Company&#146;s common stock in September 2013, in which 7,015,000 shares of Sangamo common
stock were sold at a public offering price of $10.58 per share. The net proceeds to the Company from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were
approximately $69.5 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most significant use of capital pertains to salaries and benefits for our employees and external
development expenses, such as manufacturing and clinical trial activities, related to our ZFP Therapeutic programs. Our cash and investment balances are held in a variety of interest bearing instruments, which can include obligations of U.S.
government agencies, U.S. treasury debt securities, corporate debt securities and money market funds. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital preservation and
liquidity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our agreement with Shire, we received an upfront license fee of $13.0 million. We are also eligible to receive milestone
payments, however, our eligibility is based on our achievement of specified research, regulatory, clinical development, commercialization and sales milestones and depends upon ours and Shire&#146;s ability to continue to progress our programs under
collaboration. We will also be eligible to receive royalty payments that are a tiered double-digit percentage of net sales of products developed under the collaboration, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of our agreement to acquire Ceregene, we issued 100,000 shares of our common stock, with a market value of approximately $1.2
million on the closing date of the acquisition, to the stockholders of Ceregene, and we also agreed to make certain contingent earn-out payments to the stockholders of Ceregene based upon revenues generated from license or sales transaction of
certain existing products of Ceregene. We do not expect the acquisition, including the operation of the ongoing Phase 2 clinical trial of Ceregene product candidates, to have any significant impact on our operating expenses or cash balance in 2013.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Cash Flow </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash
used in operating activities for the nine months ended September&nbsp;30, 2013 and 2012 was $17.8 million and $8.3 million, respectively. Net cash used in operating activities for the nine months ended September&nbsp;30, 2013 primarily reflected the
net loss for the period, the decrease in deferred revenues related to our collaboration agreement with Shire and decrease in account payable and accrued liability, partially offset by stock-based compensation and other non-cash expenses included in
net loss. Net cash used in operating activities for the nine months ended September&nbsp;30, 2012 primarily reflects the net loss for the period, an increase in deferred revenues due to the $13.0 million upfront received from Shire under the
collaboration and license agreement, a decrease in accounts payable and accrued liabilities and an decrease in accounts receivable, partially offset by stock-based compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by investing activities for the nine months ended September&nbsp;30, 2013 and 2012 was $0.1 million and $4.4 million,
respectively. Cash flows from investing activities for both periods primarily related to purchases and maturities of investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net
cash provided by financing activities for the nine months ended September&nbsp;30, 2013 and 2012 was $75.6 million and $1.0 million, respectively. The increase for the nine month period ended September&nbsp;30, 2013 was primarily attributable to
$69.5 million in net proceeds from the public offering of the Company&#146;s common stock completed in September 2013, as well as proceeds from the issuance of common stock upon exercise of stock options. Net cash provided by financing activities
for the nine month period ended September&nbsp;30, 2012 was primarily attributable to proceeds from the issuance of common stock upon exercise of stock options. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Operating Capital and Capital Expenditure Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate continuing to incur operating losses for at least the next several years. While our rate of cash usage may increase in the
future, in particular to support our product development endeavors, we believe that the available cash resources as well as funds received from corporate collaborators, strategic partners and research grants will enable us to maintain our currently
planned operations through 2014. Future capital requirements will be substantial and if our capital resources are insufficient to meet future capital requirements, we will need to raise additional capital to fund our operations, including ZFP
Therapeutic development activities, through equity or debt financing. We regularly consider fund raising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of
operation. Additional capital may not be available on terms acceptable to us, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, our business and our ability to develop our technology and
our ZFP Therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to our stockholders, and any debt financing may include covenants that restrict our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future capital requirements will depend on many factors and are not limited to the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, progress, timing and completion of clinical trials for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the outcome, timing and cost of regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success of our collaboration with Shire; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays that may be caused by changing regulatory requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of product candidates that we pursue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and terms of future in-licensing and out-licensing transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of procuring clinical and commercial supplies of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we acquire or invest in businesses, products or technologies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of litigation. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx595389_8"></A>ITEM&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary exposure to
market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. We do not have any foreign currency or other derivative financial instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our market risks at September&nbsp;30, 2013 have not changed materially from those discussed in Item&nbsp;7A of our Form 10-K for the year
ended December&nbsp;31, 2012 on file with the SEC. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B><A NAME="tx595389_9"></A>ITEM&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONTROLS AND PROCEDURES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Disclosure Controls and Procedures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in
our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#146;s rules and forms and that such information is accumulated and communicated to our management,
including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls
and procedures, no matter how well designed and operated, can provide only reasonable, and not absolute, assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply
its judgment in evaluating the cost benefit relationship of possible controls and procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As required by the Securities and Exchange
Commission Rule 13a-15(b), we carried out an evaluation, under the supervision of and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of
our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the
reasonable assurance level. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Change in Internal Control over Financial Reporting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has been no change in our internal controls over financial reporting during our most recent fiscal quarter that has materially affected,
or is reasonably likely to materially affect, our internal controls over financial reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx595389_15"></A>PART II. OTHER INFORMATION </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx595389_10"></A>ITEM&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LEGAL PROCEEDINGS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not party to any material pending legal proceedings. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx595389_11"></A>ITEM&nbsp;1A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RISK FACTORS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An investment in our common stock involves significant risk. You should
carefully consider the information described in the following risk factors, together with the other information appearing elsewhere in this report, before making an investment decision regarding our common stock. You should also consider the risk
factors set forth in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2012 (&#147;2012 Annual Report&#148;) under the caption &#147;Item 1A. Risk Factors,&#148; together with the other information appearing elsewhere in this
report, before making an investment decision regarding our common stock. If any of the risks described below or in our 2012 Annual Report actually occur, our business, financial conditions, results of operation and future growth prospects would
likely be materially and adversely affected. In these circumstances, the market price of our common stock could decline, and you may lose all or a part of your investment in our common stock. Moreover, the risks described below and in our 2012
Annual Report are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business, operating results, prospects or financial condition. You should carefully consider these
risk factors, together with all of the other information included in this Form 10-Q as well as our other publicly available filings with the Securities and Exchange Commission. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Development, Commercialization and Regulatory Approval of our Products and Technology </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>ZFP Therapeutics have undergone limited testing in humans and our ZFP Therapeutics may fail safety studies in clinical trials.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2008, in collaboration with scientists at the University of Pennsylvania, we filed an Investigational New Drug (IND)
application for a Phase 1 trial of our CCR5 ZFN-based therapeutic, SB-728-T, for treatment of HIV/AIDS. In September 2009, we announced the FDA&#146;s review and acceptance of our IND application to initiate an open-label, repeat-dosing Phase 1
clinical trial of SB-728-T (SB-728-902). Preliminary data from these studies demonstrated that, to date, treatment of aviremic HIV-infected subjects with SB-728-T has been well-tolerated. We also have an on-going Phase 2 (SB-728-902, Cohort 5) and
two Phase 1/2 trials (SB-728-1101 and 1002) for this indication. In addition, we have previously completed enrollment and the treatment phase of a Phase 1 and several Phase 2 clinical trials of our ZFP Therapeutic, SB-509, for diabetic neuropathy
and ALS and the drug was well tolerated in these studies. However, if one of our ZFP Therapeutic fails one of its safety studies, it could reduce our ability to attract new investors and corporate partners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of these studies are designed primarily to evaluate the safety and tolerability of this ZFP Therapeutic approach. Our clinical studies are
a highly visible test of our ZFP Therapeutics. Since we have increased our focus on therapeutic research and development, investors increasingly assess the value of our technology based on the continued progress of ZFP Therapeutic products into and
through clinical trials. If clinical trials of our ZFP Therapeutic products were halted due to safety concerns, this would negatively affect our operations and the value of our stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our progress in early Phase 1 and Phase 2 trials may not be indicative of long-term efficacy in late stage clinical trials. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results in early phases of clinical testing are based upon limited numbers of patients and a limited follow-up period. Typically, our Phase 1 clinical
trials for indications of safety enroll less than 25 patients. Our Phase 2 and late-stage clinical trials generally enroll a larger number of patients. Accordingly, any positive data obtained in early Phase 1 and Phase 2 trials may not be indicative
of long-term efficacy in late-stage clinical trials. In September 2011, we announced preliminary data from our Phase 1 clinical program to develop SB-728-T for the treatment of HIV/AIDS. The data demonstrated a statistically significant relationship
between SB-728-T and the reduction of HIV viral load. In January 2012, we initiated a Phase 2 clinical study (SB-728-902, Cohort 5) and a Phase 1/2 clinical study (SB-728-1101) for the treatment of HIV/AIDS. In May 2013, we presented preliminary
data from these two ongoing clinical trials. Two of four evaluable subjects in Cohort 5 showed a decrease of greater than one log in their viral load during a sixteen week treatment interruption (TI) with one subject achieving a transiently
undetectable viral load during the TI period. In subjects in which viral load decreased, a measureable anti-HIV immune response was also observed. Additional data were presented from the Company&#146;s Phase 1 study (SB-728-902, Cohorts 1-3) that
demonstrated a long-term decrease in the peripheral blood mononuclear cell (PBMC) HIV reservoir. In October 2013, we presented new data from our ongoing Phase 2 clinical trial (SB-728-902 Cohort 5) for treatment of HIV/AIDS, demonstrating functional
control of the virus at or below the limit of detection in HIV-infected subjects treated with SB-728-T, as well as additional data demonstrating depletion of the HIV viral reservoir in SB-728-T treated subjects in cohorts 1-3 of the SB-728-902
study. We expect to present a full data set from these trials in the second half of 2013. However, there is no guarantee that these and other future studies of SB-728-T in later stage trials involving larger patient groups may produce positive or
similar results as those obtained in earlier trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the initial results from the Phase 1 clinical trial of our ZFP Therapeutic product,
SB-509, became available in the first half of 2006 and the complete data set was presented in June 2008. The primary end point of the trial was clinical and laboratory safety; however, we collected some preliminary efficacy data that showed trends
of clinical improvement in some subjects. Notwithstanding this preliminary efficacy data, the top-line data from our Phase 2b clinical study for SB-509-901 did not meet the key primary or secondary endpoints for the study and as a result we
discontinued development of our SB-509 program in October 2011. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A number of companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in late stage clinical trials even after achieving promising results in earlier stage clinical trials. If a larger population of patients does not experience positive results, or if these results are not
reproducible, our products may not receive approval from the FDA. Failure to confirm favorable results from earlier trials by demonstrating the safety and effectiveness of our ZFP Therapeutic products in late stage clinical trials with larger
patient populations could have a material adverse effect on our business that would cause our stock price to decline significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our potential therapeutic products are subject to a lengthy and uncertain regulatory process, and we may encounter unanticipated
toxicity or adverse events or fail to demonstrate efficacy, causing us to delay, suspend or terminate the development of a ZFP Therapeutic. If these potential products are not approved, we will not be able to commercialize those products.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA must approve any human therapeutic product before it can be marketed in the United States. The process for receiving
regulatory approval is long and uncertain, and a potential product may not withstand the rigors of testing under the regulatory approval processes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before commencing clinical trials in humans, we must submit an IND application to the FDA. The FDA has 30 days to comment on the application
and if the agency has no comments, we or our commercial partner may begin clinical trials. While we have stated our intention to file additional IND applications during the next several years, this is only a statement of intent, and we may not be
able to do so because the associated product candidates may not meet the necessary preclinical requirements. In addition, there can be no assurance that, once filed, an IND application will result in the actual initiation of clinical trials.
Clinical trials are subject to oversight by institutional review boards and the FDA. In addition, our proposed clinical studies require review from the Recombinant DNA Advisory Committee (RAC), which is the advisory board to the National Institutes
of Health (NIH), focusing on clinical trials involving gene transfer. We will typically submit a proposed clinical protocol and other product-related information to the RAC three to six months prior to the expected IND application filing date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">must be conducted in conformance with the FDA&#146;s good clinical practices, within the guidelines of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for
Human Use (ICH) and other applicable regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">must meet requirements for Institutional Review Board (IRB) oversight; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">must follow Institutional Biosafety Committee (IBC) and NIH RAC guidelines where applicable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">must meet requirements for informed consent; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">are subject to continuing FDA oversight; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may require oversight by a Data Safety Monitoring Board (DSMB); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may require large numbers of test subjects;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may be suspended by a commercial partner, the FDA, or us at any time if it is believed that the subjects participating in these trials are being exposed to unacceptable health risks or if the FDA finds deficiencies in
the IND application or the conduct of these trials. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have limited experience in conducting clinical trials.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ZFP Therapeutics may fail to show the desired safety and efficacy in initial clinical trials. We have an ongoing Phase 2 trial
and two Phase 1/2 studies of a ZFP Therapeutic for HIV/AIDS. However, the FDA will require additional clinical testing which involves significantly greater resources, commitments and expertise and so it is likely that we would need to enter into a
collaborative relationship with a pharmaceutical company that could assume responsibility for late-stage development and commercialization. We have limited experience in conducting clinical trials and may not possess the necessary resources and
expertise to complete such trials, and there is no guarantee that we will be able to enter into collaborative relationships with third parties that can provide us with the funding and expertise for such trials. In our collaborative agreement to
develop ZFP Therapeutics with Shire AG (Shire), we are responsible for all activities through submission of IND Applications and European Clinical Trial Applications (CTA) and Shire is responsible for clinical development and commercialization of
products arising from the alliance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>While we have stated that we intend to file IND applications for several ZFP Therapeutic
programs over the next three years, we may encounter difficulties that may delay, suspend or scale back our efforts. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
previously announced a strategy for our ZFP Therapeutic programs that enables the potential filing of seven IND applications by the end of 2015. The preparation and submission of IND applications requires us to conduct rigorous and time-consuming
pre-clinical testing, studies, and documentation relating to, among other things, the toxicity, safety, manufacturing, chemistry and clinical protocol of new ZFP Therapeutic products. We may experience unforeseen difficulties that could delay or
otherwise prevent us from executing this strategy successfully. For example, we may encounter problems in the manufacturing of our ZFP Therapeutic products and fail to demonstrate consistency in the formulation of the drug. Our pre-clinical tests
may produce negative or inconclusive results, which may lead us to decide, or regulators may require us, to conduct additional pre-clinical testing. If we cannot obtain positive results in pre-clinical testing, we may decide to abandon the projects
altogether. Furthermore, the filing of several IND applications involves significant cost and labor, and we may not have sufficient resources and personnel to complete the filing of all intended IND applications, which may force us to scale back the
number of IND applications or forego potential IND applications that we believe are promising. Any delay, suspension or reduction of our efforts to pursue our pre-clinical and IND strategy could have a material adverse effect on our business and
cause our stock price to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to find acceptable patients or may experience delays in enrolling patients for
our clinical trials. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience difficulties or delays in recruiting and enrolling a sufficient number of patients to
participate in our clinical trials due to a variety of reasons, including competition from other clinical trial programs for the same indication, failure of patients to meet our enrollment criteria and premature withdraws of patients prior to the
completion of clinical trials. The FDA and institutional review boards may also require large numbers of patients, and the FDA may require that we repeat a clinical trial. Any delay resulting from our failure to enroll a sufficient number of
patients on a timely basis may have a material adverse affect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>As we cannot predict whether or when we will obtain
regulatory approval to commercialize our product candidates, we cannot predict the timing of any future revenue from these product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot commercialize any of our ZFP Therapeutics to generate revenue until the appropriate regulatory authorities have reviewed and
approved the applications for the product candidates. We cannot ensure that the regulatory agencies will complete their review processes in a timely manner or that we will obtain regulatory approval for any product candidate that we or our
collaborators develop. Satisfaction of regulatory requirements typically takes many years, is dependent upon the type, complexity and novelty of the product and requires the expenditure of substantial resources. Regulatory approval processes outside
the United States include all of the risks associated with the FDA approval process. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in FDA
policy during the period of product development, clinical trials and FDA regulatory review. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Regulatory approval, if granted, will
be limited to specific uses or geographic areas, which could limit our ability to generate revenues. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory approval will be
limited to the indicated use for which we can market a product. Further, once regulatory approval for a product is obtained, the product and its manufacturer are subject to continual review. Discovery of previously unknown problems with a product or
manufacturer may result in restrictions on the product, manufacturer, and manufacturing facility, including withdrawal of the product from the market. In Japan and Europe, regulatory agencies also set or approve prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if regulatory clearance of a product is granted, this clearance is limited to those specific states and conditions for which the product
is useful, as demonstrated through clinical trials. We cannot ensure that any ZFP Therapeutic product developed by us, alone or with others, will prove to be safe and effective in clinical trials and will meet all of the applicable regulatory
requirements needed to receive marketing clearance in a given country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, our ability to market a product is
contingent upon receiving a marketing authorization from appropriate regulatory authorities; therefore we cannot predict whether or when we would be permitted to commercialize our product. These foreign regulatory approval processes include all of
the risks associated with FDA clearance described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Commercialization of our technologies will depend, in part, on strategic
partnering with other companies. If we are not able to find partners in the future or our partners do not diligently pursue product development efforts, we may not be able to develop our technologies or products, which could slow our growth and
decrease the value of our stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to rely, to some extent, on our strategic partners to provide funding in support of
our research and to perform independent research and preclinical and clinical testing. Our technology is broad based, and we do not currently possess the resources necessary to fully develop and commercialize potential products that may result from
our technologies or the resources or capabilities to complete the lengthy marketing approval processes that may be required for the products. Therefore, we plan to rely on strategic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
partnerships to help us develop and commercialize ZFP Therapeutic products. If we are unable to find partners or if the partners we find, such as Shire, are unable or unwilling to advance our
programs, or if they do not diligently pursue product approval, this may slow our progress and defer our revenues. Our partners may sublicense or abandon development programs or we may have disagreements with our partners, which would cause
associated product development to slow or cease. There can be no assurance that we will be able to establish further strategic collaborations for ZFP Therapeutic product development. We may require significant time to secure collaborations or
partners because we need to effectively market the benefits of our technology to these future collaborators and partners, which may direct the attention and resources of our research and development personnel and management away from our primary
business operations. Further, each collaboration or partnering arrangement will involve the negotiation of terms that may be unique to each collaborator or partner. These business development efforts may not result in a collaboration or partnership.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loss of partnering agreements would not only delay or terminate the potential development or commercialization of products we may
derive from our technologies, but it may also delay or terminate our ability to test ZFP Therapeutic candidates for specific genes. If any partner fails to conduct the collaborative activities successfully and in a timely manner, the preclinical or
clinical development or commercialization of the affected product candidates or research programs could be delayed or terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
typical partnering agreements we would expect to receive revenue for the research and development of a ZFP Therapeutic product based on achievement of specific milestones, as well as royalties based on a percentage of sales of the commercialized
products. Achieving these milestones will depend, in part, on the efforts of our partner as well as our own. If we, or any partner, fail to meet specific milestones, then the partnership may be terminated, which could reduce our revenues. For more
information on risks relating to our third party collaborative agreements, see &#147;Risks Relating to our Collaborative Relationships.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to license gene transfer technologies that we may need to commercialize our ZFP technology. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to regulate or modify a gene in a cell, the ZFP must be efficiently delivered to the cell. We have licensed certain gene transfer
technologies for our ZFP in research. We are evaluating these systems and other technologies that may need to be used in the delivery of ZFP into cells for in vitro and in vivo applications, including ZFP Therapeutics. However, we may not be able to
license the gene transfer technologies required to develop and commercialize our ZFP Therapeutics. We have not developed our own gene transfer technologies, and we rely on our ability to enter into license agreements to provide us with rights to the
necessary gene transfer technology. Our approach has been to license appropriate technology as required. The inability to obtain a license to use gene transfer technologies with entities which own such technology on reasonable commercial terms, if
at all, could delay or prevent the preclinical evaluation, drug development collaborations, clinical testing, and/or commercialization of our therapeutic product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our gene regulation and gene modification technology is relatively new, and if we are unable to use this technology in all our intended
applications, it would limit our revenue opportunities. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our technology involves a relatively new approach to gene regulation and
gene modification. Although we have generated ZFPs for thousands of gene sequences, we have not created ZFPs for all gene sequences and may not be able do so, which could limit the usefulness of our technology. In addition, while we have
demonstrated the function of engineered ZFNs and ZFP TFs in mammalian cells, yeast, insects, plants, and animals, we have not yet demonstrated clinical benefit of this technology in humans, and the failure to do so could restrict our ability to
develop commercially viable products. If we, and our collaborators or strategic partners, are unable to extend our results to new commercially important genes, experimental animal models, and human clinical studies, we may be unable to use our
technology in all its intended applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected value and utility of our ZFNs and ZFP TFs is in part based on our belief that
the targeted modification of genes or specific regulation of gene expression may enable us to develop a new therapeutic approach as well as to help scientists better understand the role of genes in disease, and to aid their efforts in drug discovery
and development. We also believe that ZFP-mediated targeted gene editing and gene regulation will have utility in agricultural applications. There is only a limited understanding of the role of specific genes in all these fields. Life sciences
companies have developed or commercialized only a few products in any of these fields based on results from genomic research or the ability to regulate gene expression. We, our collaborators, or our strategic partners, may not be able to use our
technology to identify and validate drug targets or to develop commercial products in the intended markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective delivery of ZFNs
and ZFP TFs into the appropriate target cells and tissues is critical to the success of the therapeutic applications of our ZFP technology. In order to have a meaningful therapeutic effect, the ZFP Therapeutic must be delivered to sufficient numbers
of cells in the targeted tissue. The ZFN or ZFP TF must be present in that tissue for sufficient time to effect either modification of a therapeutically relevant gene or regulation of its expression. In our current clinical and preclinical programs,
we administer our ZFP Therapeutics as a nucleic acid that encodes the ZFN or ZFP TF. We use different formulations to deliver the ZFP Therapeutic depending on the required duration of expression, the targeted tissue and the indication that we intend
to treat. However, there can be no assurances that we will be able to effectively deliver our ZFNs and ZFP TFs to produce a beneficial therapeutic effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are conducting proprietary research to discover ZFP Therapeutic product candidates.
These programs increase our financial risk of product failure, may significantly increase our research expenditures, and may involve conflicts with future collaborators and strategic partners. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary research programs consist of research which is funded solely by us or by grant funding and in which we retain exclusive rights
to therapeutic products generated by such research. This is in contrast to certain of our research programs that may be funded by corporate partners and in which we may share rights to any resulting products. Conducting proprietary research programs
may not generate corresponding revenue and may create conflicts with our collaborators or strategic partners over rights to our intellectual property with respect to our proprietary research activities. Any conflict with our collaborators or
strategic partners could reduce our ability to enter into future collaborations or partnering agreements and negatively impact our relationship with existing collaborators and partners which could reduce our revenue and delay or terminate our
product development. As we continue to focus our strategy on proprietary research and therapeutic development, we expect to experience greater business risks, expend significantly greater funds and require substantial commitments of time from our
management and staff. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if our technology proves to be effective, it still may not lead to commercially viable products.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if our collaborators or strategic partners are successful in using our ZFP technology in drug discovery, protein production,
therapeutic development, or plant agriculture, they may not be able to commercialize the resulting products or may decide to use other methods competitive with our technology. To date, no company has received marketing approval or has developed or
commercialized any therapeutic or agricultural products based on our technology. Should our technology fail to provide safe, effective, useful, or commercially viable approaches to the discovery and development of these products, this would
significantly limit our business and future growth and would adversely affect our value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if our product development efforts
are successful and even if the requisite regulatory approvals are obtained, our ZFP&nbsp;Therapeutics may not gain market acceptance among physicians, patients, healthcare payers and the medical community. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A number of additional factors may limit the market acceptance of our ZFP Therapeutic products including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">rate of adoption by healthcare practitioners; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">rate of a product&#146;s acceptance by the target population; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">timing of market entry relative to competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability of alternative therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">price of our product relative to alternative therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability of third-party reimbursement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extent of marketing efforts by us and third-party distributors or agents retained by us;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">side effects or unfavorable publicity concerning our products or similar products. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therefore,
even after we have obtained the required regulatory approval for our ZFP Therapeutic products, we may not be able to commercialize these products successfully if we cannot achieve an adequate level of market acceptance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We do not currently have the infrastructure or capability to manufacture, market and sell therapeutic products on a commercial scale.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order for us to commercialize our therapeutic products directly, we would need to develop, or obtain through outsourcing
arrangements, the capability to manufacture, market and sell our products on a commercial scale. Currently we do not have the ability nor the financial resources to establish the infrastructure and organizations needed to execute these functions,
including such infrastructure needed for the commercialization of any product from our HIV/AIDS programs, which can be complex and costly. If we are unable to establish adequate manufacturing, sales, marketing and distribution capabilities, we will
not be able to directly commercialize our therapeutics products, which would limit our future growth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to fully
realize the expected benefits from the acquisition of Ceregene, Inc., and the operation of the new business of Ceregene, Inc. may subject us to additional risks. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;1, we closed the acquisition of Ceregene Inc. (&#147;Ceregene&#148;), including all of its therapeutic programs and related
intellectual property and other assets. Although we expect to realize strategic, operational and financial benefits as a result of the acquisition, we cannot be certain whether, and to what extent, such benefits will be achieved in the future. In
particular, the success of the acquisition will depend on our ability to efficiently and successfully integrate Ceregene&#146;s business, including the prosecution of its CERE-110 Phase 2 clinical trial, and to apply Ceregene&#146;s technology for a
delivery vector based on adeno-associated virus (AAV) to advance our ZFP Therapeutics. There is no guarantee that any existing and future clinical trials of Ceregene&#146;s product candidates, including CERE-110, will produce positive results, and
failure to so may adversely affect our ability to validate the AAV delivery </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technology and apply such technology to our ZFP products as well as negatively impact our stock price. In April 2013, Ceregene reported that its top line data for the CERE-120 Phase 2b clinical
trial for Parkinson&#146;s disease did not demonstrate statistically significant efficacy in the primary endpoint. In addition, even if we obtain positive data from such clinical trials, there is no guarantee that the AAV delivery technology can be
applied to our ZFP Therapeutics safely and effectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The acquisition of Ceregene also subjects us to additional operational and
financial risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional costs that we may need to incur in order to conduct and complete Ceregene&#146;s therapeutic programs, including the CERE-110 Phase 2 clinical trial, and to comply with new regulatory requirements;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties acquiring and developing the necessary expertise to continue the development of AAV technologies and other acquired assets of Ceregene; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in coordinating research and development activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">uncertainties in the business relationships with our collaborators and suppliers due to the acquisition; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in integrating Ceregene&#146;s accounting systems and procedures, including internal control over financial reporting as required by Sarbanes-Oxley Act; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of previous experiences in conducting Phase 2 trials of a gene therapy based on AAV vector delivery system. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the market price of our common stock may decline as a result of the merger if the integration of Ceregene is unsuccessful, takes
longer than expected or fails to achieve the expected benefits to the extent anticipated by financial analysts or investors, or the effect of the acquisition on our financial results is otherwise not consistent with the expectations of financial
analysts or investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to our Industry </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If our competitors develop, acquire, or market technologies or products that are more effective than ours, this would reduce or eliminate
our commercial opportunity. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any products that we or our collaborators or strategic partners develop by using our ZFP technology
platform will enter into highly competitive markets. Even if we are able to generate ZFP Therapeutics that are safe and effective for their intended use, competing technologies may prove to be more effective or less expensive, which, to the extent
these competing technologies achieve market acceptance, will limit our revenue opportunities. In some cases, competing technologies have proven to be effective and less expensive. Competing technologies may include other methods of regulating gene
expression or modifying genes. ZFNs and ZFP TFs have broad application in the life sciences industry and compete with a broad array of new technologies and approaches being applied to genetic research by many companies. Competing proprietary
technologies with our product development focus include but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For ZFP Therapeutics: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">small molecule drugs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">monoclonal antibodies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recombinant proteins; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">gene therapy/cDNAs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">antisense; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">siRNA and microRNA approaches, exon skipping; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">TALE proteins; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Meganucleases. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For our Non-Therapeutic Applications: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>For protein production:</I> gene amplification, meganucleases, TALE technology, insulator technology, mini-chromosomes and CRISPR/Cas9 technology; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>For target validation:</I> antisense, siRNA, TALE technology and CRISPR/Cas9 technology; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>For plant agriculture:</I> recombination approaches, mutagenesis approaches, meganucleases, TALE technology, CRISPR/Cas9 technology, mini-chromosomes; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>For transgenic animals:</I> somatic nuclear transfer, embryonic stem cell, TALE, CRISPR/Cas9 technology and transposase technologies. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to possessing competing technologies, our competitors include pharmaceutical and
biotechnology companies with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantially greater capital resources than ours; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">larger research and development staffs and facilities than ours;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">greater experience in product development and in obtaining regulatory approvals and patent protection. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These organizations also compete with us to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attract qualified personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attract parties for acquisitions, joint ventures or other collaborations;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">license the proprietary technologies of academic and research institutions that are competitive with our technology, which may preclude us from pursuing similar opportunities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, our competitors may succeed in obtaining patent protection or commercializing products before us. In addition, any products that
we develop may compete with existing products or services that are well established in the marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Adverse public perception
in the field of gene therapy may negatively impact regulatory approval of, or demand for, our potential products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our potential
therapeutic products are delivered to patients as gene-based drugs, or gene therapy. The clinical and commercial success of our potential products will depend in part on public acceptance of the use of gene therapy for the prevention or treatment of
human diseases. Public attitudes may be influenced by claims that gene therapy is unsafe, and, consequently, our products may not gain the acceptance of the public or the medical community. Negative public reaction to gene therapy in general could
result in greater government regulation and stricter labeling requirements of gene therapy products, including any of our products, and could cause a decrease in the demand for any products we may develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Laws or public sentiment may limit the production of genetically modified agricultural products, and these laws could reduce our
partner&#146;s ability to sell such products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genetically modified products are currently subject to public debate and heightened
regulatory scrutiny, either of which could prevent or delay production of agricultural products. We have a research license and commercial option agreement with Dow AgroSciences (DAS) through which we provide DAS with access to our proprietary ZFP
technology and the exclusive right to use our ZFP technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. The field-testing, production and marketing of genetically modified
plants and plant products are subject to federal, state, local and foreign governmental regulation. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of our genetically modified
products in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays or other impediments to our product development programs or the
commercialization of resulting products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA currently applies the same regulatory standards to foods developed through genetic
engineering as those applied to foods developed through traditional plant breeding. Genetically engineered food products, however, will be subject to pre-market review if these products raise safety questions or are deemed to be food additives.
Governmental authorities could also, for social or other purposes, limit the use of genetically modified products created with our gene regulation technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the regulatory approval for genetically modified products developed under our agreement with DAS was obtained, our success will also
depend on public acceptance of the use of genetically modified products including drugs, plants, and plant products. Claims that genetically modified products are unsafe for consumption or pose a danger to the environment may influence public
attitudes. Our genetically modified products may not gain public acceptance. The subject of genetically modified organisms has received negative publicity in the United States and particularly in Europe, and such publicity has aroused public debate.
The adverse publicity in Europe could lead to greater regulation and trade restrictions on imports of genetically altered products. Similar adverse public reaction or sentiment in the United States to genetic research and its resulting products
could result in greater domestic regulation and could decrease the demand for our technology and products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to our Finances </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable
future. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have generated operating losses since we began operations in 1995. Our net losses for the years ended
December&nbsp;31, 2012, 2011 and 2010 were $22.3 million, $35.8 million and $24.9 million, respectively. The extent of our future losses and the timing of profitability are uncertain, and we expect to incur losses for the foreseeable future. We have
been engaged in developing our ZFP </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technology since inception, which has and will continue to require significant research and development expenditures. To date, we have generated our funding from issuance of equity securities,
revenues derived from strategic partnering agreements, other collaborations in non-therapeutic applications of our technology, federal government research grants and grants awarded by research foundations. As of September&nbsp;30, 2013, we had an
accumulated deficit of $294.0 million. From 2005 to date, we have generated an aggregate of approximately $226.7 million in net proceeds from the sale of our equity securities. We expect to continue to incur additional operating losses for the next
several years as we continue to expand and extend our research and development activities into human therapeutic product development. If the time required to generate significant product revenues and achieve profitability is longer than we currently
anticipate or if we are unable to generate liquidity through equity financing or other sources of funding, we may be forced to curtail or suspend our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to raise additional capital, which would harm our ability to develop our technology and products. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred significant operating losses and negative operating cash flows since inception and have not achieved profitability. We expect
capital outlays and operating expenditures to increase over the next several years as we expand our infrastructure and research and ZFP Therapeutic product development activities. While we believe our financial resources will be adequate to sustain
our current operations at least through 2014, we may need to seek additional sources of capital through equity or debt financing. In addition, as we focus our efforts on proprietary human therapeutics, we will need to seek FDA approval of potential
products, a process that could cost in excess of hundreds of millions of dollars per product. Furthermore, we may experience difficulties in accessing the capital market due to external factors beyond our control such as volatility in the equity
markets for emerging biotechnology companies and general economic and market conditions. We cannot be certain that we will be able to obtain financing on terms acceptable to us, or at all. Our failure to obtain adequate and timely funding will
materially adversely affect our business and our ability to develop our technology and ZFP Therapeutic products. Furthermore, any sales of additional equity securities may result in dilutions to our stockholders and any debt financing may include
business and financial covenants that restricts our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are at the development phase of operations and may not succeed
or become profitable. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We began operations in 1995 and are in the early phases of ZFP Therapeutic product development, and we have
incurred significant losses since inception. To date, our revenues have been generated from strategic partners, other collaborations in non-therapeutic applications of our technology, and federal government and research foundation grants. Our focus
on higher-value therapeutic product development and related strategic partnerships requires us to incur substantial expenses associated with product development. In addition, the preclinical or clinical failure of any single product may have a
significant effect on the actual or perceived value of our stock. Our business is subject to all of the risks inherent in the development of a new technology, which includes the need to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attract and retain qualified scientific and technical staff and management, particularly scientific staff with expertise to develop our early-stage technology into therapeutic products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain sufficient capital to support the expense of developing our technology platform and developing, testing and commercializing products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop a market for our products; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successfully transition from a company with a research focus to a company capable of supporting commercial activities. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to our Relationships with Collaborators and Strategic Partners </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If conflicts arise between us and our collaborators or strategic partners, these parties may act in their self-interest, which may limit
our ability to implement our strategies. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If conflicts arise between our corporate or academic collaborators or strategic partners
and us, the other party may act in its self-interest, which may limit our ability to implement our strategies. Some of our academic collaborators and strategic partners are conducting multiple product development efforts within each area that is the
subject of the collaboration with us. Our collaborators or strategic partners, however, may develop, either alone or with others, products in related fields that are competitive with the products or potential products that are the subject of these
collaborations. Competing products, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of partner support for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our collaborators or strategic partners could also become our competitors in the future. Our collaborators or strategic partners could
develop competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely, or fail to devote sufficient resources to the development
and commercialization of products. Any of these developments could harm our product development efforts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our collaborators and strategic partners may control aspects of our clinical trials, which
could result in delays and other obstacles in the commercialization of our proposed products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For some programs, we depend on
third party collaborators and strategic partners to design and conduct our clinical trials. As a result, we may not be able to conduct these programs in the manner or on the time schedule we currently contemplate, which may negatively impact our
business operations. In addition, if any of these collaborators or strategic partners withdraws support for our programs or proposed products or otherwise impair their development; our business could be negatively affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January&nbsp;2012, we entered into a research and collaborative agreement with Shire AG (Shire), pursuant to which we are engaging in a
joint program with Shire to research, develop and commercialize human therapeutics and diagnostics for hemophilia, Huntington&#146;s disease and other monogenic diseases based on our ZFP technology. Under this agreement, we are responsible for all
research activities through the submission of an IND or European Clinical Trial Application (CTA), while Shire is responsible for clinical development and commercialization of products generated from the research program from and after the
acceptance of an IND or CTA for the product. Under the agreement, we may be eligible to receive milestone payments upon the achievement of specified clinical development, commercialization and post-commercialization milestones. The total amount of
potential milestone payments for each gene target, assuming the achievements of all specified milestones in the agreement, is $213.5 million. We may receive royalty payments based on specified percentages of net sales of products, if any. Once an
IND or CTA is submitted, Shire will have control and broad discretion over all aspects of the clinical development and commercialization of any product developed under the program, and we will have little, if any, influence on how such programs will
be conducted. Our lack of control over the clinical development of gene targets in our agreement with Shire could cause delays or other difficulties in the development and commercialization of our product candidates, which may prevent us from
receiving any milestone, royalty payments and other benefits under the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our collaborators or strategic partners may
decide to adopt alternative technologies or may be unable to develop commercially viable products with our technology, which would negatively impact our revenues and our strategy to develop these products. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our collaborators or strategic partners may adopt alternative technologies, which could decrease the marketability of ZFP&nbsp;technology.
Additionally, because many of our collaborators or strategic partners are likely to be working on more than one development project, they could choose to shift their resources to projects other than those they are working on with us. If they do so,
this would delay our ability to test our technology and would delay or terminate the development of potential products based on our ZFP technology. Further, our collaborators and strategic partners may elect not to develop products arising out of
our collaborative and strategic partnering arrangements or to devote sufficient resources to the development, manufacturing, marketing or sale of these products. If any of these events occur, we may not be able to develop our technologies or
commercialize our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we do not successfully commercialize ZFP-based research reagents, ZFP-modified cell lines for
commercial protein production, or ZFP-engineered transgenic animals under our license agreement with Sigma-Aldrich Corporation or ZFP-based agricultural products with Dow AgroSciences, or if Sigma or Dow AgroSciences terminates our agreements, our
ability to generate revenue under these license agreements may be limited. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July&nbsp;2007, we entered into a license agreement
with Sigma to collaborate in the application and development of ZFP-based products for use in the laboratory research reagents markets. The agreement provides Sigma with access to our ZFP&nbsp;technology and the exclusive right to use our ZFP
technology to develop and commercialize products for use as research reagents and to offer services in related research fields. This relationship was expanded in October 2009 when we amended our license agreement with Sigma to provide Sigma with the
exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and, certain ZFP-engineered transgenic animals for commercial applications. In June 2008, following a research period, Dow
AgroSciences (DAS) exercised its commercial license option under a license agreement with us relating to plant agriculture. This agreement provides DAS with the exclusive right to develop agricultural products using our ZFP technology in plant
cells, plants, or plant cell cultures. Both companies also have the right to sublicense our technology in their respective areas. In addition to upfront payments, we may also receive additional license fees, shared sublicensing revenues, royalty
payments and milestone payments depending on the success of the development and commercialization of the licensed products and services covered under both agreements. The commercial milestones and royalties are typically based upon net sales of
licensed products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that we or our collaboration partners will succeed in the development of commercially viable
products in these fields of use, and there is no guarantee that we or our collaboration partners will achieve the milestones set forth in the respective license agreements. To the extent we or our collaboration partners do not succeed in developing
and commercializing products or if we or our collaboration partners fail to achieve such milestones, our revenues and benefits under the license agreements will be limited. In addition, the respective license agreements may be terminated by Sigma
and DAS at any time by providing us with a 90-day notice. In the event Sigma or DAS decides to terminate the license agreements, our ability to generate revenue under such license agreements will cease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our collaborations with outside scientists may be subject to change, which could limit our
access to their expertise. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We work with scientific advisors and collaborators at academic research institutions. These scientists
are not our employees and may have other commitments that would limit their availability to us. Although our scientific advisors generally agree not to do competing work, if a conflict of interest between their work for us and their work for another
entity arises, we may lose their services. Although our scientific advisors and academic collaborators sign agreements not to disclose our confidential information, it is possible that some of our valuable proprietary knowledge may become publicly
known through them, which may cause competitive harm to our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to our Intellectual Property and Business Operation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Because it is difficult and costly to protect our proprietary rights, and third parties have filed patent applications that are similar
to ours, we cannot ensure the proprietary protection of our technologies and products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success will depend in part
on obtaining patent protection of our technology and successfully defending any of our patents that may be challenged. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and can involve complex legal and
factual questions. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date. Accordingly, we cannot predict the breadth of claims allowed in patents we own or license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to various license agreements that give us rights under specified patents and patent applications. Our current licenses, as our
future licenses frequently will, contain performance obligations. If we fail to meet those obligations, the licenses could be terminated. If we are unable to continue to license these technologies on commercially reasonable terms, or at all, we may
be forced to delay or terminate our product development and research activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to our present and any future sublicenses,
since our rights derive from those granted to our sublicensor, we are subject to the risk that our sublicensor may fail to perform its obligations under the master&nbsp;license or fail to inform us of useful improvements in, or additions to, the
underlying intellectual property owned by the original licensor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are unable to exercise the same degree of control over intellectual
property that we license from third parties as we exercise over our internally developed intellectual property. We do not control the prosecution of certain of the patent applications that we license from third parties; therefore, the patent
applications may not be prosecuted as we desire or in a timely manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection for our proprietary rights is
uncertain, and we cannot ensure that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our licensors were the first to make the inventions covered by each of our pending patent applications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our licensors were the first to file patent applications for these inventions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the patents of others will not have an adverse effect on our ability to do business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others will not independently develop similar or alternative technologies or reverse engineer any of our products, processes or technologies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any of our pending patent applications will result in issued patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any patents issued or licensed to us or our collaborators or strategic partners will provide a basis for commercially viable products or will provide us with any competitive advantages; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any patents issued or licensed to us will not be challenged and invalidated by third parties;&nbsp;or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we will develop additional products, processes or technologies that are patentable. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Others
have filed and in the future are likely to file patent applications that are similar to ours. We are aware that there are academic groups and other companies that are attempting to develop technology that is based on the use of zinc finger, TALE and
other DNA-binding proteins, and that these groups and companies have filed patent applications. Several patents have been issued, although we have no current plans to use the associated inventions. If these or other patents issue, it is possible
that the holder of any patent or patents granted on these applications may bring an infringement action against our collaborators, strategic partners, or us claiming damages and seeking to enjoin commercial activities relating to the affected
products and processes. The costs of litigating the claim could be substantial. Moreover, we cannot predict whether we, our collaborators, or strategic partners would prevail in any actions. In addition, if the relevant patent claims were upheld as
valid and enforceable and our products or processes were found to infringe the patent or patents, we could be prevented from making, using, or selling the relevant product or process unless we could obtain a license or were able to design around the
patent claims. We can give no assurance that such a license would be available on commercially reasonable terms, or at all, or that we would be able to successfully design around the relevant patent claims. There may be significant litigation in the
genomics industry regarding patent and other intellectual property rights, which could subject us to litigation. If we become involved in litigation, it could consume a substantial portion of our managerial and financial resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trade secrets to protect technology where we believe patent protection is not appropriate or obtainable. Trade secrets, however,
are difficult to protect. While we require employees, academic collaborators and consultants to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other proprietary information or enforce these
confidentiality agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our collaborators, strategic partners, and scientific advisors have rights to publish data and
information in which we may have rights. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborations and strategic partnerships, then we may not be able to receive patent
protection or protect our proprietary information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we use biological and hazardous materials in a manner that causes injury or
violates laws, we may be liable for damages. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development activities involve the controlled use of potentially
harmful biological materials as well as hazardous materials, chemicals, and various radioactive compounds typically employed in molecular and cellular biology. We routinely use cells in culture and gene delivery vectors, and we employ small amounts
of radioisotopes in trace experiments. Although we maintain up-to-date licensing and training programs, we cannot completely eliminate the risk of accidental contamination or injury from the use, storage, handling, or disposal of these materials. In
the event of contamination or injury, we could be held liable for damages that result, and any liability could exceed our resources. We currently carry insurance covering certain claims arising from our use of these materials. However, if we are
unable to maintain our insurance coverage at a reasonable cost and with adequate coverage, our insurance may not cover any liability that may arise. We are subject to federal, state, and local laws and regulations governing the use, storage,
handling, and disposal of these materials and specified waste products. To date, we have not experienced significant costs in complying with regulations regarding the use of these materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Failure to attract, retain, and motivate skilled personnel and cultivate key academic collaborations will delay our product development
programs and our research and development efforts. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends on our continued ability to attract, retain, and motivate
highly qualified management and scientific personnel and our ability to develop and maintain important relationships with leading research and academic institutions and scientists. Competition for personnel and academic and other research
collaborations is intense. We have experienced a rate of employee turnover that we believe is typical of emerging biotechnology companies. If we lose the services of personnel with the necessary skills, it could significantly impede the achievement
of our research and development objectives. If we fail to negotiate additional acceptable collaborations with academic and other research institutions and scientists, or if our existing collaborations are unsuccessful, our ZFP Therapeutic
development programs may be delayed or may not succeed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to our Common Stock and Corporate Organization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our stock price has been volatile and may continue to be volatile, which could result in substantial losses for investors. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three months ended September&nbsp;30, 2013, the closing price our common stock price, as reported by the NASDAQ Global Select
Market, ranged from a low of $7.92 to high of $11.28. During the fiscal year ended December&nbsp;31, 2012, our common stock price fluctuated, ranging from a low of $2.95 to a high of $6.49. Volatility in our common stock could cause stockholders to
incur substantial losses. An active public market for our common stock may not be sustained, and the market price of our common stock may continue to be highly volatile. The market price of our common stock has fluctuated significantly in response
to various factors, some of which are beyond our control, including but not limited to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us or collaborators providing updates on the progress or development status of ZFP Therapeutics; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">data from clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiation or termination of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in market valuations of similar companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overall market and economic conditions including the equity markets for emerging biotechnology companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">deviations in our results of operations from the guidance given by us or changes in recommendation, estimate or coverage by securities analysts; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us or our competitors of new or enhanced products, technologies or services or significant contracts, mergers or acquisitions, strategic relationships, joint ventures or capital commitments;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions or departures of key personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">future sales of our common stock or other securities by us, management, employees or directors, liquidation of institutional funds that comprised large holdings of our stock;&nbsp;and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in our cash balances. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our stock price is also influenced by public perception of gene therapy and government
regulation of potential products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reports of serious adverse events in a retroviral gene transfer trial for infants with X-linked
severe combined immunodeficiency (X-linked SCID) in France and subsequent FDA actions putting related trials on hold in the United States had a significant negative impact on the public perception and stock price of certain companies involved in
gene therapy. Stock prices of these companies declined whether or not the specific company was involved with retroviral gene transfer for the treatment of infants with X-linked SCID, or whether the specific company&#146;s clinical trials were placed
on hold in connection with these events. Other potential adverse events in the field of gene therapy may occur in the future that could result in greater governmental regulation of our potential products and potential regulatory delays relating to
the testing or approval of our potential products. These external events may have a negative impact on public perception of our business, which could cause our stock price to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If securities and/or industry analysts fail to continue publishing research about our business, if they change their recommendations
adversely or if our results of operations do not meet their expectations, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of these analysts cease coverage of our company or fail to publish reports on us
regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. In addition, it is likely that in some future period our operating results will be below the expectations of
securities analysts or investors. If one or more of the analysts who cover us downgrade our stock, or if our results of operations do not meet their expectations, our stock price could decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our certificate of incorporation and Delaware law could make an acquisition of the Company more difficult
and could prevent attempts by our stockholders to remove or replace current management. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Anti-takeover provisions of Delaware law
and in our certificate of incorporation and our bylaws may discourage, delay or prevent a change in control of our company, even if a change in control would be beneficial to our stockholders. In addition, these provisions may frustrate or prevent
any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. In particular, under our certificate of incorporation our board of directors may
issue up to 5,000,000&nbsp;shares of preferred stock with rights and privileges that might be senior to our common stock, without the consent of the holders of the common stock. Moreover, without any further vote or action on the part of the
stockholders, the board of directors would have the authority to determine the price, rights, preferences, privileges, and restrictions of the preferred stock. This preferred stock, if it is ever issued, may have preference over, and harm the rights
of, the holders of common stock. Although the issuance of this preferred stock would provide us with flexibility in connection with possible acquisitions and other corporate purposes, this issuance may make it more difficult for a third party to
acquire a majority of our outstanding voting stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, our authorized but unissued common stock is available for future issuance
without stockholder approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our bylaws: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">state that stockholders may not act by written consent but only at a stockholders&#146; meeting; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish advance notice requirements for nominations for election to the board of directors or proposing matters that can be acted upon at stockholders&#146; meetings;&nbsp;and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prohibit stockholders from calling a special meeting of stockholders. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx595389_12"></A>ITEM&nbsp;6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>EXHIBITS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Exhibits: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;2.1&#134;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Agreement and Plan of Merger, dated August&nbsp;26, 2013, by and among the Company, CG Acquisition Sub, Inc., and Ceregene, Inc. and the Stockholders&#146; Representative (incorporated by reference to Exhibit 2.1 to Current Report
on Form 8-K filed on October&nbsp;7, 2013)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Second Amendment to Triple Net Laboratory Lease, between the Company and Point Richmond R&amp;D Associates II, LLC, dated March 15, 2007</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.2</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Third Amendment to Triple Net Laboratory Lease, between the Company and Point Richmond R&amp;D Associates II, LLC, dated August 1, 2013</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Rule 13a &#151; 14(a) Certification by President and Chief Executive Officer</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Rule 13a &#151; 14(a) Certification by Principal Financial and Accounting Officer</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Certification Pursuant to 18 U.S.C. Section 1350</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"><I>Confidential treatment has been requested for certain information contained in this document. Such information has been omitted and filed separately with the Securities and Exchange Commission.</I> </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx595389_13"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: November&nbsp;4, 2013 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SANGAMO BIOSCIENCES, INC.</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp; H. W<SMALL>ARD</SMALL>
W<SMALL>OLFF</SMALL></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>H. Ward Wolff</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Executive&nbsp;Vice&nbsp;President&nbsp;and&nbsp;Chief&nbsp;Financial Officer</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Principal Financial and Accounting Officer)</B></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d595389dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SECOND AMENDMENT TO LEASE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS SECOND AMENDMENT TO LEASE (&#147;Second Amendment&#148;) is entered into as of March&nbsp;15, 2007 (the &#147;Effective Date&#148;), by
and between POINT RICHMOND R&amp;D ASSOCIATES II, LLC, a California limited liability company (&#147;Landlord&#148;), and SANGAMO BIOSCIENCES, INC., a Delaware corporation (&#147;Tenant&#148;), with reference to the following facts: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Landlord and Tenant entered into that certain Triple Net Laboratory Lease dated as of May&nbsp;23, 1997, together with an Addendum thereto
dated May&nbsp;28, 1997 (the &#147;Original Lease&#148;), as amended by those certain letter agreements dated June&nbsp;15, 1999,&nbsp;April&nbsp;21, 2000 and November&nbsp;3, 2000 and by that certain First Amendment to Lease dated March&nbsp;12,
2004 (the &#147;First Amendment&#148;) (the Original Lease, as so amended, is referred to herein as the &#147;Lease&#148;), pursuant to which Landlord leased to Tenant certain premises consisting of approximately 21,860 rentable square feet
(&#147;Original Premises&#148;) in the building located at 501 Canal Boulevard, Point Richmond, California (the &#147;Building&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B.
Tenant has requested that additional space containing approximately 4,769 rentable square feet shown on Exhibit A hereto (the &#147;Expansion Space&#148;) and commonly known as Suite C of the Building be added to the Original Premises and that the
Lease be appropriately amended and Landlord is willing to do the same on the following terms and conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in
consideration of the foregoing, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Landlord and Tenant hereby agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Incorporation of Recitals and Defined Terms</U>. Recitals A and B above are hereby incorporated herein. Capitalized terms which are not
otherwise defined in this Second Amendment shall have the meanings set forth in the Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Expansion</U>. Effective as of the date
(anticipated to be on or about April&nbsp;16, 2007) that the current tenant in the Expansion Space is completely relocated to another suite in the Building (the &#147;Expansion Effective Date&#148;), the Premises, as defined in the Lease, is
increased from 21,860 rentable square feet to 26,629 rentable square feet by the addition of the Expansion Space, and from and after the Expansion Effective Date, the Original Premises and the Expansion Space, collectively, shall be deemed the
Premises, as defined in the Lease. The term for the Expansion Space shall commence on the Expansion Effective Date and end on the Extended Expiration Date. The Expansion Space is subject to all the terms and conditions of the Lease except as
expressly modified herein and except that Tenant shall not be entitled to receive any allowances, abatements or other financial concessions granted with respect to the Premises unless such concessions are expressly provided for herein with respect
to the Expansion Space. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Relocation of Existing Tenant</U>. Landlord confirms that relocation of the current tenant in the Expansion
Space shall be completed at Landlord&#146;s sole cost and expense. Any Landlord owned furniture, fittings and equipment located in the Expansion Space may be removed prior to the Expansion Effective Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Base Monthly Rent</U>. In addition to Tenant&#146;s obligation to pay Base Monthly Rent for
the Premises, Tenant shall pay Landlord Base Monthly Rent for the Expansion Space as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:31.15pt; font-size:8pt; font-family:Times New Roman"><B>PERIOD</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>APPROXIMATE</B><br><B>MONTHLY&nbsp;RATE</B><br><B>PER&nbsp;SQUARE&nbsp;FOOT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BASE<BR>MONTHLY&nbsp;RENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expansion Effective Date &#151; August&nbsp;31, 2007</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;1, 2007&#151;August&nbsp;31, 2008</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;1, 2008&#151;August&nbsp;31, 2009</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;1, 2009&#151;August&nbsp;31, 2010</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;1, 2010&#151;August&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;1, 2011&#151;August&nbsp;31 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;1, 2012&#151;August&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;1, 2013&#151;August&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Tenant&#146;s Pro Rata Share</U>. For the period commencing with the Expansion Effective Date and ending
on the Extended Expiration Date, the calculation of Tenant&#146;s Pro Rata Share for the Premises shall include the rentable square footage of the Expansion Space. Such Share is estimated to be 32.62% of 501 Canal Boulevard. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Operating Expenses</U>. For the period commencing with the Expansion Effective Date and ending on the Extended Expiration Date, Tenant
shall pay for Tenant&#146;s Pro Rata Share of Operating Expenses applicable to the Expansion Space in accordance with the terms of the Lease; provided, however, that the cap on Tenant&#146;s Pro Rata Share of Operating Expenses in Section&nbsp;6 of
the First Amendment shall not apply to the increase in Tenant&#146;s Pro Rata Share due to the addition of the Expansion Space to the Premises. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Condition of Expansion Space</U>. Tenant agrees to accept the Expansion Space &#147;as is&#148; without any agreements, representations,
understandings or obligations on the part of Landlord to perform any alterations, repairs or improvements, except as set forth. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.
<U>Tenant Improvement Allowance</U>. From and after the Expansion Effective Date, the Extension Term Allowances for the periods September&nbsp;1, 2008 to August&nbsp;31, 2009,&nbsp;September&nbsp;1, 2009 to August&nbsp;31, 2010 and September&nbsp;1,
2010 to August&nbsp;31, 2011 are hereby amended to $0 per year. There shall be no Tenant Improvement Allowance associated with the Expansion Space. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Accelerated Expiration</U>. Landlord and Tenant hereby confirm that Tenant&#146;s Acceleration Option shall apply to the Expansion Space.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Deleted Provision</U>. The right of first refusal contained in Section&nbsp;9 of the First Amendment with respect to Suite C is
hereby deleted in its entirety and is of no further force or effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Brokers</U>. Tenant shall indemnify, defend and hold Landlord harmless from and against
any and all claims by any real estate broker, salesperson or finder claiming to have represented Tenant for a commission, finder&#146;s fee or other compensation in connection with this Second Amendment. Notwithstanding anything to the contrary
contained in this Section&nbsp;11, Tenant shall be solely responsible for any commission, fees or costs payable to any real estate broker, sales person or finder claiming to have represented Tenant in connection with any future amendment to the
Lease or Tenant&#146;s exercise of any extension option or right of first refusal contained in the Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Authority</U>. This
Second Amendment shall be binding upon and inure to the benefit of the parties, their respective heirs, legal representatives, successors and assigns. Each party hereto and the persons signing below warrant that the person signing below on such
party&#146;s behalf is authorized to do so and to bind such party to the terms of this Second Amendment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Status of Lease</U>.
Except as amended hereby, the Lease is unchanged, and, as amended hereby, the Lease remains in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF,
Landlord and Tenant have entered into this Second Amendment as of the date first set forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">TENANT:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5">LANDLORD:</TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SANGAMO BIOSCIENCES, INC.,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a
Delaware corporation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">POINT&nbsp;RICHMOND&nbsp;R&amp;D&nbsp;ASSOCIATES&nbsp;II,&nbsp;LLC,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a California limited liability company</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Edward O. Lanphier II</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Richard K. Robin</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Print&nbsp;Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Edward O. Lanphier II</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Print&nbsp;Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Richard K. Robin</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">President and Chief Executive Officer</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">Managing Member</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>OUTLINE AND LOCATION OF EXPANSION SPACE </U></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>POINT RICHMOND TECH CENTER II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">501 CANAL BOULEVARD, RICHMOND, SUITE C </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>+</U>4,769 SQUARE FEET
AVAILABLE </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g595389g50d01.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d595389dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THIRD AMENDMENT TO LEASE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS THIRD AMENDMENT TO LEASE (&#147;Third Amendment&#148;) is entered into as of August&nbsp;1, 2013 (the &#147;Effective Date&#148;), by and
between POINT RICHMOND R&amp;D ASSOCIATES II, LLC, a California limited liability company (&#147;Landlord&#148;), and SANGAMO BIOSCIENCES, INC., a Delaware corporation (&#147;Tenant&#148;), with reference to the following facts: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Landlord and Tenant entered into that certain Triple Net Laboratory Lease dated as of May&nbsp;23, 1997, together with an Addendum thereto
dated May&nbsp;28, 1997 (the &#147;Original Lease&#148;), as amended by those certain letter agreements dated June&nbsp;15, 1999,&nbsp;April&nbsp;21, 2000 and November&nbsp;3, 2000 and by that certain First Amendment to Lease dated March&nbsp;12,
2004 (the &#147;First Amendment&#148;) and by that certain Second Amendment to Lease dated March&nbsp;15, 2007 (the &#147;Second Amendment&#148;) (the Original Lease, as so amended, is referred to herein as the &#147;Lease&#148;), pursuant to which
Landlord leased to Tenant certain premises consisting of approximately 26,629 rentable square feet (&#147;Premises&#148;) in the building located at 501 Canal Boulevard, Point Richmond, California (the &#147;Building&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Tenant has exercised the first Extension Option as set forth in Section&nbsp;8(a) of the First Amendment, and Landlord and Tenant have
agreed on the terms respecting the Option Term. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. Landlord and Tenant now wish to enter into this Third Amendment to memorialize the
terms respecting the first Option Term, to grant Tenant an additional extension option, and otherwise amend the Lease subject to and in accordance with the following terms and conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and adequacy of which are hereby
acknowledged, Landlord and Tenant hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Incorporation of Recitals and Defined Terms</U>. The Recitals above are
hereby incorporated herein. Capitalized terms which are not otherwise defined in this Third Amendment shall have the meanings set forth in the Lease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Additional Extension Option</U>. The first sentence of Section&nbsp;8(a) of the First Amendment is hereby amended and restated in its
entirety as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Landlord hereby grants Tenant options to extend the Extended Term (each, an &#147;Extension Option&#148;) for
three (3)&nbsp;additional periods of five (5)&nbsp;years each (each, an &#147;Option Term&#148;), commencing immediately after the expiration of the Extended Term, in the case of the first Extension Option, the expiration of the first Option Term,
in the case of the Second Extension Option, or the expiration of the second Option Term, in the case of the third Extension Option.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Exercise of Extension Option / Lease Term</U>. Landlord and Tenant acknowledge that Tenant has exercised the first of three Extension
Options pursuant to Section&nbsp;8(a) of the First Amendment (as amended herein). Accordingly, the term of the Lease is hereby extended for a period of five (5)&nbsp;years and shall expire on August&nbsp;31, 2019. The portion of the term from
September&nbsp;1, 2014 through August&nbsp;31, 2019 shall be referred to herein as the &#147;first Option Term.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Base Monthly Rent</U>. The schedule of Base Monthly Rent payable with respect to the
Premises during the first Option Term is the following:: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:31.15pt; font-size:8pt; font-family:Times New Roman"><B>PERIOD</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>APPROXIMATE<BR>MONTHLY&nbsp;RATE</B><br><B>PER&nbsp;SQUARE&nbsp;FOOT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BASE</B><br><B>MONTHLY&nbsp;RENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;1, 2014&#151;August&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,122.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;1, 2015&#151;August&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56,775.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;1, 2016&#151;August&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58,478.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;1, 2017&#151;August&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,233.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;1, 2018&#151;August&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,040.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Operating Expenses</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) During the first Option Period, Tenant shall pay for Tenant&#146;s Pro Rata Share of Operating Expenses in accordance with the terms of the
Lease, including without limitation, the cap on Tenant&#146;s Pro Rata Share of Operating Expenses as set forth in Section&nbsp;6 of the First Amendment (which by its terms, as modified by Section&nbsp;6 of the Second Amendment, applies only to the
Original Premises (as defined in the Second Amendment) and does not apply to the Expansion Space (as defined in the Second Amendment) (the &#147;Original Premises CAM Cap&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) In addition to the Original Premises CAM Cap, during the first Option Term, Tenant&#146;s Pro Rata Share of Operating Expenses attributable
to the Expansion Space shall not increase by more than 5%&nbsp;per calendar year on a compounding and cumulative basis throughout the first Option Term, prorated and adjusted for any partial years (e.g. Tenant&#146;s Pro Rata Share of Operating
Expenses for 2015 shall not exceed 105% of Tenant&#146;s Pro Rata Share of Operating Expenses for 2014; Tenant&#146;s Pro Rata Share of Operating Expenses for 2016 shall not exceed 105% of the maximum allowable amount of Tenant&#146;s Pro Rata Share
of Operating Expenses permitted for 2015; etc.). If Tenant exercises one or more of the remaining Extension Option(s) provided in Section&nbsp;8 of the First Amendment, then Tenant&#146;s Pro Rata Share of Operating Expenses during each Option Term
shall be subject to the foregoing 5%&nbsp;per annum cap, with the cap on Tenant&#146;s Pro Rata Share of Operating Expenses for the first calendar year during each Option Term to be 5% in excess of the maximum allowable amount of Tenant&#146;s Pro
Rata Share of Operating Expenses permitted for the calendar year immediately preceding the first calendar year of the applicable Option Term; provided, however, Landlord shall have the right, by written notice delivered to Tenant no later than sixty
(60)&nbsp;days prior to the commencement date of the applicable Option Term, to designate that the cap on Tenant&#146;s Pro </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Rata Share of Operating Expenses for the first calendar year during such Option Term shall instead be 5% in excess of the actual Tenant&#146;s Pro Rata Share of Operating Expenses for the
calendar year immediately preceding the first calendar year of such Option Term. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Landlord Improvements / Condition of Expansion
Space</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Tenant acknowledges that it has been, and continues to be, in possession of the Premises, is familiar with the condition of
the Premises and continues to occupy the Premises in its &#147;as is, where is&#148; condition, with all faults, without any representation, warranty or improvement by Landlord of any kind whatsoever, except as expressly provided in
Section&nbsp;5(b) below or in the Lease. As of the Effective Date, Landlord has not caused the Premises to have undergone an inspection by a Certified Access Specialist (CASp). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Landlord shall cause the following improvements to be constructed at the Property: (i)&nbsp;add Building exterior lighting on the south and
west exterior walls of the Premises, (ii)&nbsp;relocate the exterior light below the canopy on the east exterior of the Premises to be raised above the canopy, (iii)&nbsp;increase the number of security cameras at the Property and strategically
locate the new cameras to improve overall camera coverage of the Property, (iv)&nbsp;add signage around the perimeter of the Property warning that the site is patrolled by security guards and subject to video surveillance, (v)&nbsp;add color to the
landscape beds at the main suite entry and on the south and east sides of the Premises, and (vi)&nbsp;slurry seal and re-stripe the parking lot on the east side of the Building from the main Canal Boulevard entry all the way to the entrance to Suite
E (collectively, the &#147;Landlord Improvements&#148;). The type and quality of the Landlord Improvements shall be typical of standard improvements constructed by Landlord which are of the nature and quality required by specifications developed for
the Building by Landlord. The parties anticipate the Landlord Improvements to be substantially completed on or about November&nbsp;1, 2013 (the &#147;Anticipated Completion Date&#148;). If for any reason whatsoever, Landlord cannot substantially
complete the Landlord Improvements by the Anticipated Completion Date, this Amendment shall not be void or voidable, nor shall Landlord be liable to Tenant for any loss or damage resulting therefrom. However, in such event, Landlord shall provide
Tenant with notice of such delayed completion and shall continue with commercially reasonable diligence to substantially complete the Landlord Improvements as soon as practical. Notwithstanding anything in the Lease to the contrary, the cost of the
Landlord Improvements shall not be billed to Tenant, as part of Operating Expenses or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Extended Term Allowance</U>. In
accordance with the terms of Section&nbsp;7 of the First Amendment (as subsequently modified by Section&nbsp;8 of the Second Amendment), Tenant is entitled to an Extended Term Allowance in the amount of $43,720.00 per year i.e. each 12 month period
from September&nbsp;1, 2011 through August&nbsp;31, 2014) which may be used by Tenant toward the cost of performing Alterations in the Premises in accordance with the terms and conditions of Section&nbsp;7.3 of the Original Lease (the &#147;Extended
Term Alterations&#148;). Notwithstanding the provisions of Section&nbsp;7(a) of the First Amendment, any portion of the Extended Term Allowance that is not claimed by Tenant prior to August&nbsp;31, 2014, shall be added to the first Option Term
Allowance (as defined in Section&nbsp;7 below) and shall be available to Tenant during the subsequent years. Any portion of the Extended Term Allowance that is not claimed by Tenant prior to August&nbsp;31, 2019, shall accrue to the sole benefit of
Landlord, and Tenant shall not be entitled to any credit, abatement or other concession in connection therewith (unless Tenant exercises the second Option Term pursuant to Section&nbsp;8(a) of the First Amendment, in which event such August&nbsp;31,
2019 date shall be revised to August&nbsp;31, 2024). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>First Option Term Allowance</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) During the first Option Term, Landlord agrees to contribute the sum of $46,600.75 per year (collectively, the &#147;first Option Term
Allowance&#148;) for each year during the first Option Term i.e. each 12 month period from September&nbsp;1 through August&nbsp;31 during the first Option Term) toward Tenant&#146;s cost of performing Alterations in the Premises or improvements to
the infrastructure servicing the Premises (e.g. HVAC equipment, vacuum pumps, etc.) as performed in accordance with the terms and conditions of Section&nbsp;7.3 of the Original Lease (the &#147;first Option Term Alterations&#148;). The first annual
increment of the first Option Term Allowance shall be available to Tenant on and after September&nbsp;1, 2014, and each subsequent annual increment of the first Option Term Allowance shall be available to Tenant on and after each September&nbsp;1
thereafter through August&nbsp;31, 2019. If Tenant does not submit a request for full payment of any annual increment of the first Option Term Allowance to Landlord for any year in which such annual increment of the first Option Term Allowance is
available, such unused amount shall be added to the increment of the first Option Term Allowance available to Tenant during the subsequent years. Any portion of the first Option Term Allowance that is not claimed by Tenant prior to August&nbsp;31,
2019, shall accrue to the sole benefit of Landlord, and Tenant shall not be entitled to any credit, abatement or other concession in connection therewith (unless Tenant exercises the second Option Term pursuant to Section&nbsp;8(a) of the First
Amendment, in which event such August&nbsp;31, 2019 date shall be revised to August&nbsp;31, 2024). The first Option Term Allowance may only be used for hard and/or soft costs in connection with the first Option Term Alterations; and in no event
shall the first Option Term Allowance be used for the purchase of equipment, furniture or other items of personal property of Tenant. Tenant shall be responsible for all elements of the design of Tenant&#146;s plans for the first Option Term
Alterations (including, without limitation, compliance with law, functionality of design and the structural integrity of the design), and Landlord&#146;s approval of Tenant&#146;s plans therefor shall in no event relieve Tenant of the responsibility
for such design. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The first Option Term Allowance shall be paid to Tenant or, at Landlord&#146;s option, to the order of the contractor
that performed the applicable first Option Term Alterations, within thirty (30)&nbsp;days following receipt by Landlord of receipted bills or invoices covering all labor and materials expended and used in such first Option Term Alterations.
Notwithstanding anything herein to the contrary, Landlord shall not be obligated to disburse any portion of the first Option Term Allowance during the continuance of a default by Tenant under the Lease (beyond the expiration of all applicable cure
and notice periods), and Landlord&#146;s obligation to disburse shall only resume when and if such default is cured. Landlord and Tenant acknowledge that all first Option Term Alterations shall, without compensation or credit to Tenant, become part
of the Premises and the property of Landlord at the time of their installation and shall remain in the Premises, unless, at the time of Landlord&#146;s consent to the applicable first Option Term Alterations, Landlord notified Tenant in writing that
Landlord would require removal of such first Option Term Alterations from the Premises upon the expiration or earlier termination of the Lease. Landlord shall not be entitled to receive (or deduct from the first Option Term Allowance) any
construction management fee or oversight fee in connection with any first Option Term Alterations. Notwithstanding the foregoing, Landlord and Tenant agree that if the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
property management company (currently Wareham Property Group) provides construction management or administrative services in connection with any first Option Term Alterations, such property
management company shall be entitled to a construction management or administration fee in connection with any first Option Term Alterations in accordance with the schedule contained on <U>Exhibit D</U> to the First Amendment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Right of First Refusal</U>. The right of first refusal contained in Section&nbsp;9 of the First Amendment is hereby amended such that the
definition of Refusal Space shall include each of Suite C-2 (as shown on Exhibit B to the First Amendment) as well as Suite F containing approximately 7,000 rentable square feet and as shown on Exhibit A hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Brokers</U>. Tenant shall indemnify, defend and hold Landlord harmless from and against any and all claims by any real estate broker,
salesperson or finder claiming to have represented Tenant for a commission, finder&#146;s fee or other compensation in connection with this Third Amendment. Notwithstanding anything to the contrary contained in this Section&nbsp;8, Tenant shall be
solely responsible for any commission, fees or costs payable to any real estate broker, sales person or finder claiming to have represented Tenant in connection with any future amendment to the Lease or Tenant&#146;s exercise of any extension option
or right of first refusal contained in the Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Notices</U>. Section&nbsp;19.2 of the Original Lease is hereby amended to provide
that Tenant&#146;s address for notices under the Lease is as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Sangamo BioSciences, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">501 Canal Boulevard, Suite A100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Richmond, California 94804 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attn:
Mr.&nbsp;Ward Wolff </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Executive Vice President and CFO </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Authority</U>. This Third Amendment shall be binding upon and inure to the benefit of the parties, their respective heirs, legal
representatives, successors and assigns. Each party hereto and the persons signing below warrant that the person signing below on such party&#146;s behalf is authorized to do so and to bind such party to the terms of this Third Amendment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Status of Lease</U>. Except as amended hereby, the Lease is unchanged, and, as amended hereby, the Lease remains in full force and
effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Landlord and Tenant have entered into this Third Amendment as of the date first set forth above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">TENANT:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5">LANDLORD:</TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SANGAMO BIOSCIENCES, INC.,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a
Delaware corporation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">POINT&nbsp;RICHMOND&nbsp;R&amp;D&nbsp;ASSOCIATES&nbsp;II,&nbsp;LLC,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a California limited liability company</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ H. Ward Wolff</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Richard K. Robin</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Print&nbsp;Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">H. Ward Wolff</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Print&nbsp;Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Richard K. Robin</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Executive Vice President and Chief Financial Officer</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Managing Member</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite F&#151;Refusal Space </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WINE STREET </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g595389g77q05.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>d595389dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CERTIFICATION </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Edward O.
Lanphier II, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this quarterly report on Form 10-Q of Sangamo BioSciences, Inc. (&#147;registrant&#148;) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a &#151; 15(f) and 15d &#151; 15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter that has materially affected, or is reasonably
likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;4, 2013</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Edward O. Lanphier II</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Edward O. Lanphier II</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>d595389dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CERTIFICATION </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, H. Ward Wolff,
certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this quarterly report on Form 10-Q of Sangamo BioSciences, Inc. (&#147;registrant&#148;) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a &#151; 15(f) and 15d &#151; 15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter that has materially affected, or is reasonably
likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;4, 2013</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ H. Ward Wolff</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">H. Ward Wolff</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Executive&nbsp;Vice&nbsp;President&nbsp;and&nbsp;Chief&nbsp;Financial&nbsp;Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Principal Financial and Accounting Officer)</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>d595389dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification Pursuant to 18 U.S.C. &#167;1350, as Adopted </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the undersigned hereby certifies pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002 in his
capacity as an officer of Sangamo BioSciences, Inc. (the &#147;Company&#148;), that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) the Quarterly Report of the Company on Form 10-Q for the
quarterly period ended September&nbsp;30, 2013, as filed with the Securities and Exchange Commission (the &#147;Report&#148;) fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Edward O. Lanphier II</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Edward O. Lanphier II</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Principal Executive Officer)</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;4, 2013</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ H. Ward Wolff</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">H. Ward Wolff</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Executive&nbsp;Vice&nbsp;President&nbsp;and&nbsp;Chief&nbsp;Financial&nbsp;Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Principal Financial and Accounting Officer)</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;4, 2013</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>sgmo-20130930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2013-11-04T20:27:09Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:sgmo="http://sangamo.com/20130930" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="sgmo-20130930.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <sgmo:OneTimeLicenseFeeEarned contextRef="eol_PE72223---1310-Q0003_STD_0_20051031_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_1982133_99AC701F-D323-4582-9B9A-6A256D0D6AC7_3001_0">6000000</sgmo:OneTimeLicenseFeeEarned>
  <sgmo:AgreementDate contextRef="eol_PE72223---1310-Q0003_STD_0_20061031_0_925277x1044992" id="id_1982133_306AC1B8-3E4C-405A-8CC8-AF6A1F6E8F86_2001_0">2006-10-31</sgmo:AgreementDate>
  <sgmo:AgreementDate contextRef="eol_PE72223---1310-Q0003_STD_0_20091031_0_925277x1137514" id="id_1982133_BFE60265-5558-4A89-8BCB-59EC00C49ED1_2001_3">2009-10-31</sgmo:AgreementDate>
  <sgmo:ExpectedAmountToBeReceivedForResearchAndDevelopment contextRef="eol_PE72223---1310-Q0003_STD_0_20091031_0_925277x1137514" unitRef="iso4217_USD" decimals="-5" id="id_1982133_BFE60265-5558-4A89-8BCB-59EC00C49ED1_2001_2">5200000</sgmo:ExpectedAmountToBeReceivedForResearchAndDevelopment>
  <sgmo:RoyaltyRevenuesExpectedToBeReceived contextRef="eol_PE72223---1310-Q0003_STD_0_20091031_0_926233x928673_933025x982693" unitRef="iso4217_USD" decimals="-5" id="id_1982133_ADD7B12E-9870-4F5A-AAC3-57F4CD0496AC_2001_0">5000000</sgmo:RoyaltyRevenuesExpectedToBeReceived>
  <sgmo:AdditionalMilestonePaymentUnderAgreement contextRef="eol_PE72223---1310-Q0003_STD_0_20091031_0_933025x982693" unitRef="iso4217_USD" decimals="-5" id="id_1982133_ADD7B12E-9870-4F5A-AAC3-57F4CD0496AC_1001_2">25000000</sgmo:AdditionalMilestonePaymentUnderAgreement>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE72223---1310-Q0003_STD_0_20131031_0" unitRef="shares" decimals="INF" id="id_1982133_2B2E1E42-53B5-47E4-8AE0-EE38D9D241FC_2_500005">61797202</dei:EntityCommonStockSharesOutstanding>
  <sgmo:AgreementDate contextRef="eol_PE72223---1310-Q0003_STD_0_20110430_0_925277x1019175" id="id_1982133_7C424DF9-0408-4EAF-8754-570A5530545D_2001_1">2011-04-30</sgmo:AgreementDate>
  <sgmo:FundsDueUnderAgreement contextRef="eol_PE72223---1310-Q0003_STD_0_20110430_0_925277x1019175" unitRef="iso4217_USD" decimals="-5" id="id_1982133_7C424DF9-0408-4EAF-8754-570A5530545D_2001_0">1300000</sgmo:FundsDueUnderAgreement>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE72223---1310-Q0003_STD_0_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1002_25">13724000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE72223---1310-Q0003_STD_0_20130923_0_926956x930643_931707x926487" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1982133_27786E8E-AA7B-4063-953F-19A09B5DD307_3001_1">10.58</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_27">61420655</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_26">61420655</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_25">80000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_24">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_28">419490000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_18">7004000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_30">26000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_31">126141000</us-gaap:StockholdersEquity>
  <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_16">2039000</us-gaap:AccruedEmployeeBenefitsCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_15">2665000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_29">-293989000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_17">2300000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_23">614000</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_32">140366000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:Liabilities contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_20">14225000</us-gaap:Liabilities>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_19">7221000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_21" />
  <us-gaap:MarketableSecuritiesCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_3">39913000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_8">126143000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_5_1">62335000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:MarketableSecuritiesNoncurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_9">12690000</us-gaap:MarketableSecuritiesNoncurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_7">684000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:Assets contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_12">140366000</us-gaap:Assets>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_1_4">62361000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_2">80309000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_5">4880000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_5_4">62361000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:OtherAssets contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_11">39000</us-gaap:OtherAssets>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_6">149000</us-gaap:OtherAssetsCurrent>
  <us-gaap:InterestReceivableCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_4">208000</us-gaap:InterestReceivableCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_1_10">1494000</us-gaap:PropertyPlantAndEquipmentNet>
  <sgmo:InvestmentsMaturityDatesAvailableForSaleSecurities contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" id="id_1982133_EF6B9391-05E2-454F-AFB8-DC08919CA275_1001_0">P1Y</sgmo:InvestmentsMaturityDatesAvailableForSaleSecurities>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_5_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_5_2">26000</sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x924099_929790x925736_932040x927011" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_1002_2" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x924099_929790x925851_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_1003_2">52603000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x924099_929790x929831_932040x927011" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_1004_2" />
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x924099_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_3_1">52577000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x924099_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_1001_2">52603000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x924099_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_3_4">52603000</us-gaap:AvailableForSaleSecurities>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x924099_932040x927011" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_3_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x924099_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_3_2">26000</sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x932359_929790x925736_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_2002_0">9758000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x932359_929790x925851_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_2003_0" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x932359_929790x929831_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_2004_0" />
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x932359_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_1_1">9758000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x932359_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_2001_0">9758000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x932359_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_1_4">9758000</us-gaap:AvailableForSaleSecurities>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x932359_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_1_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x932359_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_1_2" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_929790x925736" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_2_4">9758000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_929790x925736_932040x927011" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_3002_3" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_929790x925736_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_4002_1">9758000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_929790x925851" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_3_4">52603000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_929790x925851_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_3003_3">52603000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_929790x925851_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_4003_1" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_4_4" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_929790x929831_932040x927011" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_3004_3" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_929790x929831_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_4004_1" />
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_4_1">52577000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_3001_3">52603000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_4_4">52603000</us-gaap:AvailableForSaleSecurities>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_932040x927011" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_A9DE8E6B-270A-4B34-A2E2-AF62E0B41407_1004_0" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_4_2">26000</sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_2_1">9758000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6ACA73A8-CD31-472D-82BD-915D5CCC1CD1_4001_1">9758000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_2_4">9758000</us-gaap:AvailableForSaleSecurities>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_2_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_2_2" />
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20130930_0_933025x992959" unitRef="iso4217_USD" decimals="-5" id="id_1982133_21376AB0-ABB4-44FB-AB8B-05B4619A981D_1001_0">9500000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="eol_PE72223---1310-Q0003_STD_0_20131001_0_932504x931597" unitRef="iso4217_USD" decimals="-5" id="id_1982133_B61B2002-C9F6-4F40-AD7A-371872587755_1002_1">1200000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE72223---1310-Q0003_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_2001_24">16766000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_27">53058525</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_26">53058525</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_25">80000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_24">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_28">339848000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_18">8790000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_30">26000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:StockholdersEquity contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_31">64896000</us-gaap:StockholdersEquity>
  <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_16">2473000</us-gaap:AccruedEmployeeBenefitsCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_15">4013000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_29">-275509000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_17">2304000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_23">531000</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_32">82533000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:Liabilities contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_20">17637000</us-gaap:Liabilities>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_19">8847000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_21" />
  <us-gaap:MarketableSecuritiesCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_3">41868000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_8">68365000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_11_1">73262000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:MarketableSecuritiesNoncurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_9">12584000</us-gaap:MarketableSecuritiesNoncurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_7">296000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:Assets contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_12">82533000</us-gaap:Assets>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_1_5">73288000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_2">21679000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_5">4129000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_11_4">73288000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:OtherAssets contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_11">41000</us-gaap:OtherAssets>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_6">203000</us-gaap:OtherAssetsCurrent>
  <us-gaap:InterestReceivableCurrent contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_4">190000</us-gaap:InterestReceivableCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A5310860-F5EB-48CA-84B1-3AC3B19D3977_2_10">1543000</us-gaap:PropertyPlantAndEquipmentNet>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_11_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_11_2">26000</sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments>
  <sgmo:PostAmendmentFundsDueUnderAgreement contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_925277x1019175" unitRef="iso4217_USD" decimals="-5" id="id_1982133_7C424DF9-0408-4EAF-8754-570A5530545D_1003_4">2100000</sgmo:PostAmendmentFundsDueUnderAgreement>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_929790x925736_932040x927011" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_1002_3" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_929790x925736_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_2002_0" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_929790x925851_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_1003_3">54452000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_929790x925851_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_2003_0">2997000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_929790x929831_932040x927011" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_1004_3" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_929790x929831_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_2004_0" />
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_9_1">54426000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_1001_3">54452000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_9_4">54452000</us-gaap:AvailableForSaleSecurities>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_932040x927011" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_9_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_9_2">26000</sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_6_1">2997000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_2001_0">2997000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_6_4">2997000</us-gaap:AvailableForSaleSecurities>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_6_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_6_2" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x932359_929790x925736_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_3002_1">15839000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x932359_929790x925851_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_3003_1" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x932359_929790x929831_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_3004_1" />
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x932359_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_7_1">15839000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x932359_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_3001_1">15839000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x932359_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_7_4">15839000</us-gaap:AvailableForSaleSecurities>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x932359_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_7_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x932359_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_7_2" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_929790x925736" unitRef="iso4217_USD" decimals="-3" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_2_5">15839000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_929790x925736_932040x927011" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_4002_4" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_929790x925736_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_5002_2">15839000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_929790x925851" unitRef="iso4217_USD" decimals="-3" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_3_5">57449000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_929790x925851_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_4003_4">54452000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_929790x925851_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_5003_2">2997000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_4_5" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_929790x929831_932040x927011" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_4004_4" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_929790x929831_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_5004_2" />
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_10_1">54426000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_4001_4">54452000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_10_4">54452000</us-gaap:AvailableForSaleSecurities>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_932040x927011" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_10_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_10_2">26000</sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_8_1">18836000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_B5E89FD2-7A28-4E17-854B-46FA95257E71_5001_2">18836000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_932040x932792" unitRef="iso4217_USD" decimals="-3" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_8_4">18836000</us-gaap:AvailableForSaleSecurities>
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_8_3" />
  <sgmo:AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments contextRef="eol_PE72223---1310-Q0003_STD_0_20121231_0_932040x932792" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_26BA4639-A430-498C-B15F-16BD0AB6F883_8_2" />
  <dei:EntityRegistrantName contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_2B2E1E42-53B5-47E4-8AE0-EE38D9D241FC_1_400001">SANGAMO BIOSCIENCES INC</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_CF2E2C17-9528-4CD1-BC06-95E057C88160_1_1">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_2B2E1E42-53B5-47E4-8AE0-EE38D9D241FC_1_400004">Accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_CF2E2C17-9528-4CD1-BC06-95E057C88160_1_3">2013</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_CF2E2C17-9528-4CD1-BC06-95E057C88160_1_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_CF2E2C17-9528-4CD1-BC06-95E057C88160_1_2">2013-09-30</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_2B2E1E42-53B5-47E4-8AE0-EE38D9D241FC_1_400002">0001001233</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_2B2E1E42-53B5-47E4-8AE0-EE38D9D241FC_1_400003">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_CF2E2C17-9528-4CD1-BC06-95E057C88160_1_4">Q3</dei:DocumentFiscalPeriodFocus>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_96B1E967-765E-48BA-B376-F6F80E8AB683_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;NOTE 6&amp;#x2014;STOCK-BASED COMPENSATION&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following table shows total stock-based compensation expense
 included in the condensed consolidated statement of operations for
 the three month and nine months ended September&amp;#xA0;30, 2013 and
 2012 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Costs and expenses:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;732&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;774&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,140&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,195&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;659&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,816&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,391&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,404&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,098&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,011&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_1C5D74BD-BD47-4621-ABFD-8556F1CC51E1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In February 2013, the FASB issued ASU No.&amp;#xA0;2013-02,
 Comprehensive Income (Topic 220): Reporting of Amounts Reclassified
 Out of Accumulated Other Comprehensive Income (ASU 2013-02). This
 newly issued accounting standard requires an entity to provide
 information about the amounts reclassified out of accumulated other
 comprehensive income by component. This ASU is effective for
 reporting periods beginning after December&amp;#xA0;15, 2012. We
 adopted this standard in the first quarter of 2013 and the adoption
 of this standard did not have an impact on our financial position
 or results of operations.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_FDF5EE1C-DDD1-466A-9140-2E0FDBF6849C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The table below summarizes the Company&amp;#x2019;s available-for-sale
 securities (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Amortized&lt;br /&gt;
 Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gross&lt;br /&gt;
 Unrealized&lt;br /&gt;
 Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gross&lt;br /&gt;
 Unrealized&lt;br /&gt;
 (Losses)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Estimated&lt;br /&gt;
 Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Cash equivalents:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,758&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,758&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,758&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,758&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Available-for-sale securities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,577&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,577&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total cash equivalents and available-for-sale securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;62,335&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;62,361&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2012&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Cash equivalents:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,997&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,997&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,836&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,836&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Available-for-sale securities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,426&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,426&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total cash equivalents and available-for-sale securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,262&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_A6D15DB9-068C-4845-A20C-5627A4B5314F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value Measurement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company measures certain financial assets at fair value on a
 recurring basis, including cash equivalents and available-for
 sale-securities.&amp;#xA0;The fair value of these assets was determined
 based on a three-tier hierarchy under the authoritative guidance
 for fair value measurements and disclosures that prioritizes the
 inputs used in measuring fair value as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt"&gt;
 Level 1: Unadjusted quoted prices in active markets that are
 accessible at the measurement date for identical, unrestricted
 assets or liabilities;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt"&gt;
 Level 2: Quoted prices in markets that are not active or inputs
 which are observable, either directly or indirectly, for
 substantially the full term of the asset or liability;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt"&gt;
 Level 3: Prices or valuation techniques that require inputs that
 are both significant to the fair value measurement and unobservable
 (i.e., supported by little or no market activity).&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt"&gt;
 The Company generally classifies its available-for-sale debt
 instruments as Level 2. Instruments can be classified as Level 2
 when observable market prices for identical securities that are
 traded in less active markets are used. When observable market
 prices for identical securities are not available, such instruments
 are priced using benchmark curves, benchmarking of like securities,
 sector groupings, and matrix pricing as well as model processes.
 These models are proprietary to the pricing providers or brokers.
 These valuation models incorporate a number of inputs, including,
 listed in approximate order of priority: benchmark yields, reported
 trades, broker/dealer quotes, issuer spreads, two-sided markets,
 benchmark securities, bids, offers and reference data including
 market research publications. For certain security types,
 additional inputs may be used, or some of the standard inputs may
 not be applicable. Evaluators may prioritize inputs differently on
 any given day for any security based on market conditions, and not
 all inputs listed are available for use in the evaluation process
 for each security evaluation on any given day.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_D4318EEE-E030-4A97-B262-BF3C544CE01F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Revenues from research activities made under strategic partnering
 agreements and collaborations are recognized as the services are
 provided when there is persuasive evidence that an arrangement
 exists, delivery has occurred, the price is fixed or determinable,
 and collectability is reasonably assured. Revenue generated from
 research and licensing agreements typically includes upfront
 signing or license fees, cost reimbursements, research services,
 minimum sublicense fees, milestone payments and royalties on future
 licensee&amp;#x2019;s product sales.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;Multiple Element Arrangements prior to the adoption of ASU
 No.&amp;#xA0;2009-13, Revenue Recognition&amp;#x2014;Multiple Deliverable
 Revenue Arrangements (ASU 2009-13)&lt;/i&gt;. For revenue arrangements
 entered into before January&amp;#xA0;1, 2011, that include multiple
 deliverables, the elements of such agreement were divided into
 separate units of accounting if the deliverables met certain
 criteria, including whether the fair value of the delivered items
 could be determined and whether there was evidence of fair value of
 the undelivered items. In addition, the consideration was allocated
 among the separate units of accounting based on their fair values,
 and the applicable revenue recognition criteria are considered
 separately for each of the separate units of accounting. Prior to
 the adoption of ASU 2009-13, the Company recognized nonrefundable
 signing, license or non-exclusive option fees as revenue when
 rights to use the intellectual property related to the license were
 delivered and over the period of performance obligations if the
 Company had continuing performance obligations. The Company
 estimated the performance period at the inception of the
 arrangement and reevaluated it each reporting period. Changes to
 these estimates were recorded on a prospective basis.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;Multiple Element Arrangements after the adoption of ASU
 2009-13.&lt;/i&gt; ASU 2009-13 amended the accounting standards for
 certain multiple element revenue arrangements to:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;provide updated guidance on whether
 multiple elements exist, how the elements in an arrangement should
 be separated, and how the arrangement consideration should be
 allocated to the separate elements;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;require an entity to allocate
 arrangement consideration to each element based on a selling price
 hierarchy where the selling price for an element is based on
 vendor-specific objective evidence (&amp;#x201C;VSOE&amp;#x201D;), if
 available; third-party evidence (&amp;#x201C;TPE&amp;#x201D;), if available
 and VSOE is not available; or the best estimate of selling price
 (&amp;#x201C;ESP&amp;#x201D;), if neither VSOE nor TPE is available; and&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;eliminate the use of the residual
 method and require an entity to allocate arrangement consideration
 using the relative selling price method.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 For revenue agreements with multiple element arrangements, such as
 license and development agreements, entered into on or after
 January&amp;#xA0;1, 2011, the Company allocates revenue to each
 non-contingent element based on the relative selling price of each
 element. When applying the relative selling price method, the
 Company determines the selling price for each deliverable using
 VSOE of selling price or TPE of selling price. If neither exists
 the Company uses ESP for that deliverable. Revenue allocated is
 then recognized when the basic four revenue recognition criteria
 are met for each element. The collaboration and license agreement
 entered into with Shire AG (Shire) in January 2012 was evaluated
 under these amended accounting standards.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Additionally, the Company may be entitled to receive certain
 milestone payments which are contingent upon reaching specified
 objectives. These milestone payments are recognized as revenue in
 full upon achievement of the milestone if there is substantive
 uncertainty at the date the arrangement is entered into that
 objectives will be achieved and if the achievement is based on the
 Company&amp;#x2019;s performance.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Minimum annual sublicense fees are also recognized as revenue in
 the period in which such fees are due. Royalty revenues are
 generally recognized when earned and collectability of the related
 royalty payment is reasonably assured. The Company recognizes cost
 reimbursement revenue under collaborative agreements as the related
 research and development costs for services are rendered. Deferred
 revenue represents the portion of research or license payments
 received which have not been earned.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Sangamo&amp;#x2019;s research grants are typically multi-year agreements
 and provide for the reimbursement of qualified expenses for
 research and development as defined under the terms of the grant
 agreement. Revenue under grant agreements is recognized when the
 related qualified research expenses are incurred.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_F673D6C2-5E9C-4932-924F-CB348695E0BE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;NOTE 4&amp;#x2014;MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC
 ALLIANCES&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Collaboration Agreements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Collaboration and License Agreement with Shire AG in Human
 Therapeutics and Diagnostics&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In January 2012, the Company entered into a collaboration and
 license agreement (the Agreement) with Shire AG (Shire), pursuant
 to which the Company and Shire collaborate to research, develop and
 commercialize human therapeutics and diagnostics for monogenic
 diseases based on Sangamo&amp;#x2019;s novel zinc finger DNA-binding
 proteins (ZFP) technology. Under the Agreement, the Company and
 Shire may develop potential human therapeutic or diagnostic
 products for seven gene targets. The initial four gene targets
 selected were blood clotting Factors VII, VIII, IX and X, and
 products developed for such initial gene targets will be used for
 treating or diagnosing hemophilia. In June 2012, Shire selected a
 fifth gene target for the development of a ZFP therapeutic for
 Huntington&amp;#x2019;s disease, an inherited neurodegenerative disease
 for which there are currently no therapies available to slow the
 disease progression. Shire has the right, subject to certain
 limitations, to designate two additional gene targets. Pursuant to
 the Agreement, the Company granted Shire an exclusive, world-wide,
 royalty-bearing license, with the right to grant sublicenses, to
 use Sangamo&amp;#x2019;s ZFP technology for the purpose of developing
 and commercializing human therapeutic and diagnostic products for
 the gene targets. The initial research term of the Agreement is six
 years and is subject to extensions upon mutual agreement and under
 other specified circumstances.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Under the terms of the Agreement, the Company is responsible for
 all research activities through the submission of an Investigative
 New Drug Application (IND) or European Clinical Trial Application
 (CTA), while Shire is responsible for clinical development and
 commercialization of products generated from the research program
 from and after the acceptance of an IND or CTA for the product.
 Shire reimburses Sangamo for its internal and external research
 program-related costs.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company received an upfront license fee of $13.0 million. The
 Company will also be eligible to receive up to $213.5 million of
 contingent payments for each gene target if specified research,
 regulatory, clinical development, commercialization and sales
 milestone events occur, including payments for each gene target
 through the acceptance of an IND or CTA submission totaling $8.5
 million. The Company will also be eligible to receive royalty
 payments that are a tiered double-digit percentage of net sales of
 licensed product sold by Shire or its sublicensees developed under
 the collaboration, if any. To date, no products have been approved
 and therefore no royalty fees have been earned under the Agreement
 with Shire.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 All contingent payments under the Agreement, when earned, will be
 non-refundable and non-creditable. The Company has evaluated the
 contingent payments under the Agreement with Shire based on the
 authoritative guidance for research and development milestones and
 determined that certain of these payments meet the definition of a
 milestone and that all such milestones are evaluated to determine
 if they are considered substantive milestones. Milestones are
 considered substantive if they are related to events (i)&amp;#xA0;that
 can be achieved based in whole or in part on either the
 Company&amp;#x2019;s performance or on the occurrence of a specific
 outcome resulting from the Company&amp;#x2019;s performance,
 (ii)&amp;#xA0;for which there was substantive uncertainty at the date
 the agreement was entered into that the event would be achieved and
 (iii)&amp;#xA0;that would result in additional payments being due to
 the Company. Accordingly, revenue for the achievement of milestones
 that are determined to be substantive will be recognized in its
 entirety in the period when the milestone is achieved and
 collectability is reasonably assured. Revenue for the achievement
 of milestones that are not substantive will be recognized over the
 remaining period of the Agreement.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company has identified the deliverables within the arrangement
 as a license to the technology and on-going research services
 activities. The Company has concluded that the license is not a
 separate unit of accounting as it does not have stand-alone value
 to Shire apart from the research services to be performed pursuant
 to the Agreement. As a result, the Company will recognize revenue
 from the upfront payment on a straight-line basis over a six-year
 initial research term during which the Company will perform
 research services. As of September&amp;#xA0;30, 2013, the Company has
 deferred revenue of $9.5 million related to this Agreement.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Revenues recognized under the agreement with Shire for the three
 and nine months ended September&amp;#xA0;30, 2013 and
 September&amp;#xA0;30, 2012, were as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine months ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Revenue related to Shire Collaboration:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Amortization of upfront fee&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;542&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;542&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,625&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,444&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Research services&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,968&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,675&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,340&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,747&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,510&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,217&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,965&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,191&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Related costs and expenses incurred under the Shire agreement were
 $3.5 million and $2.2 million during the three months ended
 September&amp;#xA0;30, 2013 and September&amp;#xA0;30, 2012, respectively
 and $10.3 million and $3.8 million during the nine months ended
 September&amp;#xA0;30, 2013 and September&amp;#xA0;30, 2012,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Agreement with Sigma-Aldrich Corporation in Laboratory
 Research Reagents, Transgenic Animal and Commercial Protein
 Production Cell-line Engineering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In July 2007, Sangamo entered into a license agreement (the
 Agreement) with Sigma-Aldrich Corporation (Sigma). Under the
 Agreement, Sangamo agreed to provide Sigma with access to our
 proprietary ZFP technology and the exclusive right to use the
 technology to develop and commercialize research reagent products
 and services in the research field, excluding certain agricultural
 research uses that Sangamo previously licensed to Dow AgroSciences
 LLC (DAS), a wholly-owned subsidiary of Dow Chemical Corporation.
 Under the Agreement, Sangamo and Sigma agreed to conduct a
 three-year research program to develop laboratory research reagents
 using Sangamo&amp;#x2019;s ZFP technology during which time Sangamo
 agreed to assist Sigma in connection with its efforts to market and
 sell services employing the Company&amp;#x2019;s ZFP technology in the
 research field. Sangamo has transferred the ZFP manufacturing
 technology to Sigma.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In October 2009, Sangamo expanded its Agreement with Sigma. In
 addition to the original terms of the Agreement, Sigma received
 exclusive rights to develop and distribute ZFP-modified cell lines
 for commercial production of protein pharmaceuticals and certain
 ZFP-engineered transgenic animals for commercial applications.
 Under the terms of the Agreement, Sigma made upfront cash payment
 of $20.0 million consisting of a $4.9 million purchase of 636,133
 shares of Sangamo common stock, valued at $4.9 million, and a $15.1
 million upfront license fee. The upfront license fee was recognized
 on a straight-line basis from the effective date of the expanded
 license through July 2010, which represents the period over which
 Sangamo was obligated to perform research services for Sigma.
 Sangamo is also eligible to receive commercial license fees of $5.0
 million based upon a percentage of net sales and sublicensing
 revenue and thereafter a reduced royalty rate of 10.5% of net sales
 and sublicensing revenue. In addition, upon the achievement of
 certain cumulative commercial milestones Sigma will make milestone
 payments to Sangamo up to an aggregate of $25.0 million. In April
 2013, the Company recognized $1.3 million in sublicense revenues
 under the agreement with Sigma.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Revenues recognized under the agreement with Sigma for the three
 and nine months ended September&amp;#xA0;30, 2013 and
 September&amp;#xA0;30, 2012, were as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Revenue related to Sigma Collaboration&lt;b&gt;:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Royalty revenues&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;201&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;428&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;711&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,035&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 License fee and milestone revenues&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;101&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,351&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;302&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;428&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,062&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,035&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Related costs and expenses incurred under the Sigma agreement were
 $0.1 million during both the three months ended September&amp;#xA0;30,
 2013 and 2012. Related costs and expenses incurred under the Sigma
 agreement were $0.1 million and $0.3 million during the nine months
 ended September&amp;#xA0;30, 2013 and 2012, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Agreement with Dow AgroSciences in Plant
 Agriculture&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In October 2005, Sangamo entered into an exclusive commercial
 license agreement (the Agreement) with DAS. Under the Agreement,
 Sangamo provides DAS with access to its proprietary ZFP technology
 and the exclusive right to use the technology to modify the genomes
 or alter the nucleic acid or protein expression of plant cells,
 plants, or plant cell cultures. Sangamo has retained rights to use
 plants or plant-derived products to deliver ZFP transcription
 factors (ZFP TFs) or ZFP nucleases (ZFNs) into humans or animals
 for diagnostic, therapeutic, or prophylactic purposes. The
 Agreement with DAS provided for an initial three-year research
 term. In June 2008, DAS exercised its option under the agreement to
 obtain a commercial license to sell products incorporating or
 derived from plant cells generated using the Company&amp;#x2019;s ZFP
 technology, including agricultural crops, industrial products and
 plant-derived biopharmaceuticals. The exercise of the option
 triggered a one-time commercial license fee of $6.0 million,
 payment of the remaining $2.3 million of the previously agreed $4.0
 million in research milestones, development and commercialization
 milestone payments for each product, and royalties on sales of
 products. Furthermore, DAS has the right to sublicense
 Sangamo&amp;#x2019;s ZFP technology to third parties for use in plant
 cells, plants, or plant cell cultures. Sangamo will be entitled to
 25% of any cash consideration received by DAS under such
 sublicenses. In December 2010, the Company amended the Agreement
 with DAS to extend the period of reagent manufacturing services and
 research services through December&amp;#xA0;31, 2012.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Agreement also provides for minimum sublicense fees each year
 due to Sangamo every October, provided the Agreement is not
 terminated by DAS. Annual fees range from $250,000 to $3.0 million
 and total $25.3 million over 11 years. The Company does not have
 any performance obligations with respect to the sublicensing
 activities to be conducted by DAS. DAS has the right to terminate
 the Agreement at any time; accordingly, the Company&amp;#x2019;s actual
 sublicense fees over the term of the Agreement could be lower than
 $25.3 million. In addition, each party may terminate the Agreement
 upon an uncured material breach by the other party. In the event of
 any termination of the Agreement, all rights to use the
 Company&amp;#x2019;s ZFP technology will revert to Sangamo, and DAS will
 no longer be permitted access to Sangamo&amp;#x2019;s ZFP technology or
 to develop or, except in limited circumstances, commercialize any
 products derived from the Company&amp;#x2019;s ZFP technology.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Revenues under the agreement were $0.4 million during the three
 months ended September&amp;#xA0;30, 2012, and $1.3 million during the
 nine months ended September&amp;#xA0;30, 2012. Related costs and
 expenses incurred under the agreement were $0.1 million during the
 three months ended September&amp;#xA0;30, 2012, and $0.4 million during
 the nine months ended September&amp;#xA0;30, 2012. There were no such
 revenues or related expenses during the three and nine months ended
 September&amp;#xA0;30, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Funding from Research Foundations&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;California Institute for Regenerative Medicine&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In October 2009, the California Institute for Regenerative Medicine
 (CIRM), a State of California entity, granted a $14.5 million
 Disease Team Research Award to develop an AIDS-related lymphoma
 therapy based on the application of ZFN gene editing technology in
 stem cells. The four year grant supports an innovative research
 project conducted by a multidisciplinary team of investigators,
 including investigators from the University of Southern California,
 City of Hope National Medical Center and Sangamo BioSciences.
 Sangamo expects to receive funding up to $5.2 million from the
 total amount awarded based on expenses incurred for research and
 development efforts by Sangamo as prescribed in the agreement, and
 subject to its terms and conditions. The award is intended to
 substantially fund Sangamo&amp;#x2019;s research and development efforts
 related to the agreement. The State of California has the right to
 receive, subject to the terms and conditions of the agreement
 between Sangamo and CIRM, payments from Sangamo resulting from
 sales of a commercial product resulting from research and
 development efforts supported by the grant, not to exceed two times
 the amount Sangamo receives in funding under the agreement with
 CIRM.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Revenues attributable to research and development performed under
 the CIRM grant agreement were $0.5 million and $0.3 million during
 the three months ended September&amp;#xA0;30, 2013 and 2012,
 respectively and $ 1.2&amp;#xA0;million and $0.9 million during the
 nine months ended September&amp;#xA0;30, 2013 and 2012, respectively.
 Related costs and expenses incurred under the CIRM agreement were
 $0.5 million and $0.3 million during the three months ended
 September&amp;#xA0;30, 2013 and 2012, respectively, and $1.4 million
 and $0.9 million during the nine months ended September&amp;#xA0;30,
 2013 and 2012, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;CHDI Foundation, Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In April 2011, Sangamo entered into an agreement with the CHDI
 Foundation, Inc. (CHDI) to develop a novel therapeutic for
 Huntington&amp;#x2019;s disease based on Sangamo&amp;#x2019;s proprietary ZFP
 technology. Under the agreement with CHDI, and subject to its terms
 and conditions, CHDI paid the Company $1.3 million, the total funds
 due under the agreement, over a period of one year which is
 intended to substantially fund the Company&amp;#x2019;s research efforts
 related to the agreement. During 2012, the agreement was amended to
 extend the project through August 2012 and to increase total
 potential funding from $1.3 million to $2.1 million, plus
 reimbursement for certain direct expenses related to the project.
 The research grant from CHDI was completed in August 2012.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Revenues attributable to research and development performed under
 the CHDI collaboration agreement were $0.3 million and $1.1 million
 during the three and nine months ended September&amp;#xA0;30, 2012,
 respectively. Related costs and expenses incurred under the CHDI
 agreement were $0.3 million and $1.1 million during the three and
 nine months ended September&amp;#xA0;30, 2012, respectively. There were
 no revenues or related expenses during the three and nine months
 ended September&amp;#xA0;30, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;The Juvenile Diabetes Research Foundation
 International&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In October 2006, Sangamo entered into an agreement with the
 Juvenile Diabetes Research Foundation International (JDRF) to
 provide financial support for one of Sangamo&amp;#x2019;s Phase 2 human
 clinical studies of the Company&amp;#x2019;s product candidate SB-509, a
 ZFP Therapeutic that was in development for the treatment of
 diabetic neuropathy. In January 2010, JDRF and Sangamo amended the
 agreement and, subject to its terms and conditions, JDRF agreed to
 provide additional funding of up to $3.0 million for a Phase 2b
 trial in diabetic neuropathy.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In October 2011, the Company announced of the termination of its
 SB-509 program. In March 2012, the Company received a final payment
 of $0.8 million for work performed under the JDRF agreements. The
 Company does not expect to receive additional funding under these
 agreements.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Revenues attributable to research and development activities
 performed under the JDRF agreements were $0 for the three months
 ended September&amp;#xA0;30, 2012 and $0.8 million during the nine
 months ended September&amp;#xA0;30, 2012. There were no such revenues
 during the three and nine months ended September&amp;#xA0;30, 2013.&lt;/p&gt;
 &lt;!-- xbrl,n --&gt;

 &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:InvestmentPolicyTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_27A593A4-7CD9-48BE-9DA0-963C6D64CCD7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Investments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Sangamo classifies its marketable securities as available-for-sale
 and records its investments at fair value. Available-for-sale
 securities are carried at estimated fair value based on quoted
 market prices, with the unrealized holding gains and losses
 included in accumulated other comprehensive income. Marketable
 securities which have maturities beyond one year as of the end of
 the reporting period are classified as non-current. The
 Company&amp;#x2019;s investments are subject to a periodic impairment
 review and the Company recognizes an impairment charge when a
 decline in the fair value of its investments below the cost basis
 is judged to be other-than-temporary. The Company considers various
 factors in determining whether to recognize an impairment charge,
 including the length of time and extent to which the fair value has
 been less than the Company&amp;#x2019;s cost basis, the financial
 condition and near-term prospects of the investee, and the
 Company&amp;#x2019;s intent and ability to hold the investment for a
 period of time sufficient to allow for any anticipated recovery in
 the market value.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_47E0D0A8-8378-45ED-8EBF-45A1090796EB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt"&gt;
 The fair value measurements of our cash equivalents and
 available-for-sale marketable securities are identified at the
 following levels within the fair value hierarchy (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;br /&gt;
 Fair&amp;#xA0;Value&amp;#xA0;Measurements&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Cash equivalents:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,758&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,758&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,758&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,758&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Available-for-sale securities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total cash equivalents and available-for-sale securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;62,361&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,758&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;br /&gt;
 Fair&amp;#xA0;Value&amp;#xA0;Measurements&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Cash equivalents:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,997&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,997&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,836&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,997&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Available-for-sale securities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total cash equivalents and available-for-sale securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,449&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_CF088BDA-B723-485F-BA13-4B100F35AF4A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;NOTE 1&amp;#x2014;BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT
 ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The accompanying unaudited condensed consolidated financial
 statements of Sangamo BioSciences, Inc. (&amp;#x201C;Sangamo&amp;#x201D; or
 the &amp;#x201C;Company&amp;#x201D;) have been prepared in accordance with
 U.S. generally accepted accounting principles for interim financial
 information and pursuant to the rules and regulations of the
 Securities and Exchange Commission (&amp;#x201C;SEC&amp;#x201D;).
 Accordingly, they do not include all of the information and
 footnotes required by generally accepted accounting principles for
 complete financial statements. In the opinion of management, all
 adjustments (consisting of normal recurring adjustments) considered
 necessary for a fair presentation have been included. Operating
 results for the three and nine months ended September&amp;#xA0;30, 2013
 are not necessarily indicative of the results that may be expected
 for the year ending December&amp;#xA0;31, 2013. The condensed
 consolidated balance sheet data at December&amp;#xA0;31, 2012 were
 derived from the audited consolidated financial statements included
 in Sangamo&amp;#x2019;s Form 10-K for the year ended December&amp;#xA0;31,
 2012, as filed with the SEC. These financial statements should be
 read in conjunction with the financial statements and footnotes
 thereto for the year ended December&amp;#xA0;31, 2012, included in
 Sangamo&amp;#x2019;s Form 10-K, as filed with the SEC.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates and Classifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The preparation of financial statements in conformity with
 generally accepted accounting principles requires management to
 make estimates and assumptions that affect the amounts reported in
 the financial statements and the accompanying notes. On an ongoing
 basis, management evaluates its estimates, including critical
 accounting policies or estimates related to revenue recognition,
 clinical trial accruals, and stock-based compensation. Estimates
 are based on historical experience and on various other market
 specific and other relevant assumptions that the Company believes
 to be reasonable under the circumstances, the results of which form
 the basis for making judgments about the carrying values of assets
 and liabilities that are not readily apparent from other sources.
 Actual results could differ from those estimates.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Revenues from research activities made under strategic partnering
 agreements and collaborations are recognized as the services are
 provided when there is persuasive evidence that an arrangement
 exists, delivery has occurred, the price is fixed or determinable,
 and collectability is reasonably assured. Revenue generated from
 research and licensing agreements typically includes upfront
 signing or license fees, cost reimbursements, research services,
 minimum sublicense fees, milestone payments and royalties on future
 licensee&amp;#x2019;s product sales.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;Multiple Element Arrangements prior to the adoption of ASU
 No.&amp;#xA0;2009-13, Revenue Recognition&amp;#x2014;Multiple Deliverable
 Revenue Arrangements (ASU 2009-13)&lt;/i&gt;. For revenue arrangements
 entered into before January&amp;#xA0;1, 2011, that include multiple
 deliverables, the elements of such agreement were divided into
 separate units of accounting if the deliverables met certain
 criteria, including whether the fair value of the delivered items
 could be determined and whether there was evidence of fair value of
 the undelivered items. In addition, the consideration was allocated
 among the separate units of accounting based on their fair values,
 and the applicable revenue recognition criteria are considered
 separately for each of the separate units of accounting. Prior to
 the adoption of ASU 2009-13, the Company recognized nonrefundable
 signing, license or non-exclusive option fees as revenue when
 rights to use the intellectual property related to the license were
 delivered and over the period of performance obligations if the
 Company had continuing performance obligations. The Company
 estimated the performance period at the inception of the
 arrangement and reevaluated it each reporting period. Changes to
 these estimates were recorded on a prospective basis.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;Multiple Element Arrangements after the adoption of ASU
 2009-13.&lt;/i&gt; ASU 2009-13 amended the accounting standards for
 certain multiple element revenue arrangements to:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;provide updated guidance on whether
 multiple elements exist, how the elements in an arrangement should
 be separated, and how the arrangement consideration should be
 allocated to the separate elements;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;require an entity to allocate
 arrangement consideration to each element based on a selling price
 hierarchy where the selling price for an element is based on
 vendor-specific objective evidence (&amp;#x201C;VSOE&amp;#x201D;), if
 available; third-party evidence (&amp;#x201C;TPE&amp;#x201D;), if available
 and VSOE is not available; or the best estimate of selling price
 (&amp;#x201C;ESP&amp;#x201D;), if neither VSOE nor TPE is available; and&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;eliminate the use of the residual
 method and require an entity to allocate arrangement consideration
 using the relative selling price method.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 For revenue agreements with multiple element arrangements, such as
 license and development agreements, entered into on or after
 January&amp;#xA0;1, 2011, the Company allocates revenue to each
 non-contingent element based on the relative selling price of each
 element. When applying the relative selling price method, the
 Company determines the selling price for each deliverable using
 VSOE of selling price or TPE of selling price. If neither exists
 the Company uses ESP for that deliverable. Revenue allocated is
 then recognized when the basic four revenue recognition criteria
 are met for each element. The collaboration and license agreement
 entered into with Shire AG (Shire) in January 2012 was evaluated
 under these amended accounting standards.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Additionally, the Company may be entitled to receive certain
 milestone payments which are contingent upon reaching specified
 objectives. These milestone payments are recognized as revenue in
 full upon achievement of the milestone if there is substantive
 uncertainty at the date the arrangement is entered into that
 objectives will be achieved and if the achievement is based on the
 Company&amp;#x2019;s performance.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Minimum annual sublicense fees are also recognized as revenue in
 the period in which such fees are due. Royalty revenues are
 generally recognized when earned and collectability of the related
 royalty payment is reasonably assured. The Company recognizes cost
 reimbursement revenue under collaborative agreements as the related
 research and development costs for services are rendered. Deferred
 revenue represents the portion of research or license payments
 received which have not been earned.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Sangamo&amp;#x2019;s research grants are typically multi-year agreements
 and provide for the reimbursement of qualified expenses for
 research and development as defined under the terms of the grant
 agreement. Revenue under grant agreements is recognized when the
 related qualified research expenses are incurred.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In February 2013, the FASB issued ASU No.&amp;#xA0;2013-02,
 Comprehensive Income (Topic 220): Reporting of Amounts Reclassified
 Out of Accumulated Other Comprehensive Income (ASU 2013-02). This
 newly issued accounting standard requires an entity to provide
 information about the amounts reclassified out of accumulated other
 comprehensive income by component. This ASU is effective for
 reporting periods beginning after December&amp;#xA0;15, 2012. We
 adopted this standard in the first quarter of 2013 and the adoption
 of this standard did not have an impact on our financial position
 or results of operations.&lt;/p&gt;
 &lt;!-- xbrl,n --&gt;

 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="shares" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_3_12">54013000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_CD7BB46A-D6FE-4B62-990C-D67A5E6B3961_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;NOTE 7&amp;#x2014;STOCKHOLDERS&amp;#x2019; EQUITY&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On September&amp;#xA0;23, 2013, Sangamo completed an underwritten
 public offering of its common stock, in which the Company sold an
 aggregate of 7,015,000 shares of its common stock, including
 915,000 issued to the Underwriters pursuant to a 30-day
 overallotment option, at a public offering price of $10.58 per
 share. The net proceeds to Sangamo from the sale of shares in this
 offering, after deducting underwriting discounts and commissions
 and other estimated offering expenses, were approximately $69.5
 million.&lt;/p&gt;
 &lt;!-- xbrl,n --&gt;

 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_1E21974B-9569-4F59-B202-36208F1E0880_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following table shows total stock-based compensation expense
 included in the condensed consolidated statement of operations for
 the three month and nine months ended September&amp;#xA0;30, 2013 and
 2012 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Costs and expenses:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;732&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;774&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,140&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,195&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;659&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,816&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,391&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,404&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,098&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,011&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1_13">-17825000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_3_11">-0.34</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_50750370-271A-424A-8250-3718283D2284_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;NOTE 8&amp;#x2014;SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Acquisition of Ceregene&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On August&amp;#xA0;23, 2013, Sangamo and its wholly-owned subsidiary CG
 Acquisition Sub, Inc., a Delaware corporation (&amp;#x201C;Merger
 Sub&amp;#x201D;), entered into an Agreement and Plan of Merger (the
 &amp;#x201C;Merger Agreement&amp;#x201D;) with Ceregene, Inc.,
 (&amp;#x201C;Ceregene&amp;#x201D;) and a stockholders&amp;#x2019; representative.
 Pursuant to the Merger Agreement, the Company acquired all
 outstanding shares of Ceregene, a privately held biotechnology
 company focused on the development of adeno-associated virus
 (&amp;#x201C;AAV&amp;#x201D;) gene therapies. The acquired assets include all
 of Ceregene&amp;#x2019;s therapeutic programs, including CERE-110, an
 AAV vector delivery system for the treatment of Alzheimer&amp;#x2019;s
 disease that is currently in a Phase 2 clinical trial, certain
 intellectual property rights relating to the manufacturing of AAV,
 and certain toxicology and safety data from Ceregene&amp;#x2019;s human
 clinical trials (the Acquisition). The Acquisition was closed on
 October&amp;#xA0;1, 2013 (the Closing Date).&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On the Closing Date, Merger Sub merged with and into Ceregene, with
 Ceregene continuing as the surviving company and a wholly-owned
 subsidiaries of the Company. On the Closing Date, each share of
 Ceregene&amp;#x2019;s issued and outstanding capital stock held by its
 stockholders converted to the right to receive a portion of the
 merger consideration for the Acquisition, which consists initially
 of (i)&amp;#xA0;100,000 shares of Sangamo common stock with a market
 value of approximately $1.2 million on the Closing Date, and
 (ii)&amp;#xA0;amount of cash and cash equivalent of Ceregene on the
 Closing Date less certain liabilities and expenses. In addition to
 such initial merger consideration, during the term of the Merger
 Agreement, the Company is required to make contingent earn-out
 payments (the &amp;#x201C;Earn-Out Payments&amp;#x201D;) to the stockholders
 of Ceregene as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;If the Company grants a third-party
 license to develop and commercialize Ceregene&amp;#x2019;s CERE-110 for
 the treatment of Alzheimer&amp;#x2019;s disease or CERE-120 for the
 treatment of Parkinson&amp;#x2019;s diseases or Huntington&amp;#x2019;s
 disease (the &amp;#x201C;Earn-Out Products&amp;#x201D;), the Company is
 required to pay a double digit percentage of any upfront and
 milestone payments the Company receives for such license, subject
 to certain reductions based on expenses incurred by the Company in
 the development of the Earn-Out Products; and&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;If the Company commercializes any
 Earn-Out Product itself, the Company is required to pay, for each
 Earn-Out Product, royalty-like earnout payments as a percentage of
 net sales that range in the low double digits depending upon the
 amount of net sales, subject to certain reductions by the
 Company.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Also on the Closing Date, the Company, Ceregene and certain of its
 stockholders entered into an indemnity escrow agreement, pursuant
 to which a portion of the purchase price was deposited in an escrow
 account for the benefit of the Company to satisfy indemnity
 obligations of the stockholders under the Merger Agreement. Due to
 the relatively short time from the Closing Date of the Acquisition
 to the completion of the accompanying unaudited interim
 consolidated financial statements, the accounting for the initial
 purchase price allocation as well as certain required supplemental
 disclosures with respect to the Acquisition have not been
 completed.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_6841CE8A-39E1-4CB0-8CAE-712398FF5E9F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;NOTE 5&amp;#x2014;INCOME TAXES&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company maintains deferred tax assets that reflect the net tax
 effects of temporary differences between the carrying amounts of
 assets and liabilities for financial reporting purposes and the
 amounts used for income tax purposes. These deferred tax assets
 include net operating loss carryforwards, research credits and
 capitalized research and development. Realization of deferred tax
 assets is dependent upon future earnings, if any, the timing and
 amount of which are uncertain based on the Company&amp;#x2019;s history
 of losses. Accordingly, the net deferred tax assets have been fully
 offset by a valuation allowance. Utilization of operating losses
 and credits may be subject to substantial annual limitation due to
 ownership change provisions of the Internal Revenue Code of 1986,
 as amended and similar state provisions. The annual limitation may
 result in the expiration of net operating losses and credits before
 utilization.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_42DCED16-F33D-4DE2-B736-B44CFD421B66_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The accompanying unaudited condensed consolidated financial
 statements of Sangamo BioSciences, Inc. (&amp;#x201C;Sangamo&amp;#x201D; or
 the &amp;#x201C;Company&amp;#x201D;) have been prepared in accordance with
 U.S. generally accepted accounting principles for interim financial
 information and pursuant to the rules and regulations of the
 Securities and Exchange Commission (&amp;#x201C;SEC&amp;#x201D;).
 Accordingly, they do not include all of the information and
 footnotes required by generally accepted accounting principles for
 complete financial statements. In the opinion of management, all
 adjustments (consisting of normal recurring adjustments) considered
 necessary for a fair presentation have been included. Operating
 results for the three and nine months ended September&amp;#xA0;30, 2013
 are not necessarily indicative of the results that may be expected
 for the year ending December&amp;#xA0;31, 2013. The condensed
 consolidated balance sheet data at December&amp;#xA0;31, 2012 were
 derived from the audited consolidated financial statements included
 in Sangamo&amp;#x2019;s Form 10-K for the year ended December&amp;#xA0;31,
 2012, as filed with the SEC. These financial statements should be
 read in conjunction with the financial statements and footnotes
 thereto for the year ended December&amp;#xA0;31, 2012, included in
 Sangamo&amp;#x2019;s Form 10-K, as filed with the SEC.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_C5C0B137-AFCC-46CC-92C7-7357B6D096E3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;NOTE 3&amp;#x2014;BASIC AND DILUTED NET LOSS PER SHARE&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Basic net loss per share has been computed by dividing the net loss
 by the weighted-average number of shares of common stock
 outstanding during the period. Diluted net loss per share is
 calculated by dividing net loss by the weighted average number of
 shares of common stock and potential dilutive securities
 outstanding during the period.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Because Sangamo is in a net loss position, diluted net loss per
 share excludes the effects of common stock equivalents consisting
 of options, which are anti-dilutive. The total stock options
 outstanding excluded from consideration in the calculation of
 diluted net loss per share for the nine months ended
 September&amp;#xA0;30, 2013 and 2012 were 7,853,936 and 8,075,898,
 respectively.&lt;/p&gt;
 &lt;!-- xbrl,n --&gt;

 &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_1982133_0D22B7AA-EFE6-4802-937E-B1BBCD9F0428_1_0">7853936</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:UseOfEstimates contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_0A400CCA-C4DF-4AEF-AEE7-83E35354FD21_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates and Classifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The preparation of financial statements in conformity with
 generally accepted accounting principles requires management to
 make estimates and assumptions that affect the amounts reported in
 the financial statements and the accompanying notes. On an ongoing
 basis, management evaluates its estimates, including critical
 accounting policies or estimates related to revenue recognition,
 clinical trial accruals, and stock-based compensation. Estimates
 are based on historical experience and on various other market
 specific and other relevant assumptions that the Company believes
 to be reasonable under the circumstances, the results of which form
 the basis for making judgments about the carrying values of assets
 and liabilities that are not readily apparent from other sources.
 Actual results could differ from those estimates.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_D8C48A38-6E64-4B86-817F-C978E8323DE4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Basic net loss per share has been computed by dividing the net loss
 by the weighted-average number of shares of common stock
 outstanding during the period. Diluted net loss per share is
 calculated by dividing net loss by the weighted average number of
 shares of common stock and potential dilutive securities
 outstanding during the period.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_34458F92-8F18-45A5-A4E0-E16DE4D14056_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;NOTE 2&amp;#x2014;INVESTMENTS AND FAIR VALUE MEASUREMENT&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Investments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Sangamo classifies its marketable securities as available-for-sale
 and records its investments at fair value. Available-for-sale
 securities are carried at estimated fair value based on quoted
 market prices, with the unrealized holding gains and losses
 included in accumulated other comprehensive income. Marketable
 securities which have maturities beyond one year as of the end of
 the reporting period are classified as non-current. The
 Company&amp;#x2019;s investments are subject to a periodic impairment
 review and the Company recognizes an impairment charge when a
 decline in the fair value of its investments below the cost basis
 is judged to be other-than-temporary. The Company considers various
 factors in determining whether to recognize an impairment charge,
 including the length of time and extent to which the fair value has
 been less than the Company&amp;#x2019;s cost basis, the financial
 condition and near-term prospects of the investee, and the
 Company&amp;#x2019;s intent and ability to hold the investment for a
 period of time sufficient to allow for any anticipated recovery in
 the market value.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The table below summarizes the Company&amp;#x2019;s available-for-sale
 securities (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Amortized&lt;br /&gt;
 Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gross&lt;br /&gt;
 Unrealized&lt;br /&gt;
 Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gross&lt;br /&gt;
 Unrealized&lt;br /&gt;
 (Losses)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Estimated&lt;br /&gt;
 Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Cash equivalents:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,758&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,758&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,758&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,758&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Available-for-sale securities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,577&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,577&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total cash equivalents and available-for-sale securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;62,335&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;62,361&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2012&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Cash equivalents:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,997&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,997&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,836&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,836&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Available-for-sale securities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,426&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,426&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total cash equivalents and available-for-sale securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,262&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 As of September&amp;#xA0;30, 2013, none of the available-for-sale
 securities held by the Company had material unrealized losses and
 there were no realized losses for the three and nine months ended
 September&amp;#xA0;30, 2013. The Company had no other-than-temporary
 impairments of available-for-sale securities for the three and nine
 months ended September&amp;#xA0;30, 2013 or the twelve months ended
 December&amp;#xA0;31, 2012.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value Measurement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company measures certain financial assets at fair value on a
 recurring basis, including cash equivalents and available-for
 sale-securities.&amp;#xA0;The fair value of these assets was determined
 based on a three-tier hierarchy under the authoritative guidance
 for fair value measurements and disclosures that prioritizes the
 inputs used in measuring fair value as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt"&gt;
 Level 1: Unadjusted quoted prices in active markets that are
 accessible at the measurement date for identical, unrestricted
 assets or liabilities;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt"&gt;
 Level 2: Quoted prices in markets that are not active or inputs
 which are observable, either directly or indirectly, for
 substantially the full term of the asset or liability;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt"&gt;
 Level 3: Prices or valuation techniques that require inputs that
 are both significant to the fair value measurement and unobservable
 (i.e., supported by little or no market activity).&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt"&gt;
 The Company generally classifies its available-for-sale debt
 instruments as Level 2. Instruments can be classified as Level 2
 when observable market prices for identical securities that are
 traded in less active markets are used. When observable market
 prices for identical securities are not available, such instruments
 are priced using benchmark curves, benchmarking of like securities,
 sector groupings, and matrix pricing as well as model processes.
 These models are proprietary to the pricing providers or brokers.
 These valuation models incorporate a number of inputs, including,
 listed in approximate order of priority: benchmark yields, reported
 trades, broker/dealer quotes, issuer spreads, two-sided markets,
 benchmark securities, bids, offers and reference data including
 market research publications. For certain security types,
 additional inputs may be used, or some of the standard inputs may
 not be applicable. Evaluators may prioritize inputs differently on
 any given day for any security based on market conditions, and not
 all inputs listed are available for use in the evaluation process
 for each security evaluation on any given day.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt"&gt;
 The fair value measurements of our cash equivalents and
 available-for-sale marketable securities are identified at the
 following levels within the fair value hierarchy (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;br /&gt;
 Fair&amp;#xA0;Value&amp;#xA0;Measurements&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Cash equivalents:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,758&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,758&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,758&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,758&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Available-for-sale securities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total cash equivalents and available-for-sale securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;62,361&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,758&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;br /&gt;
 Fair&amp;#xA0;Value&amp;#xA0;Measurements&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Cash equivalents:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,997&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,997&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,836&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,997&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Available-for-sale securities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt"&gt;
 U.S. government sponsored entity debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total cash equivalents and available-for-sale securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,839&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,449&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
  <us-gaap:Revenues contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_3_3">17264000</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1_9">387000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_50D71D74-58BC-4FE7-9EA0-AF98DC2047DD_3_2">-18480000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_3_9">52000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:RevenueFromGrants contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_3_2">2199000</us-gaap:RevenueFromGrants>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_3_8">-18532000</us-gaap:OperatingIncomeLoss>
  <us-gaap:PaymentsToAcquireInvestments contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1_15">37161000</us-gaap:PaymentsToAcquireInvestments>
  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1_7">18000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1_8">696000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:NetIncomeLoss contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_3_10">-18480000</us-gaap:NetIncomeLoss>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1_17">395000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_1982133_50D71D74-58BC-4FE7-9EA0-AF98DC2047DD_3_1" />
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1_11">-434000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_3_6">9595000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1_22">75627000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1_12">-1630000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1_10">-1348000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1_5">4098000</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1_23">58630000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1_21">6135000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1_18">828000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1_20">69492000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_3_5">26201000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1_16">38384000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1_3">445000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_5B1E4B3C-1A37-4E46-9FD9-D6A660E9964D_3_3">4098000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_3_7">35796000</us-gaap:OperatingExpenses>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_1_4">625000</us-gaap:AmortizationOfDebtDiscountPremium>
  <sgmo:CollaborationAgreements contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_3_1">15065000</sgmo:CollaborationAgreements>
  <sgmo:PotentialRoyaltyPaymentsToEntity contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0" id="id_1982133_A18837AC-1725-4881-B43E-8CF79BFFDC03_1_0">Two times the amount  Sangamo receives in funding under the agreement</sgmo:PotentialRoyaltyPaymentsToEntity>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_925277x1019175" unitRef="iso4217_USD" decimals="-5" id="id_1982133_787F2C8E-E7C5-480B-8351-D8B2F2D40370_1004_1">0</sgmo:ResearchGrantRevenue>
  <sgmo:ContractualAgreementTerminationDate contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_925277x1019175" id="id_1982133_7C424DF9-0408-4EAF-8754-570A5530545D_1002_3">2012-08-30</sgmo:ContractualAgreementTerminationDate>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_925277x1019175" unitRef="iso4217_USD" decimals="-5" id="id_1982133_787F2C8E-E7C5-480B-8351-D8B2F2D40370_1004_0">0</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_925277x1044992" unitRef="iso4217_USD" decimals="-5" id="id_1982133_5E6C72B6-C754-47A3-893F-E2A8662EFFD6_1004_0">0</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_925277x1137514" unitRef="iso4217_USD" decimals="-5" id="id_1982133_99949649-9CBF-4255-AB1A-B851A5664669_1003_1">1400000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_925277x1137514_926233x928673" unitRef="iso4217_USD" decimals="-5" id="id_1982133_99949649-9CBF-4255-AB1A-B851A5664669_2003_0">1200000</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_926233x928673_933025x982693" unitRef="iso4217_USD" decimals="-5" id="id_1982133_98126775-E8C9-436E-BBB6-93F478FBAA50_1003_0">100000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_927015x925832" unitRef="iso4217_USD" decimals="-3" id="id_1982133_5B1E4B3C-1A37-4E46-9FD9-D6A660E9964D_1003_2">1958000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_927015x928963" unitRef="iso4217_USD" decimals="-3" id="id_1982133_5B1E4B3C-1A37-4E46-9FD9-D6A660E9964D_2003_1">2140000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A9DE8E6B-270A-4B34-A2E2-AF62E0B41407_1002_2">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A9DE8E6B-270A-4B34-A2E2-AF62E0B41407_1002_1">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
  <us-gaap:LicensesRevenue contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_1982133_253D454B-ACD2-4B30-88C8-E2B84321649C_1004_0">0</us-gaap:LicensesRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_1982133_253D454B-ACD2-4B30-88C8-E2B84321649C_1004_1">0</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x982693" id="id_1982133_75FF357F-5DE8-4F97-9AFD-E8895FFE2B98_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Revenues recognized under the agreement with Sigma for the three
 and nine months ended September&amp;#xA0;30, 2013 and
 September&amp;#xA0;30, 2012, were as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Revenue related to Sigma Collaboration&lt;b&gt;:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Royalty revenues&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;201&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;428&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;711&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,035&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 License fee and milestone revenues&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;101&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,351&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;302&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;428&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,062&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,035&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock>
  <us-gaap:RevenueFromRelatedParties contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A3D19734-B311-4658-8422-A751ADD08E4F_1003_3">2062000</us-gaap:RevenueFromRelatedParties>
  <us-gaap:LicensesRevenue contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A3D19734-B311-4658-8422-A751ADD08E4F_1003_2">1351000</us-gaap:LicensesRevenue>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A3D19734-B311-4658-8422-A751ADD08E4F_1003_1">711000</us-gaap:RoyaltyRevenue>
  <us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x992959" id="id_1982133_50701882-26A3-4621-A23B-CEFC5AC5979A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Revenues recognized under the agreement with Shire for the three
 and nine months ended September&amp;#xA0;30, 2013 and
 September&amp;#xA0;30, 2012, were as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine months ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Revenue related to Shire Collaboration:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Amortization of upfront fee&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;542&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;542&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,625&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,444&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Research services&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,968&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,675&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,340&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,747&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,510&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,217&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,965&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,191&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock>
  <us-gaap:ContractsRevenue contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x992959" unitRef="iso4217_USD" decimals="-3" id="id_1982133_8A5368F6-176E-45EF-AFC8-33112DE79055_1003_3">12965000</us-gaap:ContractsRevenue>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x992959" unitRef="iso4217_USD" decimals="-5" id="id_1982133_650E6CAC-062F-470E-98E8-32E2DE4874E5_1001_1">0</us-gaap:RoyaltyRevenue>
  <sgmo:InitialResearchTermOfAgreement contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x992959" id="id_1982133_5C1F23E2-B61D-42E8-A6EE-5392A1B97EA2_1001_0">P6Y</sgmo:InitialResearchTermOfAgreement>
  <sgmo:ResearchServiceRevenueUnderCollaborationAgreement contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x992959" unitRef="iso4217_USD" decimals="-3" id="id_1982133_8A5368F6-176E-45EF-AFC8-33112DE79055_1003_2">11340000</sgmo:ResearchServiceRevenueUnderCollaborationAgreement>
  <sgmo:DeferredUpfrontContractFeeRevenue contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x992959" unitRef="iso4217_USD" decimals="-3" id="id_1982133_8A5368F6-176E-45EF-AFC8-33112DE79055_1003_1">1625000</sgmo:DeferredUpfrontContractFeeRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x992959" unitRef="iso4217_USD" decimals="-5" id="id_1982133_203FBC31-1CF2-48AC-A219-9840ACFB29C3_1003_0">10300000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x992959" unitRef="iso4217_USD" decimals="-5" id="id_1982133_C4415E8D-185D-445A-9F76-876653E77A43_1002_1">213500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized>
  <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x992959" unitRef="iso4217_USD" decimals="-5" id="id_1982133_C4415E8D-185D-445A-9F76-876653E77A43_1002_2">8500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication>
  <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement contextRef="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x992959" unitRef="Product" decimals="-6" id="id_1982133_650E6CAC-062F-470E-98E8-32E2DE4874E5_1001_0">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="shares" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_4_12">52664000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_2_13">-8305000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_4_11">-0.36</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="shares" decimals="INF" id="id_1982133_0D22B7AA-EFE6-4802-937E-B1BBCD9F0428_2_0">8075898</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Revenues contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_4_3">12723000</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_2_9">364000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_50D71D74-58BC-4FE7-9EA0-AF98DC2047DD_4_2">-18783000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_4_9">43000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:RevenueFromGrants contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_4_2">3058000</us-gaap:RevenueFromGrants>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_4_8">-18829000</us-gaap:OperatingIncomeLoss>
  <us-gaap:PaymentsToAcquireInvestments contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_2_15">70570000</us-gaap:PaymentsToAcquireInvestments>
  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_2_7">-20000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_2_8">2585000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:NetIncomeLoss contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_4_10">-18786000</us-gaap:NetIncomeLoss>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_2_17">363000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_50D71D74-58BC-4FE7-9EA0-AF98DC2047DD_4_1">3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_2_11">159000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_4_6">9125000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_2_22">1041000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_2_12">11818000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_2_10">-3770000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_2_5">4011000</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_2_23">-3042000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_2_21">1041000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_2_18">4222000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_4_5">22427000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_2_16">75155000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_2_3">500000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_5B1E4B3C-1A37-4E46-9FD9-D6A660E9964D_4_3">4011000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_4_7">31552000</us-gaap:OperatingExpenses>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_6C94554B-933D-4AD5-A969-68A5F5664856_2_4">692000</us-gaap:AmortizationOfDebtDiscountPremium>
  <sgmo:CollaborationAgreements contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_4_1">9665000</sgmo:CollaborationAgreements>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0_925277x1019175" unitRef="iso4217_USD" decimals="-5" id="id_1982133_787F2C8E-E7C5-480B-8351-D8B2F2D40370_1002_1">1100000</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0_925277x1019175" unitRef="iso4217_USD" decimals="-5" id="id_1982133_787F2C8E-E7C5-480B-8351-D8B2F2D40370_1002_0">1100000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0_925277x1044992" unitRef="iso4217_USD" decimals="-5" id="id_1982133_5E6C72B6-C754-47A3-893F-E2A8662EFFD6_1002_0">800000</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0_925277x1137514" unitRef="iso4217_USD" decimals="-5" id="id_1982133_99949649-9CBF-4255-AB1A-B851A5664669_1004_1">900000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0_925277x1137514_926233x928673" unitRef="iso4217_USD" decimals="-5" id="id_1982133_99949649-9CBF-4255-AB1A-B851A5664669_2004_0">900000</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0_926233x928673_933025x982693" unitRef="iso4217_USD" decimals="-5" id="id_1982133_98126775-E8C9-436E-BBB6-93F478FBAA50_1004_0">300000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0_927015x925832" unitRef="iso4217_USD" decimals="-3" id="id_1982133_5B1E4B3C-1A37-4E46-9FD9-D6A660E9964D_1004_2">1816000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0_927015x928963" unitRef="iso4217_USD" decimals="-3" id="id_1982133_5B1E4B3C-1A37-4E46-9FD9-D6A660E9964D_2004_1">2195000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:LicensesRevenue contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_1982133_253D454B-ACD2-4B30-88C8-E2B84321649C_1002_0">1300000</us-gaap:LicensesRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_1982133_253D454B-ACD2-4B30-88C8-E2B84321649C_1002_1">400000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <us-gaap:RevenueFromRelatedParties contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A3D19734-B311-4658-8422-A751ADD08E4F_1004_3">2035000</us-gaap:RevenueFromRelatedParties>
  <us-gaap:LicensesRevenue contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A3D19734-B311-4658-8422-A751ADD08E4F_1004_2">1000000</us-gaap:LicensesRevenue>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A3D19734-B311-4658-8422-A751ADD08E4F_1004_1">1035000</us-gaap:RoyaltyRevenue>
  <us-gaap:ContractsRevenue contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0_933025x992959" unitRef="iso4217_USD" decimals="-3" id="id_1982133_8A5368F6-176E-45EF-AFC8-33112DE79055_1004_3">6191000</us-gaap:ContractsRevenue>
  <sgmo:ResearchServiceRevenueUnderCollaborationAgreement contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0_933025x992959" unitRef="iso4217_USD" decimals="-3" id="id_1982133_8A5368F6-176E-45EF-AFC8-33112DE79055_1004_2">4747000</sgmo:ResearchServiceRevenueUnderCollaborationAgreement>
  <sgmo:DeferredUpfrontContractFeeRevenue contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0_933025x992959" unitRef="iso4217_USD" decimals="-3" id="id_1982133_8A5368F6-176E-45EF-AFC8-33112DE79055_1004_1">1444000</sgmo:DeferredUpfrontContractFeeRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_274_20120930_0_933025x992959" unitRef="iso4217_USD" decimals="-5" id="id_1982133_203FBC31-1CF2-48AC-A219-9840ACFB29C3_1004_0">3800000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:AgreementToReceive contextRef="eol_PE72223---1310-Q0003_STD_30_20110430_0_925277x1019175" id="id_1982133_7C424DF9-0408-4EAF-8754-570A5530545D_1001_2">P1Y</sgmo:AgreementToReceive>
  <us-gaap:LicensesRevenue contextRef="eol_PE72223---1310-Q0003_STD_30_20130430_0_933025x982693" unitRef="iso4217_USD" decimals="-5" id="id_1982133_ADD7B12E-9870-4F5A-AAC3-57F4CD0496AC_1003_3">1300000</us-gaap:LicensesRevenue>
  <sgmo:NumberOfGeneTargets contextRef="eol_PE72223---1310-Q0003_STD_30_20120630_0_933025x992959" unitRef="Targets" decimals="INF" id="id_1982133_8B519CF1-755A-4CB8-81C1-4DAE07AE1DE8_1002_2">5</sgmo:NumberOfGeneTargets>
  <sgmo:NumberOfAdditionalGeneTargets contextRef="eol_PE72223---1310-Q0003_STD_30_20120630_0_933025x992959" unitRef="Targets" decimals="INF" id="id_1982133_8B519CF1-755A-4CB8-81C1-4DAE07AE1DE8_1002_3">2</sgmo:NumberOfAdditionalGeneTargets>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="eol_PE72223---1310-Q0003_STD_30_20131001_0_932504x931597" unitRef="shares" decimals="INF" id="id_1982133_B61B2002-C9F6-4F40-AD7A-371872587755_1001_0">100000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE72223---1310-Q0003_STD_31_20051031_0_926233x928673_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_1982133_99AC701F-D323-4582-9B9A-6A256D0D6AC7_1001_2">4000000</us-gaap:RoyaltyRevenue>
  <sgmo:AnnualFeesRelatedToAgreement contextRef="eol_PE72223---1310-Q0003_STD_31_20051031_0_926437x923140_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_1982133_DE1DBE42-3613-4054-A11D-C434E79B0059_2_500000">3000000</sgmo:AnnualFeesRelatedToAgreement>
  <sgmo:AnnualFeesRelatedToAgreement contextRef="eol_PE72223---1310-Q0003_STD_31_20051031_0_926437x932953_933025x1094419" unitRef="iso4217_USD" decimals="1" id="id_1982133_DE1DBE42-3613-4054-A11D-C434E79B0059_1_400000">250000.0</sgmo:AnnualFeesRelatedToAgreement>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE72223---1310-Q0003_STD_31_20051031_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_1982133_99AC701F-D323-4582-9B9A-6A256D0D6AC7_2001_1">2300000</us-gaap:RoyaltyRevenue>
  <sgmo:MinimumSublicenseAnnualFeesSpecificReckoningPeriod contextRef="eol_PE72223---1310-Q0003_STD_31_20051031_0_933025x1094419" id="id_1982133_DE1DBE42-3613-4054-A11D-C434E79B0059_3_600001">P11Y</sgmo:MinimumSublicenseAnnualFeesSpecificReckoningPeriod>
  <sgmo:InitialResearchTermOfAgreement contextRef="eol_PE72223---1310-Q0003_STD_31_20051031_0_933025x1094419" id="id_1982133_6BE28DD3-8EB4-458C-A592-43DBE4163079_1001_0">P3Y</sgmo:InitialResearchTermOfAgreement>
  <sgmo:FeeDue contextRef="eol_PE72223---1310-Q0003_STD_31_20051031_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_1982133_DE1DBE42-3613-4054-A11D-C434E79B0059_3_600002">25300000</sgmo:FeeDue>
  <sgmo:PercentageOfRoyaltiesToBeReceivedFromSublicensing contextRef="eol_PE72223---1310-Q0003_STD_31_20051031_0_933025x1094419" unitRef="pure" decimals="2" id="id_1982133_99AC701F-D323-4582-9B9A-6A256D0D6AC7_2001_3">0.25</sgmo:PercentageOfRoyaltiesToBeReceivedFromSublicensing>
  <sgmo:InitialResearchTermOfAgreement contextRef="eol_PE72223---1310-Q0003_STD_31_20070731_0_933025x982693" id="id_1982133_9F065770-20B7-4DD8-BDB6-EE1AE2CDAD87_1001_0">P3Y</sgmo:InitialResearchTermOfAgreement>
  <sgmo:GrantFundingAmount contextRef="eol_PE72223---1310-Q0003_STD_31_20091031_0_925277x1137514" unitRef="iso4217_USD" decimals="-5" id="id_1982133_BFE60265-5558-4A89-8BCB-59EC00C49ED1_1001_0">14500000</sgmo:GrantFundingAmount>
  <sgmo:AgreementToReceive contextRef="eol_PE72223---1310-Q0003_STD_31_20091031_0_925277x1137514" id="id_1982133_BFE60265-5558-4A89-8BCB-59EC00C49ED1_1001_1">P4Y</sgmo:AgreementToReceive>
  <sgmo:UpfrontLicenseFee contextRef="eol_PE72223---1310-Q0003_STD_31_20091031_0_926233x1007904_933025x982693" unitRef="iso4217_USD" decimals="-5" id="id_1982133_B9597350-F8FD-47CA-9F58-3B8D05FDD733_1001_3">15100000</sgmo:UpfrontLicenseFee>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE72223---1310-Q0003_STD_31_20091031_0_933025x982693" unitRef="shares" decimals="INF" id="id_1982133_B9597350-F8FD-47CA-9F58-3B8D05FDD733_2001_2">636133</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE72223---1310-Q0003_STD_31_20091031_0_933025x982693" unitRef="iso4217_USD" decimals="-5" id="id_1982133_B9597350-F8FD-47CA-9F58-3B8D05FDD733_2001_1">4900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <sgmo:UpfrontLicenseFee contextRef="eol_PE72223---1310-Q0003_STD_31_20091031_0_933025x982693" unitRef="iso4217_USD" decimals="-5" id="id_1982133_B9597350-F8FD-47CA-9F58-3B8D05FDD733_2001_0">20000000</sgmo:UpfrontLicenseFee>
  <sgmo:ReducedRoyaltyRate contextRef="eol_PE72223---1310-Q0003_STD_31_20091031_0_933025x982693" unitRef="pure" decimals="3" id="id_1982133_ADD7B12E-9870-4F5A-AAC3-57F4CD0496AC_1002_1">0.105</sgmo:ReducedRoyaltyRate>
  <sgmo:GrantFundingAmountMaximumUnderAmendedAgreement contextRef="eol_PE72223---1310-Q0003_STD_31_20100131_0_925277x1044992" unitRef="iso4217_USD" decimals="-5" id="id_1982133_306AC1B8-3E4C-405A-8CC8-AF6A1F6E8F86_1002_1">3000000</sgmo:GrantFundingAmountMaximumUnderAmendedAgreement>
  <sgmo:AggregateNumberOfGeneTargets contextRef="eol_PE72223---1310-Q0003_STD_31_20120131_0_933025x992959" unitRef="Targets" decimals="INF" id="id_1982133_8B519CF1-755A-4CB8-81C1-4DAE07AE1DE8_1001_0">7</sgmo:AggregateNumberOfGeneTargets>
  <sgmo:UpfrontLicenseFee contextRef="eol_PE72223---1310-Q0003_STD_31_20120131_0_933025x992959" unitRef="iso4217_USD" decimals="-5" id="id_1982133_C4415E8D-185D-445A-9F76-876653E77A43_1001_0">13000000</sgmo:UpfrontLicenseFee>
  <sgmo:NumberOfInitialGeneTargets contextRef="eol_PE72223---1310-Q0003_STD_31_20120131_0_933025x992959" unitRef="Targets" decimals="INF" id="id_1982133_8B519CF1-755A-4CB8-81C1-4DAE07AE1DE8_1001_1">4</sgmo:NumberOfInitialGeneTargets>
  <sgmo:ProceedsReceivedForWorkPerformedUnderAgreement contextRef="eol_PE72223---1310-Q0003_STD_31_20120331_0_925277x1044992" unitRef="iso4217_USD" decimals="-5" id="id_1982133_94E48B9B-5AAB-4FF1-979B-64B1F2B20AB2_1001_0">800000</sgmo:ProceedsReceivedForWorkPerformedUnderAgreement>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="eol_PE72223---1310-Q0003_STD_31_20130923_0_926607x960063_926956x930643_931707x926487" unitRef="shares" decimals="INF" id="id_1982133_27786E8E-AA7B-4063-953F-19A09B5DD307_1002_0">915000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="eol_PE72223---1310-Q0003_STD_31_20130923_0_926956x930643_931707x926487" unitRef="shares" decimals="INF" id="id_1982133_27786E8E-AA7B-4063-953F-19A09B5DD307_1001_0">7015000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="eol_PE72223---1310-Q0003_STD_31_20130923_0_931707x926487" unitRef="iso4217_USD" decimals="-5" id="id_1982133_27786E8E-AA7B-4063-953F-19A09B5DD307_2001_2">69500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="eol_PE72223---1310-Q0003_STD_366_20121231_0_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A9DE8E6B-270A-4B34-A2E2-AF62E0B41407_1003_2">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0" unitRef="shares" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_2_12">52768000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_2_11">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_2_3">4907000</us-gaap:Revenues>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_50D71D74-58BC-4FE7-9EA0-AF98DC2047DD_2_2">-5768000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_2_9">12000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:RevenueFromGrants contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_2_2">717000</us-gaap:RevenueFromGrants>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_2_8">-5802000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_2_10">-5790000</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_50D71D74-58BC-4FE7-9EA0-AF98DC2047DD_2_1">22000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_2_6">3139000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_2_5">7570000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_5B1E4B3C-1A37-4E46-9FD9-D6A660E9964D_2_3">1404000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_2_7">10709000</us-gaap:OperatingExpenses>
  <sgmo:CollaborationAgreements contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_2_1">4190000</sgmo:CollaborationAgreements>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0_925277x1019175" unitRef="iso4217_USD" decimals="-5" id="id_1982133_787F2C8E-E7C5-480B-8351-D8B2F2D40370_1001_1">300000</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0_925277x1019175" unitRef="iso4217_USD" decimals="-5" id="id_1982133_787F2C8E-E7C5-480B-8351-D8B2F2D40370_1001_0">300000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0_925277x1044992" unitRef="iso4217_USD" decimals="-5" id="id_1982133_5E6C72B6-C754-47A3-893F-E2A8662EFFD6_1001_0">0</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0_925277x1137514" unitRef="iso4217_USD" decimals="-5" id="id_1982133_99949649-9CBF-4255-AB1A-B851A5664669_1002_1">300000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0_925277x1137514_926233x928673" unitRef="iso4217_USD" decimals="-5" id="id_1982133_99949649-9CBF-4255-AB1A-B851A5664669_2002_0">300000</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0_926233x928673_933025x982693" unitRef="iso4217_USD" decimals="-5" id="id_1982133_98126775-E8C9-436E-BBB6-93F478FBAA50_1002_0">100000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0_927015x925832" unitRef="iso4217_USD" decimals="-3" id="id_1982133_5B1E4B3C-1A37-4E46-9FD9-D6A660E9964D_1002_2">630000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0_927015x928963" unitRef="iso4217_USD" decimals="-3" id="id_1982133_5B1E4B3C-1A37-4E46-9FD9-D6A660E9964D_2002_1">774000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:LicensesRevenue contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_1982133_253D454B-ACD2-4B30-88C8-E2B84321649C_1001_0">400000</us-gaap:LicensesRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_1982133_253D454B-ACD2-4B30-88C8-E2B84321649C_1001_1">100000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <us-gaap:RevenueFromRelatedParties contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A3D19734-B311-4658-8422-A751ADD08E4F_1002_3">428000</us-gaap:RevenueFromRelatedParties>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A3D19734-B311-4658-8422-A751ADD08E4F_1002_1">428000</us-gaap:RoyaltyRevenue>
  <us-gaap:ContractsRevenue contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0_933025x992959" unitRef="iso4217_USD" decimals="-3" id="id_1982133_8A5368F6-176E-45EF-AFC8-33112DE79055_1002_3">3217000</us-gaap:ContractsRevenue>
  <sgmo:ResearchServiceRevenueUnderCollaborationAgreement contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0_933025x992959" unitRef="iso4217_USD" decimals="-3" id="id_1982133_8A5368F6-176E-45EF-AFC8-33112DE79055_1002_2">2675000</sgmo:ResearchServiceRevenueUnderCollaborationAgreement>
  <sgmo:DeferredUpfrontContractFeeRevenue contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0_933025x992959" unitRef="iso4217_USD" decimals="-3" id="id_1982133_8A5368F6-176E-45EF-AFC8-33112DE79055_1002_1">542000</sgmo:DeferredUpfrontContractFeeRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_92_20120930_0_933025x992959" unitRef="iso4217_USD" decimals="-5" id="id_1982133_203FBC31-1CF2-48AC-A219-9840ACFB29C3_1002_0">2200000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0" unitRef="shares" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_1_12">54786000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_1_11">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_1_3">5707000</us-gaap:Revenues>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_50D71D74-58BC-4FE7-9EA0-AF98DC2047DD_1_2">-6118000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_1_9">14000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:RevenueFromGrants contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_1_2">882000</us-gaap:RevenueFromGrants>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_1_8">-6159000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_1_10">-6145000</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_50D71D74-58BC-4FE7-9EA0-AF98DC2047DD_1_1">27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_1_6">3163000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_1_5">8703000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_5B1E4B3C-1A37-4E46-9FD9-D6A660E9964D_1_3">1391000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_1_7">11866000</us-gaap:OperatingExpenses>
  <sgmo:CollaborationAgreements contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_1982133_42CDE507-4F9D-465E-961C-0087C273ACBA_1_1">4825000</sgmo:CollaborationAgreements>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_925277x1019175" unitRef="iso4217_USD" decimals="-5" id="id_1982133_787F2C8E-E7C5-480B-8351-D8B2F2D40370_1003_1">0</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_925277x1019175" unitRef="iso4217_USD" decimals="-5" id="id_1982133_787F2C8E-E7C5-480B-8351-D8B2F2D40370_1003_0">0</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_925277x1044992" unitRef="iso4217_USD" decimals="-5" id="id_1982133_5E6C72B6-C754-47A3-893F-E2A8662EFFD6_1003_0">0</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_925277x1137514" unitRef="iso4217_USD" decimals="-5" id="id_1982133_99949649-9CBF-4255-AB1A-B851A5664669_1001_1">500000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <sgmo:ResearchGrantRevenue contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_925277x1137514_926233x928673" unitRef="iso4217_USD" decimals="-5" id="id_1982133_99949649-9CBF-4255-AB1A-B851A5664669_2001_0">500000</sgmo:ResearchGrantRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_926233x928673_933025x982693" unitRef="iso4217_USD" decimals="-5" id="id_1982133_98126775-E8C9-436E-BBB6-93F478FBAA50_1001_0">100000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_927015x925832" unitRef="iso4217_USD" decimals="-3" id="id_1982133_5B1E4B3C-1A37-4E46-9FD9-D6A660E9964D_1001_2">659000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_927015x928963" unitRef="iso4217_USD" decimals="-3" id="id_1982133_5B1E4B3C-1A37-4E46-9FD9-D6A660E9964D_2001_1">732000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A9DE8E6B-270A-4B34-A2E2-AF62E0B41407_1001_2">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_932040x927011" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A9DE8E6B-270A-4B34-A2E2-AF62E0B41407_1001_1">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
  <us-gaap:LicensesRevenue contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_1982133_253D454B-ACD2-4B30-88C8-E2B84321649C_1003_0">0</us-gaap:LicensesRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_933025x1094419" unitRef="iso4217_USD" decimals="-5" id="id_1982133_253D454B-ACD2-4B30-88C8-E2B84321649C_1003_1">0</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <us-gaap:RevenueFromRelatedParties contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A3D19734-B311-4658-8422-A751ADD08E4F_1001_3">302000</us-gaap:RevenueFromRelatedParties>
  <us-gaap:LicensesRevenue contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A3D19734-B311-4658-8422-A751ADD08E4F_1001_2">101000</us-gaap:LicensesRevenue>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_933025x982693" unitRef="iso4217_USD" decimals="-3" id="id_1982133_A3D19734-B311-4658-8422-A751ADD08E4F_1001_1">201000</us-gaap:RoyaltyRevenue>
  <us-gaap:ContractsRevenue contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_933025x992959" unitRef="iso4217_USD" decimals="-3" id="id_1982133_8A5368F6-176E-45EF-AFC8-33112DE79055_1001_3">4510000</us-gaap:ContractsRevenue>
  <sgmo:ResearchServiceRevenueUnderCollaborationAgreement contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_933025x992959" unitRef="iso4217_USD" decimals="-3" id="id_1982133_8A5368F6-176E-45EF-AFC8-33112DE79055_1001_2">3968000</sgmo:ResearchServiceRevenueUnderCollaborationAgreement>
  <sgmo:DeferredUpfrontContractFeeRevenue contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_933025x992959" unitRef="iso4217_USD" decimals="-3" id="id_1982133_8A5368F6-176E-45EF-AFC8-33112DE79055_1001_1">542000</sgmo:DeferredUpfrontContractFeeRevenue>
  <sgmo:CollaborationAgreementRelatedCostsAndExpenses contextRef="eol_PE72223---1310-Q0003_STD_92_20130930_0_933025x992959" unitRef="iso4217_USD" decimals="-5" id="id_1982133_203FBC31-1CF2-48AC-A219-9840ACFB29C3_1001_0">3500000</sgmo:CollaborationAgreementRelatedCostsAndExpenses>
  <context id="eol_PE72223---1310-Q0003_STD_92_20130930_0_933025x992959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20130930_0_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20130930_0_933025x1094419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20130930_0_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20130930_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20130930_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20130930_0_926233x928673_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20130930_0_925277x1137514_926233x928673">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20130930_0_925277x1137514">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20130930_0_925277x1044992">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:JuvenileDiabetesResearchFoundationInternationalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20130930_0_925277x1019175">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:ChdiFoundationIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20120930_0_933025x992959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20120930_0_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20120930_0_933025x1094419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20120930_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20120930_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20120930_0_926233x928673_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20120930_0_925277x1137514_926233x928673">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20120930_0_925277x1137514">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20120930_0_925277x1044992">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:JuvenileDiabetesResearchFoundationInternationalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20120930_0_925277x1019175">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:ChdiFoundationIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_92_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_366_20121231_0_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_31_20130923_0_931707x926487">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-08-24</startDate>
      <endDate>2013-09-23</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_31_20130923_0_926956x930643_931707x926487">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-08-24</startDate>
      <endDate>2013-09-23</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_31_20130923_0_926607x960063_926956x930643_931707x926487">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sgmo:UnderwritersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-08-24</startDate>
      <endDate>2013-09-23</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_31_20120331_0_925277x1044992">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:JuvenileDiabetesResearchFoundationInternationalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-03-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_31_20120131_0_933025x992959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_31_20100131_0_925277x1044992">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:JuvenileDiabetesResearchFoundationInternationalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_31_20091031_0_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_31_20091031_0_926233x1007904_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:UpfrontLicenseFeesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_31_20091031_0_925277x1137514">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_31_20070731_0_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2007-07-01</startDate>
      <endDate>2007-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_31_20051031_0_933025x1094419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2005-10-01</startDate>
      <endDate>2005-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_31_20051031_0_926437x932953_933025x1094419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2005-10-01</startDate>
      <endDate>2005-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_31_20051031_0_926437x923140_933025x1094419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2005-10-01</startDate>
      <endDate>2005-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_31_20051031_0_926233x928673_933025x1094419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2005-10-01</startDate>
      <endDate>2005-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_30_20131001_0_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-09-02</startDate>
      <endDate>2013-10-01</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_30_20120630_0_933025x992959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-06-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_30_20130430_0_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_30_20110430_0_925277x1019175">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:ChdiFoundationIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_274_20120930_0_933025x992959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_274_20120930_0_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_274_20120930_0_933025x1094419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_274_20120930_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_274_20120930_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_274_20120930_0_926233x928673_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_274_20120930_0_925277x1137514_926233x928673">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_274_20120930_0_925277x1137514">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_274_20120930_0_925277x1044992">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:JuvenileDiabetesResearchFoundationInternationalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_274_20120930_0_925277x1019175">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:ChdiFoundationIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_274_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x992959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_273_20130930_0_933025x1094419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_273_20130930_0_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_273_20130930_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_273_20130930_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_273_20130930_0_926233x928673_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_273_20130930_0_925277x1137514_926233x928673">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_273_20130930_0_925277x1137514">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_273_20130930_0_925277x1044992">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:JuvenileDiabetesResearchFoundationInternationalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_273_20130930_0_925277x1019175">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:ChdiFoundationIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_273_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_929790x929831_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_929790x929831_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_929790x929831">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_929790x925851_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_929790x925851_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_929790x925851">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_929790x925736_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_929790x925736_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x932359_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x932359_929790x929831_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x932359_929790x925851_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x932359_929790x925736_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_929790x929831_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_929790x929831_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_929790x925851_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_929790x925851_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_929790x925736_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_928628x924099_929790x925736_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0_925277x1019175">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:ChdiFoundationIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20131001_0_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-10-01</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_933025x992959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_929790x929831_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_929790x929831_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_929790x929831">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_929790x925851_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_929790x925851_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_929790x925851">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_929790x925736_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_929790x925736_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x932359_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x932359_929790x929831_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x932359_929790x925851_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x932359_929790x925736_932040x932792">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x924099_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x924099_929790x929831_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x924099_929790x925851_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0_928628x924099_929790x925736_932040x927011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20130923_0_926956x930643_931707x926487">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-23</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20110430_0_925277x1019175">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:ChdiFoundationIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-04-30</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20131031_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2013-10-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20091031_0_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20091031_0_926233x928673_933025x982693">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20091031_0_925277x1137514">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-10-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20061031_0_925277x1044992">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">sgmo:JuvenileDiabetesResearchFoundationInternationalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2006-10-31</instant>
    </period>
  </context>
  <context id="eol_PE72223---1310-Q0003_STD_0_20051031_0_933025x1094419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2005-10-31</instant>
    </period>
  </context>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Product">
    <measure>sgmo:Product</measure>
  </unit>
  <unit id="Targets">
    <measure>sgmo:Targets</measure>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>sgmo-20130930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2013-11-04T20:27:09Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31"
  xmlns:us-types="http://fasb.org/us-types/2013-01-31"
  xmlns:sgmo="http://sangamo.com/20130930"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://sangamo.com/20130930"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/StatementOfIncome" id="Role_StatementOfIncome">
        <link:definition>105 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/StatementOfOtherComprehensiveIncome" id="Role_StatementOfOtherComprehensiveIncome">
        <link:definition>106 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>107 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <link:definition>108 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock" id="Role_NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock">
        <link:definition>109 - Disclosure - Investments and Fair Value Measurement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock" id="Role_NotesToFinancialStatementsEarningsPerShareTextBlock">
        <link:definition>110 - Disclosure - Basic and Diluted Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" id="Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
        <link:definition>111 - Disclosure - Major Customers, Partnerships and Strategic Alliances</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
        <link:definition>112 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>113 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>114 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>115 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
        <link:definition>116 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables">
        <link:definition>117 - Disclosure - Investments and Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
        <link:definition>118 - Disclosure - Major Customers, Partnerships and Strategic Alliances (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
        <link:definition>119 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformation" id="DisclosureInvestmentsAndFairValueMeasurementAdditionalInformation">
        <link:definition>120 - Disclosure - Investments and Fair Value Measurement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementScheduleOfInvestments" id="DisclosureInvestmentsAndFairValueMeasurementScheduleOfInvestments">
        <link:definition>121 - Disclosure - Investments and Fair Value Measurement - Schedule of Investments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAndAvailableforSaleSecurities" id="DisclosureInvestmentsAndFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAndAvailableforSaleSecurities">
        <link:definition>122 - Disclosure - Investments and Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShareAdditionalInformation" id="DisclosureBasicAndDilutedNetLossPerShareAdditionalInformation">
        <link:definition>123 - Disclosure - Basic and Diluted Net Loss Per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation" id="DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation">
        <link:definition>124 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement" id="DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement">
        <link:definition>125 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense" id="DisclosureStockBasedCompensationStockBasedCompensationExpense">
        <link:definition>126 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation" id="DisclosureStockholdersEquityAdditionalInformation">
        <link:definition>127 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://sangamo.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation" id="DisclosureSubsequentEventsAdditionalInformation">
        <link:definition>128 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="sgmo-20130930_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="sgmo-20130930_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="sgmo-20130930_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="sgmo-20130930_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2013-01-31" schemaLocation="http://xbrl.sec.gov/exch/2013/exch-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AdditionalMilestonePaymentUnderAgreement" id="sgmo_AdditionalMilestonePaymentUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized" id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AggregateNumberOfGeneTargets" id="sgmo_AggregateNumberOfGeneTargets" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AgreementDate" id="sgmo_AgreementDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AgreementToReceive" id="sgmo_AgreementToReceive" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AnnualFeesRelatedToAgreement" id="sgmo_AnnualFeesRelatedToAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" id="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" id="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessAcquisitionTable" id="sgmo_BusinessAcquisitionTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="CaliforniaInstituteForRegenerativeMedicineMember" id="sgmo_CaliforniaInstituteForRegenerativeMedicineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ChdiFoundationIncMember" id="sgmo_ChdiFoundationIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationAgreementRelatedCostsAndExpenses" id="sgmo_CollaborationAgreementRelatedCostsAndExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationAgreements" id="sgmo_CollaborationAgreements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" id="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ContractualAgreementTerminationDate" id="sgmo_ContractualAgreementTerminationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredUpfrontContractFeeRevenue" id="sgmo_DeferredUpfrontContractFeeRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="sgmo_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DowAgroSciencesMember" id="sgmo_DowAgroSciencesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ExpectedAmountToBeReceivedForResearchAndDevelopment" id="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FeeDue" id="sgmo_FeeDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FundsDueUnderAgreement" id="sgmo_FundsDueUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GrantFundingAmount" id="sgmo_GrantFundingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GrantFundingAmountMaximumUnderAmendedAgreement" id="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InitialResearchTermOfAgreement" id="sgmo_InitialResearchTermOfAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InvestmentsMaturityDatesAvailableForSaleSecurities" id="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="JuvenileDiabetesResearchFoundationInternationalMember" id="sgmo_JuvenileDiabetesResearchFoundationInternationalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MinimumSublicenseAnnualFeesSpecificReckoningPeriod" id="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfAdditionalGeneTargets" id="sgmo_NumberOfAdditionalGeneTargets" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfGeneTargets" id="sgmo_NumberOfGeneTargets" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfInitialGeneTargets" id="sgmo_NumberOfInitialGeneTargets" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OneTimeLicenseFeeEarned" id="sgmo_OneTimeLicenseFeeEarned" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfRoyaltiesToBeReceivedFromSublicensing" id="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PostAmendmentFundsDueUnderAgreement" id="sgmo_PostAmendmentFundsDueUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialRoyaltyPaymentsToEntity" id="sgmo_PotentialRoyaltyPaymentsToEntity" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsReceivedForWorkPerformedUnderAgreement" id="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReducedRoyaltyRate" id="sgmo_ReducedRoyaltyRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchGrantRevenue" id="sgmo_ResearchGrantRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchServiceRevenueUnderCollaborationAgreement" id="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyRevenuesExpectedToBeReceived" id="sgmo_RoyaltyRevenuesExpectedToBeReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShireAgMember" id="sgmo_ShireAgMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SigmaAldrichCorporationMember" id="sgmo_SigmaAldrichCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UnderwritersMember" id="sgmo_UnderwritersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontLicenseFee" id="sgmo_UpfrontLicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontLicenseFeesMember" id="sgmo_UpfrontLicenseFeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>sgmo-20130930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2013-11-04T20:27:09Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DocumentandEntityInformation" roleURI="http://sangamo.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_StatementOfIncome" roleURI="http://sangamo.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_StatementOfOtherComprehensiveIncome" roleURI="http://sangamo.com/taxonomy/role/StatementOfOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://sangamo.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureInvestmentsAndFairValueMeasurementAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureInvestmentsAndFairValueMeasurementScheduleOfInvestments" roleURI="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementScheduleOfInvestments"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureInvestmentsAndFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAndAvailableforSaleSecurities" roleURI="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAndAvailableforSaleSecurities"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureBasicAndDilutedNetLossPerShareAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShareAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpense" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssets" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.2000" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_CollaborationAgreements" xlink:label="sgmo_CollaborationAgreements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="sgmo_CollaborationAgreements" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromGrants" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1.1200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="1.0500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1000" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementScheduleOfInvestments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" order="1.0300" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAndAvailableforSaleSecurities">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShareAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_DeferredUpfrontContractFeeRevenue" xlink:label="sgmo_DeferredUpfrontContractFeeRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractsRevenue" xlink:to="sgmo_DeferredUpfrontContractFeeRevenue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractsRevenue" xlink:to="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RoyaltyRevenue" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_LicensesRevenue" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>sgmo-20130930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2013-11-04T20:27:09Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DocumentandEntityInformation" roleURI="http://sangamo.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_StatementOfIncome" roleURI="http://sangamo.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_StatementOfOtherComprehensiveIncome" roleURI="http://sangamo.com/taxonomy/role/StatementOfOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://sangamo.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureInvestmentsAndFairValueMeasurementAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureInvestmentsAndFairValueMeasurementScheduleOfInvestments" roleURI="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementScheduleOfInvestments"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureInvestmentsAndFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAndAvailableforSaleSecurities" roleURI="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAndAvailableforSaleSecurities"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureBasicAndDilutedNetLossPerShareAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShareAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpense" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DocumentandEntityInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassified">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfIncome">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfOtherComprehensiveIncome">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfCashFlowsIndirect">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="us-gaap_AvailableforsaleSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" xlink:label="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AvailableforsaleSecuritiesMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementScheduleOfInvestments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="us-gaap_AvailableforsaleSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AvailableforsaleSecuritiesMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAndAvailableforSaleSecurities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="us-gaap_AvailableforsaleSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AvailableforsaleSecuritiesMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="3.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShareAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AdditionalMilestonePaymentUnderAgreement" xlink:label="sgmo_AdditionalMilestonePaymentUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AggregateNumberOfGeneTargets" xlink:label="sgmo_AggregateNumberOfGeneTargets"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AgreementDate" xlink:label="sgmo_AgreementDate"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AgreementToReceive" xlink:label="sgmo_AgreementToReceive"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AnnualFeesRelatedToAgreement" xlink:label="sgmo_AnnualFeesRelatedToAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ChdiFoundationIncMember" xlink:label="sgmo_ChdiFoundationIncMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ContractualAgreementTerminationDate" xlink:label="sgmo_ContractualAgreementTerminationDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_DowAgroSciencesMember" xlink:label="sgmo_DowAgroSciencesMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment" xlink:label="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_FeeDue" xlink:label="sgmo_FeeDue"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_FundsDueUnderAgreement" xlink:label="sgmo_FundsDueUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_GrantFundingAmount" xlink:label="sgmo_GrantFundingAmount"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_GrantFundingAmountMaximumUnderAmendedAgreement" xlink:label="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_InitialResearchTermOfAgreement" xlink:label="sgmo_InitialResearchTermOfAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_JuvenileDiabetesResearchFoundationInternationalMember" xlink:label="sgmo_JuvenileDiabetesResearchFoundationInternationalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_NumberOfAdditionalGeneTargets" xlink:label="sgmo_NumberOfAdditionalGeneTargets"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_NumberOfGeneTargets" xlink:label="sgmo_NumberOfGeneTargets"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_NumberOfInitialGeneTargets" xlink:label="sgmo_NumberOfInitialGeneTargets"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_OneTimeLicenseFeeEarned" xlink:label="sgmo_OneTimeLicenseFeeEarned"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_PostAmendmentFundsDueUnderAgreement" xlink:label="sgmo_PostAmendmentFundsDueUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_PotentialRoyaltyPaymentsToEntity" xlink:label="sgmo_PotentialRoyaltyPaymentsToEntity"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ProceedsReceivedForWorkPerformedUnderAgreement" xlink:label="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ReducedRoyaltyRate" xlink:label="sgmo_ReducedRoyaltyRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ResearchGrantRevenue" xlink:label="sgmo_ResearchGrantRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_RoyaltyRevenuesExpectedToBeReceived" xlink:label="sgmo_RoyaltyRevenuesExpectedToBeReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ShireAgMember" xlink:label="sgmo_ShireAgMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_SigmaAldrichCorporationMember" xlink:label="sgmo_SigmaAldrichCorporationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_UpfrontLicenseFee" xlink:label="sgmo_UpfrontLicenseFee"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_UpfrontLicenseFeesMember" xlink:label="sgmo_UpfrontLicenseFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="sgmo_CaliforniaInstituteForRegenerativeMedicineMember" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="sgmo_ChdiFoundationIncMember" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="sgmo_JuvenileDiabetesResearchFoundationInternationalMember" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_DowAgroSciencesMember" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateNumberOfGeneTargets" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfInitialGeneTargets" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfGeneTargets" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfAdditionalGeneTargets" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_InitialResearchTermOfAgreement" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_UpfrontLicenseFee" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RoyaltyRevenue" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_RoyaltyRevenuesExpectedToBeReceived" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ReducedRoyaltyRate" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AdditionalMilestonePaymentUnderAgreement" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_OneTimeLicenseFeeEarned" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AnnualFeesRelatedToAgreement" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_FeeDue" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_GrantFundingAmount" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AgreementToReceive" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AgreementDate" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_PotentialRoyaltyPaymentsToEntity" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ResearchGrantRevenue" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_FundsDueUnderAgreement" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ContractualAgreementTerminationDate" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_PostAmendmentFundsDueUnderAgreement" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_UpfrontLicenseFeesMember" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RangeAxis" order="4.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_DeferredUpfrontContractFeeRevenue" xlink:label="sgmo_DeferredUpfrontContractFeeRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ShireAgMember" xlink:label="sgmo_ShireAgMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_SigmaAldrichCorporationMember" xlink:label="sgmo_SigmaAldrichCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenuesAbstract" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_SalesRevenueServicesNetAbstract" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="sgmo_DeferredUpfrontContractFeeRevenue" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ContractsRevenue" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_RoyaltyRevenue" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_LicensesRevenue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_RevenueFromRelatedParties" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LaborAndRelatedExpenseAbstract" xlink:label="us-gaap_LaborAndRelatedExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_LaborAndRelatedExpenseAbstract" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LaborAndRelatedExpenseAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_UnderwritersMember" xlink:label="sgmo_UnderwritersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommonStockMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sgmo_UnderwritersMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_BusinessAcquisitionTable" xlink:label="sgmo_BusinessAcquisitionTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sgmo_BusinessAcquisitionTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_BusinessAcquisitionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:label="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ShireAgMember" xlink:label="sgmo_ShireAgMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_SigmaAldrichCorporationMember" xlink:label="sgmo_SigmaAldrichCorporationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>sgmo-20130930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2013-11-04T20:27:09Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_1982133_928978_1_1">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_1982133_928978_2_1">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xml:lang="en-US" id="id_1982133_925277_1_1">Accounts Notes Loans And Financing Receivables By Legal Entity Of Counterparty Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xml:lang="en-US" id="id_1982133_925277_2_1">Legal Entity of Counterparty, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_1982133_935297_1_1">Accounts Payable And Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_1982133_935297_2_1">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_1982133_938700_1_1">Accounts Receivable Net Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_1982133_938700_2_1">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US" id="id_1982133_934751_1_1">Accrued Employee Benefits Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US" id="id_1982133_934751_2_1">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_1982133_934223_1_1">Accumulated Other Comprehensive Income Loss Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_1982133_934223_2_1">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AdditionalMilestonePaymentUnderAgreement" xlink:label="sgmo_AdditionalMilestonePaymentUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AdditionalMilestonePaymentUnderAgreement_lbl" xml:lang="en-US" id="id_1982133_977420_3_1">Additional milestone payment under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AdditionalMilestonePaymentUnderAgreement_lbl" xml:lang="en-US" id="id_1982133_977420_1_1">Additional Milestone Payment Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AdditionalMilestonePaymentUnderAgreement_lbl" xml:lang="en-US" id="id_1982133_977420_2_1">Funding available under the amended agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AdditionalMilestonePaymentUnderAgreement" xlink:to="sgmo_AdditionalMilestonePaymentUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_1982133_933723_1_1">Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_1982133_933723_2_1">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_1982133_929248_1_1">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_1982133_929248_2_1">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized_lbl" xml:lang="en-US" id="id_1982133_1200730_3_1">Aggregate additional revenue recognition milestone method revenue to be recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized_lbl" xml:lang="en-US" id="id_1982133_1200730_1_1">Aggregate Additional Revenue Recognition Milestone Method Revenue To Be Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized_lbl" xml:lang="en-US" id="id_1982133_1200730_2_1">Potential amount to be funded for certain Shire milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication_lbl" xml:lang="en-US" id="id_1982133_1200731_3_1">Aggregate additional revenue recognition milestone method revenue to be recognized on acceptance of application.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication_lbl" xml:lang="en-US" id="id_1982133_1200731_1_1">Aggregate Additional Revenue Recognition Milestone Method Revenue To Be Recognized On Acceptance Of Application</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication_lbl" xml:lang="en-US" id="id_1982133_1200731_2_1">IND or CTA submission amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AggregateNumberOfGeneTargets" xlink:label="sgmo_AggregateNumberOfGeneTargets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AggregateNumberOfGeneTargets_lbl" xml:lang="en-US" id="id_1982133_971460_3_1">Aggregate number of gene targets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AggregateNumberOfGeneTargets_lbl" xml:lang="en-US" id="id_1982133_971460_1_1">Aggregate Number Of Gene Targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AggregateNumberOfGeneTargets_lbl" xml:lang="en-US" id="id_1982133_971460_2_1">Aggregate number of gene targets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AggregateNumberOfGeneTargets" xlink:to="sgmo_AggregateNumberOfGeneTargets_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AgreementDate" xlink:label="sgmo_AgreementDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AgreementDate_lbl" xml:lang="en-US" id="id_1982133_1012685_3_1">Agreement date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AgreementDate_lbl" xml:lang="en-US" id="id_1982133_1012685_1_1">Agreement Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AgreementDate_lbl" xml:lang="en-US" id="id_1982133_1012685_2_1">Agreement date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AgreementDate" xlink:to="sgmo_AgreementDate_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AgreementToReceive" xlink:label="sgmo_AgreementToReceive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AgreementToReceive_lbl" xml:lang="en-US" id="id_1982133_1059161_3_1">Agreement to receive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AgreementToReceive_lbl" xml:lang="en-US" id="id_1982133_1059161_1_1">Agreement To Receive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AgreementToReceive_lbl" xml:lang="en-US" id="id_1982133_1059161_2_1">Agreement to receive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AgreementToReceive" xlink:to="sgmo_AgreementToReceive_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_1982133_940280_1_1">Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_1982133_940280_2_1">Total stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_1982133_921947_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_1982133_921947_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" id="id_1982133_940746_1_1">Amortization Of Debt Discount Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" id="id_1982133_940746_2_1">Amortization of premium / discount on marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AnnualFeesRelatedToAgreement" xlink:label="sgmo_AnnualFeesRelatedToAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AnnualFeesRelatedToAgreement_lbl" xml:lang="en-US" id="id_1982133_1131664_3_1">Annual fees related to agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AnnualFeesRelatedToAgreement_lbl" xml:lang="en-US" id="id_1982133_1131664_1_1">Annual Fees Related To Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AnnualFeesRelatedToAgreement_lbl" xml:lang="en-US" id="id_1982133_1131664_2_1">Annual fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AnnualFeesRelatedToAgreement" xlink:to="sgmo_AnnualFeesRelatedToAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_1982133_931668_1_1">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_1982133_931668_2_1">Stock options outstanding excluded from the calculation of diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_1982133_938186_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_1982133_938186_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_1982133_928450_1_1">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_1982133_928450_2_1">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_1982133_937150_1_1">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_1982133_937150_6_1">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_1982133_926145_1_1">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_1982133_926145_2_1">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_1982133_938194_1_1">Assets Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_1982133_938194_2_1">Total cash equivalents and available-for-sale securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_1982133_939245_1_1">Available For Sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_1982133_939245_6_1">Estimated Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xml:lang="en-US" id="id_1982133_937265_1_1">Available For Sale Securities Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xml:lang="en-US" id="id_1982133_937265_2_1">Amortized Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_lbl" xml:lang="en-US" id="id_1982133_939687_1_1">Available For Sale Securities Gross Realized Losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_lbl" xml:lang="en-US" id="id_1982133_939687_2_1">Realized losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments_lbl" xml:lang="en-US" id="id_1982133_1196717_3_1">Available for sale securities gross unrealized gains accumulated in investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments_lbl" xml:lang="en-US" id="id_1982133_1196717_1_1">Available For Sale Securities Gross Unrealized Gains Accumulated In Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments_lbl" xml:lang="en-US" id="id_1982133_1196717_2_1">Gross Unrealized Gains</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments_lbl" xml:lang="en-US" id="id_1982133_1155293_3_1">Available for sale securities gross unrealized loss accumulated in investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments_lbl" xml:lang="en-US" id="id_1982133_1155293_1_1">Available For Sale Securities Gross Unrealized Loss Accumulated In Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments_lbl" xml:lang="en-US" id="id_1982133_1155293_14_1">Gross Unrealized (Losses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="us-gaap_AvailableforsaleSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableforsaleSecuritiesMember_lbl" xml:lang="en-US" id="id_1982133_927011_1_1">Availableforsale Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableforsaleSecuritiesMember_lbl" xml:lang="en-US" id="id_1982133_927011_2_1">Available-for-sale securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableforsaleSecuritiesMember" xlink:to="us-gaap_AvailableforsaleSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" xml:lang="en-US" id="id_1982133_923573_1_1">Available For Sale Securities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" xml:lang="en-US" id="id_1982133_923573_2_1">Schedule of Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_1982133_930060_1_1">Basis Of Accounting Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_1982133_930060_2_1">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_lbl" xml:lang="en-US" id="id_1982133_935550_1_1">Business Acquisition Equity Interest Issued Or Issuable Value Assigned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_lbl" xml:lang="en-US" id="id_1982133_935550_2_1">Market value of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" id="id_1982133_928408_1_1">Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" id="id_1982133_928408_2_1">Shares acquired from acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" id="id_1982133_932380_1_1">Business Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" id="id_1982133_932380_2_1">Business Acquisition [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_BusinessAcquisitionTable" xlink:label="sgmo_BusinessAcquisitionTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_BusinessAcquisitionTable_lbl" xml:lang="en-US" id="id_1982133_1022768_3_1">Business Acquisition [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_BusinessAcquisitionTable_lbl" xml:lang="en-US" id="id_1982133_1022768_1_1">Business Acquisition [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_BusinessAcquisitionTable_lbl" xml:lang="en-US" id="id_1982133_1022768_2_1">Business Acquisition [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_BusinessAcquisitionTable" xlink:to="sgmo_BusinessAcquisitionTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" id="id_1982133_932588_1_1">Business Combinations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" id="id_1982133_932588_2_1">Business Combinations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember_lbl" xml:lang="en-US" id="id_1982133_1137514_3_1">California institute for regenerative medicine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember_lbl" xml:lang="en-US" id="id_1982133_1137514_1_1">California Institute For Regenerative Medicine [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember_lbl" xml:lang="en-US" id="id_1982133_1137514_2_1">California Institute for Regenerative Medicine [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CaliforniaInstituteForRegenerativeMedicineMember" xlink:to="sgmo_CaliforniaInstituteForRegenerativeMedicineMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_1982133_938283_1_1">Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_1982133_938283_4_1">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_1982133_938283_5_1">Cash and cash equivalents, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_1982133_938283_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_1982133_938600_1_1">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_1982133_938600_6_1">Net increase / (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsMember_lbl" xml:lang="en-US" id="id_1982133_932792_1_1">Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsMember_lbl" xml:lang="en-US" id="id_1982133_932792_2_1">Cash equivalents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ChdiFoundationIncMember" xlink:label="sgmo_ChdiFoundationIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ChdiFoundationIncMember_lbl" xml:lang="en-US" id="id_1982133_1019175_3_1">CHDI Foundation, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ChdiFoundationIncMember_lbl" xml:lang="en-US" id="id_1982133_1019175_1_1">Chdi Foundation Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ChdiFoundationIncMember_lbl" xml:lang="en-US" id="id_1982133_1019175_2_1">CHDI Foundation, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ChdiFoundationIncMember" xlink:to="sgmo_ChdiFoundationIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses_lbl" xml:lang="en-US" id="id_1982133_1116705_3_1">Collaboration agreement related costs and expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses_lbl" xml:lang="en-US" id="id_1982133_1116705_1_1">Collaboration Agreement Related Costs And Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses_lbl" xml:lang="en-US" id="id_1982133_1116705_2_1">Collaboration Agreement Related Costs and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_CollaborationAgreements" xlink:label="sgmo_CollaborationAgreements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_CollaborationAgreements_lbl" xml:lang="en-US" id="id_1982133_959148_3_1">Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_CollaborationAgreements_lbl" xml:lang="en-US" id="id_1982133_959148_1_1">Collaboration Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_CollaborationAgreements_lbl" xml:lang="en-US" id="id_1982133_959148_2_1">Collaboration agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CollaborationAgreements" xlink:to="sgmo_CollaborationAgreements_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_lbl" xml:lang="en-US" id="id_1982133_1200732_3_1">Collaboration and license agreements number of products approved under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_lbl" xml:lang="en-US" id="id_1982133_1200732_1_1">Collaboration And License Agreements Number Of Products Approved Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_lbl" xml:lang="en-US" id="id_1982133_1200732_2_1">Number of products approved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:to="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_1982133_924261_1_1">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_1982133_924261_2_1">Major Customers, Partnerships and Strategic Alliances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_1982133_936604_1_1">Commitments And Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_1982133_936604_2_1">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_1982133_930643_1_1">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_1982133_930643_2_1">Common stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_1982133_931741_1_1">Common Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_1982133_931741_2_1">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_1982133_930676_1_1">Common Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_1982133_930676_2_1">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_1982133_925763_1_1">Common Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_1982133_925763_2_1">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_1982133_923588_1_1">Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_1982133_923588_2_1">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_1982133_935685_1_1">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_1982133_935685_2_1">Common stock, $0.01 par value; 80,000,000 shares authorized, 61,420,655 and 53,058,525 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_1982133_933343_1_1">Comprehensive Income Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_1982133_933343_6_1">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractsRevenue_lbl" xml:lang="en-US" id="id_1982133_933360_1_1">Contracts Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ContractsRevenue_lbl" xml:lang="en-US" id="id_1982133_933360_6_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractsRevenue" xlink:to="us-gaap_ContractsRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ContractualAgreementTerminationDate" xlink:label="sgmo_ContractualAgreementTerminationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ContractualAgreementTerminationDate_lbl" xml:lang="en-US" id="id_1982133_1080300_3_1">Contractual agreement termination date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ContractualAgreementTerminationDate_lbl" xml:lang="en-US" id="id_1982133_1080300_1_1">Contractual Agreement Termination Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ContractualAgreementTerminationDate_lbl" xml:lang="en-US" id="id_1982133_1080300_2_1">Contractual agreement termination date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ContractualAgreementTerminationDate" xlink:to="sgmo_ContractualAgreementTerminationDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" id="id_1982133_933025_1_1">Counterparty Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" id="id_1982133_933025_2_1">Counterparty Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_1982133_922004_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_1982133_922004_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_1982133_935460_1_1">Deferred Revenue Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_1982133_935460_2_1">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_1982133_935460_12_1">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_1982133_936354_1_1">Deferred Revenue Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_1982133_936354_2_1">Deferred revenues, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_DeferredUpfrontContractFeeRevenue" xlink:label="sgmo_DeferredUpfrontContractFeeRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_DeferredUpfrontContractFeeRevenue_lbl" xml:lang="en-US" id="id_1982133_1068074_3_1">Deferred upfront contract fee revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_DeferredUpfrontContractFeeRevenue_lbl" xml:lang="en-US" id="id_1982133_1068074_1_1">Deferred Upfront Contract Fee Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_DeferredUpfrontContractFeeRevenue_lbl" xml:lang="en-US" id="id_1982133_1068074_2_1">Amortization of upfront fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_DeferredUpfrontContractFeeRevenue" xlink:to="sgmo_DeferredUpfrontContractFeeRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_1982133_939791_1_1">Depreciation Depletion And Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_1982133_939791_2_1">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_1982133_930617_1_1">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_1982133_930617_2_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_1982133_923166_1_1">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_1982133_923166_2_1">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_DocumentAndEntityInformationAbstract" xlink:label="sgmo_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_1982133_951207_3_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_1982133_951207_1_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_1982133_951207_2_1">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="sgmo_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_1982133_922019_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_1982133_922019_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_1982133_921974_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_1982133_921974_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_1982133_921989_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_1982133_921989_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_1982133_921984_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_1982133_921984_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_DowAgroSciencesMember" xlink:label="sgmo_DowAgroSciencesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_DowAgroSciencesMember_lbl" xml:lang="en-US" id="id_1982133_1094419_3_1">Dow AgroSciences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_DowAgroSciencesMember_lbl" xml:lang="en-US" id="id_1982133_1094419_1_1">Dow Agro Sciences [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_DowAgroSciencesMember_lbl" xml:lang="en-US" id="id_1982133_1094419_2_1">Dow AgroSciences [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_DowAgroSciencesMember" xlink:to="sgmo_DowAgroSciencesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_1982133_929815_1_1">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_1982133_929815_2_1">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_1982133_929231_1_1">Earnings Per Share Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_1982133_929231_2_1">Basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_1982133_931897_1_1">Earnings Per Share Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_1982133_931897_2_1">Net Loss per Share, policy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_1982133_930641_1_1">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_1982133_930641_2_1">Basic and Diluted Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_1982133_932976_1_1">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_1982133_932976_2_1">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_1982133_921997_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_1982133_921997_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_1982133_922042_1_1">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_1982133_922042_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_1982133_921955_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_1982133_921955_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_1982133_921937_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_1982133_921937_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_1982133_932367_1_1">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_1982133_932367_2_1">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment" xlink:label="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment_lbl" xml:lang="en-US" id="id_1982133_1054426_3_1">Expected amount to be received for research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment_lbl" xml:lang="en-US" id="id_1982133_1054426_1_1">Expected Amount To Be Received For Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment_lbl" xml:lang="en-US" id="id_1982133_1054426_2_1">Expected amount to be received for research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment" xlink:to="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_1982133_926674_1_1">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_1982133_926674_2_1">Summary of Fair Value Measurements of Cash Equivalents and Available-for-Sale Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="id_1982133_932752_1_1">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="id_1982133_932752_2_1">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="id_1982133_926956_1_1">Fair Value By Asset Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="id_1982133_926956_2_1">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_1982133_929790_1_1">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_1982133_929790_2_1">Fair Value, Hierarchy [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_1982133_930808_1_1">Fair Value Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_1982133_930808_2_1">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_1982133_925736_1_1">Fair Value Inputs Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_1982133_925736_2_1">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_1982133_925851_1_1">Fair Value Inputs Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_1982133_925851_2_1">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_1982133_929831_1_1">Fair Value Inputs Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_1982133_929831_2_1">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_1982133_924053_1_1">Fair Value Measurement Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_1982133_924053_2_1">Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_1982133_930398_1_1">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_1982133_930398_2_1">Fair Value Hierarchy [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_FeeDue" xlink:label="sgmo_FeeDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_FeeDue_lbl" xml:lang="en-US" id="id_1982133_1109820_3_1">Fee due.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_FeeDue_lbl" xml:lang="en-US" id="id_1982133_1109820_1_1">Fee Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_FeeDue_lbl" xml:lang="en-US" id="id_1982133_1109820_2_1">Fee due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_FeeDue" xlink:to="sgmo_FeeDue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_1982133_932819_1_1">Financial Instruments Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_1982133_932819_2_1">Investments and Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_FundsDueUnderAgreement" xlink:label="sgmo_FundsDueUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_FundsDueUnderAgreement_lbl" xml:lang="en-US" id="id_1982133_1139773_3_1">Funds due under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_FundsDueUnderAgreement_lbl" xml:lang="en-US" id="id_1982133_1139773_1_1">Funds Due Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_FundsDueUnderAgreement_lbl" xml:lang="en-US" id="id_1982133_1139773_2_1">Funds due under agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_FundsDueUnderAgreement" xlink:to="sgmo_FundsDueUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_1982133_937408_1_1">General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_1982133_937408_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_1982133_925832_1_1">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_1982133_925832_2_1">General and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_GrantFundingAmount" xlink:label="sgmo_GrantFundingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_GrantFundingAmount_lbl" xml:lang="en-US" id="id_1982133_942370_3_1">Grant funding amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_GrantFundingAmount_lbl" xml:lang="en-US" id="id_1982133_942370_1_1">Grant Funding Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_GrantFundingAmount_lbl" xml:lang="en-US" id="id_1982133_942370_2_1">Funds due under the agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_GrantFundingAmount" xlink:to="sgmo_GrantFundingAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_GrantFundingAmountMaximumUnderAmendedAgreement" xlink:label="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement_lbl" xml:lang="en-US" id="id_1982133_989402_3_1">Grant funding amount maximum under amended agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement_lbl" xml:lang="en-US" id="id_1982133_989402_1_1">Grant Funding Amount Maximum Under Amended Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement_lbl" xml:lang="en-US" id="id_1982133_989402_2_1">Grant funding amount maximum under amended agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement" xlink:to="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_1982133_927850_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_1982133_927850_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_1982133_927015_1_1">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_1982133_927015_2_1">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_1982133_931901_1_1">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_1982133_931901_2_1">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_1982133_932322_1_1">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_1982133_932322_2_1">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_1982133_929775_1_1">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_1982133_929775_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_1982133_935454_1_1">Increase Decrease In Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_1982133_935454_14_1">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US" id="id_1982133_935362_1_1">Increase Decrease In Accrued Interest Receivable Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US" id="id_1982133_935362_14_1">Interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_1982133_938117_1_1">Increase Decrease In Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_1982133_938117_2_1">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US" id="id_1982133_937388_1_1">Increase Decrease In Employee Related Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US" id="id_1982133_937388_2_1">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_1982133_924543_1_1">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_1982133_924543_2_1">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="id_1982133_938317_1_1">Increase Decrease In Other Accounts Payable And Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="id_1982133_938317_2_1">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_1982133_933216_1_1">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_1982133_933216_14_1">Prepaid expenses and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_InitialResearchTermOfAgreement" xlink:label="sgmo_InitialResearchTermOfAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_InitialResearchTermOfAgreement_lbl" xml:lang="en-US" id="id_1982133_1008271_3_1">Initial research term of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_InitialResearchTermOfAgreement_lbl" xml:lang="en-US" id="id_1982133_1008271_1_1">Initial Research Term Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_InitialResearchTermOfAgreement_lbl" xml:lang="en-US" id="id_1982133_1008271_2_1">Research program to develop laboratory research reagents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_InitialResearchTermOfAgreement" xlink:to="sgmo_InitialResearchTermOfAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xml:lang="en-US" id="id_1982133_940810_1_1">Interest Receivable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xml:lang="en-US" id="id_1982133_940810_2_1">Interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="id_1982133_934440_1_1">Investment Income Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="id_1982133_934440_2_1">Interest and other income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_1982133_925992_1_1">Investment Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_1982133_925992_2_1">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xml:lang="en-US" id="id_1982133_928016_1_1">Investments All Other Investments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xml:lang="en-US" id="id_1982133_928016_2_1">Investments, All Other Investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" xlink:label="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_1982133_1065501_3_1">Investments maturity dates available for sale securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_1982133_1065501_1_1">Investments Maturity Dates Available For Sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_1982133_1065501_2_1">Investments maturity period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" xlink:to="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" id="id_1982133_932040_1_1">Investment Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" id="id_1982133_932040_2_1">Investment Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" id="id_1982133_932609_1_1">Investment Type Categorization [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" id="id_1982133_932609_2_1">Investments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_1982133_926487_1_1">I P O [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_1982133_926487_2_1">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_JuvenileDiabetesResearchFoundationInternationalMember" xlink:label="sgmo_JuvenileDiabetesResearchFoundationInternationalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_JuvenileDiabetesResearchFoundationInternationalMember_lbl" xml:lang="en-US" id="id_1982133_1044992_3_1">The juvenile diabetes research foundation international.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_JuvenileDiabetesResearchFoundationInternationalMember_lbl" xml:lang="en-US" id="id_1982133_1044992_1_1">Juvenile Diabetes Research Foundation International [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_JuvenileDiabetesResearchFoundationInternationalMember_lbl" xml:lang="en-US" id="id_1982133_1044992_2_1">Juvenile Diabetes Research Foundation International [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_JuvenileDiabetesResearchFoundationInternationalMember" xlink:to="sgmo_JuvenileDiabetesResearchFoundationInternationalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LaborAndRelatedExpenseAbstract" xlink:label="us-gaap_LaborAndRelatedExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpenseAbstract_lbl" xml:lang="en-US" id="id_1982133_928858_1_1">Labor And Related Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LaborAndRelatedExpenseAbstract_lbl" xml:lang="en-US" id="id_1982133_928858_2_1">Costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpenseAbstract" xlink:to="us-gaap_LaborAndRelatedExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl" xml:lang="en-US" id="id_1982133_931651_1_1">Legal Entity Type Of Counterparty [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl" xml:lang="en-US" id="id_1982133_931651_2_1">Legal Entity Type of Counterparty [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_1982133_936129_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_1982133_936129_6_1">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_1982133_935778_1_1">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_1982133_935778_6_1">Total liabilities and stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_1982133_924388_1_1">Liabilities And Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_1982133_924388_2_1">Liabilities and stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_1982133_934201_1_1">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_1982133_934201_6_1">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_1982133_929787_1_1">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_1982133_929787_2_1">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xml:lang="en-US" id="id_1982133_928673_1_1">License Agreement Terms [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xml:lang="en-US" id="id_1982133_928673_2_1">License agreement terms [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US" id="id_1982133_934341_1_1">Licenses Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US" id="id_1982133_934341_2_1">License fee and milestone revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US" id="id_1982133_934341_12_1">Revenue attributable to research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="us-gaap_LicensesRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xml:lang="en-US" id="id_1982133_928628_1_1">Major Types Of Debt And Equity Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xml:lang="en-US" id="id_1982133_928628_2_1">Major Types of Debt and Equity Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xml:lang="en-US" id="id_1982133_928856_1_1">Major Types Of Debt And Equity Securities [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xml:lang="en-US" id="id_1982133_928856_2_1">Major Types of Debt and Equity Securities [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US" id="id_1982133_936967_1_1">Marketable Securities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US" id="id_1982133_936967_2_1">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xml:lang="en-US" id="id_1982133_937619_1_1">Marketable Securities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xml:lang="en-US" id="id_1982133_937619_2_1">Marketable securities, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_1982133_923140_1_1">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_1982133_923140_2_1">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_1982133_932953_1_1">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_1982133_932953_2_1">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_lbl" xml:lang="en-US" id="id_1982133_963942_3_1">Minimum sublicense annual fees specific reckoning period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_lbl" xml:lang="en-US" id="id_1982133_963942_1_1">Minimum Sublicense Annual Fees Specific Reckoning Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_lbl" xml:lang="en-US" id="id_1982133_963942_2_1">Minimum sublicense annual fees specific reckoning period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:to="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" id="id_1982133_932359_1_1">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" id="id_1982133_932359_2_1">Money market funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_1982133_937453_1_1">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_1982133_937453_6_1">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_1982133_924600_1_1">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_1982133_924600_2_1">Financing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_1982133_939292_1_1">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_1982133_939292_6_1">Net cash provided by investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_1982133_924425_1_1">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_1982133_924425_2_1">Investing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_1982133_928832_1_1">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_1982133_928832_6_1">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_1982133_930909_1_1">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_1982133_930909_2_1">Operating Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_1982133_935636_1_1">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_1982133_935636_2_1">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_1982133_935636_6_1">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_1982133_923522_1_1">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_1982133_923522_2_1">Recent Accounting Pronouncement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_NumberOfAdditionalGeneTargets" xlink:label="sgmo_NumberOfAdditionalGeneTargets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_NumberOfAdditionalGeneTargets_lbl" xml:lang="en-US" id="id_1982133_1105034_3_1">Number of additional gene targets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_NumberOfAdditionalGeneTargets_lbl" xml:lang="en-US" id="id_1982133_1105034_1_1">Number Of Additional Gene Targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_NumberOfAdditionalGeneTargets_lbl" xml:lang="en-US" id="id_1982133_1105034_2_1">Number of additional gene targets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NumberOfAdditionalGeneTargets" xlink:to="sgmo_NumberOfAdditionalGeneTargets_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_NumberOfGeneTargets" xlink:label="sgmo_NumberOfGeneTargets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_NumberOfGeneTargets_lbl" xml:lang="en-US" id="id_1982133_1009088_3_1">Number of gene targets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_NumberOfGeneTargets_lbl" xml:lang="en-US" id="id_1982133_1009088_1_1">Number Of Gene Targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_NumberOfGeneTargets_lbl" xml:lang="en-US" id="id_1982133_1009088_2_1">Number of gene targets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NumberOfGeneTargets" xlink:to="sgmo_NumberOfGeneTargets_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_NumberOfInitialGeneTargets" xlink:label="sgmo_NumberOfInitialGeneTargets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_NumberOfInitialGeneTargets_lbl" xml:lang="en-US" id="id_1982133_1131802_3_1">Number of initial gene targets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_NumberOfInitialGeneTargets_lbl" xml:lang="en-US" id="id_1982133_1131802_1_1">Number Of Initial Gene Targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_NumberOfInitialGeneTargets_lbl" xml:lang="en-US" id="id_1982133_1131802_2_1">Number of initial gene targets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NumberOfInitialGeneTargets" xlink:to="sgmo_NumberOfInitialGeneTargets_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_OneTimeLicenseFeeEarned" xlink:label="sgmo_OneTimeLicenseFeeEarned"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_OneTimeLicenseFeeEarned_lbl" xml:lang="en-US" id="id_1982133_1119987_3_1">One time license fee earned.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_OneTimeLicenseFeeEarned_lbl" xml:lang="en-US" id="id_1982133_1119987_1_1">One Time License Fee Earned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_OneTimeLicenseFeeEarned_lbl" xml:lang="en-US" id="id_1982133_1119987_2_1">One-time license fee earned on exercise of option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_OneTimeLicenseFeeEarned" xlink:to="sgmo_OneTimeLicenseFeeEarned_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_1982133_940683_1_1">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_1982133_940683_6_1">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_1982133_927909_1_1">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_1982133_927909_2_1">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_1982133_934856_1_1">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_1982133_934856_6_1">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_1982133_927825_1_1">Organization Consolidation And Presentation Of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_1982133_927825_2_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_1982133_927054_1_1">Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_1982133_927054_2_1">Basis of Presentation and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US" id="id_1982133_939846_1_1">Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US" id="id_1982133_939846_2_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="id_1982133_939944_1_1">Other Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="id_1982133_939944_2_1">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="id_1982133_936748_1_1">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="id_1982133_936748_2_1">Changes in unrealized loss on available-for-sale securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_lbl" xml:lang="en-US" id="id_1982133_936998_1_1">Other Than Temporary Impairment Losses Investments Availableforsale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_lbl" xml:lang="en-US" id="id_1982133_936998_2_1">Other-than-temporary impairments of available-for-sale securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US" id="id_1982133_935237_1_1">Payments To Acquire Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US" id="id_1982133_935237_14_1">Purchases of investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_1982133_936514_1_1">Payments To Acquire Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_1982133_936514_14_1">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_lbl" xml:lang="en-US" id="id_1982133_1136308_3_1">Percentage of royalties to be received from sublicensing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_lbl" xml:lang="en-US" id="id_1982133_1136308_1_1">Percentage Of Royalties To Be Received From Sublicensing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_lbl" xml:lang="en-US" id="id_1982133_1136308_2_1">Percentage of royalties to be received from sublicensing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:to="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_PostAmendmentFundsDueUnderAgreement" xlink:label="sgmo_PostAmendmentFundsDueUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_PostAmendmentFundsDueUnderAgreement_lbl" xml:lang="en-US" id="id_1982133_1026774_3_1">Post amendment funds due under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_PostAmendmentFundsDueUnderAgreement_lbl" xml:lang="en-US" id="id_1982133_1026774_1_1">Post Amendment Funds Due Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_PostAmendmentFundsDueUnderAgreement_lbl" xml:lang="en-US" id="id_1982133_1026774_2_1">Funds due under agreement as per amendment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PostAmendmentFundsDueUnderAgreement" xlink:to="sgmo_PostAmendmentFundsDueUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_PotentialRoyaltyPaymentsToEntity" xlink:label="sgmo_PotentialRoyaltyPaymentsToEntity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_PotentialRoyaltyPaymentsToEntity_lbl" xml:lang="en-US" id="id_1982133_1200734_3_1">Potential Royalty Payments To Entity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_PotentialRoyaltyPaymentsToEntity_lbl" xml:lang="en-US" id="id_1982133_1200734_1_1">Potential Royalty Payments To Entity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_PotentialRoyaltyPaymentsToEntity_lbl" xml:lang="en-US" id="id_1982133_1200734_2_1">Receivables from sale against the grant funded to entity from sale of product</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PotentialRoyaltyPaymentsToEntity" xlink:to="sgmo_PotentialRoyaltyPaymentsToEntity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_1982133_937707_1_1">Prepaid Expense Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_1982133_937707_2_1">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_1982133_939370_1_1">Proceeds From Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_1982133_939370_2_1">Proceeds from public offering, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_1982133_938994_1_1">Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_1982133_938994_2_1">Proceeds from issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments_lbl" xml:lang="en-US" id="id_1982133_939625_1_1">Proceeds From Maturities Prepayments And Calls Of Longterm Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments_lbl" xml:lang="en-US" id="id_1982133_939625_2_1">Maturities of investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ProceedsReceivedForWorkPerformedUnderAgreement" xlink:label="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement_lbl" xml:lang="en-US" id="id_1982133_1085939_3_1">Proceeds received for work performed under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement_lbl" xml:lang="en-US" id="id_1982133_1085939_1_1">Proceeds Received For Work Performed Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement_lbl" xml:lang="en-US" id="id_1982133_1085939_2_1">Received for work performed under agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement" xlink:to="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_1982133_940861_1_1">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_1982133_940861_2_1">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_1982133_926437_1_1">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_1982133_926437_2_1">Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_1982133_930818_1_1">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_1982133_930818_2_1">Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ReducedRoyaltyRate" xlink:label="sgmo_ReducedRoyaltyRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ReducedRoyaltyRate_lbl" xml:lang="en-US" id="id_1982133_1070754_3_1">Reduced royalty rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ReducedRoyaltyRate_lbl" xml:lang="en-US" id="id_1982133_1070754_1_1">Reduced Royalty Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ReducedRoyaltyRate_lbl" xml:lang="en-US" id="id_1982133_1070754_2_1">Reduced royalty rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ReducedRoyaltyRate" xlink:to="sgmo_ReducedRoyaltyRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_1982133_932122_1_1">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_1982133_932122_2_1">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_1982133_926607_1_1">Related Party Transactions By Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_1982133_926607_2_1">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="id_1982133_924049_1_1">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="id_1982133_924049_2_1">Counterparty Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US" id="id_1982133_924247_1_1">Research And Development [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US" id="id_1982133_924247_2_1">Research and Development [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="id_1982133_926233_1_1">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="id_1982133_926233_2_1">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xml:lang="en-US" id="id_1982133_932671_1_1">Research And Development Arrangement Contract To Perform For Others [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xml:lang="en-US" id="id_1982133_932671_2_1">Research and Development Arrangement, Contract to Perform for Others [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="id_1982133_924269_1_1">Research And Development Arrangement Contract To Perform For Others Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="id_1982133_924269_2_1">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_1982133_939407_1_1">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_1982133_939407_2_1">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_1982133_928963_1_1">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_1982133_928963_2_1">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ResearchGrantRevenue" xlink:label="sgmo_ResearchGrantRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ResearchGrantRevenue_lbl" xml:lang="en-US" id="id_1982133_981565_3_1">Research grant revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ResearchGrantRevenue_lbl" xml:lang="en-US" id="id_1982133_981565_1_1">Research Grant Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ResearchGrantRevenue_lbl" xml:lang="en-US" id="id_1982133_981565_2_1">Revenues under agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ResearchGrantRevenue" xlink:to="sgmo_ResearchGrantRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement_lbl" xml:lang="en-US" id="id_1982133_1048214_3_1">Research service revenue under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement_lbl" xml:lang="en-US" id="id_1982133_1048214_1_1">Research Service Revenue Under Collaboration Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement_lbl" xml:lang="en-US" id="id_1982133_1048214_2_1">Research services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:to="sgmo_ResearchServiceRevenueUnderCollaborationAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_1982133_935451_1_1">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_1982133_935451_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US" id="id_1982133_934838_1_1">Revenue From Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US" id="id_1982133_934838_2_1">Research grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromGrants" xlink:to="us-gaap_RevenueFromGrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xml:lang="en-US" id="id_1982133_933653_1_1">Revenue From Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xml:lang="en-US" id="id_1982133_933653_6_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_1982133_924259_1_1">Revenue Recognition Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_1982133_924259_2_1">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_1982133_933119_1_1">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_1982133_933119_6_1">Total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="id_1982133_929243_1_1">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="id_1982133_929243_2_1">Revenue related to Shire Collaboration:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="id_1982133_929243_12_1">Revenues:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyRevenue_lbl" xml:lang="en-US" id="id_1982133_936050_1_1">Royalty Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyRevenue_lbl" xml:lang="en-US" id="id_1982133_936050_2_1">Royalty revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RoyaltyRevenue_lbl" xml:lang="en-US" id="id_1982133_936050_12_1">Royalty revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_RoyaltyRevenuesExpectedToBeReceived" xlink:label="sgmo_RoyaltyRevenuesExpectedToBeReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_RoyaltyRevenuesExpectedToBeReceived_lbl" xml:lang="en-US" id="id_1982133_1116860_3_1">Royalty revenues expected to be received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_RoyaltyRevenuesExpectedToBeReceived_lbl" xml:lang="en-US" id="id_1982133_1116860_1_1">Royalty Revenues Expected To Be Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_RoyaltyRevenuesExpectedToBeReceived_lbl" xml:lang="en-US" id="id_1982133_1116860_2_1">Royalty revenues expected to be received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RoyaltyRevenuesExpectedToBeReceived" xlink:to="sgmo_RoyaltyRevenuesExpectedToBeReceived_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" id="id_1982133_939571_1_1">Sale Of Stock Consideration Received On Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" id="id_1982133_939571_2_1">Net proceeds from the sale of shares, after offering expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_1982133_931590_1_1">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_1982133_931590_2_1">Sale of Stock, Name of Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" id="id_1982133_931930_1_1">Sale Of Stock Number Of Shares Issued In Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" id="id_1982133_931930_2_1">Sale of stock, number of shares issued in transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" id="id_1982133_932019_1_1">Sale Of Stock Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" id="id_1982133_932019_2_1">Sale of stock, price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueServicesNetAbstract_lbl" xml:lang="en-US" id="id_1982133_927102_1_1">Sales Revenue Services Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueServicesNetAbstract_lbl" xml:lang="en-US" id="id_1982133_927102_2_1">Revenue related to Sigma Collaboration:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_SalesRevenueServicesNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" id="id_1982133_926059_1_1">Schedule Of Available For Sale Securities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" id="id_1982133_926059_2_1">Schedule of Available-for-sale Securities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US" id="id_1982133_929659_1_1">Schedule Of Available For Sale Securities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US" id="id_1982133_929659_2_1">Schedule of Available-for-sale Securities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" id="id_1982133_928783_1_1">Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" id="id_1982133_928783_2_1">Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_1982133_925602_1_1">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_1982133_925602_2_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xml:lang="en-US" id="id_1982133_931043_1_1">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xml:lang="en-US" id="id_1982133_931043_2_1">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:label="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_lbl" xml:lang="en-US" id="id_1982133_929345_1_1">Schedule Of Revenue Sources Health Care Organization Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_lbl" xml:lang="en-US" id="id_1982133_929345_2_1">Revenues Recognized under Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_1982133_938471_1_1">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_1982133_938471_2_1">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ShireAgMember" xlink:label="sgmo_ShireAgMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_ShireAgMember_lbl" xml:lang="en-US" id="id_1982133_992959_3_1">Shire AG [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_ShireAgMember_lbl" xml:lang="en-US" id="id_1982133_992959_1_1">Shire Ag [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_ShireAgMember_lbl" xml:lang="en-US" id="id_1982133_992959_2_1">Shire AG [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShireAgMember" xlink:to="sgmo_ShireAgMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_SigmaAldrichCorporationMember" xlink:label="sgmo_SigmaAldrichCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_SigmaAldrichCorporationMember_lbl" xml:lang="en-US" id="id_1982133_982693_3_1">Sigma-Aldrich corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_SigmaAldrichCorporationMember_lbl" xml:lang="en-US" id="id_1982133_982693_1_1">Sigma Aldrich Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_SigmaAldrichCorporationMember_lbl" xml:lang="en-US" id="id_1982133_982693_2_1">Sigma-Aldrich Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_SigmaAldrichCorporationMember" xlink:to="sgmo_SigmaAldrichCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_1982133_926570_1_1">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_1982133_926570_2_1">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_1982133_932756_1_1">Statement Of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_1982133_932756_2_1">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_1982133_924693_1_1">Statement Of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_1982133_924693_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="id_1982133_932352_1_1">Statement Of Income And Comprehensive Income [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="id_1982133_932352_2_1">Statement of Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_1982133_926771_1_1">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_1982133_926771_2_1">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_1982133_934682_1_1">Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_1982133_934682_6_1">Total stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_1982133_925186_1_1">Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_1982133_925186_2_1">Stockholders' equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_1982133_927127_1_1">Stockholders Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_1982133_927127_2_1">Stockholders' Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_1982133_932873_1_1">Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_1982133_932873_2_1">Public offering, common stock shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_1982133_936512_1_1">Stock Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_1982133_936512_2_1">Common stock, valued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_1982133_931597_1_1">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_1982133_931597_2_1">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_1982133_925770_1_1">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_1982133_925770_2_1">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_1982133_929519_1_1">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_1982133_929519_2_1">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_1982133_932504_1_1">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_1982133_932504_2_1">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_1982133_929873_1_1">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_1982133_929873_2_1">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" id="id_1982133_932319_1_1">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" id="id_1982133_932319_2_1">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_1982133_931707_1_1">Subsidiary Sale Of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_1982133_931707_2_1">Subsidiary, Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" id="id_1982133_930726_1_1">Subsidiary Sale Of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" id="id_1982133_930726_2_1">Subsidiary, Sale of Stock [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_UnderwritersMember" xlink:label="sgmo_UnderwritersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_UnderwritersMember_lbl" xml:lang="en-US" id="id_1982133_960063_3_1">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_UnderwritersMember_lbl" xml:lang="en-US" id="id_1982133_960063_1_1">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_UnderwritersMember_lbl" xml:lang="en-US" id="id_1982133_960063_2_1">Underwriters [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_UnderwritersMember" xlink:to="sgmo_UnderwritersMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_UpfrontLicenseFee" xlink:label="sgmo_UpfrontLicenseFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_UpfrontLicenseFee_lbl" xml:lang="en-US" id="id_1982133_1065069_3_1">Upfront license fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_UpfrontLicenseFee_lbl" xml:lang="en-US" id="id_1982133_1065069_1_1">Upfront License Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_UpfrontLicenseFee_lbl" xml:lang="en-US" id="id_1982133_1065069_2_1">Upfront license fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_UpfrontLicenseFee" xlink:to="sgmo_UpfrontLicenseFee_lbl"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_UpfrontLicenseFeesMember" xlink:label="sgmo_UpfrontLicenseFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sgmo_UpfrontLicenseFeesMember_lbl" xml:lang="en-US" id="id_1982133_1007904_3_1">Upfront license fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sgmo_UpfrontLicenseFeesMember_lbl" xml:lang="en-US" id="id_1982133_1007904_1_1">Upfront License Fees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sgmo_UpfrontLicenseFeesMember_lbl" xml:lang="en-US" id="id_1982133_1007904_2_1">Upfront license fee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_UpfrontLicenseFeesMember" xlink:to="sgmo_UpfrontLicenseFeesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_1982133_931855_1_1">Use Of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_1982133_931855_2_1">Use of Estimates and Classifications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_1982133_924099_1_1">U S Government Sponsored Enterprises Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_1982133_924099_2_1">U.S. government sponsored entity debt securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_1982133_927104_1_1">Weighted Average Number Of Share Outstanding Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_1982133_927104_2_1">Shares used in computing basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>sgmo-20130930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2013-11-04T20:27:09Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DocumentandEntityInformation" roleURI="http://sangamo.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_StatementOfIncome" roleURI="http://sangamo.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_StatementOfOtherComprehensiveIncome" roleURI="http://sangamo.com/taxonomy/role/StatementOfOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://sangamo.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureInvestmentsAndFairValueMeasurementAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureInvestmentsAndFairValueMeasurementScheduleOfInvestments" roleURI="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementScheduleOfInvestments"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureInvestmentsAndFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAndAvailableforSaleSecurities" roleURI="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAndAvailableforSaleSecurities"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureBasicAndDilutedNetLossPerShareAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShareAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement" roleURI="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpense" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://sangamo.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sgmo-20130930.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_DocumentAndEntityInformationAbstract" xlink:label="sgmo_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssets" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_CollaborationAgreements" xlink:label="sgmo_CollaborationAgreements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="sgmo_CollaborationAgreements" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromGrants" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="1.1200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.1300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="us-gaap_AvailableforsaleSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" xlink:label="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AvailableforsaleSecuritiesMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementScheduleOfInvestments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" xlink:label="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="us-gaap_AvailableforsaleSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AvailableforsaleSecuritiesMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAndAvailableforSaleSecurities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="us-gaap_AvailableforsaleSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AvailableforsaleSecuritiesMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShareAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AdditionalMilestonePaymentUnderAgreement" xlink:label="sgmo_AdditionalMilestonePaymentUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AggregateNumberOfGeneTargets" xlink:label="sgmo_AggregateNumberOfGeneTargets"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AgreementDate" xlink:label="sgmo_AgreementDate"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AgreementToReceive" xlink:label="sgmo_AgreementToReceive"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_AnnualFeesRelatedToAgreement" xlink:label="sgmo_AnnualFeesRelatedToAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="sgmo_CaliforniaInstituteForRegenerativeMedicineMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ChdiFoundationIncMember" xlink:label="sgmo_ChdiFoundationIncMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="sgmo_CollaborationAgreementRelatedCostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ContractualAgreementTerminationDate" xlink:label="sgmo_ContractualAgreementTerminationDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_DowAgroSciencesMember" xlink:label="sgmo_DowAgroSciencesMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment" xlink:label="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_FeeDue" xlink:label="sgmo_FeeDue"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_FundsDueUnderAgreement" xlink:label="sgmo_FundsDueUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_GrantFundingAmount" xlink:label="sgmo_GrantFundingAmount"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_GrantFundingAmountMaximumUnderAmendedAgreement" xlink:label="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_InitialResearchTermOfAgreement" xlink:label="sgmo_InitialResearchTermOfAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_JuvenileDiabetesResearchFoundationInternationalMember" xlink:label="sgmo_JuvenileDiabetesResearchFoundationInternationalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_NumberOfAdditionalGeneTargets" xlink:label="sgmo_NumberOfAdditionalGeneTargets"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_NumberOfGeneTargets" xlink:label="sgmo_NumberOfGeneTargets"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_NumberOfInitialGeneTargets" xlink:label="sgmo_NumberOfInitialGeneTargets"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_OneTimeLicenseFeeEarned" xlink:label="sgmo_OneTimeLicenseFeeEarned"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_PostAmendmentFundsDueUnderAgreement" xlink:label="sgmo_PostAmendmentFundsDueUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_PotentialRoyaltyPaymentsToEntity" xlink:label="sgmo_PotentialRoyaltyPaymentsToEntity"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ProceedsReceivedForWorkPerformedUnderAgreement" xlink:label="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ReducedRoyaltyRate" xlink:label="sgmo_ReducedRoyaltyRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ResearchGrantRevenue" xlink:label="sgmo_ResearchGrantRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_RoyaltyRevenuesExpectedToBeReceived" xlink:label="sgmo_RoyaltyRevenuesExpectedToBeReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ShireAgMember" xlink:label="sgmo_ShireAgMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_SigmaAldrichCorporationMember" xlink:label="sgmo_SigmaAldrichCorporationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_UpfrontLicenseFee" xlink:label="sgmo_UpfrontLicenseFee"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_UpfrontLicenseFeesMember" xlink:label="sgmo_UpfrontLicenseFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="sgmo_CaliforniaInstituteForRegenerativeMedicineMember" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="sgmo_ChdiFoundationIncMember" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="sgmo_JuvenileDiabetesResearchFoundationInternationalMember" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_DowAgroSciencesMember" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateNumberOfGeneTargets" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfInitialGeneTargets" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfGeneTargets" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfAdditionalGeneTargets" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_InitialResearchTermOfAgreement" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_UpfrontLicenseFee" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RoyaltyRevenue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAgreementRelatedCostsAndExpenses" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_RoyaltyRevenuesExpectedToBeReceived" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ReducedRoyaltyRate" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AdditionalMilestonePaymentUnderAgreement" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_OneTimeLicenseFeeEarned" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AnnualFeesRelatedToAgreement" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_FeeDue" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_GrantFundingAmount" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AgreementToReceive" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AgreementDate" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_PotentialRoyaltyPaymentsToEntity" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ResearchGrantRevenue" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_FundsDueUnderAgreement" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ContractualAgreementTerminationDate" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_PostAmendmentFundsDueUnderAgreement" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_GrantFundingAmountMaximumUnderAmendedAgreement" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ProceedsReceivedForWorkPerformedUnderAgreement" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_UpfrontLicenseFeesMember" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RangeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_DeferredUpfrontContractFeeRevenue" xlink:label="sgmo_DeferredUpfrontContractFeeRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="us-gaap_RoyaltyRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueServicesNetAbstract" xlink:label="us-gaap_SalesRevenueServicesNetAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ShireAgMember" xlink:label="sgmo_ShireAgMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_SigmaAldrichCorporationMember" xlink:label="sgmo_SigmaAldrichCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenuesAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_SalesRevenueServicesNetAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="sgmo_DeferredUpfrontContractFeeRevenue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ContractsRevenue" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_RoyaltyRevenue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_LicensesRevenue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueServicesNetAbstract" xlink:to="us-gaap_RevenueFromRelatedParties" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LaborAndRelatedExpenseAbstract" xlink:label="us-gaap_LaborAndRelatedExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_LaborAndRelatedExpenseAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LaborAndRelatedExpenseAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_UnderwritersMember" xlink:label="sgmo_UnderwritersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommonStockMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sgmo_UnderwritersMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_BusinessAcquisitionTable" xlink:label="sgmo_BusinessAcquisitionTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_BusinessAcquisitionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_BusinessAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="sgmo_BusinessAcquisitionTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:label="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_ShireAgMember" xlink:label="sgmo_ShireAgMember"/>
    <loc xlink:type="locator" xlink:href="sgmo-20130930.xsd#sgmo_SigmaAldrichCorporationMember" xlink:label="sgmo_SigmaAldrichCorporationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://sangamo.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g595389g50d01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g595389g50d01.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X0Z/17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```$L````
M`0```2P````!061O8F4@4&AO=&]S:&]P(#<N,``R,#$S.C$P.C(Y(#$P.C(S
M.C`Y``````.@`0`#`````0`!``"@`@`$`````0```B&@`P`$`````0```AP`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```-80````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`'\`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/2<:AEK'V/=8YQMM&MCXAMCVM`:';6[6M13AT$039_V
M[9_Y-1P?YEQ_X:[_`,^V*RDI!]CHB/<?B]__`)).,2@=G?YSO_)(R22FGDMP
M\5HML;8=Q#6MK]6QQ)GBJK>[_HJE=U;H^/`NKR6%\[0ZC(DQSM;LW.6CE?SN
M+_QW_HNU-U$/&'=;4XLNJK>^MXY#@TD>+7-_D/24TSEX)`'V3*<.TTV_]^"8
MY6"8!P<H@<'T'K1M>0ZH-(AS]KO@&O=_WU,S(87V-<YHV.ANO(VM?/\`TTE.
M<_.P&M,X>5!@?S%O)T:./WE%EM>-3C5YN+;9D75->[TJBX!^V;JW>D75M<UZ
M+D49N<:+Z7-K%66UQ;O,.HK<YK_YMNUUEKO?L=[/YOWJUE.:W+Q-V@+GZ]OH
M.24TOM.$2?\`)F0XG36CG_/*B^_!#"3TBXM:"3^A9P/ZSUL*%_\`,6?U7?D2
M4UZ,/IEM5=]6/5LL:'L.P`PX;AV_=*)^SL"(^S51X;&_W(?2/^2<+_PO5_U#
M5<24UST_`(VG'J(YC8V/R(63C8]%0?14RMWJ4MEC0TQZM?[JNJOF@FC3_25'
M[K&)*?_0]-POYEW_`!MW_GVQ6%6P/YAW_'7_`/GVU64E*22224U.H,ML^SMJ
ML]&PVZ6;0Z/99/M?[?<U4\[$ZDS!R'OZ@YX;4\EGHU@&&G^U[OZRO9;FM?C.
M<0T"W4DP/YNU5^I]1P*Z?1NRZ,<9+7,%MKVAO&UVV7,WO]_T-R2FF.E=3#;&
M69S@;KGEGZ.N-6._2:>[W?UTS>G]3;:QK,JUXH>`7-JHC^;9_I7>JM>RS'<6
M$W-;Z;@[Z0\"V.?Y2?[1BMD^K6),D[@)*2D73`\8318=SPZS<2`"3O?,M9+&
M_P!E2SZ,O(I:S$R!C.W2]YK%NYD.!KV/<UK?=M]RSNJXV,X4.JLJ;5]LINNJ
MTAQ+O2L,#]_U=]F__1JQC8N+]N?;A[JV5O\`TP9814YYK:`&XS7>E_-OKWV;
M6?024RPF]2^SAIOI=Z9=4'&ITGTR:M[MMS6[G[-WL:C&OJ.T[KJ3H?\`!/\`
M_>A4\7JW3JLV[`;D;G,=:^P/:6['EPLLK]4M979_/^S_`+^KO[0P2W=Z[(B9
MG2$E(^B_\C8'_A:G_J&JZJ/0S/1>GGQQJ?\`SVQ7DE*5?.$XY'\IA^Y[$<B4
M'-DXSX\6_P#5!)3_`/_1].PP12Z?]+<?OML1T##,U._XVW_SY8CI*4DDDDIK
MY/\`.8W_`!O_`*+M1X`0<G^<QO\`C?\`OEJ.DI:!X)0/!.DDI:!X*MBM(R<P
M]C:TC_MJD(]PM=2]M+MEI:0QT3#H]KH*K]/;M%NZU]MI>#;ZC6M(.UC=L5-8
MSZ(^G[_ZZ2F6(;+7/OM,N:^RIC0(`:UY9_:>_P!-F_\`Z"LK,HQ\LYMPKS7_
M`&3<\^FVM@V/<0XL%[VO]3W>I_@_[:M#$N_[F7'Y5?\`I!)2+H?_`"+T_P#\
M*T_^>V*\J/0X_8G3XX^RTQ/_`!;%>24I5\X$XKP.=/\`J@K"!F$MQ;'#D"?N
M24__TO3L0`5.C_26_P#GQZ.@87\R[_C;O_/MB.DI22222D&3_.8W_&_]\M1U
M5S6-L=CL=.TVZP2TZ,L=])A:Y/\`L[$F8?\`]N/C_JTE-E)9V/A8S[\ICFN+
M:[&AH+WF!Z=;M/?^\Y2RL'&94"UI!-E0^F[@V,:[\[]U)3=+&%XL(&\`M#N\
M&"X?]%!QP1DY4B`7M(\_8Q,>GX9F:YGGW._\DFQ*V56Y#*V[6AS3XS[&I*1X
MUUK#<WT++`+GPYNR()W?GV-=^<C#*M)C[+</,^G_`.E5'&>*[[:'EN][W/9!
M!D&#!;])KVJTDIH=!,]#Z<8B<6G3_K;%?5#H/_(F`/#'J'W,:%?24I`S21AW
M$:D,=^1'0LEI=CV-'):8^Y)3_]/T[$CTG1_I+?\`SX]'0,,14[_C;?\`SY8C
MI*4DDDDIK9CBPX[@PV$6_1;$GV6?O%K5`YEUCC371;79I+WAFUH=^?\`SGZ3
M:W_1[U/,#]V/L(#O5T)$CZ%GYLL0WX>;9<VUV7#6$%M3:P&2)U=[G7.W;O\`
M3)*18;LZBS+^T466^ID%U+V^EK5LK97,/K_==])J%U?]L7X>[I];Z[18V*R:
MPX@2YS]SW/K]K_3_`#OS%H;,V/YVJ?\`BW?^EDV-;<ZV^JTM<:G-`<T%L@M:
M_ASK$E*-N14XL-3[VS+'MV#0_FNWV5^YO]5/C^H;+K'UNK#W#:'%I)AH$_HW
M/0<8Y]^/5<;JFFUC7P*CIN&Z/YY&H.0+'UW.:^`US7-:6<[A&K[/W$E-&KI?
M3;^HWYOV9GJAQ9:]TN+W;6-_FR?3:UK-O\O_`-&7?L&%,_9ZY_JC^Y+$C=D?
M\<?^I8K"2G/Z!M_8N$UNC6TL:!_5&S_OJT%G]`$='Q1S#(^XE:"2E(>02,>T
MC4ACB!\D1#R-*+#S['?D24__U/3L0S4X_P#"6C[K'A'0,)I;2X'_`$MQ^^VQ
MR.DI22222FOE?SF+_P`=_P"B[5857-:UYQV.)`=;RUQ:?H6?GL+7*7V*G]ZW
MB/YZW_THDI.2&@N<8`$D^2!C!YNOM<TM986[-VA(#0)V_F_VT/(Z;3=195NM
M_2,<W6VPCW#;JU[W,=_;:A=&P<7`KNQ\=KV'>'6M>01N+6-_1EFUFS:U)2NG
M9^`RAN*,K'><5K:RYEK3HT;/>V?T;_9]!6JK:[,BSTWM>`QD[2#&MG@A]/IJ
M^P8P+&F*V1('[H3=/P\?!]3'HIJJ`#7;JVAA</<UOJ[1[K&[/II*8TT/?;E%
ME]E0-WT6;(G97^_6]R,,:T?]J;3\17_Z22Q1%F5_QW_HNI6$E.?T!I9TC'83
M):'`GQASEH+/Z"".EU`B"'6`CX66+024I#R#&/:?!COR(B'?_,6?U7?D24__
MU?3L1VZIQ_X6T?=98$=`Q!MJ</\`A;3]]EA1TE*22224ULUS&.QWV.#&MMU<
MX@#5EC>2I_;<.)]>N#P=[?[U#,$NQO*X'_HO5B!X)*1?;<.)]>N/Z[?[TV)[
MJW6_Z9[G@^+?H5'_`+996C0%7S\JS&H%E3/4>7L:&:\%P]5WMW?S=/J6_P!A
M)3#&?DTX]=+L:QSJV!I+75P2T1[=UC7(M#K7VOLLJ=2"UK0'%I)@O/\`@W/_
M`'E$G,L<\TNKKK!AF]CG$Q])^EE?MW?02V=0@?IJ9[_HG?\`I=)35?GFGJCL
M9F)D[7F7W;6^B\^GO_1.+]_J-:S9^Y_.*V<MXC]7N,]X;_Y--BLL]2UU[A98
MU^UI:"UH:6L=M:QS[/'W*RDIS^A$GIS200?5OT=R/TUNA6@J/1B3@F=/T^0/
MNON5Y)2D/(`-%@/!8[\B(AY`FBP<2QWY$E/_UO3L,DU.)_TMH^ZRP(ZKX]C6
ML<"#/J6<-)'TW]V@HOJM\'?YKO\`R*2F:2'ZS/!W^8[_`,BG]5O@[_-=_P"1
M24@SIG&C_3M_(Y6E4S&T9%8J>^VH[@6/KW-<'#W>QVU5QT]LZYF:8_E._A6D
MITT$['9;1RZIA,>&\[6G_P`">J3,3T'MNKR,NU[3HRTO+#V+7MV?])!JPS8;
M+,NW,;<^RQVRNRUK0PO?]F:&T_HV[<?T_H_^?$E.RDLG[!BN_P`+GB-/YW('
M_?DOL6(3'J9^G_"Y('_5)*=&D?I+_-X_ZBM%62W"Q2=P.>23!'K7C_JK6J?V
M"C]W-,'_`+DW#_W9:DI/TG^B.G_3Y'_G^Y7%4Q75T4MJQZ;#6"_4N%AW;G&W
M?8^U]CW^KOW(IOL!CT+#Y^R/_/B2DRA<)J>/%I_(AG(L'_:>T_YG_I1.+G.T
M=4]H/<[8_P"B]R2G_]G_[1,^4&AO=&]S:&]P(#,N,``X0DE-!"4``````!``
M````````````````````.$))30/M```````0`2P````!``$!+`````$``3A"
M24T$)@``````#@`````````````_@```.$))300-```````$````'CA"24T$
M&0``````!````!XX0DE-`_,```````D```````````$`.$))300*```````!
M```X0DE-)Q````````H``0`````````!.$))30/U``````!(`"]F9@`!`&QF
M9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!
M`#4````!`"T````&```````!.$))30/X``````!P``#_________________
M____________`^@`````_____________________________P/H`````/__
M__________________________\#Z`````#_________________________
M____`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X`````
M``0`````.$))300:``````-I````!@`````````````"'````B$````:`$4`
M6``Q`#``7P`Q`"``+0`@`%,`90!C`&\`;@!D`"``00!M`&0`;@!E`&T`90!N
M`'0`-0````$``````````````````````````0`````````````"(0```AP`
M`````````````````````0`````````````````````````0`````0``````
M`&YU;&P````"````!F)O=6YD<T]B:F,````!````````4F-T,0````0`````
M5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N9P```AP`
M````4F=H=&QO;F<```(A````!G-L:6-E<U9L3',````!3V)J8P````$`````
M``5S;&EC90```!(````'<VQI8V5)1&QO;F<`````````!V=R;W5P241L;VYG
M``````````9O<FEG:6YE;G5M````#$53;&EC94]R:6=I;@````UA=71O1V5N
M97)A=&5D`````%1Y<&5E;G5M````"D53;&EC951Y<&4`````26UG(`````9B
M;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG````````
M``!,969T;&]N9P``````````0G1O;6QO;F<```(<`````%)G:'1L;VYG```"
M(0````-U<FQ415A4`````0```````&YU;&Q415A4`````0```````$US9V54
M15A4`````0``````!F%L=%1A9U1%6%0````!```````.8V5L;%1E>'1)<TA4
M34QB;V]L`0````AC96QL5&5X=%1%6%0````!```````):&]R>D%L:6=N96YU
M;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L=`````EV97)T06QI9VYE
M;G5M````#T53;&EC959E<G1!;&EG;@````=D969A=6QT````"V)G0V]L;W)4
M>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90````!.;VYE````"71O<$]U
M='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG``````````QB;W1T;VU/
M=71S971L;VYG``````````MR:6=H=$]U='-E=&QO;F<``````#A"24T$%```
M````!`````(X0DE-!`P`````#7T````!````@````'\```&```"^@```#6$`
M&``!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B
M90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,
M#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.
M#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#/_``!$(`'\`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!!0$!`0$!
M`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'
M"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"
M(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#
MTW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W
M$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P
M,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S
M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$`
M`A$#$0`_`/2<:AEK'V/=8YQMM&MCXAMCVM`:';6[6M13AT$039_V[9_Y-1P?
MYEQ_X:[_`,^V*RDI!]CHB/<?B]__`)).,2@=G?YSO_)(R22FGDMP\5HML;8=
MQ#6MK]6QQ)GBJK>[_HJE=U;H^/`NKR6%\[0ZC(DQSM;LW.6CE?SN+_QW_HNU
M-U$/&'=;4XLNJK>^MXY#@TD>+7-_D/24TSEX)`'V3*<.TTV_]^"8Y6"8!P<H
M@<'T'K1M>0ZH-(AS]KO@&O=_WU,S(87V-<YHV.ANO(VM?/\`TTE.<_.P&M,X
M>5!@?S%O)T:./WE%EM>-3C5YN+;9D75->[TJBX!^V;JW>D75M<UZ+D49N<:+
MZ7-K%66UQ;O,.HK<YK_YMNUUEKO?L=[/YOWJUE.:W+Q-V@+GZ]OH.24TOM.$
M2?\`)F0XG36CG_/*B^_!#"3TBXM:"3^A9P/ZSUL*%_\`,6?U7?D24UZ,/IEM
M5=]6/5LL:'L.P`PX;AV_=*)^SL"(^S51X;&_W(?2/^2<+_PO5_U#5<24UST_
M`(VG'J(YC8V/R(63C8]%0?14RMWJ4MEC0TQZM?[JNJOF@FC3_25'[K&)*?_0
M]-POYEW_`!MW_GVQ6%6P/YAW_'7_`/GVU64E*22224U.H,ML^SMJL]&PVZ6;
M0Z/99/M?[?<U4\[$ZDS!R'OZ@YX;4\EGHU@&&G^U[OZRO9;FM?C.<0T"W4DP
M/YNU5^I]1P*Z?1NRZ,<9+7,%MKVAO&UVV7,WO]_T-R2FF.E=3#;&69S@;KGE
MGZ.N-6._2:>[W?UTS>G]3;:QK,JUXH>`7-JHC^;9_I7>JM>RS'<6$W-;Z;@[
MZ0\"V.?Y2?[1BMD^K6),D[@)*2D73`\8318=SPZS<2`"3O?,M9+&_P!E2SZ,
MO(I:S$R!C.W2]YK%NYD.!KV/<UK?=M]RSNJXV,X4.JLJ;5]LINNJTAQ+O2L,
M#]_U=]F__1JQC8N+]N?;A[JV5O\`TP9814YYK:`&XS7>E_-OKWV;6?024RPF
M]2^SAIOI=Z9=4'&ITGTR:M[MMS6[G[-WL:C&OJ.T[KJ3H?\`!/\`_>A4\7JW
M3JLV[`;D;G,=:^P/:6['EPLLK]4M979_/^S_`+^KO[0P2W=Z[(B9G2$E(^B_
M\C8'_A:G_J&JZJ/0S/1>GGQQJ?\`SVQ7DE*5?.$XY'\IA^Y[$<B4'-DXSX\6
M_P#5!)3_`/_1].PP12Z?]+<?OML1T##,U._XVW_SY8CI*4DDDDIKY/\`.8W_
M`!O_`*+M1X`0<G^<QO\`C?\`OEJ.DI:!X)0/!.DDI:!X*MBM(R<P]C:TC_MJ
MD(]PM=2]M+MEI:0QT3#H]KH*K]/;M%NZU]MI>#;ZC6M(.UC=L5-8SZ(^G[_Z
MZ2F6(;+7/OM,N:^RIC0(`:UY9_:>_P!-F_\`Z"LK,HQ\LYMPKS7_`&3<\^FV
MM@V/<0XL%[VO]3W>I_@_[:M#$N_[F7'Y5?\`I!)2+H?_`"+T_P#\*T_^>V*\
MJ/0X_8G3XX^RTQ/_`!;%>24I5\X$XKP.=/\`J@K"!F$MQ;'#D"?N24__TO3L
M0`5.C_26_P#GQZ.@87\R[_C;O_/MB.DI22222D&3_.8W_&_]\M1U5S6-L=CL
M=.TVZP2TZ,L=])A:Y/\`L[$F8?\`]N/C_JTE-E)9V/A8S[\ICFN+:[&AH+WF
M!Z=;M/?^\Y2RL'&94"UI!-E0^F[@V,:[\[]U)3=+&%XL(&\`M#N\&"X?]%!Q
MP1DY4B`7M(\_8Q,>GX9F:YGGW._\DFQ*V56Y#*V[6AS3XS[&I*1XUUK#<WT+
M+`+GPYNR()W?GV-=^<C#*M)C[+</,^G_`.E5'&>*[[:'EN][W/9!!D&#!;])
MKVJTDIH=!,]#Z<8B<6G3_K;%?5#H/_(F`/#'J'W,:%?24I`S21AW$:D,=^1'
M0LEI=CV-'):8^Y)3_]/T[$CTG1_I+?\`SX]'0,,14[_C;?\`SY8CI*4DDDDI
MK9CBPX[@PV$6_1;$GV6?O%K5`YEUCC371;79I+WAFUH=^?\`SGZ3:W_1[U/,
M#]V/L(#O5T)$CZ%GYLL0WX>;9<VUV7#6$%M3:P&2)U=[G7.W;O\`3)*18;LZ
MBS+^T466^ID%U+V^EK5LK97,/K_==])J%U?]L7X>[I];Z[18V*R:PX@2YS]S
MW/K]K_3_`#OS%H;,V/YVJ?\`BW?^EDV-;<ZV^JTM<:G-`<T%L@M:_ASK$E*-
MN14XL-3[VS+'MV#0_FNWV5^YO]5/C^H;+K'UNK#W#:'%I)AH$_HW/0<8Y]^/
M5<;JFFUC7P*CIN&Z/YY&H.0+'UW.:^`US7-:6<[A&K[/W$E-&KI?3;^HWYOV
M9GJAQ9:]TN+W;6-_FR?3:UK-O\O_`-&7?L&%,_9ZY_JC^Y+$C=D?\<?^I8K"
M2G/Z!M_8N$UNC6TL:!_5&S_OJT%G]`$='Q1S#(^XE:"2E(>02,>TC4ACB!\D
M1#R-*+#S['?D24__U/3L0S4X_P#"6C[K'A'0,)I;2X'_`$MQ^^VQR.DI2222
M2FOE?SF+_P`=_P"B[5857-:UYQV.)`=;RUQ:?H6?GL+7*7V*G]ZWB/YZW_TH
MDI.2&@N<8`$D^2!C!YNOM<TM986[-VA(#0)V_F_VT/(Z;3=195NM_2,<W6VP
MCW#;JU[W,=_;:A=&P<7`KNQ\=KV'>'6M>01N+6-_1EFUFS:U)2NG9^`RAN*,
MK'><5K:RYEK3HT;/>V?T;_9]!6JK:[,BSTWM>`QD[2#&MG@A]/IJ^P8P+&F*
MV1('[H3=/P\?!]3'HIJJ`#7;JVAA</<UOJ[1[K&[/II*8TT/?;E%E]E0-WT6
M;(G97^_6]R,,:T?]J;3\17_Z22Q1%F5_QW_HNI6$E.?T!I9TC'83):'`GQAS
MEH+/Z"".EU`B"'6`CX66+024I#R#&/:?!COR(B'?_,6?U7?D24__U?3L1VZI
MQ_X6T?=98$=`Q!MJ</\`A;3]]EA1TE*22224ULUS&.QWV.#&MMU<X@#5EC>2
MI_;<.)]>N#P=[?[U#,$NQO*X'_HO5B!X)*1?;<.)]>N/Z[?[TV)[JW6_Z9[G
M@^+?H5'_`+996C0%7S\JS&H%E3/4>7L:&:\%P]5WMW?S=/J6_P!A)3#&?DTX
M]=+L:QSJV!I+75P2T1[=UC7(M#K7VOLLJ=2"UK0'%I)@O/\`@W/_`'E$G,L<
M\TNKKK!AF]CG$Q])^EE?MW?02V=0@?IJ9[_HG?\`I=)35?GFGJCL9F)D[7F7
MW;6^B\^GO_1.+]_J-:S9^Y_.*V<MXC]7N,]X;_Y--BLL]2UU[A98U^UI:"UH
M:6L=M:QS[/'W*RDIS^A$GIS200?5OT=R/TUNA6@J/1B3@F=/T^0/NON5Y)2D
M/(`-%@/!8[\B(AY`FBP<2QWY$E/_UO3L,DU.)_TMH^ZRP(ZKX]C6L<"#/J6<
M-)'TW]V@HOJM\'?YKO\`R*2F:2'ZS/!W^8[_`,BG]5O@[_-=_P"124@SIG&C
M_3M_(Y6E4S&T9%8J>^VH[@6/KW-<'#W>QVU5QT]LZYF:8_E._A6DITT$['9;
M1RZIA,>&\[6G_P`">J3,3T'MNKR,NU[3HRTO+#V+7MV?])!JPS8;+,NW,;<^
MRQVRNRUK0PO?]F:&T_HV[<?T_H_^?$E.RDLG[!BN_P`+GB-/YW('_?DOL6(3
M'J9^G_"Y('_5)*=&D?I+_-X_ZBM%62W"Q2=P.>23!'K7C_JK6J?V"C]W-,'_
M`+DW#_W9:DI/TG^B.G_3Y'_G^Y7%4Q75T4MJQZ;#6"_4N%AW;G&W?8^U]CW^
MKOW(IOL!CT+#Y^R/_/B2DRA<)J>/%I_(AG(L'_:>T_YG_I1.+G.T=4]H/<[8
M_P"B]R2G_]D`.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``
M:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H
M`&\`<``@`#<`+@`P`````0`X0DE-!`8```````<`"`````$!`/_A$DAH='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTG[[N_
M)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^"CP_861O8F4M>&%P
M+69I;'1E<G,@97-C/2)#4B(_/@H\>#IX87!M971A('AM;&YS.G@])V%D;V)E
M.FYS.FUE=&$O)R!X.GAA<'1K/2=835`@=&]O;&MI="`R+C@N,BTS,RP@9G)A
M;65W;W)K(#$N-2<^"CQR9&8Z4D1&('AM;&YS.G)D9CTG:'1T<#HO+W=W=RYW
M,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R<@>&UL;G,Z:5@])VAT
M='`Z+R]N<RYA9&]B92YC;VTO:5@O,2XP+R<^"@H@/')D9CI$97-C<FEP=&EO
M;B!A8F]U=#TG=75I9#HP,C`S.&9F8BTT,#4V+3$Q93,M.#$T9BUA-#DU,C9E
M-64W9#DG"B`@>&UL;G,Z>&%P34T])VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]M;2\G/@H@(#QX87!-33I$;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H
M;W1O<VAO<#HS-&8Y-F0V."TT,#4T+3$Q93,M.#$T9BUA-#DU,C9E-64W9#D\
M+WAA<$U-.D1O8W5M96YT240^"B`\+W)D9CI$97-C<FEP=&EO;CX*"CPO<F1F
M.E)$1CX*/"]X.GAA<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H\/WAP86-K970@96YD/2=W)S\^_^(,6$E#
M0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`
M,0``86-S<$U31E0`````245#('-21T(```````````````$``/;6``$`````
MTRU(4"`@````````````````````````````````````````````````````
M```````````18W!R=````5`````S9&5S8P```80```!L=W1P=````?`````4
M8FMP=````@0````4<EA96@```A@````49UA96@```BP````48EA96@```D``
M```49&UN9````E0```!P9&UD9````L0```"(=G5E9````TP```"&=FEE=P``
M`]0````D;'5M:0```_@````4;65A<P``!`P````D=&5C:```!#`````,<E12
M0P``!#P```@,9U120P``!#P```@,8E120P``!#P```@,=&5X=`````!#;W!Y
M<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`
M````````$G-21T(@245#-C$Y-C8M,BXQ```````````````2<U)'0B!)14,V
M,3DV-BTR+C$`````````````````````````````````````````````````
M`````````````````%A96B````````#S40`!`````1;,6%E:(```````````
M``````````!865H@````````;Z(``#CU```#D%A96B````````!BF0``MX4`
M`!C:6%E:(````````"2@```/A```ML]D97-C`````````!9)14,@:'1T<#HO
M+W=W=RYI96,N8V@``````````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`
M````````````````````````````````````````````````````````````
M9&5S8P`````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="```````````````N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````````````````````````````
M`&1E<V,`````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$``````````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ````````````````````````````````
M``!V:65W```````3I/X`%%\N`!#/%``#[<P`!!,+``-<G@````%865H@````
M``!,"58`4````%<?YVUE87,``````````0````````````````````````*/
M`````G-I9R``````0U)4(&-U<G8````````$``````4`"@`/`!0`&0`>`",`
M*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5
M`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!
M#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A
M`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"
M9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/
M`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$
M<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U
M!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'
M/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG
M"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*
MW`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS
M#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/
M7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H
M$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4
MSA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2
M%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;
M.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^
M'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(B
MKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W
M)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K
M-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'
M+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XT
MV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY
M.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_
MHC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D55
M19I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+
MFDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F
M4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8
MRUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S
M8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG
M/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$
M;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV
M^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C
M?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(
M!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6
MD3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R:
M:)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/F
MI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN
M+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9
MN-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#
M6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XV
MSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9
M\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$
MY@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q
M__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+
M_MS_;?___^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#
M`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@"'`(A`P$1``(1`0,1`?_=``0`
M1?_$`:(````&`@,!``````````````<(!@4$"0,*`@$`"P$```8#`0$!````
M````````!@4$`P<""`$)``H+$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'
M$R(`"#$403(C%0E10A9A)#,74G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B
M1%1S148W1V,H5597&K+"TN+R9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H
M:6IV=WAY>H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7
MV-G:Y.7FY^CIZO3U]O?X^?H1``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`
M(A-!40<R811Q"$*!(Y$54J%B%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4
M-D5D)PIS@Y-&=,+2XO)59756-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'
M5V8X=H:6IK;&UN;V9W>'EZ>WQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9
MZ?DJ.DI::GJ*FJJZRMKJ^O_:``P#`0`"$0,1`#\`W8OD]\E\!\9=H[&W%D=K
M;@WYF>S>VME]);!VAM:3'PY3<?8&_&RBX'%1UV5GI<1CHY6Q$P>>KFA@C*V9
MU)'OW7N@0?Y6_+262G;&_P`MCNJKHJJA%7#75/>/QCQNB226(14]30U79PR%
M.STSF0WCU(5T,H;Z>Z]TH:;O+YCUU*9U^%]1AIS$2M'E^X^LZB1)B>%DFQ.X
M*J`QA1R5)-SQ[]U[KGB^V?FY5PU4V1^+.T<6T/W!IZ-^U\#4U%8(49XE22FJ
MY*:)JI@$76P"L;M8<^_=>ZXKW?\`,BDU05OPTDR<Z,?\MP?</7$6.E0_H\<>
M7S])7*XYU:D`^EK^_=>ZQ+\@OE\BK)-\%=T3+]S/$\%+W5TP*CPPQPO%5(U1
MNV.GT532,BJ6U*8R6`!!/NO=8JSY)?+4*_V'\OCLEI(YEYJ^\OCTD<U.'TN8
MO#OR1EG*FX#67CD^_=>Z1N4^2GSVC:$8C^7EE:A3`S3M6]_=+PZ9S(VA(Q#N
MQ[QB(#43SJ^EQ[]U[J=BOD'\]*J.-\G\$$QKFH6.2(=Y]7U++`Z)^^K1;B9"
M8I&.I;W*CTW/OW7NE7+W+\UI9JB.D^(F(IXR\$%'/D>W=FE!)*P\E96)1Y2:
M1:&G4'4L8:9B1I4B_OW7NI,6_/GG-4#5T7TA24@6;49^R<U)4M(+"`QK3X]X
MO&2"6U$$*1;F]O=>ZP5^]_Y@!-5_"ND_C^J@0+1_Q3LC<ZL[BWW3U'V6)G5(
M6/\`FM-VM^H#W[KW2>&]?YEQCA!Z4^*RSD*)V/9V_P`TZN9I06C*[=,K1K!H
M/(U:M0M:WOW7NGBDW?\`S%=3I7]0?&)?&"?+1]C[\>*<FH:)!"LVWTD4B$"5
MM8'I-AZN/?NO=3L=N_\`F!5BZJSJ'XXXD_=Q4^BH[$WI4GP.LADKKT6$F'AA
M*`%/\X=0L#8^_=>Z=VJ_G,<C]T-G?&GR^%:6*0[_`.UQC4B666226;&KMSPM
M.X<!)%C:2W#$`#W[KW4"GRW\P]I*7[K9GQ`2)A>J\.]^WVDC*WU"(/L\*_DM
MZ;D?7FWOW7NHE5N/^8DE/-]IUM\49:LQR?;"3?\`V<E.)8Y7(^Y8;6,@BG@*
MZ=`+!PVH`6)]U[I+5>]/YG*R0BBZ4^)DD1I7-0:CM#L1'%:58Q)"$VTP:G5]
M(=FLWUL#Q[]U[J75[Z_F1TE%)6Q]%_&?*3+X4CQ-#VAO*GKI'8,9YA49#"08
M]:>,K909/(=0X^OOW7NECM[<?SWR]#3U.6ZV^-.U:F:1TEQ^1WWV!DIJ1%@2
M59I)L/MZJII5>5S'9&+!E)/I(/OW7NH]35_S&=/^1X#X4%_W?^!.[N]%7_-O
MX/\`-;)8\RZ=?]%O;FWOW7NF6&L_F=ZOW]N?`[1H-O#O7Y!:M?&G]>P;:/K?
M\^_=>Z4^+J_YA#5$?\:P/PVCI#H\G\,W9W;+4KPOD""JV7%$UC>UR+^_=>ZQ
MY.;^882/X1C?AFJZFN<AG.[=6@A@@M3[<(+`D$_0<6_/OW7NDS4)_,X:)A3#
MX/1RGPZ6DR7>3JH2-%FX&V^3,ZEO]IU6'`'OW7NIE*W\RL1I][2_"(RK)*'-
M/F>]/'+#(_DC-GVRK1S4X01@`E75RQLR@'W7NE'FHOGSD,-+28B;XH;=S4L*
MJN82L[6S,5+-8:WAQM9@*>*9`;V#O]/?NO=!1_<G^:3YI9#W7\4_"QB,=/\`
MW#WE^T$T^4>7['6_FL?J/3?CW[KW7FV1_-':%4'=OQ5285D<IE&PMXL&I`LH
MDI/&U$`I9F0B0>H:;?GW[KW2TP>TOYA<<RON+MGXZ5$*)(IAQ>S=SQF9FN8Y
M7DGI%:,QDVTK<$#GW[KW47*[`_F&U2R+B^_^BL69:N.02MUCD*UJ6D1M;TT4
M<RJD[R@:-;D%5)(Y`]^Z]TF:SK;^9NKHV-^2?QWE2,UY:/(=2Y*+[C[FWV2N
MU*CM$,;;@K<S7]5O?NO=08=A_P`U)*F*67O?XIS4Z0HDM+_H\W='YI5BT/-Y
MUHS)'KE]>D"P^GT]^Z]TI8=N?S,H(/')V'\2JZ<6_P`HFV_V+2Z[WOJBI\6R
MK8@6L?R??NO=2)\#_,L$$II=\_$AJD)3&`5&'[)6`R&-/O!,T6*:01K+J$6D
M$E;:K&_OW7NE(<3_`#`UK*>==T_%YZ2.E:.HH7Q_8B"HJO/2R)4BJ3%&:)3#
M'+&4`M^X&'*CW[KW25W#M;^997RUQV_VA\5\!#/4T4U$)-K;ZRKT%/#(9*VC
MO4XY!5+6(WC$CV>,*&`N3[]U[I(+U[_-8,B:_D)\5TB,[M(8^LMT-(('EU+'
M&'I0I>"+T@G]1Y/OW7NE9BNOOYD$-;429;Y!?'ZMH9J>,P4]/UAE:>6CJ@9!
M*J2Z/\IIBND@O9]5Q:UO?NO=.#]>_P`PMK:?D+T<EIED/_&+:QM4(C"FGY^F
MIQJU_47M]/?NO=,U7UG_`#(V69J/Y-=%1R-&JP1S=/S-%')Y%+2,ZGR./'<`
M6M?W[KW4N+JS^8B0?/\`*GJ`'T6\/2=*1?QIY+ZY@;";5I_VFU^;^_=>ZC5/
M2?\`,-R*PR?[.YL+;<J54AFI\5\;MI9JGGHA&Z0KYLODJ>>*H=RKO8:1:PX]
M^Z]TBL?\</YG-.Q^_P#YDFSLBABCC'_.'?6=&RNM35R/./#G6!:2FFBBT'T@
MPZOJ[`>Z]TLXOCQ\_'@9:G^8K0PS@.L<M)\1.I9%):Y221*G/?5+VTBP('U]
M^Z]TD,S\4?YBF3IA#2_S4:[$RK/%*E12?"WHPMXTBJ(Y(71LZ!(LK3*US^DQ
MBWU]^Z]U%Q7Q`_F!T(J&K?YJ&Y,I/.U*5DE^)/3<$<*T[7E6.GCSS1C[D<,?
MQ[]U[I2U7Q5^<E7%0PO_`#*=P1+01QQ1M2_%_J>FEJ!&``];+%FPU7*P'J9[
MD_GW[KW2(K/A+\[IX9OMOYJ78-'6SPSPR50^-O5T\2I-+Y%>"B?<*T]/-"H"
MJZV8+_K^_=>Z8:SX.?S&*D>*G_F];WHX))JJ6J6/XB],232K6*Z3105+;C$M
M&L:2'PZ/\RP#+8CW[KW4%O@A_,:*SQ+_`#A-_+!)_F5_V4CIIIJ<J\9BM4G<
MOED"HK*P/Z]5S]![]U[K*/@M_,>9J`3?S@M\O!1NPECC^(72U/)64S5$D_AG
MJ(]R"0R`2:!+RX4`?@>_=>ZS+\&?YBZQA!_-[WT2((X];?$CIIF,ZHWDJ+G<
MG^[)M+:/TJ%*CAC[]U[H2,-\5OY@]/AY<7N/^:'7[AG>53'E*7X<]*[=K8X$
M1`L);&YYP[%E)9^&:]C[]U[I#9KX*?.[(13/C/YK_9V%R)AIJ>EJX_CKUG6T
MM-#33QU`+XN?<B4E552F/2\S^MT)4\'W[KW4_P#V2+YV24E#!4_S5.Q9*BG,
M35M7#\<>L:1L@4BG27]J'<6BD6:21'LEPOCL.&/OW7NE9!\)_DY,:.7-_P`Q
M'N+(U5'2Q(),=L/;NWZ>HKXP4:MJJ'';@\$\<D5@8&O'J&KZGW[KW2(S_P#+
M]^666JZB;&_S/^^<%2S-3-'1TVP-N5`IS!%+'($GEW,DA6H:0,PL!=1[]U[J
M+#\`OFC114IQW\U7NB.MH["&IR/3NR,Q#(BEV45=%6[F,%8UY#=GN2+#^R/?
MNO=*B#X7_.&,[;\_\T+?]0,=+,=S`_'7K.([JIY2P6!&3<%]OO%&P"R4VIKC
M5]??NO="'0_%#Y/TVWJG#U'SW[!K<A4P-`^=?JO:$=7'_E0J(I:>%<TR02QQ
MJ(RRM=UO?ZGW[KW0897X-?,S(3++#_,][6H1":L4L-/TSLF.*..OEE>I^Y\6
MY(FKY(4G84YD_P`QI33;2/?NO=)Z+^7S\R8D=%_FJ=YL)*8TI:3JK:$CJC,&
M,L;-N>Z5(MQ(/4!Q[]U[IZQ/P3^9F'FHY(?YHO;M9'3TS4TT.5Z9V/DUJP69
MA*[56XW*3B]M8N2![]U[I\S/PQ^:E7CZV#"?S-NP\%DJAV:GR;=!==99:-/M
MI8HXTH*S/K3RZ)V64DD%BFD\$^_=>Z,)UQT)WKMG;U!A.P/EENSLVJI]Q?QZ
MNS;=?[;V;D<C`M-00QX77@\G,:3%B:EED:-&*N:@@BRB_NO=)'XM=A]M;E^0
M_P`^NO\`L?>,>[MM]2]X]?8KJ@+M[$;??;VRM[=';"[#;;DG\+J)Y,M_!LON
M2>G%;4A*BI$7D906/OW7NCS^_=>Z_]#;._F)[?K,N?@HE/4NHQ/\RGXR[@E$
ML,3^2CHDWQ)-3(1+"%0//</9F&G]+'GW[KW5E7OW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NJ3-G[H[L[\_F@_S`^@Y/D9W)USL;H79_Q?W!U;M_8M?M"FVQBZG?75
MV-S.Z8\WBLOL_*9/-1Y;.U1J'TY"GLMT73]??NO='IINWNV>C]T8#:7R+BPN
M[]G[SS%#A-I=Z[$PLFU\)B\[6B2--M=E;/R><S4FV1(L2/29>#(U<%=))-&\
M%)X8S/[KW1RO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5;OQ`KY:KYG?S4Z22
M2-TQO?WQ[@@1(V62*.?X>]*U3+*[.PD+2RL00%`!M];GW[KW5D7OW7NO_]';
M<_F*O4PI\%UI(:Z4S?S&?C)#,]'#%4-34\K;W:6IJ?/%.(J.*P#N-)6XL1[]
MU[JQSW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UCEEBA1I9I(XHUM
MJDE=8T6Y"C4[D*+L0/\`7/OW7NFW(9_!8E2V4S6)QJ@1L6K\C1T8`E-HB343
M1V$AX7^OX]^Z]TT?W^V+_P`]GM3_`-"'$?\`U7[]U[KDN_-CO<+O+:K6!8VW
M!B391:Y/^5\`7]^Z]TELCWITGB))X<KV_P!88V:F:=:B*OWYM:DD@:F=HZE9
MDJ,I&T;02(5<&VD@@^_=>ZB1_(/H654>+NOJ:1)`#&R=B;297!-@4*Y<A@3]
M+>_=>ZR-W[T6EM?<W527O;5V#M-;Z25:U\L+V8$'_'W[KW6-OD%T,BL[]U]3
MJB*69F[#VD%55!+,Q.7L`H%R??NO=,=?\JOC%BB@R?R*Z.QQDACJ$%;VML6E
M+P3/)'#.OGSJ:HI9(F56'#%2!]/?NO=-G^SB?$K_`+R>^/O_`*./KW_[(??N
MO=<C\P?B8%#GY.?'\(Q*JQ[AZ^TDK;4`?[P6)%Q[]U[J/-\S/B%3F$3_`"E^
M/$)J9XJ6G$O<_7<9GJ9F"0T\(;<0,L\K&RJMV)^@]^Z]TQS_`#S^#]+,*>I^
M8?Q?IZ@^2T$W?/5\4I\()FM&^Z%?]H`EN.`.??NO=<I/GA\(8BBR_,+XP1M+
M&)8Q)WQU>ADB,:RB1`VZ`7C\3AKCC20?I[]U[IS7YF?$/(4TW\/^5OQX)>+2
ME52]R];U'@::,F&90=PR1,0"&4,"K?T(]^Z]TX4ORX^*SB&G7Y-]"U=08E(9
M>W.OO+.!P91'#G@MF(_LBWOW7NGD?)WXVM8+\@.EC>)9Q;M#91O`[^-9N,W_
M`)II!I#?2_'OW7NDQ6_-+X>XU5;(?*KXZ4*O`*I&J^Z>N:8-3--'3K4*9MQH
M&A,\R(&'IU.!]2/?NO=<*;YK_#BL1)*3Y6_'&JCE9DC>G[KZWF21T<QLJ-'N
M1@S+(I4@?0@CW[KW57GP;WYLWL3^<K_-9W+L#=6W=[;6KNM_AY%1[EVGEL=N
M'!5=3CNIL)25U/2YO%3U=#/+23G1)&DIT..0"/?NO=71=I;)PO9'76\]C;@Q
ME'F,3N7;^1QU1CJ\7I)Y&A:6B:;U+805T4<@-QI9`?Q[]U[HDGQ\^?GQ<?J+
M:6([3^570>"[+V32UG7?8='NWNCKO%9]]Z];B;;V[:_)45=GJ.I@FK:S#S5K
M:HUM%)K_`$\^_=>Z%H?S!?@<2`/FE\4R20`!\@>J;DG@`?[^OZD^_=>ZY_\`
M#@7P1LY_V=#XJVC(5S_LP'57H))`#?[^K@DCW[KW2.RW\SW^79AZU<=4?-OX
MM5%<2JM2X[O7K+(S1L\BQ*DJ4>YI3&Y=QP>;>_=>ZPT_\T7^7/4"75\WOBU1
MM%,D`CR'>G6=#+.SA_72QU.YHWJ8HS&0[H"J'@D$CW[KW3;EOYK7\MS$4U-4
MR_-[XP5HJQ(\<&)[NZWRE6D44ABEGGI:/<DLT$$;*278!0HO>WOW7NFG_AW'
M^6YJJ$_V<CH#7221Q52_Z4=E:J>657>*.<?QR\4DB(Q4-8D`D>_=>ZX)_-U_
MEL22F&/YE_'YYAIO$G:>R6D&O]%T&=+>K\?U]^Z]U!RW\X3^6GAZ.:LJ/F/T
M1.*<J):7']D[.K\@NJJAH[_8TV;>HLL]0H8Z?2.3[]U[I,Y?^==_+$Q&7CPA
M^77465K91"$.!WCMW-TYDFA298/N<?E9XA4(L@#)?4K`@BX]^Z]U"C_G=_RQ
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M4W\QCXT/4O.FI:J*G_OE+_#U.M`LE619?K?3;W[KW5E'OW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[JO[^:K55=#_+I^7];CZVIQU=1]+[DJJ*OHZN
MNH:JCJH&I9:>H@JL;#/70R12J"#&A8VMP"2/=>ZIW^!7\C?X#_(3X3?%KN3L
M_9O:,F_^R>D^OMW;VK*'O#=]13YS<62P5)/D,S*4JY8U?*SDSM#PT!D\;`,A
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M?Y5"2"4?$#KTR*I17>7-RE4("Z%\N3>R67@?0>_=>ZR2_P`BW^59+')$WQ"Z
M\"R(T;%?XHK`.I4E6%=<&QX]^Z]UZB_D7?RJZ&:JGB^('7+O54L5*XF&5E2-
M8Y$D,T*-7VCJ)3&`[#]0%O?NO=3(OY&_\J1'J99OA7U%75%56TM:U37T&1J9
MXOM9$D%+3R-D1X:*<H1+&OZPQN?I;W7NG./^2-_*6B_3\!/CFQ"-%JEV6LS^
M-V5V3R35;OI9E%^??NO=1ZG^1]_*9G@D@B^"'05`)2?)+C=K/13NK`*\;2PU
M@8Q.H`*_2P]^Z]TS2_R*OY4\MQ_LG?6L0U%T$$>2A$36LK1!*X:3&/T_6WOW
M7NFN?^0S_*NEF\T7Q8VK1@Q>!X:*ORT$#Q<D(Z"K8V5SJ%B/5S[]U[ID3^0#
M_*YCA,*_']@K034[M_>K-ZY(YY&EDUMY[DEG(']![]U[I0'^0]_*M-3#4CXH
M;+'A#JL'FR+TQA)C,5.\4E2X:"DT?M+>RZC]>+>Z]T3N;^3M_+87^86G5P^*
M6P?[E+\7,!OJ+#1I61T,&Z9^Q]^8B;+-&*]&-1+C\9!&"JGF.YM[]U[JX?XO
M_!#XG_#.?>%5\:>F=K=55._CCCN^HV_#,D^=_A,"4V.^]EGFF>04D$:J@OP!
M[]U[HW)`(((N"""#]"#P0?\`7]^Z]U2M\N_Y2/\`+=H>J?DWWQ_LF716?[7D
MV#VIV0F?W5M2LS=/+OML/G-QMGZK'4]9')/45&:D\LPB`>4>GZ$@^Z]T&'P4
M_E`_RP^QOA]\=-^;V^#OQ\W#O#='5^!S&X,]7;+26OR>4R$#FNK*B>2I,S2U
M!)O<W`XX^GOW7NC8C^29_*9"Z?\`9`OC=I"A;?W$IOTA%C`/[_-D0#_8>_=>
MZYK_`"3_`.4RM7!7K\`/C2*VFEEG@J?]'U#YHYI[^60/KN6?4;WO[]U[I^G_
M`)._\KBI6-:CX)_'&58=?B#]>XQM'D"A])^HU:!?_6]^Z]U*H?Y0?\L+&Q5,
M%!\&/CE2Q5D9BJDBZ[Q($T9%BC$J3H(^H!%_?NO=+=?Y9?\`+[6-HE^'W08C
M8EG7_1]A?6Q54U,?!=B$4`$_0>_=>ZPO_+#_`)>LA5G^'70+,BJJM_H]PH8*
MOZ1<0`V'OW7NLM)_+)_E\T%2E91_#SH*"JCUZ)TZ\PGD'D!5^6@-]0/-_?NO
M=*ZA^`WPIQD*4]!\6NCJ2&,.J)#UYMU=(D8N]F^RU79F)O>_OW7N@:^2_P`*
MOB#MSXZ]];CQ7QBZ8&7P/3/9V8Q<L&Q=NTU5%D,=LO-5M')35;4\/VTZ5,*L
MLFM=+`$D?7W[KW06?R')UG_E"?`[0E-$D'2E+21QTDADBC2EW'N"!4YCC".H
M3E1<#\$CGW[KW5N/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JNKXD8R*C^8G\T2M2BI::
M3*]]=`SS5,"%9Z]J;XB],TBRUC%B'EACA$:D6LB@>_=>ZL5]^Z]U_]/;<_F,
M2T4</P<%=3TU4LW\Q+XS04T-0&+FM<[T-,]':2/361%2RDW`4-<'W[KW5C3H
MLB/&X)2161@&9258%6`92&4V/U!!'OW7ND[M#;AVEMS&;=.;S>X_X9'-'_&M
MQU%-5YJN$U5/4AJZHHZ2AIY7A$_C0K$EHT4&YN3[KW2D]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]T0?^:5Y/^&[OF$8I9H77H[>+B6"2.*9`E*C,8Y)8Y8T)0$7
M*GW[KW2?_E%1I'_+*^#XCC2-'^.O74P6,A@WGPT,QD9E"J\LQDUNP`#.2??N
MO=6,>_=>Z][]U[HBWR'GIOC_`-Q[5^8-;!FJS8E+LENG.[AC*>"KIMI;#K<^
M=Q8SM&LI$AAJ%Q^T<X4?-5TE08J+!QRR",E+^_=>Z.I@L[A]SX;&;AV]DJ/,
M8/-4--DL5E,?.E315]!61)/355-/&2DD4T3A@1^#[]U[IU]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UTS*JEF(55!9F8@*J@7
M))/``'OW7NB7;X^>_P`?]I?WA7`5F[.WIMH4N6K=W0=,;;;L";:U+@:>>LS,
MV=%#64ZT*8RDI999B2="1L3]+>_=>Z+'T1\@NKODU\]MN]K=19T[@V9N;X0;
M2S>'R#4B02RT59VYV=3QF;]R8QN3!?QAN`;DF_OW7NK;O?NO=>]^Z]T$O?8#
M=']O*RAE/6V]05(#`@[>R`((-P1_7W[KW0$_R[%T?!_XR)J5M/56!&I#J0V-
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MIH9GIM6B,N%4:K:B+<V]^Z]U8=[]U[K_U-L7^99]HW^R!1U4<<NO^9A\5O`C
MB%K3H=]/'(BS,/5$1>ZW<?CW[KW5F?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[JO/^;'4?:_RWOF/,9$B"])[E4R2%%11*])%R7(07UV%S]3[]U[
MJ7_*GHS0?RW/A+2DL='QPZO<%M%],VVJ*9;^,LGZ9!]"??NO=6`^_=>Z][]U
M[K'+%%/')#-''-#*C1RQ2HLD<B,+,DB."KHP-B"+$>_=>Z)]EOAGL['YN7<_
M3F^^R>BLJL\M90[=Z_W7F:'J&ER-4_FKLC4=+TV0H-@U]9D:G]VHD>F#S2%F
M8DL;^Z]T$7\N+NKO#MO#_)G"][;VQF_]P=.?)G?G5>W]Q8W:>%V?]WM7!TN*
MJ\4U9C<!/4XYZR1:YG<JY*:O&;%+>_=>ZLB]^Z]U[W[KW1=>VMW[AP'<_P`6
M=N8K)S4>'WSOSL;%[HH8TC:++T.'Z9WSN/'4\[-(CHM+F<9!.I57):,`@#D>
MZ]T8KW[KW4/(9''XFCJ,CE:ZCQF/I(VFJZ_(54%'1TT*"[RU%54O'!#&H^K,
MP`]^Z]U+5E=5=&5D90RLI#*RL+JRL+@J0>#[]U[KOW[KW7O?NO=>]^Z]T2'L
MVER_R)[VCZ0I\KD,;TWU'3X;='>$&-E>G_TA;ES-+#E=K=29>1)(ICMEL-54
MV3RM.1+2Y.CJ/M9E*EA[]U[H5._MN[=VK\6^]L3MS"XO;F'Q?0W:=)04&`QM
M%C:;'T5/L#/K%!04E)%!3PI"@]"J%4'W[KW6O+_)KRL-%V/_`"_L5%4O&<Y_
M*ZHI#1M)%JJ(\?WKW)41U4S^2]5.?-=E37XC];`CW[KW6U)[]U[KWOW7N@B[
M_>./HSN"2:4P1)UIO9Y)@H8Q(NW<@6<*Q"MI`^A^OOW7N@/_`)>`=?A%\91(
MJHXZJP.I45507\Y&E4)0`C\#W[KW1S??NO=,F*&X159@9K^$FC^_8X%L<]4U
M2<:0;+E$GABB2K1K#]HNI'Y]^Z]T]^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7N@B^0'_`#(CNG_Q%'8?_O)9;W[KW58?_"?^,I_*E^,3E9E6HQN[*B/S"1;Q
MON_,A3"C@*D!T^D)>/\`H?K[]U[JYGW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
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M;RU-!$"48@$:G%_Z#D<^_=>Z5O\`*Y01_P`N7X1QBQ$?QFZA0%22I"[-Q8!4
MGDBP^OOW7NCY>_=>Z][]U[KWOW7NO>_=>ZJF_E?86OP&5^>./R0*U+_-KLK(
MA/V]*TN6PNV\G1:?&\@`>DJD8^J]R;@?0>Z]U:S[]U[J/50&IIY8%J*BE,JZ
M144K(E1%R#JB:2.5%;C\J??NO=%'^0=+65/?WPH:@K*.BJH.S^V722LI9:Q6
M#_'KLN-TCIXZBEUOI?ZEQ8<\_3W[KW1OD#A$$C*SA5#LJE%9P!J94+.54GZ"
MYM_7W[KW14_G6:5?AG\HGKIIJ:DCZ,[)DGJ:;4*FGC3:V19IZ<H0ZSQ`:D*\
MAAQS[]U[HR6V"#MO;Q4EE.#Q)5FY9A]A3V+$\W(^OOW7NGSW[KW7O?NO=$=^
M47R;[KZE[5Z6Z9Z%^/>"[WWOVUM3MG>]4FY^W?\`1%A]M[=ZHJ^N<?D)(LBO
M7^_WS.1R%=V12JL'BIA&D9;6U[#W7NI_PVVIW90TW<O8OR`Z\VUUAV-VUV6V
MXZS:FV-[R]AT-%B<'@L;M3`AMTRX#:_\0(Q&'A"$4,&E``02+^_=>Z,%WAM/
M+[]Z6[?V+@#`N>WIU=O_`&GA#4R>*F&7W'M/+8?&FHE"OXX!65B:VL;+<V]^
MZ]U0'_+)^#WS(Z9[U^(N>[ZZ?VAUMMCXS_"_,?'G(Y+:W:/]_:3<VZ*W>.[=
MQKEZ2!]H[:FHH:J//IJ0F41L"`3]??NO=;)OOW7NO>_=>Z"#Y!4SUG17<=)'
M+3025'66]X4FK6*4D3R;<R*K)4N%<K`I-V-C8>_=>Z!#^7;4+5?!_P",E0B5
M,:R=4X`A*NGCI:D6\Z_NT\535QQ,;?02N+?GW[KW1SO?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]T$7R`_YD1W3_XBCL/_`-Y++>_=>ZK!_P"$
M_22)_*=^+'DGJ)R^&W4ZBJ?7+3JV\<YIIK!5$:16X7FP/U]^Z]U<W[]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>ZK:^-BK_`+/W_,'?]S5_%ND%_4/%I_T*]>G]&F_DO^=5
MK?C\^_=>ZLE]^Z]U_];;"_F7RU$3?R_1!"LJR_S-/BK'.S%OV82-^%I`%Y+7
M``_`OS[]U[JS;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6C_./I
M*FN_E?\`S5IZ.EEK9STKF)12PI)))+'39+%5,X"Q`R$+!"Q)'(4$^_=>Z77\
MK:LI*_\`ER?"6KH/^`DWQIZD:%;DA`-H8U7C#,69ECD4J"220.>??NO='T]^
MZ]U[W[KW7O?NO=>]^Z]U6I_+UQL6)WE\[:.%'C0_+W<=9IDIS3-KR.P]CU\K
M>)E0E6DJ"5>UG!U"][^_=>ZLK]^Z]U[W[KW13^\YTB^0'PN1EE8S=G=JQJ8X
MI)%5O]`'8YO*R*1$EA^IK"_OW7NC8>_=>Z*;\\0K?"SY4*RNZGH;LX%$DJ(7
M8':F3]*RTC)51D_UC(<?@W]^Z]T97:__`![.W;7M_`L1:Y8G_BWT_P!2UV)_
MU^??NO=/OOW7NO>_=>Z(QVEQ_,+^'ALYU?'/YI)=:>1T!_O3\3'&NI5#'3W"
M&P8@N?I>W'NO='G]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0+_(\R+\?N[6A0RRCJ
MG?QCC4,S2.-L9,JBJOJ)8\<<^_=>Z*S_`"F69_Y;?PV=YVJF;I';):H82!I2
M6J[L1+^X#^.>??NO=6'>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[H)N^XGGZ-[EAB4M)+U7V!'&H^K.^U,LJJ/\2Q]^Z]U5;_`,)ZJX5W\ICX
MO,6D::FH-XT=4\AJ"[5-/O/-K(6:H)+<$"Z>CCCW[KW5U?OW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[HBG3?\`#J3YM_+2FH_"M9E,5UEF,HM-1!`]13;)VEBZ>3(5ZQ`2
MUPI(D"1ERP@L;6]^Z]T>OW[KW7__U]M+^9#2I5?[(5KGG@^V_F3_`!;JD\%O
MWGB_OSI@FN1^Q)J]7U/'OW7NK)O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW5>_\`->Q[97^7!\R*%:G[3R](;J=YO#YR(:=:>IGC6/RP^J>&%HPV
MKT%M5C:Q]U[K#_*6J8:S^6A\'ZBF5$IG^.'68IHTD:;Q4\>WZ:.&)Y6CB,DT
M4:!7;2+N"??NO=6'>_=>Z][]U[KWOW7NO>_=>ZK9^`>2IJK=?SLK(6J"D'RT
MW+'+!.99)(9*/8.RHI$2>2*-9HYC%K31J5%8)>ZGW[KW2"Q'>O>6%VOUE\QM
MR[V?-]2=J=E8G;%1TGC<$E*=M=:=F92IVYUGDJ&JJJF.>LWQ@=QUV).7=DCC
MFHWJG2Q14;W7NK8_?NO=$/\`E+)51_)K^7>:>%YT;O7M9*E5J1`J0O\`&_M-
M3-(A(^X$#$,$YN1[]U[IG^0F[>TNP.W-S]3]4]JY+J&;HSJBD[PW'68_;_\`
M$I]\9/-UF4H]H[;J*BNEH:&;:L='MG+KDJ>*5I#45%'*Q3Q*LGNO=-7>G:N2
M[A_E8]J]NO#!LW.[Y^(>ZMU5D-=3#(4.W<]DNNZJJR"^&22D3)XS'Y-I/&VN
M-:B!58$!O?NO=*/#].?.#(8?;\R_-38-%CWQV*G-+COBGBH)C2MB0GVR5LG;
MLY4F:1)`XC'":=-CQ[KW1),7V?\`S0]PX7<_9O6/:?5?8'06S,UNC;M1NC-]
M&Q[>[5WA%L/<&2PF[]P=?;#@WO7X?.4U!D:&HH:?^(Y;%-5S8^9M"*4>3W7N
MCN[4V=\Q-][=VYO?:/S>ZKS.T=UT&)W+@,E3_$J)8<KMO*T<5=0RP-4=T0SQ
MBNI9UD5WC5U#6*7]^Z]T`:[8[RVG_,A^'E'WCW)LON'^(?'/YHR[9DV]T\O5
MU7@*RFW-\6#7/*]/OG>"Y.*OII8D57\0C,3$7+&WNO=6Z>_=>Z][]U[KWOW7
MNO>_=>Z][]U[IKSF$Q.Y,-E=O9V@I\IA,YCJS$Y?&U2EZ:OQN0IY*6MHZA`5
M+0U-/*R,+BX/OW7NB8XC^7YT/U[MZ#;?Q\GWY\8<?2Q4L,%-T3NZKVK0/%0S
M25-)1U>-R$.:I)L8L\A,D$:PB125N+W]^Z]T]]9]G]L]==C8WH;Y%2T6Z<EN
M@9.KZD[OVUA&P>WNP*'&4L5?E-N[OV\M170[$WO@35+301"KK(,S`B5,<J32
MR4L/NO='']^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TA>T8?N>M.PZ>
MY'GV/NN&X1I"/)@J]+B-%9W(O]`"3]![]U[JG?\`X3KU2U7\JCHH)5U=2M+N
M'L^C6*J$07'BGWSEU_A]&(V+?94][IK"OZC<#W[KW5X7OW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[JO;J_*R1?S$_DCM]$QRT]1U%L'/RMZFRSU:#;F,4ZD#11XX4Z@:7(
MD,HN!IL??NO=6$^_=>Z__]#;?_F)P&?_`&16S!3#_,9^,<_-^1'_`'W!7C\L
M&XOQ[]U[JQGW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T0W^:'30U
MG\O/YA4U1/)312]%;V4S17UHPH-48!`-@\@"D_@$^_=>ZKU_EB_-REZZ_EZ_
M#S9-=\:_F!NZKVW\=^N:0[CV7\=]W9G:V9E7;E'/#_!,M10K2UU'HE$0J%]#
MLA:_/OW7NCX_\.'X&U+J^*7SD0ROIJ0?C%OG_)%TDAS^V//=@!9>>;^_=>Z3
M6X_YD\.+3'_P'X5_/'<\U;6_:R11?&[=N(2B@!L:VJJ,D$B2$?4"]R/?NO=,
M\/\`,FW?4Y27&P_`+YM*BU$E/#D*OJR6CH)PLY@CG\\TH6*"4C5J;A4.H\>_
M=>Z>ZG^8=N:@B67)_"CY68]75A'YMF4Y66H$L4:TT;I.5=W60L"..+?4CW[K
MW1,/C=\J=\=#2_*BI[&^(WR>PE/VGWAN;L;9Q;9$U<#MO-;8P=%"U8U&P--6
M15U%*TD*VD2,@_7D^Z]U7Q/V/V97?&/K7XR4_P`9.W5P75/8'7/8-)O"KVWW
M[-FTW;M#.1YG*[@_BK[Y:"K3*8P5M/!0S1OB(JNJBT4JLD13W7NK<MM?S5]Z
M9TPT.(^!?REFIJ=Q1)FMT1[8VHF1CI8(0V62/,5$,S4M1(Q&LJ+N&%KCW[KW
M2)[9^9/:V\>P^A=\GX2]IT-'TMO_`'1NC-#);JV-)6&GS?66Z]J446+GAK&@
MHZRHR^;AB<R\>$O]+W'NO=`8O=?RBQOR#[=[EQ'\O'MS?C=V;-Q.QX*K<G9O
MV:XS8\O\2JLMLG'89-T4VUW@9S'-!D*"E2H=3(OG('OW7NDWC^YNQ]B_`/>O
MPFW!\5^W!O??^R._-F]<[>DR,^7H:#:^\\]O&JV5MFC;<.7R6YZS;O7VW\U2
M8:29ZB0::!C&PC*6]U[H[U%_--I-O8_%X&I^*'?QR.,QU-C9:6&BP[J*O'T2
M0M312^8)(S2Q:5M^.?H/?NO=5YU_SA^4>P^O=]]6]6=';]V1U'E-Q;CRF'W%
MNC9&4S/:&S-L[\SV1W1OFDH*_%U,>TZC.1YG/UG\,EJ*&>"%9!YED`'OW7NK
M#^I/G]2;8VULKJS8OPK^2&,VWM/"8C9FV8JJDQ+TE#B\%AXX,5!69*:ILB/0
M4B)'+(;2RD*/41[]U[I(R=X[B[B_F?\`PHI<CT[OKJ2JP'QW^9]9.N_XH%CW
M%B<AG_B_$LFWZC&5!IYI\;44I,PDU`+,O'/OW7NKJ_?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]UPDD2*-Y9&"1QHTDCM]%1%+,Q_P51?W[KW5,.X?^%"/\H?;?W"U7
MS%V)7RTM6E%-3X2CSF8J!/:K^YTQ46.D9X\?)2&.H876&1XU;EU]^Z]T4_Y,
M_P`_+^5CVAUE2Q]9?*/&Y'L_9N[]I]F=;[=?`[OQ(W'N_9>8CK\-@Z^=J&BT
M8O+SW24/(L;H1?@^_=>ZV2Z:4ST]/,0`9H8I2!]`9(U<@?X"_OW7NLWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[IMS,?EP^5B$DT1DQM=&):>-):B/72RKY(
M(I4DCDF2]U5E968`$$<>_=>ZHV_X3C2K)_*]Z_CUH\M)VSWA25!2)H2)X>P,
MGK$JFT;368%B@5+_`$`M[]U[J]OW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6GU)3)'_,
MX^4=0'#//TIUQJ7[>9&0(-L*!YV_8E5M-[#D>_=>ZLL]^Z]U_]';D_F&RJLO
MP7B++KF_F(_&S2I8!B(X][NQ5?JP6PO_`$O[]U[JQ3W[KW7O?NO=>]^Z]U[W
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M55CC4O=K*JCZF_OW7NN+_P`J'^6W+(DLGPL^/[R1Q""-VV'C2R0B(0"-3;A!
M"--OZ>_=>ZQR_P`IO^6M/3T5)-\*/CY+38UZN2@@?8.,:.D>O,)K7@4@A&J3
M3IKM]=(_I[]U[JK?X(_RX?@9VON_^83B-]?$?HK<E!UA\L]R;&ZZARVT:>N_
MNIM7_17U_F5P>,DFFFFH<?#F<K4SHD84H9C:_'OW7NBD9?\`ES]09+X0]0]U
MS=6Y:@WSE.W_`(]+D\A7?(#L7.[/R&S=[]H;=P\FY\?C*?;$E7D*_<^.KA0U
M>*GBB6DBKY?*RK&3[]U[K8A'\LG^7\U(M')\0^BVIPH!@;9..DCN26;U2)K>
M[L22>23<\^_=>Z+5VY_+B^".$[@^*V%P_P`3NE*+&;E[(W]39['4NS,='2YB
MDH>F=]9"&/(4WDABJXJ.JI8ZA->LQR1*ZJ2+'W7NB\=]?R?.F:3N;=&]>O/C
MOD<AU=NS8&"PN`V1T+V6G466V3V)AZC.KD-Q9K&Y2NQ&`S&V-S4N:IC*8:IJ
MNDDQMT@?RV]^Z]TINY?Y7OQ4ZN_EX=JU.Z/CGTKD.\]H?&C>K93L2';LFX<R
MV\:79]?++F(MQ9"&DS>6JXJX!ON'2*2=EU%03;W[KW1U]I_RQ?Y?$&(V]DXO
MA[T-%D?X1C9S5IL/&"832X^'RR!V5I-3ZS<DD\\GW[KW5<>W_P"6/\/>\.I>
MR/D;E=B=<;'W)B=T]GC`;`PT<6*Z6V%'U?NK-[>Q6,["VDM3%1;PR66@P7\4
MK*C(+32Z,I'"J>&&*23W7NCM=&?R^_Y?';?3/57:==\&^B=L5W8G7VTMZ5>W
MIM@T*382IW)@Z++38N1:B&*H5Z&2J,9UJKC3R`??NO=`Q6?%?XV?&7^:1\)*
MWX_]+[`ZCR&^/CW\T*+>51LC;\>#EW'18K/?%Z;"0Y&>$"FJ8\;/653)'?R`
MS$@$?3W7NKL??NO=>]^Z]U[W[KW7O?NO=>]^Z]U'JX7J:6IIXY3`\]/-"DZJ
M':%Y8V190A(#F,M>Q-C;W[KW5'W4G\J[Y4]*;!Z_Z_V!\ZNH<9C.OL%+M[&5
M>8_EX],;JS\^.-?-74BUVY:_L"BR5=5TAF*FH=5>8DLP!/OW7NAP?X;_`,P@
M+$M-_,CZWHA'*CDT_P#+QZ<U&,!2\2>7LV1(_(X)U!;B_'OW7NBK=5]6?S/.
M[^W_`)$;&K_YITNU%^/W8^UMOTM;M[X;=8T=+NNERVU:FND^^PX['G@HJ193
M<(LKF1E#O9A;W[KW1L=J_#/Y_P"#AJ4SG\U#=&Z9IJUZB">J^+?7E`*:ETJ8
M:(10;ZF601S-(S.2"ZLJD607]U[I9S?%7YOR54<B?S(,Y%2+2)&](OQKV&7D
MKEB`-9]U_?,2+$TPUF"VFWIO;GW[KW3)4_$#YU5L:I4_S.-T1Z9(Y0^.^->P
M<:YDB+:%=H=ZN7@</ZX_H]A?Z>_=>Z1?^R$_."HJJBIK_P":[W'()8:M(*?'
M]+[.Q5/333N\L$PC@WA()!2R/8(;!HP$X`]^Z]TK:3X/_+*!Z+[C^9;W55P0
M4IBJXFZ\VY%)6U.@JM5]PNY6>GL_J**"#]+^_=>ZFQ?"CY61$G_AR#N61BLJ
MCR]?;==1KMH;0=R6+16/^O?W[KW4>J^&?RNH<1E!)_,>[9GA-%5R3/5]9;9J
M)4C6FDUB)WW.F@:`3:]K^_=>Z*9_PFRIIJ/^5YLNDJ*A:NHINY>\H)ZM8XX1
M5S0[WJ8Y*OQ0O)%&U4ZF1E5F`9B+GW[KW5]WOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J
MNCJK'>#^9#\FL@&8BMZ>Z\4K+%41%6A7;<?^3,\0IJFG(3U.CDK)=2./?NO=
M6+^_=>Z__]+;=_F&4!J\I\#YUA+M0_S!?C[.9Q&"((V@W@KJ96J(EC\QL+:)
M&>W%K&_NO=6-^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB'?S02!
M_+V^7Q)L!T?O$DW`M:D4WN00+?U/'OW7NL'\K(L?Y<7PE9HEA+?&OJ=@JSBH
M#(VTL<4D\P5`WE4AK``"]OQ[]U[H_'OW7NO>_=>Z][]U[KWOW7NJH_Y;"UH[
M8_F94V5@\=9%\VZL27-.1-25'2/4M1CFTTR+&H.,FB%C=_RQU7]^Z]T/.W?A
M_D<%O;&8T[^H)?C?MO?N;[5VUTK#M>6+(1[WS,>3--C\WNRHSE71Y#K_`&SD
M<Q)7XO%P8RDFI:VEI'-2ZQ,DGNO='C]^Z]T4WOI:I^\OAZE#+#3UK]A=MK1S
MU,+U%/#4GX_=D""6>G26G>>&.2Q9!(A8<!A]??NO=&NA$JPQ+.Z23B-!-)&A
MCC>4*!(\<;/(T:,]R%+,0.+GW[KW16OG+!#4_#;Y04]165>/@GZ,[*BEKZ!0
M];1H^U<DK5-*I5@U1"#J2X(N/?NO=(7;7Q8["&+P3#YE?)V;%R8VDF>*?+=<
M')F.HQ/C2)*\=<K$G@GE61286/H`-^3[]U[H'-X?RH^F]^9^HW5N?N?Y*U6Y
M:UHYLCFJ#L/!8=\U6Q+&%R&=PN+V;2[3RM:6B#,\F.M*?\X']^Z]T.E+\0=T
MTJ-''\T/F$8M7[4)W;U&D5-$!9*>FCAZ8B2*GB4`*MC8"WOW7NBUU_2^<ZW_
M`)B'Q#J<UW[V]VG0U_2/RP:@QO:U?M'+_P`+R-%F/CMYGPM1MK9^U7IWRD%4
MJS"02@BG6UO?NO=6S>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[JOOXH.K_*3^8(5%M/:'5B'])]2[`J`Q]*J.3_6Y_J3[]U[JP3W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U#R,(J<?74[1"<3T=5"86;2LPE@=#$6_LB0-:_
MXO[]U[JB#_A-QY1_+#VJ)HQ%*O>/?JO&/I&5[!KU"#D\*!;Z^_=>ZOK]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=$(V718^A_F*]ORF>1LMF/CMM7("G+3M&F-I=T8O'>
M10;TZ,:J"UAZC]?I[]U[H^_OW7NO_]/;;_F)S4D=5\$(:C'_`'LU1_,2^-PI
M9&H9ZN.ADCCWI(U69HXI(Z*5`+)(Y7DFQ^OOW7NK'??NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW1!OYIDI@_EV?,241F8IT7O,B*VH/>D468'@ISZ
MOQIO[]U[KE_*R8O_`"W_`(/.51"_QAZ=8I%;Q(6V7BCHBT^D1K]!;BWOW7NC
M[^_=>Z][]U[KWOW7NO>_=>ZK1^!.,@QW=_\`,G:E@A@AKOF!B:P)!'!`K2R?
M'CIA:B1H*>RQR25"LS$@-(3K/+'W[KW5EWOW7NO>_=>Z*KW=_P`S]^&?_B2N
MU?\`WP/8_OW7NC5>_=>Z*W\WTDE^'GR;CB\AD?I#LA4$5O+J.U\B!X[V&N_T
M_P`??NO=&)VT"-N8`&]QA,4#?ZW%#!>_^/OW7NGOW[KW7O?NO=5>?,+N?ICH
M;YJ?"??G>W<'6/2FRTZO^6N*BW9VQOC;G7^VJO,5=7\=YZ7"TV=W3D<7BY,O
M54]++)%3^7RR1Q.RJ0C$>Z]T>[J'O7I/Y`[:EWGT1V]UGW/M""NFQ<^Z>J]\
M[9W_`+>AR5.`9\?+F=JY/*X^.MA!&J(R!UOR/?NO="A//#30S5-3-%3T]/%)
M///-(L4,$,2&26:65RJ1Q1HI9F)``%S[]U[HH<W\PGX%T[U$4_S4^*<4E)43
M4E5&_P`@>JA)3U5.S1STTR?WJUQSPR(59"`P8$$7]^Z]TEZ3^9U_+OR%/25=
M!\U_C+74E<CR4U51]R;%J::1$E\1/GAS3QK=_I<BZ\CCGW[KW0F]3?-/XB]\
M[L_N)TI\E^CNU]Z''Y3++M;K[LW:.[,^^)PLE!%E<M'BL)E:RMDQ=#-DX$DJ
M`AA#R!=5[CW[KW1G/?NO=>]^Z]U[W[KW59_PFR=#6?*7^9+14\[2UN,[UV''
MD(FG>I%.:C9%3-2JLKEM`>$7\8-H_H`/?NO=68>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NN$H+1R*!J+(X"V4W)4BUG]!O_`$/']??NO=41_P#"<BBJ,;_+
M1V_058=:FE[W^0$4RR:2ZO\`Z0*Y[,5NMPK#Z<>_=>ZO?]^Z]U[W[KW7O?NO
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MO>_=>ZKU_FPSSTW\M[YE3TTD$4J=';J&NI=XX1&ZT\<X9HXY7U-`S!1IY8@$
M@&X]U[J-_*0J(:G^69\'I:?5X#\<>M$B#QI$XCAP%-"@:..HJ44A4`_6?\0#
MP/=>ZL3]^Z]U[W[KW7O?NO=>]^Z]U7A\(HBG<'\P9]#*)OE9CG#'QV<#HKJ1
M+KH=GL"MO6%-Q]+6)]U[JP_W[KW7O?NO=$H^4]2^/[>^%.1#5<$,7?N4H)ZR
MG(6"`9KK3=V)BAK&!,@AR$U4M.H5&U/(`VE26'NO='7]^Z]TG=W;3VYOS:^X
M-E[PQ%+G]J[JQ%?@=PX2N#M1Y7#Y.G>DKZ"J$;QR&"JIY61M+`V/U]^Z]T^T
M\$-+!#34\:Q4]-#'!!$OZ8X846.*-;W.E$4`?ZWOW7NLOOW7NO>_=>Z0&_.J
MNL^T8L9!V1L':.^X,+/-4XF'=N`QF>BQM14>#SS4<>2IJA*>284T88J`6"`'
MCW[KW17.D<3M;J'Y3_(SJ[&X'%[5A[0H]A=V[,QV`P=)@MNO@L;M'"=:9^EI
MQ1)!0S9W^\NV:BKFAB02+!*LCBS!C[KW1L^P:.'(["WOCZB-)8*[:&Y:.>*1
M6:.2&JPU;!+'(J/&S(Z.00&4D?D?7W[KW6JE_(?VML'=&=Z3IJ_9^R,W15?P
M7W9#D8ZK8N&K:>JJ-O\`S]^7.#H:B27*&2II*BGHJ".`2^.IDGCB5&=513[]
MU[K:;AZDZJIXTA@ZRZ^@BC`5(H=F;<CC10+!41,:JJ`/P![]U[JE_P"=.ROD
M=T?_`#!/AK\F?B+\):OY!;<V/\>?E5UMV+C-@Y/876U+B<IV+N+H[(;2?(Y/
M)SX]JB:2/:->8T6"86U<H2;^Z]TJ)OYA/\S>.Y3^3CVG,JQR2,$[[ZFU,5!T
MQ1!JU0TKL/H2HM^??NO=')^$'RK[F^3,7;5'W?\`&3,_%[=G6&X-OX0;/W!O
M?`;URN5BS5!D:U\C-/MM'QM!#$:)5C3SRR.&)8)8`^Z]T?#W[KW55GP5S8K_
M`)D?S3<.:>!9L#WGU(LE;`RR?>)D^M:FL@CED54/FHH_VV0KZ/I=OK[]U[JU
M/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UTRAU9&%U8%6']0PL1_L0??NO=4
M(_\`"<>O:I^`.\L=KJ#!MKY@?)[;E)%41)&*:EQ^]8)(J:GD2:?[FEC-2=$K
M%6:YNHM[]U[J^_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=,6V\!3[8PU)A*2LR5?340=(:C+5?WM<4=VD"25/CB,BQE
MK+<7`]^Z]T^^_=>Z][]U[KWOW7NJ]?/)_P`.N?;77Q?\-Z^>VD:O)_LR'COJ
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MQ11J2S$@`"Y]^Z]T3ZL^6&9W?))_LM_1V]/D#C:2MJ*6KW=19G!]==>5D--*
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MG>?QAVCV+MS=>PMS1_`7MV3+;-WOB,KMW<E%)6_S!_E]G\=%D,+5K3/33'$9
M6"HM41E@DPT6]^Z]UMZ^_=>Z][]U[I%]A]B;*ZHV;N#L'L/<>+VGL_:^/GRF
M;SN8JHJ.AHJ2G0N[/+,R*9'MI11ZG8@#D^_=>Z`+XC;8RT&S]Z=I;EV_/MK<
M?>_8.<[2EPN1B>/.X/;V82GCVQM[-%P+U6*HHW8!?0HGX^I]^Z]T;'W[KW1,
MLE\$.B9>RNQ>X=M2]G]?=D]JYC&;BWQG]@]N=B[9H<]GL-C9L1B\KD]IT&XD
MV?D9Z/'SM&JU%!+&0;E;@$>Z]TU;@WCW1\7*['Y/?V>KN[N@*NKH:+.[[R&-
MPN/[*ZIFK:J#'Q9#<,&V\?A,/N/8D?EB)GCHFR-/+Y7J)FC:)5]U[H\".DJ)
M)&ZR1R*KI(C!T=&`*LC*2K*P-P1P1[]U[KE[]U[KWOW7NO>_=>Z][]U[KWOW
M7NJ`_P#A-]#X/@9V8NHL6^;7RJD),\<Z7?>5"?VC%Q'';Z(?4OY]^Z]U?Y[]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>ZKO_P"ZL?\`YCO_`/GD_?NO=6(>_=>Z_];;`_F9
M0I-_PWYK2!_%_,X^*,R>=HUT.G]_-+P^1UU3J"=(6[?T'OW7NK./?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1/\`^8&CO\'_`)7B*>III!T+V6Z3
MT<IAJ8VCVOD'7QR*&*ZBMCQRI(_/OW7N@&_DQ>4_RL/@PTY+3/\`'[9<DK,P
M9F>2GE=F8@D:B6Y_(/U]^Z]U9S[]U[KWOW7NB8]\TE#WCV]M'XIYD2_W%J]E
M3]Q]P8UW>"#?&Q*#<!VSB=A+44[&=L?F=T)&,S3N$BJ\0TL.N[V]^Z]T;[$X
MG&8+&4&%PU!2XO$XJD@H,=CJ&%*>CHJ.EC6*GIJ:",*D444:@``>_=>Z</?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW50&1@(_GA85Z@4-,(OY?6(7%QTTHDJ:R&3N+M5ZMJRG*HU*89V8JP!20
M']6K4![KW5O_`+]U[JO[Y)]R]VTWRI^-WQ8Z;W+MC8$G=757R#[)W#V%G]L1
M[RJ]OT_3>4Z=QE'2X?;M154-%D*G(OV:[,LT\26A'J'OW7NA#VU\4I,IGL#O
M+Y"]I;A^06ZMLY"GRN"HLMB:/:'6>)RM#4I5XO-X_K#&UN3PL6?QL\:M'5O-
M(X90;7'OW7NC>@`````````6``X``'``'OW7NN_?NO=$3[M_F:_`OXX]A[IZ
MD[Q^4/5?6/9NSJ#;^2SNR=X9TX/-P4FZL6^9V]-3I7P0TU='E,>FM7ADD2.X
M$A0FWOW7NBO]C_SN?Y1M3@:_9V?^:W3553;OQU3M_*P4F8EJCC<3G:.JH*S)
MUC-1BG--0I(2XC:26Y4JC`W]^Z]T8W^67W)UWW3\2MFY?J?L3`]H];;+W%OW
MJGK[>>"KA71YS8'5N\LUL78V3KBS&ICR.0VO@J6:42@.7<G\^_=>Z/\`^_=>
MZ][]U[KWOW7NO>_=>Z][]U[K7]_X3<2&3X%]H7,9T?-_Y6Q@(LZE0N\Z"RR>
M:**\HOR4U1_T8\^_=>ZV`O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1`-'_8T[R7'_;O_
M`$:;-?\`[**U7O;3;_"]_?NO='_]^Z]U_]?;4_F/+4L?@6*:."2W\R3XO-4>
M>))?'3*N^FEDAU_YN=;#2PY6YM[]U[JR3W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]T3#^8K4"D^"?RRJ"L[A.BNP?33,%F.O!5,8T$HXL"UVX_3?
M_7]^Z]U4O_+"_F';4ZG_`)>'Q#V)-\5/GEO:IVOT7LFFK,[UY\6]U[LVM7O4
M8U*N.IPF=I,A%2Y6@J'J?'%+'PSJ00+'W[KW1RZ7^:[+D,I58^A_EZ_S)FBA
M=A#65OQ7W/0I4Q&K@HH9E22LD\:23U*7NQTI=N0#[]U[I;T_\R7(.JO5?`K^
M8?3(R2V$7QDW#52B6)M(C>)<A&520W*O>Q%C;GW[KW57_P`Q.]OF5O[N'_3;
M\1]E_/[H+*R=4IU]E-NYC^75DNRJC-RQYO\`CN*DHLWF-ZT5)M^"2J*)4@TL
MP@.J1M5BI]U[HGX^3?\`/$AJU@J<]\[_`+-(Y%DKJ;^5?05DAGAA0E4I4WC&
MTJ2SN%5PP#`,P%A;W[KW1]_@M_,"_F#[1VQVG@/E]\0?G'W;N).P*/(]5[YI
MOB?+U-'6=9S;'VP,C197;E#6Y5,?GL7V`F6@CADEDEJZ1(JE62.5(U]U[JQ"
MH_F#;^IX!;X#?-.>M6)VEIX.ILE)3">(KKABKA&$F1DU%)`@#D`6%_?NO=>_
MX</W:(XF;X$_.;RRQ@^->D,NRQR^,,8Y9-8"J'.G5;W[KW2<F_F(=WUU"LVV
M/Y<'R\K,BDDZU=#NC:E1LV&*.&AEK%DI:ZKQ602N\S1B%0J+>5@OOW7NN$'S
MU^5503&G\M+ON*6"2M2K^ZW%3T\`2B;%@R4,[;29:\52Y.\`4+Y/MYK6\9O[
MKW2DJ_G%\BZ9(9T_EZ]^U-.TL\51X*V-JR#0H\,B47]W"U1%-)P6#+I'//T]
M^Z]TWCY\=^*T7E_EU_)Q8Y`2S18]IGC`_#QC"*0Q/XO]/?NO=)S-_P`PGY/4
MD&O`_P`LGY+YR?[D1^"IJ8\,OVO&JI\TNV*L:UY_;M<V^O/OW7ND@/YEWRP2
MJJ%J/Y4'RN3'QM*D%73SI55-08Y3$&-`NU$>))/U*2YNO/OW7NA>IOG!\EM,
M"9'^7AWI25,U/%,8Z/,P9*FA>4,W@EJX]L0HLD8`U>G@FWX]^Z]UU/\`.GY"
M4R2-)_+R^1$C1*A=*0K4ZF=`Y6`KM]/,$)L2`.1[]U[I-9O^8'\F:&`-A_Y:
M/R4S50T"3+`]0F-34\L2^%YY-LU"I(L+.[7'!4+_`&KCW7NB7XSMOYR;R^<V
M(^6<'\LSLW`T.$^/_P#H5J<1NCLK%86OJ)$WCNG<U-D*2JDV0[STS+N`*\?C
M*QE2;W)]^Z]T=B7YM?-P0SO#_+)W_+-'$SQ0OW/B(A-(!9(A(>O&"ZV(N;'2
M.??NO=%QV%W=W_W-_-1^(DO>'Q,S'QL;`_%;YG?P"KR_8U#OH[DBR>Z?C$,A
M3PQT.V=N#'R4$E#"7UB4D2BUK^_=>ZO@]^Z]U[W[KW7O?NO=:?G\Q*:BVG_,
M;^5\F^]M?(:+`;\I_BQD]K9KJGX&]?\`RHQF?H]O]35V`S5'3[LWAMK-5N$K
M*?-31P/2T\L<>I@[J2H]^Z]TB,SVWCMLT%'1[`^,G\P/<\2PF.HJ=U_RI_C5
M0I!'%&&^['FZ1DJ9%J]9#*9"(DA7ZW/OW7NK4?@#LOO'OOH3`=@=8?*/MKH7
M;V0SF^\=6=59_P"-G1O6V9Q.;VSNC);=SU2VW,)U]@Z&CA_O!22K?[>[@<V)
MO[]U[HU^6^'GS;R>/%#3_P`S/MK"RR9`U=1D\5U!T<<@M,63_<=1_P`1V/7T
M4-,$#<R0RR7-]7%O?NO=/6V?A5\EJ.>H;=?\S7Y9YRG:&3[:+%;5^+^$EAJ'
M+`/+-+T!E!-!$EM*!5;7<EB#8>Z]TL'^'_=!\PC_`)AWR]4:RU(7QWQB=XU:
M-D,=45^.T:U(1F#*5$5B!>XX]^Z]TU/\/_D4(@(?YB_R>^X60$//M;XXR0M$
M/JCQ)TC$Y<_ZH,!_A[]U[IIR'PR^35?`D*?S+?E)BW%8E0]1B]G?&D3-`MBU
M):OZ-KHEB<CDZ=0!^OOW7NB!?\)G:&IQ7\OCL7#UM?596NP_S8^4^,K<O720
M25N7JJ7=F,6;)U@I8*6EBJJUCK=(HTC5CZ5`X]^Z]UL,>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NB*R29(?S+Z:..FI3BF^#D[5-6:B'[Q*M>^8Q#`E+XA4>!D))D\A2
M_&F_/OW7NCU>_=>Z_]#;@_F)I&W^R+>12VC^8Q\9'2TBQ@2#^^X5CJ(\@%_T
MBY)]^Z]U8Q[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)#_,HJZJA
M^`_RUJJ-5>HCZ/WP$1K699<8\,H]7&HPR-;_`!]^Z]T'G\H"GCIOY8WPCABC
M>&,?'_8[K%)IUH):$R6;22-7KY_/]>??NO=60^_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NJH/DU6ST/\U;^7"T4QI8JWI7YH8R>>*:2&:=*G)_&^
M9<<P0@34=6],&D1K@M$A_'OW7NK7_?NO=>]^Z]U[W[KW7152;D`G^I`O[]U[
MH*NZ^TL#TYUMN7?.=R$%$U%1O1;?IG1JBKSF[,BCTVV]OXK'PJ]7E<GE<HR)
M'3P(\KKJ(6RL1[KW22^+_7&5ZSZ;V]CMS4$6+WSNRNW!VCV5C:=J5Z/']G]J
M9NMW[V)0T#T3/328^DW?GJR.!D)#1*I]^Z]T8/W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=4!?\)UH<CBOAUW5@JR@KC)2_.KY;-5Y.H'BA9SNW`R4A1)RCS"NBG<K
MX`\<?A(8@LH/NO=7^^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJZ:ZNR*_P`V'`XZ"RXZ
M3X!Y:JKF6"D9Y'3O^&.GC>HD(JXXE<Z@(P06_5Q[]U[JQ;W[KW7_T=MC^8E'
M%-D/@7&VIID_F'?':IAB`NI$$&]/+,YU#3X%<$&QY/OW7NK(/?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1%/YG(<_P`OSY<!%D9O]">[O3"I:4@4
MR%M"KR6TW]^Z]TFOY2S1-_+5^%30R1RQGX_;"*O&H07_`(6FI&19)0LT;75Q
MJ/K!_P!;W[KW5B'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JH'Y;
MO*/YK/\`+%CCQWW8;K3YAM)5O!)-%01I6?'K5("DT*PU#ZO0[:P`#Z3^/=>Z
MM^]^Z]U[W[KW7O?NO=5T4OR;[N[@^5WR9^*O4VT]A;1Q_P`:9>BIMS=N[FW+
ME<SE*U.W-E3]@4\.*ZVH\%CZ>N2@CH113B3-P!TE+J00%]^Z]T+NSOBW63=B
MX[M_O?LO(]U[^P`J4V=CFP4.T^K]A&JD22IK]G["?*;FJ:/-U@@A$U75Y.L>
MU/'XEB(8M[KW1NO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5"G_"?3*"I^-O
MREQ7$CXOY[?)25IQ4-,-&1S.(>.E,;(HIVI?MS=06'J^OOW7NKZ_?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW59>7A@D_G!;0E>:1)J?\`E[;@:&$#]J7R]_PQR%F\J^I%
MY'I;_8>_=>ZLT]^Z]U__TMNC^8%Y&R7P8CCIH)B?GYT#*\\JR^2FBA@W<7:"
M2,A5:34`0W##_6]^Z]U8A[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z)?_,7HILA\$_EC2P1SRRMT9OZ54IFE68BFPM14OH,)64Z4A)(!Y`(]^Z]T
M&?\`*&(?^63\(Y%J,35"7X^;#F$V%M]@1-C1)XPH)*5<.K14*>5J%<'GW[KW
M5CGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JK?Y*[?GK/YFW\O/<
M2BH^VPO5?RUH9F6J04HFR]=T&T"S4#F]1,PQ[:)0MX0&%QKY]U[JTCW[KW7O
M?NO=>]^Z]U5E\5:8+_,U_FKU+&9I'A^$D:M]A!3P+%_H(R+"/[U85FKI@P/U
M=A&O'''OW7NK3??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:^__``GD
M"?Z!_F%H5U)^>GR!+ZY(I-3_`,5HM3+XO\VA_"MZQ^??NO=;!'OW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[JL[*^(?S@-J%S#Y'_EZ9Y(`X=I@R_(*!Y##H],8,?ZB_!'`
MY]^Z]U9C[]U[K__3W+?F)19RLJ/BHV&:-8J/YA],5>8UYFIQ+'$QIN45"I'!
M25299F9E_P`ED,22?76+>_=>Z.7[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z*]\VYO!\/?D_)XH)K=#]HJ8ZB$5$3"39V6C8M"2-;*'NO]&`/OW7
MNBO?R6():;^5=\'X9:N2M9.C-NVJ)9VJ',9GKFAC:1D1AX(BJ:2/0%T_CW[K
MW5H7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JNKY"@-\^O@W=BMM
MD_(QETMIUD5/3_H/^K6W-O\`"_OW7NK%??NO=>]^Z]U[W[KW5</QGIYT_F#_
M`,S2HDFJ7AG?X;+3Q,Z_:1"/H[)K((H@=0E:079B.0;?CW[KW5CWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM?S_A/5_S(?Y>_M"+_`)SM[]^B*GE_
MW*TG[ITLVHO_`%-B?Z>_=>ZV`_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1$)\'CO^',Z
M#<LZP')?[([5X*@8M(U0L9[U3(5>B,1F*.,H`"Y8$WT@'W[KW1[_`'[KW7__
MU-Q[YJF-7^)+29@8D?[.QT2B(WATY660;J$>*O*C-KJ;$KH*MZ??NO=':]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%=^;;:/A_\FGO;3T?V2UR"
M0-.ULD;D#DVM[]U[HI/\C]57^5+\*=":%?J5)K:WDN9MQ9V4N"[,P#E[Z2?3
M>WX]^Z]U:Q[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK8^3N&QVX
M?G+\*L+EH9)\=D-A?(N*IBAJJNAF94K^FYE\590STU93.)(E.J.1&M<7L2#[
MKW5D_OW7NO>_=>Z][]U[JN[XXU`_V?S^9#2>O4?]E#J?\T?&%_T+Y&+F>^G6
MQ'Z+7L+^_=>ZL1]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK[?\)XW
M=^A_F'KCACT?/;Y!1KX9'D+HN4H=,DVMW\=0Q)U*+`<6`]^Z]UL$^_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NBF5SB+YP8/3XT:I^,V3A=F$.N>*'LF.=8(SXQ4`QR>L^
MLI;^S?GW[KW1L_?NO=?_U=P#YYHS_P"R8Z4D?1\^/CJ[>-M.A1_?"[O_`%C6
M_(]^Z]T?CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T5CYQKJ^&_R
MA744U=$=GKK&JZ7VCE!K&D%KK]>.?Z>_=>Z*Q_))`'\J;X/JJ!`G26&3B_[A
M3(9-&G.JSZJDKY#J`:[<\^_=>ZM.]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T67
MY<_(>N^+_2N8[4Q'6&ZNY,[3YC`[>V_USLNHQ-'N#<N<W%7+C\=14E9G:W'8
MFE4S-=Y)YHT4?4CW[KW58F%_FM_-#/5,./QW\G;Y8R9&IDB6&*KW[T/AZ4*\
MJ1MYJ_,=BT5%$;,2"9`H'U/OW7NI&V.S_FC\E?FE\6-^[T_E\=K?&SKSJW'=
MI8W=6].RNS>B]UT;P;UDV6:6&@Q/7'86Y\ZE<C[7DL[TZPA6Y;D7]U[J\WW[
MKW7O?NO=>]^Z]UJX?,'YMR_"[^8C\MWKN]:CHG$]D83XV5,^8_V6;L;O<3T.
M$ZHRE$V:BJ]E;$W<M+3TF3,=']H"'>HF5V3QAF'NO=!/1?SP=G0MX\]_,^J8
M9:DP'&_P_P#EG_(9X9H0T_W+SM4]%)(DVGQ6`&B^KGCW[KW5E'Q:[5^7'S3Z
MR';_`,;OGIL3>/7\F9K\",ON7XI9;KG()D<5(T-=$NW]];)V]FB$J4*"0T_B
M9>58^_=>Z,8>G/YHBRJR_,+IAX5!71)TIB4:4Z6`=V3"G0P)!LO''OW7NDC6
M?'_^;34BL:F^?W4F->04XHHX?C=LRKBIM,S-4%WJL+Y)3)"0JWO8B_OW7NE#
M2?&S^9D*6`5O\R7"M6>)/N33?%#IW[<S6]?A\E`'\=_I<`V]^Z]U*I/C7_,A
MIGF:7^9!05?GG$Q6;XM=/A8[(B-%!IH1XH6$8.D?1B3]2??NO=2,G\=/YD%5
MC,A28[^8KA\5D*N2,T65'Q:ZBK7Q48E5I$CHJBA^VK2T0*@R_0F_OW7NB4?\
M)^,3NG;?7'SWVMOK-8C.[WP'\PWOBFW7D,5AL+ME*S,21X!JC(-M?;G^X#`P
M9#2)(X:/]BY:W-_?NO=;`OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HBN]LC38_\`F$])
M4T]1D!/N#H#L/'T-+34D$M"9<9G#E:B?(U;GSTP%.I6()P\G!]^Z]T>KW[KW
M7__6V^?GW4K3?[)7JBJI?N/G_P#'&F'VK*OC:7^^-I:G4#JI4T^L#GZ>_=>Z
M/_[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*U\X`Q^'7R?"*6;_0
M5V:54`FY&TLH?P"0..3;@>_=>Z+9_)EIXZ7^5O\`".*)="GHS;<I4,&`>>6L
MGDLP`##R2&Q]^Z]U9Q[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H(.^^O\IVAU%O
MO96W\H,#N?+X&L7:NX!$)9MO[EAB:7#YFE']BKH:M0T;?V6Y]^Z]UBZ2[?Q/
M;NT*7(>-<'O7$0T^-[$V%65,<FX=A;NAA5<MMS.0`(ZU-%5AE$H7Q3`:D)'O
MW7NAD]^Z]U[W[KW7O?NO=>]^Z]TR5^V=MY6:2HR>W\)D:B5$CEGK\305DTB1
M6\:22U%/([I';T@D@?CW[KW2)WGC>K=C;4W%O/<6U-HTV%VKA<CG,A.^W\(I
MCI,=2R54L<)EI57S3>/1&MQKD8`<GW[KW0+_``HP(H^E$WN,(-NQ=T;SWSW=
MB<(]&N.KL1M7M3<^2WGLS#Y?&QPP18S-8G:V8I:>KID&F"H1T!(4'W[KW1N?
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0U_)2R#_Z3?YM6W]:B'"_S&NS:F"#R1F1
M$R^*Q\IJ)(Q$LB_=&DX8NP?1P%L;^Z]U?+[]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZKJ
M[9F*_P`R?XF0BG602=-=VEJB[AZ<+12$#APK)*>+%38^_=>ZL5]^Z]U__]?;
MP_F!S"'_`&22X)\O\PCXV0BUN"_]\[$W_`M[]U[JPCW[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]T7?Y>4*Y+XH_)BB8R`3]!=O`>&4P2%TV!GY(U$
MJE2@9T`/-K$WX]^Z]T47^2M5BN_E4?!6J"21^7X_[0)26)X7#*E0K$)(`^@L
MI*G^TMB.#[]U[JT+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%[[,^.NU]
M\YZ7?^V,SG.JNW!304]/V;L69:/*50I85I*-=VX.;5MOL&EH*'5%309NFK8:
M8$-$JLBD>Z]T4[=&_P#Y(_&ON[XP=;[F[@C^0&U^]-X9'9>X\EO'8>UMG[AP
M/VL-+5KFL4W7&#PN(:1$E\82H01G4;BX!]^Z]U9K[]U[KWOW7NO>_=>Z)5O_
M`.3/9J]^9[XZ=-=*C?&Y-O[&Q&\,[OG<&\\#MW:&VESE920X^.OQ%14P[CS4
M1@F8N*$,X:WX!]^Z]TY1=$=K=K9W;F;^2^]=L9';VUZP5]/TWU=29:BZSW%E
M:6HIJS$9O>E3N(?WEW$^,J(6`QD\KXB;TO)`S*+>Z]T</W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]UKT_P`DM<FGR,_G!HCTTV&'SRW,TM54B8Y.>K?%$T:T
MDD9^U?&PP^4-KO)K*VXO[]U[K86]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5S]ST4"?S
M'_ACE'KHTGEZT[]QD..BJ2E3-HVS/625-52ZPLU"BBR'22LWOW7NK&/?NO=?
M_]#;K_F$",CX0ZW=#_PX9\:S$5C$EY;;U\:N#)'IC)^I%S_A[]U[JP6D2I2E
MIDK)HZBK2"):J>*(PQ35"HHFECA+N8HY)`2%U'2#:Y]^Z]U(]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW0(_)E!+\;_D%&VBTG2/:Z'R?YNS[#SRG7_M%C
MS_A[]U[JOG^0W7R9'^45\')Y1&&CZD>A'A5UA\>-W7N/'Q&%9`K"(QTPT\?3
MW[KW5NGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HM&POEITSV3\B>W_B[M7,Y.J[9Z/P&
MV]R;[QM1A,E1XVFQNYY98*%J'*U-/'25TD,\860(;>H%"P#$2KS'[,\\\K>V
M/)/NYN]C$G)N_P!S/!:.LJ,[/``7UQJ2R`@U6H\J-0T!0P[C;3WMS81L?J(@
M"PH:4/SZ,O[BKI=U[W[KW58WS<JJB'Y1?R[X(JB98JCO'+^:ECC,B3A,51:9
MI2&7QBGU'U<VU_3W[KW5G/OW7NO>_=>Z][]U[JO'K90/YE'R081NI;H;J[4[
M5'E2334XX#1!H7[70.#ZFUGGCW[KW5AWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NM>C^1^@7Y"?SD/V6A;_9\J\,K.&9@,)D+2.D9>&-WOR%=OQ>Q]
M^Z]UL+^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB*=Z8R2/YM?!C."H41U"?(G!/3$,&9
MDZHK,FDH8(58#QD6)']>??NO='K]^Z]U_]'<`^>=#-7'X8B&FDJ/M/GQ\=JZ
M4QA2((:?^^&NHD+`Z8X]8N1S<^_=>Z/Q[]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z!/Y++K^.7?Z7`U=)]JK<VL-6Q,\+G4"MA?\@CW[KW5>O\AG
M4/Y1?P@1B"8^JJJ*X70&$6\-S1JRCZ6*J/I8'\`#W[KW5NWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[IBI=K[:H<[D]T4.W<%1[FS=-2469W%2XF@I\[EZ/'ZOL*3)Y>&
MG3(5]-1:V\,<LCK'<Z0+^S";=MUN-OM-HN-SN'VJW=FBA:1VBC9_C:.,DHC-
M0:BH!:F:]4$:!VD"`.>)ID_:>GWV7]7Z][]U[JL7YM2K!\I_Y=[O)'$)>Z\Y
M2J[RF-WEFQ>.9*=%U`2>41$VL?T^_=>ZLZ]^Z]U[W[KW7O?NO=5M=<Y+Q_S1
M_D3AFDB8U'QLZVR\<1`2=$I\QB*%REE!E@9YN6))5N!Q[]U[JR7W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5`_\FZEH<7\M?YW.&HXF@-#_,'K9?#J
MD$24U=M1JBF,,,C,8T)U^H>E_J`/?NO=7\>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB(
M?(*;'TOS4_E^^>JJDR&3R_R7H:*D$DAHITI.C\E7U,K1`^):N)%&ER-10L/I
M[]U[H]_OW7NO_]+<8^;BTS'XB"IF>&WS?Z#:`J8@)*I?[U^&%_*Z$I+S^F[<
M<#W[KW1X/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0)_)4!OCGW\
MI+@'I/M0$QAFD`.Q<\"45069Q^`!<GW[KW5??\B&G%+_`"DOA)3!'3P]6U<9
M612DH9=X[F#&56`992>6!`.J]_?NO=6X>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NJJ/Y@=-A9ODC_+2FJFIVS=/\JJ-L5!)D<C05!I6P%8,C40)
M#"<;7K`PA#03R+(^H&-6L]O=>ZM7]^Z]U[W[KW7O?NO=54]>5%<G\XCY`4>K
M/4^.F^'.P:S[>5T&V\A61;TVY3C(4T9D\K92BA<P,P0H$8@FYM[]U[JU;W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6O=_)SKZQOGK_`#Z,,53^$XWY
MW[7K:!PJB7[S,;$R<N6A8_J,4<M-&4OQ=S;\^_=>ZV$??NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW5=GR;JJ1/G=_+,HWJBE9/N?Y820T:26:H@A^.N7:626(&YAA<*0QX
M#6`^OOW7NK$_?NO=?__3W'/FPU,!\214UE31ZOFYT(M.::BBK#4U.K=1BHY_
M+_P$II[$/,OJ2W'U]^Z]T=SW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]T`GRJE,'Q@^1DPG:F,717;4@G3]49386?8,+`D\C\<V^A!Y]^Z]T0K^1#
M(TW\I'X12O(LSR]4U$C2H'"2L^[MRLTBB1Y9`KDW`9F:QY)//OW7NK</?NO=
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MU/3-72S01QHO`:5S<DW^@'NO=.'^RS?,;_O-W+_^B]Q?_P!7>_=>Z\/C/\QP
M;CYN94D<@-UYBRI(^@8"O4E;_4`CCW[KW3+-\8_G3-513GYU)!"D%1%)34W5
M5,L<DKR.:>>\NXI6#11E0PO9B+BWOW7NFNF^&7S!MCWKOYB_<,DT<\TF36CV
MCL2GIJF,0RBCAHXI<'424J"H*&;6\ID0$+H)!'NO=/3_``T^3JL9*?\`F&=_
M%SSXZK"];2TZL0"^E(MFP2Z`_P"D:[A>"2>??NO=9D^)GRUCFI9%^>_94B))
M0M613[/V@ZS)2O').D!3'1F$5K(5?5K_`&V(%CZO?NO=5I?R.<-FMN?.#^>W
M@-R;GJ]Y;AQGS4Z^CS.Y*VFAHY\O62[&W%)]X:2G`@IU:'0@5;_HO_3W[KW6
MR5[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>ZK,^4E./^'$_P"5Q5:(KC*_,.G,E_W])^.V
M0DT:=/\`F05O?5^HCCW[KW5F?OW7NO_4V^?GU692C_V2O^&023?=?/\`^.-'
MD/'34U3X<7-_?+[N=_N4?P1II6\D=I5OZ2+GW[KW1_\`W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]T7GY<0U-1\5ODE#1SQ4U0W1/;!CGFDFBBC";
M%SCR-))`1*J>-2#;Z_0\7]^Z]T1G^1+XO^&DOA!X86AB_P!$AT(Q'J']Z=Q7
MECT\"&8^M!]0A`//OW7NK;/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW5=OS_`$-3N#X#4@I*BHT_S`NE,EY8"I%**#:/9R&6>._D,'^5\L!93:_U
M'OW7NK$O?NO=>]^Z]U[W[KW5?M`\W_#G^70,WV_^R65#LEZ?09_],&TPKE3_
M`)7J$9(N/VK?7U6]^Z]U8%[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MK7,_D]5GV_\`,I_G[TADFJ(:SYG]8O!'2T$DE/13Q;"W**LUU;3QFFAFJ?+'
MI61A(1&2??NO=;&?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HB?R'P=+7_,S^7GFI9)5J
M<#N7Y-BE1+>.097H++TL_EOSZ4C!6WY]^Z]T>SW[KW7_U=O#^8&+_P"R2>LI
M;^81\;#_`)XPZO\`C\_1P#Y0?]1]&]^Z]U81[]U[KWOW7NO>_=>Z][]U[KWO
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M,HKNMZ?(4HBABCCITIZ;^_=/X&)5FF;4WF+#A;<^Z]UTOPW^<*UT3_\`#C^Y
M6QHFC:>C;I>F-5+#8+411U_^DL&%Y%OH?QMXV-[&WOW7NG"7X-_(^MI9!7_S
M#>_TR#S).E5AJ6GQ-(C.Y^\B&/\`XU5@T[Q*@A3R#PL&-VUV'NO=>?X(=]&:
M!H_YAGR:2G1I?N86R,#O.K7\(CF^]7P&/BYTMJ_P]^Z]T4?YF]%_*_XP_'W<
M?<.W_P"8/WQG,C@MZ]08.FQV6BI4IYJ/?_<6Q-@91*B=LO()'BQ&YYVB.BXF
M"L+D6/NO=&QV_P#";Y#2PTE=4?/_`+\.-R5/'538VFBBIY*>"MB2?Q45<^9G
M>GJ8VD)\QC:YYTCZ>_=>ZQUG\NCL6N=IW_F)_.NEG=S=<?VU!2T:Q`:8TCI?
MX1)H<+;4^LZCS87]^Z]U)B_EY]D1!1_PX7\WI=$#0`S=HP.6UM&WF?\`W%C5
M4+X[!OP&;CGW[KW4]O@-VA`K?8?/_P"8BR.:=7;)[^@R2")`%J1"GVE+XIIU
M!(>YT$WL??NO=8JK^7[V3D:FH:N_F!_-."B?'I3TU-@^RX<1405J,A^^DK/X
M=5^<.%(:/0M[_J]^Z]TYP_R\*Q:*.*?YV_S#9JX4X22M3Y')#&]2$L9UI/[F
MNJ1E^=&H\<7_`#[]U[HJWQL^,/9?96^?DUMG<OSI^<M3B>J^VX-C;4K(>ZH*
M6JDPE)C&DR,=4!MJ1GR!R"6%43ZE!]'/'NO=&VJ?@?N^26B%-\YOFG3TE'&4
M\3]LPS557PRH];6?P5#.XU7)T"Y`^GOW7NF]/Y=E7_$4RDWSQ_F)/+X*".6@
MC^2$46'>:EF$U3/'0#9;F+[X>AE\ATKQ<^_=>ZS-_+MU/D7_`-GI_F,+_$7I
MWT+\F[)0_;N7T8Y?[D?Y,D][2#U:AQQ[]U[J'E?Y;\&7H#CZGYT_S'883)3R
M-+1?**6DJ6-/4/4*C3P[+#F.0OI=?HR*!^/?NO=0<7_+*P6)FQ<M/\UOYBDR
MXF@J<?%3UGRDKZFGJHZN4S33UT;[3'W569#<.2"/QQ[]U[HO?>OQ#AZ2[3^$
MFY<;\A_E-V>D_P`T^M#4;:[K[JGWYM*G5]L[X$M=08";`X[3E$LJQRB?]I21
MH;5Z?=>ZNV]^Z]U[W[KW7O?NO=5]T#R?\.A9>/6/%_LE50YBTC49!W#M("0-
M>X`4D6M^??NO=6">_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU[/Y0\
M4L?\Q[^?@_V-+CJ67Y?=1-%!',E15UE0-@[L%5EZJ150Q1Y`:/%"5O'XV]37
MX]U[K83]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$L[Z('RS^!]R!?<_R'`N0+D]&9NP%
M_J3_`$]^Z]T=/W[KW7__UMN7^8=)!'_LC7GD$?D_F)_&:.&ZPMKG;^^OCC'F
MCDTEK'E;./P1[]U[JQ/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T
M#GR)C$OQ^[TB*-().G>S4\:N\3/JV5FUT+)&5="U[7!!'X]^Z]U6A_PGZDJ9
M?Y0?PQ:KEGEG7:.^8F^XE:>6)(>VM_Q14QE<EW2EB18UN;Z5'OW7NKDO?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U6Q_-MBIYO@SOZ.IABGB/9_P`9&,<S*D>M/DWU
M"\+DMQJCE564?D@>_=>ZL0V__P`6#"7^O\(QOU_Z@H??NO=._OW7NO>_=>Z]
M[]U[KWOW7NO>_=>ZKY^%4WG[6^<3F0NZ_([(PLI1$\8@H9HT%XU57!5;W_5_
M4D^_=>ZL&]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5;O\P/+4.-WK_+YAKZF)!D_G
MIU-CZ*E\C1U$^1EVIV$]/+'XV1WA@2-PZDF,ZUU`\>_=>ZLB]^Z]U[W[KW7O
M?NO=5BTV81?YQ=1M_P"]E$DW\NW,YH8[[9C"Z0?(78=`:XUOZ5EC:;QB+ZD-
MJ_'OW7NK.O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:\G\IRJIJ;^:
M+_/@Q,U%)B,A4_)#I3+04M2^B?,4#;)W9$<[%#)>:6BFD94B<'QBS!0+GW[K
MW6PW[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z(=\FJZGH/E7_`"_9:E&=)^QN[J&,(KN1
M45O2V:IX'(0@JBR,"6-P!]??NO='Q]^Z]U__U]O'^8%5)2_[))J8K]Q_,'^-
MM*OZ?4\W]\[+ZB/KI_%S[]U[JP?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]T#_R&D$70/>,I!(CZ?[,D(4V8A-EYMB%/X/''OW7NJP?^$]<IG_D]
M?#&<JJ>?:W84X52K66;N+L.1-3*S`OI8:C>]_K[]U[JY[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=5C?S@Y1#\#=_.9WIK]L_%6,2QHKMJF^5/3$2I9R%"RLX5B3Z
M5)/X]^Z]U9)@05P>&4\%<3C@0"&`(HX0;$$@_P"O[]U[IU]^Z]U[W[KW7O?N
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MUV+M';F^MGY),OMC=>'Q^=PF06"II7J,?DZ6*KIC445;#3UV/JUBE`EIZB.*
M>"0%)$5U*CW7NE3[]U[KWOW7NO>_=>Z][]U[KWOW7NM?[^6[5R#^;C_.BH[-
M()MZ_'Z:9I)2GVZT^U]WI2)!`P7SQSK,Y9UN$*@'ZCW[KW6P#[]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z*UWQ2;&/:WQ>RN[:'$U.5QG8VX8MF55;/GX\G09W+;3J\>9
M,-#A\;7451+-3R%)Q724].D)+!RP`]^Z]T:7W[KW7__0V[?Y@T@C_P!DANH;
MR?S"_C7&+K&UBW]]+,/(CZ2+?5;,/P1[]U[JPOW[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]T#7R,-OCWWN>1;IKL\W6U_^/(SGTN&%_\`7!'OW7NJ
MU/\`A/W314O\G_X510ERAV-NZ6[M&SEY^T=\SR%S%%#'J,DAO91;Z>_=>ZN0
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW58W\X%&D^"6]8P0`_<WQ'20L$*K"WRUZ2
M69FUAE"K$22;&P%_?NO=66XY$CQ]#'$RO''1TJ1NI!5D6!%1E(`!5E%QP/?N
MO=3/?NO=>]^Z]U[W[KW7O?NO=>]^Z]T03X84U13=E_-1*F&6!Y/D;F:B-949
M&>"H@GE@F4,`3%-$P93]"#<>_=>Z/W[]U[KWOW7NO>_=>Z][]U[KWOW7NJY_
MYA:ALI\`;^+T_P`QCH-AY51N1L[MP?M:U;3+SP18CGGW[KW5C'OW7NO>_=>Z
M][]U[HN_=/RV^,_QSR^`P/>O=_7?56:W305F4V[C-Z;AI</69G'8^IAHZVMH
M(9R&GIJ6JJ$1W'"LP!]^Z]T#8_F:_P`OFI29!\N.C:F/[5IYHUWC03!J-O,C
M2-&`VN!A"X/!!TD>_=>Z2/P#[_ZG[CSGRGVKT=V#@.S>K.M.Y*&MVQNG;M1#
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MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@:^1:L_Q\[V1`S.W379Z
MHJR)"Q9MDYP*%ED9(XF)/#,0J_4D#W[KW5=?\AA)X_Y2/PMBJ:,4%1%UYGHY
MJ854%<4=.P=WJ7:KI9IZ>HDFMK9D=E+,;'W[KW5O/OW7NO>_=>Z][]U[KWOW
M7NO>_=>ZK)_FM28G=GPOWQ@L;F\1-64?<WQ2FKX(ZJ"LDI!C/E;TQ6U$-730
M/+)"S)2E/6H56/JL`??NO=67490TE*8PHC-/`8PNC2$,2E0OC_;TA?IIX_IQ
M[]U[J1[]U[KWOW7NO>_=>Z][]U[I&[L[%Z_V$D,F^-[[2V='4KKIWW/N'$X%
M)U#^,M"V3JZ42*'XN+\\>_=>Z(QT;W)UMM7Y`_-:GWEV3MW;T$/;'7E!CZG>
M.X\9@*2HGK.L:;++C\*<S54;U*4](K-Z-2NB%T)CY]^Z]U89CLECLO1P9'%5
MU'DJ"J19*:MH*F&KI)XV`97AJ('DBD1E((()!!]^Z]U-]^Z]U[W[KW7O?NO=
M>]^Z]U73_,)D"93X!WC1]?\`,6Z$C&L7T%MG=MD2)_1UMP?\??NO=6+>_=>Z
M][]U[KWOW7NM:O\`FX]9MG_G9TYOK<_3O=^^]A8WX4=N[:H=T=4_"G;_`,SJ
M*EW[/V_L7.4VS:S;^\NLNS-L;-S6X=N8^J-/7-!2SR(&B\IC9E/NO=5Y4^W4
MQE;`=G?%;YWXJ.@QJTL5;2_R7?B%3/-35BB9(HILU\<(:ZGCI9O(K4ZZ5#$E
MEL5O[KW5D?\`+TZQ[W[<A[>/4'RA^3?Q&J-C;QP.'[$Z[["^`OPRZAR>;R^5
MVCCLWA,FF!H^GL36&G;!5L++,(@KW_4;D>_=>ZLDH?B7\T8ZM)\M_-"[CR],
ME69OLE^.GQ9P\;4IGIIA1--B.MZ6=D"0,GDU>33(W/T]^Z]T^9;XI?*/)L##
M_,3[HQ@2KJ*N):'J7HA-!G01K`Y.S+S4T"*-"/=0UVM<D^_=>ZAU'Q.^6CI#
M'2_S)NZ*2.G+&'_C"GQWJI/7$\+"HGJMB22U@TN2!(6TM9A8@$>Z]UG'Q=^9
M`,9_X<L[5/C0H`?CG\72&!`%Y`>N?W']/U-S_M_?NO=1<E\3/EMF**:BR/\`
M,H[H5*C0DL^(Z2^.VWZL01L)4B@J</L2DFI9/.H+2QE9'2\9)0D>_=>ZJX_E
M,;&SW7G\UO\`F^;:W1O7</8V=ILWT3+5[WW508V@SF?BEP&YS3SU:8BGIJ!U
MBLRH446'X'OW7NME3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T6'Y%%QG^@?'JO\`Z9-N
MAM.C]&M==_)QIM];>K^G/OW7NC/>_=>Z_]+<4^<$5)(OQ$:K^UTT_P`X>@JF
M$U1D%JB([K$1I_''(6JAJ.@&P//(]^Z]T>3W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]T$7R!C,W0O=L2N(VEZB[)C$AX$9?9N:4.3S8(3?W[KW5?
MO\CD1)_*J^'D4-53UJP;"SM,U52RQ3032T^_MVP3.DD),9)FC;5;D-<$`W'O
MW7NK7_?NO=>]^Z]U[W[KW2"[/[%V[U1L7<._=T5<5+B\%1^15E=T:OR-3(E)
MBL53"**HF:JRF1GB@C"QN0SW(L#[]U[HL>U>@]Y=TTD.]OE9F<ED'RS+D]O]
M%;>R-=M[9/76/J$6>@QVX:W"5E)E-[[WQS.WGR1DHZ<%O"M,1%Y7]U[K76^2
M.U=H]5?S'_GQLO:R9#`[-HOCO\,Z^CP,&X,_D\=CZS(]\]%BNK4Q>8R&1IQ/
M75,BM+*H$C*#ZU+7]^Z]UMS[9T_W;V_H8.O\$Q.EU4HK+]A3V949G90PY`))
M']3[]U[I[]^Z]U[W[KW7O?NO=%)WMN+>7<W:&2Z7ZYW5D-B[/V!'CZ_NC?V#
M6GEW#D*C+TTSX/K;8]=*DM+A<E,T;564R9^XEHXJ0T7VNJK$\/NO=5._SPOC
MAU'U%_+#^3FZ>O-K5.(WED7V755FZ'W'N?(Y^KR#[CPM%/6K6Y',U/V=15P1
M?N"F6"-B2=(O[]U[HK?:N$VQFOYLGQ\VC6X_[W';@^;B3;BH*V>I?&9>EPO\
MOK?T6.I*G'++%&(:*:)"BNTJRR()K*WI]^Z]UL`YOXF[;VK0YC/_`!RR>1Z5
M[*DD7)TF3QV2R^:VIN.NH5J)*'!;WVMFLE64F1VM//.WDAI'HI5<JXD(30?=
M>Z$?H#MK(=K;.J7W3MZHV?V/LS+56S>RMJU#B:+%[MPY\-968>K"0G(;7W`B
MBOQ-4T<+U./J(I&CC+%1[KW0Z>_=>Z][]U[KWOW7NJ\?Y@,,<V4^!?DJ:6F\
M/\P[H>:,5.N]1(FS^V`M-3:`?\JD#$K>PLI]^Z]U8=[]U[KWOW7NO>_=>Z][
M]U[IBW/N7";-V[F]U[ER%/B<!M[&5F7R^1JG6."DH*&%YZB5BQ&IM"651=G8
MA5!)`]^Z]T6SXI+DMV8?L#OC+T-;BY>^]YR[OV[0UL+TTK=:X:D3;75&8EI)
MH*:JH:O<?7N/Q]?/3S(LM/+.8WNRDGW7NC8>_=>Z][]U[KWOW7NO>_=>Z][]
MU[J@/X!XVHH/YRW\WZ6JF,LN0A^-U9"!Y%CBH7P&]%I(ECD1#Y5L^ME!1N+$
MV/OW7NK_`#W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T3OY7;QPVS\_P#&=LR*HKN#Y`[+
MVSCQ2M&I_B>9JHZ2B,YD9?\`)Q,XU@7)'`]^Z]T<3W[KW7__T]QWYKM.H^)7
M@56+?-KH59-41E"PD[I\C"W^;(7Z/_9]^Z]T=OW[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]T$W?8#=%]T*65`>INQ@7==:J#L_,`LR?VE4<D?D>_=
M>ZH._DR?/SX3]#?RR_BUUAV-\@NKMC;RVSMS>JYS:M3F:5*W%S9'L_>V7A:K
MI:&$Q4LM?0U\57XS9U2<:N;^_=>ZLZ;^;+_+B2Y?Y?\`3*A;AR=RQV1PP7Q/
M^UZ96O<+]2H)^@]^Z]UGD_FN_P`N:*GI:I_E_P!*^"OK5Q>.<;KI_P#<GF9(
M_+#@\<I0-6YJHCYCIHPTKCZ#W[KW3%%_-P^`\XU4_>%+4`RSPKX=N;ED+O3.
MT<^@+BSJ6*12"?I<>_=>Z267^6/Q^^8G<'QTZHZ@WF^\TPG85;V]NR.CQ==#
M30XW8.#JL70XK.P9&CC4T&5K]X+,IM_G:);'Z^_=>ZM3]^Z]UJ*?.^MCVK_-
M"^<%;D\-EZM]Z?&?XG4.UX:+$UF3?-2[>[>Z:R^=-%'11-,T6"QF-GJZDWLD
M4#,>![]U[J]O`?S(OBAB\!@:&OWIN&*2DQ.*Q\M5_<+=_P!A+6PTD=-)#3U@
MQ303,9H&"A6-[<7]^Z]UEK?YI7PLQP0UW9]=3&75XEEV=NM7F**S,L2_PHL[
M`*>![]U[J*?YK'P?%,*QNV9UI2;>=MH[I$8:U])8XJP8?D>_=>ZRI_-,^&=9
M$9,)V!N#<SC[8?;;8V!O+.5@:LG:F@'VU#AY)+M,I4\>G\\>_=>Z%GX3XMCT
M90=@U-#E,9E>\MR[F[SS6,SE#/C,UB\GV9D#G9\7DZ&H2.2DJJ!9%C:((B1D
M650/?NO=%+_GE==;N[/_`)8/R=V[L?!Y;<NXJ3;F'W%2[?P.-K<MF<O#M_<&
M-R-91XZAQ]ZN6I:EB=AI!(TGW[KW5+N=WK4]O?S6?COOSK/;/8=5LRG^:>%W
M@VX<]L'<V-Q5/LRJ^)&Z=@S9%9'I:2NIH$W'D8Z!_.[1Q5+@N-`(]^Z]UN&^
M_=>ZKE[7[OQWQ8^4VX,YNC:7;.:ZV[AZNVYEZBLZWZKWKV:@[3V[F9MKLN1;
M:&+R9PT2;%QM';SA%>UP?Q[]U[ISC_F5]"R0M/\`W%^3T06.*013_&'N6&HE
M,P<B*&!]K"269`A+HH)4?7W[KW2;B_FG=#5>4J\+B^H/FCF\M2?;%J#"?#7O
M[*5,ZU/Z)*2.DV9(:J./_=A2X3\V]^Z]TK8/YB&P)YQ`OQO^>J,8O+Y)OA!\
MAX8`/]0TS[*$8E_VF^KW[KW12OD[\C)ODAO_`.#>TNM?CM\QJ>NV7\[^F>R=
MY9+>OQ8[CV%MW;77^V=L]CX[/;IS6X-S[:QV,I,/CZS/TB.[2<F7@$`V]U[J
M[/W[KW7O?NO=>]^Z]T0WN3Y`]X+\L]H?$SHK'=68[/Y?X\;F^1.9WIVQ0;KS
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M>_=>ZK%_D(Q8W(_RF?B-6+0T+++A.R;6I8N`G<W8D>DEX]99=-B3SQ[]U[JX
M'^&8W_G7T/\`YR0?]>_?NO=$&_F`_'WM#NK:OQLGZ4H=O'</2_S#Z1[ZW!29
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MSH[6^TIK?T\$5O\`H7W[KW7:TE*GZ*:G7_@L,:_[TH]^Z]UG``````'``X`_
MUA[]U[KQ`(((!!X((N"/Z$'Z^_=>ZQB&%2"L40(^A$:`C_6(''OW7NLOOW7N
MNB`?J`?]<7]^Z]UUH3_4K_R2/^*>_=>Z["J/H`/]8`>_=>Z[]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW52>_LI44'\[3X]4<0J&@S7\O7O"BJ1';P(M-W?U]D8Y)[
M7)_<I0%!`%S];\>_=>ZML]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
MKN?'MU7_`(47?-U!+*YF^'O3CJCCT1&#+%)`I.DV8R"P`(_Q]^Z]UL1^_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NB"_/W`QY7`_&/)MD%HY,!\T?C'5PT\@(CR#5?9F'H
MGIM85BLJ1RET'`9EM?W[KW1^O?NO=?_5VZ/YA8O_`+([Q>W\Q#XT'Z7M;^^O
M/OW7NK$/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UBGC::&6))I*=Y(W19
MX='EA9E($L?E22/6A-QJ4BXY!]^Z]T"_;N/J<+\=^VJ"MS.1W#4474?8XFS&
M86B&1KS_`'4S<OEJUQ='C:+6JL$_:AC&E1Q>Y/NO=5S?R"YJFH_E*?$*>J:!
MI9=O]BN#31I%"(CW%V%]NJQQJ@4K!I#7NQ8'42UR?=>ZN&]^Z]U[W[KW42OH
M*'*T-;B\I14F2QF2I*F@R..KZ:&LH:^AK(7IZNBK:2H22GJJ2JIY&22-U9'1
MBK`@D>_=>Z)YU7/-TEWYN#X]RR.G7O8&W\IVCT50R?O/@TVY58JB[9VC321K
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M=99D6*2J[CVU13LT4<BQ3AJ6=U`D5@I-Q9@#[]U[H]7OW7NO_];;M_F#)4/_
M`+)#]NZ)H_F%_&MYM1<:Z=?[Z>1%T`W=KBP/']??NO=6%^_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7N@A^03F+H7NZ4:;Q]0]DN-9`2Z;,S3>LL0H
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MEO?NO=/?QL\/77R`VMW%\B/YT/QS^2FV]G[+WMMC;VSZ[-?';94]-4;UJ=LU
M%3E3F\!N-:R30FVXP8]>EKB][<>Z]U:K_LZOPV_[RU^,O_H^>K/_`+*O?NO=
M3J7YA_$BN(6B^4OQSK&,<DH6E[NZSJ"8HF5)9`(=SN3'&[@,?H"0#]??NO==
MY+Y@?$K#0PU.7^4?QTQ5/4+`]/49+NWK2AAG2JEE@IFAEJMS1)*M1-`Z1E20
M[(P%R#[]U[I.2_.WX50U\-`_RZ^,(>:*63R'Y`=2A$:(V:)U.[@X<CGZ6X]^
MZ]U*7YQ_"EY$B3Y@_%MY9)##'$OR!ZF:224(TAB1!NTLT@12VD"]@3[]U[K(
M_P`WOA<D#U+?+OXPBGC1Y'F'??531JD8)=BR[K(LMC?W[KW0U=?=D]?=L[8H
M][=8;UVOV#L[(RU$./W3L[-X_<6WZ^2DD,-2*++XJHJJ&K$,HTL8W87_`#[]
MU[I;>_=>Z][]U[HE&]/YB/Q`V#N?=NS=Q=KRG<FQ-QU^T=X8S!;"[)W8VWMR
MXNGQU5D,/DJC:VT,Q20UE+3Y:F=E\A%IEYY]^Z]TEC_-"^$@D$+=M9A9B700
MOU'W,LNN,V:(Q-U^'$M_HA&H_@>_=>Z=*#^95\-,HSI0]J92HD31^R.K>W$G
M?R7T&&&38J2SA[&Q0,#;W[KW3%4?S1_AM2P-4S;M[86%:Z;'ZU^+_P`GI+U$
M"JTC(L?3[.]+9QIG`,+&X#D@^_=>Z;V_FM_"E)/%)O+MN.7TWCE^+/REB8:D
M,@U"3IM2MT'YMSQ]>/?NO=3X/YI7PQJ89JB/>O9PB@BJ)I6E^-7R5@*Q4J"2
MHDT3=2(Y6.,ZC8?0$CZ&WNO=&^Z@[@Z[[YZ]V_VIU5N#^]&Q-TP2U."SG\+S
M&&^^A@GDII'&.SV/Q>5IPLT3#]V!";7''OW7NA,]^Z]U[W[KW5>^^I+?S+^B
M8B6`?XN]J,MU70S+O;`7`>^HR!;FP_'/OW7NK"/?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=:Y/QNA>G_X4:_.H*\\:U/Q(ZBJ)Z:6>G.LG*H*:I2&"
M5F\,BEM!<!QS>WOW7NMC;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T2;YU2O#L3HYH[7?
MYC?$R)KB_HD[KVLKC_`E3]?Q[]U[H[/OW7NO_]?;Z^=[&1/A@TC)$1\_?CT`
M"2FOQR[T1$6Z27=U4<<7_J/?NO='^]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=`[\B+?[+_WG==0_P!#O9MUL#J']RLWZ;'@W]^Z]U3C_(.Z>ZEW
ME_*<^&^8W9U7L_/YN':6^;YS.[1P55)4ANU=]QH$FD@F:=Z2!5AU.`P\=@>/
M?NO=6Y'XK?&XL'/1_61<+H#G:6(U!#8Z`WVUPEQ]/I[]U[KA)\4OC3+H\W1?
M5\WCD66/R[/PTOCE2^B6/72MXY4N;,+,+\'W[KW7>)^*GQOPU1DJFDZ0ZNEE
MRHD2J^^V-MFO3[>6_DI8HZO&2I%3/<ZE`]9-V)/OW7NE,.@NB54(O2O4H55"
MJHZXV<%"@6"@##6"@"UO?NO=1V^/'0#1RPMT=U`8IPZS)_HUV8%D$B"-PP&%
M%]2``_X#W[KW6&@^.'Q\Q<M1/CNCNI**:J$HGDI^O-IQLZS*5F2ZXD:$E5CJ
M5;!OR/?NO=.$G0O1LT203=,]4SPQ^#QQ3]>[2FCC^UN:;QI+B'5/`6)2UM+,
M2.22?=>ZPGX^]"LVL](]0E^?4>M=F%N?KZCA;\^_=>Z\/C[T(K*Z](=0JZ/K
M5AUKLP,KD%2ZL,+<.5)%_K;W[KW7;]`]$>)T_P!"G4F@HP*?Z-]FE""#<%3A
MM)!_(]^Z]T2W^5-%BZ;XV;OH<-1T6/QN.^1W?M!2T6.H:;&45-'2[ZJXQ%3X
M^C5*6DC6W"1JJK^`/?NO=67^_=>Z][]U[JKW^7CA,57[M_F/3Y+#XJLE_P"'
M(>ZTCGJL=0U$S0?Z,ND&"&62%Y&0/<@,>#[]U[JR`[0VF7\AVOMTR:M>LX7&
ME]?^KU&FU:O\?K[]U[KDFT]JQNLD>VMOQR)I"R)AL<KKIOITLM,&&F_%OI[]
MU[IW-%1D`&DIB`ND`P1$!;DZ0-%@MS]/?NO=<'Q]!(2ST-&['ZL]-"Q/^N2A
M)]^Z]TF-Z4&-BV=NR7^'4A\>V,^Q"4T".5&)J]2JPC])9;C_`&/OW7NB(_RF
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M>Z][]U[H)>_(!5=%=TTI;0*GJ7L:`OSZ!-L_,QZN.?3JO[]U[JLG_A/_`(S^
M#?RC/B!BP9V%%@.QJ=34:#(1%W'V$FO4@&I)2I=;W:S6)]^Z]U<A[]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ;E2.>0?IR?I^/\??N
MO=5A?RG)I7^/O;%,T<L5-B_EW\G,5CEJJ9*3('&T/8U9%2-DX%CB=,B8_P#.
M^11(3^KGW[KW5GWOW7NO>_=>ZK1_ESL#NG^8[9U;3_,C[K4A8PA0_P"C'I`Z
M6-AY&YOJY^OOW7NK+O?NO=>]^Z]U[W[KW7O?NO=-.>IQ5X/,TA`856)R-.0P
M!4B:CFC((;TD'5^>/?NO=5[?RIL(FV_A_AMOQ+'''A>V>_,6D<,<4,42T/<>
M\Z=8XXX$2)401V&D6M[]U[JQ_P!^Z]U[W[KW5?F^G1?YE/12LRJS_&/M,(I8
M`N1O/!,0H)NQ"@GC\>_=>ZL#]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]UK^=:5#4__``I#^35(6(7(_P`O'I:J1/6-7\/WIE(78?V&"FL`_)%_?NO=
M;`?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
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M=>Z][]U[JJ#^6!N"FR^_?YI>/@0J^"_F>]UT50RHHC>9^J^CW)UB1F:;2HU`
MJH`M:]S;W7NK7_?NO=>]^Z]U[W[KW7O?NO=1,A_P`K?^H2I_ZTO[]U[H@W\L
MT-_LLE3J;5?O7Y(,K:_("C=X;Y*68(@MI(L/Q_4^_=>ZL$]^Z]U[W[KW55/>
MU714?\U[X0HT4HK\ITGWSCHJ@B1J=J:&AGR4E,!&C*E09*0.&<JNE2`2Q`/N
MO=6K>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUZ-B92L_Z"7N]<.(8
MXZ#_`(;;ZYK7F0J)*JH'8,,<8F#$,PID9@F@$#6=5N+^Z]UL+^_=>Z][]U[K
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M@Q%P`#8>Z]U=-[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[JN;^6QX?[B?*'[=(XX/]GU^7?BCAE\\2)_I-J;+'-_NU1_7W[KW5
MC/OW7NO>_=>ZJ@_E@T]-3[]_FEFGP389ZC^9[W545,[58J1FYGZKZ04Y=8_%
M&U*LRH$\=V'HN#]??NO=6O\`OW7NO>_=>Z][]U[KWOW7NF_+OX\5DY+%M&/K
M7TBUVTTTIL+@BYM^??NO=$#_`)8%1]W\5*>K$;1?==S?(2H\3Z=<7E[HWJ_C
M;0J)J2]C8`?T`]^Z]U89[]U[KWOW7NJ>?G-OO>G67SC^%>\=@]-9?N;<$&VN
MX,='MS;V6CP^8GIZO:^66>.&JJ*')0&&FC)J74Q7M$>1[]U[H9\?\R/E'7R&
M$_R].UZ)_`T@:MW_`(F"G,H.D0>=MHZ06)7FW`)/X]^Z]TX97Y-_-ZD_AJXO
M^7E+EIIH)),LK_)G:F/AQ<RU#*D%/42=<3KE3)2`2:D$8#'1]>??NO=,2_*K
MY[B::.7^6LZ1QL5CFC^5NSIA*MB0P5>L%*@FP^I]^Z]U+/RI^<B0-+-_+CKA
M('"B&#Y,;3J&*-&I#W7K=;6E)4BW`&KZ'W[KW2B?Y,?,/[2KJ(?@-E))::,E
M*5^_MM0R5,I=(DCA+;"8,I=[EK65`6^@]^Z]TY5_>?SJBJ%BQGP.VE7P'&PU
M;U%3\O=J8[36S![XT1'JBJ9GA*6>2X47%@;^_=>Z;4[Y_F`D.7_E]['4A;H%
M^:6T7UM>UB3TX@1?ZGG_`%O?NO=5`_&K<?:6[?\`A21W5FNX.L:+J/>'_#;F
MSJ;^Y6*[`QO9N/HL8G8N+-)DFW5C-O[<ADJ<K(9`:;[<&`0@ZF#BWNO=;/OO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[HB/\P!E3K_`*"U231ZOFS\.U!A8*SLW>FTP(WU
M*]XI#PPX)'Y'OW7NCW>_=>Z__]/<4^<,L4,?Q'>:DBJD_P!GAZ`7]V&>?[9F
MDW2%JXEIX9F6:%CZ68*@)Y8>_=>Z/)[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z"3O\`=8^B.ZY&(54ZD[(=F/T"KL[,DD_X`#W[KW53W_"<B..+
M^35\-Q%YC')C^XZA&G\FMUJ?D!VK.KCRJK^-Q)=.+:"+<>_=>ZN\]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6U_+'DCEZU^2
MTL2"..3YW?+AT18F@55/9E38+"RJT0%OH0+>_=>ZLE]^Z]U[W[KW5:/7&R_D
M9\8^Q/E#N3&]1+W7M+N[OO<7;^`I=C[SP6'W-B\9E]O[:PT6*JJ#?63V[@QD
MO+A&=RE2(RI`U7X]^Z]T;GJKY!;)[0K*O;+1978W9.(!7/=8[XHWPF[*"2./
MR5$N,2<#';PQ%+^F3)8:>OQRR`IYM0(]^Z]T.OOW7NO>_=>Z][]U[IKSA"X7
M,,UM*XO(%K_2PI)B;\'BWOW7NJ_/Y6,D<WQ&Q4L14Q2]M]^21E`0AC?N/>;(
M4#!6"Z2+7`-O?NO=6+^_=>Z][]U[JO'NZ21/Y@?PU5`Y67:?<:2E6`55&TLT
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MU[KWOW7NO>_=>Z!WY$'3\?\`O1M'DMT[V:=`L"]ME9LZ!?CU?3GW[KW557_"
M<VK:M_DS_"NI=M3/MWL]2-&CQ^+N_LN(0%?I>`)H)'!TW'OW7NKM_?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T$O<7;^`Z<VY09;*4E=F\]N7
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MC6_PM[]U[H3??NO=>]^Z]U#R,0GQ]="R/()J.IB,<9"R2"2%T*(S*RJ[`V!(
M(!_'OW7NJ[?Y5]9!5_%2JCIH6IH<7\@OE!@TII)UJ9Z;^"=^;_Q9IJJ=(*:.
M2K@-+IE*HJZP;"WOW7NK'O?NO=>]^Z]U7;WBJM_,%^&!8D%=K=RE`$+`L=GY
ML$%O(@C]-^;/?Z6'U'NO=6)>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>ZHIHJ:*/_A0]D:E5`FJ/Y<V225K*"RP=H;%$8)`#'3Y#]2;?CW[KW5ZWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[JMC^:7)'%T#U>\N0DQ>GY=_$_171)))-#+_IHVSX
MVA2*:GD:75^D!TN?R/K[]U[HZEU_YVM7_P!2)/\`ZL]^Z]U__]7;1_F0U=12
M#X%BG1&^Z_F3_%JDGU'3IIY6WPTKK_5QH''Y]^Z]U9/[]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z![Y#!#T#WD)`#&>GNS`X-B"AV7F]0(;TVT_U
MX]^Z]U5M_P`)W9/)_)Q^%S#7H&VNR4B$@16$$7=/8\<"@1@($$*J%MQIM[]U
M[JZKW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5\YWN[JG$_-_
M>>W>XNP^M]DQ=2=)=?97K>GWMO/!;=DK,AW!N+=2[NR=-09_(45/-78V/K''
M0T]3"KS0QU<R:E64A_=>Z,56?*OXP8]F2O\`D;T51.L33LE7VUL.G9843RO,
MRRYY"(EC]1;Z!>?I[]U[H4MF;ZV3V-@:?=77V\-K[ZVQ62SPTFXMGY[%[EP=
M3-2OXJF*GRN&JJRAFEIY!I=5D)1N#8^_=>Z57OW7NO>_=>ZU0>_?DA_-VW_\
ME_E!AOC/W?V;A^ONJ?D1O#J79VQ>M_C;T7O_``T>&VIMG:^;E?/=A;ZV5EJG
M'9AGW.+T]34>2143QWNWOW7N@KPFX?\`A15F8?XC'\A.]8\+)0SU<+Y/XL?#
MK%YAG\!$-/-BYNO8JF%C4#Z:0^GW[KW5I'Q6^1ORY^.'QZZOZ:["^&G>G;NZ
M=A[:7%9'L&EKNNMM1[E^WEDE%:FV]NXRFQ6$+B:RTL2*%MP/Z>Z]T.$/\P_Y
M`U2N*3^7%\B'F#11Q15.X-M4*RRS$K$IFJJ!(HH]0];L=,8Y:P]^Z]U#G^?/
MS%I!.]=_+,W;CECF,<<.3^6?QUQV1>/PO*M1-BZO(Q5U'$Y4`>1!];_3W[KW
M4&7^8%\LJAJK&O\`RV]TB22G95:'Y<?'=8Y8YXBJF&NAR6B.4EB!I.M38_T]
M^Z]T\?R8ZC(U?PH^ZS&"J]K9>I^1_P`MJC*[8R&=@W17;<R,WR.[(DK<%6[F
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MYZ/Y0_&;(3TSU"0)CZ*A[:V]45F=<2`I4KA8$-082#Y=&G\^_=>Z-K]TW^KA
M_P#.2+_HSW[KW7__UML+^9C*8O\`AOVRR-Y/YFWQ2B/C(&D.=^79[_6,6Y`Y
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M?'%S3VE*D^E^`1[]U[I2YC/?S,<CM]XL/UA\0ML;DDJJ/35S=S=G;EQE+1JK
M-6D4\G2F%EJ9Y78*@)C"A;WNUA[KW2/+_P`V01(@QWPQ:4NI><[K[,"A%`+*
ML'^CPW,A!%]0TW_/OW7NE`N5_FA0TT:G8OP]KJI2[22/VEV;0QR`(-$0C3J*
MK\89_JUR0/P??NO=--'N#^:^96%?U5\)UA*SLKTW=_;+R(XB5J>(QR=$QJZ-
M/=7?4"$L0I/'OW7NI<H_FE5>2R9C@^(.&Q430Q8=%W!V+F*NM18V$]7D#)L?
M&QT$DT@!$,?G5`3ZS;W[KW46IIOYJBQ@TE5\0)I?*H9*BO["@00E1K</'M.8
MF0,2`M@"!>_X]^Z]U#,7\V.YLWPV(LEB<QV."29`'%ALL@!8KD?U;C@<^_=>
MZHI_F$5GQF3Y'4U'_,OZ<^$6^ODHVR-G)39S'=3_`"C[8S-)U=45>\!M@96N
MV/MW$XJB@I<W%6+2T[:YI//*6*A$U>Z]T42DI?Y3=!*T^W?C'\2*#+TE5113
MYG_91OG-E/L66D@+T]3C9-OU:R+-.3/I9UM$XC((`8^Z]UL2_P`C&KQU1\--
M]5V#VY'M#94_RP^2]5L/$T^Q]W=:X.'8C[[>3;]7MO:&^Z:CW+AMKU-&3)1+
M4K?PD&_OW7NKET=)$62-E>-U5T=&#(Z,`RLK*2K*RFX(X(]^Z]UR]^Z]U69_
M+Q2JH]__`,Q"DRBS4&2R?SO[)W52X6LJJ":NI]O9;8?6E!B\C+!05%2M+#D:
MC#U`C61O(1$;@<>_=>ZLS]^Z]U[W[KW7O?NO=46=@?RQ/A;\M/G#\ILG\G>N
MLQN_?N2H^JMT;(FEWWO+;ZUNPZ39=#@\Q483&X3.T5(<;B-RU"4E2XC%ZAEN
M;GW[KW0L8K^0_P#RKL90U-`_Q<QF52IIJ2F%1F-^]FUE92_:-4LM115*[QA>
MFJ9C4GR,OZPB@BPY]U[JQSHKH/IWXS=:X7I[H?8.%ZSZTV[496KPVT=O_>'&
MT-5G<G59G,5*/7U5;623Y'*ULL\KR2LSR2$D\^_=>Z%_W[KW7O?NO=5H_):L
M%!_,&_EXB&II5FS60[VQ%32!ZE:^2A@Z7WWEUG*_:M1R4*5E$@(,RRB0J0I6
MY]^Z]U9=[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K7;W,Q'_"E?K\,
MQ$3?R[]XV4.X#5`[%V%XR45/59-7)8`7^AO[]U[K8D]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=$E^?<9?HW#-X1.*?N7INJ9-#.P2FWWBI6>-5EB_<0+=;DB_P"#]/?N
MO=#5]S'_`*F3_DAO?NO=?__7VQ/YE\5/+_PW_P#<&G'C_F:?%.6#[B:6&]0A
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M,;;'R,ZTV=L#:%16PPJN*[$ZARVX\O3[<^XJ4"2Y+>V#W]5U5'%&S.4P4YL`
MOOW7NCIJB*79556D8/(54`NX18PSD"[,(T5;GFP`^@]^Z]UYT21&CD57C=61
MT=0R.C`JRLK`JRLIL0>"/?NO==1QQQ1I%$B1Q1HL<<<:A(XXT`5$1%`5$118
M`<`>_=>ZY^_=>ZK!^%F!P^!^6O\`,+_A$<*OG>V]O[CR\D<LLTCY>NQM935`
ME,LDGATPT,=HTTHM[@<GW[KW5GWOW7NO>_=>Z][]U[HOO=_4VX-WR8'L'J[)
M87;'=FP5K/[F[@S=)-/A,IC<C&\.6V?O!*#QY/(;5R<4K2>".1?#6)%.MGC!
M]^Z]T'=)\LZK:T]'@N[^E.U^MMQ`1KD\SB]LUN]^JH#)Z(IXNS<-"F!3[ID=
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M<[*G2>-=F"JO:_4[,Q-@H&],822?P`/?NO="UYX?^.B?\E#W[KW7_]#<6^;N
MUZ?='^RB?<54=-_=[YQ=`[H@\D$4_P!Q48C^]GBI8_*R^&27[@VD6[+;@<^_
M=>Z/%[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z#OM\VZF[1.L1VZ
MZWL=;'2J?[]K)^LM_9"_6_X]^Z]U4E_PGEKGKOY4?Q^+S&I%/NKOZG2?[B2I
M65$^0/9K:XY'4)XF=B0$)7_&]_?NO=78^_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[H/\`L[K':7;NT,ALK>=%-4XJN,<L5513FAS&(KH&U4V5
MP64C5JG$Y:E)/CJ(2LBAB`;$CW[KW1=X<7\P>JDH</@:SKSY`;,H)8X5RN\L
MOF-D=J4N"BE,5'CM-%B,Y@-XYBBQX1)LC79"CGKID,T@5G8#W7NEI\7OD;C_
M`)+;.WSN.FVAN'8V5ZV[E[/Z,W?MW<;8V2JIMY]3[@?;FXIJ&IQ-?DJ.LP]1
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M_P"%+72]9.D53_&OY>79,-,A`U44F,[)ZU#5!,FD%V%39=!9K7O;W[KW6Q;[
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z)S\Y?^9*XS_Q+'4__`+VF,]^Z]T+MA_0?[8>_
M=>Z__]'<Q^8>.I<C_LK7W4LT7V/S'Z1R-/X9/'Y*JF_O/X8I?2WDA?6=2\7_
M`*^_=>Z./[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z#/ND@=.=LD
MZ;#K/?A.LV6PVME;ZC8V6WUX/'OW7NJ>_P#A.&L4?\I7X_QPMKC7=7>[!DC:
M.G)E[V[%D/VI+MY806_4`H+7X'T]^Z]U>A[]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>ZZ)"@L38*"2?Z`"Y/^V]^Z]U7Y_+FV]DL=UAW
MAO*J,4F%[I^7_P`E^\-CU<$PGAR&P^R=_P!1F=KU\<@2/TU-"+V(!'Y]^Z]U
M8)[]U[KWOW7NJX_B:86^67SK:)@6&^-I1S!8RJB1:;-$W?@.Y!Y_IQS[]U[J
MQSW[KW7O?NO=>]^Z]U[W[KW7O?NO=5Q?RNWCD^/W:#1R>1?]G3^="FQ!"/'\
MK>UXWC'`(TLIO?\`-_?NO=6.^_=>Z][]U[JO3Y:/3K\M_P"6,KQJ\\GR`[Q2
M!S)(AB4?$;NZ25@J@I-J"!=+6M>XY'OW7NK"_?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=4+]Y8I8/^%!/POR@F75D?@I\EXVB9$32,=V;T8JZ9%3R2
MM)]T;!C9;<6OS[KW5]'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HD/\P?+KM_XYUN>:!J
MIL)OSKO+14:OXOOI\?N>CJH:(U!5Q3+521!#+I?Q@ZM)M;W[KW2Q_OY+_P`Z
M<?\`G>/_`*D]^Z]U_]+<V^7TU/#_`+*]]PY3R_,+I.&&UO74.=R^-#<CAM)_
MQ]^Z]T<+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T%O>3!.E.X7)
M*A>K>P6+*NLJ%VGER2%L=1%OI^??NO=5&_\`"<6,I_)Y^*D@>*6&IKN]JFGF
MC\@\L4OR&[4U/(D@5HIA,K!EL`I''OW7NKQ/?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW1:/F/V1G.IOC!W?OG:4S+OC$]=[G'7])#)$
ME?E]]U.*JH-IX7%)-Z:C+93,M%%3Q@$O(P`!]^Z]TM/CWUGB.F^C^J^K\%%+
M#B]E;(P&$IDG>66<&"AB>H:>6=Y)I)GJ97+%V+$GGW[KW0Q^_=>Z][]U[JNS
MXH3M)\JOG+"'D,<._-K6C90JK(]+EM;H#:1@X`&K])MQ]#[]U[JQ/W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=5M_RMX:B#H/MI)Z*EH`?FS\Y)((Z6>BG$T,WRC[.
ME%5,U!)+$D]2[LS(Y$JWLX#<>_=>ZLD]^Z]U[W[KW5=OS3RDVT^^/Y?O859A
M=Z9/:&R.]NUZW>>0VCLC=F]HMNX[+_&'N/`XW*[@BVKB<L^$Q4F;R%/3"KJ5
MCA$TZ1AM3@'W7NCC;)[DZL[%K)\5LS?NU\[G:.BI\AD=LTF8H?[TXFCJ_(*:
M?+[:>9<WBDF,+A3/!'<HP^H-O=>Z$SW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]UK^_*7<-1@?Y_7\O&.F8D9[XE?)?;M8D:/,ZT]=O\`Z7K-4B1J[0PE\>MY
M&TH#P3<CW[KW6P%[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZKS_FC>0?#G?\`)&*O5#E=
MKSEJ#6*R)8LM&[2T[QE7CEB`NK`C21>X]^Z]U"^Y/_'7*_\`4^7_`*^^_=>Z
M_]/<>^:]9!1)\36GE\7W'S8Z%I(CXHY`TT[;H"HWDEB$88`^L%BOX4^_=>Z.
MU[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z"SO/CI/N$^.2;_`(Q9
MV#^U$"99?]^EE_VXP`Q,C_06!Y/OW7NJD?\`A./3I!_)V^)Q2(0)/4]ZSK$4
MFCFBU?(GM=6AJDG5'6J@="C^E>5^GOW7NKP??NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW1#_`):U4V\NX?AYT322P!=U]QIV[G+ZGEI\
M1T`E!V!2QSA!)XJ3,Y*G%,!(NB=@4N.??NO='P]^Z]U[W[KW7O?NO=5R?$:H
MCG^4WSL#RI]W3]D[=@,"/?11+0Y!J69T*#3)*[2`\FX7W[KW5C?OW7NO>_=>
MZ][]U[KWOW7NO>_=>ZK_`/Y<8T].]L`TST9_V;WY>G[=I7FCLWR"WZ14Q,])
M2!16&\A5=85F(U'W[KW5@'OW7NO>_=>ZZ95=61U5D92K*P#*RL+,K*;@J0>1
M[]U[H%^ROC_UAVA11KF=NTN+S^/J%R>WMX[=1<'NG;F>ID?^&YW'93'B"26M
MQD[>2)*@30ZOU(03[]U[I+]!;TW,:G>73/8^6FS?8G4E;18]]S5=/#0OO_9N
M3HX*_:N\:>`3-+6U9Q=3#39B=(UA7,),B\6]^Z]T9'W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=:YWS?BI3_/I_E=3S-:9>G^\XX!#(R5+,^X>OB?(+QQR40T^L%F;
M5ILAY*^Z]UL8^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBB?/'#U.9^)7>,4%#C\A%0;!
MW'FLC#D7,4:8G#XBMK\I4T\B_HKJ:CA=X3P!(!R/?NO=`A]QB?\`CFW_`%/_
M`.-^_=>Z_]3;=_F.9*LQF)^&4U$)&DG_`)@GQGI)(X:2&NGE@J*G=BRQPP30
MSJ9&`X8#4H%P1[]U[JQOW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MTCNQ(5J.O]\P.I=9]G;FA9!KNRR86M0J-!#W8-;@@_T]^Z]U45_PGWJHI?Y7
M73U"CQ:\-VA\IL5+!'/43O2?;_*+N!H*>?[F662.5*:1+K<6!Y&JY/NO=73>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB*;(VTF_OGQ
MW-VV\\[X_I;J+8_QYQ^*JGDDI(-T9RH?N#,[IQ,+$P05=9@-[TN,J)4`D9*4
M(38>_=>Z/7[]U[KWOW7NO>_=>ZJCISW?\?OE-\J]_P"QOC+V1V_MSL["=?93
M`+MW<&S-O8S*[JP];O!,Y#3UNY9Z-H*FHHJ^C+232_;J(P%`8F_NO=";/\NO
ME/%5K"G\N3NJ>D-#1U!K4[4Z=`6LJ***IJ,<:8YW[C715$C0-+;QNR$J2MO?
MNO=1J;YA_*>5%^Z_EO\`>%'/+/%##"W9_3]0IUJ[22RSP9UH:>*$(+LY`)8`
M<^_=>Z>LU\F?F92X0Y3;W\M_L#<E>TVB+"-\DOCEM^L>(.4:=Y<WNRFIX`+$
MA6(8CD#D>_=>Z0[?+;^8((&D7^4SV,TPOI@_V<+XD`O:0*/W#OCQK=#JY/XM
M]??NO=38/EA\]61WJOY578U*1.(D1?EI\5*MGC*H1/:FWJ^A-1((/(T_XCW[
MKW2[_E];&[FV1U)OQN[^NJWJ;=&\^^>[.Q<=U[7[ZVYV'4;=V_OOL3/[FQ,4
MFX=I5M=M^22JI<DLKQT[Z4=B"`??NO='N]^Z]U[W[KW5<O\`,G^;^[/@SU;L
M3>^RNLL#VCN#?._3L^#$;HW]MWK3;^-I*7;F9W/D\OE-V[IR6*PN/BIL=A)=
M(EF'DD*H+LP]^Z]U3C%_PH,[_GW!08<?%OXS40K*^.EEBRGST^.=#4T<<D<,
MB-533;]2EA\BR%E=O1I(_/OW7NC(?%3^9*W9_P`L,]VG\EZ/XN?'O9%+TL>J
M]O[BP_S*Z$[/J,MN"7?HW91T$^*VCNW)Y.D:;'N!=@J&7D<$>_=>ZMAI?GO\
M)JU/+2?*WH&IC-K/#VCM&1>20.5RA'U4_P"V]^Z]U*_V>KX9'Z?*/HH_ZW9F
MU3_O62]^Z]TG\M_,6^!F!D,6:^8/QTQ4JKK,=?VSLVE<)XVFU%9LJA"^)"U_
MZ"_OW7NF4?S.?Y=I`(^;7QB((!!_TR[&L01<$?[F/H1[]U[K(G\S3^7E)K,?
MS7^,CB-=;Z>Y-CG0@^K-;,<+_C[]U[JD[Y0]Y=-=T_SSOY5FY^G>T>M^V\%'
MU_W9AZVKV)O/"[F7#Y";,;&J*::MCQ%7/)`TD,3^(L=#@MQ<<>Z]UM*>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NBP?-BF-5\/_D]$*EZ51T+VQ+(ZZ=,D<.Q\Y))3S:@
M2*>H52DFFS:2;$'W[KW1/]$?_3-_MG_Z.]^Z]U__U=MS^8Y%-+0?"=(*>*JD
M_P"'#OC$PIYY/%%*%J=W$J[@,P%OZ`F_OW7NK'/?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW27WN;;+W>?Z;7SY_'XQ-6?R0/?NO=4@?R#>RMIX#^
M7%LRBWGO7:.VI%[O^5KXB@SVZ<'BZC^%R?)WMD^6*CK:V"2*"3(-,+C4KOJ(
M/-O?NO=74Q]K=72FT79.P9"!>T>\=NN;`@$V7(DVN??NO=9X>S.MZAI$I^P=
MD3O$;2K#NO`RM&;7M(J5[%#;GGW[KW395]S]/8^FEK:_M?K6BHX9?!-5U>^M
MKTU-%-H\GAEGFRJ11R^/U:20;<_3W[KW4.#OCHZJ1I:;N;JFHB159Y(.Q-H3
M(JM?2S/'F&55:W!/U]^Z]TXIW!U+*+Q]H]=2"RM=-[;:<690ZFZY,BS(01_4
M&_OW7NNI^X>HZ:,S5/:?7-/"I4&6?>^V8HP7(5`7DR:J"[$`<\GW[KW2<G^2
M7QVIII*>I[[Z6IZB&7P2P3]I;&BFBGL#X9(I,ZKI+8@Z2`;'W[KW7'_9E/CH
M?IW]TH>;?\S4V+]?Z?\`%]^OOW7NH63^4?QMQ&.K\G5]^],"FQU%55]0(^T-
MCR2F"C@DJ)?%$N=U22>.,Z5')/'OW7N@B^!^*JJKIC(]L96LFRV6[][&[$[A
M@S<[L9,IL7=>\,S4=0L$:_BBHNIAAJ=%N?3%>]C;W[KW1U??NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1'/G#\5
MM_\`R=V_U5)U7VAM7JCL+J+L&IW]MK<.^.L<=W!M&HGK=I9_:%=CLYL'*Y3#
M4&9IZG&;@F"%ZA?!+IE`9D"GW7NB6S_`#^8A)J"_-GX?^M%4RG^6AUNLRLR%
M9&1AVF]C&UM!_/Y`]^Z]TW?'+XY?(+8_R]AZ=^3G:?QN^1FT9.@<GO\`EH-L
M?$_:O3F8QZR[N?:5#75&7QFXMQ',U4M4=$D<B1`0DD-Q8^Z]U;"OQWZ)66*=
M>H^OEE@E,\+KM?%`QS-HO(MJ:P8Z!_MO?NO=*S$=8]<X&.&+#;%VEC8X&JGA
M6DP&,B\35LK3U;(5IM0-1*Y9N>2??NO=3:W86QLDDT>0V;M6M2>%X)A5;?Q,
M_EA=&C>)S)2,61HV(M_0^_=>Z99.G^J)8C!)UIL1X3X;QMM3!Z3X%T0\?8_[
MK7@>_=>Z@2]%]+S@++U3U\X!N`=I83@VM^*(?CW[KW5#OSUVGC\)_.R_D_U&
M$VS@\/C5VKWW1_=XMZ.@D<4^2Z^,=&^'@IX-4<"RW64%^&TV%O?NO=;&_OW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[HM'S/8K\0OE$P^J_'WN!OUB+Z;!SQ_SC>E/I]3P/
M?NO=$WUC_#_SIB_XI[]U[K__UMM;^8ZZI'\$P:F.F>3^8_\`%V.`RJ[)-,TF
M]2L&E""6D4&UR!<>_=>ZLB]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=(SL9_'U[ON345\>S-T/J6VI=.$KFU"X(N+>_=>ZUO/Y"?Q1^.?=W\OG&[
MF[.ZXP^^\\_=_P`D:&3,9"JW-2R/1GO3?]5%3(*7.4]&1$:@ZC!%"HD+"Q8%
MC[KW5P\_\LKX,5'D,O0.%O(T;N8]V=AP$M%&T<?,&[XR`$<\"P)Y-R![]U[I
M:8_X&?$C%1T46/Z8PM*F/QU5BJ71G-WEEH:R1):B*:1]Q-)5.[QBTDI>10+*
MP''OW7NLN1^"/Q&RQG.3Z-VE7+52F>HAJ)LY)333E=)E>E.7^V,FCB^B]N/I
M[]U[J!%_+]^&D"E(/C_LF!"`&2$YF)&"_I#)'EE5@M^`1Q[]U[J!/_+L^%M2
MDD4O0NV]$K!G6/,[P@N5<R+8P;CC*A6;@"P`X^@`]^Z]U+VK_+Y^&VRLP,]M
MSHC;%)E!!5T_FK,ENG-0>&MDBEJ%-!F\_D<>S-)"I5C%JCMZ2O/OW7NE')\(
MOB1-5U-?-\?>LYJRL97J:B;;\,LDSJTC+(QD9AY096]0LUN+V`M[KW4.H^"?
MP^JH(Z:;X\=9M#%1M0(HP2QD4KIXVC,D<J2,Q3^V27'];^_=>ZRX'X,_$';5
M1]SAOCSUC3S6F4F?;T.10K41>&8&')/5PL'CXY7C\6/OW7NC-83"XG;>&Q.W
ML#CZ7$X/`XRAPV&Q5#$L%%C<5C*6*BQ]!20KZ8:6CI($CC4<*B@>_=>Z<_?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7%W2-6=V5$479W8*J@?4LQ(``]^Z]T#O9??G5O5,&)&ZMSTAR^Y<B<)M
M+;>)$F7S^ZMQ.J_:[?PU!0+.TF3K9)%2,2F)"S<L!<CW7ND5T+L3<K9G>_=_
M9F&;#=D=G5QAI,'--#42;)ZWQ<BP;-VHIC,C4N0GQ=-3UN7B\CJ<M),5""R#
MW7NC,^_=>Z][]U[KWOW7NO>_=>Z][]U[J@S^83%K_G`?R@&,42JD/R";[MBO
ME\@FZXT4B+I\A$P+->^D:.1S[]U[J_/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T3C^8C
M/CZ;X#?-:HRV5J<%BH/BGW_-DLU1PO4U>)H8^K-TO59*EIXU>2>HHH`TB(H)
M9E``]^Z]U7E_$-K_`//893_SW5'_`%[]^Z]U_]?;Q_F!XNIR@^$PII(8CC_Y
M@_QKRDQFF,.NFHWWBTT<5B/+-(K65/[7OW7NK!_?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW2&[/?Q]:]AOI#Z-C;M?2PNK:<!D#I(/!!M;W[KW5(
MO_";L0+_`"V<*L%7%6C_`$X_(65Y((IHX8Y*GN+>=4U+$TL:+*M)YO$2EU!4
MB]P??NO=7Y^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNBP4%F(4#ZDD`#_7)X]^Z]TS5N
MY-NXU_'D<]A:"2^G16Y2AI7U6#6TSSQM?20?]8^_=>ZBKO+:#VT;JVV^IUC7
M3G,6VJ1OTH+51N[?@?4^_=>Z=5RN+8(5R5`PEU>(K64Y$FG2&T$2>O3J%[?2
MX]^Z]TW9S=NU=L0P5.Y-RX#;]/5&5::?-YC'XN&H,"&2<02UU1`DIAC&IM).
MD<GW[KW26@[EZAJB@INT^NJ@R,%C$&]=MRZV(+!4T9)M3%5)L/P#[]U[J5_I
M7ZN\4\W^D?8GAI462IE_O;@/'3QN[1J\S_?Z8D:1&4%B`2"/Q[]U[HCOS"WU
MA=V]B?"SK;!=BUK[:[9[VW)M[>&&V!N\TYW?MO%],]A[G_A>8EP5;Y:G!PY+
M$4]1(K7C+1K?W[KW1RNO^B^G>JZO(9#KOK79NT,GE_$V8RN#P-!0Y3+RQ1B)
M)\ID885JZZH\:V+R.S'^OOW7NA7]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M:_\`_,>R%+1?S=OY-L51)5J]?FN]:2F2GD*1/4-%L>134A6!DC"1MP01?W[K
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MS(;-W10TE,A`>HJ:O"5U/!`A9E4-++(%%R!<_7W[KW5*7_"="#*4?\N+#XS,
MTAH<CA>]?D=@:RC:)(Y:2KP?=V^\35TLQB+0R2TU32,A9&8$K>Y]^Z]U>_[]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NF
M?<.;HMMX+,[@R4T-/083&5V4JYIY4@A2"AII*F0O-(0D8*QVN?R??NO=:Z?\
ML;,;TRG\R?N?>&Z\UFH$^1/Q*;Y/8W9V6S>4R<F-P':7=.#SVRX*BCK9H:3%
M5&S]KYJ+$)!!21E(UTN[,#?W7NMD)W6-6=V5$12[NQ"JJJ"69F-@%4"Y/OW7
MNJGMI_!_XI_,G>/:7R=[RZ9@W1O3=W8>Z-FXC(R[R[.P+Q[4ZIR%1U?AYX:'
M`;UQ.&:GS5)M45T<L-+&9$J`Q9R=1]U[H6\5_*L^`^$QTF)QG0%'3XZ:.>*2
MF;L+MJH#1U,\-3,ODJ=^S2@//`C<,+6XL+^_=>Z;*O\`E)?R[Z^4SUOQLPE5
M,8_$9)][]IR-XRH0CU;Z(!TBU_K[]U[J)'_*"_EQPO')'\8]OH\4BRQL-Z]I
M^F1"&1P/[]6U*1[]U[I5?\-=?`X4M%0CX_XL4N-DFEHHAO;LX"GDJ#$TS*PW
MMK/D,"7!)'I]^Z]T\5'\MCX159<UG0N$K=;!BM;NC?\`6(&$8BND=3NR5([Q
MBQT@7'U]^Z]U"3^6+\#HG+Q_'':,;MIN4RV\E_0"%MIW*`"`Q'']??NO=<)?
MY87P.G=))?CGM5V0H1_N<WN%/C=I$#HNZ`DBJ[$@,"+GW[KW1;>XOAI\5/CI
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M&QDI:WKG<5/.@)!`+12$7L??NO=$;_NAA/\`E7?_`)+'_1OOW7NO_]'<J^94
M'G_V53_._L_,[HR?]IY$_P`W_>C_`#N@C7%ZN5/I/Y]^Z]T<[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TUYLLN%R[)^M<77E.;>H4DI7D<CGW[K
MW5+_`/('\I^!N1DF,AEE^4OS$DD#O,Z+(?DWVIY!%Y&9`FN_Z+*3<GF_OW7N
MKM/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]T1C^8GFJZ/XSYKKK"5;4.Z._]V;-^/^TJI*B6DDAW'V?EEQ-"T=7"Z/2N
M8XI`)+@*3[]U[HADN].D/CG_`#IX\9NS<VS>KMNK_*]H-J[?R.Z\S28*FK/X
M#WYL^.BP-%D<M/#'7U%'AZ7R&-&9Q&A9AP3[]U[JPC=?:G87?=.-B_'K#9W`
M[7S@FI=V]][GP53B<#BMM3*8)_\`1C29F*!MZY[-02G[.OIXJG'4J([2$2-"
M??NO=&HV/LW"=>[0VYLG;D,T.%VQA\?A:#[J>2KK9X<?31TPJ\C6S%JBOR=8
M8_+4U$A:6>9V=R68GW[KW2J]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U7]\[V9*SXJR(Q21/DSL8*ZDJZB5*N*0*PL0)(G*G^JDCW[KW5@/OW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM<K^;E#0?\.C_`,B>I2CKHLZORFWC
M3Q9J*KC6@3!S;+KGRF$JJ",BMGFR=5#321R\T\0IV#^ID]^Z]UL:^_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NBR?-7_LCWY3?^*]=Q?\`OO\`/^_=>Z)E[]U[K__2W-OE
M_%42)\86@@IIQ!\P.DYZAJFI:F6FID;<@EJ8V5'$LT08:8S8.3]1[]U[HX7O
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[ICW.R)MK<+R?H3!Y9G]6C
MT+05!;U_V.!]?Q[]U[JE3_A/C61U7P$KHHWCM2_)[Y;((5GFGE@2H^1G959"
MDYEAC57>&I5U*%U=&#7NQ`]U[J\?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$"[>5>U_G)\>.K%F2JP?1>RMP_(G?>"
MGEG6"HR>Y*ZJV=TUFDA2%Z>:JV_N?:66ECUNC(7U*#S[]U[H[=9M':F0RISF
M0VU@:_-&C&/_`(K6XF@JLB*$2"44:UD\$DZTOE4-XPP4L`;7'OW7NGZ***"-
M(8(HX88U"1Q1(L<<:CZ*B(`JJ/Z`6]^Z]UD]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW5?OSR_P"!/Q7_`/%FMA?[W4>_=>ZL"]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK]?S<((4^?W\CZO6RUJ_.&3'JX2[FBJ^
MMMZS5,1=M*)&\E+&2-6LD"P(!M[KW6P+[]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+'\U
MB!\//E.20`/CSW$220``.O\`/DDD\``>_=>Z)AY(_P#CHG_)2_\`%??NO=?_
MT]RCYHU<5%0?&>::K%'&?F!T?&96I_N0Q>?<($1BU*I\AXN;@?6WOW7NCH>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NF#=9(VMN0A=1&`S!"V5M1
M_AU3Z=+JRF_]""/\/?NO=45_\)T<C/6?!S?U-,&(QGRT^4=+%*:%J59$F[GW
MC7%8Y]7CKTIWJC%K0*B%#&`-'OW7NK\_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U7M\+:3^_P#V7\LOD?5_Q6LAWYW/
MD.O.M\GE:=J5H^JNK,1A=OG$T,3C4]!!VE#N29'!*L9C;\D^Z]U83[]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JOWYX_\``GXK
M_P#BS6PO][J/?NO=6!>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZH,_
MFW2^+YR?R2BZP/&_SSH8@)+B1)I>L]_K'+"=0#.MR+6)L2?Q[]U[J_/W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]T67YIH)/A]\I8SHL_QZ[B0^0@1V;K_`#X.LG@)SS?B
MWOW7NB9_;)_TS_[=/^*>_=>Z_]3;A_F/C&':OQ2_B]'65E&/G/\`',F.AAII
MJF*7[[<GBG0U+QK"(FY+J=:CZ#GW[KW5B_OW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[I-[RU?W0W7H_7_`';SFCZ?J_A=5I^O'U]^Z]U0O_PG`I7I
M_A9VQ(\$-,:OY<?(NH:",J)%D/8N;29ZB->(Y)ID9Q_JD8-^??NO=;!GOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@.^2G:5#T
MOT3V=V/69.+$38+;%538.NG"M$N[MP2P[:V53L'M'>NW;EZ*`:R$#2#40MR/
M=>Z:/B7UW6]5?&WIS966A>GW#1[+H,WNZ&0PEDWQO&6?>>^1>G>6#2=W[@K2
MNAF33:Q(]^Z]T8CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW1!OG=^W'\:*EA*8J?Y*]<>7Q0U,[?Y37BDBNE-%+9/-.MV>R*.
M21;W[KW1^??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4!?S?93#\U?Y
M)\D<"5%0/GW@%IHWG%-:238N](I'60D`NE*\A"?[L_3^??NO=7^^_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NBW?,B::G^)/R<GIXHYYX>@NW)889814Q2RQ[#SK)')3D$
M3H["Q0_J''OW7NB?_?5__*G3?^>Y/^C??NO=?__5VZ/YBL@7`?$B%GF2&L^=
MWQRI*@P!#(8):O<Y<#R`@`E1<_6WOW7NK$/?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW3+N6"2JV[GZ:&)ZB:HPN5@B@C`+S234,\:1("5!>1F`'(
MY/OW7NJ+O^$\B5D/P\[<I:^&2EK*#Y@?)K&5-%-$B34,^,[6W+0RT<SQNZ32
M024Y4D?I(TW-KGW7NKZ_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=$&^;;Q]@YOXX?&.2EEK\-WIV_25/87V"15&2V_L3J?"Y7
MM>BW&8)?)%%CI>Q]G8+&RRR1O&/O@HL[(??NO='Y````%@.`!P`!]`![]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB!?S
M#C#3]:]19)JB.CJ*#Y.?'1:2KEF>G2-\CV_L[%30^5-1#UM-6O`JE6#M(%-K
MZA[KW1_??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:]W\YDU"?+_P#D
MM34TWV\D'S^VE*U0I3S0QG;&YXI&@5T=9)&$NBQMZ6//OW7NMA'W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]T#'R.B$_Q^[OA:FI*U9>INPHS1U_D^QJ@^U,JIIZSQ/'+]
MM,#I?2RMI)L0??NO=%X^TB_YU&'_`/5G_P"J/?NO=?_6V_\`^8!B3D=L_&6O
M6E%8=L?,[H+=`IWGB@IW_A=9N!?\J:1E9J9?N;LJ?N$VM^??NO='Y]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=8:A&DIYXT"EWAE1`X5E+,C!0RN
M"K*2>0>"/?NO=44?\)_/+!\7/D)C*B"*GJL/\Z_F%CZF&`*(5G3O7>TDGB$=
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MM6;FVAV/+0FFK54_;X\#$R>9`0TC:".%/OW7NK\??NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW05]Z4GW_2O;=#HDD^\ZVWM2^.&%ZB5_/MS(Q:(J>-7>:1M5@@!+'@#W[K
MW0(?P8?\<*G_`,X)O^O7OW7NO__7W)OFW10U^U>C(JC*-B88_E#TW.\ZTIJO
M/XJS,$49"L&IUJ";>4!BEOTF_OW7NCI>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>ZTZ?@'_`#,L3_+XH_D[T7OSX.?/+LS=.Y_F3\K^U<=N
M/IKI;:N;VKG=M;C[AW=7X_(TF4W9V5LRHF0PL((RU.AD,=U!32[>Z]T?^/\`
MX40=82"75_+C_FDQ&)Z=`LOQ_P"L`91-(B/)%I[U8%*8,6DO8A5-KGCW[KW3
MZO\`PH(ZF,L<9^`G\RQ%>.21IFZ%Z^\4)0V$<A'<Q;R2#E;`BWY]^Z]TFQ_P
MH>Z]R$]=0[7_`)=/\RW<V4AR5+CZ/&T?2'7])45"5$2#[R>3(]O4E)!3BL;Q
M+IED)_4=(]^Z]TKHOY[4WB$U5_*J_FE0@`>1(NH.E)Y4(#&1]+=_PJT*V%CJ
MU'^G]?=>ZA57\_C;>/5'R7\L'^:K1Q.FM9VZ*Z:FA8>,2W0P?(624JR$$712
M;\@'CW[KW21K_P#A1'LU4OB_Y:G\S>1P&O'END>MZ!GU%1!)"*3N7)AX&!)8
MDJR@<*??NO=3,)_/?[#W13M5;7_E.?S$<W3&*62&>+8?6%&CBG`:HD9<CVO1
MS+#$CK_9UDGA3;W[KW0V=$?SA-U]L]M]=]9;\_EZ?,GX[XG?NY,?M5^R^X]K
M[`QVQ=OY?,R1T>!I<K6[:[#W-DEDW!EYXJ*DT4K*U1,@D,:W8>Z]U=G[]U[J
MI3YU?S1,K\1/D)U7\8NNOB5WK\K>W.T^L\[VOC=M=,1;+>IH=J[=RV2Q.4J*
MH[MW?M=3)2/C7E<(6'B(L2W'OW7NJ]?C[_,L^7_3F)[*7=7\G3^8!EMT]F=S
M=I]M5LN-Q/3=90XNDWSF9,KMK;D>1J^WZ6LGI<'"PIV!B"P1W\>O\^Z]T)V0
M_F_?S%*ZIISLS^2)\NJV@--$*E]RYSK3#5@K[VF%+3T.]<K%+CR3:*1Y$D:Q
MU(MA?W7NGZE_FD_S/ZG,5F'/\D_Y#1/1QQLU;)O_`*X7'N:G_@,R53;G"21`
M?YW1J=+&RFWOW7NI2?S1/YG@CD$W\DCY)?<QTT<H\/8/4STTLWDE2:GBE?>T
M<A95564E`"&YM[]U[K$/YJO\RPTT?_8CGY;"OF%4$0[SZ4^QA=59*/[JH_TE
M^9(Y9P#(5C<I$;J&;T^_=>Z0DO\`--_G(RUTZ4'\BSM-<<QG:BGR?=6PZ:J,
M(0O3K74]-6UD5/4/I*NJ22*K$68@DCW7NO#^:=_.0M`Y_D5]K:3'JJ4'=.PO
M-&Y%E2%37!);."3=ELI%KGCW[KW2WQ/\RO\`FW5[TYK?Y+?8V+AD1I9ON.XM
MF-/%'X&E2$1Q5,B-5ZP$*ZM`8_J(Y]^Z]TH1_,>_FGJ\PE_DX=H%%O)`T':^
MQW+Q672D@?(QZ*HM>ZBZ@6]7OW7NDSD?YDW\WQ,C218K^2[O*HQLD;&LJJ_N
MO:M+4P2M,?"D-/!'51RH*:QD)=2LEU`8`,?=>Z@4?\QW^=#7R5ZQ_P`F"?')
M%5+'CWR_R!Q</W5+(K*D\XH\!6^"2.8J9%76%CN06(TGW7NEG3_.S^<P*:`U
MW\IG9HK&5ON(Z'Y&54]-&ZNR6BFGV#32.C!002BFQ^GOW7N@)^2W??\`.&^0
M?7.-Z]G_`)6FU<&E'V;TIV4,G_I[J*\I+U%VULOM1<8*7^Z%&&?,G:'V+.7M
M`*@RJ&*`'W7NA-E^=_\`/&^ZD$/\IKK3[5YXVA#_`"!RQ>.D1F$Z32C9R!JE
MT*E"J:2=5[`"_NO=/>+^;'\\3,5LE+'_`"L^A,&@BGGIY-T?*#>M`U0L+D+"
MG\)Z:SE.LTB`$ZI5TW^A_/NO=.S?*_\`GK/J9?Y<'Q4ISXET1_[,YV/4@3"0
M%BTO^AFFO&T5Q^BX//OW7NFH?)?^??D*R:*#X(?$K"B>%12&K[V[$JZ"DF,\
MEY*FM3K!:J1?#I&D0<6OS]/?NO=*&G[R_GX1I$:GX>?!FH9J:>:81_(#MV)H
MGIE+)%&/]"Q$E17JILI(1)++J*DL/=>Z26Y.]_\`A035I2'!?$;X8[?\3R_>
M>+MSLG<DE5%*L+0-&E9UMATIY:;2X878.6^O'/NO=/VWMW?\*(,[2-D_]%?\
MN3!TTS0)#B=X=G=U8O/TY8IYGJ8,)T_GZ`HBD_IJ";CZ>_=>Z!3NCXF?SG/E
MSVW\,ZKY-8;X!;;ZE^.'RKZY^1F<GZAW]W!N+?>0DV30;DQ+8O'1;GZBVWC/
MM9Z/<LCM$]0@DEC0EET\^Z]ULG^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND?V%&TNP]Y
MQ*0&DVMGD4FX`+8RI`)M<VN??NO=(#[63^J?[=O^C??NO=?_T-R?YM?Q)]L]
M#4^,E:&6L^4W3-+42)"9W6CDJ\R:C0!_FV*J/6>%]^Z]T='W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]T#'?\`L_/[SZMW!2;1A%5O7;\N*WUL:@DJ(:6FR>]]
MAY.EW;M'%UU34*T,&/R6?Q%/#.[#2L;DGZ>_=>ZG]*]JX#N'8&*W5AJ^"IKH
M"V"W=CD'BK-N;UQ$<4&Y=NY2C:TM#7XW(%@8W`)C9&'I8'W[KW5/'=OA/_"A
MKX4AI!YQ\!N\#'$K`N5.[]T!WD2VI8^+!OH6X]^Z]U>_[]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z:-P4,63P69QT[5205^+KZ.9Z*-9:Q8JFEEBD:EB9)%DJ`KG0I5@6L
M+'W[KW3#_=^C_P".N7_\YHO_`*G]^Z]U_]'<C^;V9I=N[9Z$S=768_'PXWY4
M=,U)K<M7TV,QE,14YM#+75E;+!210*KF_D=5O;GW[KW1L8-Y;0J0IIMU;;J`
M\8E0P9S&2AXF`*R*8ZIM49!%B./?NO=.`S>%+M&,OBS(B>1D%?2%UCN!Y&7R
MZ@EV')XY]^Z]U@;<VVT8J^X,(C*2K*V5H%964V((-0""#]??NO=<?[T;9_YZ
M+!?^??'_`/U1[]U[K$V\-I(P5]T;=1F)`5LWC%8E0"P`-2"2`PO_`*_OW7NO
M+O#:3EPFZ-NL8]0D"YO&,8RALX>U2=.D_6_T]^Z]U%K=^[%QII!D=Z;3H#D*
MF.BH!6[CP]*:VLE5FBI*03UD?W-3(JDK&FIR`;#W[KW29R'>/2F)F>GRO<'5
MN,J(Y)89(,AV!M.CFCF@8K-$\53EHW62%E(92+J1S[]U[J$?D)T$%UGO#J`)
MQZCV7LL+S>WJ_C5N;&WOW7NNF^0O02%0W>/3ZE@&4-V7LL%E/T*@YH7!]^Z]
MU,'>G21TV[BZK.L*R6["VD=:O^EEME_4&_!'U]^Z]TU3_)+X[4M744%3WWTM
M3UU'+%!5T<_:6QH:NEGG77!#44\F=6:"69!=%8`L.1[]U[KMODA\=T8J_?72
MZ,/JK=I;'5A<7%P<Z#R/?NO=8W^2OQRCC6:3O_I..%P2DK]J[%2-P/J5=L\%
M8"WX/OW7NIB?(;H&2*.=.\>GG@E%XID[,V6T4@L&O'(,V4<:6!X/T/OW7NIB
M=Z](RD"/N/JN0LS(H3L+:+EG16=D`7+DEE122/J`"??NO=8*GOWHJCB,]5W/
MU3#$"JZW["VE8LVK2B@9<EG8H;`<FQ]^Z]TEC\KOCGY8X8NX=DU;R`E?L<O%
M7HH$AB/DEHQ/'%:0$'418^_=>ZE4WR@Z`JX:FHA[4VF8Z5HEF,E?X7O+KT>.
M.5$DF'H-R@8+^;7'OW7NG=?D/T&88IY.Z^J*59UUHE=V#M2@GMR+24U9EH*B
M)P1RK*&']/?NO=<)OD;\?H*>:J?O'J-H*=0TK0=C;0J60%E4?MT^7ED:[,/H
M#[]U[I)S_,+XO4U%-D:CO;K2&C@G6F::7=.,023,;!:=6F#U0+`B\8==0(O<
M>_=>ZET_RU^,U2(C#WIU@1,\,8U[OP\7B>H95C%3Y:I/M?4X#>33H_M6L??N
MO=/\'R0^/-1&)8>]NG61B0"W9>S8S=25-TDS*..1^1S[]U[INR'RE^-F*%2U
M=WWU!"M)1K73$=B[3F`IFE>$,GARLGF<.ANB:G4<D`$'W[KW333_`"[^-M7&
M9:3M[:55$'>(RT]7+/&)(SIDC+Q0,ODC;AEO=3]??NO=9C\LOCL`2>U=LV`)
M-I:H\`7/`IB3P/?NO=!UE?Y@WQ#PE=_#\GV_1TU08$J5;^Z^]9J5XGD6%3'7
M0;<DHY',K!=`D+ZN+>_=>Z`+>W;/QAS.X:CLKIWN_=O2_8F:"OG-T[8ZB[!S
M^W]Y4K*S1S;LV?6[6@P&YJR`L&I:R8F6!6<(;2-[]U[HI%)E=AY;^87TE\T>
MQ?D1L_,0]0]$=A=%FGQ?5O:^%W-O>AW1E\KE\7FZO&?W$3!XJLI*K)D2TE-4
M2)=?06)M[]U[JQ_(_P`QWX@8NK^PG[)SE16&."44V+ZI[<S,S)4PR5$++'B=
MBUK-JAA9B!<K;FWOW7NNH_YBWQ<E0R1Y;M]HQI/E'QD^2GB9619%=)/]$VAT
M9'!#`D'W[KW6;_AP[XQ?\[+N+_TF+Y*__:F]^Z]TB]Q_S3OAWM2EAK,SFN\H
MX)XYI4-#\1?EEEY`E.467RP8GI2MF@93(.'520>![]U[K+MW^:1\/MTT^.JL
M-FN\)H<J:P4?W?Q(^5^+D8T!<5(GARG2U'+2%?&=/E5/(.4U`CW[KW2O_P"'
M#OC%_P`[+N+_`-)B^2O_`-J;W[KW7'_AQ'XPZS'_`!+N/4%#G_G&'Y+6TDE1
M9O\`1+I)N/I]??NO=-]1_,E^*M+/34TV4[I$M7(\4.CXK?*&9-:-I822P]/R
M10+?Z%RH(Y!]^Z]TALG_`#:?A;A\A'C*[,?():N6JKJ-!3_"_P"8]=!Y\<:,
M50:KHNB:BD2,&NCT.7"2^K06T/I]U[J7B/YKGPUSF5&&Q^8[]:O,E?%IJOAM
M\P,?3:\;%)-5_P"7Y#HRFH=(2,Z#Y+2GA"Q(!]U[I3-_,M^*"T460.4[L^VF
MA2="/BE\I3-XY'T+JI?]#GW*/J^JL@8#DBWOW7NF3.?S1OBKAE3Q1_(#,3RZ
M1%3XSXH_)DL[N`4C,M7U12P1E@?JS!1^2#[]U[IEV_\`S5/CCNK)0XK`;/\`
MDI55<QI(S]]\8>]\#315-6FH4\E9GM@8VE!A/#N',0/]KW[KW0DQ?/CJV41L
MNPN\U221HPS=-[_7249U=F0X+6%7QDWMR/I>XO[KW20R'\Q_KR*MKZ/"=,?(
M[<@HHH94J:+J#=6-IZQ9M)44QSU#BWU!6N0X4C\\^_=>Z$#&_,')Y:@H\G1?
M&SO8TE=`E33FHQNU**?Q2?I\U)5[FAJJ=^.5D16'Y'OW7NN%7\P\I1B7R?&G
MOAVB0N5AQNU)2WIU`(R;F9&8@_U]^Z]TVX/Y?]F;HJYJ7;OPI^1%>(UJIH:B
MMS'2FWH*JDI*F.DEJ8FW'VABC'>>50L4@69U)8(5!(]U[I1M\CN]%$__`#@Q
MWR3`NI@-_?&WU74L!&?]-%I2;?V;V_/OW7ND[/\`+#O&F\9G^`OR-2.2.HE\
MB;S^-\^A*6D>HG+I!W3+(&6:,PJMB9'L5!4ZO?NO=/V*^27>N4Q0R1^"O?=#
M(V@Q8ZMW]\;(JV16)NUAW2T,>D<D,ZGGW[KW3_C^^.ZZR*.2J^&7=&+=YVB:
M&JWY\>)GBB4V6I9J+N"IC,3CD`$O_A[]U[I`[H^4GR1P4:OAOY='R-WBS58I
MVCPW:7Q'H62"S?Y:3N#Y!8A##P/2"9.?T_7W[KW2VI>_N[Z@(9OA3W91EJ2A
MJ&$^_P#XY.8YZHS"IHF^W[DF!GQPC4R,+Q-K'C9[-;W7NG+_`$X]R7<?[)]W
M#Z68*?[\]`6<!20R_P#&6K@.0`+V-SS[]U[IKS??_>6,@>3&_"?NS<$RS11K
M3T/8/QRI&>-R-<XDRG<='&$B'U!.H_@?GW[KW2`D^57R<3*/1C^6Y\C9<<)(
MXTR\?;7Q#\3!FM),U))\@8ZI(8UY^A<_ZGW[KW4^B^4/R0J<A!2U'\NWY$8^
MDE%9Y<G4=I?$N2"F-.Z+3AX*3OZHJW%<K%D*H2NFSA21[]U[IVJ?DE\@89*5
M8O@-W]5+.9Q-)%V3\6T6C\0!C,PG[TB>3[@\+XP]O[5O?NO=9X/D;W[+3Q32
M?`_OFFEDT:Z:7L?XPO+#J8!M;P]X2PMH!N=+&X''OW7NFZ+Y,_(>3RZ_Y??R
M$AT&71K[-^*;>;QWT%/%WS)I$WXU6M^;>_=>Z:D^5/R4+VD_EQ?)&*,8NLKV
ME/:7Q%D`JZ9YU@Q`CA^0DDSUM<D2M&ZJ8`)`'=2&`]U[J$WR\^0:5M'0/_+I
M^3*RU;Q4XD&__BP]/!6/3S53TTU0G?#0J(8:=BTU_`6LH<L0#[KW2EI_DQ\A
M)IFCD^`'R"IT6I\!FE[)^+)C,?BCD^Z41][.[0:G*<`MJ4\6L3[KW4V;Y)]X
M4V@U/P:[[B$LDL<9CWU\<:N[112S`L*/N:<Q+(D)TEK"]A]3[]U[J=A?DWOC
M)/5)DOBQW;M[[+'&OJ&R-;UC5!6,GAAHHOX5ONO^YJIY>!X]:J/4Q"\^_=>Z
M&K:F^\UNO+/A,OUIN_9\#[3Q>>FRF<J]LST*5V42G-3M>^$SN3J6S.*^X(F=
M4-(3&WCE?B_NO="3]O%_0_\`)1]^Z]U__]+>L[<_T4?W)R'^FC^Z?]P_-3_?
M_P!\_M/X-]U=OM/^!GH^\U7\6C]R]]/OW7NJ^-Q?\-7?8U7\<_N#]E]Q1_<_
M;?Z2+>7^(T_V>G^%?N>'[_QVT?M_U]-_?NO=!3%_PS1_'5\7]V?X[^]:W^G_
M`,NGT>77?]CQ7TVU>F]K>_=>Z7.(_P"&F+2?PO\`N=^F7RZ_],&JWW,OEU?>
M>K5]SK_QO_A[]U[ITH?^&JO/0_9?W,\_\$J/LO\`F:W_`!9_-#Y_\[Z;^;1^
MO][^G%_?NO=.D'_#7.J;Q?W#U^?]WR?Z1M7G^VIOT^?F_P!OX[Z>+6OS?W[K
MW4M?^&P[R:/[AWNWFT?Z0KWN=?ET\_7ZZOS]??NO=0Z__AK*]#_%O]&FK[N+
M^&?Q7^_.K^(:6\'\-^]Y^_T7T>+]VU[<7]^Z]T_[7_X:Y\5;_`_]E[M_>?;?
MWW\8^W^Y_O/_`!J#^`>7^\O^5?<?QK1K_P!UZK^?TW]^Z]T+^+_V0K[N'^&?
M[+3]S]P/#_QX6G[CQ3VM]Q^S_FM=K\?['W[KW3G/_LCG\+S?G_V6G^&ZZG^,
M:O\`1W;5XX_/;_=]M&FWBXO^GGW[KW3)#_LA5L7X?]EZMX?]Q=O[J_YCSI;Q
MWYT^;3IU?[#CW[KW3[C?]D9^XJ/L?]E?^^^XHOO/-_HQ_B/WEZK^'_>?>?Y;
M]Y;R^'R?N:;Z>/?NO=*=_P#91-1\G^RX:^+Z_P#1CJ^G%]7/T]^Z]UAE_P!D
M\\$?F_V6K[?2?%Y?]%W@T\W\>O\`;T_7Z>_=>Z<(_P#94?!%XO\`9>OMM/[/
MC_T;^#1I7_-:?V].BWTXM;W[KW3A%_LL]U\'^@J_D;3XO[@7\NAM>G1SY-&J
M]N;7]^Z]UQE_V632/-_H(T:TMY?]'^GR7;QVU\:[WM^;W]^Z]TY4/^R]V?\`
MAO\`H:T\Z_L?[D6_4;Z_!Q^N_P!?S[]U[J>?]!_%_P#13?\`%_[H?3_#W[KW
M2:KO]E>\Q_B7^@3SZCJ^^_T>>;5S>_W'KU?U]^Z]U@A_V5;U?;_[+[;C7X?]
M'/\`A;5H_P!A]??NO=9)_P#96_##]S_H!^WO_D_G_P!'?AU:V_S/D]%_)?\`
M3^;_`)]^Z]UW_P`XM_O_`/,@K7;[G_F7?ZK^KS_XW^NKW[KW44_[*=^?]EWO
M_C_HV]^Z]UP?_92K?N?[+KI]5M?^C2WT]?ZN/T_7_#W[KW2KH_\`0)X3_#_]
M$'@\LNK[/^YGA\^K]Z_@]'EU?J_-_K[]U[J7_P`81_[]7_ZZ/OW7NNJC_0CX
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M?NO=>]^Z]U[W[KW2%W__`!+^$T'\+_OAY_XYCO+_`'*_@O\`$OMK3^;[W^._
MY+_!_IY_'^_?3H_/OW7NLO7?\1_N9@/XM_>W^(?8Q?=?WY_@W]Z_);G^-?W?
M_P!P_P!Y_JO!Z/Z>_=>Z6OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
<O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g595389g77q05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g595389g77q05.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X0[^17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```$L````
M`0```2P````!061O8F4@4&AO=&]S:&]P(#<N,``R,#$S.C$P.C(Y(#$P.C(R
M.C,Q``````.@`0`#`````0`!``"@`@`$`````0```C:@`P`$`````0```<0`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```-T`````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`&8`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/54E0ZIUOI_232,U[F')=Z=(:QSR72UH;^C#OI/L8U5
M*?K?T3(S'8%-KWYC+#4^CTW`M<U_V>SWO#:G>C?^BM].S_H)*=I)83_KGT-N
M1=C"Q[KL;US:W;M`;BN<S,L]2WTZMM.S]_W_`.#06_7WH#^HGI;#=]M#BT4O
MK-).T;W$NR_L[*O^O.J_\$J]1*>C4+;:J:S;<]M=;?I/>0UHG35SEB=)^N?1
MNKY;<7"]4O<`9L:*XW--S/T5KV9#_P!$W?OJH?5_-^_](KO76!V'3(D-S,,P
M=?\`M30$E)SU7I8,',H!`DS:SC_.5?,S^CY>+;C.ZE72+6EAMIR&UV-G\^JU
MC]S+&J[]FQYGTF3X[0I^G7^Z/N"2GFJ.E=`#'4_MS)O%UM3@+.H.>Z:R]C**
MW>IZGIVNO_2U?X3]$M'IOU:Z?TW)^U569-UH!:TY&1;<`#]+:VY[FJSU5C?V
M?=#1,`\#LYKE=24TG=;Z,UQ:[/Q@X$M+3<P$.!VEOTOI;E$]>Z&"`>HXLG@>
MM7KIN_?_`'5'#RZ,7I%5^0[TZFPR8)U<_P!&MH:T%WO>YC%//_IO3?\`CW_^
M>,A)2W[=Z+,#.QW'P;8UW']4JUCY./E4B_&L;=4Z0VQA#FDM)8\;F_N/;L<I
M"QIL-?Y[0'$08@EP;[OH_F*GT7^AV?\`AO,_]NLA)3>3I))*?__0]'ZQZPPG
MNHQZ\JPQ4ZJUI<TU6N97D-<UC;'N9Z?Z1[-OZ3TUS574>I8]._%^K]7VBMMC
MJJ&4/82\-<YUK<HU>BWWT48_I/\`UG)_G:_\"NS224\IU'(ZR[-LJHZ3CW,:
M^TL]7'>X;JXMP?UEOZ)_VNRV_(]9K/3PO4]&[]9]3U%==]:KJI=T_%+LEH/V
M>RDG:XC'<ZK(N%]U3]CG7_I=E3/U6O9ZO\TNK224Y72[>N693OVIC555MHI+
M+*X)]9S1]MKW>I8[TVV_S?Z-'ZP)Q&>63B'[LF@JZJ?5G`89U`(LI.ICBVI)
M3=22224UNHB<"\?R#^`5E5NHN:W`R"X@#TW<F.Q\5924X?3^N]/H-/3WO/J%
MUC"_38UXMLJ;CO?/](>]OLJVJ[E/%V9@&MKG!ESG/.QPV@T9#-SCMVM]SMBY
MBUW3<3K?3GVUUNKR,C-9D`!KIL^TOIINO:[]RV_^<_,72W8&";Z;&NJIJK+O
M6I%=1;:"TM:RQSV&QGI/_2_HG,24Z*H]'$8UK?#*RO\`I7W/_P"_)O0Z%_H\
M7_-K3=&](4Y#:2TUMR;@T,C:)=OANSV_G)*=!)),2!R8GA)3_]'U5))))36K
MS#:USJZ7N:U[ZY]HDUN=4[Z3_H[F*9NN[4/^]G_DT#I<^E>/#)O_`!L<[_OR
MNI*0^K?'\P?\YO\`>LS#R\"BW-;F.KJL^U/]KX)]S*GM[?N.:ME5<.!?F_\`
M'C_SS0DI'T;;^SV[!##9<6:%HVFVS86M=M]CF_05TS!C4]@G224T,QN[.Z<Y
MP$A]@(Y@FI_=7U3S8^U]/D2?7<`?#]!D*XDIY+ZYXGJY^!9Z8=6&65VO@':'
MOQ]KO3EK[/<W\Q-]6NF.JSK.HM:+JVUNQO296&.#G&G(G]+;]':MGJ=.+=U'
M&9E-<ZLTW.AF^=S7XI:[]![_`&[D]%>/AAC.GM=52ZXV90?7?8YP+"S]"7_0
M?O;1_(]/U/T:2EOL]U.'F-M;?D^L;7L-OHRQCP=N-7L<S]#5_@]ZT<:/L]4:
M#8V`/@A6Y-3J7C;9JTC^:L\/^+1,3^BT_P#%M_($E+/95=86BUP?7&]C'D$3
MJW>UAW>Y5']$QW.K>+;IJ<YTOL=9.]WJ[3ZSG^UG^"K_`)JO_1JO@;1]9NJM
M`J:35C.<&"SU3(M9ZF0ZQ@H_,].G[/9^9^E6RDI__]+T3]BLW6N^V9GZ8DQZ
M[H;N)=%7[FV?8I8W2&8X<!E9=H<ZMY]6][]:W;V[2[W-99]"ZO\`F[F?SBOI
M)*:73-/M8';)L_':[_ORNJE15FX]F1MKK>RVTV,)>6F"UC8<WTG^[<UR-OS8
MUJJG_C7?^D$E)U7QA^FR_.T?^>J5(.RH$UUSW_2'_P!)(+<.]UEMK[GU>JX$
M,J<"T`-:S\^O=N=M24W$E5^Q.@@Y-QGON;/X,2."#$WWZ?RX_(DI'E74ORL%
MK+&N<,AX(!!,BC)W#^RKRI8_2,/&<QU6_P#1V/N:"]Q'J6^IZUKFS[GV>O;_
M`)ZNI*:+K:W]9H8Q[7.9CY`>`02T[\31T?15Y4>DQZ>2`(C*O_%[G*\DI9PE
MI`\"J_3[:K<.HUO:_:QK7;3,.#6RUW\I653P?Z5U#_PPW_VWQ4E-7#8:_K)U
M`["1=30[U=I`&W>QM&_;MM_/M^G^>M996/@9E?UER\\D#"NQ::V`..MK76>H
M75SM]M?I_I-JU4E/_]/U5,0"(.H3I)*:SNH8XLLK`L>ZIVU^RJQP#B&V;=[6
M;'>Q[4_VUG^BN_[;=_<H87\_G?\`'C_SSCJT9C34^"2D'VL3`IM_S#_%3HO;
M<'PUS#6[:YKA!F&O\_S7HJK/P<&ZU]EV/58]Q$N<P..@$;B\)*;*8D#DJO\`
MLSIO_<2G_MMO_D5&GIW3PT@8E;!N=(<QLGW'W?G>UWYB2F8RV.MLJK8ZQU,!
MY;$`N&]H]SF_FE!S.KX^"SU,FNUC=U;9#=YFUWI5>VISW>ZQ/@5U59&;74QM
M;18PPP`#6JKLW^JBEC'Y3VO:'#TV&"`=0ZS75)3P_4LW*JZOG5MOOH`O)]-M
MSV``LJ</93;Z?Z3=O75_5>VV[H>/9:]UCRZT%[W%[CMMM8W<]Y<YVUK5:=TG
MI3W%[L/'<X\N-3">(_=0.G78.%B^BZRK';ZV1Z=9+:Q`NL_FV>WVM]1OT4E-
MS%Q,;#H;CXM8JI:7%K&\`N<;'_YSWN<@X)G)Z@/#(:/_``#%4G=5Z6T@.S*`
M7':V;&"3&[:/=^ZA=,OJOOZ@^E[;&?:&@/80X']!C=VI*;Z2222G_]3TAV'G
MF^ZP9[Q78(JJ].N*S[-6NV>I9]%_\X[_``J'7T_JC18'=4LLWM+6$TT@L,AW
MJ-VUMW?N>]:``'"=)35Q/Z1F_P#'M_\`/..IY>+]I;6WU;:?2M9;-+MA=L._
MTK?WZ+/\-7_A%7KR:<?+RV6;PY]C7MACW`M].IDAS&.;]*MRG^UL3]V\_#'O
M/_HE)3<4&$[GSP"(U![#_-50]9Q`8]/*^6)DG_W70Z.H9>5=>,3'/I5[-MF4
MVW'W.(.]M==N/ZCV,AGZ5)3;HQ*J+LBYA>793Q98'.+F@M8RC]&QWMK;LJ;]
M!#.+5D,++6;!7>+6[7G5S'"UCW;?WG?2J3[^I_Z&C_MU_P#Z00FCK#'/VU8H
M#WEPASP8('T_T7Z2S^6DI%]DQ\OJ&73>TEM;\>]D.+8>P;JW2PM_.K1,/%HP
M<EF'C-+*6TDM:7%Q_G-SO?87/=[K/SG(%%N7C=3RK,VDQ=51Z;\=EEC26F]M
MK'%K/I,_1_\`;BD<X'J++Q1D^FVE["?0L'N+ZG,&K?SFM>DIO48.+CY&1DTU
MAEV6YKLA\D[BQHJK.IVMVUM_-6+<'U9[;*V!UU=>8ZG<=LO.3CN95ZC6V/V7
M>ILV;%J'JC0-,;)/D*G?Q65M]?K-.3;AY3*::\H"W:YI#KWX;V!OHV>M[FT7
M?F)*99EO4#ETNOHI%M672*`'N<W98RYCW^H['9LW>YGL]3_1_HU?Z4ZYV5U(
MW,;6\9#&EK'%PTQ\9V[>YM7[_P#HUE5=,ORF]/\`M.+D6/Q\Q]SK,FTD"H')
M;2_:Z][MVQ]&UGI[_H>I]!=!CXF/BM<W'K%8L=O?'+G0&;G'\YVQC&)*3)))
M)*?_U?54E\JI)*?JI)?*J22GZJ27RJDDI^D\G-^L[+K&XW2\:ZII(KL?F&LN
M`)V$UC$NV[F_R_\`TJI>O]93>&MP\1M`R(<]U[RXXT_SC:VT?TK9_@O4]+_A
M5\U))*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22G_]G_[1.J4&AO=&]S
M:&]P(#,N,``X0DE-!"4``````!``````````````````````.$))30/M````
M```0`2P````!``$!+`````$``3A"24T$)@``````#@`````````````_@```
M.$))300-```````$````'CA"24T$&0``````!````!XX0DE-`_,```````D`
M``````````$`.$))300*```````!```X0DE-)Q````````H``0`````````!
M.$))30/U``````!(`"]F9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&````
M```!`#(````!`%H````&```````!`#4````!`"T````&```````!.$))30/X
M``````!P``#_____________________________`^@`````____________
M_________________P/H`````/____________________________\#Z```
M``#_____________________________`^@``#A"24T$"```````$`````$`
M``)````"0``````X0DE-!!X```````0`````.$))300:``````-G````!@``
M```````````!Q````C8````9`$4`6``Q`#``7P`R`"``+0`@`%0`:`!I`'(`
M9``@`$$`;0!E`&X`9`!M`&4`;@!T`#<````!````````````````````````
M``$``````````````C8```'$``````````````````````$`````````````
M````````````$`````$```````!N=6QL`````@````9B;W5N9'-/8FIC````
M`0```````%)C=#$````$`````%1O<"!L;VYG``````````!,969T;&]N9P``
M````````0G1O;6QO;F<```'$`````%)G:'1L;VYG```"-@````9S;&EC97-6
M;$QS`````4]B:F,````!```````%<VQI8V4````2````!W-L:6-E241L;VYG
M``````````=G<F]U<$E$;&]N9P`````````&;W)I9VEN96YU;0````Q%4VQI
M8V5/<FEG:6X````-875T;T=E;F5R871E9`````!4>7!E96YU;0````I%4VQI
M8V54>7!E`````$EM9R`````&8F]U;F1S3V)J8P````$```````!28W0Q````
M!`````!4;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG
M```!Q`````!29VAT;&]N9P```C8````#=7)L5$585`````$```````!N=6QL
M5$585`````$```````!-<V=E5$585`````$```````9A;'1486=415A4````
M`0``````#F-E;&Q497AT27-(5$U,8F]O;`$````(8V5L;%1E>'1415A4````
M`0``````"6AO<GI!;&EG;F5N=6T````/15-L:6-E2&]R>D%L:6=N````!V1E
M9F%U;'0````)=F5R=$%L:6=N96YU;0````]%4VQI8V5697)T06QI9VX````'
M9&5F875L=`````MB9T-O;&]R5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y
M<&4`````3F]N90````ET;W!/=71S971L;VYG``````````IL969T3W5T<V5T
M;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S
M971L;VYG```````X0DE-!!0```````0````".$))300,``````WL`````0``
M`(````!F```!@```F0````W0`!@``?_8_^``$$I&248``0(!`$@`2```_^T`
M#$%D;V)E7T--``'_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*
M"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!F`(`#`2(``A$!`Q$!
M_]T`!``(_\0!/P```04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!
M`0$!`0`````````!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#
M!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#
M)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6
MIK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($
M05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$
MDU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U5)4.J=;Z?TDTC->YAR7>G2&L
M<\ETM:&_HP[Z3[&-52GZW]$R,QV!3:]^8RPU/H]-P+7-?]GL][PVIWHW_HK?
M3L_Z"2G:26$_ZY]#;D78PL>Z[&]<VMV[0&XKG,S+/4M].K;3L_?]_P#@T%OU
M]Z`_J)Z6PW?;0XM%+ZS23M&]Q+LO[.RK_KSJO_!*O42GHU"VVJFLVW/;76WZ
M3WD-:)TU<Y8G2?KGT;J^6W%PO5+W`&;&BN-S3<S]%:]F0_\`1-W[ZJ'U?S?O
M_2*[UU@=ATR)#<S#,'7_`+4T!)2<]5Z6#!S*`0),VLX_SE7S,_H^7BVXSNI5
MTBUI8;:<AM=C9_/JM8_<RQJN_9L>9])D^.T*?IU_NC[@DIYJCI70`QU/[<R;
MQ=;4X"SJ#GNFLO8RBMWJ>IZ=KK_TM7^$_1+1Z;]6NG]-R?M55F3=:`6M.1D6
MW``_2VMN>YJL]58W]GW0T3`/`[.:Y74E-)W6^C-<6NS\8.!+2TW,!#@=I;]+
MZ6Y1/7NA@@'J.+)X'K5ZZ;OW_P!U1P\NC%Z15?D.].IL,F"=7/\`1K:&M!=[
MWN8Q3S_Z;TW_`(]__GC(24M^W>BS`SL=Q\&V-=Q_5*M8^3CY5(OQK&W5.D-L
M80YI+26/&YO[CV['*0L:;#7^>T!Q$&()<&^[Z/YBI]%_H=G_`(;S/_;K(24W
MDZ222G__T/1^L>L,)[J,>O*L,5.JM:7--5KF5Y#7-8VQ[F>G^D>S;^D]-<U5
MU'J6/3OQ?J_5]HK;8ZJAE#V$O#7.=:W*-7HM]]%&/Z3_`-9R?YVO_`KLTDE/
M*=1R.LNS;*J.DX]S&OM+/5QWN&ZN+<']9;^B?]KLMOR/6:ST\+U/1N_6?4]1
M77?6JZJ7=/Q2[):#]GLI)VN(QW.JR+A?=4_8YU_Z794S]5KV>K_-+JTDE.5T
MNWKEF4[]J8U55;:*2RRN"?6<T?;:]WJ6.]-MO\W^C1^L"<1GEDXA^[)H*NJG
MU9P&&=0"+*3J8XMJ24W4DDDE-;J(G`O'\@_@%95;J+FMP,@N(`]-W)CL?%64
ME.'T_KO3Z#3T][SZA=8POTV->+;*FX[WS_2'O;[*MJNY3Q=F8!K:YP9<YSSL
M<-H-&0S<X[=K?<[8N8M=TW$ZWTY]M=;J\C(S69``:Z;/M+Z:;KVN_<MO_G/S
M%TMV!@F^FQKJJ:JR[UJ1746V@M+6LL<]AL9Z3_TOZ)S$E.BJ/1Q&-:WPRLK_
M`*5]S_\`OR;T.A?Z/%_S:TW1O2%.0VDM-;<FX-#(VB7;X;L]OYR2G0223$@<
MF)X24__1]522224UJ\PVM<ZNE[FM>^N?:)-;G5.^D_Z.YBF;KNU#_O9_Y-`Z
M7/I7CPR;_P`;'._[\KJ2D/JWQ_,'_.;_`'K,P\O`HMS6YCJZK/M3_:^"?<RI
M[>W[CFK957#@7YO_`!X_\\T)*1]&V_L]NP0PV7%FA:-IMLV%K7;?8YOT%=,P
M8U/8)TDE-#,;NSNG.<!(?8".8)J?W5]4\V/M?3Y$GUW`'P_09"N)*>2^N>)Z
MN?@6>F'5AEE=KX!VA[\?:[TY:^SW-_,3?5KICJLZSJ+6BZMM;L;TF5AC@YQI
MR)_2V_1VK9ZG3BW=1QF937.K--SH9OG<U^*6N_0>_P!NY/17CX88SI[754NN
M-F4'UWV.<"PL_0E_T'[VT?R/3]3]&DI;[/=3AYC;6WY/K&U[#;Z,L8\';C5[
M',_0U?X/>M'&C[/5&@V-@#X(5N34ZEXVV:M(_FK/#_BT3$_HM/\`Q;?R!)2S
MV576%HM<'UQO8QY!$ZMWM8=WN51_1,=SJWBVZ:G.=+['63O=ZNT^LY_M9_@J
M_P":K_T:KX&T?6;JK0*FDU8SG!@L]4R+6>ID.L8*/S/3I^SV?F?I5LI*?__2
M]$_8K-UKOMF9^F),>NZ&[B715^YMGV*6-TAF.'`967:'.K>?5O>_6MV]NTN]
MS66?0NK_`)NYG\XKZ22FETS3[6!VR;/QVN_[\KJI459N/9D;:ZWLMM-C"7EI
M@M8V'-])_NW-<C;\V-:JI_XUW_I!)2=5\8?ILOSM'_GJE2#LJ!-=<]_TA_\`
M22"W#O=9;:^Y]7JN!#*G`M`#6L_/KW;G;4E-Q)5?L3H(.3<9[[FS^#$C@@Q-
M]^G\N/R)*1Y5U+\K!:RQKG#(>"`03(HR=P_LJ\J6/TC#QG,=5O\`T=C[F@O<
M1ZEOJ>M:YL^Y]GKV_P">KJ2FBZVM_6:&,>USF8^0'@$$M._$T='T5>5'I,>G
MD@"(RK_Q>YRO)*6<):0/`JOT^VJW#J-;VOVL:UVTS#@ULM=_*5E4\'^E=0_\
M,-_]M\5)35PV&OZR=0.PD74T.]7:0!MWL;1OV[;?S[?I_GK665CX&97]9<O/
M)`PKL6FM@#CK:UUGJ%U<[?;7Z?Z3:M5)3__3]53$`B#J$Z22FL[J&.++*P+'
MNJ=M?LJL<`XAMFW>UFQWL>U/]M9_HKO^VW?W*&%_/YW_`!X_\\XZM&8TU/@D
MI!]K$P*;?\P_Q4Z+VW!\-<PUNVN:X09AK_/\UZ*JS\'!NM?9=CU6/<1+G,#C
MH!&XO"2FRF)`Y*K_`+,Z;_W$I_[;;_Y%1IZ=T\-(&)6P;G2',;)]Q]WYWM=^
M8DIF,MCK;*JV.L=3`>6Q`+AO:/<YOYI0<SJ^/@L]3)KM8W=6V0W>9M=Z57MJ
M<]WNL3X%=561FUU,;6T6,,,``UJJ[-_JHI8Q^4]KVAP]-A@@'4.LUU24\/U+
M-RJNKYU;;[Z`+R?3;<]@`+*G#V4V^G^DW;UU?U7MMNZ'CV6O=8\NM!>]Q>X[
M;;6-W/>7.=M:U6G=)Z4]Q>[#QW./+C4PGB/W4#IUV#A8OHNLJQV^MD>G62VL
M0+K/YMGM]K?4;]%)3<Q<3&PZ&X^+6*J6EQ:QO`+G&Q_^<][G(."9R>H#PR&C
M_P``Q5)W5>EM(#LR@%QVMFQ@DQNVCW?NH73+ZK[^H/I>VQGVAH#V$.!_08W=
MJ2F^DDDDI__4](=AYYONL&>\5V"*JO3KBL^S5KMGJ6?1?_.._P`*AU]/ZHT6
M!W5++-[2UA--(+#(=ZC=M;=W[GO6@`!PG24U<3^D9O\`Q[?_`#SCJ>7B_:6U
MM]6VGTK66S2[87;#O]*W]^BS_#5_X15Z\FG'R\MEF\.?8U[88]P+?3J9(<QC
MF_2K<I_M;$_=O/PQ[S_Z)24W%!A.Y\\`B-0>P_S54/6<0&/3ROEB9)_]UT.C
MJ&7E77C$QSZ5>S;9E-MQ]SB#O;77;C^H]C(9^E24VZ,2JB[(N87EV4\66!SB
MYH+6,H_1L=[:V[*F_00SBU9#"RUFP5WBUNUYU<QPM8]VW]YWTJD^_J?^AH_[
M=?\`^D$)HZPQS]M6*`]Y<(<\&"!]/]%^DL_EI*1?9,?+ZAETWM);6_'O9#BV
M'L&ZMTL+?SJT3#Q:,')9AXS2REM)+6EQ<?YS<[WV%SW>ZS\YR!1;EXW4\JS-
MI,754>F_'998TEIO;:QQ:SZ3/T?_`&XI'.!ZBR\49/IMI>PGT+![B^IS!JW\
MYK7I*;U&#BX^1D9--89=EN:[(?).XL:*JSJ=K=M;?S5BW!]6>VRM@==77F.I
MW';+SDX[F5>HUMC]EWJ;-FQ:AZHT#3&R3Y"IW\5E;?7ZS3DVX>4RFFO*`MVN
M:0Z]^&]@;Z-GK>YM%WYB2F69;U`Y=+KZ*1;5ETB@![G-V6,N8]_J.QV;-WN9
M[/4_T?Z-7^E.N=E=2-S&UO&0QI:QQ<-,?&=NWN;5^_\`Z-9573+\IO3_`+3B
MY%C\?,?<ZS)M)`J!R6TOVNO>[=L?1M9Z>_Z'J?0708^)CXK7-QZQ6+';WQRY
MT!FYQ_.=L8QB2DR2222G_]7U5)?*J22GZJ27RJDDI^JDE\JI)*?I/)S?K.RZ
MQN-TO&NJ:2*['YAK+@"=A-8Q+MNYO\O_`-*J7K_64WAK</$;0,B'/=>\N.-/
M\XVMM']*V?X+U/2_X5?-222GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDD
MI__9.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`
M;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@
M`#<`+@`P`````0`X0DE-!`8```````<`"`````$!`/_A$DAH='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTG[[N_)R!I9#TG
M5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^"CP_861O8F4M>&%P+69I;'1E
M<G,@97-C/2)#4B(_/@H\>#IX87!M971A('AM;&YS.G@])V%D;V)E.FYS.FUE
M=&$O)R!X.GAA<'1K/2=835`@=&]O;&MI="`R+C@N,BTS,RP@9G)A;65W;W)K
M(#$N-2<^"CQR9&8Z4D1&('AM;&YS.G)D9CTG:'1T<#HO+W=W=RYW,RYO<F<O
M,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R<@>&UL;G,Z:5@])VAT='`Z+R]N
M<RYA9&]B92YC;VTO:5@O,2XP+R<^"@H@/')D9CI$97-C<FEP=&EO;B!A8F]U
M=#TG=75I9#HS-&8Y-F0V-RTT,#4T+3$Q93,M.#$T9BUA-#DU,C9E-64W9#DG
M"B`@>&UL;G,Z>&%P34T])VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M
M;2\G/@H@(#QX87!-33I$;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO
M<#HS-&8Y-F0V-2TT,#4T+3$Q93,M.#$T9BUA-#DU,C9E-64W9#D\+WAA<$U-
M.D1O8W5M96YT240^"B`\+W)D9CI$97-C<FEP=&EO;CX*"CPO<F1F.E)$1CX*
M/"]X.GAA<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H\/WAP86-K970@96YD/2=W)S\^_^(,6$E#0U]04D]&
M24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`,0``86-S
M<$U31E0`````245#('-21T(```````````````$``/;6``$`````TRU(4"`@
M````````````````````````````````````````````````````````````
M```18W!R=````5`````S9&5S8P```80```!L=W1P=````?`````48FMP=```
M`@0````4<EA96@```A@````49UA96@```BP````48EA96@```D`````49&UN
M9````E0```!P9&UD9````L0```"(=G5E9````TP```"&=FEE=P```]0````D
M;'5M:0```_@````4;65A<P``!`P````D=&5C:```!#`````,<E120P``!#P`
M``@,9U120P``!#P```@,8E120P``!#P```@,=&5X=`````!#;W!Y<FEG:'0@
M*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`````````
M$G-21T(@245#-C$Y-C8M,BXQ```````````````2<U)'0B!)14,V,3DV-BTR
M+C$`````````````````````````````````````````````````````````
M`````````%A96B````````#S40`!`````1;,6%E:(```````````````````
M``!865H@````````;Z(``#CU```#D%A96B````````!BF0``MX4``!C:6%E:
M(````````"2@```/A```ML]D97-C`````````!9)14,@:'1T<#HO+W=W=RYI
M96,N8V@``````````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`````````
M````````````````````````````````````````````````````9&5S8P``
M```````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="```````````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="`````````````````````````````&1E<V,`
M````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV
M-BTR+C$``````````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ``````````````````````````````````!V:65W
M```````3I/X`%%\N`!#/%``#[<P`!!,+``-<G@````%865H@``````!,"58`
M4````%<?YVUE87,``````````0````````````````````````*/`````G-I
M9R``````0U)4(&-U<G8````````$``````4`"@`/`!0`&0`>`",`*``M`#(`
M-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5`)H`GP"D
M`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!#0$3`1D!
M'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A`:D!L0&Y
M`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"9P)Q`GH"
MA`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/`UH#9@-R
M`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$<01^!(P$
MF@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E
M!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'/0=/!V$'
M=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$`DE
M"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*W`KS"PL+
M(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS#0T-)@U`
M#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/
MLP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%
M$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5
M-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA`
M&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;
MLAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^'ND?$Q\^
M'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC
M."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=)
M)WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K-BMI*YTK
MT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L
M,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TU
MAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR
M.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_HC_B0"-`
M9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D5519I%WD8B
M1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,
M<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F4C%2?%+'
M4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9
MN%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8`5@5V"J
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M,XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6D3^1J)(1
MDGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;
MKYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4X
MI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:O
MB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"
MNCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#6,/4Q%'$
MSL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^X
MT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;
M@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?
MYZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q__*,\QGS
MI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?__
M_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!
M`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#_\``$0@!Q`(V`P$1``(1`0,1`?_=``0`1__$`:(`
M```&`@,!``````````````<(!@4$"0,*`@$`"P$```8#`0$!````````````
M!@4$`P<""`$)``H+$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$4
M03(C%0E10A9A)#,74G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W
M1V,H5597&K+"TN+R9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY
M>H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7F
MY^CIZO3U]O?X^?H1``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R
M811Q"$*!(Y$54J%B%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS
M@Y-&=,+2XO)59756-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6
MIK;&UN;V9W>'EZ>WQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI:
M:GJ*FJJZRMKJ^O_:``P#`0`"$0,1`#\`W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7"0Z5)M<W`4<"[$@+]>/
MK[]U[JCS^<__`#7]W_RJ=O=([_H>HL=V'L/LG/;FVSNW<%;7UE"FULA0X&IK
M\"I^WB92N1R$:(-3+>_%_?NO=4!]5_\`"M[N[LZ39U;C_BULB;;,&=V;M7M7
M*R9_,4_\`R>]-U18G'55!$('^X1,?*K$6-WXX]^Z]T_TO_"M'L7)Y;.;%AZ`
MVC2=A83M[L;;]#Y\GDQA\YU]MFFR?\(KZ5Y*2%OO?OZ-%FTL=)X/)M[]U[JR
M[^2[_.%^2G\R/L&:F['V/LW:^RWV9E=P-!@-I;QI*@5%+*8XH%W5EJ>';U:2
MX`<12,;>_=>Z*#GOYW?SMW9\[>Q_C7L;*?'[K'`XSN^;I79N([*PV5D5'DHI
M1B]Q+O2AB;$9*JFJ"K-0B1G8>GB_OW7NB_\`:O\`.Y_FL=/]4=U=A[DW1T!4
MT/4WRCQ'QDS%?MOK;(U]7'EZT_<56Z:+$N^K)1_:@^.G.DRGA;GW[KW17J;_
M`(42_P`T'?VX]E=?]?YO:N8S-;V3NG:2U^V>I(Z7<FZH\;C&K:/R;.SD]/%A
MY%DY='DL5Y-A[]U[I?9'^;Q_.'W+\O*+X[0[DW`E3C=B;$W3NG&;;V!L/#YW
M"2;E9XJK^/4>6RRXJ&&`6;]B1V;_`%_?NO=6N?#?M7^8AN3^<%O'XG]S_+3/
MYSK'K#IO9G>4N$&T,#B9-T#>-`9I-HUJ8]I(HQBIV!:5)"&"^_=>ZVL(5((%
MBH&MG'J_6[74%CPP"G\?0^_=>ZE>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO7M]??NO=8!54K5#4BU$!JUB6=J831FH6!F*+,80WD$3,+!K6)]^
MZ]UG]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]#?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]UZ]_I_K>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKBPNIXN?Q?\`K_7_`&'OW7NB1_/3X#]&?S$NCVZ#[\H\E4[27<^"W;1U6(F%
M+E*/+8"IBJJ9H*HJ=$-08]$R_P!M"1[]U[JO2A_X3L_R_,)B>QL1@L%O/#4G
M9.Z^NMXY;^&YI(6Q^2ZVJ:*KP\.,`C`@IJFIHEDG46U&_OW7NF3*?\)OOY=V
M7P6R\1-A=]1UNR]X[YWA1[BIMPRT^>R+]C25$V<Q>3KHXUEJ,<KU#&.,FRG^
MGOW7NC:_"C^53TS\$ZK!GJ'L;N>MVOMO$9;$8?K[=6ZWR6TJ6#+%EJ"N)":9
M&.HE=3FQL??NO=`_7_R(?A'D_DPGR6J*?L,9"G[/I.Y8^MSNFHEZ[7LFCM,N
MXX\0\;2Q3-+9FC63QW'`]^Z]T83(?RIOAME]N;_VKD>NVJ<-V1WK@OD7NBCJ
M*B2>"K[,V[-'/CLC$9`66D206,7`9;@\>_=>Z#;>'\D3^77O/=F1WK7=+_PO
M<^2W57[SGR^W\SE,-5IF,I0_8U$\$E#-$U,#$+!8R/\`'W[KW4=OY&O\M^?-
M0[HKNDJRNW4F.QV$K=RU&\-S/FLQC\5()Z&/*5Z9!*FI2"3D7;BWOW7NK`-D
M_&?H_8/8?^EC:?7>&Q'8IV/B>MY=X+"SYRHV=@%5,5B*BLD>2:>&G5``SDNP
M^I]^Z]T/GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNF^G^
MQ%Q:]Q_3GW[KW32N(QRYALV*2,95Z-<>]6-0<T:.9DA']DJ':_\`A[]U[IW]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__T=_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]UQ:]C;ZCGZ7^G^']??NO=1EJ(/.M/K)F96E"Z3IL?J-5K7%O?NO=2
M_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]UXFW)X`Y)/X]^Z]UX&_(Y!Y!'Y]^Z]UX$'
MD&_^M_AP?]Y]^Z]UZ]OK_K>_=>ZZN.1<7%K_`.%_I?\`U_?NO==^_=>Z]?\`
MWGZ>_=>Z]>WU_P!;W[KW75QSR./KS]/]?W[KW7?OW7NO>_=>Z][]U[KWOW7N
MO>_=>ZZN/ZC^OU'T^E_]O[]U[KN__%??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]+?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]UQT+JU:5U?ZJPO_M_K[]U[KE[]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KQ(`N38#ZD\#W[KW3+D=R;=P\@ARV?PN+F8*5BR.
M5H:*0AC92$J9XF(8_3CGW[KW7J?<FWJPZ:3/86J;ZVI\I0SG_;13L??NO=3&
MR>-61(FR%"LLAM'&U7`))#_1$,FIC_K>_=>Z:J/>&T<A]T*#=.W*XT-2U'7"
MCS>,J?LZM!=Z6J\-4_V]2H'*/9A_3W[KW4N+<.WYC*(<YAY3!_GQ%DZ*0P\7
M_="SGQ\?UM[]U[I/5O:'6F-JC0Y'L38M!6JJLU'6[MP%+5!7-D8T\^0CE"L?
MH;<^_=>Z@5/<?45&0M7VIUO2LPNJU.^-L0$B]K@2Y121?W[KW47_`$Y=)^2.
M'_3#U;Y93:*+_2#M+R2'^D:?Q?4Y_P!8'W[KW7=1WATK22"&J[?ZNII25415
M&_\`:<,A9S9`$DRRM=R;#CGW[KW6*7OCHZ"403=R]4PSDZ1#+V)M".4M:]A&
M^8#DVY^GOW7NH+?(OX^*S(W>W3:LK^)E;L[9(*R7MXV!S?I>_P"#S[]U[J2.
M_P#HAA$5[KZD83N8X"O9&SB)I!]4B(S)\CC^@N??NO=<7^070L:ZY.[NHD3R
M-%K?LG9JKY4%VCU'-`:U'U'U'OW7NF',?*7XT82AJ:[*?(+I:DIJ9-4S2=G;
M,9@";`"*/-F5BQXX'OW7NA7VINK;>]L%C-T;0SN*W)MK+TJU6*S.%K:?(XVO
M@8V\M-64TDL,Z`\75B+^_=>Z4GOW7NN+`D<&QN/]M?D?['W[KW7+_7]^Z]UQ
M87'^Q%K_`$O^#_C;W[KW12?D]\X/BW\,J79E;\E^X=L]4T6^LC4XS;59N226
M%:^KHXS+4@+3Q3.D,<?%]%KFU_?NO=%7B_GA?RHY*&'(K\W.FA!,]5#%#)F*
MQ)FDI=;L[1&@U@2*OH-K-?W[KW2BQ'\YK^5QG:^#%8[YL=)2UE1`E5%%+N*:
M%'67GQ>6>B2-94ORI-Q[]U[J9_P\1_+&7/Y';A^:72*9/%QPM4P'<J>",S$!
M1%4B`Q3N2>0"=(]^Z]T\Y'^;=_+4Q/V7WOS/Z+IUR$?FI].[89Q-$;`2?LQ2
M%4+<7(^OOW7ND1N?^==_*PVG1PUV6^:W3,D-2["!<=G)ZZ0Q@E?)XX*-F$:D
M6+?0'W[KW2-7^?1_*892X^9?6BHJJS3.V5\,:N=*/(ZXY@JLWT/T/OW7NG&7
M^>W_`"EXJAZ4_-GJ*:5*=9[PUF4D$EQ<1IHQ9U2V^J_CW[KW7.I_GJ?RFX:&
MFKF^:W4\T587$<=/59>6=&B4ET>-,7J1Q8W'U]^Z]USR/\]#^4_CL?C<E/\`
M-+JB2GR<3S4OV]7E)93%'P[RI_#5\:J38D_GW[KW4)_YZO\`*ITM_P`Y>;#0
MB`55S#FE_8-BLU_X<O[+7X:^G_'W[KW2"W'_`,*#_P"5YA,N<)CN[,QO;()0
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MOOO?O<6:V#TUL#8>6V7MW`]@;DVUA<1ELQEX:2LBAI**KAA9(HF)32+7'OW7
MNK<J?^0?\*Z.1&H]R_(:B<$%C2]W;X@9@!PNN+)J5`_P/OW7NL&;_D*?$;*5
MD%?_`*2?E/1R4D<@B%)W[OO0NJ/3J`;*:M8'(M^??NO=!S2_\)QOA%C1ECBN
MQ/E5C?XSDXLOD_M>^]\*:RK6S/+);)@L9[$2'ZD&W^/OW7NE3B?^$^GPTPU1
MFZBF[!^4;KF7IFD@E[[WT8(/"HXIE_BC-IE(L^N_!]^Z]T[TO_"?+^7LLM+/
MFL#VMN:O@DFDDRF>[6WA75M2)U,:02S')ARE,S!E_`(]^Z]TH(_Y`W\MIH*>
M"OZKW3EOMZ:H@$U=V%N^9F\Y(!(;*7U1WNO^M?W[KW7.C_D`_P`L6CB@0]'Y
M*IFIF9X*N;?&[#)%J_-VRC>I1]/\??NO=3)?Y!_\L6H9)ZSH6HR$L#QS)-5[
MRW3-([0N'0,IR(/H(X]^Z]U+F_D*_P`KRIG:IF^.5)-.]7%5+.^Z-SF2,QHH
MTJ3D^$<<$>_=>ZSP_P`A;^5='25%)_LK6W9DJYY9Y99LYN-IQ*VJTJ2_Q(,K
MJ3<'\'GW[KW2?V'_`"`?Y7^QI*Z:+X^C/2562EKZ8;CW;N7)IB78EC'C=>0C
M$$7-K6^GOW7NEO7_`,C'^5_DZ?[2J^+NV_`:P5Y$><W&A-46#,Y(RGT:W/\`
M4>_=>Z*[\[_Y+O\`+@VK\-/DKNK:'QJVM@-V;0Z3W_G=M9['U69.1QN5Q&W:
MZMHJF)WR!#.DT0-S[]U[HPW\@N66;^4S\.)*BIJ*N=NO)`\]2S/*0N3KE"AR
MTC.L:HHN3[]U[JXWW[KW7O?NO=>]^Z]UT?I^+D@"_P!+_P"P]^Z]UJU_SDME
M[?WO_-A_DUX#>>V\1O/9F>[1WCCLGM?/P097#9%3A*YI%K<15"6"IB5E!Y4\
MCW[KW5\:?!SX<"30OQ7^/Y5E8._^B?9^@21,H1`K8HV`C_IQ<>_=>ZC5WP(^
M%&3B>&L^*G0TBL""8^L-J4_(']EX<9&RG_$>_=>Z#P?ROOY?B;DQNZE^(71W
M\:PYF%/4C8V%T`5$1C<U%.U"8*STD_J#6/OW7NG@?RV?@5'/35!^)714\E$:
MLQ23=?X)S#]^2:@(K4+*8QJ.A0+)^+'W[KW3YC_Y?/P?QL%-3TWQ0Z$,=%3R
MTD+R=7[4E;P3MY)4O)C"QNQ_Q]^Z]T_I\(?AS2JRP?%SH9%:-(Y47JK9Q5X%
M8:8[/BQ&0".0;_ZWOW7NJ$?Y<_Q5^,63_FJ_S3-K570G4N0V[L_);!7;V"R&
MP]NUV,P$^4@6IJ3B:*JH)8<<DVDAO&J@W]^Z]U?N?A7\04CC4?&+HC1!(TT:
MKU;L\VG?_.,H&)OJ8?DW^OOW7NL?^R2_#\^$'XN]#GQ0R4R`]7;/$<<$K>21
M$4XHA59O\+W]^Z]T[R?#_P"*4@97^.'23!J5*-@>M-I<T<?Z*<6Q/^:6WT]^
MZ]T][?\`C5\>MK5SY/;G1G4^"R3$2"KQ>P-LTD^E(Q%&/-!C8RI"\6'XX]^Z
M]TO).N>OIE>&;8FS'60!IE;:V&,<@)L0;T9#&PYO^/?NO=(Z/K#9%71;EI,U
MU;UPE#+]Y2T<,.UL$\>3Q[TCH8JQ30,@#*+&XL/?NO=42?\`">+%8C!C^9)A
M\'BJ3"8S&_-;<]/2XJAB@@HZ",4=5:FI8J>.**.)`.`%''OW7NMD3W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M_]3?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=<7%QQR001_K@W'OW7NM:3X!U5/2?S_\`^:?C(WIH
M5K.DNHZU*>,*'GJ!GHC/,I'ZU"WN??NO=;+OOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HK?S@B6?X;?*>)D5U?
MX_\`;0*M;2?]^/FB+WXX(O[]U[JOS_A/9E5R_P#*1^)$PC,1H]I93':3_P!,
MN;K59A].#<>_=>ZNG]^Z]U[W[KW7O?NO=<)20C$`DBU@OU)N+6]^Z]UK6_S8
M\-5TW\VK^2CNFAG$TLW=V\,*N/F9$IXQ_=C)3R3V)N':,&W]2/?NO=;*:FX_
M%[DD`W_)]^Z]UR]^Z]U[W[KW7O?NO=>]^Z]UQ8V%[:A<7'^%^3_C;W[KW5`G
MP$I8\-_.*_FIXJ-YZI\AB.J,_/5FG,,"&HB6&.FUZ0LDBK<_6_%_?NO=7^^_
M=>Z]<?6_'^^/OW7NO7OR.1[]U[KWOW7NN#BZVL""0&O_`*G\GC\CW[KW21JL
M/D?XY5YO^-U2XU<%/02;>$*FC-3^Y(M>LI]7F*&Q`]^Z]UK]_P#"??\`XNO\
MSC_Q>'='_N#4^_=>ZV-??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_U=_CW[KW7O?NO==!@?H0?J."#].#_MC[
M]U[KQ(%KD"YL+_D_T'^/OW7NO7%B;BPN2;\"WUN?IQ[]U[KL&_(Y!Y!'Y]^Z
M]UUJ7_5#\'ZC\\#_`&Y]^Z]UZXM>XM_6XM[]U[KOW[KW75Q>UQ>U[7YM]+V^
MMK^_=>Z\&4VL0;WM8@WM];?UM[]U[KOW[KW7191<D@`?4D@6O]+W^E_?NO=>
MN/I<7^EO]A?_`'KW[KW7K@7N1QR?\/\`7_I[]U[KP((N""/Z@W']?Q_A[]U[
MKOW[KW7K_P"^_P!X_P![/OW7NNKB^FXU6OIN+VO:]OK:_OW7NN_?NO=>O;D\
M#W[KW7O?NO=>]^Z]U[W[KW7%U##F_I(8`&URIN!_MQ[]U[K6U^+TV&V[_P`*
M-?GAA)1'39;='Q5ZJRM'%'&%%0L67:>=]5A<B-#_`+$>_=>ZV3/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW16_
MG`2/AO\`*<J"Q_V7_MJR@$DD['S0L`+DGW[KW5;/_"<BIIZK^45\6VIY&D$6
M,W-!*6-S'/'GZH2Q-_1E/X^OOW7NKRO?NO=>]^Z]U[W[KW7O?NO=:S'\Z/,R
M[>_F._R6<O"&+TWR,SZ#2+FU1MK(0$?[9_?NO=;,$1!=QI(*>BY_M6"MJ']1
M=_?NO=9_?NO==$@?4@7-A?BY/T'^N??NO==W_'Y'OW7NO>_=>ZXM^D_[#_>Q
M[]U[JBWX0$#^<!_-$4D`G;/2[!2>2OV\PU`?4B_%_?NO=7IG\?7ZCZ?\3_A[
M]U[I,;@R>9Q\F&7%[?DSJ5>2BI<A+%4Q4QQ5([:9,@4F'[RP#DJ.6M8>_=>Z
M4$9)DYU`JA72RV#`,/W00-(+'\>_=>ZD7_WCZ_X>_=>Z][]U[J/5_P#`2J_Z
MAYO^M;>_=>ZUT/\`A/PK)F_YG:."KK\X-T:D8%66]!.1J4V(N/?NO=;&_OW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[K_];?X]^Z]UBF!,3JK!68:5+&PUD@+].;ZO?NO=:XW:W\^#?V.^9'?_P]
M^.?P-[E^16Z_CI500;XS&T\CAJ:F6.:G@GCJXJ6JJHY#2U33LJ.0+E?Z^_=>
MZY8C_A2-\2X_C1V5W!OO8_8.Q.Z>L]^IU/D?C#E8Z=^Q\MV36,(\9AL-#&YA
MFAJ:EU1I-7I4GZ^_=>Z"9OY[_P`K>BLELOL#YS_RZ=\]%?&CLW-8''X3M3#9
MR',Y'9M'N*:*#'3;\QP?QT$25,\?EY!TW]^Z]T(W>'\_./KW=GSOVSL7J'%[
MRH_B1TKM7N#:FY(]Q(,9V+BMV&B>@J&2)BU-%%#5J#IX#?7CW[KW3SA/Y].T
M>S_Y2>\?YB_4>Q\/G=^;`AIJ#?\`U!6YEEEVKN$5U-2U*RD$SO0BGG\L3D`.
M?Z^_=>Z*7\K?YW/\SSXW?&_#?,[)?"/IF#XP[II.OIMN[F?LBMJ-Q5\F_J6D
M_AZ38%8M4*+6U!1B6&@`_4BWOW7NKF/Y<?R&_F!?(?!5&\OEW\?.KNE-A[BV
M?M[=76&:V%OBIW57;CI=PTL&0@_BE'4PPMBWBH9PQ!XY]^Z]U6S\B/YE7\RO
M='\T#M3X`_"WKSI2L3KCK_"[X.7[.J*RFDJJ;(1N9_W8HG(MXRZBUB!_3W[K
MW1?=S_SR_FQTGM[^8!\?_DAU9UYM[YA_&3H^?N;KG+[`?^\NP<OB5>%#!FXH
M6UTM6GK8QN%>P^GOW7NN6;_G&_-SY4;>^#'Q0^%Z]<TWR_\`DQTI1=M]N=EY
M6@G;9'6F#FDK-5504,:S,DS0T;`"0`,P.F]O?NO="/UE\I?YP?P;[WK/C-\Y
M,7C_`)/]?]C]<;JSW67R?ZJVI5K0;/W?0XBNKX*/=](\$*T^-HZF-8BTEO3R
M+DCW[KW4C^5__.=H>S_@!W'O/Y;?)CJW;WR<V]NONO%;:Q>XLC18#,QI@FK5
MVHBX>5XW\"R1Q"+4`7OS?W[KW6N;VQ_/,_F3[=^*/Q%[TA[_`-R55?E?D=V7
MB-^?PRCHY(-X[;V?N..2CQ$D*)=\?_"6T*1P5]^Z]U:/_/Q_G?\`:.S_`(M?
M`_)?#3M[*;&WI\A\'ANU=SYC;8A7(Q86F@BIZ[%2RHTJTT:Y\M&\9L&B7^A'
MOW7NE/LWY-?-_P#G)?)K9GPMZ,^1F\_CAU#T'\>.NMW_`"0[5P*FEWSO;L7/
M[=Q.0EQ\<<(98DDKJSZZT]/)]^Z]TQ]\]P?/'^3+W+FOB]W#\FM[?)/XV?)[
MJ#LBEZ>[)W.[MV+UMV'#@ZFIIFEKR=31PU:<%7++'R/?NO=%]_D??SC>Q]T_
M&KY'?$+Y:;_W;!O_`'1U5V_OGX\=J[JR-4U7N67'X6O;(X'%9Z>;[I<CCYM#
M4JAB0]K6]^Z]T5+:G8_?OR4^._\`)WV7V)\D.\L)BNW^\-_]:;[W1MGL#-X7
M<^4HZ?(1QT,5;DJ>L66L^TBD`URLU@/?NO=6U_*OJ7N;^0E\COBC\C.JOE#W
M?W5\;>X>U,'TSV_U7W'OG*;M^T3<S^*/.8DY&>=(I*4N'6Q4W'OW7NMS7#Y6
MCS%!C,I12EZ7+XVBR='J'ZZ6LIHZF%[_`(+13C_7`]^Z]T\>_=>Z][]U[KHW
MMP+G^E[?G_B/?NO=:TO2%15)_P`*8OEE3TU'255))\,NM&KJV5D^[H&7)5;0
MI3!CKTRN=+6_!]^Z]ULM^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NB]_+2B.2^+OR(QZJ'-;TMV53:6;2")MH9
M:,W/XL&O[]U[JJ?_`(3?41Q_\J/I''E-'\/W/V/2HH8,I6+<DRW!!((O?_6/
MOW7NKW/?NO=>]^Z]U[W[KW7B`18\@^_=>ZUFOYXT2I\X?Y,%>L9\O^S49NE!
M(LH4;8JV'/\`CJ-O?NO=;,27-B5`]/U_/U^G^L1S[]U[KG[]U[H.NVNR=N=0
M=9;Z[2W:]4NV-@;8RN[,\^/B6HK$Q6'I)*RK>FA9E$DHAB)`OS[]U[I/=`]U
M;,^1O4'7'>77CUDFR.S-KT6Z-MOD:84U>V-K_)X/NHP[^*:/PL&6_!(]^Z]T
M,WOW7NO'_?7]^Z]U0=\*%2F_G7?S0:)_*)SUMTC6H'8Z3!,\X5UC)O8EA8_3
MW[KW5^/OW7NNC?\`%OKS?^GY_P!C[]U[HK_S'^5G7GPL^/N^OD3VG#EJC9>Q
M(*&;*0X2)9LC*<A70T-.E/&S*"3-,+_X>_=>Z'39&ZJ'?&TMJ;TQ<4T.-WCM
MG![JQL52I2I3%Y[%TF4H%J%'I2H6"K76OU!]^Z]TK??NO=89U9HG5259E*JX
M`;QD@@.5/#!#R1^??NO=:XG\@ALC%VS_`#=:#)RS3STGSKR@69X32HT<F$JF
M712N$>+TV/*BX]^Z]UL@^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZQ
MR^3QN8@IE"L8@Y(0R`'1J(YTW^OOW7NL%&:IH8VK$BCJ66\JQ,S(+$Z=)/\`
M@>??NO=2_?NO=>]^Z]U[W[KW7__7W^/?NO=<6!MQ^"#P`20#?2+\7-O?NO=:
M+E%TO\V>U?Y]/\R?!_`SOK:7QSW-!UUL:O[%S&[<-4YA=P457)30T=-104\,
MVF>EG))D/%_SQ[]U[HI7SN_E:[^_EE9CXC_*?Y#;_E^1%?O?YK83LOY0[XQ.
MWY:7;6UW$E)!0U<T<D0:/%,:J[2R!461;'W[KW6R?_/5^4/QARO\J3O*CA["
MZ\WQ6]M[0PV`ZHP&(W#@-P9;)[HW'44@VW+B\115=16))3RR*0R(2A'OW7NM
M+#;VQ^T.FZ;Y^]==CQ5,&[Y/Y='7&4W#29":2:K_`(:8Z"HI3*\UG44L7C&A
MK6*V]^Z]UW\Q.CNV/@;\.>KN_.KJ&NR/Q7_F"_&?:V%[4P>'EE_@V"[9QBQK
M0Y>NIE7[*A6K2&.3R(1K<6Y]^Z]U?U_,S2LWW_PEOZ!R)?S34.`Z$R-3(M]$
M46)S]'!)+*5N#'&$`U'CU#GW[KW6V-\.I8YOB9\:9`R>-^B>J/R"+'9F)!)^
MME>UK_3W[KW6GE\M?A/6?./_`(4@=N=4P]V]G="1P?&W9^X)]S]69FMP&X*U
M:9:S_(Y:NCF@>6"5%M;5:Q]^Z]T2#-=$R_R_/E;_`#7?A1G\UNCN>3L_X/9[
M>VV.U.P(ZO.]@SQ45)+7?;-EZIJBJFH'^S*O9F7G^OOW7NG?X+;BR'\M[N/^
M5U_,.[6VYNB3XO=O?$23IS?N[]O8;(9J#8^;QN7W!!15^?@@IWEHZ19*Q0-1
M6_\`K>_=>ZO+[%_G*]D_,OYB]7_'C^6OMVD[3^/\^S=SY3Y*]L[CV)D(L-A,
M5_",@XQ6W\[54SQ')2(@&B/EI/2??NO=%:_DG_RS?B;WM\'_`)(=E]^?&[";
ML[4JN[?D1CJ;-[IP=?'GY,=1Y3)G#S)1U@@8*K(OB**;@<>_=>ZH)PGQ*[1W
M]T9\/^FZ/JG?.'P;?-OO_8:R2[$W"M)@L5N"JK*;%96MI9\==,;3P*HCE>R$
M#@^_=>Z+]A/@#\O,SM;YOQ]G=7]@Y7"?!S9.2ZWZMI:_:N<J1+)DMVQI31[0
MI31229<5%*?NM5*)`@])M[]U[J]OXGY+NC^3-\H-E_-#L3I7M[L_XL_,+XT=
M>8_?>0Z\VKDL[NO9?8N)PN.IH#EMNPTIK88()J)48.H<*>.??NO="E\JLWVI
M_/G^6>R-T]&]$]Q;'^*_Q7ZK[.W%-O3LW:=?LVM[![#R.VJZ/&8#`8O*11US
M?<U<JPW9;'W[KW0![!_DS=X]W_R&]BR;=ZLW-UM\Y?C]V7V/NS8E#6XS^![W
MS>UZJN,&5VPTVJ.>N@RE"[&G5V"M;@'W[KW0`;!^%?\`,*ZA^'G\KG=U1\1N
MY-W;X^/WR?[!WOO7KW!8FE3=='MQJBEEIVJX:VL%+!%D#`Q5C8$-P3[]U[JX
M?Y#=>?/?^=I\E?B_L;LCXB;W^'OQ$Z`[$Q_;&]LQVCD<?/NC>.8V_)&U!CJ'
M'8R2H@>.>10H#,+*2??NO=;>>-HZ>AIJ2BI(13TM!1TU%3PA=*)!301PPQQJ
M!95AC0*!_2_OW7NG/W[KW7O?NO=<6M;G^HM]?J>!]/\`'W[KW6NEL?[3%?\`
M"D#M)<=1TRS[F^&.$?-50_X$,<3E)!2AN+\EP!_@/?NO=;%_OW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H&?D9!
M]S\?^[:<BXFZIW_&0!<D-M?*`@#^MC[]U[JI+_A.?615/\KWK)(Q84?8W;E#
MI(`(,&\*O\?T(/OW7NKT_?NO=>]^Z]U[W[KW71%Q;Z?3_>#?W[KW6M=_/'IZ
MI_F/_)HJQH%%3_+;*B<E@"LDNU:I8C<_@\?['W[KW6R@I!`L0>![]U[KSC4I
M_J.1>]KCD7MS;W[KW52_\V#XT?-GY-=5;9V?\.NUMI;%%94YO`]L;3WM#.,)
MO;96Y<5-B942JIH9)(JO$-4>>-#969>??NO='$^%W0%7\6?B[T1\>J_-+N*N
MZEZYPFT*S,01O%25U9C4F^\JX`ZJVB>HJFTZ@"54'W[KW1IO?NO=<'OI.D78
M6(%[`D'Z$_T]^Z]U0O\`$-_#_/._F7T8T,LO1'0E;K=E%0&>KD1T1#ZS3(2+
M$>F_'OW7NKZ_?NO==&_%OZB_^M[]U[HA'\R_XA9SYU?#KM#XS;<W-0;.RW8`
MPT4&X<G!+44F/BQV6ILA.[10H\C.\4&E;#ZGW[KW1NNL=JS;#Z\Z_P!BS5/W
M[[,V3M7:4E:B>..LDVU@*##R5ZJUG1:N2D)"GD`^_=>Z7WOW7NNC_KVY_P!\
M/]C[]U[K7-_DAUT\ORV_G0TGD#TD7S6IIX0H-E>3:VEN?I]![]U[K8S]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=?_T-_CW[KW7%[Z3I%V'*@_0D<C^GY'OW7NBJ[`^'/0_6'R/[6^5>T-I#&=
MS=T87$;;WYN(SS2IE,=B)!44<20\K'IG%R??NO="UVMU-UMW7L+<'67;6S<-
MO[8FZJ*7&YW;.XZ"FR6.JZ>I73(1'47*/&3J1ELR,`1R/?NO=5@=9_R'OY:/
M5F_<3O\`PG0%+ELOMW*TV:VU0;IS>7W#MS;^0I26I)<1A<E53T<'VG!0%-,9
M`(^GOW7NCD;S^!?Q&W[O?LSLC>'1FRLWO/N'9-)UMV-E\A0"63<^RZ50E/@9
MT!$7VT"@:`JJ%:Q]^Z]TM\[\3OCINSI+"_''<_3^SLWTE@<;C\=A>O<MB*6K
MP&)H\28VQU-2TLRN(986Y#*;GGW[KW3IGOC1T5N?J"'X_9_K#:F3Z9IJ2BQ%
M'U_+B8#MREQ]`\5124\=&1XU2&H@5A8<,/?NO="[A,!AMN87#[:V_04^+P>"
MQU)B,7C*)!%2T6+QM.M)28^*$6*P0P(%2W`M[]U[I.)U9UU#OVI[4I]C[5I^
MS:[%Q82KWNF%H?[T3X:&_@Q\^7\7WLE)`S<+JT_CW[KW4+-=.]4;AW/4;QW#
MUMLG/;MK<%+M:KW/E=M8FNSM5MZ;69\+5Y.HI)*F7$SEB#`6*&_(M?W[KW4J
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M<7YT^_=>Z<4C2-;*%CC`!$8"JJ?XC3:U_?NO=9.!;GZ_3F]_]:YY]^Z]UW?\
M?GZV]^Z]U[W[KW7O?NO=>]^Z]UT2`"3]!S_MO^)]^Z]UKRXJE\'_``HSR]44
M2,5_PP!C9+:YQ%D'#&4#D!/ISQ?W[KW6PW[]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z#;N6E6NZB[0HVCEE6JZ
M^WC`8X;F5Q+M_():,#G5SQ[]U[JE7_A-M/33?RU,?3TOW"IB/D/\@L,4J;>5
M&QV]YHC&1R5"Z_\`7]^Z]U?G[]U[KWOW7NO>_=>ZZ-K<_3Z?[?W[KW6M[_/9
MR<6#^07\I7+3QQ214_S$H*:Q(\FJNP\U,I53SI&JY/X]^Z]UL>PMK57`LKQQ
MLMQ8V*@\_P"(O[]U[K-[]U[KWOW7NO>_=>Z][]U[KA)?0P'U(L+&QY_H??NO
M=40_&2EIH?Y\7\P.:.%DGJ?BQT:TTAN%>VX+`B_U''^W]^Z]U?#[]U[KWOW7
MNO>_=>Z][]U[KWOW7NNB+V_P8'_;>_=>ZUXOY,N&3;_S-_G)4"^-6J_EGA,I
MH4OKT5.UW`<JX'I8_0^_=>ZV'O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__1W^/?NO=>]^Z]U!R=?18O'5N2
MR-5!18_'TTU96UE3(L-/2TM,AFJ*B:5_1''%$A8D\`#W[KW5?6X/YL7\MW:C
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MMI?PB<8_^ZT*S7D;,6$!E9:=WT#GCW[KW6?YK?.7X_?`7J&L[F^0NYI\)MP5
ML6'P>*Q%$^5W/N?.U0!@PN`QB,):ZJJ)6``0$K>_OW7NJUOBM_PH0^)OR0[<
MVWTGN_KSN_XS;UW^TIZK'=^TS@,3V+31TTM7!-A\C)I@BFJH83H1[NQ('Y]^
MZ]T"^'_X4>;1W_V#VML;HG^7W\P.]X.H-[9WK[<^Z>NL5MJMPASV!R$E#5K!
M)/5Q2Q)++$6CUV)'OW7NLO<G_"CKJOX\5GQJA^0'Q3[]Z';Y"[FR&`EH.R8L
M-0YG9.)I,K%B5W)DJ&&J(DI34S*[$>KQW(]^Z]T=7YN_S7-K_$7L+XI;!V]U
M3G.ZC\M)JZ'8&3VAD*`4=7(<6<EAXZ1JJIA5QE8@!>^D$W'OW7NJINU_^%"W
MS>ZZ[\V-\=V_E7[]QO9'9V/J\EUSM/<FZ:6#+[EI:"-6JGHEI:@02&)#J90^
MI01<>_=>Z=MR?SZ/GM4?)K9GPUZ[_EL+D/DQN+JVG[3S77>[=_28F3"XL135
M-8%J8)6B*T\$7D8$@D>_=>Z$+O;^;Q_,T^*/Q4[O^37RH^`6RNL*#8M=L?%[
M#Q=+ORNS*;BR&YLG#15R5HBUO2TU$CES(;`$<^_=>Z![L#^<=_-LZ0^/NQ/G
M#W1\*NE,?\2<U/M?,;DJ]K]AU&9WC3;.W=-!#09"&BDAA,+TL,S%U)//`]^Z
M]UL*]D?)>K;X*[G^674M%!4SS=!S]N[)QN;5HZ=FGVV,]04V0559R$#Z"/H?
M?NO=:]?6W\[WY9;[RO\`*-+;2V50X;YP9G)8SMF>#%O))3U&-KYZ-8\'4LQ6
ME8+$&95%V7W[KW6V['S(5*:7CUW-R1I=B05/T))'T/('OW7NI'OW7NO>_=>Z
M][]U[KH_3GZ?[?\`/OW7NM>NN_A6+_X49;8,[SC);C^%>>CH$22\!2@R)J*C
MR(#]1&/]@3[]U[K85]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=)+?X)V)O4*"2=I;C``Y))P]98`#DDGW[KW5&
M/_";7C^79GP>"/EM\H`1^0?[_MP1^#[]U[J_OW[KW7O?NO=>]^Z]UTPU`C^O
MOW7NM>W^>ECHUWI_+3W)-!1O!@?F;L^&2>J"$P')0/1Q:-7-Y"UO]?W[KW6P
M;&PTJ;BS:=-QIL"BV4`V)O?W[KW64D#ZD#_7]^Z]UW[]U[KWOW7NO>_=>ZCU
M533T<$E55U$-+30*9)JBHDCAAB0?5I)966.->?J2![]U[JB[XYUE!'_/=^<L
M*AQ49+XG=*RTTJL9:>JBCW#Y6DBD4L@'CL1SR/I[]U[J]GW[KW7O?NO=>]^Z
M]U[W[KW7O?NO=<7)"W`+$$<#ZGD>_=>ZU[_Y25)!B_Y@?\XB@@JYZQ:COW9F
M2>2HU!XI*C`5.J!`_/B2_I/T_I[]U[K807\_\&/OW7NN7OW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__TM_CW[KW7O?N
MO=-V7QM!F<5D<1E*6*NQN4HJG'U]',H>*JHZR%Z>IIY$/#)+#(5(_P`??NO=
M:5_\\+X)?%?IWY;_`,IMNONF.O-H;-WQ\CFVKOK#XS"4=-3[CI)IL95*NXTE
M7QUU-JEE!5K_`%-_?NO=(3^>1T_L_P"-/\T/^5M5?'WXE]8]A8ZOQ.\\-A>A
M:#"83`[4WMNJNS4,D,-=2&E%#ZXX@S,RDM;^I]^Z]T*GS5[6^8FU?@_\O,]5
M?RJ>K_AA3Q=4Y3%3=Q]>5>WZ?=>-ARE4N/R,=+-A*.EKDI)\;/('9&``//OW
M7NK2_BG_`"_/@-V#_*"ZFV'O[KGK>FZSW9\?\5NO>W9D>)Q4&?IJR?"0UVXM
M[G=ZP-DH\O0U)D9:GR,R^,?GW[KW6N5NBBW/TC_.$^$$_P#*W[1VS\I&JOBQ
ME^ONO]Q=F[LK:C!5F,P4V7H\K05VYIX/NJZ3'TS#2`C?I`'OW7NC+=+;H^9N
M)_X4S]"9OYQ;/Z]VYV?O3X[YC:N*H>KJV7([6CP;T&9%-5I75<4$\U2K&[C2
M;`>_=>Z.Q_.L%)'_`#=/Y-[=M)!5?'*I["RM'EZ;-@S[4F[$FJI%P4F7I:RV
M(GD%,ED\A+`D$#W[KW5JG\S&7^77U_MCHG?GS0V?B*I,7VKMC%='56W\1%/N
MB#>-?5P#"KA(L6M)7'&02/&98HF9?%]01[]U[K5E_ES?'?\`F"=J?)?^9!'\
M-OF=LOXD=:XKY-Y&3<VT\]AXYLSDJO-1560H,IBHJAI5A@FI'5I-9!5VM^HC
MW[KW0C?S>/AKOK=O8W\ICJ'YE=V8SO\`W?OOM[>?5NZNY\?3PT-!-C,_%428
MJAGC@L(JR@E,;@FQ.@D?3W[KW5:/8>8^1?QC^=OP!_EU?);(;CS^=^+?ROPE
M?TIOZ:6JFH]T]*[MF:3;R4^2J]-1+48H5$<#H;A%%O?NO=;0G\S+$5N-_G7_
M`,GK>TV0@I<?49'?.V$6?4LDU7-2151B$O'[DX!`%^>>/?NO=5R_S4/CY2=M
M?\*"NM<!E/DQG?AS1;U^*.:K!W;@LY2X&O*[>I_'-@H<K65%-3PKE!>`J7_-
MN/?NO=<OGG\7NKNB/Y2OSFQ&T_YB&X_F3N/.;9V[G9\7O7L/&;OGV[08C<"O
M-D\-1TU;63T[LHM=0`/R??NO=$%^2?\`+G^4.U_Y,G2_S.S7SH[3[AZ?VUMG
MJ;?^0^,.ZEE38O\`=2/(PJ^"C>A,AJ:2$`$^8:+'D^_=>ZW2I<_A>X/Y3-7N
M/;^&QV$PV]/AC-D<;@<+*C8[$I-UHTE+C:%HB8Q#3%`H"_2UO?NO=:9?6K9+
M$?$_^0%VAC'J$K=F?*C<&PYZ)*68O!)!D*HS/Y0GI!`/U()]^Z]U]&*%RRQW
MY)CC9S_M31AO]@3_`$]^Z]U(]^Z]U[W[KW7O?NO=<)-)0AKV/!M]>>./\??N
MO=:_7;>$^Q_X42?$S-!1!%F?ACW7&6`M]Q)03TL0$K?34JN2`>>/?NO=;`]Q
MQR.>1S]?SQ_7CW[KW7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z:,^GDP6:CL"),3D4*D7#!J.8%2/R#?W[KW5$7_">
M8TE+\4>],)1U!<87YF?(^":C7TP4+56\6J`(XS^GR$'W[KW5^GOW7NO>_=>Z
M][]U[KIC8$WM;\^_=>ZU\?Y_-/4G:GP3R2*BTE+\W>G4GF8Z=#5&4$<89S8+
MK9@!_6_OW7NKV][;UV_U_L;<>_=S5+4^WMGX"MW'G*B&,U$E/C<71M6U<B0J
MRF1EIT)"W%_?NO=4PQ_S\OB!+3XO(4'6_P`EZO#;BI\OD]LYF+JAUQ6?PV!#
MMD\]C:C^,`2X*`1EC4.5C(^A)X]^Z]U9_P#%7Y.=8_+WI_;O>'4,^4DV;N.2
MLA6/-X\XO*TV0HI1!4TM;1O-.T,D9/X8@@CW[KW1D[BU[\?U_'OW7NO>_=>Z
M:\SB\?F\=58G*4T5905J""JIIB0DL;G]#`<FY'T_/OW7NJ/>ML/C]L?SY^X(
M\4DD2;H^%>U9<A$)/V(WP.YJ*DHE13R2L#A>/I[]U[J];W[KW7O?NO=>]^Z]
MU[W[KW7O?NO==$@?7\FW^Q/OW7NJ%/Y=6/GV[_-2_FQX,JB4^1S'4NY@(_TL
M]9C:V`%O]J*^_=>ZOL]^Z]U[W[KW7O?NO=='Z&UQ_K"Y_P!M[]U[J(M036O3
M?;S@1PK(*@V\!U&VA>;ZQ[]U[J9[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[K__T]_CW[KW7O?NO=<'MI)*ZK68`B_*G4/]C<>_=>ZI[_FL?R\>Q/GC
MDOAYE>NMT;6VKD?CE\A<+VSF:K<U/4M45NW:5J85^,Q;TL4@^XGC@(LQ`^GO
MW7N@<_FW?RN_D5\V^W?B=WY\9>Y]G]/]J?&'*Y',X;*[NQ=9DJ>2MJ?5#+2Q
M4T$P`#B]FM;Z^_=>ZQ]*?R^_YD^>RLF*^='SDVQWMTKNC;>XMK]D=,XS8PI\
M)N7$9S'RTAIS65%.DL+TP<NK@7#`>_=>Z)YD_P"05\O,+LG-?%'JW^9'V%M+
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MOKN[Y:Y/J>>*HZFVYW-NBNS>U=DU%,LB4>2AQ%3/-35>3IE?B5EU7`-^/?NO
M=/W9'_"?;X2=B]Q=F=SOF^\=H;I[:W5_?+=U'L;LO-[5PD^52#[82_PW%3P0
MRP%%`",3:]_Q[]U[H=-M?R9?AGMO$]/X2JQ6_=W1](]IQ]O;'K-X;US.Y,A1
M[M6"2'SU-;E*B>5Z(>0VB!L.+#W[KW1K>]?@Q\7/DGV'U=VOW)U#MK=_8?3N
M5ILYL#=D\'BS>"KZ.17I6CK8@DM53QE!:.1B%_'OW7NEWV9\9.D.WM_]5]H]
MA;`QFY=]])Y6?,=89ZK$JUNV,G/`8)*FC*L$N8&*W;Z>_=>Z!KY-?RX_AA\P
MMZ;;["^1W0VUNT=W;2QDV#VYG<RM5][C<3-**N:E1H)Z?]MZI;V-P??NO=)7
MKG^51\`>JL?O'#[*^,_7^*QF^\*=O;JHY:%J^GS6(DF6H-'40UK31QH9%!]-
MO?NO=&Z3I?JM>KZ?I/\`N!M:HZFI,)%MI-@5>(IZK;JX6!0L>-&,FB:D>F6/
M](*V!]^Z]TJ\-LS:VW-I4.QL)MW$XS9^,Q0P>/VS0T%-#AJ+#I!]M%C(L:J+
M2FC2G.@QZ=)4VM[]U[I(0]&=-4^+V]@X>K-@18;:>4?<&V<5'M'#1T&W\]*6
M:?,8>E6E$&.R$K,;R1!7)/U]^Z]T*L8/HNIL.1JL'7TE0S`$@DCC_#W[KW6?
MW[KW7O?NO=>]^Z]UQ8Z5+$7MS[]U[JA;Y19Z7;'\]'^7M4BD29-S=$=X[5:H
M`!,:UB4SW+6XM:X_K[]U[J^6/26;2.%L@%OTZ"R_7_$'_;>_=>ZS>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J#E$,F-
MR$0.DRT55&&_U)>"10Q_P6]_?NO=44_R&-J3[*ZP^9&WZBN6N:E^:_<4P=8V
MC"?>Y`5IC]2KJ(,_/OW7NKY/?NO=>]^Z]U[W[KW7%AJ4C^OOW7NM>+_A2MGY
M=I?!OJS=]$V,AR>U_EU\>LUC*S+R2QXZCGHMYTLGEK9(")TI"5`D*<Z3[]U[
MHI/8G\R?YN=L=6=C[6W!M;X_X_8^[^MMR4==#"V[I,Q0;?S0&W=JM4K"J2#-
M=BY*I"XVD'^4"']PJ4Y]^Z]T3GI_;^]Z;;`V9W[##-A.K]C[)PG<%+U^U7`K
MQM`C]=_%+K*=[209[=#^.JSU0C*4B5UE_/OW7NA`Z/\`YDWR>^&&`EZ#V+US
MT:,7O'OBIQVR9,IE-QS1T>Y.Q,K2C(;(Q"T*B.O7K+$QQ15]2A-/Y6(#:N/?
MNO=;"M51_P`VVIIR*/*_$"B5X%:)Y8M]331GR7*-IA\;%H>-5_K[]U[I:/%_
M,\:+%JL_Q522'Q_Q-U_ON_W8$=I!"K1A8];_`$Y%O?NO=,55COYJS92NJ*;/
M?$Y,0\1%!CS0[R%322V&EYJEHY%E"GGW[KW0:_'CX>?*[$_/;/\`S.^0>[^H
MJL9OI/\`T3?W:ZYILY&T?V^4@R5+6F3*1(G,L7KM^/?NO=6\W%[7Y_I^??NO
M=>]^Z]U[W[KW7O?NO=>]^Z]UCE76A2Y758:@;%>1R#^/?NO=49_"NNI:+^<;
M_-%VY//3C,5.Q^@=R1TD(8E<-/!F*.&5R;6=J@<^_=>ZO0]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_4W^/?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW71%Q]+_`)`/]1]/?NO=4A_.6AI,5_-+_E>;HKHDIJ>OK^X-
ML4V2"_N2US[7-9'CRUN0574J_4_T]^Z]U=LO^<(*L""2&^BM<`7(OS[]U[K/
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNL4Z>6&:/C]R-T%_I=U*B_\`A<^_=>ZH9_DE'*8_?'\S?:N1JI95V]\VMS24
MU-(&"T:YC%?>M&@:VG78$BWOW7NKZ_?NO=>]^Z]U[W[KW6.8D1.5Y(7C\^_=
M>ZH-_P"%(E`U5_+7S\]-CTR63QO;W4==A832K72?Q.'=U$U(8*9N)YC/8*OT
M)X/OW7NJ4]E9SY+[9VE1;DQ/PE^56\LKMW!4^Y,%D,ULW$RP]@=S96E^WF[!
MW;135XA_NOUWB':/"T*J5N%8!3S[]U[I2X+M@[^ZXVS6[+$VP\5L^/?%/7Q;
MLH::/=>W]Y1RB+N3OCL3'K--#%NJGKJK^%[7HI':423J5``]^Z]U*^+GP\^8
MWR]V=DNVNK>L.F\1L[879V%VOT]_ICW+N>CWW@<'UID\?G,MD,AC\7!-2QYG
ML&OJTJZR5B)V5E4\#W[KW6Q`NX_YP"CQQ=;_``WT1K$@,N[]_"0@1DE[+2Z2
M2;`^_=>ZR+N+^<&38]<_#11_7^]^_?\`B:3W[KW7I-Q?S@54D==_#5CP/^/N
MWX;`FQ-OM5O8?X^_=>Z4%-7?S8)J5&J]N_#FFJ&7U4XS'84R*W'^[$I['3S]
M/?NO=9ZR/^:G5P0QTTWQ&Q=0`3,T9WU5H"/H%2>`W!/^'OW7NDA78'^<'*UZ
M'?/Q%I5U#A\%NR8A;^K]5,`3;W[KW7<^V?YP*QPBF[(^)#R6_>,FU]TA0;?0
M?M$G_8>_=>ZB';?\XVUO](WQ#YXNNV=U7%_R-4('`]^Z]T\G:O\`-P$,`7L_
MXH^41N:@G:>YSJE*^@)>,C2&]^Z]UBI-H?S;Y"[9#MKXLTI!(C^UVAN&4'^F
MI9(]!O\`[Q[]U[HE?\OC`]S8?^<;_,&D[WRFSL[ONJ^.W0#39;95!-C,7/1)
MELL(E^WGCC=])/\`R"??NO=;$/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__5W^/?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7%B0."H/`&J]KDV`-N>??NO=-U-E*"JK:J@IZJ*6L
MH]/WD*DEH=7T^OT]1Y]^Z]TY^_=>Z][]U[KWOW7NO>_=>ZZ/T_WG_;<^_=>Z
MH[_F;UCTGSN_D\Z58_<_)#L"$V6]O)UY4D!OZ7%_]L??NO=7ABQ)-K$'2#_4
M?7C^O/OW7NN7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>ZXM:US>P(/'^!!]^Z]U0A_*)7-XKYB_SA<!E(I8J=_EMAL[0
M*]@/!D-FP:)`O#!91]#]#;W[KW5^/OW7NO>_=>Z][]U[KH\"YO8<\?X>_=>Z
MI,_G]TE+4?RY][UM2]7%)A^R^I,K1R4D<CO%44^^L+XGDT`Z$!;ECP+^_=>Z
MM?ZPEEFZ>Z]E:?7+4]<[9L\K.-4TVW:-S(["[#@W_K[]U[K1E09&IG[PV9M#
M;T$^2/R][?9JO*UJ)5=@;KQ^;2OQ6X=RJ&T8[JWK#&M)6U*/:.KJ1$&!('OW
M7NMB/^0ODL=4_&3M"DQ6^<CV;1IWYORM'8%92ST-/NJLK/L?XID<915*I/3X
MN'(1/#3\!7@5"O`]^Z]U>9[]U[KWOW7ND3V559"BZ]WQ68F::GRE)M3/U..G
MIUU3PUT&+JI:66%`#JDCF4,!^2/?NO=:G7\K[YJ?S#.ROE9\1MH?("JW`_4&
MYMD?(VC.1FJ*RIDWU6[7W=/!@\UN2E-&L&/FH*5;0%Y`2%XN/?NO=;>Z*."#
M?]0'^L6)]^Z]UD]^Z]U[W[KW7O?NO=>]^Z]UQ<D#B_)`N+&W^-C[]U[JASHR
MKS6/_GU?+NCR&,JL70;@^*O54F*J?NHYJ;-Q8O-9)I)C`K%X/MV(^H')]^Z]
MU?+[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z__UM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UQ8$
MC@Z3P;VOP/KQ[]U[J+#1TT-1/4PTL$4M1;S3I&JS3V_29&`!('^/OW7NIGOW
M7NO>_=>Z][]U[KWOW7NNB+CZVL0?]L?H?]?W[KW5#_\`-NRLF%^77\GO(P!%
MF_V<2MH_,Q`98:[9U33S("?PT;F_OW7NKWQ^HW/U(L/Z$"Y/^QO[]U[KE[]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN+
M6(L0"#:]S86_K_L/?NO=42?RUMS0?\.._P`V;9Y@*UR=G=;9Z68L#JIY-LRT
ML8M>Y`)_IQ[]U[J]WW[KW7O?NO=>]^Z]UQ;A21?_`&'U]^Z]U3Y_/>=J?^63
MWY5K%-*U)7=?U02&,R2,8]]8#39+&_JM[]U[JR;I*H-?TEU+,T<A-1UEL622
M-E`8&?;./5U8?V)%U7/]/?NO=:/N^I-I;/[?^=FU8:7=4\=!\I-X8/=FZ&M#
M-D=M92;&9*EZ,V5%$01E^P\PZOD*F+UP8^%M1`/OW7NM@+^0UNE-R]&=U+/7
M[1FR>)[DR-/68;8U/]MM;:<$U$JXK;.+]*"=\121?;SR@$2U",P)]^Z]U>]<
M7M<7M>WYM_6W]/?NO==^_=>ZPU"+)$Z.@DC<%)$;E61P5976QUHRFQ'Y!]^Z
M]TDL/L;9F&.+&)VGMW&'"Q5E/C#C\114QQ2UTGW%=!0O%!&\$59*Y>320')Y
M]^Z]TLN`0/I_0#Z?[X>_=>Z[]^Z]U[W[KW7O?NO=>]^Z]UTWT_V/'^!_!_V_
MOW7NJ5MHP4T?\\SLN6,#[F3X=;;,Y'Y`W+*`?]O[]U[JZKW[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__7W^/?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7`R1AE0N@=[E$+*&:PN=*WNUAR;>_=>ZY^_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZU"^FXU6OIN+V^E[?6WOW7NNFM
M8@\C\CZFW^L.??NO=46_S?Z.DJ.^/Y5-5+&'K:7YI8L8\@78";`RI/I`!)O'
M?W[KW5Z"LI=K,#8<V(/T(!^G]"+>_=>ZYW%[7%^3:_-@;$V_P)]^Z]UW[]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K'(5``)7D
M@6-O5;U$`?VFL/I[]U[J@WX"X./;/\X+^:AC@9)'S.&Z:W5Y75@L:Y2A95@#
M6"ZU\?T]^Z]U?M[]U[KWOW7NO>_=>Z][]U[JI/\`GF-1Q_RO?D_/7M5Q4M+@
MMKU4L]%I%13>#>FWY%J4+D*!"X!/^'OW7NK`/CK4Q3=!=(3I5&H2IZGZ\DBG
ME`62I63:N**2/:ZM+)?U<_GW[KW6BK\J-PT^T_D[\Z)<COVCQT6([]W]GJB"
MEB2LCZWVSE,?A*7);BD1-25W9.Z9#_"L,G,\9G+J+*??NO=!_P!%]K_+WXB;
M0W;O#8/R0I_B[U_NO*X#>K=54FVZ?<YQ*5L24^T]I;CJY*:>JGWQO/'RM7UJ
M@EJ169FL#[]U[KZ`?2V?K=U=3=8;IRE;%DLEN#K[:6:R61B&E*VORN"H*VJJ
MU!L!'42REA;BY]^Z]T*1(')(`_QX]^Z]UXD#ZD"YL+\7)^@_US[]U[KOW[KW
M75Q_4<\#GW[KW7?OW7NO>_=>Z]<?U]^Z]UUJ%P+BY^@N+G_6_K[]U[KC(0$;
M42`!<V%S:X^@%S<^_=>ZI`Q=54X/^?'EZ2MHG$&]OAHDN'K4:\<D>$W$9*H/
M]`=)XXO8_7W[KW5X7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KJX_J/Z_7^G!_VQ]^Z]U[4MR+BZ\D7%P/ZD?CW[KW7=Q:]^/K?\6_K
M?W[KW7__T-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U@\$321RM$C20ZO%*0-2:P5;3
M^1=3;W[KW6?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T$'?W:T71G2_9G<$^
M!K=S4W7&S\UNZJP6.EBAK<E38:DDJYZ>GDG_`&U=HXS]?Q[]U[JJSHK^8I\V
M_D7UAL_N'K?^7;E&V-OG%)GML5V=[9VWBZFOQ<TLB4\QIFAFDB$RKJ4$6]^Z
M]T,-)\D?YD]?5-.OP/VIBL=''+Y:?*=SX^?*2R:#X/M124WVFGR6U:K>GZ>_
M=>Z(3\Y-F_S.OD7N'XH]B8CX>[)H)_COWOB^VZC"XOM>AGR^5Q-#CWIZG',*
MND%/'6M?]L(>6M?W[KW1S-R?S"?E1L3"Y;=.[/Y:?>$.W\#C*_,YJ;"[[V+7
MSTE#CJ:6LKJN.'4IJ8UC5FTWU6'`O[]U[H\OQ'^2VS/E]\?NM/D1L#'Y7$[8
M[(PTF4HL-F!!_%<)+%4STM9C<J:=C']W3U-.RL!Q?W[KW1EO?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW02]]=C5'4'2?:_:M+BDSM1U
MSU]NO>L.&DE:!,H^VL-5Y84!F0JT7W7VNC4#P3?W[KW57'QM^6/\RGY1_'WK
M+OG8/0/QEQ6#[5V^=T8&'</8N[DJ\1CJFJFAH(,C34U&^NJ6&`ZRCD7/OW7N
ME9\*?BA\I-C_`#1^4WR\^0U5UAM^/O[9/7.UZ#KGK:KRN6IL7DMD&HBJ,U5Y
M7+PQ3L,A$]U12;7Y]^Z]U;K[]U[KWOW7NO>_=>Z][]U[HEO\P[XOY;YF_#?O
M+XU8'.T6VLUVCM>+#XK-Y&.:6@H*^ERM!E*:6KC@_=:G,M"`P'X/OW7NB:]?
M]4_SANOM@;(V#C^R_B-4T.Q]K8#:-%7S;?W49:RAV_CJ3&TU5.GVMHZN6&E`
M;3[]U[K3[[6S_P`D-W?,/Y4/O/:?0V]MP;`^3N2QN[=CT,N3P^(WUV5A]HP5
M@["R*I`7FV-L2F'W;1U)\9J$`L6(]^Z]TV[ORGREWUUUNFFJ=K]15`R>T:K+
M5&7-;G:BNH,AN7.04.)W%!1RTY:?=W8Z)]OA8F!GI*"-M("'W[KW5V_4'\V;
M^8MLS:6R>L<3\>NB]S-M"'K_`*.PU,FY-P0UF5WUC\!1PYK'02>$13+M7&P"
M7*3@F&F:ZL5:P]^Z]T.'_#JW\R3,56%_N=U!\;,Y#NO?<W6G7N/I\YNA:KL3
M,8DWW?N'`23TX2/9FTFC>.IKY+0F1#9K>_=>Z8=]?SBOGGA:&:OVQU3\>-P4
M<>9SVV\%7TNX,Z!O:IV732UF^MP[?CJXXT7:&V'IWIY:QR$DG`"$W'OW7NCU
M_&#O7^:W\E^E^K^^=OX+XB[?VEV3@O[Q8_"5N1WE4UHHYJV>E3S3T],ZK(@I
M7/H8@\?CW[KW1G\A#_-(FH:J.AJ_BE05\JG[6<C>=1%3RV%@8YJ<ZPQN/Z^_
M=>Z0<F$_G"2:C!O?XA1WJ"RWPVZY0(!%H*$"F'J$X/OW7NL)P/\`.-^B[^^'
MP:Q(!V_NPW`_P,'TOQ?W[KW6.3:W\XRII]/^DSXB8RH$T3^6+;&ZZA6C5@9(
MRCPA;R*+7_'OW7NLM;MW^<-'1UTM-V)\1GJH8&:CCJ=M[HCIY94%]4TD4)>.
M(@<CW[KW1)_A7WY_-E^:6`[JS]#VW\=>L9>JNU]Q]1KBH^N*K/4-3EMM2^*M
MS%'5SD5<M)4:O2KD$7^GOW7NC._'CX,_,R@^=^%^9WRL[XZQ[!FVQTQG>H<)
MMGK_`&94[93[?+UQK?XC+KM$&\@#,.2;6]^Z]U<W[]U[KWOW7NO>_=>Z][]U
M[KHD#ZD#\<\?7Z>_=>Z]J']1P0/J/J?H/]<^_=>Z[]^Z]UQ9E12SLJJ!<LQ"
MJ!_4DV`'OW7NN$SA8Y""HTCU$@L%!^I95]5K>_=>Z*!WE\I!UQO/$=2]:[&R
MO;W=NY*)LCCME86IAQN/V_AVB;Q9W>^:JP:?%8C@L@'[LEB%%_?NO=`IE^XO
MGWL"7'9+?74?QXW%29NJ"XG:.S^PL[0;WR$XC,\F&P39Z*+&9++_`&P.E0WC
M8C\>_=>Z&C#_`"\V;F^BMV]SXW9.^*C([,RV.VSN+J5,:H[`Q^^LIG\5MFBV
MK/0^4Q&JJ<QEZ<)-<0F$F6^@$^_=>Z__T=_CW[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1-OYAE;3X_P"#_P`I:JJF
MJ8(DZ5WTODI$+S"23"U*1```V1I&`8\`+?W[KW08?RDIII_Y;GPVEG?7(_2&
MUC=2A4KX6M<J2+C_`'@^_=>ZL8]^Z]U[W[KW08=V4;Y#ISM2A27P/5]>;QIT
MFY_;:7`5Z*_'-E)]^Z]U7+_)"QD>'_EO="8V'(19$4B;S@J9HHA&%JEWCFC(
MK<`DK^?]?W[KW5M/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO1('$]>Z][
MWU[KWOW7NBQ_-1=?Q!^3JW"WZ'[3Y-K#_?F9@W-[#W[KW1:/Y.*-'_+)^&Z$
M@Z>G\4#_`.==;I/^V_W@^_=>ZLS]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M8YN8V_1^/U@E?U#ZVY]^Z]U\][?VRZG(?S`OYD%;CMOUE96YOY73[5BQU%5Q
M09[=LTFU:+(P[2A1'\6*V1$*?[_-U_I+4D7C8W-O?NO=+#%4VX)8\7+BZ[%F
M2:NW#NO'[JGC2+%Y+*;7IGQVZ>]<E2\0IM#KJC4XG:=#_FIZL>1`3S[]U[H>
M=G8JIPVWJ&IES5;@#2];9S<N4S^1<1UO3W0FXZLMG<[4Z;--WK\A,DUX)7M-
M!2R*%(]^Z]TKUK9]LXORUF??KC-IU:M-D:DJ9X?BC\2\G]NV-V;B`-7G[Y[I
MJM+2%+U8%23]`??NO=%([LR-1E,+FL/D-KY2BH4ZRFV/'U_MN9:6OVCUSE(I
M,OM#J"CR*E#2[PWVL9R^YJ^-O+#`/'(P)M[]U[K;>_E%^2/^7%\/X)*:EH/#
MU/3TRT%*Y>''_;Y7)I#C8'<:YHZ6F4#R'EBI/Y]^Z]U9')8K8\>H:?\`@U^+
M?X^_=>ZJ:_F/_P`Q//?#G/\`3G5G7/7F%WSV;W7-N"HHZS>.9J,!L;96VMLT
MJ5N7S6>K,;#4Y.9Q&28XX8G+,.;>_=>Z&3^7%\V*7YV]#'MA\/AMO;CPN[-P
M;,W9AMO9B7,X:'*8.H-*M;BJJHBBJCBLE&GEA64+(/R![]U[JP3W[KW4:LM]
MI57^GVT]_P#6\3>_=>ZI$_D=M&>O_F0BV#Q_-'MP2)_;0FI@(UK]5N/I?W[K
MW5XGOW7NO>_=>Z][]U[KWOW7NNB`?K_4'_;'W[KW2![.WK-U]LW*[JI]L;AW
MC/CEB\.W=KTT=5FLC+-(L:1TD<KI&H!-V8FRCGW[KW11O]G$[):/S#X:=\OJ
M4RJFO;:R+>/TB3576U.>!]=/OW7NH$ORF^3]902U6`^`_9,C/$S8_P#CG9FQ
M<:TY;])JJ8B:>G1A_4W]^Z]U6M_-@[Z_F+83X6[X[`ZKZ$W7U7VMM*;!Y'8>
M9Z\WY'N;)T6=JLK1TT%#F-MT=',FXJ"I:7QRPA&0J220!?W[KW1AOY8':_\`
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M]U[KWOW7NO>_=>Z][]U[KWOW7NNKC^HY]^Z]UW[]U[HI_P`[,92YGX:?)[&U
MD4DU-4=)=A&6*%M,C"';M=.NDCFP>($C\@$>_=>Z+K_)GS%/G?Y8'POR5,%\
M4W3.#15`"M%X:BN@*NOU4WBM[]U[JSKW[KW7O?NO=('M4:NL>Q!_79&Z?_=)
M7>_=>ZK+_D>UC5O\N[J=VA6#PY_L2`*OT/CWGEAJ_P!<^_=>ZMR]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=<6L%))``Y)/``']3[;DC,JZ%XU'^'K8X]0Z>
MOHJN2JBI*NEJ9J200U<=/40S24TQ19!#4I&[-!*8V#!6`-C?Z>[W,<\<.H1D
M$\*@BOV=6I@5X=2DYL2.1^?:2RDF>*DHI3KS8P#CHNOS"QS9?XH_)'&(K.]?
MT?V?2HBFS,TNSLNJJ"/R2?:SJG13OY,4U1+_`"Q?A\E9'X:FEZOCH'C<W<?P
M_-96C']#](1?W[KW5G_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K'*+I^+AE
M87U6U*P*W"\D7]^Z]UH;]L14&/\`G]_-#:/'Y3"XRC[DVO#O3?J&H&8?`9C;
ME)">M>O*>`:3O?LG*.E$TT?[J4;.?H#[]U[I&93M;K;979.<V!O+:V\L[O2A
MVS1;YWSU3L#`Y#.4^-@P)IJ;K/XY83^&(ZTN#VHT\-?N67TQ5%2Y#DM[]U[H
M5*OY(;/VY1I%OKK'M[=QP-;0=F[NQB=5;K%/WG\@<A&D>R-J'32*L74735#+
M%:C<B"::'4%/OW7NDSO+N(R+70S]9=O;P7!Y:@WYN9ZSJK<X'=WR(W`%;$Y[
M.*(M5)UGT[CI&6AH^(WDA6R\^_=>Z!BNW0-S_=;>GVEWUAJ/)G<F-R6[*WJ7
M=E14^>LHY*[<^^:IQ`:MMS[VJ6&-QZ+>.DH/Z'W[KW6XW_*8HLOC?Y??QEQ&
M=V_FML9/![%EQ,N'SU'44&1@@AS>5DHY*JCJO\HAJGHI8]6L!K>_=>ZL9E_1
MP5#7`0L"RA[^DD#W[KW5>_SB_E[]>?-B+KW-93=V[.LNR^J*O+U?7G8^RI(#
MF,0F<IUI,O1UM-712TF1QU;"-)AE5A_Q'NO=.G\O?X"=;_R].H<OU/UWN+<V
M[SN?=^5W[NW<FZYHI,EE=U9LL<C7(D")!34]01=88P$C_`'OW7NC\7M]?];W
M[KW7"0!D920`WI:X!!#<:3_35>WOW7NJ3OY,-1#]O\\<=%3I2G'_`#7[-22)
M4*/JD6F8-(I`*EE%P#^/I[]U[J[3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=1JNE@K(?!4PPSQ%T<QU$*3QZD8,K:'!74I%P?P??NO=<KZ47
M3&$"^E8R+`*G"A0EU46^G^'OW7N@7[H^/W5/?^#I,#VCLZBW'38ZHCK,-6.\
M]#F,'6*X8U.*S%%)%D,?+?ZF-Q<?6X]^Z]T61?Y?^"BIZC`T??GR+I=CU#B*
M?9)["KGQ4]#]7QWW\NO+?92+Z6'EU:>+^_=>Z,3!\;^F:;I^NZ(IM@X^#K+(
M4D5/D-O1"1?O:J.NI\G%DZJJ$HK9,I'E:.*J6J\IE\T8:]P/?NO=?__3W^/?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UCEOH:QLUO2;7LWU!`
M_K[]U[JI7Y@?,?Y+]>_,SXZ_$3XV]?\`6>X\_P!S;`WUOZNW!VAELMC,3A:+
M:F@.@7#135;/*Q(4*O+GGCW[KW3G-3_SC:ZHD6*K^&>!I``86C&^LK,#_J6,
M],@/].1]/?NO=88=N_SCI:J(5?8?Q"IJ$L/.])MO=$E4B_6\8GIO$3?ZW_'O
MW7ND5G.O/YWE=ELB^%^0/Q"Q&'"+_#(I>M,O6U99K:S,\D03TCZ7!]^Z]TJ*
M+JG^<5]K3_>_*GXRQU7VR">.'IJ=XA4WO(4=AJ9+7M[]U[KE4=1_SA)H9(E^
M6/QMA9U*B6+IJ421W_MH6#"Z^_=>Z3C_`!Y_G!5=!]O4_./IFAJ$>5TJ,=TU
M3^64FYBC=YHB`@8\_P"'OW7NG#&_%/\`FDB2-\E_,6VYH:!3-'2]*8201US?
MYR.+S*MZ9/P20??NO=9E^)O\SY:DR-_,=Q#1&:%FC'1^W%8P!P9(U8HRH\B<
M`\V]^Z]TKH?BK_,%DR1ER'\PBI?%:`J4=#U%MBDJ4E*V#-4B,EUU_P!?Q[]U
M[IXIOBG\VZ6B:-OGUN>JKV6H$=14]>;=,"2.3X6>-8`66(D>GZ$#^GOW7NFN
M?XB?-S*X?&4.5_F$[VQ^9IO/]SD=M["VWBX:T%M2:X)*:4DH/SJ%_?NO=-[?
M!OY?S4,--4?S(^\!.TC)55%-@=L0ZH'!#K$10ZHY-/Z6OP??NO=`OWW_`"WN
M[*CHCN2EK?YB/RGRRR=<[N<4.0R>".*KHAA*QZO'Y&GCQ_DDI:R(&/TFZWN/
M?NO=+W^0]DIJS^5K\6,54?N3;/VMEMGM4W#"K_@&?R=%]TS@(?)46+$$>_=>
MZN"]^Z]UZ_X_/UM[]U[I)[\IHZ[8^\:*0C16;5W#3GD?27$U:&W];`^_=>ZJ
MV_DA-21_`+8=%2SI.F/WUVA0DQNL@62#>>6U(Q0L%*_D&Q!]^Z]U;K[]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>ZP5-_"Y"LS"Q55%RS7]*V^A!/]>/=E8(P8
M\.M@T->@3ZHZ+Z^Z@S_9>Y-E8S(8[*]O;M_OOOJ6KRV4R4&2W*E!#COO,?39
M"HJ(L13"E@"F"`1Q:N;>S+<]SDN88A*0R1BB@#(!\C3B?.O3FH4(`R>AP!N0
M>1:_!_XCV2P3"5?@(/S%.J'&.@9^2"J_Q\[O1V*(W5&_PSCZJO\`=;*7/^V]
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MZ(Y3;\>[L/!5==[;-3/M^KG6GH*_PO5^2CER50X2GA8*\RFZ`CW[KW3ODOYW
MW1V(K]P468^'GR,QU1M:/"G/0U.PMMJ:&3<-.)\-13DUA)R%:C`)2V$P^NGW
M[KW0I]5?S4,-W)L;%=A;$^!WR3S&VLVM?+0U<.S]I+]RF/JYZ"9D4U89FCDI
MM)M]&X//OW7NA#3^9EN*G@B6+X%?,!4%U$<&S<&%CT_X#+(H'X^GOW7NNF_F
M=;I"DK\"OF.2!>W]S\$.!R?KER+V]^Z]THJ'^8IO*OIX:Q?@K\K(%D1W5:G`
M8"*5=(N59/XJ;&WT]^Z]U*/\P[>BRTL/^R.?*4FJ61D;^"8'2IC%],C')6C+
M?B]O?NO=8\7\_P#LW(#*?\X%?)^ABH9(E62J@VS']S&[$-)`!DF)90+@`>_=
M>Z8<C_,JWIC9C`WP)^7=1I!"STVV]O3PR.K+9?+_`!75J-N"18^_=>Z*'_(B
MWUE.QMV?S-]VY#:>YMAQ9GYH9')TFS=X)!!N+`K6[9A>>ERE-2R2T\,YF2^D
M-<>_=>ZV$_?NO=>]^Z]U[W[KW7O?NO=>O;Z^_=>ZZ!!%P00?R.1[]U[KOW[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_]3?X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7"0D(Q%[@7%OK_L/]?W[KW5+OR.PL\?\Y_X
M#[DBJHECGZ+[VPE12D#RLHI):Q&O]0-:_P"\>_=>ZNEN..?K]/\`'\\?UX]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=!+WUMMMW])]K[83)U.&;.=?[KQRY2CD\531&HPU6@GBD/Z67^OOW7NM
M:#^33V__`#"MB?!S:&P>GOBOU]VCU]LC?/8^U=O;TW#VM!ALKFZ7$;KR$,E;
M6TM[I-++<V;F_OW7NK1,I\BOYM0BD&)^"73C3^*3Q25G=J^-9=)T`I&5=@6_
M(/OW7N@R@^0'\\"9G>7X3?'*E2)"RQMW!42/-I-Q'K60G4W^'OW7NLQ[C_G:
M;KQ>Y<95?#WXS[6%3@ZVGH9:OMNMK%DFJ:>6`V$;27D"R<*>+^_=>Z'[^4;\
M5NV?A[\/-O=2]W3XENQZG>^_M\9ZDP=6:_%8R7=^X*G*#'T57QY(H3-Q_A[]
MU[JS[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T'W;6.
MI\OU9V3BZJ(3TV0V'NZDGA)L)8Y\!7QM&2/PP:WOW7NJX_Y*U=AZC^7MU'C\
M$2*#;N>[%VRL;*X\4N(WKFHY(%U@'1&6X_'OW7NK7??NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7CS_MQ_O!O[]U[JC;X-2+C?YL?\TW`*P'WL/36X2-0',^-
MJ*758_K^MK'Z^_=>ZK0^3^,VW3_SAOE7ELU24>XF;I3I^>BZ_C@^WBW'E,9-
M4U"Y_?\`N%PD>,V/@47S30-(D=2$$5B38^Z]T(F/Q==+D3V#FY,1DM[;EAFW
M7L2BS47^X^&CQR>"7Y`[\Q\X$."V%M6!#!MO`6C,\B)(L1!O[]U[J%G<C%14
M)R<.X*;$4M+2Y'?U)FMZTWWN1IY*VAJ*;-?(7L>"56EJ]QYIKT^U<%(+PQ2J
MZ1^F_OW7NKIOY3LB2_`7X^S))-+3U&&W)4T-56PF#(5E)4[PS\ZUE?"0O@K*
MYG\[I86#@?CW[KW5C?OW7NO>_=>Z][]U[KWOW7NO>_=>ZZ)M;_$@?[?W[KW5
M'?\`*3K<>?DA_-EQ%!"RC'_,*@JYY@2T<T^2V?Y'TR#TLRM$0?Z'W[KW5XOO
MW7NO>_=>Z][]U[KWOW7NL4[B.*20E0$4N2WZ0%%V8_X!02?\/?NO=5GY_P#F
MV_`_;?:E=U37=QRMG<1N:+9V8SU'M;<.1V!A]QU<J4L.*R>^*>@;;U!.E:XB
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MZ2'8(8["WN%!+':&Y0H`N2QPU;8`?DD^_=>ZJ<_D1-,?Y?>V_N#>1>X.[UM_
M:`7?V3]+#ZAAS<'W[KW5R7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KIOI]2
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M=J?O/@7T/.U3-73_`,(SAKI:JMIJ^J^_;<N8:H6HJ*,_;"I!8>2-0%C)LO%O
M?NO=6(P4SQ5-1,U1)()])6!B-$(7@Z!];?@^_=>ZF`@WL0;?6Q!M_K_T]^Z]
MUW[]U[KWOW7NO>_=>ZZ-N+V^HM?^O_%1[]U[JBS^55#%C/FA_-PQ-&ZI0R?(
M_9N56F!`/W53M2L%1,$_5I9C:_T]^Z]U>I[]U[KWOW7NO>_=>Z][]U[J%DJ<
M5>/K:5F=%J:2H@)1Q&UIH7B]+GA6]?!_K[]U[K0\[1VSM7X[R=Q?!'Y*?)WL
MOXB=*]O]_;BW3@LAV'TGM/.4.[)MU;LH\S&^$[(PT55E*3%U%9`J(\]GCOQ8
MGW[KW6\GUA08O%==[`Q>$R7\;P^+V/M7&XG.7)&8QE)@Z&#'Y2,GAX\A2Q+*
M#]?5[]U[I>^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_];?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7%VT(S6OI%[<_C_`%O?NO=4B_S!
MZ66@_F1?RG=Q*\:+5]G]A;;8EBI?[C:M74B-;\,S#\#DV]^Z]U=RMOQR1Z2?
MZ?G_`&WOW7NN?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>ZA9)#)CZ^,'29**J0$_@M`Z@_["_OW7NJ>/Y'^.IL)\5^T<
M%#4K4RXGY8_(N&H*_P"ZY)M^UE0(R/J"!)>WOW7NKE/?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=,6Z*=
M*O;.XJ60D1U."R]/(5-F"38^HC<J1R"%;CW[KW55G\E7$46WOA7_``3'RR2T
MN-[X[UIDEE-VDU;YKYF&HW)]<G^\>_=>ZMPO_P`4]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=<)+Z&T\-;TG^C?@\_X^_=>ZHO\`C=65`_GH_/VC+,M*GQ>Z
M.J$4"Y,[9NSR:3^I=)]^Z]T=7MS^6M\3>[.TMS]Q[[V/D9]][VP-+MC>F1P6
MY<UMQ-TXZCA,-/39<8JJIFJ8UA:UB=)'!]^Z]TUXW^5E\&L5C:3&T?2.-DI*
M/"IMJD6HS.>J'&$AG6H7'2S35S2M`*E=5N02/?NO==G^5I\%A4553_H-PKRY
M.K6LJS)D\Z_GJ!3?8"J9?O?^!24Q\:M^%]^Z]T:WI+I'K7X[]<XGJKJ#;4>T
MMCX22MJL5@XIIIQ2RU]0TU4S253R2,LL[7Y8GW[KW1+-\_S5?C!L#Y.YGXD5
MH[!S7<.W:G;=+E\5MK:-9D<=2/NA2U-*]>T\<;QQM8N5!L#_`%]^Z]U932.7
M2&6TP2J03H)0RRHKQB14G5CZ)`#8CFQX]^Z]U.]^Z]U[W[KW7O?NO=<6^@/`
ML1<M]+7Y_P!C[]U[JB;^63AJ[!_S"?YM$&35Z.LK.VNN\A%0278-CZC;U::6
MLC;Z`3`\CW[KW5[?OW7NO>_=>Z][]U[KWOW7NL4QM$_-KJ0#QP3^1?BX^H]^
MZ]UJE?.7=?\`*SZ@J>_^V\E1Y+Y2_,/:.9KLKLS8O<^$[(W[A*+>*5E/]OM_
M;F*FPTNW*:CIW8O&L=U!`/TY]^Z]ULC_`!LWO6=D=#].[[R&`_NK6[NZWVIG
MJS;+43XXX*LK,/1M48V&@9(_L:2C<F..+2NE0!8>_=>Z'/W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U__]??X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=4<?S/94B^<'\H!I)3#?Y4;B4,M]19MCY<*H`Y.OZ?ZWOW
M7NKQ;^JWTN#_`+'Z?7_6]^Z]UR]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4>KO]K4V`)^WFL#]"?&U@?\"??NO=4I_R
M.I)I.E_E'YWM*/FS\A-5.#Z8`=SG3I`X&H#_`&/OW7NKM/?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=-F
M;%\-E@+7_AE?:_TO]I+]?\/?NO=4Y_R1LQ4[W^'&ZZG*$PRX#Y:_)#%4XH6,
M*/%B-_S+")%4`.KA^;\'W[KW5S:?\%TEB792;D$\<'Z>_=>ZR>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KIB%!+&P'U_WWY]^Z]U2!\>L1447\\WYS92=K4^4^*/2
M7VH*E;B#<2JY5B`"%MS_`*_OW7NKP+CZWX_K[]U[KJX/T(]^Z]UZX^EQ?^E_
M?NO=<7`9?U$"X)*_D7^GYX/OW7NJ>=F_RK]BUO\`,(^1/S5[<Q&V]VS;^FZ_
MJ.IQ3567H\MM6?:=&\%;+7I3U,5/4/-468!@5/OW7NK@(5<,I*FVCEF]+%E.
MD#Q\Z;+^1]??NO=2??NO=>)`Y)L/ZGCW[KW7O?NO=89@&0J=.EF59-5_T$\\
M@C23^#[]U[JCKX`9/)C^:/\`S4\'F*J/(U:9'IO*4U;$AB2'&R8?(4]+0,MO
M740`>IOS;W[KW5Y?OW7NO>_=>Z][]U[KWOW7NL%3Y#$RPE%D8A49U+*C-P'L
M"/TWO[]U[KY_'S2^'O\`-RWQ\M.UL[@-F_(S=&-';V\\CLQMKY':^$V"<2YH
MY=AY"GD?34S4)D6U2'-]`L??NO=;RWQEHNPL=T#TUCNVX8Z?M#&=<[7QN_(%
MEBJ#%N2DQ-+%DXC/!:"1UG7U%+@F]O?NO=#Q[]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z__0W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UQ
M<A5)/T_XKP/]Y]^Z]U2G_,VQ\=3\R/Y2-?)74].U!\L:[QT4D0:>M,VSLI'^
MQ+;T:%.HBXN/?NO=76#]1/XTK_O;^_=>ZY>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J/56^VGO_`,<9;?ZYC8#W[KW5
M)7\CRI@DZN^6U+&Y\])\U^]A4*5()U[ADT'GZ#CW[KW5WOOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NFK
M._\`%DS'_:JR'_N)-[]U[JF#^0B"/AEV4"""/F/\H+@\'_C^(_?NO=7:>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NL<H)C8*0K6X8_0'^O\`K^_=>ZUYMT_)
M38_QD_G9]SU/9+YNDVYO[XC;*BAJ<+@LKN6=*K&[HCEC:2BP]-65$$4KJ%#,
M`H)]^Z]U81/_`#//C!'*OA@[BK@P.F>@Z<WO/#;_`(,,<MN/\/?NO=87_FA?
M&95N<7WB_(%ATIOEC<GZV%`#_L?Q[]U[IHJ_YK7QEI:R&A7;7R'JZF<V1:+H
M/?=4+?VB9!0Z0H'UN??NO=*"@_F6=&Y.H^WQW7'R7J9M.I?'T%O-0R@7;29(
MHA<+]?I[]U[IXD_F%]7(Z*>I?E`RN#=UZ&W3:_!47,@`))_I[]U[I`9G^9QL
M_&U,U-C_`(Q?+_-"%P!44W2>7@A<$@%E::I!M;Z<>_=>Z:V_FAX3QAA\3/F(
M"750#U#6K^H@<EJ@@?7W[KW2BI_YC=!5QQ2Q_%3Y4VDM_P`".M9X64&W)4SG
MD#_6]^Z]U)_X<(KIXZA\1\1_E!DG@9%,4FS(Z#6&-BR-55`6RC_;^_=>ZQ_[
M/]NR6%M?PJ^394VU+_`<26*D@ZB#6+POU/OW7NJ^OY67:%;VG_-"_F@[AKNN
MMY=;2UN(Z5J?X'O2&*#)`B'+1*S11%O&61;@$\CZ>_=>ZV*_?NO=>]^Z]U[W
M[KW7O?NO=89P3'86_4OU!)MJ%]`']NWT]^Z]UI+_`#9_FU?S&L;WMWYMGJWM
MSJKX][9Z@['W?M7!]<[QPT$G86Y<)MO`K78?(XW&55-)D-P/NVO(AIOM3(JL
MPN+#W[KW6UU\'>T>P>Y_B;\>.U.U<%D=M]A[^ZOP.XMWXC+4@HLE1YRKA;[F
M.KH]"&E>I5!.`54A7`//OW7NC:>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M_]'?QFJJ6G*"HJ8(#(P1!--'$79N`J:V74Q/T`Y]^Z]U%3+XF2IK**/*8YZS
M'Q)-D*1*VF:IH89%9HY:R`2F6FB=5)#.%!`/OW7NNL7F</G*./(87*XW+T$K
M,D5=BZZER%'(R.8W6.II)98799`5(#7!%OK[]U[J/0;DV[E:S(X[%Y_"Y+(8
MA_'EJ"@RM#65F+?Z:,C2T\\D]$]_Q*JGW[KW71W+MQ:>FJVW!A%I:RK_`(?1
MU)RM`*>JKRYC%%33&?QSU9<%?&I+W%K>_=>ZQ3[LVK2TLM=5;EV_344%:F-G
MK)\SCH:6'(R.L<=!+425*Q1UKNX41$AR2!;W[KW3G!DL=4U=704U?15%=C_"
M:^B@JH):NB^X3R4_W=-'(TU-YX_4FM5U#D7]^Z]U,+*!<D``V))`%_Z7_K[]
MU[KC</I*LI'#"Q!NI^A%KW!]^Z]U2'_-@R=9A_D7_*IRF.HH)YHOF=A:62KF
M`U4,-;@ZZFE,>JUO(LA7_6]^Z]U=W_:`*D?@$?IOI)8_ZWXY]^Z]UD]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6.8!H
MI%:]FC=3I_59E()'^(!]^Z]U1;_)5@3!9[^8ELF%Y9:?:_S8[&\,TK$E_P"*
MRO7-]>;`OQ[]U[J];W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4#*QB7%Y*)F*K+05D98?50]/(I86YN`
M??NO=4]?R1<?0X#XS]S;7I))G;"?,?Y'&9Y59&D>OW3!5+<.H)&EK_X\'W[K
MW5RGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K'+?1P6'J6^E`Y*ZA<:3_4?[
M;W[KW5'&WZ>EJ?Y\G8-)D6>:*I^%6+EI\754]+5T-5X=VT!,[^>G=XVAM=;-
M:_OW7NKMDP^+B.F+$XZ./_4QT5(@^GY"Q#Z>_=>ZS#&X_P#YUM$/]:EI_P#K
MV/?NO=<ACZ%3=*"D4_U6G@4_[=5O[]U[J2D:Q_H5$'^I1%4?[Q[]U[K)[]U[
MKWOW7NO>_=>Z][]U[KWOW7NN#MI%[Z>;#B]S^!;_`!]^Z]U2C\0PM!_.'_F8
MXX",-7]:?'?.,1(NL^2#-4US%?6%/];6]^Z]U=C[]U[KWOW7NO>_=>Z][]U[
MK')JTV73<E1ZM0%B>>5Y!M[]U[K1-_FOYGO;<O\`,#R^R^L*SMS:D&%W-C:_
M)]];KZ#PN]=M;0H8T\[4.Q$I,1/F<M4Q(-,4TC%0QN>/?NO=;EOQ6J\G7?'[
MIRJRV\<YO^NGV%A36;SW)@O[L9W<E9%3"&?(Y+;_`(XABC(Z^B$*"H`N/?NO
M=&)]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?__2N:_F\[?[KF^4?5&[^N<M
MW)793;>SL5%UWUAM_:^X<WU;V'ND;LQ\]1+G\Q@*JG&&S-#1!OW:DB)4%^1<
M>_=>Z)%L#:ORAI>[]^U&]^G_`)-U/8G_`!GNK^3U+M_)YP;>W;USGL)!+UWB
M=C9^>K7'5];0S%XJ:"EM+"`RW!/OW7NK&OY/.P.[\'TC\RL-2XK?6U]L;BS3
M3?'>HWUBLKM6MQ;UFT\E3RX>FPV:FGJZ-]NYQH4GJ;!*B<F12?K[]U[HN/2V
M.[$ZBV]_QCOX=_(1OEAM+JOLW"]]=CY/+9F@V]NS?6=Q];C]NY6AFJ<A)0;Z
MJ*W+U*R0R1+:DB.KBWOW7NB8[*^!7\T$].;1^&?9F+[%HI/]F#V#\E=O]P;4
MW?75F.VI1;CC_B.Y,!4Y:IK36OF=O;H1144A/@^W=]`/OW7NGC</P=_FO=[=
M.9[X^[GV35[-S53\J=Y]W;AWE5;KF@V_G3L/!XH[3FQ%535GW$5/N_/8B"1*
M4VA1G<D6)]^Z]U:Q\*NP?ESUW\A-X[H[R^*?<=6W=NQNCL37;CQ-9B*O;VVM
MQ;3P]7MS=&1K:9JSS)225=/YF*C6R$'\^_=>ZD?SBOB#_-E^2,\8^!_RIHNH
M>M1L:/&;GZVB$.+S.Y-SQY5*M<GC-P>,55#(D*K_`+M4'01^??NO=6[?%#97
M<'7/QZZCV5WYO-.QNX-N[*Q.+WWO2GIUI:;,9JFIH8ZAXT6P8KIL7/ZF5C^?
M?NO=5P?S<J=E[*_EN9@RQI!B_FCL?SJPL2*JGJ(%]9X6Q;_>/?NO=74J27!'
MZ2M^?KR%M_K<>_=>ZR^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[K@[Z`#_5E7_6U,%O_`+"_OW7NJ1OY1=/'0=S_`,T'
M&E@:FF^:6YGG6UG`GQL;QLP/J`9>1_4?3W[KW5WGOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH]6`:6I!
MY!IY@?\`6,;>_=>ZIL_DR5E34;(^8--,28:+YH=P)3`_54>>B)%O\=/OW7NK
MF_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6.5@D;.5+!/59?KQ_2W]/?NO=4
MT5<M/B_YY^WXZBKITJ=U_!W/-0TPA/W%2F%WKBVF+2V(`A1[_7W[KW5S?OW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KIOTFWUL;?Z]N+
M?X^_=>ZHQ^+<42?SR_YC4BB999?C7\<#+<D0L5R>9`**?K:_X^GOW7NKS_?N
MO=>]^Z]U[W[KW7O?NO=<6-A_KD#Z$_4@6X_K[]U[K4(RF!W-WE\XOG7@=R_$
M#OSY"XOK_LS$8O;^:ZQ[9K^O\-C,558&.48RKI<IE:6DJ*R29R4,%]-[GW[K
MW6T1\<<3_`NDNM<,NQLYUJF,VS14B[(W/F%W!N';ZQH5%%E,NDLZUU6A_5)K
M-_Z^_=>Z''W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]/?N>G@F:*66*.5
MX6)@9XE+PL1I+(2/3Q[]U[K+H74Q*#419Y-"WD6W*D@7(]^Z]UQ1`MD14CA7
M]"*+$FUR>/H+^_=>ZS6_U_\`;G_BOOW7NN_?NO=>]^Z]U[W[KW7O?NO==$7!
M%[7_`#[]U[JE#^<U!/#BOA/EZ>C,[XWYF]2+Y/.L2HM3D)86U%V`_2Y]^Z]U
M=3%](V^AD2,NI/(M&>!]1P?K[]U[K/[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNF`8$'D&UQ_L??NO=4@?RLL@)?F!_
M-PQ20)%%C_E;B*A9%(O.U?M36S26YN#%[]U[J\#W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7"0!D<,"5
M*D,H^K+;E?\`8CW[KW5.'\H26%#\Z\5!"D$>*^:?9D44:.K>BHAH9RY53Z06
M/OW7NKDO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7%C8?2_(OS;B_P!3?\#W
M[KW5&/8-+,__``H$^.]4GE,$7P2[>5M#@0J7W5APODC_`+1/X_I[]U[J]#W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT;<7_!O_`,C_
M`,/?NO=4(?&7_<;_`#ZOY@%.CUE5_&OC#T/42M+*33T?V^7RT@CB0V!5CQQ]
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO==$`VN+V(/^Q_
MK_L/?NO=4@?RQTQ=#\YOYN>-H6J'J'^1&RLC5M*MDUS[2F4A&L-5FOS_`('W
M[KW5X'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KJX_J/\`D7U_VWOW7NO'Z?X'C@_@\7]^Z]U39_*7H*+%[S_F
M)XZE=I9*7YG[Q\[O]?\`*,51SIIN.5.K\<>_=>ZN4]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO==&Q%OJ#;_8@^_=>ZI%['CBIOY]7QMJ?,1+D?A-W'3^'Z:D
MI=Q8B35_B`6'^Q/OW7NKN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7![Z;`<L=/UM:_%S]+@?T]^Z]U1MUQB(L9_/C[RR%#*]]P_#[
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MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW73$`7/TN/\`;WX/^W]^Z]U29_.]
MFIZ+J+XM5U6YBIH/F=T:)6!M8S;DCCCO_KN1[]U[JZFE<O'"P),;P1,FKA@&
MBC/(^MS]??NO=2_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]UPDTZ=37LA#\7OZ3?\<G_`%OS[]U[JCG^7/AZ_!_S'_YL
M,$V1IZRCRG8_7.9IH(HW26F-5A*JZR%@`U@2+C\^_=>ZO)]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW75P?H1[]U[KOW[KW7O?NO=%N^7?>=5
M\:OCCVMWE0[?DW36]<[8J=P4F!2.ME7(U$#QI##.N.22L%-KD!D9%)5`3^/?
MNO=5_=!_,WY9?)^DV[N[IBF^(&ZL#4[7-5N3;-#V)N.?<V%W*:76*.IBLDD,
M5)6S(LX"-8JRDW]^Z]T9FGW'_,29<,'Z^^-XD_@N57/3?WLW0T8W'^Z<33TD
M:JK?9Q2:?(?RM_?NO=$D_DJS[[J<U_,)J.V9=O0=M/\`+_.)V#@]G2U%1M'!
MY)-O8_[&#"5-7>>9*BC]<A)(U^_=>ZO4]^Z]U[W[KW7O?NO=>]^Z]UXD#ZFW
M^O[]U[IOR58E'0UU2"CM14D]7)$#=S'!$\S`*IU:F5./ZGW[KW5"73'SX_F9
M?+3;&^>SOC;\7^C3UC0=H[[ZVVG6;YW[DL?N)VV!FCAJO+YC&(RA(*]XFT(G
M*W]^Z]TI>B.B?YA?8'\R'K3Y7?*CKCI7K_8_7G1'8/6=+3==;EK,YE*K*;FK
M,;40SR&I+$4DDE)?3_9'OW7NKV/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7%S923]/H3_0'BXL#SS[]U[JG;O_`.''R_B^<DWS*^*W
M875.'K,_T[3]5;BVSV?@LA7H(<;D_OZ6KI)**>,$R,Q)/U^GOW7N@[[`^2W\
MQOXO=K_%W$_(;(?'G=?7_>?<^+ZMS4NQ<'E\;FL7'E:8-!/335=2\5DJ#ZB0
M;C@>_=>ZO&C_`%K^DL%=?1J"B)F)0E3QK.GG^GOW7NI/OW7NO>_=>ZX26*'5
M^GC5]?H#<_3GW[KW5*??_P`+_A;\COE'VW68[Y%[^Z3[\FVAMS#]_;>ZR["B
MV/)O':.121-OIN*EK5C@F$]*SQB:%C(5-B0??NO=68_&GH?J#XU=0;0Z?Z+Q
M5#B>M]LTT\>'BHJ\9-JV>9R^1S.0R6N4Y+*9&LU-/+JY;W[KW0_>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO__6W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]UT387/OW7NJ7OYWJ4G^R^]!S5<'W)@^8/0)AC*ZKO+NZ%`
M;'@Z20?]A[]U[JY>F8&.$"]Q#"3<#@&($`'Z_7W[KW4OW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO==$@"Y-@.2?];W[K
MW5%GPO[`VOMC^9W_`#0\=NK<>W-L1OD^J*ZFDW!F\9AC4I_":I'DA&1J:;S1
MKJY9;@>_=>ZN%_TV],?\_=ZP_K_Q_P!M3Z?U_P"+M[]U[KW^FWIFW';G6'^O
M_?W:O_UV]^Z]UC?O#I@.D?\`I=ZO#/<B^_\`:=[*+FRG+ZCQ[]U[KE_IPZ6#
M*A[>ZOU,"RK_`'_VGJ*C^T!_%KD?XCW[KW7)N[>F$TZ^W.L%U?IU;^VHNK_@
MM\L+^_=>ZXOW=TPJ,Y[=ZP"*+LYW_M1551]26_BI``'OW7N@^J?E[\6Z*J>@
MF^0O42U:,5>%M^8&60,OU5?#6L#;_`^_=>ZY_P"S<_&72TG^GKJS1';6Z[OQ
MC*ES8:S]P56Y/%_?NO=<9/EY\8X::2MD[XZS-)$+R3Q[FH)447^NJ)WO[]U[
MH-Y_YBWP<HZIZ:H^4'4Z3QL5DB?.L'5KVM=8"I-_?NO=<H_YC/P<G=HX?DUU
ME*R#4WCRU2R*!]29%H2G'^O[]U[JOO\`FH_/;X<[K^`?R7VMMSY'T%=FMP=?
MU6'HJ?JW(5%9OII,C404Q_@$(H65ZO0Y-C]5O[]U[HB7\K/)?!'XHY?K+LS-
M_-W9F5RM)T-2]:XK9L6Q<UM1X:;(9&+<%5E=[308>1,UO%*ES'45KG6[C3?3
M[]U[J\I_YH?P&6`S_P"S+[(:-:H4EHJ/<C2-4AQ<JBX(L58_GZ>_=>Z(]_)<
MW5MWL+L/^9?V5LS)#-[(WY\PZW,[4S45'7T=-DJ&#;%+25%13BOIZ9YHVJ!P
MP4CZ\^_=>ZO?]^Z]U[W[KW7O?NO=>]^Z]UTPN/\`;6XO;GZV]^Z]TE,YB:(4
MN?R:>1*^HP>1IGD$T@0***<*1%_FPR_@GW[KW5/_`/(6I:JA^$>Z*6K67RQ_
M*;Y)'SS2B5ZA7["K6#WN=*@?0>_=>ZNL]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4@_S@:B3_`$B?RWJ97`@J
M/F-L]Y%)`8F.-&4V/]#[]U[J[M38Z?\`@Q_/^K/OW7NN?OW7NO>_=>ZX.0JE
MB0+<W-[#_'CDD#W[KW6DU_,W[/\`C-U%_,A^4V^MW])[D[VWIF-G=%=>Q;<K
M.R,AU[CX=\9*:K&!I\5!C:VBJ,AAWQ[F6HJ^8H6'J86]^Z]UL9_RDOD!UW\C
M?AMM'>W6O7^2ZPP>&W/NS8M9LS(YNLW*N)S^U\AX,U'C<_723S9;&O4RZHY@
M[(X^A/OW7NK-??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__U]_CW[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO==-JMZ;7X^O\`K\_[Q[]U[JE'
M^>UDZC"_$WK#-4E,E5/BOE?\>*I==OV4._,?'),MR.467C_'CW[KW5T-"Y-/
M2AA=C2PDN?J?V8F/^PNQ]^Z]U.N.>?I]?\/]?W[KW7O?NO=>O_Q3W[KW71(%
MKD"YL+_D_P!!_C[]U[KOW[KW7KC^OOW7NO>_=>Z][]U[KWOW7NO>_=>ZZN!R
M2+#ZF_T]^Z]UQ?Z?2_(N";"U^2?K<`?C\^_=>ZUK?C1\5NG?D]_,[_FCY+O[
M8-)O9]O;HZXP>W&KI:ZBCAQ#8BIE50M'50>53I`#$6-O?NO=6RXW^69\%<7'
M''2_&_83>*,1#[F')5&I5X&MI*YBQ_H??NO=2I?Y:_P:ED#-\;]@@_D+35Z1
MFW]0*[Z?T]^Z]U`K?Y8OP1R">.?XW[$4W4ZX8\E%(MC<%76O!MQS[]U[ING_
M`)6WP*K,KA,Y/\<=G??X*DJ**BM_%(HWBJ$:*3[JECKQ#4L%8E6;E3R/?NO=
M+./^7=\)86IV3XW=;VI`RQM+C:N0@.I4V#UC`_7\^_=>Z=1\!_AG&I7_`&73
MK0(1R#A78&_X*F<\'W[KW6"G^`?PLI)Q54WQDZECJ%8E94VK2227(MJ)8DB]
M_?NO=*&'X7?%"-)84^/G6$<52`*A5VO2!7TFZWNOX//OW7NG2E^(_P`8,=`:
M6DZ,ZU@IQ8-$NV*$K<VT@@Q,&!_/OW7NL?\`LG?Q7<LS_'OJ4EB"S-LK".[?
MD$L:75>X]^Z]TY4_Q2^--'`]+3]&=70PR@HT<>S<*JL"+$$"E_H??NO=<J3X
MK?&S'R&2DZ,ZPIW=1$3'LW"'4BFXU!J1EL/\1<>_=>Z4*="=(*%$7477,:J!
M&`NR\`OI0\``8\W'^/OW7NI)Z.Z95-*=4==+;D$[+V^=%OHPU8_G1];?GW[K
MW2FVELG:&R*:;';-VQ@=JX^:=ZNHH<#AZ3#4L]7+?R59@H8X87>4_4E;^_=>
MZ6'OW7NO>_=>Z][]U[KWOW7NO>_=>Z:LZ-6$S"GZ-BL@#_L:28>_=>ZIN_D0
M.[?#+?"O*TIA^6/R5A#-?]*;\?2.3R!?W[KW5TWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ/T/)'^(]^Z]U1[_`#A8
MRW87\M^4QH-/S'V<-1(U@E%NJB]R/?NO=7A#Z?[$_P"]GW[KW7?OW7NO>_=>
MZQ36\;7_`,#Q];WXL?P;_G\>_=>ZT>_YS/=F2V?_`#+,]@]T=&[2WQM&/;/4
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M]T`Z5OP?K[]U[I64G;O\SK)UDZP_$_HG#T<-/JCFS?;U<99Y@O,:1T4;ZD+<
M"_T]^Z]TD)]W_P`XG+4\E1C^H?B)M=ONIA%C\AO7=>5E^U%Q"QFA*QZKV)OS
M[]U[IDBR'\ZN?/TPJ-O?"_'[;>.-:IH<EN^KR$$IMY)8ED<1NJG\$_3W[KW2
MZIX?YL[PRQU-5\4HITJ&-//'2[ED#4X!,;-&9@%9S8-;D#D>_=>ZC8ZG_FY2
M&3^)UOQ,I0*BT7VE#N><20DV,DNN<%'T\\>_=>Z@MC/YP<N6JM.Z/B12X=+?
M;@8#<TM5,2/[1:KLH4\F_OW7NH9P7\XUI'OOOXCQP:V(U;3W%(5CY(X%8-3>
M_=>Z56W]I_S7*G(,FYNW/C!C<<8OVY,7U[G*N=I`"0-$U>%TW^M[6'OW7NGZ
MIZ]_F=.U3]I\B/CK`I*_:B7J')2:;$:M=LGSZ?I[]U[I+U74?\UBLF$@^6WQ
M^QL8U6@I>C*B="3?3J>2O+FW^)]^Z]U-Q/2G\SN2<?WC^8_30I&6573"]'I3
MU8.DB)XY)ZUXE*O8G@\>_=>Z3&2^+?\`,HJ\G#/1?S!\/0XEVD:II(^F,&U0
MKD-X!3S.[?LK+;4#]5]^Z]TM_A#\$=V_%_L[Y`=U=G]X9+O'M'Y"9+!5NX\U
M4;>HMM4&.I]OTTE/34]%04)\8U^3GCW[KW5D_OW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z:LX+X7+B]O]Q>0Y/^-',/\`B??NO=4F
M?R"\Y2U_Q*[<PT,T,D^WOE_\C*.H",Q;][>3SK?5S]3[]U[J\CW[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U1U_
M.&B=NQOY;TVI0J?,;9ZE-0U$F-?4%^I`!]^Z]U>(/R/S<\?ZY-O]O[]U[KOW
M[KW7O?NO=8Y2!&Q;Z`<\Z?R/S8V]^Z]UI#?\*.\_W'L[Y<]7Y7I]:_$P9/;6
MWZ7=FY>K*[/9SN7'TD>5<LV$V3%!+@ZC7&U@[@EA^KCW[KW6RS_*ESN8W'\-
M>N<CG:[N3)Y%):^FDK>]]K46T.P*E:=88Q4UF(H8H8%IIBW[;VNPO?W[KW5D
MGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__T=_CW[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>N+VOR?H/R;?7_;7]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=-N975B,JMR-6-KEN/J-5-*+C_`%K^_=>ZHV_D%"&D^.OR,PGV:05F$^9?
M?U-7U.A5EK)JG<[544CLO+!86%O?NO=7M^_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>ZZN+7N+?U_'OW7NN_?NO=>]^Z]U[W[KW7O?NO=4F_SB**E?/_
M`,O?*3UL-(]%\T.O8HKE5FE-3(B%8B3J*\>H#\>_=>ZNQMR3:WTY'U/%N?ZV
M]^Z]UW[]U[KWOW7NL<H#(5.DAB!9KV/(X.FQ]^Z]TCJ_96S\AFH]PY/9^V\K
MG8HOMDS=?AL559.*%22M-%65--)4QQQGZ68#W[KW2OB145$1%CCC72D:J%1%
M`TJL80*@4#\6^GOW7NLWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__2W^/?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<)/T-<$BW(`))'Y``(-S[]U
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M?ZC_`&]^/]Y]^Z]U2O\`SA,!25-;\!]R5TR+2[=^:?6<4D<HU1R2Y>J%-3^F
MW+)(.#[]U[JZ?G5S8C^R1^..;_Z_OW7NN7OW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>ZXM^.;<BW^O^`?\/?NO=-$,N1_BTD#4L`Q*4BR4]:)6
M-1+6,Y$T)B_2(T%R"??NO=//OW7NO__3W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U%KM`HZHR?H%/,6&K3
M<"-KC4`2O^N/I[]U[KY\>W.H\=OCN#Y392MVC!Y\5\ONTL3L>A3.93#9+L_L
M'(GPP5V2IZ"L@6+K;K;"SR5^2F<!)98AJ:Y]^Z]T(N$^+O7.4K<?@-K5^;II
M:_$97KS:F\*S>^XX<;!M+%U#9#NWY*9<29+PQ;5Q\ODH=O.^D'2`A-_?NO=0
M,CU1TOE<S52[+K=W[1ZOI,'2P4>5GWWN63)XCHW:$R+D^S,A3OD4:LWYW#N&
MF^TPJ-^X5E+(I!O[]U[I3YOXZ=(YF:OJ-Z;8W)B(,]48/L'L)*G.[A.9ZIZM
MIC%3]8=,8**/)>23N3M.H"252$&:*)R2H'OW7NKQ/^$_T4-+U-\JL7_="JZ^
MJ,/\H-T4R[(J,E5Y9=L8J7#X^?!X<U%=///!74^/D#54=["=V_-_?NO=;`OO
MW7NO>_=>ZX2?IO;Z$&YMZ/\`:^?J5_I[]U[HA/8G\MCXB=H=WU_R'W7US6#M
M[+1X"/-[JP6Y<]@&S4>W)#)B?XE38VK@IJM:9VY5@0??NO='KH*:.AIZ>A@C
M>.GHJ6"E@4LS*L4"+'$H=RTDC*B\L3S[]U[J=[]U[KWOW7NO>_=>ZIT_G#I)
M)M7X:)%61T+GYM]'GSR0"H4J,UZHA$W%Y1Q?^S]??NO=7"+_`)T\$?J_43SR
M.5`XT\?4^_=>ZS^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[K_]3?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>O;Z\?0?[?@?[<^_=>ZZN/K<6_K?W[KW7?OW7NO>_=>Z][]U[
MKU_]Y^GOW7NO>_=>Z][]U[KWOW7NO7'`OR?H/ZV_I[]U[KJX^MQ;W[KW7?OW
M7NO7M]??NO==7`%R0!];_C_;^_=>Z[N#^?I]?\/?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT""
M+@@CZW!N/?NO==W']?K]/?NO=>]^Z]U[W[KW7KB]K\_6WYM_6WOW7NO7%[7Y
M^MOS;^MO?NO=>N.!?Z_3_'\\?[#W[KW46MN*2I*@DB"8Z0-1:T;>D#_:O?NO
M=?/\ZOJMGP]R_.@5%9FI#'\C>U/]+O8`GJF78'5\V1H?!U;U[3@!6[%[AS(2
MA#07G%&7`M[]U[H<=S9-,=1Y3;.6PE11;FW'B=NR=D[3PSD3X':4E1"W2?PY
MVK+$2L&9RJ>+*;D9072)'\YL3[]U[K!A?#C<FM?EJ&AW5N:BW+1)3;:H448;
MM7Y,04RC#X6DF0&D?HSXXX8'[L(!2??1EF-_?NO=**&IS39O'P8G/4&Y,M4[
MAK,GM'<F7\?\-["[:9&?M+Y2[F$S*G^C;JN@U4&"$C+3-4JIBN;>_=>ZM0_X
M3QU^!GV;\X*#;FZ<]OK%T/RLSE1!OC<*21U^[I,EAJ6>LSS+*JNM+7UD;O3`
MCB`BW'OW7NMC'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71%Q;W[KW
M5)O\[K)2X;K+XAY:!K347S?Z#*?U;S;FAA95%P22K^_=>ZNP%BS$"UFTL>>;
M"XM_@"_OW7NN?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z__U=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>-OS_O/OW7N@F[M[LZP^/'6^Y>V^X=U4.S-@;2HUKL]N'):OM,?3F9(8
MY'"@LS--(H`'))]^Z]T0K&?SD_Y?>8C\V([IJ,S$WV[I)CMD;MJH_#5(KQ3C
MPXG2Z,Q`+`FU_?NO=*6;^;+\'T8Q?Z3<W-)I5_'3;!WG+*X)](C"8HECQR.>
M/?NO=)RJ_F]?#:*I6G@K>XJT>HA\=T?V'74\NE2;I-#B>>!Q_7W[KW3K'_-8
M^.61HON]N;)^2FXYB;0T&)^/O8)J:LCZJBU6-B4*HY)O]/?NO=,[_P`U;KA<
M<]=_LM_S%,JU/@%".@-X?<,JFWEB/V^D1D<G_#W[KW47_AV'KCQ%_P#9:/F6
M9!;]@?'_`'@7-[?3_)P.`;^_=>ZPG^;'UZP(7XP_,Y3:]V^/N[;<<V]<)7GW
M[KW3[B?YG^Q\S&]1#\:/E[`(^":OH[<U.Q_UD9`/5_K>_=>ZA2_S-TJ/O9L!
M\._E]GDH"`0G6%;CVF#-I+0Q5JQLVD<FQ]^Z]TG6_FE[B9)FA^`WS,F:+4?&
M>OXXA*5!-@TD@0:K<7/OW7NFRG_FH;VK&1!_+K^:2*XDUL^S<>B0^(,R_6<#
M]T@"_P#C[]U[I0K_`#&>\<C0+5[?_EN_*ZK:0JL*Y*/;.+#,6X\D<E4T@O\`
MZPM^??NO=!CFOYA/\P&?+8W'[6_E6]K5-%65305M;G=[X#'?9QLI$;MXW*C6
M>".1[]U[H0?@5_,4[8^57R-^1?QR[F^,F4^.^\_C_AMKYVH@R>X(,S)F*7<\
MKT\+`TY"%5M<$<'W[KW5N'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KJX_J/
MZ>_=>Z[]^Z]U[W[KW7O?NO=>]^Z]UU<?2XO[]U[HG7S_`._]W?%SX?=Z=\["
MQ>-S6\NN=FU.:VWC,LDDN.J\OYZ>FHXZN.(K))%Y9P2`>??NO=$JZ^R?\X[?
MVPME[\IMR_$C%Q;RVIM[<\&*JML;A:KQJYS$TV1^TFE2M\;/%]S:X_Q'OW7N
MEH<+_.0DIV5=[?$."H,<FB5MK[CEC5])*@HM8+W/U_'OW7NL5-@_YR\<,0JM
M\?$&:?3::2+:NY(Q]?[(-;;C_;>_=>ZG3X7^<.IIQ3[Y^)+*Q`G>3:VX_1>X
M]*K6#5;W[KW1/?F/W5_-_P#C/MCJW==7VA\531;\[>V+U;5I0]>Y>IGHVWMD
M4QT=9&:RN`(I9FU'GZ+[]U[H0/E'B_YQO3O0^_.T]J?);H#<^7V1@'SD&VZ7
MJ1<=49EHY86-`<C75R0P@+(1J)%Q]/K[]U[HN?2.\?YF'=IVE#N3^9_\7NM^
MR.P,)B*VGZ?P6Q<%GL_@,M4T7W=3@XJ=ZM_N,G!$"TJ*Q;3R![]U[HV]=\2/
MYOYQ\D4?\RC8<T\BS1%DZ&QJDK)&R+I\;ZD>[?J_L_7W[KW6K/T)L/O+I#M#
MY@;5^0.]<'V+V5M?Y);@;J?"0X^BQN,SO9F0QK3[B^0O9U#2,L=-LKKO#2M4
MT258$8JM-KFWOW7NA:QE/A<GF_N$WG5X2AC$N5R^^L]'4RY##]<M(?\`23W?
M7ZV\S;_[9S1.-VLMQ,E&P$26Y]^Z]T++?W3EIYZNNDKMDT@Q2KF,+3+43;DZ
M@Z0CF']TNDZ`(///W?\`(3(%:RO,8^]2D<A[#W[KW3)E9(I<W2T\NVZ^LR.1
MH\?_`'AV/M]#5+3Y5)$;K+XJ;5DA)AAP>UJ5DR.\'6ZF13YF_'OW7NK@/^$]
MD=1!A_G-!DMP83<N>C^1]'_>+([:-,-NQ9P[4A:NQ&WX:,"GAQ&`NM%&%N-4
M!Y]^Z]UL:^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JC7^>G_
M`,RH^'O^'SL^/%_\/]_5!]??NO=7D']2_P"Q_P!Z]^Z]UR]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_];?X]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71L0;\C_;^_=>ZJ0_GA4]!+
M_+7^051D:23)08V+:M?]@L,DZ5G@W9A9/M9XD5BU-+;2]_3;Z^_=>Z/'T1L#
MKQ^G^JZVEZZV7BC6=>;2J)*:#:V&I]#U6#H)VB<?8EY`&)))))(O[]U[H7_[
MA[)7U#9VTT(L0Z;>Q08&_P!05I`?]Y]^Z]TXQ[?P<5@N#PZ*O"Z,50H$_P!8
M)'<#_;>_=>Z<X:6F@(\%-!"!>QABAC'/'&A`0#[]U[J5[]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NN+D`7+:0"+GZWY^G^N??NO=:W7QT[>Z\
MZ;_GC_S(XNX>Q=F[!.X^E^E*O;(W;N6CPRU](F2K6(HCD:B"*8QI]5341[]U
M[JYVJ^<'P_I4E>H^3'2ZK"VB8KOS;\WB?Z:7$-:Y5O\`#Z^_=>Z;ZOYX_"ZC
M@AGK/D_TG30SFT$DV_<&@D_)NK58-A_C]/?NO=28_G+\-)(TFB^3?2C1N`5D
M3L';Y60'_4?Y:=6K_#W[KW4V/YM_$*2))X_DGTR\,C^.-AOW`6,GTT*?O+ES
M_3Z^_=>Z;ZCYU_#6GJ31U'R;Z66I%KTYWW@_+'<\>715,8K_`.U:;^_=>Z@5
MWS]^%&+$CY#Y2=*4\45F+/O?#E([FPU2I4.I)8_Z_OW7NFEOYB_P7BEIX9?E
M-TX\M2DE1#]ONNEGB>,+=G,D*R1@6'%R"??NO=,U5_,Z^`M,2DGRDZMXD$0,
M66GD5I.3XT9:32[\$V!OQ[]U[KN'^9C\$:B188?DKU[)*XU+&*JO#,H_M#_(
M@2O^/T]^Z]UQJOYEOPH@`,'>6`R$1NODQ=#F,@I>]@/\GQ[,2+7/^`]^Z]U!
MR7\SGX4XEHEKNXJ6/S1)*L@V[N.2-5D.D:G3&D(QO]#R/?NO=)ZH_FP_!RFF
M:).UZVI"K<-1;+W54QR?7]#QXJ\A']`/?NO=5]_S3/YE_P`3NQ_@;WYL+86^
M<OF-[[ZVO3;=V=AVV9N>A?+[@R&6H(L?CH:FLQL5/!4U$UE4EK@GW[KW5W?Q
MTBR4'0O2--EJ&?%92GZFZ_ARF-J03-154&UL;%-2RD@%9XYKAK\\>_=>Z&OW
M[KW7O?NO==$V!)^@]^Z]U3E_.AQ<>2Z%Z#\DK0"B^7_0%9Y%^H*;P@:Q(%@&
M+6_V/OW7NC._S*HL7/\``[Y*'-;=R6Z\53=8Y&LK<!A\C5XK*Y6"`4\CP4-=
M1*U7#5`+J70-1(M[]U[K6?\`Y=?\O+X0]<=B?'[Y=2_-=J*LR6^-O]J;'Z=W
M9F:ZKRFVLG'MC['/;)KLE6(*NJGIJEC=I%XT^_=>ZVCT^=_P_D@I)8N_M@>*
M?<4FT8&3)3$OG*52U5B@WVS7FA$=V/T/TO[]U[K2G[X^370.3^:'SS7`;4P6
MT]CS]J4N5['[#K-S9)<OWX_V5#C]J]=;4@R<!DQ>`K\_%%-EGI?VVI8&#<'W
M[KW3@W=G1.&:N^_[*ZOR>9VCF=MY*L6LS]/2X3LGY+9V.*+9^WZD31+3#ICH
M_#R&0AKPRUD0))/OW7NGF3O+JXU\E%@N[]@[AS-)NQ\1@MR2YVBF;=7;.0HF
MK.T_DMGAXVFJ<+LG%E\=MR-[1>0KXQQ[]U[K/MGN'H''8^B_@W?>U<!#NQ\[
MCL9F:K.)79[8/0>&:2;M+?56HC^Y7N#N'-JL%*Q`D@I9/2+#W[KW5QG_``G'
MW'M'<V$^=-?L'"XK;NRW^0.$FVOA,;7?Q"?'8&IVS.V*_C%0PUR9C(TD:U4Y
M_P!7*0>??NO=;+WOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN+DA6(%
MR`;#_'W[KW5(/\\;#5F6ZB^)?V36_A_S?^/]=4V_,4>ZJ<O_`($7;W[KW5WM
MO4;C\W4VY!TV87_V'OW7NN?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z_]??X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=5<_SI)!#_`"Q_EE.TR0"GV%23^6071/%N3"/=A_3C
MW[KW1X_CQ4BKZ&Z6JD<2K4=5["E$B?I;5MC&-J'^#:N/?NO=#'[]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NL4UO&U[V^
MAL+FQXO^"+?U_'OW7NJA<+\,.HNU_P"8E\F.U^Y^@L)O%5ZWZNP.Q]Y[MVZE
M9B9H*9Z^:NH\15S@K/60RG]X@FR\>_=>Z.31?!+X<XYIY:/XV=202U,S33E-
MHX\^2:06>0ADY!O]??NO=>K/@E\-\GZ,C\:NH:O2"H,NS,:P`<<@7BL./?NO
M=8/]D+^&)%.B_&;J-12G32I_<['K%&4%U(`BX`T\>_=>ZE+\%_AY&BQK\;^I
M$C2?[I4CVC07%4"#Y0/']1[]U[KD/@U\/S4S5O\`LMO41JZL+]W4'9F,$LX3
ME`[-$;Z3_7W[KW4S_9)_B0(VB_V7+J3QN-!!V9AY%Y%A=6IR#;W[KW2CQWQ6
M^-F'0+B^B>JZ58H?`$BV1@1:.WT351,/I]./K[]U[HH_S8^/O4T>P^J5V_T'
M'F4IN].M9JREZVVCA:?+T5%_'8EJ<EEO#C2TVWZ-&+UJMZ6IPP/'OW7NCQP]
M+=.B6GJDZIZ[2ICB2..<[)V_&_B,:\`+CK*.;$?U]^Z]T^4O677E#&D-%L+9
M='&DC2M%3;6PL43,X8$Z5H0+\W]^Z]U*?K[8CJ4?9&SG5N"K;:P[*?\`7!HB
M/?NO=8QU]L2(1K'LG:JB)@56/;>&1!_CZ:$<`?T]^Z]U5]_.$Z]VM+\+\M/1
M[?PF/FQO:74602:AQ-!2SQF/?>&+!)H*6.10WT-B+C@^_=>ZM;VX^K`8(@6!
MPN,-B""#]E!Z3?Z$7]^Z]T]^_=>Z][]U[K'*-4;C^HM[]U[JIS^<+3+/\=^K
M)"0!2?)_HJHN2`/3O2CYN3].??NO=6J3T5)E<8:*OIH*REK*6-:FDJXHYZ:H
MC=%U15$,J21R1-]&4@W'OW7ND1!U+U?3+1F/K;8<+X\RR4/VVTL&/M'E#"22
MD8X\-%.X8W(M?W[KW7"/J3JRG6&.+K78\*Q5CY.G"[4P02+(SD^;(!?L>*X@
MW=OJP]^Z]TB=P_%?XW[NK6R.Y^B>K<Y623>>2KKMEX"65YP`?NB?M`WDD/']
M??NO=(O*?`_X9YJG-)EOC'TU74[3"7Q3;%PA77>X<VI@=0]^Z]UUCO@9\,,3
M,M3COC'TQ13I`U(CP[&PH*P.-+QC_)N%=>#_`(>_=>ZR#X*?#:&JFK5^,_3B
M5-2JPS2+L;"DRH&N`P%-R#^??NO=5Y_RIMN;3V+\H?YINQ=F;;Q&U\%A?DAM
M.2BQ>#IHZ'&4U--LZ3QQ4U)"%CAM?D6'/OW7NKP/?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO==&_%OZ\_ZWOW7NJ7_YU<<DG3'QG\=2*1$^9/0KS2E@
MG[:[NIKQW:P'D:P_V/OW7NKG5+%VN+`"P_QY'/OW7NLGOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__0W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW56/\[%`_\K?YB*8WE!ZQ
M:Z(I=B!G,0;Z5!-A]??NO='5^+K*WQNZ!9""C=.=<%;6Y4[1Q-B".#<6]^Z]
MT//OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KJX/T(-OKS[]U[KOW[KW7O?NO
M=>]^Z]U[W[KW7"3]/(N/R+@<?GZ_6P]^Z]T&VW^Q*+-]A;IV!%0S156V,1B<
MO)6O402PU4.6:1$6**,F2$QF/G5;W[KW0F>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>ZZN..1S].?K_`*W]??NO=>!!N`02/J`0;7^E_P"E_?NO==^_
M=>Z][]U[KH_0_P"L??NO=5C_`,WMXXO@[O\`FE+)'%O#K&4NH:Z:-\X0A_3S
MZ3[]U[JQO:\B2[<P$L;^1)L+BI5EOS)JH*<AC_B1S[]U[I^]^Z]U[W[KW71_
MXD?[V/?NO=5)_P`Y'('&?%S8E8(/N-'R4Z'C:.Q("S;^Q\9<V^FC5?W[KW5L
MU,=5/3N!8/!$UC]0#&"!;_8^_=>ZS^_=>Z][]U[KWOW7NO>_=>Z][]U[KHV_
M(O\`GZ7]^Z]U2C_+:I)<=\[/YL]*[J\=3WIUYD4TD$6GV=.+W!/'U_VWOW7N
MKK_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<).4;DCCZCZCGW[KW5+
M/\[ZKAH?CUT-45%*M7$OR]Z!0HSZ-#R;VH5CE!X-XV/'];>_=>ZNF!]1'IM;
M4.26N;W)!^@_I[]U[KG[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO__1W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW5</\W95?^6Q\P`U.U4%Z?SCF%#9FT34CA@?]H(O_`+#W
M[KW0^?"C*1YKXB_&3)Q+H6JZ,ZS]#$,R&GVGC(&%Q^2ZGW[KW1HO?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]UP<$J0IM_7B]Q^0/Z$CW[KW2.Q2;S3=68&3.(;:'V&
M/&#\`899:]489(UI_2R.Y73_`*WOW7NEI[]U[KWOW7NO>_=>Z][]U[KBXNO_
M`!07-OS;_&WOW7N@JP74FU]O=I;L[8H37C=&],)BMOY9)*R5L::#"R/+2O34
M7^:2L+MZW^I7W[KW0K^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+1\
MJ>]Z_P"._5)['H=LT^YY$W3M+;LM!4Y*+%100;FW!0X.6N%5-Z-=&E9Y%3_=
MA72/K[]U[HQ=.1(L+@`AHQ(3JNRL5'H+)99-.HCGW[KW4SW[KW7O?NO=>]^Z
M]U5Q_.5,L?\`+R[PJ(/*)Z-]G5L#0QF1TEIMXX:6-](!.E647/X'OW7NK!.I
MZF2KZQZYJIKM-5;$VI4S/I`O-+@Z!G9N>"Y/^\>_=>Z$/W[KW7O?NO=<7)",
M0+D*3;^O'T]^Z]U4Q_.;B=?AB<E&C/-ANZ.D\FA52VAH=_84:FL.%&OG\>_=
M>ZM3PU0U5B\7.Q!DDQU!+,?]49Z.*6Z_CEV]^Z]T[>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KB][`@D692;?D`\C_8^_=>ZJ'^$$-!COY@O\SK'TT4<$M3O#J+*2
M(I77+YMKY!6F('JTZC]?I<^_=>ZMZ]^Z]UU<?U'^W'OW7NN[_P"\_3W[KW7O
M?NO=>N/Z^_=>Z][]U[KWOW7NNB>/]<V_UK\$_P"P]^Z]U1/_`#^<XV"^,'1$
MRI22+4_,/X\P.E4KV9/[\8[_`#<D8)28']+'@$^_=>ZO-I6\D-/*(WB$D:OX
MRVIE#(2/*]R7^O'OW7NIGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z__TM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U7?_-GA>?\`EO?,2-('J+]*;I+PQ!S+)&L<32"+0"PD
MT`V/X//OW7NGO^6'EJ'.?`/XE9''),M'/TKL\1BJJ/N:E&IL='3N'F!99+.A
M_/`X]^Z]T?7W[KW7O?NO=>]^Z]U[W[KW7B0/J;<VY_J?H/\`7/OW7NO>_=>Z
MZN#]"#^??NO==^_=>Z][]U[KWOW7NO>_=>ZXO^F_].>20!;\\<\>_=>Z`G$;
MHSC?(+<FSZG=&+JL`G7F-W!CMK)32C*8ZLERJTDV0DJROBDIJB,E0@-P>??N
MO=#Q[]U[KWOW7NO>_=>ZZ!!)`()'U`/(O_7^GOW7NO7']1_7W[KW7?OW7NO>
M_=>Z0W8/7>SNSMMR[5WWA:7/X"2LQ^2DQ]8@>%JS$5L.0Q]05(/KI:N!'7^C
M#W[KW2RA4!(P"A$8L#&1HU"ZLH`_"_3W[KW6?W[KW7K_`/%?]]_M_?NO=>]^
MZ]U75_-A6G;X`?(EJN804\6UZ":29F"I&L6=Q<FIV;TJOIY)L![]U[HX_3<L
M4G4?5E1#(DL$G7>S66<.&1H_[NT++(K@Z2KZOK]#?W[KW0G7]^Z]U[W[KW7%
MC=3;G@'CGC^O^M[]U[JKG^<;5TM!\$NP*ZM?QT=+O7JFHJ9+@:((]_X`NUR0
M``/?NO=60[.JH*W:FUJND<24M5MW"3T\@(/E@EQE.\;$_P#!6!O^;^_=>Z4_
MOW7NO>_=>ZZN"+@@C^OX]^Z]UW?_`'GZ>_=>Z][]U[KBYTC58$`@F_X%^2/\
M0/?NO=4F?#9):#^;K_,WQYJ9'@J=I]%92"![@+YL;4B3QW_4B,UKC\\>_=>Z
MN+WEO;9W7^#GW)OK=.WMG[?I9(HZC-;FRU%A<7#+(UHHWK:^:"!99&'I75<^
M_=>Z"]ODW\<8\>N5?OCI]<:S1^.L?L/:OC<S&RA[Y,'4Q_3[]U[K-/\`);X\
M4L,$\_>?4L<-3=J:5NP=L$.-.OT,N1.GT\_ZWOW7NH#_`"M^-$2N\O?G4*HB
MZI&._P#;A"J/J6/WY`7W[KW2?/S6^(BN5_V97I16#%2!V#MEO4/J-0KP.#_K
M^_=>ZC5/SC^'-(NJ?Y-=)0J-6IV["VX5&D:F'%<0+#D\\>_=>Z9H?Y@/P@JD
M\M-\KNB9HUE$>N'L3;;J9;V\89*TAFO^!?W[KW3P?FY\.U90?DQTHDFDRA6[
M"VZMU;ZNR-7#BWY]^Z]U39_.T^4_QR[%^,_4>VNONW>K^QMPU7RIZ':'#[;W
MAA<OE8(X]\XZ2:MBH*2JEG:.!.6:U@HO]/?NO=;%^+4C'8\:RX6BIOW#SY`T
M"D<_D"_OW7NG'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=?_T]_<D#ZD#D#GCD\`?ZY/OW7NO`@\@@CD7'/T-C_MC[]U
M[KQ('U(%^!<V]^Z]UZX/T(/Y]^Z]UZXM>XL?H;\<_3W[KW7=Q_7_`'W'_%??
MNO==7%[7%Q]1?G\?C_8^_=>ZZU+R-2W!L1<<&P-C_C8^_=>Z[#`_0@_G@@_7
MZ?3_`%O?NO=$O_F+154_P4^5\=$(S.>C]^D"10Z&./"SO/J']!"K<_CZ^_=>
MZ!7^35)!+_+*^'[TSTSQ?Z*L;9J.<U-.6%36!K2DGG5?@&P]^Z]U9W[]U[KW
MOW7NO>_=>Z][]U[K'+?02-/%C=OHHN+M]#R![]U[HH._OFW\:NM/DYUA\1MX
M]@4V&[\[;PN1S.Q-H/3SR/E,?0,H8O4+>"%Y;DJK6+V-O?NO=&Z5U,JJ!;T2
M6(6P_;?QNAN+@:N1_7W[KW4CW[KW7O?NO=>]^Z]U[W[KW7"0@+<D#D6N;`G\
M+?\`Q/OW7NF>+&XI<S_%!2TG\;:@^SEKEBB%6]")1(M/Y.9?!%);_"_OW7NG
MOW[KW7O?NO=<)+Z38!F/"@WMJ_!-N0!^??NO=4=_S5/YQV%_EH;ZZUV5/U3%
MV3D-_;7W+OFKJ\AO&AVE2XS![6:&*L@QS54,ARF3D$A\4`Y=B`.3[]U[JU[X
M]]QX;Y"=,=9]U[?H*S&X?LK:.)W7CZ"N\?W=%2Y2E2H%/,\9*3"*1M(9?K]?
M?NO=#3[]U[KWOW7NBY_++L3<75'0'86_]J3I39W;F.I*NBFD19$4OD:2"6ZO
MQS%*1_A[]U[H9=GU[Y?:^VLM,4:HR>"QF0G*C0#-64<514.J#C2TTOOW7ND%
M\A>X<)\?>C^U.[=QTLU?A>K=C[AWK7X^FXJ<A%@<=-7+04[6.B>MDB$:M]`6
MN>/?NO=51?!CY_?,3Y![SZ6W#W+T3UAM'HGY-[*SN_.I]P;3W]#-O#;U%BY)
MUI,/NW`ULIDRT]73*K&2D&F)R-7`]^Z]U=ZEN/K=68>O]0M]=/\`4?\`$>_=
M>ZKD_FZX<9[^7#\L\:7JD$W5>6DO1Q":<_;S4U1I6-N"K>.Q_H/?NO=&8^*5
M6F1^+WQZJ&5@LW2G6;$3`!C;:&*C(=/TEOV[D>_=>ZIT^6WSS^7M1\W.Y/BI
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M8E\NNMOD]_,%S&SOE)0[+VY\.:WJ7)=:?'FOQF`JE[<3=-90T65VY%%QG:NI
MJ15/H\"N58`D6]^Z]UM>=.[NR6_NKNMM]9C%MALIO38FU-T9+$E6#8W(YS!T
M>2K:619`&B^VGG,87@CZ'W[KW0G>_=>ZX.H9&4_0BQ_UOS_O'OW7NJ2/CAN"
MH/\`.U^>^U!3014R?&SI/."I4'S33297[.Q8<$)?_7]^Z]T'?_"CS;T.YOY?
MN'Q576-28V;Y$=.0Y:!:EJ2/(4%1GY(*B@J*A'C*05"R@MSR./?NO=)WXZ?#
M[XC[2SV!^./RE^..P\GF,E@,5N/K+NFNV_\`P/979&,KJ6GDH]K&K^_BI_[Y
M8J*IT^$$M4(I<"_OW7NK0L9_+H^#6+3[>C^-762I*S3)'+B'G"*5$#&/RU+V
M0J0/]C[]U[IXC_E_?"N'6(OC=U;&95:%RNWH6)C((*$,[+8KQR/?NO=1C\!/
MA'C*25O]EIZ;@IH$E=Y9=M8Z)40`M-)+-*HCB55N68D!1[]U[JKSN7X??'CY
M@;NW/TKTET#L;KSJ7KA*NK[6[A3KN!,=V1334-0J;1ZNW/CG$7W=)41%:RJ1
MCI0BW/OW7N@2_P"$_OPF^+.Y?@$%WQTCU[OC-;:^0W>^TH\WN3;5+DLR,=M3
M?%3186BJ*VL1ZBI-%2!1Y2UV/'OW7NKP:KX$_#"HD,M1\:.H9)'`5Y'VAC^4
MM8I<1_D<>_=>ZI@_GB_%'XU=(?$#;W9_5_0/7VU=T;9[]Z9R"9C;.WZ;'Y*.
MDBWCC%E5:F!`Z1.EE8?0CW[KW6QMLVM_B>T]J9*Q0Y#;6#K=&H:4-5BZ6H*6
M_)77[]U[I3^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[K_]3=Y^5&_MR]6_';N#L'9IQ*[KVGL;.9C;ISL]/2X@9BFI':
M@-?4U4D4$%/]R5U,S"WOW7NM6[:'\UKYP;FH]G]&[K[!VEU3WEN3?%#!O#?&
M:P6#KNO=F8*79>2W;AZ/"9K'966CKX,\:$1O+*P?]SW[KW5@/Q>_F#_+KM'L
M/X`#?Z=54_6'R*Q':^W-ZU>-BJES.7WOUW/D8:/*8,NW@AQN5IJ`2J!=26X/
M/OW7NC+?./Y"]Y8?Y*]5?&KJGM_8/QUQNYNI]^=K9+M/?U-23T.2KMH3)'3;
M0HAD)8:2PBU5%5I8RBG#%1Q[]U[JKCO'^=GW1U7WO\-]D87,=:=@[$JL'193
MY?;RZ]QF5S6UX(\[N4[7P61Q&9.NEP,$L=,U4?*50@\&Q]^Z]T"V#_GN_(3:
M7<.%ZV[2GPHVCN_YC9G:VP^T:#&Z-L[AZAPM=`=P;.J,HP-'!F<+13([2AKF
M,DCW[KW679/\]#Y`;KQ/RY.7RE#M2;']I;=W/\:<WE-NOB\;F>DJ??\`1[)W
M5#0/D0J[@C@B5YFJXF*JHU<`>_=>ZV<NSODYM?9/QL[#^0G7^//?3[#V?-N2
M3:75-52[CS.Y<M34-+,^$QBXV6K7^(R^5+1WU`?4>_=>ZJ*_EF?SI.Y?G?\`
M+GLGH'>OP@[:Z)VMMC;&,SN'W5NS"Y''2X*?[25\A2;P^ZABIXERM2Z"B5/5
M>]QS[]U[JWWYS8\Y3X;_`"?H%-ON.CNR`;'3J";8R$K*2/[+K&0?\#[]U[HD
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MVKY!M+#[JI<E@MW4XCK_`+1<LKI19!/K',!JC<!AR![]U[JR'XQ]";<^+_0_
M5W0.SZW*93;/5FU<=M7%9+.3I492N@H83Y*NIDC`0-45$C$(.%''X'OW7NA\
M]^Z]U[W[KW25WMLO;?86V,ML_=V,BS.W<W`*;)8V<7BJ85D24(U_Z/&#_L/?
MNO=/&.H*3&4U'CZ.**GI:&EBH:*",V$%+311Q04R#_CG%%&/]M[]U[IEWYLG
M;79.RMU]?[QQT.7VIO3`93;.X<9.+Q5V(S-'+0UU,_\`3R03$`_@\^_=>ZJY
M^*G\G_HOXJ]O8#MC#=B=N]A+UWBLOMWIC9&^-Q)5;+ZBP.=DEER&+VEC*01Z
MH)6F*@U&HKP1R![]U[JV]0#<_F_/^#6LUB??NO=$;_F9!C\!?EAHMK'2V\BC
M?F-QCG*R#_:HR+CW[KW3U_+YKZC+?"7XM5=74-4U4G2^R7>9OJ_BP]-`H?B_
MZ?\`>O?NO=!U\L/Y8OQ&^9.]L3V!W;L?-5VZ\;A_[KR9?;&XLIM>?/;=UB4X
M#<TF.D09O$2.-(@ENC7M[]U[HTD/0'4E/U`G1F,V3BL3UJNSY=DP;?H*2*A:
MEV[-0-C7HX*F%!4TTQ@8_O*P?4;W]^Z]T7;X:_RY/BW\$9<]'\;MK[DV;0;B
MIUI<AALANO-YO%2>*HDJ9:N&@R<TL,%1-4S%C*EBWOW7N@I_G5U/V?\`+'^5
ME9I=C2;*QU2%1RC'Q;GPC<,/];W[KW1V/C+4BM^/'0]65TFHZ;ZUJ`&8LX,N
MTL83?^OZOK_C[]U[H=??NO=<)/T-RP_Q478<CD`_4CW[KW12=X?!SXD]A]FR
M]M[VZ!ZZW#V74UU#EJG>%?@*>?+9"JP^F/'560J'3]^>D8AH[\@@'\>_=>Z-
M?2PPTT,-/2Q1P4U.@IX84011Q0PJ$BBA1;*(T4`#_`>_=>ZE>_=>ZXM]`;VL
M0?\`7M^/]C[]U[JCKX^45+1?SU/F]/'6-/49/XG=-2/36.FF$6Y@38VL0>/]
MB??NO=);_A1MQ_+LK7NH6'N[J2=RP)*QQ;BB9F0#DR#\?X^_=>ZLIWK\=]@_
M)?XY=9;2WK3315V.V9L?.[+W/1D1YO9V[:7;.-DQ6Y<3.74)5T$Q#%20'`*G
MZ^_=>Z2?QT[%[<Z_K,CTS\FH)I\MLJFI*3!?(K(#&X+9?;%/65(IL734L,M4
MHH=T00E4GI5/[C*6'/OW7NCRSSPQ4\U3))'&E-&9IIS-%!`L2KY&DDGE/BC1
M(_4Q8@`?FWOW7NJO>P.V=Z_,O?N?^/\`T7)783HW`/'0]P=YKCVK=L[VQ]3(
MU/EMC]?9VAF6(9)%C>*JJD9A'?\`P]^Z]T?/8'6.R^G>K*'K7KW!Q[=VCM;;
M]?0XS$Q.9FCC$$P+U,LA>6HJ*IKR.[&[,>??NO=4X?\`">?<*Y#XB]S;=\<4
M;;5^8/R&A]'#$93>=35#4#R+%#;W[KW5]3'TD@7_`,/]CS_MO?NO=4R_SYJJ
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MZ;_D5\0?C_\`*F@P>/[PZ[Q.]5VS52U6`K*MIH<CCY*ATDK(J>KIBD\=+6&,
M)-&&TR1DJ>#[]U[IKP7PE^*6`PVZ<!ANB]@T6'WKMW$[6W1C_P"!4_CRF!P:
M>+%8^6*1&M#3$EEYOJY]^Z]UPK?A#\1\CMW`[,R/Q_ZTK]M[;SE=N+"8JKVW
M324>+SN4HUI,EEL>ACM%D*ZEB59G'ZE'/OW7NN6X/A+\3]T83`;<W!T#USD\
M!M;;>0VMMVAJ,!3BEQ&V<C4K55^%IPH#)35523*5'U;W[KW0G=4]&=3]&[;J
M]H=2[!V]U_MJOJI,A6X?`4C4M$]7.D4,\^BS)K:*)!8_6WOW7NA#QNV\!C,K
MD<SC<)C*#,9D1?QG)4M#34M?D12J8J3[^:*-7J?$G"W/'OW7N@7^7D,]1\6/
MD5!2JKU$W2W9,<*N`59WVGE556!XL;^_=>ZK,_X3O9/(9'^4[\9J7)U?W%7M
M^DW-@W&D*(8Z'.5@2D7^J0F8FX]^Z]U=[[]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN#_I_'U!((!U`&Y6Q_J/?NO=%A
MS?R*QVW_`)4;%^-$V"GER&^NOMQ[]H]Q?<D11)@)O'+0?;A2K?MMP;^_=>Z-
M#[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H$/DGV/ENG^A^UNTL)%1S
MY/8&R\UNNFIJZ&:>FJFPU*U8U-)%`1*3.L94$?0F_OW7NG?I'?X[7ZDZR[-2
M#[/^_FQ]M;OEIU1DCAESV(IJVHI8UDNZ1P3RFP/-O?NO="Q[]U[KWOW7NO>_
M=>Z)3_,=-,OP1^5[U<<LT,?2&^Y#'"ADD9H\+4.@"@$D:EY_H/?NO=-'\LK-
M)N'X#?$[+1T\E,M9TOM!M#J%:T-`D`#<`W.F_OW7NCV^_=>Z][]U[KWOW7NJ
MS_YQ6+@S'\M3Y:T52VF+_1G/4L?IS1Y3&U2\_P"+1>_=>Z,/\(<RNY/B'\9\
M\K$_=](]?1\_D1;<QL(^OUXI_?NO=&I]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7"
M0Z49K7L"?I?W[KW5)^PJVEQ?\]3N*@B@\=1N7X:[;DJ)H2%2;^$[MH&3[I1R
M7&HZ2??NO=!;_P`*4*EJ/^6SF:L.D?VW<_4\S.\@B1%3<<)9FD)`4`>_=>ZN
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M8FQ?A9VQWCM7'?+WNRKR'8&QLI@X*42S[KR?^2?;Y!HA(8OQZB??NO=7-_\`
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M]U[K')PMR2`""6!`TC\M<@_I'/OW7NB]9CX];0W)\B-B?(ZOKLK%O7KO9VY-
ME8G&P5$1Q$V+W,2*BIJXP-;5!CCNEN`??NO=&)]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]T'G;77.$[>ZRWUU?N5ZN/;^_-LY;:^9DH&T5J8[+TLE+
M5-2.>%J!&YTG\'W[KW7+J_8.'ZKZ_P!E=:[<DG?`;#VSA]J8<U<ADJSC,-CZ
M>BI7JWM9JMUA!;_7]^Z]T(/OW7NO>_=>Z][]U[HI7SUH&R?PH^5E$LAB:;H+
MM$B4?5/#M'*3EA_B!'Q[]U[H`?Y-^6.;_EC?#/)/4/5M4=-8%//("'8PR54+
M!OZ:3%;_`&'OW7NK,_?NO=>]^Z]U[W[KW1`/YIV/7*?R]/EE1O%YEDZAW"Y2
MU[>+P2Z_^0-%_?NO=*7^7'-'4?!?XJ2HQ96Z6V65/X'CQ,$!'^MQQ[]U[H[7
MOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ:UK'Z'C_`&_'_$^_=>ZI<AQU#A/YZLE3
MI(J]V_"&KJD/]1A=Y8^FD`_KP_OW7N@D_P"%+>)7)_RG^Y97C+C&;HV%D?\`
M&,19N#]W\\QZK^_=>ZN0^.3(_P`=>AFN6CDZ5ZN<RWT$@[&P!!<\%5*FY/%O
M?NO=$J[&[;WQ\O\`L+<7QV^.FYI<#UEM:6IPW>_>VW*VHQFX]G9^)[0;2V+]
MQ"M'E*^4+:HF5F$2DV-Q[]U[H]6:ZTBSG4E3U/-NK=M%!4;3CVD^\*7)/#O-
M/!1K1'-C+1*=.6E5/-Y`/UGW[KW5>.P^].Q?A;V?B>A/EEN6FR_3&ZZK'[6^
M.'?64ER>2W-N+)RLJS[8[7JJ>F_A>-S`9HQ!5RE!..";^_=>ZM0JV6;&5A,D
M96IQM2YFA?R1,CT[^-XF^K(8CJ%OK[]U[K7._P"$WV1ICUA\Y-M4U7%6)MCY
MK]K0>6%=%S6YO,5!65;?J!]^Z]ULD'D$?UX_V_\`K>_=>ZUOOY]S5.&[6_E7
M;UQ[30Y#;WS-V]2Q5-F-+'#EVQU%4),H^KRQL0O^/OW7NMCY'#,RV.I?2YM8
M$@*>/ZCU^_=>ZR>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[K_]??U:6)0I:2-0[!4+.H#,?HJDGU,?Z#W[KW7.X/Y^GU
M_P`/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=0,ED:/%TCUE?4PTE,C
M1QM/.66)6FD6*-6*@D%W<`?XGW[KW0;=RTD65Z9[2H5;]C(=>;MA60'R1O'4
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MP_WE_E5?#?)&E%))_HS%++3JFA8I*;,Y5&`7\#_>C[]U[JV;W[KW7O?NO=>]
M^Z]T1S^9;0U&1^`_RPI::9H)3TOO";R+<GQTU":B5+#GUQQ$>_=>Z2W\J'.)
MN+^73\1<J@LLO3>V80020WVL+TQ:_P!#J\?^W]^Z]U89[]U[KWOW7NO>_=>Z
M][]U[KWOW7NN+_0<D#4+GZ6'^O[]U[JD[>>5>F_GT=+8P0AH\K\%^RRTWU*_
M:;SPLP'^%R+>_=>Z3/\`PH]LO\ICY&.T;R+'+M24A#I90F<I&\@_#!;?0\&_
MOW7NH6T.^=__`#'ZCZ%^*'Q4S4^W,)%TCU@GR6[B@-53Y'K/;C;/Q%`=M;$R
M***++;WR3PD.%=OMHB3]??NO=7%=,]2;2Z1V-@.NMDT#T^&P..@II,G5!9,M
MG*R)$BFRN=R!`FRN6R,@,TLSDMJ-OI[]U[H6'=``2ZCD'ZWN+V_'^/\`O/OW
M7N@N[;ZEV3W9L3/]>=@8A,QM_<-'4T%0&@C^_P`>:E#&*W$UNEI*#(TC'7#,
MEF1P#[]U[JK_`&%VQV1_+\W)1]"?(VLJ-Q?&;+BCVE\=^]:FJK]Q;MH\C,LZ
MMM3MZN=6BIGIDECCI*MF5&4:2>/?NO=$G_X39O&^$_F.%*F"JU?-S?$RS4WB
M\%1!4U.7G@J8S&3K2:)P0PX(^A]^Z]ULV,+BUK\@\DCZ'_#\^_=>ZUTOY_+O
M39#^6Y-(EZ?_`&=_K>$A2S'RR5]&$]-K'EA[]U[K8LX#<GECZ1_K#D#^OOW7
MNN7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z_]#?,SNU<;N&HP]37K7%L'6&NHDI:MZ*'SE;`SQ(0M0%_%_S[]U[I31F
MYN=.HL=7CY'TX\A(!)%O?NO=9B;<GW[KW708'@'_`'OW[KW7?OW7NO>_=>Z]
M[]U[KWOW7NL4\,,\9CJ(TEB)!9)%#J2I!4E2"#9A?W[KW2-[#%,O7N]UJ(R]
M)_='<:RQQ(!:'^$5?D554"WI]^Z]UKM_\)?:J"?X:?(&EI$,=-1?,[O/P*ZG
M4:>7,(8P&(`NO^\>_=>ZV6_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]UT?I];?XWM[]U[H'=[]X]>==[YZOZ[W9FQC]U
M]O9+.8S8^-6)F.4JMOXV3*Y)2P'I\5'$6Y//OW7NA@4@D_2X-B+`>KZDC\FX
M/OW7NN?OW7NO>_=>Z][]U[KWOW7NO7']??NO=>]^Z]TV9K$X[.XK(87+T<&1
MQ66I)\=DL?4PK44U;05D;055)40MZ7@GA<JP/X/OW7NFW:VU]O[/P>+VWM7&
M4&$V_A::.AQF'Q42T^.H*2%76.GI8([(B*7_`-O[]U[I2^_=>Z][]U[KWOW7
MN@*^4%(E?\;N^Z*2P2JZ?[&IVU<C]W:>507!^O)]^Z]T07^1G&E-_+"^,E'&
MT;)18/<-'>/Z`P[GR_'UX(_(]^Z]U;?[]U[KWOW7NO>_=>Z*5\]*85GPM^4=
M.03Y.C^Q#87))3;M;(!QSR4]^Z]T`/\`)M54_EB?#1%((7IS#+>X/(J:Z_(^
MI]^Z]U9G[]U[KWOW7NO>_=>Z][]U[KWOW7NN$@NO^`()%@=0!Y6Q_K[]U[JC
M_LVDJ,=_/L^,^9JRL&,R_P`*NXL!CWN`:O*0;AQ%=)`P^MHZ9+C_`!]^Z]U"
M_P"%'E!/6_RA?E2L0U"'`X9YI-(8QQ',4L9E(U*0D9<$D&XM[]U[H#/Y:_PT
M_F`]7_#7X^4/4GS'ZKPVS,QU;M?.4N/RO3!S&3>7+X^GKDFR&<&0C?(34L,G
MA!/X'OW7NCX/T5_-,ABD=OFMTR3;2#_H)GDTZB!KTQY4MZ?]X]^Z]U65VY\D
M/YI/57\Q'H;X$5GR:Z0J)>]>L]S[^Q?8K=3U428W(X+()3C;[XO[YGDCJXVN
MK@\'W[KW1_=P_&/^;7G&7^&_S".J]LRB&F-0F.Z'^Y5);DN8ON<@59)0MN??
MNO=`=\B?A+_,]WMT_P!D8O>WS[V!NK:;;)R<V3VK'\?J%),M_#:&>JGBIJAZ
MTRTE57^+2LL=GB)U+8^_=>ZIV_X3O?RKAVW\7.P^_=Z_)7NW;4O87='8.+?:
MG5F\<ELY<+E-E9JHPM1492JIZF8Y-JF(V6-TUP_0GW[KW6PH?Y3&V(I':C^7
M'S&IC((A?_2WD:DA4O==4T+`:P>>+CW[KW0=UO\`))Z<W-OCK+=W9'R*^3?:
MU'U7V)A>R]H[8WYOR3.82DW+@&1Z&602Q"18TG0-8$?3W[KW5UZ(H8M8DMZ[
M\L@-@GH)Y4E1R/?NO=9O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U__1W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW2>W=3?>[4W-2'S?Y5M_,4_\`DZAI_P!W'5$?[*MZ6E.K
MT@\$\>_=>ZUQO^$RE4M'\:OEALMH9J>?9_S:[MI7CJU\61*U>6$ZM6TZWCA!
M_LV^OOW7NMEKW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=8IK&,AB0&*J;?4ZF`T@_C5>U_Q[]U[JJ[^8.W5O7G;7PR^3
M'<'>>R>D]E]%]D[KK,C_`'RG^W3=4>YMKU&*?%XUV],=72:O(Q_(X]^Z]TJ:
M3^;W_+CJHUEIOE5UW4PSM>&:"JJYXI_+KE3[>6&ED250@MP3[]U[I$;C_G9?
MRU=N9&*BK_D115-4X9D7%[6W;DD*(MW;728ADTA?S[]U[KC@/YW/\L[<S2G&
M_)/$(U-)'#)%7;>W/CW1YF$0]-5B8V(!^MOI[]U[I8U'\X;^7+13TL%3\FMG
MPR5DKPP^>'+1KJ12[7UX]>`![]U[I0XO^;%_+US58<=0_*/K<UBKK9)ZVKIP
M%`U$DO2@BX^G]3[]U[J/7?S9OY=^.JWI:WY1]>131L%#-45IB=FX`BD^RTNU
MS]`??NO=-!_F[?`=I*@T'=8S,=&-4]5A]J;GR=,5_`CFIL6P>_\`M-_?NO=`
MMWG_`#A?A-6=/]E8[:_9>]Y=SY?8>[<?M5<'UYO9<D^X*G"5L.(3'R)B4:&K
M>O>/QN2-+<^_=>Z*/\%/YT_Q?ZT^'?0^U?D!O'N.O[DQ.TY:7?HK>IM]Y/,0
MY7^+9"2(9&H_AK>:<T31\ACP.??NO=&J/\^G^7W8ZL]W$R\$@=*;]7Z$&]QC
M/Q[]U[KI?Y[_`,)\A,E-MC#?(+=L\@*Q18/H[>TCR2:3^VOEH$N[?CW[KW2;
M?^?%\>OX@^(Q_P`=_F%EJVGFAAEIJ3HO=33P>=P@>753`%3>_P!3Q[]U[J/W
M/_-RV%NSI#M'&8SXM_+Z*HW#U_O/#44V1Z5SU+21U-;M^OIH'JYI4TP0:Y06
M8_0#W[KW3?\`\)OMYXG>/\KWKC^&U\E148#L;M3"Y:@J3**_#5L.YZB5L77P
M3DRTLU.)OT?0$>_=>ZOG]^Z]UXD#ZFW^O[]U[KUP/J;>_=>Z+;\Q<5-G?BE\
MBL-3R&*?)]-]@T4,@-BDM1MK(1HUSP+,P]^Z]T2G^1S(_P#PUS\2J*:62IJ,
M/L6NPM342-J_?Q.X,K2-8_2Q'_$^_=>ZMHO_`,5]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7%O[/_``8>_=>ZI$^1CQTO\ZWX+5<MQ'4]!=VTJFQ"F750LBJWT9KC
MZ?6P]^Z]TJOY_&*.:_E+?,:A%5'2>3KJ*43R"Z+]MD*:H(/]-02U_?NO=&I_
MEE5XR/\`+^^(%89UF,_0VP)/*E@DG^XB..ZVX('C/OW7NCT,1;FQO]!?ZWXX
M_K]??NO=:W/SAV[##_/U_EC;K\UI:KJOM7">'@`B&KHJD$_X^KCW[KW6R(OZ
MF_KY#_MM`]^Z]TE>P$\FQ-Z)?3JVIN$7M<C_`'$U9N!^3[]U[J@'_A,GN.'+
M?`+?F#CI]#[7^5OR#II*DBS59R&]JNJ#_0#TZ/Q[]U[K8L]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7__2W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M4#*#5C,BOUU4%8.>!S3R#D^_=>ZUI/\`A-?#+3[5_F)Q.L&D?.WM1D:"L:K#
M`UDU]1;F-A_0<>_=>ZV:O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]UT>!^?\`8"Y_V`]^Z]TRSS9X9FABIZ2B?!O'.:ZK>9A612")C`L4%@&#
MRV!/X'OW7NGOW[KW426MH8M235E)&;&ZRU$*$6_)#."+>_=>ZU</^%-XP.9Z
M^^!E-D&Q6:PJ?,W8./W+C'DH\FE3BLM-2T,]#7XI97>6DKUF\;:ETV/U]^Z]
MUL!;$^)OQAV7M[`87:O074^%Q>+H*5<;34NQ]OB*F8Q+.5B22BD="S2%CS^?
M?NO="L.J>KD;6.MMA"33IO'L_;_I7D`"V-'!'OW7NHPZ=ZC$AG'5G7@EOJ,A
MV3MPR7_JI_AI-_?NO=0,ET5TGF&B_B74G6U;+3AWA-1LC;CF,RJ8V()QI^H/
M/-_?NO=,D7QJ^/=/DQEH>D.KDR/C6)JE=B[=#!5-_3_N-L?^)]^Z]TYY#H'H
MW*I3QY+IWK6K2DF,U*LFQ=N,(G/U(!QQYY]^Z]TJZ/K?KW'PQ4^/V-L^@@1=
M*4])MC"TT(4"P'CBHD`M[]U[J=_<S:(.D;2VRHYLPP.*(X_J/MOJ??NO==_W
M+VE_SR^V?_0?Q?\`]3>_=>Z]_<O:7_/*[8(_(.`Q?T_\YO?NO=2*;:^V:(JU
M#MW!TK:M0>FQ-!`R,#PP,<"-<$>_=>ZGIC:!)GF2AI8IGT^2>.GB2232>+LJ
MZN/]Y]^Z]TS;YI6K=D[PHDTAJK:VX*9=7Z09\35Q+?\`&D:O?NO=:Y/_``F=
MRN%VW\1_D1M_*YW"T-;BOF1WFDU/4Y&BI9E23<=049HIYTD53:X-K'W[KW6Q
MW_?39U]/][-M:OK;^.XN]OK>WW5_I[]U[J)+O[8JQ2/+O+:,<<9_<>3<F%5$
M^GJ9VK-*$7XO;W[KW21R?>_2F%J:''Y?MKKBCJLD2E#3U.\]OBHJ2`6<HOWU
MM*`7)^@`]^Z]T%??_:/66=Z#[AHL7V/L.MJ,EU;OD4L<6[L`XF8X2LA4*AK;
MMJ:P]^Z]U7Y_)3[?ZQVU_+BZ`P.Z.R>O,+FL52;TCJL95;MP=-400)O+,R!G
MIY:N-TO&;_3Z'CW[KW5I&5^1_0&!IOO<SW5U;CJ0HLPJ:K>^W8XA#(RK'=C7
MV4.Q`'OW7NF:;Y7?&2FC^YJ._P#J!(?%'+YY.P-LJBQ3L$A)_P!R-M+EN#^?
M?NO=0!\Q?B@24'R-Z7N@_P"?B;7-OZ\?Q&WOW7NN9^7OQ7XM\B^FU-M0_P",
M@;8%P.;_`/%QY7W[KW2,S7\P7X.;=JTH\W\L.A,;6N#IAJ^R]M(S:1=K`9`K
M>WOW7NF27^9/\`535)\QOCHJ`\L>T]K`7'U%_P"(<D?T]^Z]U2C\V?Y@/P;J
M/YD/\NCM'!?)WJK(8'9V0[/Q&]]Q8C=E'5XO%T%7@`U'%/44\S1D5-1Z1P0?
MZ^_=>Z>OYP/\U#^7;W-_+O\`E3U'LCY4]=;FWIO#K3+4>!P>!R*5=?75@:(Q
M4<"NGC\LC@@$_2_OW7NCV_R>?D?T)G_Y<7Q(H<;W)UG65^V.D]K8?<%&F\,+
M#6X;(8^.2":BR5'45<3TE9'ILPTCG_7]^Z]U9H.YNH9Z854':77,M,#J\K;S
MP%E"FQ*Z:_4"/?NO=:P'\V3Y"]=]9?SDOY2/9U9O;%R;%P[]B4.YLMMV>/<Y
M2CFCH9!$]-A9*RH+2`^GCGZ^_=>ZN0;^<+\##(L/^E#.F62YC7_1UO1G?3J9
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MH5X)4+-^D!XV6[?U'//OW7NM:KXX_P`L[^9G\1M__)G*?'#Y"]#;2Z][[[GW
M)VK'M/<NS,AF*O`5>6D"I%#/32Q0DU<1\C\_J'^/OW7NC\4'1'\UZ:CI9,I\
MTND:/(F)#5TU'TG65=+%+>]E<Y.)W''UO]/?NO=*./X\?S*:Z+3F?G#L&DFM
M82;<Z5@I4'^)6KRDI)/^L??NO=!7D_A7_,PW!73RUG\SS*X2FBF<4-)MCIW:
M].L<<B,K&NDJ9'DE<(3HM>S6]^Z]TTS_``$_F.55!CZ!?YJO8%)%1K,//%U1
MM)*ZI,KM_P`"I60ZM`;TW]^Z]US'\N/YN515J_\`FE]VS%<<D"O2[*VC21"M
MCG5I)?&L?`(!`]^Z]TTX/^5[\Q:".NFR'\U;Y%U==4U#3TUMM[3-+!J/Z3&4
MY4`<?T]^Z]TS_P##37RJRZ53[F_FL?*-ZJ2K,U-_!:#;..B2-CZD8+$UO3P.
M/?NO=)W*_P`ECNK,),E3_-:^;,?FMY#29W#4I!#7)C$-."IO_3W[KW21A_D1
M=GHDL,O\V;Y]R4\S!Y?]_?0+.CJ=2>!O$=*Z_K_4>_=>ZP-_(K[GH&-3@/YM
MGSJBK(E/@.9W105U(!8AC-3M$HDLOT_H??NO==T?\AKL6HF+;A_FO_/O*05`
M:6NIZ;>]%CEEJYA:5H&C#F*B.HZ$MQ[]U[J'7_\`"=;8F6J7JLK_`#`_GG7S
M2TT]&?N>U`582QE&D;1`C$B]QR!?W[KW2(;_`(2\_$O);HVSO#>_R.^5W8F7
MVON7$;FQ@WIO]LS2C)X:>*:B:2FDNMDGB!N+6]^Z]ULM87&1X?&8_&PR32PT
M%#24,<M4YDJI5HZ:*E22=S^J1XX`6/Y/OW7NG;W[KW7O?NO=>]^Z]U[W[KW7
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M_P!!E4L4L34[1KO#<K1-%*NAXY$.2LT3`V8?D>_=>ZDX/^1U_+1V_P"%\?\`
M'C&((HFA2#^/[@-,NH%6\<+9#0C.?K_C[]U[I>8_^3W_`"ZJ*FFI6^-&SJ^&
M?]<>6ER.0\/Y'B\E80!<#W[KW3PO\I/^74@*#XI]9&,PI3Z6QM2PTH1;AZLK
M_K<>_=>ZAC^4)_+C!DM\3^L1Y/J?X6WYYO\`\"+FW^\^_=>ZG9'^4U_+JR8I
MHY_BCU<PHX5I4^WQ3PA46P`D_P`IN3[]U[K+!_*7_EM4DM)./AQTC+54H*4\
M]7M."KG&L:"2\\D@)(^IM[]U[KA5?RE?Y;5=!#2S_#'HHPQ2-4JT>Q\?&XJ#
M)J<Z@@-G/X/XM[]U[IVF_E7?R[)FH'F^'?1);%"]&QV3C7,2H+:1KA(((^OY
M]^Z]T[2_RS?Y?LB.K_$#H=XY5TL&V'AM)24:6%FISQ;\?GW[KW35+_*W_E^R
M1PT=)\5^K,/20B0"FPF#;"4\A<6):#'24\4AM?\`'OW7NHB_RK/@&L7VT?QM
MV0L0_4%.34DGD`$5U_K[]U[I3;(_EN_"'KG>6![&VI\<NO:+>VU)9*C;.X:O
M%MD*[!2RQF*5Z%ZZ:HC0NI^NDFWT]^Z]T;>/9FSG>_\`=#;<<B&14,F`Q9;0
M&]3H#3'2LCN>/K[]U[J4NS=JH=4>V=MH;$$K@<8IL?J+BG!L??NO=/-)1T=#
M&D%#2T])3H#HBIHH8(A?ZZ8XD0#_`&WOW7NIOOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__]3?
MX]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_U=_CW[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>O;Z_ZWOW7NO7'UOQ_7W[KW7O?NO=>]^Z]UU<7`N+FY`_)
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MA2I_#*3]&!^A]^Z]UI`]K?.7N?:_SZ^26[N]?E1WIT?OCHWY`;.VCT%\:-H;
M1JMR;%[/ZCJHW:OR.;P<$)2N@GN7J*U"3"EV_'OW7NJVLU_-Z_F;5NU_G9_>
MBK[9VE@_D%#N;>?Q1W338W*Q4VUZ38FZ/L:W';9+4QK:3^)42H(H^+O(?J/?
MNO=<J'^;)_-PDV=\I^G]V8_M'_9A-Y]<='=8=74>'H<K3S8S/YR:C@FWAM%Q
M2/`*[)8>K5JF0_2:Y)'OW7NC._!;^:7\P=D_,/X?Y+YX?Z=-H;,Z@ZD[*Z8[
MTFK=L[NS.W<IO>"N63;^X<_3X^A>&JSS4Q*F4:E!2][>_=>ZL?\`^%)N^N]\
MUL/X%[]^-^:[1?KK=._,W-O"39--O.@AJ<'D]M&JPN5W2-L0QU]+CHG92OD4
M:6^H^OOW7NJI?Y2?RN^8/07RLZ*WA\N!\K=U=#UW6W=NUQE5VSOC=^*STN1R
M\4&U\C)C33&>"CQRNR032#R"VKW[KW6#Y#_%;^8IVM\N^R/C1UVG>>X_B-G,
MCV#\Q^MMTU,VYJ2"JQN6V=E(*;8_WM;X)8,K%FG3Q46M2KVL/?NO="%_):^,
MGROV9\R/A-D]G]*?)GIL[#V9O*A^:NXNTI<Y#L3>0JZ\2[?7$T^5K9DJJQJ4
M$!E7B_X]^Z]U]`-`"[$`#D_@W:X4DG\#FW^V]^Z]UE]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
M_]??X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7"33H.N^G\VO?_#]//U]^Z]T`NZ_]
MET_T@X[^^?\`HC_TH_:2?P_^\?\`=7^^'V.A]7@^]_W(^#Q7UV_L7OQ[]U[I
MYKO]!7VF$^__`-%?\,\$W\#^_P#[L_:?:?<#[C^$^?\`:T?=VU^/B_U]^Z]U
M-;_1+_&8=7^CK^\_BI_L;_W=_B_VNO\`W&_:?\I/C\VGQZ?]A[]U[IQKO]&>
MA_XC_<+[C[S_`"C^)?P&_P#$M/[_`)?N/^4G1?Z^KW[KW2CJ?[L_P^E^_P#X
M+_"M'^2_>?P[^&^/3QX/+_DWCT_33Q[]U[KJ+^Z_CI_%_`?M>/L?!_#O#?\`
MM?;>+C_7T\6^OOW7NGY=&I-/BM8^/1IOHM_9_P`/];CW[KW6;CG^OY_XW[]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z;\GX_
MM6\OW&C7'_P%OYKZQITVYM?Z_P"'OW7NI<.GQ)HUZ=(MKOK^@_5?\V]^Z]UE
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
0W7O?NO=>]^Z]U[W[KW7_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EMCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Sigma-Aldrich Corporation [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Revenues recognized under the agreement with Sigma for the three
 and nine months ended September&#xA0;30, 2013 and
 September&#xA0;30, 2012, were as follows (in thousands):</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;months&#xA0;ended<br />
 September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;months&#xA0;ended<br />
 September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Revenue related to Sigma Collaboration<b>:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Royalty revenues</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">201</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">428</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">711</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,035</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 License fee and milestone revenues</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">101</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,351</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">302</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">428</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,062</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,035</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Shire AG [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Revenues recognized under the agreement with Shire for the three
 and nine months ended September&#xA0;30, 2013 and
 September&#xA0;30, 2012, were as follows (in thousands):</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;months&#xA0;ended<br />
 September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine months ended<br />
 September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Revenue related to Shire Collaboration:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Amortization of upfront fee</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">542</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">542</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,625</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,444</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Research services</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,968</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,675</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,340</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,747</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,510</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,217</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,965</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,191</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 605<br><br> -Section 50<br><br> -Paragraph 4<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25502053&amp;loc=SL9156464-115641<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 605<br><br> -Section 55<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=9156477&amp;loc=SL9156489-173031<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>16
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0"7#_[BQ`$``'(2```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F%U/PC`4AN]-_`]+;\W6
MM2JB87#AQZ62B#^@K@>VL+5-6Q#^O=WXB"$((9)X;EA@[7D?FO"$O;W!HJZB
M.5A7:I41EJ0D`I5K6:I)1CY&+W&71,X+)46E%61D"8X,^I<7O='2@(O";N4R
M4GAO'BAU>0&U<(DVH,*=L;:U\.&MG5`C\JF8`.5IVJ&Y5AZ4CWTS@_1[3S`6
ML\I'SXOP\8K$0N5(]+A:V&1E1!A3E;GP@93.E=Q)B=<)2=C9KG%%:=Q5P"!T
M;T)SY_>`];ZW<#2VE!`-A?6OH@X8=%'1+VVGGUI/D\-#]E#J\;C,0>I\5H<3
M2)RQ(*0K`'Q=)>TUJ46I-MP'\MO%CK87=F:0YONU@T_DX$@XKI%PW"#AN$7"
MT4'"<8>$HXN$XQX)!TNQ@&`Q*L.B5(;%J0R+5!D6JS(L6F58O,JPB)5A,2O'
M8E:.Q:P<BUDY%K-R+&;E6,S*L9B5_Y=9?7BB!]J^_OV'VXXY\DCI_+("=^:_
M@:NAQY(+84&^>QNZC[,#_)Q]B",T`T.KC0L=B8733V%3@C2[8Q,&@?4E;&N0
M?77"-C'T*Z<'[O09T#0X$N2>;-HV1OUO````__\#`%!+`P04``8`"````"$`
MM54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(`````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?V
MA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:
MCAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4<IA:-&3&:AE
MW)3E/8:_'E`M/-7!:@@'>P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+
MJ<_;J)I"RTF#%?.<TQ')^R)C`YXFVEQ/]/^V.'$B2XG02.#S/-^*<T#KZX$N
MGVBI^+W./.*GA.%-9/AAP<4/5%\```#__P,`4$L#!!0`!@`(````(0!3=PU[
MK0$``#,1```:``@!>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**``
M`0``````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````"\6,MJPS`0O!?Z#T;W
M1M[-HTF)DTLIY-JF'R!LQ3:Q)2.IC_Q]19HZ"83MQ>S%(`FOAMG=V;&7Z^^V
M23ZU\[4UF8!1*A)M<EO4ILS$^_;E82X2'Y0I5&.-SL1!>[%>W=\M7W6C0GS)
M5W7GDQC%^$Q4(71/4OJ\TJWR(]MI$T]VUK4JQ*4K9:?RO2JUQ#2=27<90ZRN
M8B:;(A-N4\3[MX<NWOQ_;+O;U;E^MOE'JTVX<87\LF[O*ZU##*I<J4,F^BTO
MCR?S440LY&TP,&9&`V,2#C<Y0+*#,V9V<$:QPYTK,E4(W-P`Q<TC,YI'"@P@
M,QI`$@XW.4"R@U-F=G!*L<.=*SI5W(H#I.)@G)ZLPPI3,E6+(>'X<&CB\.\'
MY^^:NI];\DC%XZX4LE"`G1J2&YP,62B]HSK72K]U,EDXH>J&6_!(O0-N-$#"
M06Y7@[2M&=2!AOC9H,]5<US*XY,L7^"672!E%P:5W;YUSKST6Z=N@@753=R]
M3;8V-S4D,\!-#9#<(+NU(KT5<MM@)&WP>-`F]Y5RNG@++O[GN/0TE]M_326O
M?G6L?@```/__`P!02P,$%``&``@````A`/N2"?0*`P``1PD```\```!X;"]W
M;W)K8F]O:RYX;6R4EMU.XS`0A>]7VG>(<K\D<<NO:-$"15MI097*PJ5E$I=X
M<>Q@.[1]^YVX-$R:$K%7B>/X9.;,-W;.+U:%#-ZXL4*K49@<Q&'`5:HSH9Y'
MX9_[FQ\G86`=4QF36O%1N.8VO!A__W:^U.;E2>N7``24'86Y<^59%-DTYP6S
M![KD"F86VA3,P=`\1[8TG&4VY]P5,B)Q?!053*APHW!FOJ*A%PN1\FN=5@57
M;B-BN&0.PK>Y*&TX/E\(R1\V&06L+.]8`7&O9!A(9MTD$XYGH_`0AGK)6P],
M55Y60L+LZ2`>A-&X27)F@HPO6"7=/:2W50>_R)"0H_K-VHH'P9?V8U$]#%:/
M0F5Z6;\*UJZ;T0`"6/JI1Y&Y'.;C.&Z>_>+B.7?;AR`?(7WO('S'7P/ET]LZ
M0J%2=**<<&LZ51OWA882UJY/(;,D#,R9@!LSS9(Z<*QRI57&E>49A3NKI<@8
MF$4OF60JY4B%`!6-#/D_&8B@B6:`9+SA7XAF[B"H`D<S1"K#/<%\9/*^5CE+
M]0*2+%`L8'Z3TN$>E7W.O.OAE(Z0C"<#IW3)K/"?GAEN`6#/K:_9O"IP,.04
MR1SO1C-5;T!NW0'6+[YAPM`')BM.;SE#.0V`N2:IDUV9.IK4"UP+6=65ON..
M_M;6TADW6`93<[HK<\O^:D.O*NMT`6U'9\PX!3=U.])6-`1%D\2[.E/8=PI.
M[]D*]AC$"(8DZ3`[=SI]@4P\M`7L.M:;B@4P'TF'5B^0:YG5L4]>*V@=O!AC
MD708G5=/EK]64`DZ>:OK@9=B%)(.F/TL8*0&Q]BW#IO]-+2$<-LF'3K["]D2
MPG@F'3X_J0F4]DFV:CO$?"8=0/LS`YJ:C21I!=1!M%\(`&N$AI!FTS&P9>_L
MD/U"`-J'$(:==+#M[SWL-6D)=?#M+QKV:(@;B710[A?"'A'<4##8\>BSZF^>
M(XL([BT8[--I-R;]F<'Y#6<]@^.\L1I.8%2S#M:='D4J=(IU<)\13W7D/P*'
M;<ID"G\!]:4^1CT8T?8?:/P/``#__P,`4$L#!!0`!@`(````(0"=&UBWC`0`
M`$H0```8````>&PO=V]R:W-H965T<R]S:&5E=#0N>&ULE%C;;N,V$'TOT'\0
M]!Y+U%V&[<7JDG:!+5`4O3PK,FT+L41#4N+D[SLD;8LS;FWO2Q)I#H_F<(8S
MG"R^?+1[ZYWW0R.ZI<UFKFWQKA;KIMLN[;_^?'Y*;&L8JVY=[47'E_8G'^PO
MJY]_6AQ%_SKL.!\M8.B&I;T;Q\/<<89ZQ]MJF(D#[\"R$7U;C?#8;YWAT/-J
MK1:U>\=SW<AIJZ:S-<.\?X1#;#9-S0M1O[6\&S5)S_?5"/X/N^8PG-G:^A&Z
MMNI?WPY/M6@/0/'2[)OQ4Y':5EO/OVT[T5<O>]#]P8*J/G.KAROZMJE[,8C-
M.`,Z1SMZK3EU4@>85HMU`PKDMEL]WRSMKVQ>LM!V5@NU07\W_#@8?UO#3AQ_
MZ9OU]Z;CL-L0)QF!%R%>)?3;6KZ"Q<[5ZF<5@=][:\TWU=M^_$,<?^7-=C="
MN$-0)(7-UY\%'VK84:"9><J-6NS!`?AIM8U,#=B1ZD/]/C;K<;>T_6@6QJ[/
M`&Z]\&%\;B2E;=5OPRC:?S2(2:<N)-Z)!%:<2)@W\Y*0A=%]%D=[I`06U5BM
M%KTX6I`U\,WA4,D<9'-@/BO3?ERT_I]4<$^2?)4LB@M4#!"?]U7$%LX[;&E]
M@F0:$MO6!/$Q)#]#I&I)6YQ?3&L(:WE&R.B!HHLLV"PJRX>P_W?`SBKD(J+"
MPRYFUQ""R*\148!)BFL((2FO$08)$NICH;<%2C#DGAF#$/N6:4A@0`@BOXLH
M[B+*6P@D#QPQXWA;G@0O;=B[*<4B(D]#$I6B0>)1;<C,4A>O+DPS"]V(+"]-
M>QH99J0)CMGCFB28:(JQ5YF&!$I3DI!4RDUKS,C:0ELCM=9C:8JI2]/LNV%R
M,2-!T8\(DF`B:*)5QS[3$.T45$GB<VZ:@Y2:"]/,8L\X.(J]1'8O]J8JA$1!
MI7H\2A),#A;9RDQ#($,NR4FR)[^+*.XBREL()$]>38RZ?_M@23".64R.1J8A
M.F8)=+9+IJA-STUS##'%YL(T>Y'GTC*/[%[@32F!1*4_(DJ"B2CRV4Q#M"B?
M1504-OLDXH5I3L.4A+M$9K@(7+8$26+0M1X/E$(34:0@9">,5L58$I$:F6.`
M&[M4&`+X89P2AA(#6!A./F!QLGT_G(5,-WNSOL<D)-D)H\4]12PDON<8$";N
MY-KISJ&_<F)@2>@31(DI&)3<Z2-8GFSCC\O331_)(S>'C&F,KO6,6'-L)6X7
MR&I$1%=%9`VF;<6"9-]^7)#N\DC0E.7JLQG3&-V0(5X!`>08`+E&2P<&L"1(
M"**DB#B9\A7+D_W[<7FZVR-Y$_%)GL:DJK\^N3-&*DS.[@`*"O!)T,LKP.0#
M%B=[N2%.WO3O7XGEE$.KY%1\3R+-6T(8F-NK`/F)1!^IT(LCTO`+#`A<-N6?
M8I##G73CS!`935V+U*.;GFQ:WF]YSO?[P:K%FQS+/-C_RUL],F9L#O,&C`WD
M?2%'234,7@PPR1VJ+?^MZK=--UA[O@%*=Q:#3[V>!?7#*`YJ>G@1(\QPZL\=
MS.P<)AEW!N"-$./Y0<XKE_\"K/X%``#__P,`4$L#!!0`!@`(````(0#B:RHB
M?`0``,H1```9````>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;)2878^C-A2&
M[ROU/R#N-V"^\J$DJTV`=J56JJK=]IH0)T$#.,+,9.;?]Q@#L4UJ9VYF)CF/
M7_P>'Q_L67]]KTKK#3>T(/7&1C/7MG"=DV-1GS?VSQ_IEX5MT3:KCUE):KRQ
M/S"UOVY__65](\T+O6#<6J!0TXU]:=OKRG%H?L%51F?DBFN(G$A392U\;,X.
MO38X.W:#JM+Q7#=RJJRH;:ZP:I[1(*=3D>.8Y*\5KELNTN`R:V'^]%)<Z:!6
MY<_(55GS\GK]DI/J"A*'HBS:CT[4MJI\]?U<DR8[E.#['059/FAW'R;R59$W
MA))3.P,YAT]TZGGI+!U0VJZ/!3A@:;<:?-K8W]`J18'M;-==@OXI\(T*?UOT
M0FZ_-<7QCZ+&D&U8)[8"!T)>&/K]R+Z"P<YD=-JMP%^-=<2G[+5L_R:WWW%Q
MOK2PW"$X8L96QX\8TQPR"C(S+V1*.2EA`O#3J@I6&I"1[+W[?2N.[65C^]$L
MG+L^`MPZ8-JF!9.TK?R5MJ3ZET.HE^(B7B\"OWL1%,X"+YPO/J/B]RK17<6;
M>8L0A9%Y+@[WU:4ISMILNV[(S8+:@YG3:\8J&:U`><@/=S-F[/\2!IEB(M^8
M2J<%N:"PRF];/PC7SANL3-XSNRGC+0*9V7-F;ENC3N3+2#P@;*W8LY/AB_L8
M)`])!X(5"M@>O<-ZJ-Y]J+#'M3%898-DJY[J]`&R7,ASVC]@9"*>$I&2KF2*
M>+)(.B4$$2D94%YB,O1)8/#&!O%QG;Q`>?2.,X'`*'G:&XG82"1&(M414@9@
MJF(&V%8PEP,;!)S@$BV4DMUQ1I<)(Q$;B<1(I#I"R@2T-C$3^EI@L%P+2-W7
M.\[`\\=Z46N!$XNN=X1J+<7::")&$31#90](X2"X;R+),S2_YSTS6/6L/';'
M&9UG3D2\7RXCI47$8MB+YHI^(H81\@-7L2W&@WDP'\.2;>BUS]MFL&);2&?7
MCG><T=GF!+<=A$B9=RR&?0_=Y\W;O1A&WC)2TI**\0@M[^\"R38[WRFO/?->
M9X/DO>X'T9A6;I\S.OM&(C82B9%(=824B:6<"?U>9[!2`$NUVW%&EP$C$1N)
M9"#864.IH'2(/>HVDG<$;WNQ#/3F.UIV[ZF[;M=#.OMF)#8CB1E)M8B<"'9$
M^O1^0/Q@);[\IANBA[0)X3H:)#:K)&8DU2)R0MC!24B(H3+X,4L\#Z')OD`<
MTKC<CPBK:L^]]ZZNM\12./"4]T4BA>=(&9WV8=YWD>O?&Z?LG)V7GG?.3U>R
M\_L;EO=$Q*'^R;ZK[-=]'P^Z%R&:VN;#-8E+E">$$^_2#%QA!K)W>,8GO#-:
M[@=H\CJ$RRV#-)/?]P@_^_BN<HZ.I?"#5></X*,]-U*&L]LUF\`0GRP[OSKS
M.V&%FS/>X[*D5DY>V;78@S49O^57]CU:P24,[E+*]PF[RG>7\3$`-^EK=L9_
M9LVYJ*E5XA-(NK,YG,@:?A?G'UIR[:Y4!]+"';K[\P+_,\%PO7-G`)\(:8</
M[!(W_A=F^Q\```#__P,`4$L#!!0`!@`(````(0`=."%[1AX```0D`0`9````
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;)R=6U/;R-:&[[^J[S]0W.^`;2!`
M)=FU?#Z?SW<,<1)J`DX!,YGY]WO)4MM6JZ-GD7TQ>T9^_$HV_?BE):OY\-]_
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MOMS]]?UUO/W9W#Q\_?:J/^]+?4G1*[O]_&]U\W*O;ZG&O"M>1DGWV^]Z`/K/
MD\>':&SH6W+WS\?3HN[XX?/KMX^GI:MWE^_/2P7%3_[8O+S6'Z+(TY/[OUY>
MMX^+&"HD47%(*0G1_T]""L5WQ>O+PN75&U(NDA0=F[]_*#=)2$'37(J^]+<>
M2_06QN^+_HO+>?L;4[QR[XR^@>ZMN7[[^ZL_G=W17!R]JHMW[POG-Z7W]A_3
MA7M1EX>C*;Y_^YMSZ0XG^A?WYI2LK^HL'H&[`5V]>[W[].%Y^_-$/R;TH%Y^
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M1P$FG3+.$O[Q3K*(]Z*G6<(/F661XHT7,P\PZ:-=9`E_1\LLXNUFE27\D'46
M*=YX(U<D!'D_2$EL3(F4?DV2Z'B,^,<C(1^]F(".F9B`D,6;:R\HI.2UY[X$
MK"S>>"-40EYZ.PMHF3GJ@)C>CU0"8F9B`FKJ],4[GI"<'A*0,[.OD)Q>3,#-
M3$S`SNPA!_PLG7L?!!)0U'\/`XIF#H@5%8.C$I`T>\@!3[-0P-1C*-6K.HM.
M]6HT#RKIB8'\?HV>E>I7?T/%WU"--QP+7;SV/AAJ!J9N8!H&IFE@6B'&^V1H
M&YB.@>D:F)Z!Z1N808"Y.4^K.#0P(P,S-C`3`S,U,#,#,P\QWKQY86"6!F9E
M8-8!YL+_%!(+5+9`B9<I#3.["[F:@4*R9J"0K1?>2).0KADHY&L&"@F;@4+&
M9J"0LADHY&P&"DF;@4+69J"0MADHY&T&"HF;@4+F9J"`NJ5S?_@&W,U"`7FS
M4,#>+!30-PL%_,U"`8&S4,#@8RC5MGI&]3?:-GI6JFW]#15_0S7><#@_4/,W
MU/T-#7]#T]_0\C>T_0T=?T/7W]#S-_3]#0-_P]#?,/(WC/T-$W_#U-\P\S?,
MW8:C,P3^[R<+`[,T,"L#LPXP-_XOYF*!R@YR)T,D&2Z'T2'[\7+TZF^\DP62
M&4.2&422&462&4:2&4>2&4B2&4F2&4JR'TN'@RZ=^^6R'U\'J'CC];WLQUP>
MM!^'>=!^;.9!^_&:!V7&L&0&L61&L>R'\?Z'O1^T^RV!(5HZ]]^2P!@MG?NS
M_>`@/22E/OKT<E#FHR^Z1I0_T8B>I1.2H_.NI7//@G+,Z"C?GYOUB`H2521J
M2-21:"#11**%1!N)#A)=)'I(])$8(#%$8H3$&(D)$E,D9DC,D5@@L41BA<0:
M"1%&V#IA[82]$Q9/V#QA]83=$Y9/V#YA_83]$Q90V$!A!84=%)90V$)A#84]
M%!91V$1A%85=%)91<FU,%:A^NR-5H/G%&=&[+]KL2[%T[IUN*\=,7G$B446B
MAD0=B082321:2+21Z"#11:*'1!^)`1)#)$9(C)&8(#%%8H;$'(D%$DLD5DBL
MD1!Q2/1-('_^Q+Y)Q3W_E[_+"ALGK)RP<\+2"5LGK)VP=\+B"9LGK)ZP>\+R
M"=LGK)^P?\(""ALHK*"P@\(2"ELHK*'D>IBJ3/TJSALJ,Z+]RO0<+L=,7F4B
M446BAD0=B082321:2+21Z"#11:*'1!^)`1)#)$9(C)&8(#%%8H;$'(D%$DLD
M5DBLD1!Q2%29_@DF]DTJ[ODYE<D(*R?LG+!TPM8):R?LG;!XPN8)JR?LGK!\
MPO8)ZR?LG["`P@8**RCLH+"$PA8*:RBY'J8J,[I7Y_A[\?FSS(CV*]/[@D0Y
M9O(J$XDJ$C4DZD@TD&@BT4*BC40'B2X2/23Z2`R0&"(Q0F*,Q`2)*1(S).9(
M+)!8(K%"8NV(J`^]"QDB[L%?EQW[)A5.8>.$E1-V3E@Z8>N$M1/V3E@\8?.$
MU1-V3U@^8?N$]1/V3UA`80.%%11V4%A"80N%-92]AR'54I6I=P&^H3(CVJ],
M[SO"Y9C)JTPDJDC4D*@CT4"BB40+B382'22Z2/20Z",Q0&*(Q`B),1(3)*9(
MS)"8([%`8HG$"HFU(W;W7Z:_QRKB'@QY'-_$R;Y)A5/8.&'EA)T3ED[8.F'M
MA+T3%D_8/&'UA-T3ED_8/F']A/T3%E#80&$%A1T4EE#80F$-9>]A2+5491;T
M#H-49]IN.]@]S2O/@O>-KW("Y;4G(U5&:HS4&6DPTF2DQ4B;D0XC749ZC/09
M&3`R9&3$R)B1"2-31F:,S!E9,+)D9,7(FA&]CSSR^.-ICFMZ9SDS%0,3,K)4
M\&_I,D@I!BO%H*6$O-253+S?/PQJZEWJ_!X9Y!2#G6+04^]DY^,Q""H&0\6@
MJ!@<U1O@L\><_6D8/!6#J&(P50RJZFWRV:/V3_H89-7[YO-RTMVK-_^DNC?_
M%&\APOW./7S'=_<;=#F!<CX'*HQ4&:DQ4F>DP4B3D18C;48ZC'09Z3'29V3`
MR)"1$2-C1B:,3!F9,3)G9,'(DI$5(VM&M'-C(:]WJPT5](Z'Z']>Z1B$U.5<
MXJ`<:<6@I*[PPCD&*;5RCU^8+NVV^Y_WP@Q>ZKHP?$`&,\6@IC8N[\O)F?S$
M+@NA%V;04PQ^:N7R`1D,U<KE'(.C8I!4"Y?W9=!4"Y=S#***P50MW+Q]I0LW
M6A/C^)JJ<;(;+Z6A_SQ\A;?@?4&B7(BA'(<KC%09J3%29Z3!2).1%B-M1CJ,
M=!GI,=)G9,#(D)$1(V-&)HQ,&9DQ,F=DP<B2D14C:T:T>-$UG>PR8Q!2>S?.
MN8J7%"R4+D.=89!2)[M\1`8M=;++.08Q=:K+.08UM7@YQR"G3G4YQZ"G]B[G
M&`35WN4<@Z+:NYQCD%0GNIQCT%0GNIQC$%5[-R\GW;O1@AC'O0L3W7C]#(T_
MZEMO+EXNQ%!NWR)2Y90:(W5&&HPT&6DQTF:DPTB7D1XC?48&C`P9&3$R9F3"
MR)21&2-S1A:,+!E9,;)F1/L61=*^9:9B8)R1<=]>_Z)M>5\&)W6>RSD&*W6:
MRSD&+W6:RSD&,_7$,N<8W-19+N<8[!2#GMJVO"^#H-JVG&-05-N6<PR2:MMR
MCD%3;=N\G'3;:B>^I6TCW#^M[-^@&JVKGG]YJ<)(E9$:(W5&&HPT&6DQTF:D
MPTB7D1XC?48&C`P9&3$R9F3"R)21&2-S1A:,+!E9,;)F1-L67=.V9<8@I,YN
M74[TA2W_W+5!1IW5NH3#+^O>K^K:L\P8?-2>Y1R#D=JSG&-P4GN6<PQ6:L]R
MCL%+[5G.,9BI%W`YQ^"FGDWF'(.=>C:9<PQ^ZMEDSLDW--VST=HL;YC5QDNY
MI&>U_EVMT1\@H9Y%I,HI-4;JC#08:3+28J3-2(>1+B,]1OJ,#!@9,C)B9,S(
MA)$I(S-&YHPL&%DRLF)DS8CV+(JD/<M,Q<`<C`SW+._%8*/V+.<8?-2>C7.2
M<][GT652[^JO$S)&+HK76<0)&2/O"X$4)V2,%,YW)]>]/1F,U%/'_,(-3NJI
M8\XQ6*F36<YQ7B9O<OSM`>^U&\34DN5]&=34DN4<@YQ:LISC]$Q&S^Z*RF&$
MI4LV6H?E#24;+]N2+EG_/MA"#.6\\Q4?N<B,[VJ"Z*\4^[/4WB^^-4;JC#08
M:3+28J3-2(>1+B,]1OJ,#!@9,C)B9,S(A)$I(S-&YHPL&%DRLF)DS8B6+*^C
M5$Z8V,>;X"E?)V2.;3J9/?8ZG&-04J>T?,P&*?5"+><8M-0+M9QC$%,OU'*.
M04UM6\XQR*EMRSD&/;5M.<<@J)XZYAR#HGKJF',,DNJI8\XQ:*JGCO-RTFT;
MK<]RW+;&+TC%R[JD6]>_E;:`:[]4&*DR4DN0^.,D]&E23Q&AW[P:*:(0M;__
M*W`SA=P$B%9"Y'QFM?=(8%[02>TA=)C=O*?W4D_?_?KMOX;^_OF__!UFP,B0
MD1$C8T8FC$P9F3$R9V3!R)*1%2-K1K1ET2V=RL9,K$7X:TQ.P.0WX_B;O]Z<
MQ!D8,SIG"XQ\_29R:F?1[-`?>UJS?-#.PQR%M&8YQZ"BUBSG."7SCN<@Y2^E
MTC/'O"\GIWNC`V^ADS,'<7+F($[.&`G^/`URZEEC?DT'/0.?=SJ5C1-RCO5@
M9BC`21D'A#ZUM53Y*`U6:JGFY:1+-5KDY;A4_PG^D6[W%S,+\9HPJ3(M'F;'
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MZG'16[:EG$`Y\]@*(U5&:HS4&6DPTF2DQ4B;D0XC749ZC/09&3`R9&3$R)B1
M"2-31F:,S!E9,+)D9,7(FA$1`V/P40Q"BL%(,2@I!B?%(*48K!2#EF+P4@QB
MBL%,,:@I!C?%(*<8[!2#GN+\C'\!BB_/>6<WQ2"H&`P5@Z)B<%0,DHK!4C%H
M*OF>IELW6OCBN'7S3RP7XW4RTE-<[Y?/<@+EMFW>>AN[T]-53JDQ4F>DP4B3
MD18C;48ZC'09Z3'29V3`R)"1$2-C1B:,3!F9,3)G9,'(DI$5(VM&M&U1)#'X
MJ&W+.08CM6TYQ^"DMFV2$W_$G[\K^'\H6LN6=V6P4LN6<PQ>:MERCL%,+5O.
M,;BI9<LY!CNU;#G'X*>6+><8#-6RY1R#HUJVG&.P5,LV+R==MMJ;J;*UG5<N
M1D_SI[C^VE$)E%NZ<4X.4N64&B-U1AJ,-!EI,=)FI,-(EY$>(WU&!HP,&1DQ
M,F9DPLB4D1DC<T86C"P963&R9D1+%T72TF6F8F`,1FKI\KX,3FKIQCEQYQ;#
M\RJ#ECK'Y0,RB*ES7,XQJ*ES7,XQR*ES7,XQZ*ES7,XQ"*IS7,XQ**IS7,XQ
M2*IS7,XQ:*IS7,[)%S5=N]&R%\=S7&/MQJMEZ*'L;\XI%;W;<\K%O"4U=A/9
M"B-51FJ,U!EI,-)DI,5(FY$.(UU&>HST&1DP,F1DQ,B8D0DC4T9FC,P963"R
M9&3%R)H1K5UT36N7&8.0>F:9<PQ*ZIGE.">NU&1]9^_;T`8I=;++Q^.T3/85
MO.76$..\=(>\6^'8.V0GIMM5Z+O9!C-UKLLOR^"FSG4YQV"GSG4YQ^"GSG5=
M3N@KQL[-^-T+?L7XX&8HP&GI?D2AM]_@I?:L.\Q#Q7D%I]/;/";=LSJS_)V>
MC9[F3V_]Q:.*,90S=ZTP4F6DQDB=D08C349:C+09Z3#29:3'2)^1`2-#1D:,
MC!F9,#)E9,;(G)$%(TM&5HRL&=&>1=>T9YDQ"*D]RSD&);5G.<<@I?8LYQBT
MU)/*G&,04T\J<XY!32U:SC'(J47+.08]M6@YQPD:M]S5KN3\J[P&0W5VR_LR
M.*JS6\XQ6*JMRSGYGJ9;-UHKXS=FM_$2&^G9K;^45!'7X:@P4F6DQDB=D08C
M349:C+09Z3#29:3'2)^1`2-#1D:,C!F9,#)E9,;(G)$%(TM&5HRL&='61=>T
M=9DQ"*FMRSD&);5U.<<@I;8NYQBTU-;E'(.8VKJ<8U!36Y=S#')JZW*.04]M
M7<[9"QK7[OD[_Y2G3FXYQ2"H7LCE'(.B>B&7<PR2ZDPW+R?=N=%J&,>="]^:
MBA?/2'>MOZ)4,6^%C>1,,B)53JDQ4F>DP4B3D18C;48ZC'09Z3'29V3`R)"1
M$2-C1B:,3!F9,3)G9,'(DI$5(VM&M&M1).U:9BH&QF"D7L#E?1F<U`NXG&.P
M4J_?<H[!2[U^RSD&,_7Z+><8W-3KMYQCL%.OWW*.P4^]?LLY!D-UALLY!D=U
MALLYSM+XUX/X2P+>U0%G:8S$BX'X$_=\3=-E&ZV2<5RVQLNW\>(:Z=+U%Y0J
MYJW`D90N(E5.J3%29Z3!2).1%B-M1CJ,=!GI,=)G9,#(D)$1(V-&)HQ,&9DQ
M,F=DP<B2D14C:T:T=%$D+5UF*@;&8*26+N_+X*26+N<8K-32Y1R#EUJZG&,P
M4TN7<PQN:NERCL%.+5W.,?BII9O-*97\?C(XJK6;3?(OGQHLU=KE'(.G>F*9
M<_)-3?=NM%[&<>_")#=>7B/5MR5_]8MBWAH<2=\B4N64&B-U1AJ,-!EI,=)F
MI,-(EY$>(WU&!HP,&1DQ,F9DPLB4D1DC<T86C"P963&R9D3[%D72OF6F8F`,
M1FK?\KX,3FK?<H[!2NU;SC%XJ7W+.08SM6\YQ^"F]BWG&.S4ON4<@Y_:MW&.
MFS`&%X<T**IURP=DD%3KEG,,FFK=<DZ^J.FZC5;*>$/=Q@MKI.LVL^Y%WNH;
M2=TB4BW&2/P#+%R$ED.N)8Q>V=Y_6=K[5:C.2(.1)B,M1MJ,=!CI,M)CI,_(
M@)$A(R-&QHQ,&)DR,F-DSLB"D24C*T;6C&C?HDG:M\Q4#(Q3,D<W[5O>E\%)
M[5O.,5BI?<LY!B^U;SG'8*;V+><8W-2^Y1R#G=JWG&/P4_N6<PR&:MURCL%1
MK5O.,5BJ=<LY^9ZFZK;D+S>5/[O=X=Z7E/U5U\H)E&-EA9%J`"F5O-M]:P'(
M[UM&&HPT&6D%D.*%=Z:]'8"\`^XPTF6DQTB?D0$C0T9&C(P9F3`R963&R)R1
M!2-+1E:,K!D1,3`&)\4@I82L],:O&*24NN&8#5J*P4L)B>D?L\%+,8@I!C/%
MH*88W!2#G&*P4PQZBL%/,0@J!D/%H*@8'!6#I&*P5`R:2KZGZ<:-ULDXGN#:
MKN.6XN4UTA-=;QB7$RBW>?.6Z=C-A:M)2CS1O0S]Z9(:[ZC.2(.1)B,M1MJ,
M=!CI,M)CI,_(@)$A(R-&QHQ,&)DR,F-DSLB"D24C*T;6C&CKHDAB\%%;EW.<
MD3E>:^MRCL%),4BIK<O[,F@I!B^U=7E?!C.U=3G'X*:V+N<8[-36Y1R#G]JZ
MG&,P5%N7<PR.:NMRCL%2;5W.R?<TW;I:G*G6A7ENA/OS7/]FW%(,Y5A98:2:
M()>GT2W.%^>%@G?W48TSZHPT&&DRTDH0=[!75]ZBEVW.Z##29:3'2)^1`2-#
M1D:,C!F9,#)E9)8@\4^H='->]+Y[,.>,!2-+1E:,K!G1GD7+M&>9,:BHLUO.
M,>BHLUO.,0BI/<LY3LF<3R'M6<XQ:*FS6\XQB*FS6\XQJ*FS6\XQR*FS6\XQ
MZ*FS6\YQ@N;]O`R.:L_RO@R6:L]R3KZGZ9Z-ELGP9[<7>D<1]&V\NH8>ROZZ
M::GD%6&YE%V"HU3R[A^J!"!OEEQEI,9(G9$&(TU&6HRT&>DPTF6DQTB?D0$C
M0T9&C(P9F3`R963&R)R1!2-+1E:,K!G1WLW:YHFDO<N,04CM7<XQ**F]RSD&
M*;5W.<>@I?8NYQC$U-[E'(.:VKN<8Y!3>Y=S#'IJ[W*.05#M7<XQ**IGE3G'
M(*F>5>8<@Z9Z5CDO)]V[^OM$JG>A;R/<G]]ZURK+I1C*^4VEPDB5D1HC=48:
MC#09:3'2WB.!1<DZR8/'-WVE[POKYCV]EWIZ^"_-[Y]_^%W)^V`>,#)D9+1'
M`J]SG/?@)._!:?)@_`Z%_I[Y;/_T7[[">2HD]%6\18H(?=MRF2(*H>L<JQ02
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M+KVWO\<9?48&C`P9&3$R9F3"R)21&2-S1A:,+!E9,;)F1#L73=/.9<:@H\YP
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MZV3\1NO&RVND6]?[VFVYA&MP5!BI,E)CI,Y(@Y$F(RU&VHQT&.DRTF.DS\B`
MD6&"'%]?]BXVC#AES,B$D2DC,T;FC"P863*R8F3-B+8NNJ:MRXQ!2&U=SC$H
MJ:W+.08IM74YQZ"EMB[G&,34UN4<@YK:NIQCD%-;EW,,>FKK<HY!4&U=SC$H
MJJW+.09)M74YQZ"IMFY>3KIUH^4R?J-UXU4VTJWKK3Y1+N%2'!5&JHS4&*DS
MTF"DR4B+D38C'4:ZC/08Z3,R2)#KW1U8H2\D#3EDQ,B8D0DC4T9FC,P963"R
M9&3%R)H1+5U434N7&8./6KJ<8S!22Y=S#$YJZ7*.P4HM7<XQ>*FERSD&,[5T
M.<>YF??5'H.=>E&7]V7P4R_J<H[!4+W;EG,,CNI=0)QCL%3O`N*<?$_CTCU[
M^;;9O%;O7N\^?7C</'_=5#;?O[^<W&__>M*OY.G?T#W:?/*\^?+Q5*:%6YD5
M3L^RC\SUD47PD:4^L@X]4B[>EB\"697B;26T7:J:5`LE25T?:08?:>DC[>`C
M'7VD&WRDKX\,@H\,]9%1Z)%1X78<VCXIW$Y#V_7M"KY;^F:M0OQ:=RRA!Z2L
MCU2"C^@#H;>Q5KBMA_A&X3;X%K8+MYT0WRW<]D+;!X7;X6[[V6%0??KPX^[K
MIG?W_/7AZ>7D^^:+#K#S=^_UBP?/#U^C+Q'$__&Z_?'Q5&\E_V/[^KI]W/WK
MM\W=Y\US!"C\9;M]=?^A8_#LY_;YS]T@_O0_`0```/__`P!02P,$%``&``@`
M```A``:RF9B)`@``Z04``!D```!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
MC)1;;YLP&(;O)^T_6+XO!A((B4*J-%6W2ILT33M<.\:`58R1[33MO]]G'&@.
MZY:;!-NO'][OQ/+V13;HF6LC5)OC*`@QXBU3A6BK'/_\\7"3860L;0O:J);G
M^)4;?+OZ^&&Y5_K)U)Q;!(36Y+BVMEL08EC-)36!ZG@+)Z72DEI8ZHJ83G-:
M])=D0^(P3(FDHL6>L-#7,%19"L;O%=M)WEH/T;RA%OR;6G1FH$EV#4Y2_;3K
M;IB2'2"VHA'VM8=B)-GBL6J5IML&XGZ)II0-['YQ@9>":654:0/`$6_T,N8Y
MF1,@K9:%@`A<VI'F98[7T6(SQ62U[//S2_"].7I&IE;[3UH47T3+(=E0)E>`
MK5)/3OI8N"VX3"YN/_0%^*91P4NZ:^QWM?_,155;J'8"`;FX%L7K/3<,$@J8
M($X<B:D&#,`ODL)U!B2$OO3_>U'8.L>3-$AFX20".=IR8Q^$0V+$=L8J^=N+
MH@/*0^(#9`+N#^=Q$&=)E*3_IQ#OJ`_PGEJZ6FJU1]`T\$[34=>"T0+(0V3>
MQQCK>Z%"C`ZR=I0<SS""*`R4YWD59]&2/$-.V4%S=ZDY4VP&A2L%V!L]0N3'
M'O^>]<&*$SLKK@K.VYW?`/:;MU-GFTM%.ATE)TX@0]<[<6*H]-&+HS09N=Z<
MUTR/-&>*S;\4)]X`<NS-57+Z;H\.V7*7<@P)>$M.%I]Y])JT+^LL2R;S27JJ
M@-%S%*_(PEF2S;-1X3WZT?*=)[FN^(8WC4%,[=S8Q,`>=\>)7L>NB&?[=S#I
M_5R0\0`FK:,5_TIU)5J#&EX",@QF$+SVL^H75G5]OV^5A1GK'VOXI')HDC``
M<:F4'1:N!<>/].H/````__\#`%!+`P04``8`"````"$`X*1\%1`(``#/,@``
M&0```'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6R<6]MNXS80?2_0?S#TOK9%
MW9P@R6+MQ;8%6J`H>GE6;#D6UK8,2=GL_GV'',;FD/10UDN[L<Z,#^=PYDB$
M]?#Q^V$_^5:U7=T<'Z-X.H\FU7'=;.KCRV/TS]]?/BRB2=>7QTVY;X[58_2C
MZJ*/3S__]/#6M%^[757U$\AP[!ZC7=^?[F>S;KVK#F4W;4[5$:YLF_90]O!G
M^S+K3FU5;E3083\3\WD^.Y3U,<(,]^V0',UV6Z^KS\WZ]5`=>TS25ONR!_[=
MKCYU[]D.ZR'I#F7[]?7T8=T<3I#BN=[7_0^5-)H<UO>_O1R;MGS>P[J_QVFY
M?L^M_G#2'^IUVW3-MI]"NAD2===\-[N;0::GATT-*Y!EG[35]C'Z%-^OBB2:
M/3VH`OU;5V^=\>])MVO>?FGKS>_UL8)J@TY2@>>F^2JAOVWD1Q`\<Z*_*`7^
M;">;:EN^[ON_FK=?J_IEUX/<&:Q(+NQ^\^-SU:VAHI!F*C*9:=WL@0#\=W*H
MY=:`BI3?U?_?ZDV_>XR2?)H5\R0&^.2YZOHOM4P93=:O7=\<_D-0K%-A$J&3
M),!>7Q=3L<CB+`]GF2$CM<#/95\^/;3-VP1V#7QG=RKE'HSO(;-<67%U9;`D
M&?-)!JE00'<@Q[<GD8N'V3<HX5ICEH@IHLD%0Q$K#R(_0V;`[TP2EFZ33$!$
M?_G?2<H@BV1V3J_6L41(H<HL%[8R/B`$H#*W$Y!!H+19@;2P&"`F-3`6QQ6'
M(!PAR>T<9=!C!,L^JQ0['!&S4#KG(LECNH:5>;U(Q&)QOD[XP:XR^?'B23#E
M);)+7E0/,?#M9^YV[3@$X993;K(+PAM,!H7T10S'D4,0CM!*9OV&<91!M(ZN
MOHC)E;YWA5WFE7DY7BR2*STJO<X8)+R\$DQIB<S:5DO$<*7C$*1T=Y3;L-+)
MH)"\B.$X<@C",8:!9A9P&$D512OI"JQ!J'`F\GER[E#522L*2-/L,LPI1X];
MI-!DO-@Q#GISR``'2F&I05PI60CE*>>XL1D'UA*G/S^P8P2Q/#D(Y2F'^^T\
MT1+@6\Z#SZ,YYQM:=83@MA!W=Q=OHB1AK3;)`:++*+HQA>T<RQA!;#$Y".4I
MI_WMQ42/@%*<BRD<!Y3W>K`8EB<'H3Q'F4V,/A$0'4%,HQ,`T^BCS"9VW49D
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M')2HQXC"PB>N$8G\\F2`PFL02Q3S^"&4YR@W2M!H^);7(#\);'D60GE"FA$;
M5$91UW2G?((@DZ>AJB;*8BA3CQ^%G]@2UX]$;I^Y:9#)U&YY%D)YCC*E!,TD
MH#SG.+J@'(3R'&5*"9I)H.41=-7?=9+@W7MB^1%_]Z[0=%.*_/)<H)N<>[K1
M)>0@M(0>%Y(S-\`3#28@==B%$@Y">*:C7$A%T7JZ3:Y!**7O%(X"BC2]*$(Y
MCG*@U'4@4=BG<!K$M3<+H3P]!A36/$7CX#77();G8`-*X;MN'^PJ*JBY3$T/
MCIS!KA/AOKA^#)?*^7_S0YN*HBQ%89^T:Q!;3?GM="&7N4]5]YC/`-71?`*J
M(XCER4$HSU'FDZ)I\$-=@YA.QRP:</T8+O483_@63D79FE].]'&Z:Q!;2_0F
M/X36TG*?8<=P*;I'0'/.8M"%=)XA/$>Y4(KN$="<LQC-$R&A1L\\%A067479
MHML'<AKDKQ229"%$]&R4#:FHT`.;!K$\W0>A*P,IDT9P\^!44;2>KJ5KT/5&
MIX#KC9YY+"A\QZZB*$=1V"=R&L36TG6I:[6$-"-J*:."FB.(Y<E!Z-X<94(9
MF@??Z!ID\G0LG<=0II8-\3?$F6L_HKAHA:-=@TR&%F3%0B@_CP6%[3Q#Z^!'
MNP:Q/`=;4#;*@E04[2!/E[L6Y"K.8FA%1YE0YIJ0*.P#.0UB*\KY%.$I/>?V
M7E=1H5[7((XG"Z$\1_E0[CX.N<IKD,G349['4*:CG"B7472/BL(^D=,@DZG=
M\RR$\O2X4;CG<W01ON<UB.6)>?P0RA,P(W:HC*+U]"B/().$JSR+H4P]?B1W
M.#_M<]>/1&&?R&F0R=11'O/X(92GY4;#;N1S=*6`\@CRD\![3YW'#Z$\1[E2
MCF["^[L&^4EHGJXK&9N#$O78T@#AT4U,HJ*XG`:AS>>NY3C"<Q#*<Y0IY6@F
M`>$YQ]$%Y2"$9S'*E%14J.4UR!3>4!6)\AC*U&-+X5OZPK4EL;!/Z33(9&HK
MST(HSU&F5*`I\<IK$,L3\_@AE*>TA9L?X^"M@/"PUR"3A*L\)KJ"0:;X_@#^
MO/Y0M2_5JMKON\FZ>97O!@CX@>WY4WQO81G?+X7\];GU^0K>9U"?S\X7X'6"
M4_E2_5&V+_6QF^RK+:2<3^5O]5M\(0'_Z)N3^M'[<]/#BP3JGSMX<:2"7[?/
MIP#>-DW__H=\Y>'\*LK3_P```/__`P!02P,$%``&``@````A`)I<`C^+!0``
M;AH``!D```!X;"]W;W)K<VAE971S+W-H965T,C`N>&ULE)G?;Z,X$,??3[K_
M`?&^(9B07TJR6JAZM]*M=#K=[3Y3XB2H`4=`F_:_OS'C`!Z((2]M@C^>?#WC
MF0&S^?J1GJUWGA>)R+:V.YG:%L]BL4^RX];^[]_G+TO;*LHHVT=GD?&M_<D+
M^^ON]]\V5Y&_%B?.2PLL9,76/I7E9>TX17SB:51,Q(5G,'(0>1J5\#4_.L4E
MY]&^FI2>'3:=SITT2C(;+:SS,3;$X9#$_$G$;RG/2C22\W-4@O[BE%R*F[4T
M'F,NC?+7M\N76*07,/&2G)/RLS)J6VF\_G[,1!Z]G&'='^XLBF^VJR\=\VD2
MYZ(0AW("YAP4VEWSREDY8&FWV2>P`NEV*^>'K?W-78?>PG9VF\I!/Q-^+5J?
MK>(DKG_DR?ZO)./@;8B3C,"+$*\2_;Z7EV"RTYG]7$7@[]S:\T/T=B[_$=<_
M>7(\E1!N'U8D%[;>?S[Q(@:/@ID)\Z6E6)Q!`/RUTD1N#?!(]%']OR;[\K2U
MO?G$7TP]%W#KA1?E<R)-VE;\5I0B_860JTRA$::,>*!>C;,)6_JN/Q^VXJ"B
M:H%/41GM-KFX6K!KX#>+2R3WH+L&RW)EL[LK@R7).=_DI&HJT`6$XWW'_-G&
M>0<7QHH)D%G85L/H1-A#S&O$`7VU2%@Z%>E!$/O=?Q,I)U&1M?EJ'0$BU<:I
M+H2M"YH`\,SC`N0DB'3;`[,%48#,K,7X.A&:"$TC&&EK-#M'PEL;EMM$QR>_
M'""SK.([9YY'QL/V^,)C<U8KUW3!;AJO2\)45[,I,&K(S'#?D<'PSJ"F:/Z(
M(@E31=-ZI:@(&?!'[4T:Z-"(:.H@9<;[2\)4'=UCR,QO<9R[NOJP/0YQ7"[K
M<4V7;&:M2F'>7Q*FNAJ[Z#5DVEZC.\Q$:-I6NC99Q88+A)PTE)_(F#2:"$VC
M"Q5KO`,KFGJ0^"=0$(9VM?")AT-MW%TNO29;=&FD"YACZV+AUHM'8QF#JZ"V
MYSHY869TA;(RC]Y]+M9Q72%-6@69%:*A.XRN4!;J\0JQK.L*:>*Z"-T/;WO<
M%%[0_X`T2=.=1VI&X"+4=@S9G*$1T5U'6L2X])4W8(/YJR"CSEO+:*IWLQ1=
MYT.-P^WK'(UEE28(88A]YB_('@B5%07,9JQ)-%W;0VW#[>L;C66E#:$[C5:9
MZ(SJJAYJ&FY?U^BD;;<I=`N+D=$5DM8Q4/JPV@^D+4*WF,ZG7MU0*\>&K@;,
M9OZ=.R=&.L:XO*AFT?Q=Z1("!9GRPHAH/F2D?8S4B6T$:EA]U\1H)(/*-#R2
MM""20J$1T77*:CZZ1#.L_7JLR8\'"KI;HK5QUU]Z32!T:;*4CY>&A5^71M.7
M(=1V'75O:&9TA6#H`862IIN0IC)#R*S0R.@*21LQI[)\9NXH)-4W4-#]\*(1
M'#>%EW0.F2'#C]FLIX/,.TY$J.U$LDE#9:<?T5U(NLC(3,9&,9#)MV[2I'M'
MIPG1=3[45UA?7R$_'BBHWTE8MQ6"T6:K5;-;='$/M136UU(ZN8R045P7::6[
M)E`^&HU/Y8H>2F4%F03V('<%DH9BSF2O[WFDB0W>S"C(*!#M#(77(UUD7"Y7
MLX@7Z9-XH""C2.Q*_8@>9=)2QN6RAUW#G,L*ZA>!N6)$=)U@YH'=*&GBQ\[)
ME8<01K+OKEH'[M]5>P^UE(JFVF@J*ZASWZS<A@VE,ZI[C'23@?3HZ2(^[2)>
MMXNTDE-I,S*Z0M)'!A1BW==O9SH)C!`>1_JL>U<-+P#DSE!`SUTU'N_CZ7?*
M\R,/^?E<6+%XDT?W#,['ZJOX6B%PUP&39_#D>@BO&ZKK3CT`I_V7Z,A_1/DQ
MR0KKS`]@<CI90#AS?%^`7TIQJ<ZD7T0)Y_S5QQ.\U^%PJCZ=`'P0HKQ]D6\D
MZC=%N_\!``#__P,`4$L#!!0`!@`(````(0!$I#OC=P,``#,,```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;)2676^;,!2&[R?M/R#N&S`0\J$D51/H
M5FF3IFD?UPZ8Q"I@9#M-^^]WC`.-H8/V)@GX.:_]GG/JGM7M<Y%;3X0+RLJU
MC2:N;9$R82DM#VO[]Z_[F[EM"8G+%.>L)&O[A0C[=O/YT^K,^*,X$B(M4"C%
MVCY*62T=1R1'4F`Q814I825CO,`2'OG!$14G.*V#BMSQ7#=T"DQ+6RLL^7LT
M6);1A$0L.16DE%J$DQQ+.+\XTDHT:D7R'KD"\\=3=9.PH@*)/<VI?*E%;:M(
ME@^'DG&\S\'W,PIPTFC7#SWY@B:<"9;)"<@Y^J!]SPMGX8#29I52<*#2;G&2
MK>T[M(R1:SN;59V@/Y2<Q=5O2QS9^0NGZ3=:$L@VU$E58,_8HT(?4O4*@IU>
M]'U=@1_<2DF&3[G\R<Y?"3T<)91["HZ4L67Z$A&10$9!9N)-E5+"<C@`?%H%
M5:T!&<'/]?>9IO*XMOUP,IVY/@+<VA,A[ZF2M*WD)"0K_FH(7:2TB'<1@8B+
M"/(FWGR*IN&XBJ-/5!N,L,2;%6=G"[H&]A055CV(EJ#<.-/G:+W^SRIX5")W
M2J76`A<"ZO.T\8/9RGF"G"879JN9F6VU3.B;R*Y!5`:5;M2\>(U!9DC<$*I\
M8*GU!=GJ^O*A[F]7K+&A@DP;WM3<;_L&8A*[/A$&)A+U$<\DXCYQ)6(8]4VC
MPP85#,UW50,/+<RMMYH)KIA.#G:C1#1*Q$.$X0\.\O%"JJ"U#4EL>\WSW(Y/
MS<SK;D7^HM-8.V,Y<+LEO%X.W,7<%(_-9?0J;GB#/[AK;\.U4[#IR0\ZVVXU
M`YNWOKNU&R6B42(>(@Q_X4?\*7BL-S4SY&^4B$:)>(@P_,%E=ET_=7F.7S(J
MR*QCOS<U$]2].?,[E\/.6)UU.U.OAG6LAX).V\?F\N*U/PQG:G*Y^K<PW)D*
M-AWY0?=6T<Q0Y4:):)2(APC#W^(C_A0\UIF:&?(W2D2C1#Q$&/Y@&C(*^+[6
MK*/,2O9[\P+IBS.<=@J],Y?]3OM%QC):3#LWF!KC5+(OU_(<A>W%JOWI&4V/
M,`7A![(C>2ZLA)W4_.5!U[=O]6RX14N8*V`\Z+R/U,Q83WWM`HQL%3Z0[Y@?
M:"FLG&0@Z4YF<-]Q/?3I!\FJ>DK8,PG#6OWS",,Y@8G%G0"<,2:;!S67M./^
MYA\```#__P,`4$L#!!0`!@`(````(0!P,2+MRP(``)L(```9````>&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;)16VVZC,!1\7VG_P?)[,20A-X54K:KN5MJ5
MJM5>GAUC@E7`R'::]N_WV$Y((&E"7P*$.3-GSAC,XO:M+-`K5UK(*L%1$&+$
M*R934:T3_.?WX\T4(VUHE=)"5CS![USCV^77+XNM5"\ZY]P@8*AT@G-CZCDA
MFN6\I#J0-:_@3B9520U<JC71M>(T=45E009A."8E%17V#'/5AT-FF6#\0;)-
MR2OC210OJ('^=2YJO6<K61^ZDJJ737W#9%D#Q4H4PKP[4HQ*-G]:5U+150&^
MWZ(197MN=W%"7PJFI):9"8".^$9//<_(C`#3<I$*<&#'CA3/$GP7S>^C")/E
MP@WHK^!;?72.="ZWWY1(?XB*P[0A)YO`2LH7"WU*[5]03$ZJ'UT"SPJE/*.;
MPOR2V^]<K',#<<?@R!J;I^\/7#.8*-`$@]@R,5E``_"+2F&7!DR$OKGC5J0F
M3_!P',23<!@!'*VX-H_"4F+$-MK(\I\'.4<-R6!'`L<=210'HT$\F?9@(;XC
M9_"!&KI<*+E%L&I`4]?4KL%H#LS6V>A#9V#)UMS9(E<*:`UQO"Z'<;@@KS!"
MML/<GV(&TU&#(2#?]`"ZW1Z&D-'YZ>Y[L$7='J*&W_5Y?PXS:#"M'H;M'BYK
M6S!DB-&1_V'#Z[4]9G2$B1M$2QD@GW=OBQ(,_HXZ.$S7=^`Q,Y?/>!9\(`]A
M'\M?-F[!7=D#KY?UF![&QY]1MN!K(_>8'LJ3MK)=]-<7G"WJ>A\WD7KO'C-V
M(Y^$41R&A\>B%;K=&8X>N\M3M^"N\J2C[#$^["@,XFESOZ4[:^OV<VZ+NOH'
M?N_<8WK,/H(GN[]UA[Z6^P[41_S,Z^YZ\K"UG`Z@&_T.Y+.?G8O>;R_^[5O3
M-?])U5I4&A4\@P48!A-X<I3?7/R%D;5[PZVD@4W!G>;P$<#A%0P)8Y1):?87
M=OMJ/BN6_P$``/__`P!02P,$%``&``@````A`+1;=XYE`@``$P8``!D```!X
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M[EW4I^S(W1YNZ*5@6AE5V`#HB#=ZFWE(A@28)N-<0`+7=J1YD>'7:#1-,9F,
MV_[\%GQKSNZ1*=7VBQ;Y-U%S:#:,R0U@H=3*0=]R]Q,4DYOJ>3N`=XUR7M!U
M97^H[5<NEJ6%:2<0R.4:Y?L9-PP:"C1!+W%,3%5@`+Z1%&XSH"%TUUZW(K=E
MAN,T2)[#.`(X6G!CY\)18L36QBKYQX.B`Y4GZ1U(X'H@B9*@WTN>!P^P$.^H
M#3BCED[&6FT1+`UHFH:Z%8Q&P.R2]?^9#"*YFE=7U)8"VL`T-I,X&8[)!EK(
M#ICI+:8WZ'<8`O*=!]"]]A##C.YW]^C!%5U[B#K^UN?T#B8-.\R%A_C2P\?:
M#IQA8#_E3Z^U/:9_ADGN*P/D//W'R@X,VW/&&J>]CM>G]I@'E&'.CRL[\'7F
M^$K98])V(Z+0?3K`1;/3_Q%VX&OATR+YR!XS],+!J2%>U3_7?NT;NN3?J5Z*
MVJ"*%S#`,'@&W]H_U?Y@5=.NUD)9>!K;VQ)>OAQV/PP`7"AECP?WWNA>YY._
M````__\#`%!+`P04``8`"````"$`V<*>(T$%``#X%```&````'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;)Q878^K-A!]K]3_@'C?@,U'($IR=6&U[95:J:KZ
M\<P2)T$;(`+VZ]]WS'AC>]ADD[[<NV&.Q\?'XS/@Y;>W^N"\B*ZOVF;ELIGO
M.J(IVTW5[%;NWW\]W"6NTP]%LRD.;2-6[KOHW6_KGW]:OK;=4[\78G`@0].O
MW/TP'!>>UY=[41?]K#V*!B+;MJN+`7YV.Z\_=J+8C(/J@\=]/_;JHFI<S+#H
MKLG1;K=5*>[;\KD6S8!).G$H!N#?[ZMC_Y&M+J])5Q?=T_/QKFSK(Z1XK`[5
M\#XF=9VZ7/S8-6U7/!Y@W6\L+,J/W../2?JZ*KNV;[?##-)Y2'2ZYM1+/<BT
M7FXJ6(&4W>G$=N5^9XN<IZZW7HX"_5.)U][XV^GW[>LO7;7YK6H$J`W[)'?@
ML6V?)/3'1CZ"P=YD],.X`W]TSD9LB^?#\&?[^JNH=OL!MCN"%<F%+3;O]Z(O
M05%(,^.1S%2V!R``_SIU)4L#%"G>QO]?J\VP7[E!/(OF?L``[CR*?GBH9$K7
M*9_[H:W_11!3J3`)5TD"8*_B?,:3B$7QUUD\9#0N\+X8BO6R:U\=J!J8LS\6
ML@;9`C++E06@S^<K@R7),=_EH'$HH'O8CI<U#Y?>"RA8*DB&D+GK:(B-R#]!
MQ">(!_1.'&'EMW.4@PC'Z)1^7$:&D/FHLEQ7;CRP"(`P)H'+XD@PB&BN?$XF
M1DAH0`BU_!+"H@9)KJ<FP2L75JDW)2'4$)*,FYKX@9_:\=R,<Q;/==RB!65]
M/2T))K1T6MPJA,0CK2!-64!HF?&0);%>ED4KOH66!-NT`M^>-D-(B$?`UY..
MI',SRE(]UJ($1^1ZI2284&*$$D)0J3!)]*S(R0HSKG6V2,G&9;C"Y8*78$**
M$U((09U8J"=%3F:4^WIK+4KI+90DF%#2:;&B$(*4XH385VY&>7K&EQ@8Y?4R
MC6A"BDR;*0SN'N,Q"PGMW$+$21!KY[#D8L38+V_AB";<=&(43&%.W(R"QFTD
M@,@0U:8F;?;JZF)HRJ9I!7H_%#7$*&IA2F3-50X5CPQ1;6+2=:\GAAYM$:-&
MSSY\7/;(@-:]%0WU0;9)W>3P;&KQ`;&E3&$^U/*#F.B96XB$1X&N0IO;338O
MWYC@5((DI_9#)<D4!E9QPI`ZS"]";'K$[J]\N9GZ?DA<-&.(00EY;!Q"=13,
M>.@;[<HF2,S_2H+3+F`4CSH1IL^#ITY*SXJ'\W,;?%,C8--.$-).H#!*N<`G
MRN8TKH^RK=Q-[8!-^X'A`4HQQ""QN>_KB=66FO%D;KB?18S?U!-&M.V[(9DX
M4QA%C'/M$TC,BB=)J#W()G930^#X=FZ:6T@.8J8P2(R%G!-`;@/F<7".FK3O
MJWV7H]E;U(B!90ICVHBAB](-\YS!V-K=U!@XFK[I<R'U8(4Q)Y^HAVD^A]CT
M`&/J)VUD#F9[N>=S.8K4'K&)3&'46Q(CI9E;X2C0E6G3NZE+R&]90BLB)I$I
M#%9>R-+0.(UJ<S$+(H(@38P=L,F1'O&%9M/>$.E5CU-GW/3^.Y["Y$36G$#F
M461\9]GT_E>'X-,.$5$C5ACU[4(.4'XN:I.[J3OP:7>(=-M1VB%&68I\_R7J
MYBH+(N(P.?=N#M=!DS/Q]<7&.,H^$Q$I^DQA\!.9A9^\/EF(SUZ?\*()[V%J
MT>U$+@Z'WBG;9WF)Q.%S\O04+[@RMLBXO*<@SW-Y\26?>Z<`W#L=BYWXO>AV
M5=,[![&%E/Y,^D&'-U?X8VB/X_7(8SO`C=/XYQYN&`7<@_@S`&_;=OCX(2<X
MW5FN_P,``/__`P!02P,$%``&``@````A`.?LZ76)`@``VP8``!@```!X;"]W
M;W)K<VAE971S+W-H965T,RYX;6R4E5UOVC`4AN\G[3]8OF^<A"8%1*@*5;=*
MFS1-^[@VCD.LQG%DF]+^^QW;?`5:1KF`&+_G]7..CYW)[8MLT#/71JBVP$D4
M8\1;IDK1+@O\^]?#U1`C8VE;TD:UO,"OW.#;Z>=/D[723Z;FW")P:$V!:VN[
M,2&&U5Q2$ZF.MS!3*2VIA:%>$M-I3DL?)!N2QG%.)!4M#@YC?8F'JBK!^+UB
M*\E;&TPT;Z@%?E.+SFS=)+O$3E+]M.JNF)(=6"Q$(^RK-\5(LO'CLE6:+AK(
M^R6YIFSK[0<G]E(PK8RJ;`1V)(">YCPB(P).TTDI(`-7=J1Y5>"[9#S/,9E.
M?'W^"+XV!\_(U&K]18ORFV@Y%!NVR6W`0JDG)WTLW5\03$ZB'_P&_-"HY!5=
M-?:G6G_E8EE;V.T,$G)YC<O7>VX8%!1LHC1S3DPU``#?2`K7&5`0^N)_UZ*T
M=8$'>93=Q(,$Y&C!C7T0SA(CMC)6R;]!E&RL@DFZ,1D`_68^C=)AEF3Y_UU(
M(/()WE-+IQ.MU@B:!M8T'74MF(S!V64V@/J\G1FDY&+N7)`/!;6!W7B>9MF$
M/$,%V48R.Y6D?<7\#46^DQ#`VS%"YA]G=$&0"T9[QKV]3V,6)->'DAV`5\S/
M*7J(L,XAXOGR.7&!P7N/=M-?>!8D(U_;.(J3_O3\W>D>%&1V.903'T$-^ZO.
M@B3W4,,X?/J2^5E)#PX:_W(X)SZ"&_57G@5)@,N3ZS3.CWMR?BC)!G$VS-)]
MV_;@\H_`.7$?+H^/X(+D+-RAY!VX<#^%X]O1)?].]5*T!C6\@DZ*HQM(4(?;
M*0RLZOPQ72@+MXI_K.$EPN$,QQ&(*Z7L=N#NO]UK:?H/``#__P,`4$L#!!0`
M!@`(````(0"A>I?[5ST``'Z^```4````>&PO<VAA<F5D4W1R:6YG<RYX;6S$
MG>MN'$>6Y[\OL.^0$+2P!)`T+Y9;=KL]*).4S1Z)8K,H[\P.YD.R*DE6=[&J
MNBZ2V-@/_1#[98%=P-A'\:/TD^SO?TY$9&1F%4EYW#U`MRQ51D:<./=;1'[S
M3Q]OQ\7[:KX832>_>[*WL_NDJ":#Z7`TN?[=DW<7K[9?/BD6RW(R+,?32?6[
M)W?5XLD_??M?_\LWB\6RX-W)XG=/;I;+V=>??[X8W%2WY6)G.JLF/+F:SF_+
M)?^<7W^^F,VK<KBXJ:KE[?CS_=W=+S^_+4>3)\5@NIHL?_?DX.477STI5I/1
MGU?58?CIRQ=/OOUF,?KVF^6W1]/!ZK::+`O@*(XGR]'RKCB9^`+`_<WGRV^_
M^5Q#??A7Q9OI9'FS8.BP&K:?]JO93G&PNU7L[^X=M!^^'2QYN+?^80*CMQ:,
MXM]ZEXOEO!PL_[T][6?M'])4%W>SJOWPL[W=[3^T?^R!@*$AX=6XO&X__>RJ
M'"\Z$Z55SJKY:"K4#8NC<KEYW*O18E".BW^MRGGQ"J0O.NNL0UI:)KP>5EL_
MP1\Z.`\$/:^N1T(?9#XM;SLP?M;OG7[?>_.V^.[D;?_PY/CT\+A?G)P>MB$,
MLQW"+G.V<@(+?"S^N;IKC_ML=W=WC__M'W0`.ES-Y[Q>Y-C8A+K/MK?W]K</
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M"\G%=`D3WC_'VBUM%9/I9#N\V%T5'3M'"4H?"EDS*09>J9;MH;Z)]<`[<.N?
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M=_Q:HY4P@!&Z*MZB^$QA/-)\51\'\&Z!2^)FL\`2EI]BU0X>[4QV;-YY4%)K
MQ'@\+B^GOI&BO)Y71N*.'3NO%GAB@YOB6FY1Y[&SZ"95&#`UN4[&J0-'FE\B
M/P3:\=0L29LRWZ..Y4R9?A_>CB;FJ$G(VR,=)%DGB)0MW1[W>HI/<36?WA9A
M+&Y*>TRRXJ:0S!B[4*\U=*?5LA@S:WN6[\K%:&"0#T?CE1PMK*2-+(#255_[
MG>!@K>1`24FA6%:VG<M?,%G#`VLR,[*7:2S#R0:?++U7H`9.3+45/8C6G"$\
MV!R''-Z4&*6%-K6:$)*-91D<&3+![\L1?#FNM@FMMA<X8/?X6,V5UV%^@QY,
M6S%Y/I2_]VH\_;!1GFL^[LFN;'!%AG]<+8+]74ZQ0H,IBI(-)&+SJ_YN_F4D
M;,VG!&V;ICZJH!%*-WDIY>UTOAS]Q7YH<TXO>R9UQ:NWH]5M\7DQ)+22QUF`
MZ-O'.+'F$&S#<5!('!@]I?:2&4VS_9B;;6R?>2T=!7#6<E_M!;>FZ]U"2=F#
M*&Q#>#)YCS,N=7`/!<]6*#HV:UPQLC?,G6I/]J9<!J]?^+UG8&/"V5RX:7O,
M[;G3[AC^?D3NH+B\"TL(^II)VB\&P_S`#N?3054-@]Z;K2['**;I%1XMDYM.
MLQWAA%F0-I@NNBK_K#&'[*Z-!1.PB$)$<U#:X*W=UY4[$_?N2R^B<]$4!'Z?
M%\^&E?_]N32(\8%TL_WEGICM<%-PMX6C?SV:3(1<"8ME*=K`W_,V&9'-[TGQ
M&S/!Y`L\K5J`^ZM;)/!.K_9'UQ."V8&R#GB4$E`!<T;(O,YS7S/D'@_L].W%
M<;'WM[_^K^]Z_9-^\?95<79^W#\^O>A=G+P]+7JG1T7_W9LWO?-_U;/^R?>G
M)Z].#GNG%T7O\/#MN].+D]/OB[.WKT](=_3;:%F[O?:@BYM*`1G:HYS<:6.K
M2;G""3>5$KTM5&6=(@A<@;%?1,_3D-C'<*#XBN]&TSZ8(8NPV)(AVBF>_>VO
M_R<\_=M?_V\QG1>8ZH(?92%8EA^?%S<E+OEE54VD$?%%`0`.$FCSH7'PA]'R
MIGBWT]\I")KD;(R);LF.$'=83!DI,T-8!J,9.8D"(\4D1/JCVZ(&>U3G!4V;
MS59S"<FRP``(L/E*[XIMY]6U0@P"$MNA'O932L%&'']$)6$P969O$3;%J;;=
MXT/M:L=89CX$L>.[+<U^5PPQ,U,3FO%J"/+'8[&9YFX#=C6=+AD*,'/)CE""
MMOFDW8NPXVI99=NOJ;8#>6SAZ0R'#<B!X[:<E-?F:VX9:&5F-I^)#W#L@C!.
ME+X=`YMR$/HM&_L<;<-80E6`GA`$+A:2)Q&D+*[*T5Q4KF6N)CZT$UJ&.]&/
M9UY&KL:$S7I;>%K>X`X;^M$+58%24RH746>M%(?^_%,=B,ZQ\J`\PC&"<T:3
M(3(M!S5B/ZZRO"&<O2WO8$;SBP?BK[CTG?*>K*3MQMB6E4(Z>(>T6*6=A]1:
M0VXN0VK-<MP69"AN[DRR7WP`:?C:<V!C87G`VG0FE0_(8D0A>RR2V/WO!>G:
M^6U!XOB?.[MAG2X<T!^4XR$-"Q,]`=$_/K0]HNMK>:H9"E]YNAK#I0@1V7P!
M``K^N)K@.\%>:9JU[TK@:HYGM7F%0+81OP'4!_>\:3=M??B.K2$&QW`YM8F@
M!P['^#IF!$P7M-\1T6%GE)9;$-Y?NT-'!SLB$73GV'BT,`<-L,@$5/KJMOP3
M7-H`%E!7MS-76L;+)0[$`.TF)KJ-*<T9'BJX!"3]OA9<$<1>RLV#Z2.$4^DX
M'-7KJ21!00_*OM8=1:5\D^&/'%T-X!8+2K[UTD"96=42I..#59T%JRH;4>]J
M7GF>A_V&4);_#J;89>URJQB,45^::3E7YH/YYBN*'9"<'9B[L\9)WLEIC,"Y
M&PV7WJ#A2(AI/N5LYV;*;"H>OB\IDZRP!B!FSH:5:H[Y;H\A_0D@@P)L2H<:
MPFBP>\C)>$1,O1`E7686Y+Z4N5ZA0ES9#49S,EW(F!M4O1XU%7SVX69$\"^6
M,E(9(4QF8`PA^8^KX77(.5Z26+%!@W(^-U-O.4&S;.[*VR:S8(#1:"A,L6E/
M2;0T9SF3=69K'IP;(A93?/-J(7.W!/4)0@B+.AB.Y,)&539%PA)M=]JR%#(B
MQ7E-X`U#@I<L,V(9D-KWABX85D>AZD645O"C@7J)WR"LU/D4V_)@FB5;L/QL
M./"78E^TH)"^J.;O1^S1'B?O_P/)1#WF%5Q)N`5/PI*+E:(#55(<AXC+G`R-
M6U;X"AZ#/X?0G\KJ'<X/9""CJ<RUN0GH$Q;3G%>CCP"!/`PQXV@.XP]G;<&-
M9'OZ'9,F/Z%T#H),J`%FVP&3E@@/?H,9,]F4&F\(";ZLDJ)-U"SO9I(",Y9F
ME!?%:@;1(?U"3C&C`<M?1854\O<4DC#UZ/82I\I35I;Q=1)%'*(JD-A;HMZ%
MQ3BL'2>XQ>`@?YAU2@9UMGP^O2O'*N0H.+Y:$>!5<>7J;W_%N$&1X0HMMR`G
ML6AQU5P5XC>X$/(*B^.Q9TM[-4'T^DC.A3N`Y7!J^E.&H-=_5YQ.=W[^B9+T
M5]M[!UL)GQF'XL"GZ8^<IB;%$?6-I9YIRC!;J*P!H/YWQA^+ORA53YU]]\GG
MWWX#A04657,*ZWOZ9?Y*^+<A%Z-;\'%:?2C.IZA>/;TJP=]=F$$_?&Z3+K_=
MD?6',,X*&2_*;X*OS!28%D*75,7OR\D*?^WGG]RQX4]CXV!E"Q+OCLO`P-HL
MQ)>8H/><:N!NL4(W)5D+?@U)%/EIN.539`JA1#R159D)7LELP<B=XGR)XE;)
M!:+T4J84^X$XDZJM;0KB*&$T2,S+-!47/;PPE58G8[Z`68.S$D6+)S(9V2S@
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M`1%O"-;T0R;+Q@6$1F)Z8ZS1TDF);ZJ$I,-"F\=.$5."KO'`6%Q_X6(J*LTE
MIZC;4MB+-3OW]8*"15^EIAK^_I"2+:\06-M%6\,&3JFG_?NJ0[4E?;V8E0.T
MZDR&</Z^>O*MZ?H`"3)963QI**X=5/EAPW(^]&`TJJ*D#X/V2ZR9$4>\&;*K
M.=J6W_[MK_^O[>$$]P)S2RT*(ERO:,^0,P$UHG)JKXF2DE>Q5=Q,/QB.DR9&
M5^*K9Z!D85J4;KP.\7Q\-Q\<U81KKCK"J_67,U&M*>+*OVWO*P0Q`@>KHR"(
M5^,\#0B;BS+*5%)$;]*$)8N.\?X1,O.7;D9H6++$1%?FDXEZS1%2;UH^.`'X
M3&DR;.-050WO7AD4T\L_>IVZ5O]*[?S8?WNLW`YV!WOU/A1$?@O.1_/A]@PO
M\Z[YPL79FO&&;DTEMVU"<B*;"1`%^"4RF>12ZJ>Y$\%RW#]+H$PJ$F3(ETU*
M;J9@74V>30R)VR3!<,FGQ`9K2>G.H/<1B]%0JA.;>T-GF-CCE](/]1T,G*E?
M)5V:>_$U@OC7;7JOV$74\LF/0$,I$]CF_YQ],(CN>RR2@A?X6?VR=DL8V_"`
M$#&QB*FJ=6Y0;<DBX]:6*/*I->:8`2"^AX:!V1*G"=4;,`'V<U;?*?Z[(@QB
MKK&%;/>\Z3AT;R-:E>38Q!@F%Y9DZ3,7"PX0J8R'.AP7>*K].][.%;DUYSX/
M;8R9(A`P%8V6_;.0R\&090O6\4E$)]Z903L!11;D*P@S&Z_-@T-BN2OBS<09
M&QT<>8MIDX$(,46717S&VM$12&S6Y`ICN3X27A6][XMG]C<K<0064:LHF3MS
M%:/UE5MHDHQ017.2^;?)E'38ONZ""4GCY#S%M*24IQ)S,!R[IX&-K&-PB]<$
M4)XD4%CK7HDQY6H&IQ,O#FY$\-2R5VL]HOF+&VPCL5HW)&.NC#J9,X:QN5J1
MTK;I-3DAAP*"J%;JR=QI8B+(31@H=%@ZEFRA;T6U.'=Z9`6-I7*[Q&L-P;4(
M)>EL:0G`N`3U#H1KL."IY8`Q3T,P`]MZ5%D[?!TJO0DA;#DA5J(8THQD44<L
M/5YXI9EH.:02HCH+B;?@W/$O)Y*I+7=P>7^XJI`/"WWO(KM[`J+.&V9D,"$A
MTI[`&=)WK?Q`4NR>3?.0^B[&V2+#NO0!/)#8+ZVEV*D=Z$<`0^(E2ZK`G4FL
MS'-/6@Q`&WF(7$-;==/D5_Y92KV0>D*LE-AH-^@QU4RSJ<-.*YC/*W5^52^"
M"HN2GO(+08*D9)1,LUJ$++(5HQR='>+G>?6T`^_!,<K7N1.S4]M6-\B1`'FB
MER<5Y1C)TB:"^L_PE?716B)2S:.&CK1>QZ8MT*RD<L%JTCT%+C>A;J"]05@3
MHU:^/K[UF"X0\417"<<@J@8PP13;7`T+!.:6TNJ@[QREA4[HU8[U&7DELL!T
M"_*@[:2<3(I7U25)75)E:B]W(_>JU_\."*TC,4O3[!UL[])F*#&N>_U.O"'F
MV06EKD&QO[_[_&L2.3$J`CNT9:S$.$`6DOU@D?YI80XP4Z_A6R@UWS"Y)W9L
M?2I_%R22,8L?E#]S(-<H?]!KE3W$(O>)(VLT*H(I@5MG\3-8E=T%5M9(L'HJ
M>M!`!"2AZ5%U1/U.GFVR#*`*>B"NK%H@BR*^;$>.Z,I4CW<?J2X<[;VP0Q'[
M^"P(O')HH!"O&/4>HB9B<N/TJ]$<[0'W4(.8"VH1U526Y"`/#INO#^FCEF2:
MB(*P$>5C<GZ2<?R!NH@QB[V/M@,O'K)*:'XA$]-A2&]`\<R5Q.J52I0_JF>V
M>$-.E73C>KY4VXJ_U</:.'/D<VUNM#I5Z7^?S.')Z8_'_8LW%/W[5O!_U3LY
M+W[LO7YW7+PYABCGQWK6%8FT=/M1+,0GYD".X>RU+47*HZ0`H6[J$@HD^`IT
M]6[61".;7*>>R/C'"*A^NVZ[-RV@>@.'`?1BS#)0Z1."/3N7K.^?5Q2[A[&J
M8A$=WGFJ&F;]:.K,E=MR32)0HN,=:NA'3P4R"9SV.%'8*=ZLZ[7*C0&%P)4?
M(X#[[ZCNPG%5X2H]J5;,4M2R;:%Q+-1J!9QGK?OF9D43:UY'`]NX`;@6BD0M
M6`XM,"@Q,?]H+N:#5.]'I(&%!PF05!]M%49!\SQ,NV3CZ5F8T[-@_D*)S5`!
M#3\L"&=-&62F3?U+.D`]OV`>@-QQL+ZP0I/$W0I9IGBV<<@FVR1:T;(H[L8V
MY8A:.G0!#WA%[0I)GLY%00"2T<*]@L+`:!K7/5W5_/Z"AG#1#[OWW>1I8"&!
MLR'7A(EL@4JN7AEB19?"%E.YI=>PC`]5A#&;C[LK#X)5,FP:9>H]NPFJ50X;
M\M9U6VF"V\#6J<JAR2UUEOC$B5M5=<XVD"N0WD`4M+&L`[AB=X.EY@S3SF3F
MR(`3G,==+E97:H4/NU1$]<$'P@URK^F+L8229-L*3X'FH9!I\MC1C1>@R<_3
M./$I+S,>.KB;E8._1I5DRN"9K1;.#3WOM!JN._.`658G9?<HT2'^9UOQ?0^N
M.]V][U(7:V>XE$?[QV?JL:T6G2-/QZ'&WDF@O$)<?O[)3$5[KGX\$U'WHK2'
M6.M:UAC70<H;5,U=5(G*E7<@?MJ>$YNR#I47.FC4'GNO]NX`X]U7XIR)Z9T%
M#L2">A&BY>F\875)"2ZU2+57,Q`ZS8`F,?=R3GN>VN<(G3>=QOJ>R=L:`M@A
MGI3DNG?5XJ92+PM)RDRG*K>OQA#K-,@LDMJ;$8B@@E':5E&8*/S+>J@9$;W]
M3VQB:JI/0<'<Z_1L9A<,!_=O\1="HQ29L++\4(WQ%!L=6%WB=#2*9*9XT+N2
MWHFF[-:=,.+.D.:H-6_L7<C=$KF$I>Q?Z$PS,Y5;B'9#:I<'K9*\7?,R)6`!
ME-D+*5U+D`0(E/V)I@N12&Y-R3"J,MN4K^=TE\0,=1VBA2-8=%/*[4[)?M$F
M6RZ@P+U-\9GZQ6$[?%.S5DOEP&E<D;ITS3R:<"B!HGTXI.`3R*AFLP+S%6T$
M=-=WI/TUJ9MQL?=U\6[BG7UL*KAH[INYDV5`NP$)<%CJ@\Y,>J;4RQ*2.!G\
MZG[S^$)-$M8%I`,W;(0.'NNW"R@%`UD_2J>>X!#N?UW\P3W'&JP./!.EV&E#
M`\%,&C!3)\:FETHRJ`Y).M@SF4.2?8,ET9N-C__:,@%.^2I,K.L'2WJ9Q7>V
M4/\%Z<=L`W<;P#_X6E54L*7!LL!>:%E6@QL[[1Z0&G/O`73+=@G1ER@![\<(
M3<KX"Q+-C,8YYL4XJTF]W>+9:*?:4;Y\-O.6,!0>ISE)+PH>E$SP#4)[S=WS
MCC3G<EKGI5K1QQHU9,8"$[R<KP)3+XI`4170Z]\'>&*7)"\;'G08Z4YLMI\`
M;F`%R5#BL<PR@2+84OBC/TAU3EP3<_L"CT3^T0C)3\C#?_HZFL!X[WTH%(72
M1&/?C#%X(8VEWSG<.K@1"#H73)RG+OCPB\07#AN/Z/NKE1.3PJOL]7H^7<T8
MPRNB-)9J/OIHD^M%A!V%/=9_;Z<DX>6=2DS5N045E>O5SY@Q@V@*4)RD)ND2
M>$I`:IZ0GL!;9\G+^?1/]#W%&6H.#G,IXS"'MR3R93%9V2%1MN",G"EE5?X7
M"@"A!06/^?2CM6"RQM"S!"PO_7;W=8V.XFZ$D6:W'G/QLM%3&#.P/A]B?GG;
M]!:_6B:&,UTSS+)>6WZ8;BL0B5&G7HRH;N#W<J3A=A;#K3R="Z0A591%F97`
M'/L:`P.FC)@?X_!.`6_#B38LT`_T<L4#L\>.D7(<D`/]K`U9',CBP*W<35`P
M65+%U+S&BM,N07/J`J'+T0FBT$HC`@X5105-XMUYJ&&I.C!/J'"-FB0,8[CD
M1[\D4)-5"]M,<8_@A^.,UV&Q,'F@J/@I:0";E"TQQC15Z%=03T/@1QMA9;"T
M;C:H#>1:A;1>_9E'I%S1P_;?3[?Y+KT_);FU)AZN573+031P;D<E'V-93J]3
MACUFX-0>P`/Q4--[50=:]S:25W7T\?-/;^I,52=*,'5)/]<WK9M0@AI=^S-A
M2_OWGJQ:UU5H^'P&:<<C_\X*=V*1HW#*4D>'%&W51V_;JQU3RY`RJT<\=);F
M()RE.;14VM')ZW<7QT?%Z?%%\?IMOU^<'9\7_1]ZY\?ME1RZ"1#)D5=8[><^
MK3/3D@(#DBIV.!3[.%03FP@M0YM>"I'"ATJM2-5PFP,M<\Y29"IOX4?N$6!F
MPVGVYN3&4?HAF:8PL<?VU#DVGDI5XH4.S4$X!Y]#M@DJQ/"14(E4,Q)R^&<H
M)#L:*^\I2*2U8F97`'3A[J"X&I22^IB>5-Y(7GJ"-&9MZ8O=O&/K!AL&!]=S
MU2;4#81F`;5GF@C>02IX]Q8R=%7M^BDOLAVWYV'6TN[DH`UU\*?X1H-(`0BR
MF.JDC;DL]]N"P$>RA$ZM>W840[!'GF6!*EYKQOH4O]EZR24-7QU\:;KWY=;N
M;UYLO?SJI;7<IDL6.OKQ3?E'U/KAB@W>8KFWBC-OC5[<C&9NW/JI:YJT]LA:
MS]OD?#N_+DG&^:8/E0>P.V2TWQXPGLG^Q2-U;_.+"?K$.99-7SPDS%^HK[;W
M^[?GQ>&[_L7;-\?G?6#MG5^<\K<?3LX\7]Z_..]='']_@LB_?GW2TZT_;5@/
M\P;OHK?Q-'USG`3@M35&4_2/[W@ZNA\[`:#V#RL:`N4^S<M9Q2'P@:/P:%1>
M3TA2\>\V.">3V&!KI&RV;(`T*"LG"*>KA+D>[E1X)C64('S>`C$T*VP5^3FW
M.@%Z&)+%VJUOJUX2[U@)#&^P5[NZG?\W7I.\57/=-"%7XL9P`!A-'`QK')A)
M1^5-B1!(7A.[8JP0X^1/Y!75"2FF<?$7?"H5=:Y1QD>GO>U+G=E"C'$2EA7^
M<_'L?[PZ>TZ!DT")/NEK4LSO8LM%C8XF=NM=RAF*&ZK57&<C\KKJ;6AMM9E[
M&F<!/B;65T]^E(0Z5YF)#R`=03@ZT[I4%!'%QRA/->Q#7<L.78ZGY&Z)X9>F
MGEZ%#/B/)R=;!7_PY\F_&++_Q7VKM'B`FWFD/*QG(*[96"ZV0*!V?>@2M]=5
M8=J5,$I_^71VPR4^I74N_WX%R%(RNDA*+2\);,[NC:Z(-[-5#`0Q8%Z[1].6
M!=21@8PL80-_6*%M2<Q/)Y;N#FR@[8$UQMK!TTFU`LV5%E&_-$8GC+,I$NO*
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M'H?VD0!KDA*@V(>2XY8`LR"*F"CM+>12Q*:D!J>KZQOC/#82SQ!+@"8D053D
MM39SA$`G/8[F*^Y(\/#.NL"?G9P>/9>2.D9F9A4O'<;3<!>6HVX,/KSHT;>*
M!)'=<3Y;`VHZ3I=+=)ON;O<!,RFE(*[2-/',:MJPB5O)(6P]T519*[@=X?;N
M9M\TA][EGEST:E9TK1LE-9TO6B1G4BCV4B7TT?516D3<8/]HP[$=&UBLQZA#
M;/%C-(OD`-5>!\1<B!)./\4.(OJTQ*%/]PYV=M4E-X;QW`+$MTT!6Q?8I8[&
MC*Z-'\RH>M?>:B8Y?;K/%"_B%)H3GU)Z$KT6^[/<Y%A0G$F/>I#KWKVX3_E_
M=G*=&P6SXY$9/752JS;@3DRAS(Y/91U_LG!8.SN;EJ5J'@`J9VJJ\)3!UM,W
M8WASN:5,GKZL,?&)R&QUM.79:(K`YE4-I[3I5;C[UYR-(,!2&Y)B-%"N.,2W
MSS\"B8F`XKDRE6`)L%QJ`K?5FA5)#MB%5>K,?NU*P1K@3PRN2CBV`[.A6E1<
M8.%-+19J6O++><[*OJ2:="B+P7&'UB%8'YI'&S:;OI)>RGS!#INK8V4=G]7@
MIVFD,W!U?!U9&EZ%H]7%D)W@$0-98P/^*X821#<)*`M;'TZ1_GSD\MDN:H=1
M[]]3.8FR8)H@X_R:N=V`9!4;RPE'8P\3L`+V+_4)WG(EINEI:[*SL\?BF[*>
MT=;RS#((,K\L];NR&C3,MB__0<;$6B]L,6KT#`$GUAH!(\%?J2VVGHB.E=B1
MZY-N>,-[77W2J/!0-D&DGXV>__R3[QC5!C%3GZR[Y$0V'^@[0#14+@$+<ZH9
ML(`71X3\H.3,AT"4X-%P,HJ6+L_LA2.M=G)%B*J/5JR6Z!_U$*LY2V*?;,:&
M6;<H5`AB*?K<`U31+4?3ZK[NX>0&Z"TDOPZT#!':E&$'?RN<#$Q($6\#04*:
MCW#XA9\L=YL8YI(HY5I-O-+Q&<9T3%J]53Q5@W=L"=;6-"IO3H:_:L+S-!0M
M$N>@'ZSC)D=!E$XU>83&8P"4=63+N//T5?-OK>09)I=M_3LM)3^KL74I,B*7
MV)-B7L/FH\:?L),)&>L'@$\'\6C"HV5#.`V`NXS67EA'Q5VPJ<!0ELG+DK;:
M;W8.H9&MS=O,X90RFH-(QSKD-(E'"_H]"$GGJ)CH'<LJ.:(J0H6E`0QB:\>J
MI>-#C31Z%N!7B-'Q)@1/$89.R)JVJ5MF@8S?AE-LCP:;.;"BP+;=Q!VZZ^"/
M$%&8""<YZ\+JG!0D&>V3YPN$K60-X%\AQ9F_Z?D:[R7&JUD[>H31A0HR(D7!
M)LDV*6>Z;6UHJ!^V;T3GT>BC]T['^#:!+=6);%D(E!1"PJ_!$;8B0+%<M'9'
MLM@&8)YFAETA[T%S.[)8:/LJOU%65'CZ5>VD,/T8"IDD6KMJC:=VXN=<VH4[
M:7DEB69M;<M:/>F`DU,MBM(GMHL87W:W1T1OF0>V%:K^*#7I@HU-61=J7?CY
M)^_P^/FG2H<BV]MJKM-^>MJ^HZ<](&`EQZ/O_3#/?77:$T)K6`I$(FOA&W57
M:#%`=X"3T.(!PUWJ8R<)93WLF5<7Y*DFEU*Q3W,/7M;BZ?[.OC2JHH+(J!(C
MIV2C9::)0./#S02$FU-JUT8]W=O=.4@KV=('.R_3#UEF_O$IYBY$K9M[.ZHV
M<7UPUD;7M^5V;SRD9'R#6'H%6*B`WU[[U:9$)\5YE,WS"C^<6&.KN."BC`5_
M)TW8XY:($,RAQD/"D=RR)0#U7R7C-.DA96U7'\<3[HNKR"1U[SP_(>^Z(D_$
M&=_?D-H*]Y4U_(!:U=?2N#Z]NG%_S[@Q[K;D`,"[=<G(N*I-;SJ#"$-7(A3V
MFB-/,9-:4.GPHE;)`*JV7HAOY6I$;/%42A5Y]DIO*LMC[%9G=O@U.,+&-WA@
M60HW*4E2A!YW.G;1]"P2-6?T'-)H"J!C:M->$9%ICOXS&QQ1F%JN="UL&@Y4
M(2R+B)BI>1GU`UU2T`6@1W2NPE+I*KGB]>O#XME1KT_^HC3/='RW/?V@L$?N
M`^4X]2F@FO7B(0E-N\`GX[N'Z,$FG0(U93#0=J=(;."RCN^T%<A"?HU[=VJL
MABM[Q==I6$"GVK"$GCS-W2)FTYBI:3GBJ`:)KB)Z)`*D2!(@<JN9B8#UR9N7
M=X71P-L#L%"D=PHJ)(E^"5W9W*,N@,0CN<_=`LJL@SGJ;D*-WB1B@O!8TE3R
M&FRD9M,,1`(K=72':F:#!PW-'?V!</)IC:EN$-<9_$P^/\Z`'SIK;["$WX2<
M:1G+64?_6[L6$#2*H`=@/?D)Z_)U3NR4WFE)D&$O%Q82Q[327%(!UOZVZ6WQ
MDUD#]=/(;_'\3"U3,;"7=H(MX185+8H9)>!;+AY0H8C$D`MBZ&G4Q'2MF_J2
M/U'K02IMZ,'.$J'/PS+2.7_?OV>_'2GDLJP1(GEC>#;[7!F?;(=%EF0@X1/V
M4!9/O]CY*CW$/Z3UWC/$7QY\N;5W<.!%<T-WY!!A!!18,77+?5+KF,BG4OZ?
M'\FDO=C92_-'@QZ=8@R[YQ/6/+"CMYE7Q8KK_<KD_];GG)2*T?;$-IA]9[:X
M:$QE!<.QQU=AW-NDX4@RG@X;8G'4B$]U/0R("%"L.?7+0MQ)W.B66K[3I2,)
MF`(QG2)=ESS,F"V":XDA]O+T149%#^C]1.[&I)?IB'B&502/8:D>@!KTF)V)
ME]^/5F0K,1EE\0EKXH:\^&]"9)U)VS1I0V1I_215;NAOA;[1EH0C;:H$97M.
MT2II8)E<5`*R:#?BI4=U]@:]$"GB25>R'N4UZH1+7(S\3_<SG!F`/<SN>$U4
MD/'9T[W,]4*\L461%`%_*/[D!Y@>M\YY/T\NJ#N*,+C#CPP2;./_V4&"7/Q[
M8P2['"9L#/Y)\9+3K>'GNVNN^U_"C5B77&/U=[H5*\04S?M8SEOGK=NQPNO0
M$H"HF=JJ>2U2O/W&>=CP(Z,+(VG&*A9=[&:*,3@*UODKI?4)$86JNCKU^TGA
MSH,`2<SYU$@=A`0(!=SC8PZO.*-44WC3D8V6^>\XB4C@&1\PXF1Q\CX[P6#3
MT7B1.1IY0A#M4+L$F=*)TEW39VUX@*.:&^0$=[T:#H'<_D7!T+;7+T^'Y[^:
MUV_>BO>IX]J3>,4BT=<YQD\PM3M9#<85X58YX(`M3Z*S@C6$'':I,6I]9IB5
MPT.09O_@OQJ=?J<6+X=?R:ZH:^4@DG(D;R>+T;BDRZ=(,VP/,:&J>K"Z]UB8
M9VU7<GDO@?PA;GWSZZ_B>4$U@107KQ96!-7?;3/66\*C4WZW3AIK[/!M9[Y4
M7:.VO$]L5?!M08";N[%JM0/EPE0,9V,7\'0BIQ-.%`SD]#8+F"?FJTPV/84E
M=\'24'+/S,"$1HM=&K8T1_51'37JU1`#A-O.UED/$#.]M$OPU"`4H[@8/\D%
MIF/#NKL=D74+MGERNDLRNUVXIM\BNR32PQ5)\*%W"*WI%<@K@@A$'>\-P!W,
M0<,.3696ADY$E:ZP%1.]+T<@NN$5.Y8C.J)O%A#"?->T!(&EDO2ACM40*:W!
M@O2S/*$O:T\(MO5+)>.4=4:9;$VMOGA-&X?Y8VAJXHZ2^Z*>3*%P(FDR`NPZ
M+S9IMS5LL5TNC8[P9,7=@"AWB=W%LEY+?`M=;2G((R[I)E_-`73.(4F*B6(A
MB\<`/;6`9`Y)$,DU=/2@B>NKK,RCY>11*(/`'C/V>+S8QQJ$*@[QIII]]P[5
M3FY1AP47<*)G\%(D1I%5.W&^MQI:O0?D#_4=NXWEFN&/9SR:[MG1;VND%,FP
M%A'/FM15A)CS:(:M*5H6%1.ITZ\Q-(C@I'O`]SMVZZ(!CCGT06$XJG78><UU
MJ'X5E*4=0A4IJE42R2090L`,6>+7*)K[#F4$Z1N[X\LJV""7_+=?6F/A`FJ5
M"K@%1OC`_G$P$$5"LPX$A0'OBI6;G$F*XIV]/6_(<;$-ZJ)5F!#50^#CO0#9
M]8GF#(-?V?T8OR>:2V/E_3)6[@J9&72`<PM-TNN8/VW<>*3F!U71@$>:X[=,
MGM7B,EXR.5$*HU0I-[GU'F%IVQJK%:(RJ>=/%XO2=F8#,0@-O+7B'^OJ4'E&
M)WV!*]*K!;9'</HP#REI]I[.H5["OV19P85@\LXFF\[6T6]>UD1WV+[#_"$U
MH><)=O0.EJ-IJ#5@LQ'PL$N^+Q5B^":PJ"LPD<5T`<T+?!X6O:U2,XQ`)YUJ
M)G6F\Q[MA"YBWIB-F<XMW4A3B;23]>0Q4:-]J]G=(C==!U^"5S',;=_]6^O(
M<0AA-L1TP5'_(F4P,C?X43XZ.78)6B.HS.9XC"O]R=Y]66?4`OQU!B9;^Y/@
MW]U9BX-'PG^A9(/7J>`:LP`QLI*S&,/'5*'I0"D</F:M@PY]7V%UI'!,&9Y'
M?^T55P.1)$)<.JW<A[JA:<HIE1+#1*)LJ02AC.=YWK[ZAGX8#LX]$(J0\S1V
M_*0IBV>')^=O+"ENC?521AE09G_OMKP35/(&<WV1U2Z/O`^[N*C(9*<-]SYP
MQ6DN<^BOWLE1/_7-C>]N9S=<.BV`<9HYI(;#3>@0LCBS&6%2*LSAA7O#I[J"
MA-VL?(X$<^2/,Q2**MQ^6->TV;S8OFHG4Y4J1>!I#6=B$D')'B/8=CM*PR;0
ME*/&$K*V^A0,Q@]KN=0>08]?HJ&N2@[%Y2YLXT'=D?)NPGI\_AKMS-M]+EIB
MTY2<$IVX;"H\_($63+Y-+%;!:AC9^>^AE9A,M*/]_FZ4*AMUK"2.5F\YRBYX
M0]REYPP9^@1?9"7%E,ETN^R70A6E2`<I$D&2F*1"IM@S84^RDCNLI$6M>(`M
MB;`2P<T83^1UR<103%R:U(:K+`QDO*)&L8LL6,AMQWM1`G4-/K67Z'IF2^NS
M6][V/B<[3JT]Q\7-"#\(;%0)3-6`S1EJG5QT_.2`\$;?M^9:MY-H\!,.L&G<
MA$"#7$(9.Y!<IH`#-T\M$/$Y.\K[GI)GWPCG@L42K?+!#V*C<91;>S`Y4K.A
MV6?2&GQCS%K6Y0!!+)'3KC_+X+/V5#NAE5AP4QI3&^UHTF0IRZ773>P,I7%V
MB(+;G!>\0T"#_L&]TM2AB[U&MG4PD&ZJ&V;-:&[(/SW*<!V8<'834&Z.B[V=
M?=*;H90?%JOK()G]>935V;#6IZ;E##?_*5A)7DIMY?]N2&GG4@]_.#KA6P:P
MB&E9_\)8>Q`Q8LK=\^V"*'6FADV%P8=8DPQY:KB1'*R='AO+JL\;!A%ITADE
MWHE)(S/[Z\^WU-HX@&)J#?G>D.'+4X<M(`7)HU4NADGHLN^/V^["6:_<P72G
MPVV(1)V&)QH6:Q%,ZY,44]23WSF5KD'SDMC#6CT#HJG9H]G9K,F/5M;JY3*J
M>1)@5ON+%^Q"V3S"#[Y!#-5[JVL24LH;[)L4,AJS2/2D9@D[]%D?!8MZSP/C
MO,[#6Z2+DINLK,A*6<[\^DX9V5B^\KM#@&NF#YUHY+AN&%.:R1P8-U9)N[OS
M8XL;$55&))/$%TP4-V&%L[W\O;2OF$>=GVN^1.S^>2/I;SI@K\9+M^E)(QZC
M(MN]1I]8L#!\9>P1XIHZ:_%WA/2B$;S\H^(65J6UB>9"'>PY&I7X(_#9>3>`
M(4K!H^',FGFH:_1FUH/QY2=ISE^P?/'L]T?GKTRO(@/6!%5?ZQ2\&-.JTC-R
MO;WIQ#3'F74>[(>3I^G(TF+)Q\78.J/;NB:Z4P.HS^<4B-/ZWVV_4*>)'U44
MY<()7MXE122)0\YR[UA2K7GM'*45<EF((@+XIDA@YQ:Y8.^&(QZ8H.QJ<+*4
MVJKIG&B-DL9JZ#*`:_B@F[SI.*&B=PO5(@9C(PQQ1]1@P!CBASREI[V41<#C
M)5O2D57M=\UV[F64/?L\4$H1L4F_R9=XT*D@'UKYQY!OTI8<]5)]ZJ$R=+VQ
MVDBMWV,>,26&=?A48566PT?_U(V.VA`')?\4\XP-3]+1'W,=(1B)2Z0>:H_`
M\@!L#3J3;<1H)"W3O5+VTSW@+,VYSAEN;2%J8),08TK[+.8#C:5N]QIX^T3_
ME0R31&53AB:;S5WOQRK];C;FQ.\JOB@_5IW$2_T,?1?O07OH0H$7=MWN(3<)
M%!>]?^G>$\"^8J*3Y"H1*O_/&L"7Y4>_UDLQ$PJ"HT\Z%&$:03TO>IY=29&N
M/D6D]`$\71:D&T8]5!3%TI?X//PRM15N/A/6LJO/C,BU<LQNF`V%27=GI$K"
M1=94;[P8B8.CHS8"KE'%A'M3:WNV,X;;=VFUH7!A,BD;NQ7%P$7*E&)8Z-Q*
MB.1PH,CLA'B_G''TR[\:GP9H,YD:5:2C(4DCK(5#B,=AT@5QWB`4/ONF0VAD
MD0#`C],%!U:?,?'CR2&61?FX6UK"J^E84.V*BP!!`9A%X:)J$D*6X]%N5>MM
M'-/1>"%E';#U43S=`Z<YKG3[&TF4,KO2C>S&](.J'_CW2T[;UPAH(AHN$<8B
M6E42(&F>I5BR?(FTK2H4]=ET\]]Q4=4<.U]PI4=!EYXJ/&8A_'!T4,S!&1A#
M#SN8`#Z&9FGWOGJ)]<?^12,E>!:@>,SG;TG58#SKV=QQ[<(AN&$!<A<R*T(?
MZG44RGU`T.6PUL8O_=PCK9(15QU'MZ\[6K:_L^RCB(F#;5S5-EB9CGA+@C0;
MR=[=&]>-LA@F7='CR;.S^`'"!R[Q_A*MPO4DA_^\_5VOSVU#Z)>SX].^?<*[
M#<<%6*COB?);=?FDT@<E_1`;;Y-<\[72&#R`R7!F**!464]%%2HSQSM8^(?1
M*#HH@;MXOLY6&*\]QBNODR0/'1IQ5(IG8LS3.;UQ\:CMMM%GY-9MR'#V9\4Q
M5^<O[]IC_->'3,%O(M%^>/OZB.MD4`'%\1_>G5S\:WN^MZ3UZHM\]P_LDGO^
MC'X<VC4$9:04S#?XP#46)#=1MZH:2AE0<D(YP?-2D[R0=<1"Q^[QI85.&UN&
M(FM0_,W6+E?L[^[N9EVVZ^:+%]%]%4:'KP^@$B2#[Y1<$X2@L''$JRP.=K=U
MYYO"?*DJN]@^M*&@#*B9=G9$_F+@719J_GPIS\N!<YT@"4=/*-\H!D\H2ZEK
M)3Z%EG`QEO$T682(,5:UGE,2VBO:<$!APJ_^H>R^?[7!U"5H9:NJTAA+>QE4
M]R>H3BIG-)`A\F0\"S4#1+]J$,W]],OL:%=7W9"HYG(IF:1C.QG?9I9^>\!#
M?/A2?/CNNSZ\=WQZ41S_R)^=^XMZ`SB=`D1PH`_Q)>CCZI23X%1/"G`#6X=-
MA2)QBP[UKCLZ<?@]YJY>AHUX;DWAT1$J$J.O-IOZ'(^^/_:FXMJ;><%@_PQ9
M.\/6BPZW4>2,1C%1.[QEC7/U)&FLIO+&JKC1"(F6C+_9*&U*?=X8@:`5),>I
M-1M3\!YC>[9J7L`2UD\+AKH;<JQ"<2DL6'L1A7"*/:I,6%$P,"D;B#`(-X@`
M%:D*UO'KHD?T^<<+B23J-N?5=&#^6"B09;Z0\,$%I)/I-H[?E/N4Q*KO1_,5
MUQNQVU[O1]NHR"WQ)4)-9TEK0.U2OF@:K("?`6G.C;]JIPXDD0JZ%GGIZ_#X
M_'A[3]TTD(A%B_<XML13X80L%T#>69UN;0#<&_^%+Y)RELB60BH]GR87&6&N
M[^=!O%/`V?IH-Q7[<`A"=:$UG^WTSD'+G$GT@S)K]NNP:4#7%K"&8;HEHDT*
MB]NA[.=%>:7SSX3_1).JR$12&NA^^U-*)EA(#!VD-C/9X&C71?,72Q7H+F:I
MF72.)7X]]\!G..2Y0#^"Q-U+=)%=+9,/VHJ"@GCQ%3XDC7NCE*@V4=;U8!%X
MW<C`[_&?<@70EO;Q47PXS;O@'ED.(K-\9$D7G?7:H)M!L2^^=P&TMA.3"_%Q
M7-]P&;]Y`RUR(1IX?.`RFVY8EV+*I5@[P`I)%@*E4T-;K(PB>?HT`.AF94%F
M&"+IBOZGKS:XF9%?,_+%`QPV4"Y?:-4TMQW/ADL&]G:]"ZJ6^,S8)]L=B$&D
M:%^!USVK9LSL^H[:H%`\2@TA0?Z;5!8E_'*#.G*Q!CGCXW)Q4]3W&>9HCN7V
M?#:_Q'@0F#\/(#59M'R-]B-AN'&%V#I$TM7H^7=A&M<A-3V]<0NP09<B_N'>
M:B.DG<UPYK0CA@KEMO7AHI#2";*&WCO6D[<\B4ZX:<'`"PU.R?A.`<NFR\Q/
M&@E!KRGB)\`Y]5<[8V\WRP0-[:HD==CJJKL&DT>U6?O5U!*"WX0R6JL7T:K^
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M2'<U=83T(A[DXDKWI430PDD^8]HPOJ&.+$`QAFUK1GI4L0]!A;DC0P49S^H&
M.V:]J'7+44.EAV4R$Q9GD2VG'I@9036SFLMIO#`IJ8;X]M'9([^JUN]I!2=U
M.C%E"_`)14O-XJHFX2B>9VAA67%BZ/0"W_%R^5K`@RNM8HY_!+<<6]B&+[0B
M-^0FE+_DK;_Y1BVQ-J%QQ2[&"OOE.OYVW$4&R.)&[@0@*QGOG97&ZMO7BKQU
MB]L:.;5+`:CYZ4$PPC>3,#YGX6^=K_^<(D*OX\70?:6(8$D-[F0?_,H^95ZD
M3#9]2*YX=J%^F.YGAOJ#&Y2B!\795.WM9IO2#>#=;ZE8*OE0OH/2(;@F":#>
M^_`A`OM>6U\!>#_=;-Y>YQ?=%+QY<SI(MO9.B'][4^FS`/_>7C_54,[;%Z8D
MAZ/]BE_.P4=Z-\W9WY`RW`SVIA>.O:#?AB"CVWTLL%WTAFJ(M%;!DPF>*GD*
MB?*S(YV7&C\OGKWK'Q5/.\Q([\(;'/P;/JJ,6NK>QI*Q4)/8EFVIB5W\VVMZ
M4HL3ZA2+#N;S30`7SA]Z&1/%(>?V?C_S]O_VS_8U+M)->$1>#MCT::TU0&:7
MC&\BHY<04&.H$I+U[=7?HL?X!%OC$W2?]&FD]H0Y0NX1[.UB@P@_2-9>_-09
MZ>D-WS;+L?F]:E-M((]3MJM6"^TQIA7JB();N#<('TS6^O18&EK\3]I?&X')
MYFD^]:-A__!%?AG_/9X?:@-4$X70/GU5]!?JZ@<9RC_ML)?PV6:$]O-/(>J:
M=W\9&M=,]`]AF%]YW5]M\[^2T/GV]A^@??W\TVG?>/<_LOW&1/]`VO]JZ_YJ
MF_]5:7_P`.WKYY].^\:[_Y'M-R;Z!]+^5UOW5]O\KT1[Q4$#\SJ/-GYEIWC0
M\VQ;"G.9'_$E%,6.@_`]FA"4;O[P27N17Q9K/+B7C5[TO4XT;9#_G[1KV6T;
MB(&_HIM[*%(':5/T4L!UD"!`VPA&\@%&"_20AX,H1G^_,^226G&UDI#>$N^3
M^]+N<$B>-!I<=/TE]G3KEC^@^>'&-6WT5=V'H*BC#:A<P'DKXC()AS7RW*M5
M@3MGW3TM(B^]A9E9NQ."T^@-K>.XY(-V'A._)[<I#NHDTYIJ2T>VI*-3B'2K
MX39B&WGOBC*MHH*Q3#X+9S$17I],W/7GF'CW#`T2H(0$<39T.%"3)A^:3[&B
MPHU)K98?R4R\FKZ'VN'X6.W%SAA;?,!<@//S<'@6DLCF18S`^3<`/`CU`BXB
M4:96_3H+#"1/JF[RU;AQATI]G#]578Y/V,\L&B">P@"'EN5>EBOC;DX5\%%)
MBE'*;?C_E$>_.(VK<S6#+WX_&_]]9/W$HBV4R8#\,2Y)-82N@0I&8B\!/*@$
M#&I3V,/A^>)EB#`1U"`PJD+7AYG06F.K_:Q@1-2#B+FDCUF#LZ28?!%\Y\;T
M[<"XP#&=P,GB:DU82R'7=D"F$1U<`5"T0QZ.6H<#:!'@UKDG77<LP90@'UQH
MBXTF!E]GPLC)4;#=B(^TF.<2LTB8=F^(7&YU@ZW(*?;3,A8VQMY2\[I8_L8\
MI^2G%Q43:!1#D_M>4;\KL0*<#)FZHG=4,AP7A;2QXK09B!OKR3Q1Q"0[[KPX
MD.G,;P5!8\*Y4#'^NC^0$UH%J)*#BMC`)4YL6#L5/V-BH#P`6L]]IHS_ZD3T
MBQ:2I^40*UQ]'#\!N*@E'-1@=]N:DOU-.%N(\=P$F=(K-M%W@Z8-,74G44P$
M<DXS0MQW_X<8$LYY7-N2N1$%EK7-8P>(GW`D!#>$%B*=!K'RU2VB'_VO*6FL
MU)%?G8+J\',3Y7-5S6A?-9)E/9/<0<PT86S@JM53UPPX5`FR_&Y&`:[P17UU
M$XPTP8_I`YV$FM_D*?@,3_I1TP:7)#;_UMNTCSN6C$4/T-YN3!LW"SS9V939
MN8TX^BLHH55@'ICJ#`2_H$OCVZAZ5;J2X&-8*MAV^]_@EM/_J_#)JD6DDX&<
M.O_6:MY=MS=>Y_MF'/._?F+0#[H2[]S[B>BAA,K$X.D2O5HXCW]!P+)0&^47
M#5S6D\;H@7'5@&F47"F3WZIJ*!%K\M9'[1C.!J5Y5KB=8&4)E;-@8<8NY!]T
M'Y:8R?K6<5W`LMVOD8FQD\A'U)?3:1P-:PY/,Y6HVIA[6BJ)N>_X*3#>K%W`
M"9UD%Y!Z?PM:Z()W*R<C)YMZ[;5%(H^,-:RQ\*`LGC+5VJ*@W^CYC>['<SWL
ME*I(UB&TG<:;E!4@_REE-3:`Q^H]5HSSI09SUF?^T'6O7_\!``#__P,`4$L#
M!!0`!@`(````(0#^F!JR$`L``!!@```-````>&PO<W1Y;&5S+GAM;,Q<_V_J
MR!'_O5+_!\NOK7I2$\"8`+F0TX/$[9->T].]5*W4JRH#)G'C+]0V[Y&K^K]W
M9OUM%K"]#@N;0_>"C7?F,_.9G?WJO?EAZWO:5R>*W3"8Z+W+KJXYP2)<NL'3
M1/_KHW4QTK4XL8.E[86!,]%?G5C_X?;7O[J)DU?/^?+L.(D&(H)XHC\GR?JZ
MTXD7SXYOQY?AV@G@EU48^78"E]%3)UY'CKV,L9#O=8QN]ZKCVVZ@IQ*N_86(
M$-^.7C;KBT7HK^W$G;N>F[PR6;KF+ZX_/05A9,\]@+KMF?8BE\TN]L3[[B(*
MXW"57(*X3KA:N0MG'^6X,^Z`I-N;8.-;?A)KBW`3)!/=*&YIZ2^?EA/]2M=2
MDV?A$D#\[C^;,/G^-^F?#W_X\*'[K^^^_\=/SO*?/_]^_[>?O],[N1HB$SBH
MEWG9K14+/Z>2.YD%MS>K,""&@`+FH.N7(/P66/@;!`.8AX_=WL2_:%]M#^[T
M$-XB],)(2X!EL(_="6S?29^8V9X[CUQ\;&7[KO>:WC;P!@N,[#G?!9KP9B?5
M<%X]<T23VS1"&)Q-?;Q#;?+!)!MOUMMD__N`39RN0;.N8_S'Z6)6U-LE3==^
M7.SY\!A=!5=$3_0TG^B6!3FDU^VB6REA)U(VGG5!W]F470W.9EG?ZEM#J99Q
ML;C/&RKL6S)=V:#0^CB\.YL[Y2NKLBY+P^>J`5CAY'K1A:I;4[^'%G[.$2=G
M;M!.PQB3RB5]5O7*W/CH^DZL/3C?M)]"WP[0L;118T]S;3(7>*<1SX6`?!4G
M%I\'+\N>=:Z7U#="RLZ@AG793J]GO_<E,V#E2\_9)BW:X<31HJ*Q^A9#170]
MKQA<]$WL?L.=VQL8YR1.%%APH67?'U_7T/D.8$B&X=!)GVMX^BFR7WL&ZX**
M%8A#SUTBBJ<9Z_)G7:[9U;TUNV=Z"3)1%!5"+6LV/('0^^EX)A_I;#R6+=2P
MX"-9Z,<!?B0+M>"_F32?9G7'E`6RD*<E+@[1NY?#\7@\ZEV-1J.QV>^9)G/R
M/(MH-U@Z6P='[=+<M(]@``C&_='XR@`@77/$5)T501\`#`>#T:`W-DSXGR6O
MTR.0[=.!KII5@D`1JP2!(E99/Z<C(?-G-04FS!3758)`$:L$@2)6AY(S\%`Y
MJP2!(E8)`D6LLOZOQ+H*\\2*ZRI!H(A5@D`1J](ZGUD&'BMGE2!0Q"I!<&Y6
M\V'5[/[>8C-=^SVSZOXQ&\G!V'$>1DM8Q<N7IGHX>DSOW=YXSBJ!46+D/CWC
MWR1<P[_S,$E@S>OV9NG:3V%@>_"UDY?(_]:4A%5!6`"<Z,FSNW@!9=Q408HW
M57$J#44F,K&';P[-[M`<&%?I($J2:M]9NAM_W[I"]\%8`3>B;YL-)SX,"B59
M.)03GQUD(:-/L`2CFC$M6`!B(@\)P1(R;"P7`41M)"7$;"0%!&TD)41MA*IS
MJ'+EGER&&UB0WB78LD;=;CK?*JJG7B`!?B!B#H,@9?;]V5CD@$<;R[2U%?++
M7MV8&OAA/=8#EC:4V+>SH<`!*QM*B-K(QTW.+B>\F$[`]'P`R8Z_N<??!@,4
MI05S/#M),,M/N`Z4K@0)I[O#YC:*)U:#A';-56[#CIOV;9"AI(TE.;#&,G4D
M9NTU-/\+Q_.^8(/\]U71!X"IKMN;[8KL(X'-/;C1`K>IX%>83\Z^INU]>@$^
MKBID5!;2[/7:>WW8^',GLMB.'Z:"W<5YZ_)JRCHJY?5'SWT*?(=-UNFIF!^C
M,'$6"=N1Q):#JO#T*_#T,D$B>([1;U;H!S\)^^,8_3`9=)!$\(M2_1!<POIE
MQ@/NO<J"&BB@05V'1R8"&/+G"(`$%0A@>)HC@/!4@0"&4CD""-`2`<"IB8IC
MZD&/9#.(@5(EZ#^52L@QN96<RA-:695^07^-E1:7?H]R,\FW$.BEF^&B!L!1
M*JM2K*H40VB'FE:Z`"YJ7&!!JRNGR>M5Y7QE#B%)%S"4'H$T4.<1>5%)<B[H
M+`'4>V0JL1]"@@)3D6H(`$<)!$)$3U'[VZ,8%+7`-!H4-<$4`M<&G[%.4":X
M%E(1!L"CI%:4_80>UV*<T0T$@JH,2:+!4)4B*095.;*DPE"5(@D$51F2,J$J
M15(,JG(DH4)5BB00P"-*,B1E0E6*I!A4Y<B2BKZJ%$D@J,J0A(G^B5-DATZ;
MII.H=/YT^*;Y4VV[:IQ([54-FH#WO'@Z>DI'CL`%&TN1H32^G6?G<Z?:<QBY
MO\`@$]_26\!DJA/I^%9GXB[HG6^1O7YTMC`43=>=MJOJN5Y`DL]O[`8CC[`2
M4ZD?)M=UK8URZ?XY`LOQCFBTG`WJ&R?F=R*#G]QNC)!&$#BYHQH#^CK#(#T$
M)%41K+FJW02-I'(,E"IH,,5RA06>P^33D,T:8Y4J1V=DD_YPF^O`\(GJ72BO
M65W#X:%42VC$XSHY;1+:IV39Z-YW2B81AE^%`NPD+:'*NH4C=3'3WT7=DIA5
M#,A1RBS'F0%URLDBS]GS*;R=IL[R'JEJ_=V9D;JFQ&)K&8VM6JMTK.&K26EC
M"4U&IZZG3MN-4^!6VAJ_S6GL]`FE3GL;[O2-J3VR2=>\!=F'!PA\IGY#Z++]
M<RV'<Z3O\*8(%>PUO4EV0ZM!B7R#Z0:9SCA_.JU2#@?Y[(PF^;"89HNCC3FM
M,3=4A&Z]*T0BM[*S=21AM(+5H^1==@X\IX[OQD%"T2HU)UC:E)\"=V/D`7FK
M?"Z!Y!_IG(H[K2*[OS^@S;.#E6D-%_[K^DKR,DN%VTX1:S2EB-,MX$65W5WC
M''/0;6II)2#<4R,EIBB/^2RY'(30S+T/A#7[Y>H`5K9>C>YA>R\53(BRM1M8
MK2%[W_F=[\7:CH:G'\%IC=W?:A?:QP427W1_<,PWW[@>O-6*BS:X[K;8Q/#R
MUC2]F:V4U,DJ$IZ!8T8B"ZAH*ZL((\RO5!8T8&UE@?J4\3Y82V3!:P&M94&>
MRF3A2GEIHPDYI"TN*)+)XGT_$/2]>8A'MJ>DQ(4FB^"BLDH>P7/$QCZ8W%96
MR2,01V6!R6UEE3P"0B++!"5M994\`@M4%H1;6UD%CR801V0-!'U_=9!'/E9Q
M`5@$%Y55\LC':E\P5JFLDD<^5M'DMKA*'D$J\9<)/[255?+(YPE3,$]0&TL>
M>=\/!'V_FU'YB#<$(SZ54G('WXB/L%,GXJ-42LD:'^5]P2A/I91\\?%M"L9W
M*J5D"N01BTSX0=RB@J,^[UU3T+M3>YEG73Y@L)T1@0%GURTV'IRW'.)IS6R#
M`\XA$(-PTEI(TK.S>-%F\+Y:(8BO#]B,B@BZWZX].["3,'K5<%-#(8XG?2`H
M[H]A6/B(EX#]4A%`?X*SK>'8;`W\DGJ(CV%<T&XCIJ@+O'MPAW,;,5`Z1</'
M'TYSM!$#I5,Q?%+%_I.(F$_!>E,PQ.=2;+I%1'QV@Q=GR4<.[V$#0(I(>G`V
M2607\<=7*4/0,0_XEF,A@T\1Z1F6^2N96?_S`5YJS)V(&SY(W<$^M`CPOVP2
MXD;VJD'9Y\$E*Q$ACVX"+Z/GE9C'`;"$1(2PT:@0L9-1!&7\S8X"K"U<U=V)
MT0J+RFU;T/M?;LLW7IG?$SS]G;T+6XP'P+U+9V5OO.2Q^'&BE]__S(YY@&#*
MGOK1_1HF3,1$+[]_QO,SH!;#9#2DF\\QG,D`?[5-Y$[T_]Y/A^.[>\NX&'6G
MHPNS[PPNQH/IW<7`G$WO[JQQU^C._@<NPZ/RK^&L]2..HF='YL/&K9YY'7MP
M8'V4&9N!_U+>F^CD(H7/7IH'V+"FE!O1B8NC_&__#P``__\#`%!+`P04``8`
M"````"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H96UE,2YX;6SL64]O
MVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B0-))?1O:XX`!P[IA
MEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.(
MH4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ
M)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK59B7"
M-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9
MVP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!<QM6)M85W?_-)UZ8+Q=,WP%,$H
M9UKKUUM7=G+Z!L#4,J[7ZW5[M9R>`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51
MK;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P]<YVM]MT\`9D
M\<TE?/]*JUEW\084,AI/E]#:H?U^2CV'3#C;+85O`'RCFL(7*(B&/+HTBPF/
MU:I8B_!]+OH`T$"&%8V1FB=D@GV(XBZ.1H)BS0!O$ER8L4.^7!K2O)#T!4U4
MV_LPP9`1"WJOGG__ZOE3].KYD^.'SXX?_G3\Z-'QPQ\M+6?A+HZ#XL*7WW[V
MY]<?HS^>?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P
M;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF9;@.
M<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$
M'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z
M@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<<NDA(",Q*
MA!\2YICQ.IXI')61'.*(%0U^$ZNP3,C!7/A%7$\J\'1`&$>],9&R;,UM`?H6
MG'X#0[TJ=?L>FT<N4B@Z+:-Y$W->1.[P:3?$45*&'=`X+&(_D%,(48SVN2J#
M[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ
M4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_
MJ]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C<AT&]
MSAPZ27X02T)XU)D,#!Q<(+!9@P17'U$5#D*<0-]>\S210*:D`XD2+N&\:(9+
M:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&W
MUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1
ML;:[]5'F%N.%BW21#/&8I#[2>B_[J&:<E,7*DB):#QL,^NQXBM4*W%J:[!MP
M.XN3BNSJ*]AEWGL3+V41O/`24#N9CBPN)B>+T5';:S76&A[R<=+V)G!4AL<H
M`:]+W4QB%L!]DZ^$#?M3D]ED^<*;K4PQ-PEJ</MA[;ZDL%,'$B'5#I:A#0TS
ME88`BS4G*_]:`\QZ40J45*.S2;&^`<'PKTD!=G1=2R83XJNBLPLCVG;V-2VE
M?*:(&(3C(S1B,W&`P?TZ5$&?,95PXV$J@GZ!ZSEM;3/E%N<TZ8J78@9GQS%+
M0IR66YVB629;N"E(N0SFK2`>Z%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8>
M\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D
M-9PDU0$-D*"P'ZE0$+(/9<E$WRG$:NG>94FRE)")J(*X,K%BC\@A84-=`YMZ
M;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF
M_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+A
MP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[
M.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P
M8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:<J@:&''I@\
M@.2W',W2K;\```#__P,`4$L#!!0`!@`(````(0"JW%W6@`,``+,+```8````
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&ULE);;;J,P$(;O5]IW0+YOP.0<A50-
M57=7VI56>[QVP$FL`F9MIVG??F<P(>`T%;U)./S\\WGLL6=Y^YQGWA-76L@B
M(G00$(\7B4Q%L8O([U\/-S/B:<.*E&6RX!%YX9K<KCY^6!ZE>M1[SHT'#H6.
MR-Z8<N'[.MGSG.F!+'D!;[92Y<S`K=KYNE2<I=5'>>:'03#Q<R8*8AT6JH^'
MW&Y%PN]E<LAY8:R)XADSP*_WHM0GMSSI8Y<S]7@H;Q*9EV"Q$9DP+Y4I\?)D
M\6572,4V&8S[F8Y8<O*N;B[L<Y$HJ>76#,#.MZ"78Y[[<Q^<5LM4P`@P[9[B
MVXC<T45,A\1?+:L$_1'\J%O7GM[+XR<ETJ^BX)!MF"?#-C]YQA/#4Y@YXN&,
M;*1\Q$^_P*,`@NA*@$'TOU.8NQ"C^$V8]O4IY$,U;=^5E_(M.V3FASQ^YF*W
M-Q!I#&G`;"S2EWNN$Y@&B#4(Q^B:R`PLX-?+!:XG2"-[MG0B-?N(#">#\308
M4I![&Z[-@T!+XB4';63^UXIH;65-PMH$_H_V?3@9S,;CT60V[>\RK%W@OW:A
M8/@V@F^'4V7JGAFV6BIY]&"=`K`N&:YZN@##U],!>4#M'8HC,H4)BXB&.7E:
M!4O_";*>U(JU5<!OHZ!=17Q2X,0!0P,"0^@/@F($P7E"LK5]T(X;.G$O%<-&
MT0&!++1!<*$,88V^G1G\"'2M<8\:=TMH%:.68MQ5Q&\I.H1@TB9\FPS%$8'1
M-S,RZ<9=6T6;;-I5Q)>*,WN'#!9Q?S(4=\EFW;AKJVB3S;N*^%)QA6SR'C(4
M=\FHN]"M9%P5P8B.1V[*[/LV^A4PJ*;^*4.Q`^;4U]I*VH&I6PJ7DBML>&+V
MWAQ0[+"=*\S6@)5TV)PRB2\E5]CF[V%#L<-VMK5L5M)A<PHEOI2<33IE0&&_
MZ)^X2NW0.<MI76LZ>$ZUQ*]HKO'A)MQ[8JG=LMM;"'7J<%UKVGRA4S+Q*YIK
M?+A9]^>S6WN;+W2K`D](6`$=/K<L7M%<X\.MNL77[XR`GLA=A:%;(;6FS7EF
MJ!8JME9H,ZFVG@F=SJ=A<!Z*78>V);('?<[5CL<\R[27R`.V.!0^;9XV/5O=
M3#4OH/LIV8Y_8VHG"NUE?`N?!@-L5)3MG^R-D6751FRD@;ZGNMQ#<\SA6`X&
M(-Y*:4XW>.@W[?;J/P```/__`P!02P,$%``&``@````A`(;<R;03`P``]PH`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,3DN>&ULE);;;J,P$(;O5]IW0+XO
MIY"C0JHFJ+LK[4JKU1ZN'3#!*F!D.TW[]CO&.8!)(;EI0OW-G_EGQMC+Q[<B
MMUX)%Y25(?)L%UFDC%E"RUV(_OQ^?I@A2TA<)CAG)0G1.Q'H<?7YT_+`^(O(
M")$6*)0B1)F4U<)Q1)R1`@N;5:2$E93Q`DMXY#M'5)S@I`XJ<L=WW8E38%HB
MK;#@MVBP-*4QB5B\+T@IM0@G.9:0O\AH)4YJ17R+7('YR[YZB%E1@<26YE2^
MUZ+(*N+%MUW).-[FX/O-"W!\TJX?.O(%C3D3+)4VR#DZT:[GN3-W0&FU3"@X
M4&6W.$E#].0M(L]%SFI9%^@O)0?1^&Z)C!V^<)I\IR6!:D.?5`>VC+TH]%NB
M_@7!3B?ZN>[`3VXE),7[7/YBAZ^$[C()[1Z#(V5LD;Q'1,1049"Q_;%2BED.
M"<!?JZ!J-*`B^*W^/-!$9B$:3>SQU!UY@%M;(N0S59+(BO="LN*?AKRCE!;Q
MCR(CR/ZX/K8#?SR=W:,2'%7@\Z0RN5G%T;[J,D58XM62LX,%LP>9BPJK2?86
MH*SJ$WQ8'RB,BGE2074HT`*:^KKR@_'2>85&Q$=FW64FHS:RZ2)>FXBZA!],
MSHP#'LY&H,BFD1&,R_5&GXRH(,.(Z>,*<DZ@KL9FD(BN$!^X@!&YWX4*@L%$
M5J,=TW:2:\U`A\^,870S2$1]1*L7\#--%_T]4'"(H$3GS/Q@9F2OF6;V?C!O
M,YL;F*C+7*K0<@!;X'8'"C8<C-UV=FO--!T$1HLVPTC4B[0,3.XQH&#3@+$5
MUYII&KB43N^#02+J(UK93]O9J[?2\&9604/;0#-]+@:)J(]HN5"7B,:[M7\;
M*-CL@3E$FFEFWQFB823J15H&YO<84+!IP#=V@6:"^L@PS&UZUJ+3VN4=<1F^
M5L9PEVC5_+;)J:/,W(W3:GV$9E>3[UM4%QQ5&C-2)ZZO+OI,KO"._,!\1TMA
MY22%J7?M*>QYKB\N^D&RJCZRMDS"A:/^FL$%D\#![-H`IXS)TX.Z&IVOK*O_
M````__\#`%!+`P04``8`"````"$`SFWR>O8,``#"0P``&0```'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6RLG%M3XSH6A=^G:OX#E?<A<1(@<36<(A??[W5F
MYCD=`J0:")6DN\_Y][,5:UN6EA'0TR]-\WEY:5M;EG6Q^?+'7\]/9S\V^\-V
M]W+=<\X'O;/-RWIWMWUYN.[]^T_O7Y/>V>&X>KE;/>U>-M>]OS>'WA\W__S'
MEY^[_;?#XV9S/".'E\-U[_%X?'7[_</Z<?.\.ISO7C<O=.1^MW]>'>G7_4/_
M\+K?K.Y.)ST_]8>#P67_>;5]Z=4.[OXC'KO[^^UZL]BMOS]O7HZUR7[SM#I2
M_(?'[>N!W9[7'[%[7NV_?7_]UWKW_$H67[=/V^/?)]/>V?/:#1]>=OO5UR>Z
M[K^<\6K-WJ=?P/YYN][O#KO[XSG9]>M`\9JG_6F?G&Z^W&WI"D2UG^TW]]>]
M6\>M1H->_^;+J8+^L]W\/+3^?W9XW/WT]]N[9/NRH=JF/(D,?-WMO@EI>"<0
MG=R'L[U3!HK]V=WF?O7]Z5CM?@:;[</CD=)]05<D+LR]^WNQ.:RI1LGF?'@A
MG-:[)PJ`_CU[WHJF036R^NOT\^?V[OAXW1M=GE]<#48.R<^^;@Y';RLL>V?K
M[X?C[OF_M<B15K7)4)K0SPX3RXDC>>)8G7A^Y0RFHRLJW'(>'3U%33]E@=/S
MR<7%^'+RSHF7\D1J_ASIAPJ<RO/HY^<*="BC=06W*N=#13I<.>(_LE#'^=BI
M5)]UH72]G[I.YXK/I/]\\DJI3NM"/UBY_;HIGEKV8G5<W7S9[WZ>47=!C>WP
MNA*=C^,Z9,9MNFX032M_JY%3ZQ8NM\+FND?70>WW0'?FCYOA:/JE_X/NIK74
MS%#CZ(HY*\2M(VP7)EB:P#.!;X+`!*$)(A/$)DA,D)H@,T%N@L($I0FJ%NA3
M>IH<46O^'3D2-B)'7+LS!JVD&0EA!9^R,,'2!)X)?!,$)@A-$)D@-D%B@M0$
MF0ER$Q0F*$U0M8"6$.HD?D="A,UUCPI1-\UXH&=@5FO$4Z817>B2>2-IL@1D
M"<0#X@,)@(1`(B`QD`1("B0#D@,I@)1`JC;1DD;]].](FK"ASI(Z^R8AP['1
MD<VDR):U1M)D#<@2B`?$!Q(`"8%$0&(@"9`42`8D!U(`*8%4;:)EC:H0LC:\
M."?\R2>4,#KEC>M[)@D-,YI,.E/C_ILW(CYM`60)Q`/B`PF`A$`B(#&0!$@*
M)`.2`RF`E$"J-M'21+<#I,FY.!<CQ.[1,0\<Q(EZ6FHRK@?08A0P![(`L@3B
M`?&!!$!"(!&0&$@")`62`<F!%$!*(%6;:#F@T9>6`WO%"[5>\9+4TXU3Q0-9
M`%D"\8#X0`(@(9`(2`PD`9("R8#D0`H@)9"J3;2*IV'S)RI>J/6*K\FX5?$-
M:75-(Z-K6DA1>_S@3`S1LA%Q_^4!\8$$0$(@D20JZK@AEJB3QJ@EFAK/S[01
M<=09D!Q(`:0$4DERBEI+(CT&M"36$Z%3#W9\W*Z_S7;TE*`1>L==-:()3ST-
M$B9Z;FO2SBV0A20T<E$/HHE1)<M&Q%7B`?&!!$!"()$DK40"29JS+"&FC8A#
MS(#D0`H@)9!*$LR:F/+__VD[N>AYDV@X:J9+<X5:E0!WI52-Q_4L>.",].'Z
M4@FXFCSES,A7R%)8H+Q.4^Z!,]0+"Y6`G2/ES"A6R%)8HKQD8<:5I4K`SIER
M9I0K9"FL4%[=5U8J`3M7RIF0=G,[8FK=7N;HN(MI#8YOXY/<:`_UY'Q,[4W=
MI%.CNN?R1+&<IU381&HO4G'H2W4B(P^1KY#%/E`J]@H118ABA2SVB5*Q?8HH
M0Y0K9+$OE(KM2T25AO14BTG[)U)=S_%I/L?%S9P:#6F@I9(X-1K[7*I$($J%
MJ9;VFFIL-)NE]!HU?89^%WM<%IF]79;/*JTL,Z*@4V5&%.H1C8<3/:*(7:P1
MQ:RR1I1TJLR(4CVB*\=X/F;L8HTH9Y4UHJ)39494<D3B\?_CQAF,C(69BFW>
M"DEOMV+AHMUN?VD`(M:OC1&(1".M3YJ.]83.I>J]GJNVUWJN&M&^2UT+1EX\
M-J9'N*WM-L865<!>JN,,^>JT?GELW*P1GV@-(F:55E/F#90H%?<8*:-)70>C
M"Z,2,A98R\]992V_4"HNOV0DRQ\,C%E`Q8*WRM=;HEB,:;?$=QZ6<NVFW8/6
M:*2&E'.G098$+U@U;'KC)2*/D;+W%;+8!ZQ2]B&BB)&RCQ6RV">L4O8IHHR1
MLL\5LM@7K%+V):**T<E>SRNU*RVOO];#"!=C;%2C$<VMU"T^AAZF5M&(NJ4R
M[ZZ%6.D6]EH';7:]2ZF2#\S1P'B@>NSR5L][FJWY4F6/*&`O:T2A'E''`U->
MES6B^$,1)1^**.6(ZL?3<'!I5%+&-M:0\@^%5+"7M9)*,R1\8KY32WI[%BMA
M[7[*;,]_[EZI)75.V>D)U@SVZP4U;018(ZW_:I"U]4K5M-5_`?+$Y@&U\9:]
MKY#%/F"5L@\118Q4!Q,K9+%/6*7L4T09(V6?*V2Q+UBE[$M$%:.._DLLP&&^
M/[T3(/;=J?K;S7YH]C`S*1(MMNG3C/'=7&GX2;Q`M$3D(?(1!8A"1!&B&%&"
M*$64(<H1%8A*1)6&]/M6K,']CCS6:WFBP30IPJTX\5*#>*!8$]EH5"(!+943
MJSQ$/J(`48@H0A0C2A"EB#)$.:("48FHTI">2!I.0B)_:7/.$4[&H$(B;<AZ
M9;Q3,N<359^R0+1$Y"'R$06(0D01HAA1@BA%E"'*$16(2D25AK3,#2W+IO;1
M_NE,/5,2M7?L$"T0+1%YB'Q$`:(0480H1I0@2A%EB')$!:(24:4A/2TT6-%N
MJ'=R(>1&+B12#^?Y$-`"T1*1A\A'%"`*$46(8D0)HA11ABA'5"`J$54:TG-!
MXX//Y$+(C5S4J+WW,VR0>F0Y,`=B%8F;!QON["E5\SA"Y",*$(6((D:J)<4*
MM>(RHT]8I4=O3#Y2I>+H,T0YH@)1B:ABA*-(,=O3\FK.&CZTT7=R,=)=+V%I
MZ0:TD">.M5DP;/8I%=>.A\A'%"`*$46,VKF%4!-664--E8I#S1#EB`I$):**
M44<BS66J7TLDKEX-:T0E\Q7-%;*T_(54O;WUIP3L["EG1KY"EL("Y=6]018J
M`3M'RIE1K)"EL$1YR<*,!=94"=@Y4\Z,<H4LA17*J_O*2B5@YTHY$]+[<;&D
MT)YMO/-,E2L0K=5,L29.7;N^]3<Q:F`N5>*'ZK3-SG&A5!SZ$I&'R%?(8A\H
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M?J)47'[*2.Z[.2/S]?V,%=8`<E99`RB4B@,H&=4!C*_&5_JV;L6"M\K7FZ%8
M\_I$_RF7R-KMK4:ME>WYL$'6QB55:F]KR2<JY#%2XU9?(8M]P"KE%2**&"G[
M6"&+?<(J99\BRA@I^UPABWW!*F5?(JH8=8R4*?M:7G]MI"Q<C"E/C=[9^!O6
M*C&2MW4OTE[KG<U^=RF]1O6C8'SA&#O=GA2(5R_>+LS_4$@!>UE#"O601D/'
MN`<CMK&&%'\HI(2]K"&E>DC.<'II=(P9^UACRC\44\%>UIA*/:9+QWSGMV*;
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M([0NXBYI@HYNM(CABG4*/$(K#JY85,`CM#Q`$70=F5$$L\X(YG1DWGED04?$
MZB>60RMU=*3K>FAIU!5+:'@.K9"Z<>>19.*67<TKF;IE5^.JJ#UV\84S<,4;
MY%@VO0ONBM>]\0B]N.V*=[/Q"+UE[8H7J?'(;.+.NLJ?3]QY%U],7/I$!'T6
M4Y>^.$`>35SZ[@!Y/''C$^\W39+^@L+KZF&3KO8/VY?#V=/FGF[\P6ENM*__
M!D/]RU&^[?%U=Z2_G4"=.GW,3G\K8T-?D`W$]X+WN]V1?Z&"^\U?W[CY'P``
M`/__`P!02P,$%``&``@````A`-LS<ZV/`@``L@8``!@```!X;"]W;W)K<VAE
M971S+W-H965T.2YX;6R<55UOFS`4?9^T_V#YO3B0A+0HI$I7=:NT2=.TCV?'
M&+"*,;*=IOWWNQ<GE#25FNT%\.7<<^Z7[>7UDV[(H[1.F3:G<32A1+;"%*JM
M<OKKY]W%)27.\[;@C6EE3I^EH]>KCQ^6.V,?7"VE)\#0NIS6WG<98T[44G,7
MF4ZV\*<T5G,/2ULQUUG)B]Y)-RR93%*FN6II8,CL.1RF+)60MT9LM6Q](+&R
MX1[B=[7JW(%-BW/H-+</V^Y"&-T!Q48URC_WI)1HD=U7K;%\TT#>3_&,BP-W
MOSBAUTI8XTSI(Z!C(=#3G*_8%0.FU;)0D`&6G5A9YG0=9S<+RE;+OCZ_E=RY
MT3=QM=E]MJKXJEH)Q88V80,VQCP@]+Y`$SBS$^^[O@'?+2EDR;>-_V%V7Z2J
M:@_=GD-"F%=6/-]*)Z"@0!,E<V02IH$`X$FTPLF`@O"G_KU3A:]S.IU&\\5D
M&@.<;*3S=PHI*1%;YXW^$T#QGBJ0)'L2>!](TG-)6`BHS^^6>[Y:6K,C,#,@
MZ3J.$QAG0/QV0I`)8M<(SNF"$HC501,>5W$Z6[)'J)S88VX"!IXOF`'!0'10
M!K7SE1&,REA:#.4F&,8RR=LRTW^103#T9AQ\.A]X@W+`S$:8%\11@@`Y/T$$
M0P_2$>UI;0/H#&D8JK$TCFN2XFB^TV#TZZ,8ZKRWP(YYZ6>:#B4Y2AB"?ZT:
MQ_/H757T.U;=6\;MC=/%VZHPCO^EBG['JGO+L>KE*]5P1H0]I*6MY"?9-(X(
ML\7]G\"N&*S#T;1.<'!?VV?9NA]H-OR`(Z/CE?S&;:5:1QI9`N4D6D`%;3AT
MPL*;#B*'@\-X."SZSQKN!@D;8X+E+HWQAP4(L^&V6?T%``#__P,`4$L#!!0`
M!@`(````(0`W"J-*IQT``!:S```8````>&PO=V]R:W-H965T<R]S:&5E=#@N
M>&ULK)U;4]S(EH7?)V+^`\'[,2ZH`DS8/M&4[G<ISLP\TQC;1!OC`/KT.?]^
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MG:X_GOQ3#8I;8W,]8^-:;&&ANZV6C7P0^R#Q0>J#S`>Y#PH?E#ZH?%#[H/%!
MZX/.![T/!@N<J/#L8J1Z\_]'C+2,CA%:]QI`@G;J!006*!+Y(/9!XH/4!YD/
M<A\4/BA]4/F@]D'C@]8'G0]Z'PP6<`*B)@D*R)F:?.;G<XP174K-W,X8V;@-
M?CW9Z+5A-Y`\D^W.9!<4(C&1A$A*)".2$RF(E$0J(C61ADA+I"/2$QELXL1(
M3<L4(]VNKYS8M(R:&]7<O@L(SVS&*!2UG<DN:D1B(@F1E$A&)"=2$"F)5$1J
M(@V1EDA'I"<RV,2)FFI")VKA$:6MQ^"@4:\-<1>B<W>0;7=&*!81B8DD1%(B
M&9&<2$&D)%(1J8DT1%HB'9&>R&`3)Q:JS[\B%MK:C84A:E-A#9T++Q8[HUTL
MB,1$$B(ID8Q(3J0@4A*IB-1$&B(MD8Y(3V2PB1,+U:&=6.AMVMFE/BV\=D+3
M2FZ<#%';;2M.EUZ<=D:[.!&)B21$4B(9D9Q(0:0D4A&IB31$6B(=D9[(8!,G
M3JJS.W$*SU_:VHW%1$Y/=YNT+9&(2$PD(9(2R8CD1`HB)9&*2$VD(=(2Z8CT
M1`:;.`VO>N\K&EY;NPUOB#L(/GB#8&>T&P1$8B()D91(1B0G4A`IB51$:B(-
MD99(1Z0G,MC$B84^ASO!F`Z5[R[4;!4>$&-)-S`&K:>\B#X5;AE%C&)&":.4
M4<8H9U0P*AE5C&I&#:.64<>H9S0XR`V+/E_:9_T#L9B.HVKKB]Y^O3)H2BQ-
ML2`4L57,*&&4,LH8Y8P*1B6CBE'-J&'4,NH8]8P&![FQT$?+5\1B.HDZL9C0
MVH[%#EDK^=E[=Q*+='),37YK]4/6^[.5:Q6+%:*?`$F-J2!;RZLQ@Y5;XYE;
M8RY6J+$`DAI+08$:*U@%:ZS%"C4V0%)C*RA08P<KMT9OM]N+%6H<@,8:W3ZB
MS[:OZ"/F*&R/UPDY?810I'.>W"&\5%`L5G`]`9+&2AEE0&[+>,G!7*P@7P")
M?,FH`@K*UV(%^09(Y%M&'9`K[^V.>[&"_``T$U=]^K7C:BV/+]_O;_^X?E0#
M4\VK,_/SF<JMFHRK.4/;X9Z0$VY"T<J@L]V\'C-*@*1U4D89D.I!UESB9:QR
ML4+K%$`B7S*J@%QY[SA?BQ7D&R"1;QEU0-(2/:,!:":0^NAL!W(F8.J$MHN8
M.6G;$9O0J0J)U7[^ME.GK=0`U8<]R\J;92.Q0C/$C!)&J:"`?"96D,\9%8Q*
M00'Y2JP@7S-J&+6"`O*=6$&^9S0XR)V+]<G\%:$V!WD[U!,Z53\DB&LOB%N=
M:-0G$S7ZQ8J7\)T5[B:6@D`)HU100#X3*VCEC`I&I:"`?"56D*\9-8Q:00'Y
M3JP@WS,:'.2&6A_N[5"_;7HV*0*[!TSH5/V0V*Z]C==6/Q5<,-CGK-:T9ANK
MR_&)W(>+C;=N):A,'>7$);^[I;`*SC_9K)7O4FZL]-,2J7'M[04+:'W8K5$E
M4-"):M;*=Z)>Y$0#+7&B!0HZT<U:^4[TL-H7G`$&^X+C]EJ=&;%[[8&U:$JD
MJ%&`07*MG_ZJCG<F:^96D!4LOWM$L)*D5<PH`1+Y5%!`/H.5R.>,"B"1+P4%
MY"M8B7S-J`$2^5900+Z#E<CWC`:@4=Z-J\ZRV'%]VVQD<C5VN"?DK4?>MGR[
M,E;N#LQ;M2)CI58M]*;8H#.]8?WGY[FIQ[CD;JP]Y711_1G7GZ-^9V?%\\S.
M"3A>+JJQXAKK134V*"C]H5U48X>"TL8]:MS7Q@/*[&MCIZ>=^EF[\`PRFKNI
M.H/L&4108)!$L))&B1DE0-("J:"`?`8KD<\9%4`B7PH*R%>P$OF:40,D\JV@
M@'P'*Y'O&0U`H[P;5YVALV>0`W$U"3UKJCB=T)FSZJV]4]X65LX&EQ8+8Z7.
M,AAQ,:.$4;I(/N.".:."4;E(ON*"-:.&4;M(ON."/:/!06ZHU4!W0JT7B]/S
M\3'A\LR">OHTGD'L'C"A,W?KZAW$MZ;@:7BQ@+P,A-@@LUAL3C<77N(L0:%]
M,]F8$TD7.9!!2QS(X<!Z7*U.O1LK4")8>[FH]@I:4GLMM5OS@+]6-2@H\T"[
MJ,8.!:7&'C5.*\?F]/R]MP,?4&C?+;O]3D7<Z7<'IAAM[BT=$W*6CAVR6H7G
M$V,EK1+K_J<WLH(2(&F"5%!`/H.5:.6,"B"1+P4%Y"M8B7S-J`$2^5900+Z#
ME<CWC`:@4=Z-JTX5VDO'FS:?.KOEAWM"WHKB;SY-P;,#*\JDY:PH!DU'J]GY
MQ%BH_9\<0_W.E2YR(#-6E@,Y"K[?,Y\LJ;V$2/#V*ZZ]1L'@&;M!0>MXBX+!
M&CL4E"6\!T*#S\PG!V[9[7=JI^'TNP/SB3;WYI,).?/)#@5"'NDDJSMYQ(P2
M(!F1J:"`?`8K&9$YHP)(Y$M!`?D*5B)?,VJ`1+X5%)#O8"7R/:,!:&8^41W+
MB>O;]B=:Q0OWA,Y4"D.&\]K;1&SU65<5U/.=6/F#/C)6;@K6S][$QLIL6<Y/
MS\Z\_7`"G7TKJ-FR+/$I@Y:3%O9]RN'3OEV,:;>@0Z41"3=2M<BA6ARR&IPW
M-CN_<"1H%SG1+7*BAQ/37D=%ZMQ+N0[0V=<P[MRD<ZJA-?$?C[]4YYQ]>J=&
M!AX&Z2RPWXDGY,Q9.V0U(/=88R4S>6SDSP0E0#+J4T$!^0Q6HI4S*H!$OA04
MD*]@)?(UHP9(Y%M!`?D.5B+?,QJ`9N:LUR563SFQ:I!>(V7:67NI^*VQ.K39
MF>151\)8B2$O*&&4+I+/N&#.J&!4+I*ON&#-J&'4+I+ON&#/:'"0.[1U-M`>
MV@>V'29Y:)^3)Z0G%"O47E)S>VJL#JQ#1EYZ?&P*6GG6A%&Z2#[C@CFC@E&Y
M2+[B@C6CAE&[2+[C@CVCP4%.J/7S)R?4XTYD\T[M_L)!'PNZFP^#]!1B!=W+
M(6R-U8'Q#2WEAZ7E/]>#U;3=/OWPP=OI)#!074AD_'4C7>12!JV@2SFT@F>.
M`EHR&9<HZ`P9W]4*!8-.U-`*.M%`2YQH43#H1(>"02=Z6.T+S@"#?<%Q.ZK.
MO=ISTIN.X&I/X>\V#/)2>M[6:&NLPKO!"/+65`7Y:=>UVER>>6^U)"BT;]<U
M[8\7.9!!2QS(X8"[ZGIIK@(%Y413+JJQ0D&IL5Y48X."4F.[J,8.!:7&'C7N
M;>0!A?8ULMO7E)73UPY,A=K<FPHGI&K%]F2KTG#:2CNR?RJ*8"6M$C-*@$0^
M%120SV`E\CFC`DCD2T$!^0I6(E\S:H!$OA44D.]@)?(]HP%HE'?CJA.B__<Y
M9$JKVJ\,J-/O&%MW0O33>+`*3JZ1L;)WMD#33+JZO#SS%M4$%ONF4C.'&#>#
M#F30DGUT;I">L*7O^N?7`@5E/2E1,%ACA8)28XV"P1H;%)0:6Q0,UMBAH-38
M`^UMY`$6^QK9[6LZSV?WM0-SR)06=#K5A)PY9(>L./A[A.C,6,DPB1DE0#(*
M4T$!^0Q6(I\S*H!$OA04D*]@)?(UHP9(Y%M!`?D.5B+?,QJ`9N80-<9?$U=M
M[JT-$_+.1E[6;*L?":B"AS8<1EZ:(38%[;,1HW21?,8%<T8%HW*1?,4%:T8-
MHW:1?,<%>T:#@]PAK.80)]1ORM+J@X[?`R9TZ*`T61TZ*!DMF<EB4Z,ZW^M7
MCC;KM?\<-X'%OIG,+!=+',B@)0[D!JGE0CO@UUZ@1+#V$B+*"5ES_+FN@I;4
M7J/@@:7#M)N]="RYWXYK[(%V#;[Q#JH#+/;=LMOO=!KS%4O'E/5TE@Z3")5I
M8:O/-PNVG\9*9L<8!04E0"*?"@I$*X.5:.6,"B"1+P4%Y"M8B7S-J`$2^590
M0+Z#E<CWC`:@4=Z-JY]!?=L1EA.K^G&/7BN<H;*F[:>Q4IO`_0,J,EK6\A$;
MI+8_>^<3XY,ZXNR73N%FT(&,'<CAP)[G.2@1K+U<5'L%+>D<M=1NW9R_^6U0
M4#I'NZC&#@6EQAXU[AJ<YY,##>[V.S7KO&8^T>;>EF5"SE9TAZQ6\:?G2#UW
M&6<=:96840(D39`*"LAGL!+YG%$!)/*EH(!\!2N1KQDU0"+?"@K(=[`2^9[1
M`#3*.W%=JQ7.B>N;]B>CBAMN@_0/&<[T%-E8Z:5-K*@'&"O]+%RL_">V,:RF
M%?3B[/3<6T$36*@.)3I^;>DBGS)H!7W*H;5G%P.1H$,E1(*-5$$KZ%`-+3<L
M7B:O@9:UL4'!H!,="@:=Z&&UB]2E]P!O@,6^AG'[\*&T[K*GR.I7/?TYRR![
MSA(4Z$,1K*0!8T8)D(SZ5%!`/H.5R.>,"B"1+P4%Y"M8B7S-J`$2^5900+Z#
ME<CWC`:@F3E+9T&7[VWU+^=[:Q&0T[W67E)]*U9(P$:,8D8)HY11QBAG5#`J
M&56,:D8-HY91QZAG-#C('8XZ0_B*\$P)1?OHL39(;5!DGM[X3W[%2L*S*P@4
MLU7"*&64,<H9%8Q*1A6CFE'#J&74,>H9#0YRPZ,S>Z\(SY0(=,)CD#-Z-O[3
MKO7."K&(&,6,$D8IHXQ1SJA@5#*J&-6,&D8MHXY1SVAPD!L>M72^)CS:W-MY
M&>2&Q]L+;=4W@,:",@E'C&)&":.44<8H9U0P*AE5C&I&#:.64<>H9S0XR`V/
MVO^\)CS:W`N/06YXO!W8=KVSDM%#*&:KA%'**&.4,RH8E8PJ1C6CAE'+J&/4
M,QH<Y(9'YYY>,;E-J2IG<C/(#8^?!UGOK"0\A&*V2ABEC#)&.:."4<FH8E0S
M:ABUC#I&/:/!06YX=,K!#H\^;;[MTXMKD[VP7A@#<D/G/Q01*PF=T9*Y,&:K
MA%'**&.4,RH8E8PJ1C6CAE'+J&/4,QH<Y(9.M:H3NO"SR+4V]R:^":E?AD+#
M;XV5A2)&,:.$4<HH8Y0S*AB5C"I&-:.&4<NH8]0S&ASDQ&+C)VW"L1C-W5@`
MN4/%>R-@*U:(6,0H9I0P2AEEC')&!:.24<6H9M0P:AEUC'I&@X/<\`3R$0<B
MQ2F(S834C@0QV#**&,6,$D8IHXQ1SJA@5#*J&-6,&D8MHXY1SVAPD!N6UZ4-
M-IPV`)*,QY91Q"AFE#!*&66,<D8%HY)1Q:AFU#!J&76,>D:#@]Q8O"Y'L.$<
M@4$J2R3C8K+2B2-)&_CIW0@%57C%:N.]]!N+%>031BFCC%'.J&!4,JH8U8P:
M1BVCCE'/:`#BI-O&3QN\Z<'CJ.(M15.>P`DDH<@4U&D-*VI>VC@6*XF:T9+O
MTJ5LE3'*&16,2D85HYI1PZAEU#'J&0U`,U'SLPEOBQHG&3834J\6H:6W@JP0
M\?";"NH$B`32?\X<&RUE!?E$Y(%209:67V,F6I;5QDOVYF(%^4+D@4I!EI9?
M8R5:EM6YE[^LQ0KRC<@#M8(L+;_&3K0L*_]W\WJQ@OP@\@JY4[1.-]AGM0-;
M%Y.=L,YCFPGI9SD2:O^AW-98N0_W_!N,Q`JNQXP21JD@RPE?/A,KR.>,"D:E
MH(!\)5:0KQDUC%I!`?E.K"#?,QH<Y(9:IRY>$6J3Z;!#/2'O[1&OQV\WIN"!
M!7IGA;N)I2!0PB@5%&BL3*R@E3,J&)6"`O*56$&^9M0P:@4%Y#NQ@GS/:'"0
M&^JY#,QJ,WY.?OE7;3:<?#'(>Q_1?R@`*[4(R)3@C\9HUHJ>]\-J>HH\\U4T
M&#B'7+^R%%9!E[)9*]^E'%;[7"I@$'2IA%70I6K6RG>I-E;AU^X;:$D&K`4*
M.M'-6OE.](N<&*`U.N'V6ITZ>L4$I<V]7>:$["?YFQT*]D5C)5FK&`4%)4!R
M&DD%!>0S6(E6SJ@`$OE24$"^@I7(UXP:()%O!07D.UB)?,]H`.+MZ?GK$EFC
MN1M7@[R%QT_7P\HY/?@S001Y:8;8(//:XLP<@S+.:=)73A?5GT%+ZL\/U5^@
M3+#^<E']%;2D_AKUN[MU[V%5@X+2#=I%-78H*#7VBVH<4'"LT9DJSG6^;/E4
M,9I[76K*N.EW^F6-HB_TF8('WEPS5O8O8C%*&*6+Y#,NF#,J&)6+Y"LN6#-J
M&+6+Y#LNV#,:'.2&6F?H[%"_Z=W%<ZWB]8`)Z;>PK1[@9\=-P0._70-YZ>*Q
M07@7FC\8EZ!0<%2GBQS(H"4.Y'`@.*H+%)1172ZJL4)!J;%&C>9M9+[E!H6"
MM]PN<J"#ECC0PX'@+0\H.#.MZ-RBW=?"I^'S*15I/U@VR-Z!"++ZF;]X1+"2
M.,2,$B"YYU100#Z#E<CGC`H@D2\%!>0K6(E\S:@!$OE64$"^@Y7(]XP&H%'>
MG4-4AW#B^J8$V;E6\>:0"7FK"&U,C)7*E,A,PSU@LG)6$8.FD\;,1R<3XY/^
M;,=^Z=18A9>Q#%KR$"I'02>YX_]&0X&"<JXH43!XRQ4*2HTUT-Y;;F`1O.5V
MD0,=M,2!'@6#MSR@()]BSM6.PNEK!^80;>YUJ@DY<\@.!<(<C54[G_&,&25`
M,@I300'Y#%8R"G-&!9#(EX("\A6L1+YFU`")?"LH(-_!2N1[1@/0S!RB\YSV
MVO"V?<B4+766C`GI7^61(4R_0W$^61W:AQAY)_?F']1CHV6V)C/?=TN,A?Y+
M6^*3/V.EBWS*H!7T*7=]XC-8`9F@2^4BERIH!5VJ79=F9M\&.D&?VD4^==`*
M^M3#)[4P2&#\"7F`UMC7W950IUW]7FQG!I?]%L6YR=Y:R6&#G%EKLE+(<M;O
M11$*RNH1,TJ`9-RG@@+R&:Q$/F=4`(E\*2@@7\%*Y&M&#9#(MX("\AVL1+YG
M-`#-S%I^)OC`:L0IWW.#Q/4MD#@5,8H9)8Q21AFCG%'!J&14,:H9-8Q:1AVC
MGM'@('?LZ22C/?8.Q&+*23I+Q83LI^CG.Q3H1A&LG(GJW,OPQ&*%QPX)HY11
MQBAG5#`J&56,:D8-HY91QZAG-`#QZ+GP,Y=O.C>,*NX6SR`[D(PB(">AZ?]%
MJEBL=E%CE#+*&.6,"D8EHXI1S:AAU#+J&/6,!J"9J*GUQAEG;XN:5O&B-B'[
M=8B+'0H-/V-UX'4(L9)`[N2!TD4U9J)E^46O0X@5Y`N1!RH%65K^,EZ)EF5%
MKT.(%>0;D0=J!5E:?HV=:%E6]#J$6$%^$'F%G"GZ0DV03M<)3]&CN=='M(+Z
M6\'.\9%>AS`%#[P.(59P/6:4,$H%62WCMU\F5I#/&16,2D$!^4JL(%\S:ABU
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MYCY="VGG`.+WOA1600<RL<)TD!]TH$"AH`,EK((.5&(%!VHX$,S+-"@H.<@6
M*%AC)U:HL5]4XX""G`FZT*E">U(\L-4QF44KXS,JC-^IA5-;08&I*(*5-$/,
M*`&2?I8*"LAGL!+YG%$!)/*EH(!\!2N1KQDU0"+?"@K(=[`2^9[1`#3*NW.(
MG^$[$%?.Y%V8M)T:Y[*>^"]O;V&E^H58^2,Z,E;V0RV@:=Z>^T8M+((3=[K(
M@0Q:\H0G!S(.\(>V"U@$'2@7.5!!2QRH@?:O7%,$PD_UVD7U=ZA,ZN]1T#FC
M4!(9!6>6J=<E%2\XJ6B0MW7V?XD75D[^@[L8)2ACU"B#+V&4+I+/N&#.J&!4
M+I*ON&#-J&'4+I+ON&#/:'"0.YNH(>"L$F]ZZG6A5;P=R80.[:,GJ_"#Z\C(
M.Y.,D9^&F/JRJ?]AO`2%E.'^^2LU5F$',FC)&,M1,#C&"A2TM\A+;KE"0:FQ
M!MI[RPTL@K?<&JOP+7?0$@=Z%`S>\H""/*U<JH).7PNO7*.YVZD,LI]!"0J$
M.8*5++HQHP1(II544$`^@Y7(YXP*()$O!07D*UB)?,VH`1+Y5E!`OH.5R/>,
M!J!1WIE#+M7>UHGKF_*QHXH7;BU\\&NFIN"!)^>0E]:)#<(;?#-S"`H%#Q7I
M(@<R:(D#.1P('BH*%)3PE(MJK%!0:JQ1X][OB38H%+SE=I$#';3$@1X.!&]Y
M0,'QEMV^IOQR^MJ!.42;>YUJ0LX<LD.!81)=&BN)0\PH`9)[3@4%Y#-8B7S.
MJ``2^5)00+Z"E<C7C!H@D6\%!>0[6(E\SV@`&N7=N/K9VC?M0RXYB6N0FZ^G
MMV^,57A-C(R5F]7WDT0QK*9U6GW!U/\N9@*+X#J=+O(I@Y9[F/.^$Y;#:O)I
M)H%3P"+H4[G(IPI:09]J6)G]S,7:_W1C`XN@3^TBGSIH!7WJH17>XD!K9HNC
M,[YVTL5?"I>]?G.I9;QI:T+.M+5#@9$9&2WU\6!D<6)&"9`,_%100#Z#E<CG
MC`H@D2\%!>0K6(E\S:@!$OE64$"^@Y7(]XP&H)EI2W4G)]X'EB-M[L75(/%@
M>TDH8A0S2ABEC#)&.:."4<FH8E0S:ABUC#I&/:/!0=,2<O+\_>[N);IYN?G\
M\>'NZ=O=]N['C^>CV\<_?ZJ3GWIKW,)'3W=?/QU?7VZNM)(:$;L"YLKZ_$I_
MF6[NRH6Z<C%[Y5)=N9R]\D%=&4/KU[-Y?Z4_/C13SV:EKHQ=C<JH"W,EE,NS
M'BN'9_U5[LYZJYR=]76E?%W-^1I=K*YB];2=[T*]H'"5SUY1+Q)<U;-7U`/_
MJW[VRF^KJ]_&G87?(JJIYFJ_/KT:9NW/KH;Q6Q>>SF_KJ]_V=`<5OYG;BS:;
M*_UYBYD;5U?T9RCXBOJ@Q)7^7`1?41]^N-*?=>`KZE4\%=O98)U_N+I6[\C,
ME?EPM9V]HEX3N](O2'$9]2J2:OHY-?7VE.I%LU=6JI57<ZUSO3F[NE:?,^%Z
MMNK*=O:*^J*/:H.YX*BOQJ@K<VKJ0S=J1,Q=N5XKW]3'C=F#Z[4JHSY`,W=E
MK:[,JZGI8OIVE]=Q*M4&M7J+FM6JU9FZ,E=/M5JK*W/U-$JMF;W2JBOM[)5.
M7>EG/>B4!_VL!YWRH)]52Y5:.GLE4U?RV7HR54\^6T^FZLEGU0JE5LQ>*=65
M<O;*M;IR/7MEJZYL9Z]$ZDH\ZW6DO(YGO8Z4U_&L6J+4DNG*R:XC/'_^^.OF
MVUU]\_3M_N?ST8^[KVK1>3]^BN'I_IO>_TW_>#%_!/WWQY>7QP>U"3@^^GYW
M\^7N21NH%?_KX^,+_J&ZT\E?CT]_C`O;Y_\5````__\#`%!+`P04``8`"```
M`"$`2]CU*/H%``#O&```&````'AL+W=O<FMS:&5E=',O<VAE970W+GAM;*Q9
MV6[K-A!]+]!_$/1^+5'>#=L7L:6T%VB!HNCRK,BT+<2R#$G9_KXSXB(.J<9Q
MD)<X/AP.SYDA.1-F^?VU.'G/O*KS\KSRV2#T/7[.REU^/JS\O_^Z_S;SO;I)
MS[OT5)[YRG_CM?]]_?-/RY>R>JR/G#<>>#C7*__8-)=%$-39D1=I/2@O_`PC
M^[(JT@:^5H>@OE0\W;63BE,0A>$D*-+\[`L/B^HC/LK]/L]X7&9/!3\WPDG%
M3VD#_.MC?JF5MR+[B+LBK1Z?+M^RLKB`BX?\E#=OK5/?*[+%C\.YK-*'$^A^
M9:,T4[[;+X[[(L^JLB[WS0#<!8*HJWD>S`/PM%[N<E"`8?<JOE_Y=VR11!,_
M6"_;`/V3\Y?:^-VKC^7++U6^^RT_<X@VY`DS\%"6CVCZ8X<03`Z<V?=M!OZH
MO!W?IT^GYL_RY5>>'XX-I'L,BE#88O<6\SJ#B(*;031&3UEY`@+PTRMRW!H0
MD?2U_7S)=\UQY0\G@_$T'#(P]QYXW=SGZ-+WLJ>Z*8M_A1&3KH232#J!3^F$
M30:S\7@TF4W!RSLSAW(F?,J9T6#*POGPRKR1G`>?-ZX(?%K!\"EG?EQP((+7
MYB).FW2]K,H7#S8XA*>^I'A<V`(<JR0(X3HM_Y<52`<ZN4,O*W_J>Q#P&K;2
M\YJ%PV7P#.G/I,VFQX9:;)4%YAK=QC:0&$```K0*2-\7J$`OJ$*MOU%`)RNR
M*"L+-26V@<0`"&78-U]`&;W`QB>!'U&.&V&#1TMG9TQ-MMI$ZW"0Q$2($MC)
M7Z`$O<`FG!@LW3TDC=Z3HDVT%`=)3(1(`<>VE&@\`/3&\X!^6C&*Q$8B](C8
M:=!&:EKL((F)$.X0.9-[_S6J#BP:4X(2@>JJ=PD+)]8^T4::H(,D)D((@G:3
M8'O53&>?B"XZHN0E,B?DIQ9Y;:3).TAB(H0\=AW&/?E^=-&8$I0(C>[,(JB-
M-$$'24R$$`3M)L$VNM'T$]%%1Y2\1&ATYQ9Y;:3).TAB(H0\@^[!9/]^>%MK
M2E%!),`LM#AV5IJD"R4$HC2Q_AB[`(,\FV-[<NL%P40E@^M.,=DHB(29,5N"
MG#C7$^-NHO*5$(A*P'ID26"?.H5,5#8B04`19+.[1)A=,^5$L%)\8Q=*"$0E
M8"6R)'SJEF:RI)E)$)"EP&IEMG(B4:`G*E$)L:(*L``9"JYL=UFN3)H"BD0S
MB[W2ECE0[$()@2@G+"P&)]S;D^$`N]DK]&1%,NE)R*0G(0B3L36L5B7&)@4O
MGY'>&HF"Z,2N<E(16'P,$5>8RU)E,A<0":P#Q=BE`$W#*B$0Y80UQ>#4WLQL
M])'(RFID\I.0&5D)T0`YD9569F1[)W8EGZK`PF.HN!)96:9,Y@(R8K9E#A2[
M4$(@R@GKB<$)(SN&^_$*-UF%3&X2,J,JH2M1E59F5'LG=KT(48#WC*G@?>:M
M-:U[$HHB?6"V+A2[4$(@RJFGR+$0;O8;>V#(M-U(*`A"9%P"=AO46:FK-':A
MA$!40$^)DS?9K1+<$@>1;E51"78SU%EU$O1$!27$BDJ`;6?N"]S94WC=N#T)
MZ,C:,A(B"B*[58JTE:(;NU!"(*K`*G'J;-Z:`;?V11*B_.T^J;/J^.N)"DJ(
M%>6/E<BX6ZZ<3%FWC#L%FT*,/-QQW5Z/[%ZHLU*<8A=*"$1I8B4R:&*8/]>1
MPE.?LU,D1"-M-T-JHM&1NA"^),IS`T*%!/$R*%ZC"EX=^):?3K67E4_XZ@>:
MUTL-BR?)332"-\GVLG5&QC#2/A,Z(Q/UCFF/,!@1[:LS,H.1&=ZI]D@4@K>V
M<W5&\+VTK2#.2`0C[0WMC`QA9-BWSGP!?RWUK,]@??@#I6\$UH>^OV\$UH=V
MNF\$UH<VM6\$(BW:,(LS/`O?]?N""7V>4'P?#DOWK7PW`O_M.;(6W@"CWM1#
MYGL3#]GM]3-=P)_Y/9(AYVW*`[TP/#=?T@/_/:T.^;GV3GP/&S-L.[=*/%B+
M+TUY@9,.C\YE`P_-[:]'^,<"A[X\Q$M[7Y:-^@(+!_I?%>O_````__\#`%!+
M`P04``8`"````"$`D0^OWT,%``"N%```&````'AL+W=O<FMS:&5E=',O<VAE
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MY$]GB/N-!'EQ\]U_&;FORJ)A+3MT2W#G(-%QS(F3..!IM]F7$`&7W6KH86M_
M)^O,BVUGM^D%^J>DUU;Y;+4G=OVE*?>_E34%M2%//`-/C#USZ(\]_PD6.Z/5
MCWT&_FBL/3WD+^?N3W;]E9;'4P?I7D%$/+#U_OV!M@4H"FZ6WHI[*M@9",!?
MJRIY:8`B^5O__UKNN]/6]L/E*G)]`G#KB;;=8\E=VE;QTG:L^A=!1+A")YYP
MX@-[8?>67KPBJ_!K+PXRZ@-\R+M\MVG8U8*J@3W;2\YKD*S!\RTRY#'$^EFH
M$"-W\IU[Z7U!%"WDYW47>QOG%20M!"1%2&1;`X3HB.R&X)D`=@-%"-RDZ$,*
M/Q;_QH@OTAEY*WV_]`.(CLC&B#`8(!I'D$[E.,V-@Z$$%"EB?W#;"YHB)%`@
M!OML"J%1`R?SJ7'PUH:XARQ%QL8I0N(^RPL2![&K<\\,0!2'`T`C!J6O$N.E
M]W5>^2)#.YD2U`XAP&*(P0@AFT)H%$.=XG1:.5C7+C8V3A$2]-H%@6'-5.O*
ME;)JE.`$W:\:7V10DTE!U1""U*"A#"GKK9EF3>39UJCQ<:?TDFFU.-B@%.F;
MI@@)42TWB75SIIN);"<:J40G-:_*^"*CRHS=4X1,5=D40J-(H)O-%ZY'Z\KY
MLE8PF0*#V81#:BBGF3VY6&=EC(;I=!+LWFKG\&5&!"O$"%9A8I1@)GQ@PA?>
M2CD^.C/>EV<7&L$NKC*+$UV05&`$,S\V*C$S[)]-`<*;LD)L7K'UJ_2$!C(G
M0CIL]T(:X@>CE&H`/XJD!UT[WIWOIX@]7=4P&&47,4+#P#?:<D94.UG)%.C\
MC*GP1=5A)]=XR>8DI$/,3;K0/"P9?Y*#TXX`0F+EN.C4[IH&9#P.$ID300TQ
M-VI1/.J[PHM`Q+XK&[/.S1@+7\B&[1Q*9AB1R2B=MY8O,7+OGGY&IB`ZO;M&
M`QG/!F7D".G4[K_P(Q(:`63"BY`N<N%Y>SCU.CEC1'RA';9UM>02\^F-(`:W
M]F,_'IT%%1#!([R45J/FW349>K3>2!)CYU1@;ITND1MC3@U[*$/3B1G#85ZG
M\\9#PB20"@P2C#VSSPDS2AMXGCSM.C_(C]KFIG/J<;0^[\WAE`H,-+'AS(RT
M0S<?0W1Z_VM0>-CCM=(S)E4J,*A/F`3FP<D$8`Y)WK#O'A4>7V44H9'$5&`$
M2>*/A$0?:">N,FIT%8U9,;,(QS,CD<,(NPM_H1Y&0@0OV(;,F0:88&B,C)D,
MQZ.#**\#@J(Z.U;Q>*QY*F#AN\%G1\48'3,Y8N]7:Y&X1@M./01A'CT21H;.
MF08`>R@?"?5,&_-C)L?Q'"&N5$'HB"!\GXU=WQUQ5`'$CSS94I$C7AOAK4I%
MFR/-Z/G<6@5[X5="!%Y?AE_QNBJ%ZZK^;L<9#'!;=,F/]/>\.99U:YWI`9:Z
MRPCJL,'[)OS2L4M_J_'$.K@GZC^>X%Z0PB6,NP3P@;'N]H7?HPPWC;O_````
M__\#`%!+`P04``8`"````"$`+/SB#0D#``"L"```&````'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;)Q6;6^;,!#^/FG_`?E[(9#P$I2D:D*Z3=JD:=K+9P=,
ML`H8V4[3_ON=<:"QTS75OB38]]S#/7?G,XO;IZ9V'@D7E+5+Y+L3Y)`V9P5M
M]TOTZ^?]38(<(7%;X)JU9(F>B4"WJX\?%D?&'T1%B'2`H15+5$G9I9XG\HHT
M6+BL(RU82L8;+&')]Y[H.,%%[]347C"91%Z#:8LT0\K?P\'*DN8D8_FA(:W4
M))S46$+\HJ*=&-B:_#UT#>8/A^XF9TT'%#M:4_G<DR*GR=,O^Y9QO*M!]Y,_
MP_G`W2\NZ!N:<R98*5V@\W2@EYKGWMP#IM6BH*!`I=WAI%RB.S_=1LA;+?K\
M_*;D*,Z>'5&QXR=.BZ^T)9!L*),JP(ZQ!P7]4J@M</8NO._[`GSG3D%*?*CE
M#W;\3.B^DE#M$`0I76GQG!&10T*!Q@U"Q92S&@*`7Z>AJC,@(?BI_S_20E9+
M-(W<,)Y,?8`[.R+D/564R,D/0K+FCP;Y)RI-$IQ(P.-$X@=ND(1^&%UG\71$
MO<`,2[Q:<'9TH&G@G:+#J@7]%)@'93J.4>N_I()&17*G6'HN4"&@/(^K.%EX
MCY#2_`19:TB,G!$234W(9H"H!"K:;-AX\?%-E^V`4-4#1:,L2)8M:PIE?[U@
M@PKE9*H(0O-]ZU<@)F)SB8AF)B2[A`0F8GN).",QA$[_1ZAR@AX\JT4\-R-8
M:\CL#&*E8G,5D5U%;-]"&#(AD/-ZOEU'!5XBR.'8:K$5_%I#DKY5;R)_9MDW
MACV,YQ,S/9EA]Y-98@&V%B!.HI'!$`9G[ER8.G_7&U4YF0+M]Z\U9-8+#.+Q
MW?VYVAA&J_>RP?B2O9GEOQT@ZJ"_'&)#5V3J>KM@"FSIL0[Z6D/&@OG6>-D8
M]C".+'MFV%\KF`6($UN8OAWT\&P(WY,-J6OAY.R@)G\`F1YW]:6T]E,8:3"9
MK/T,+JM^WQL-<%ET>$^^8;ZGK7!J4@+EQ(TAT5Q?-WHA6=</J!V3<$WTCQ5\
M%1`8EA,7P"5C<EBHD3A^9ZS^`@``__\#`%!+`P04``8`"````"$`45!'[=,'
M``!^(P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6RLFEUSHD@4AN^W
M:O^#Y?VHB"9*Q4S%#Q0!16H_KHEBI*)B`9G,_/L]#70W?8XA9G=O9LSCVV\?
M^G0?Z,:'[S]/Q\:/,$FC^#QJ:JU.LQ&>M_$N.K^,FG_^87X;-!MI%IQWP3$^
MAZ/FKS!M?G_\_;>']SAY30]AF#7`X9R.FH<LNQCM=KH]A*<@;<67\`S?[./D
M%&3P9_+23B])&.SR1J=CN]OIW+5/071N%@Y&<HM'O-]'VW`:;]].X3DK3)+P
M&&00?WJ(+BEW.VUOL3L%R>O;Y=LV/EW`XCDZ1MFOW+39.&T-Z^4<)\'S$:[[
MI]8+MMP[_X/8GZ)M$J?Q/FN!7;L(E%[SL#UL@]/CPRZ"*V##WDC"_:CYI!F^
MUF^V'Q_R`?HK"M_3RN=&>HC?YTFT<Z)S"*,->6(9>([C5R:U=@Q!XS9I;>89
M\)+&+MP';\?,C]\78?1RR"#=?;@B=F'&[M<T3+<PHF#3ZN9A;.,C!`#_-DX1
MFQHP(L'/4;,+'4>[[#!JZG>M_GU'UT#>>`[3S(R89;.Q?4NS^/1W(=)84,)$
M+TUZP@0^U>C!.>\4_B\[U3JM>ZTSU.\!U32\*QO"["T;UG<T+/7P_]<ZTB`1
M>8B:')CZKC0^".S#%SL#YZ(SN+Z;KDN[YRW@PQ<[@[$K.OMD$-O%3,DGWC3(
M@L>')'YOP&J&N9!>`E8;-$,#$S[EBKR)2?C1'(1YPUR>F,VH"?'#]$IAX?QX
M[/;TA_8/F.S;4C.F&DU53+B"34=F.\5@AH&)P1R#!086!DL,;`P<#%P,5ABL
M,?`PV&#@5T`;TB-R!+/V_\@1LV$YXJ,[YJ"2-)00KN!-IAC,,#`QF&.PP,#"
M8(F!C8&#@8O!"H,U!AX&&PS\"E`2`D6!)$2'(G.]3O,UPEI!1:ZN$>U.'?!Q
MH6$U7RRDOBJ9"(E("B$S0DQ"YH0L"+$(61)B$^(0XA*R(F1-B$?(AA"_2I0<
M01DF.6+C^L7"QFR@-D(M%PGI]GIJ2L:EJ"YK0B*R1LB,$).0.2$+0BQ"EH38
MA#B$N(2L"%D3XA&R(<2O$B5K,(0D:]U^Z^MY8T9YWOAXCTL"3P\RD]I`S>1$
MB'BS*2$S0DQ"YH0L"+$(61)B$^(0XA*R(F1-B$?(AA"_2I0TP7(@:=+Z+?;`
M5U\#64,U+07I%8^S[*8_(61*R(P0DY`Y(0M"+$*6A-B$.(2XA*P(61/B$;(A
MQ*\2)0?PL*7DH'[@F5H=^)(4#__YP!,R)61&B$G(G)`%(18A2T)L0AQ"7$)6
MA*P)\0C9$.)7B3+P\)3\A8%G:G7@"]*K#+P@LC1I>D<M3=-2!,\DHGYI`R2:
M"1&O7R8A<T(6A%B$+$LBH[8%J02$HW:$444T1,_]KA#QJ%>$K`GQ"-D0XI<D
MCUI)(MP&E"06^YZ\@F6':/LZCF&4X8'\RJK287]3['J8B9K;@E1S2\BT)/#D
M4DDD&I*9$/$A,0F9$[(@Q")D69)*(@EQ1*N:$%TAXB&N"%D3XA&R(<0O"<T:
MV\G_][3E+FK>2M35Q>YH(E%E$/#\GI:J7J_8]'8TM.N=20$?)E,Z<S27J*:S
MA?3*=]@=K:O6"$L*N/-2.G-D2U33F2.]RL[0E;E2P)U7TIFCM40UG7G2Z_J5
M;:2`._O2&9"RN#6VDZZ>:EQ9Q7`BQI=Q+D?SH=B+]V"^B47:U8;J<$_*ANQP
M3:AHX98J'OJ,(I.BN40U]@NIXO8614N*;(EJ[!VIXO8N12N*UA+5V'M2Q>TW
M%/D*4E/-]NA?2'6QI8?]'.]NS`X%H8IWX4%+)/$>W5<GI8C%(417,EVZ*ZH>
M6J2STDLO2L:]CKXW>5]@]G%?<ZY2^L+E:7%5A2.R4$3W:'^[Y"ZU$=E<51N1
M<U6%(W)Y1.Q>"V>)6@\E9,5M:D-:<U5M2-Y5%0YI@T,:HH,9G]M\%)(Z;]G!
M177>_JL'$'8\C9Y`2J17:](]>KJ8E*+/"E?A#BJ^6&;<O9/GY:Z/*J+)C>$.
M7C=WA7&-:L&]9/<6ZAY/]R5O4MN]S575(2*+V9$J?O4N1X/\ZK5A'QT?K+B@
MMO\U5]7V[TD5[W_#4=G_`!\?^ESP4?_J%&2G,-4I^,E=LCRTJ9;.`NGR67*B
M"523VBE7=2LSJVPHD<E5TGXN48W]@JNDET71DB-I;TM48^]PE;1W*5IQ).W7
M$M78>UPE[3<4^1SE]FI>85XI>66EI3A$^R3#K"%Z#BJ0#IMAL9Z[752,)^Q<
ME=U"85D+%5E0TU*EWD-QF9V5*KVH_)J.-XLFM_FHS.9;L_E-(2VXEW)_P"%9
M**1>A]P?RX&K#<F^*23GII!<-:1>9T@JT2TAK6\*R;LII`T.24,W'?;F/)]>
M'XU2,8F+E^/%.\I3F+R$D_!X3!O;^(V]^.YJ4'H%%F_EG_*U@OB8O:UG!0;S
MK@%O=JYPW8#7"90_]8PGB)U^,>X9<))]A?<-_ZK^SH#C/*IW!@8<75SA0P,V
MQY3[`P.VR)3#9M1@^TWZ#>P<#;8YI-_`-L]@.SGZ#>S)#+;MHM^,!\;X6O^3
M@3&YQJ<#`PZ4J,]T:,#Y!.7+@0&G%)3;`\/.>5MD%'[]<`E>0C=(7J)SVCB&
M>Y@D\/,#F&I)\?N)XH\LOD!A@]]`Q!G\[B'_>(#?N81PWMQA;Q?V<9SQ/Z#C
MMOCES.,_````__\#`%!+`P04``8`"````"$`CZ0?EDT3```@<P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6RLW5ESVTB2P/'WC=COH-#[6.*A,^R>
M:)&X;\3L[K-:IFU%6Z)#4K>[O_UD$4@6JOX0=.R\]/%#(E%$H@I`@80^_O.O
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M_8IR^/<KOFZ#%_UZ\N^W;7`F%>UVL-TYK]OD3'>.^0_=Z*`V$Y]R)ONSVZA\
MWC=]SMF9KBG_H1M]W:Z=R3[M-OK*G7O4'8J[(WM]_73]R\>'[<\#&2[D8'O\
M<6T&G]FER:K'=/>)]T?Y<P>Y'-TFRZ\FS:=#^1QR_#Y*S_SSE]GIQ<>C/Z4W
MW?0Q5R,Q;L1*(TS7,6G7/@0^A#Y$/L0^)#ZD/F0^Y#X4/I0^5#[4/C0^M`,X
MDO+L:R1'\W^B1B:-J9'NW2L%6[2Y5Q"-T%76/@0^A#Y$/L0^)#ZD/F0^Y#X4
M/I0^5#[4/C0^M`-P"B*#!`JRE/%Q_$2@?<2L)4/^L(^<';L[_*J+,2>5?4<Z
M<4-6^Y!]42`!)(1$D!B20%)(!LDA!:2$5)`:TD#:H3@UDF$9-3+[]8T#FTDC
M8Z.,[?N"<&3K@Z:JM@_95PT20$)(!(DA"22%9)`<4D!*2`6I(0VD'8I3-=F%
M3M6F>Y2)WA5'=^I5+\Z)Z&SF]:!]D*ZVA@20$!)!8D@"22$9)(<4D!)206I(
M`VF'XM1"CODWU,)$N[7HQ:V%?X;9!^UK`0D@(22"Q)`$DD(R2`XI("6D@M20
M!M(.Q:F%[,0WU,)$N[7H12[P[#!VMO#ZQ3YH7PM(``DA$22&))`4DD%R2`$I
M(16DAC20=BA.+60G.K4PE\PG<NWVQC.+2>,6J1>Y[QD4:>D5:1^T+Q(D@(20
M"!)#$D@*R2`YI("4D`I20QI(.Q2G2+(3G2)-GTA,M%N+3N;S_=7R"K*&!)`0
M$D%B2`))(1DDAQ20$E)!:D@#:8?B['AS$^[L>=,]YB<?Y#3SQ@ZRR^1614FV
M/N@B_A6RC=KW$5)`"DD1*28EI)24D7)202I)%:DF-:36(;=RYO[3GPMX7^6Z
M.UFY:M8"7,UZ<BMWZ@UN-DI77),"4DB*2#$I(:6DC)23"E))JD@UJ2&U#KF5
M,S>J?N46YV86\LV=KKOG=4K7DUNZ,[]T^RA;.E`P`X6DB!23$E)*RD@YJ2"5
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M#:EUR*V%N<5]0RWZ.^)A+3I:VAV_,D^U3+^0ZSU[B;[PYKG7&B67`S;JW(L*
M;)1VNY`4D6)20DJ5;.LS2X-V^:W/-<IMO3>U5=@H;7U)JD@UJ2&U2KO6NW4U
M=\7#N@Z&OJ=OMS>_7VUEITN!1OK>0A[>]8_T^GOK8;D[<LH-6IO'B.8(D`N&
M06V]2=C`1NG>"4D1*28EI%1I6%LT-=>HR:86-DJ;6I(J4DUJ2*W22"'ERN`_
M4$B3Q3N?=31?#,YG>QI4S3_RUW+YMZOM<O>,=WX\\^80`QN@^RKL:;"QR-+$
MQF*;RSQ0EHUY/2RQ`;JQU&96RBQ-;"RWN?J->9^LL`&:N;29E2I+$QNK;:[Q
M3];8`,W<VLQ"3G^?^U,N(_U:;@6U8^_"W>.AIZ4D&G19;P^L^BAS5VFC<(C8
M*&UZ0`I)D:6)]+&-TO0)*25EEB;2YS9*TQ>DDE19FDA?VRA-WY!:A]Q2FVF4
MX=#^0JG[69?!&#[O:"Z73+:(Y_XL<Q]EIAQL%$O=IW>BEEXO#?I<BV[,./&7
MA[HMYVSJ;RO2*&=;?E0\&N5O,7FA1:EFF6Q1IE&3+<I'H_P6%=HB<_HUWYV9
M>W.:I::9;%*E49--JD>C_"8U7I.62^\8:37-<TUR#UR)<@[<=UV3R'R\?RKK
M:>$,2N?>[EOU42\-75UZB=+>&>B*Y[O"+"Y.O=F34`/DQ/A\3XDTRFDECUYL
M/]$5N^W/3\^\3Y9JP.3V,XV:W'YNH_3S%TK=]F>SQ=*[2"\U8K(!E49--J"V
M4=J`1JEKP/)LZ4T\MAKPW/;=P]#,8KUA_.PGO8;C9T<+>V&YDBL;<U0*31P"
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M<R8\]Y^QFBM_<T#8=JY)`2DD1:28E)!24D;*206I)%6DFM206H?<[OBVR=(Y
M)TN5G%/)N3>4KFR47@*M20$I)$6DF)204E)&RDD%J215I)K4D%J'W/*8R;UA
M[S&CY?L>@<^[>4*9-]<*7"FY/<N[%5C9*%UQ30I((2DBQ:2$E)(R4DXJ2"6I
M(M6DAM0ZY)9.]NI_JG0FE7>RZ\DMG?^0=;Z/LJ4#!8P*21$I)B6DE)21<E)!
M*DD5J28UI-8AIW2+M\T\[L+=\B@YY;GP+GE7-FI?'E)`"DD1*28EI)24D7)2
M02I)%:DF-:36(;<\<KV*GC4[><4S<',OZW6DG@8/O%>D-2D@A:2(%),24DK*
M2#FI()6DBE23&E+KD%L6N?YWRC(]B;LPX5ZOZ<E>I*XTRM*:%)!"4D2*20DI
M)66DG%202E)%JDD-J77(K869NQE>-[Q0BVZJ9WAML.AH^%#4TL0-PUJCG+M!
M/`.W43KTA:2(%),24JID#YO,TD3K<XUR6N_?\18V2EM?DBI236I(K1+OIN1I
M@UM7_^[Y5<_`=UF\KM=-"#GE!JW[%5]X!FZC=.^$I(@4DQ)2JC2L+9J::Y0S
M=W7N35T4-DJ;6I(J4DUJ2*W22"'-G,.P@[ZOD-W,A=-O.Y(Y._U$*_,004;:
M%Z;Q^JCEL\_`;8!F#FUFI<C21#>+;:[Q)\6)#=#,J<VLE%F:V%AN<SWS#-P&
M:.;29E:J+$ULK+:YQC]98P,T<VLS"[GC^-MF3Q:</>G)?09^X3W,7/519AKG
M^<G7M8W2I@>DD!19FD@?VRA-GY!24F9I(GUNHS1]02I)E:6)]+6-TO0-J77(
M+?7;9F(6G(GIR4SVV")>^%]WT!6=25],ZH]&^3/H01\EPUQ_L+O?P0XUBW,V
M];<5:=1DB^+1*+]%B=NBY=R;S$@URV2+,HV:;%$^&N6WJ'!;=#;S3D&E9IEL
M4:51DRVJ1Z/\%C7:HOZI_/'">\;0:IKGFN0>MV-35/W=V.N_EF>>1/EW`QV9
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M(GCC5T_#\<O2X!C'^*51]NEI0`J5[`@069I('VN439^04B6;/K,TD3[7*)N^
M()5*-GUE:2)]K5$V?4-JE4;&+SDJG'I/GY>6)MP;J'J2<Y$=J"Z\R[:5KFC;
MN28%I)`4D6)20DI)&2DG%:225)%J4D-J'7*[X]OF2LWDEU^>GISSR(7_#05=
M\7Q_<;$F!:20%)%B4D)*21DI)Q6DDE21:E)#:AURRS,VY?F.%Y/(Q!;JUI/;
MK?RO+NB*PVZU7U&O$P-&A:2(%),24DK*2#FI()6DBE23&E+KD%LWN1MP1KWW
M?W5!'LZA=#VYI?/N]E>ZXK!T^Q5MZ4`A5XQ(,2DAI:2,E),*4DFJ2#6I(;4.
MN:7S9QU-Z=[UZ_TE)R25W,KYWURP45JF-2D@A:2(%),24DK*2#FI()6DBE23
M&E+KD%NYMTTB+CF)J"1+]I<:\D)F]Q)\9:-L>?I<]DV<`:-"4D2*20DI)66D
MG%202E)%JDD-J77(+8^9+1H^]7GA2K";7!H^WEGV-+S4D)\0^N791]GR@`*;
M2Z-"4D2*20DI)66DG%202E)%JDD-J77(+8^,24YY_A^G+)/*NXCO:3CPS?T9
M@-5R'Z5%69,"4DB*2#$I(:6DC)23"E))JD@UJ2&U#CFE.QF;(WK7*6N7R:V<
MDELY;ZYV9:/VE2,%I)`4D6)20DI)&2DG%:225)%J4D-J'7(KY\^&3(^)YLK?
MZUA*[ICH/RBP4;8\?2Y[1Q8P*B1%I)B4D%)21LI)!:DD5:2:U)!:A]SR^),7
M[[X6/.&\AI+;L?QY#1ME*[>?$%$*&!62(E),2D@I*2/EI()4DBI236I(K4-N
MY?QYC?=7CE,>)SVYE?.G/&R4EFE-"D@A*2+%I(24DC)23BI():DBU:2&U#KD
M5LZ?\GAA2.3,QDE/[I#HSVS8*%N>_8I*`:-"4D2*20DI)66DG%202E)%JDD-
MJ77(+8^9+QA>Q;^_8_4S#X/?9)SL)R.&]U_^Q(:-TC*M20$I)$6DF)204E)&
MRDD%J215I)K4D%J'W,KY$QLO="S.7ISTY(Y[_NR%C;+EV:^H%#`J)$6DF)20
M4E)&RDD%J215I)K4D%J'W/*\;?9"_B@2+@5[<LKC_]1XI2L.I@5)`2DD1:28
ME)!24D;*206I)%6DFM20S)^:VNW5W<[IRM/]Z:CN#^S<;1Z^;E:;[]\?#VZV
M?Y@_"W5JWL&SY^YO5EV=+.2/5NV^@XHE2UFR-,]`L.1$ENR^(H,EI[)D-TAB
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M2^1KW9?%Z!+Y#K:T8&R=*VG!U6@+5K)D-;I$?M`B+1C[I/)S"%DR]GGD]R>7
MYG<*;+7\#.4R&UTBKU^\-"]$Y#KR/C]9,E8%>5NB'%]C2^25=I?FK77,)N^?
MNS2OF.,2>5G<I7D?')?(F]VD!6-+KJ0%5Z,MD%=F7JY&E\AK,J4%8Y]47K(H
M2\8^C[S5\M*\_9!MDY=;7F;=DJ-]'Y>_3_CC^NNFN'[X>GO_>/!]\T5.5,>[
M7P@^='_AL/N?I_YE$[]MG^0O$\JLG_RI./E+E!MY_>JQ>;?_E^WV2?]'-GVT
M_]N6O_Q;`````/__`P!02P,$%``&``@````A`(9G<EQY"```.R<``!D```!X
M;"]W;W)K<VAE971S+W-H965T,3(N>&ULK)I=<^*X$H;O3]7Y#Q3W&S`?(;A"
MML*'P6#`N&;W7!-P@FL`I[`SF?GWV[+=EJ77\<#6N4G@<>M56RVUI<:/?_X\
M'6L__$L4A.=!W;AKUFO^>1?N@_/;H/[7-^N/AWHMBK?G_?88GOU!_9<?U?]\
M^N]_'C_#R_?HX/MQC13.T:!^B.-WL]&(=@?_M(WNPG?_3%=>P\MI&]/7RULC
M>K_XVWW2Z'1LM)K-^\9I&YSKJ8)YN48C?'T-=OXXW'V<_'.<BES\XS8F_Z-#
M\!ZQVFEWC=QI>_G^\?['+CR]D\1+<`SB7XEHO7;:F?;;.;QL7XYTWS^-SG;'
MVLD7D#\%NTL8A:_Q'<DU4D?QGON-?H.4GA[W`=V!&/;:Q7\=U)\-TS-Z]<;3
M8S)`?P?^9U3X7(L.X>?T$NR=X.S3:%.<1`1>PO"[,+7W`E'C!K2VD@BXE]K>
M?]U^'&,O_)SYP=LAIG!WZ8[$C9G[7V,_VM&(DLQ=JRN4=N&1'*"_M5,@I@:-
MR/;GH-ZBCH-]?!C4V_=WW5ZS;9!Y[<6/8BL0DO7:[B.*P]/_4B,CDTI%VIE(
M)Q>A3Q7VI)QT2O^S3HWF7<]H]ML]0A4-[[.&-'NSAM4=]3-[^G];1P8%(G'1
MD`-3W97!@R`^W-@9*:>=T?U==5\TH[(6].'&SFCLTLY^,XB-=*8D$V^\C;=/
MCY?PLT:KF>9"]+X5N<$P#1+A*9?&+9^$7\U!FGQ"Y5G(#.KD/TVOB!;.CZ>6
MT7UL_*#)OLMLAFACJ!8CMA`S6\B.=3#1@:6#J0YF.K!U,-?!0@>.#I8Z6.E@
MK0-7!QL=>`70H/#D,:)9^_^(D9`1,>+1'3(H!$T+"%MPD[$.)CJP=##5P4P'
MM@[F.ECHP-'!4@<K':QUX.I@HP.O`)2`4%*`@+0IR93G:5XCHA5E9&6-W*L#
M/DQM1,[/%Y*VC$:Y21X4(!,@%I`ID!D0&\@<R`*(`V0)9`5D#<0%L@'B%8D2
M(TK#$",QKC<F-B%#N9%R>1X0S&R94574<I,\:D`F0"P@4R`S(#:0.9`%$`?(
M$L@*R!J("V0#Q"L2)6HTA$K4JE>4L$Z"PX,ZS(CZ(.JIBVR4&W&S,9`)$`O(
M%,@,B`UD#F0!Q`&R!+("L@;B`MD`\8I$B07->2468FO0ZMZ1_8UK2`BI8<H(
M[>0*J^I!"U-NE(<)R`2(!60*9`;$!C('L@#B`%D"60%9`W&!;(!X1:*$B>8Z
MA,GHWHG-=_7J$0W5L*2DDQXMQ`9L!&0,9`+$`C(%,@-B`YD#60!Q@"R!K("L
M@;A`-D"\(E%B0!MG)0;5`R^LU8'/2'H02P8>R!C(!(@%9`ID!L0&,@>R`.(`
M60)9`5D#<8%L@'A%H@P\99`;!EY8JP.?DDYAX',B4Y/1;JJI:9P9T?XPSU_&
M@V8TR8TX?UE`ID!F0&P@\XQ(KQ<Y*3BD>^WD0@6COG8&6^9&[/4*R!J("V0#
MQ,M(XK421'$^5Z*8'D*3%!8?@MWW84C#3*>CDF75IL-F=@05*FIT$^%!O1A>
M1&-&M)4L1%,;EXFTXH&Q$$T1S1#9B.:,"C%%Y#"J='4IK=C5%:(U(A?1!I''
MJ"20X@2+U81;`YF>@VG/S>X/C12UVCD:252(FC[EQYE5IY/6))I&6UW)$VG`
MG5E2F=%4HHK.9E(K*8`TC9;:F2T-6'DNE1DM)*KHS)%:66?:G2VE`2NOI#*C
MM405G;E2J_S.-M*`E3VI3$A=[^)<79PF)>N:"I;YPDZ/X<I\2%&'EGR^9%M&
M7QWND2CW4480M<_<"G.YM&+7)X@L1%.)*N1GTHKE;41S1`N)*N0=:<7R2T0K
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MD2_N5DO+S"-1RA:;(GH6YE:PNL:9E?I`U7/N)+-JIX\!HZT?)BV6^2KG)B>W
MZ54NS5A+F;JZ2[;F4J<)#\MLX"I=6ESEDG.52TO5I4ZS#VGI&I?65[GD7N72
M1G?)T)Y`'LM\-4KJC!9U,7U&9R7(9$9_"]^_.K\7]_EI>8VZYHPZ%#^-I^F*
MT4BBROF;->SG6A-N*)'%2.:`J405\C.VDEHVHCDC*;^0J$+>82LIOT2T8B3E
MUQ)5R+ML)>4WB,2++G+LTWBG+ZZD[P^<_,N;/_*/QZBV"S_$2RFM%CUW<YR_
M,?.<)$J-#\6;-"(V.F^9]*MK"6^;]%,?\N>.^4R.XH5AQZ1?F4IXU_22'8O>
M\;U))?82^YY)95_D3M^D$E<)-YJF*)K@%:]/MUQV@8H4IJA#8!.J*)BB:(!7
MZ/AOBA,^7J&S.CE0=F78-X>E#HSZYJCTPKAO4O41^Z"2&?E5=B_SOBE*6=AD
MT3<7Z85&/O+TZM+[]LU?;B]OP3FJ'?U7FD7T[A`]""_IRT_IESA+'R]A3"\M
M)9GD0"^I^?0#15/\'/4:AC%_H9X;^6MO3_\```#__P,`4$L#!!0`!@`(````
M(0`X'L[<1!L``*Z>```9````>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;*R=
M6W/;.I:%WZ=J_H/+[QW'LGQ3)>F*)=[OK)Z99Q]'25PGCE.VSZ7__0`DEC:`
M14&TJU\Z)Y_67@"Q<2/(L#_\\^^''T=_;I^>[Q]_?CP^???^^&C[\^[QR_W/
M;Q^/_^=?\3^NCH^>7VY_?KG]\?AS^_'XW]OGXW]^^N__^O#7X]/OS]^WVY<C
MY?#S^>/Q]Y>77ZN3D^>[[]N'V^=WC[^V/]4O7Q^?'FY?U%^?OIT\_WK:WGX9
M@AY^G"S>O[\X>;B]_WD\.JR>YG@\?OUZ?[?=/-[]\;#]^3*:/&U_W+ZH^C]_
MO__U#+>'NSEV#[=/O__QZQ]WCP^_E,5O]S_N7_X]F!X?/=RMLF\_'Y]N?_NA
MKOOOT^7M';R'OY#]P_W=T^/SX]>7=\KN9*PH7_/UR?6)<OKTX<N]N@+=[$=/
MVZ\?CS^?KOK+L^.33Q^&!OK?^^U?S]9_'SU_?_PK>;K_4M[_W*K65GG2&?CM
M\?%W+<V^:*2"3R@Z'C+0/AU]V7Z]_>/'2__X5[J]__;]1:7[7%V1OK#5EW]O
MML]WJD65S;O%N7:Z>_RA*J#^]^CA7G<-U2*W?W\\7JB"[[^\?/]X?';Q[OSR
M_=FIDA_]MGU^B>^UY?'1W1_/+X\/_S>*3HW5:')F3)9B\NYT^?Y"6P3"U*]#
MV>I/4_;UN\O3]]=GE^&X"Q.G^C#J/*>X:Q.F_GQ5<:<J*4,]3ZU&FE/@*=I%
M_\?KBE0M.1:IKO4UUWAZB4#U'Z\K4K7F6.2\9CT9.]+0+S>W+[>?/CP]_G6D
M!KOJ*L^_;O74<;HZ55[HD6-'V/71?5U4]4WM\EG;?#Q65Z%ZW[,:5W]^6IQ=
M?#CY4XV%.Z.Y8<VIJUA#H3N^MMWX(/)![(/$!ZD/,A_D/BA\4/J@\D'M@\8'
MK0\Z'_06.%'IV>5(=>3_1(ZTC<X16O<&P$J:EQ`H$++Q0>2#V`>)#U(?9#[(
M?5#XH/1!Y8/:!XT/6A]T/N@MX"1$31"4D#,U[TQ/XQ@C.DI-V-884;.VV^`W
MHT8O";N!Y$G6.\DN*40B(C&1A$A*)".2$RF(E$0J(C61ADA+I"/2V\3)D9J3
M*4>Z75\YL6D;-3>JB7V7D,79I9<U(PIE;2?998U(1"0FDA!)B61$<B(%D9)(
M1:0FTA!IB71$>ILX65--Z&0M/**T>D@.&O7&$+5IV*7K=''MIFN]$R%L0R0B
M$A-)B*1$,B(YD8)(2:0B4A-IB+1$.B*]39Q<J#[OY&+<&KS3V[UP6G2@FY:1
M+,<MK5[9UT0V1"(B,9&$2$HD(Y(3*8B41"HB-9&&2$ND(]+;Q,F!VE$Y.0@W
MO%:[#6_(>`,P-#R1#9&(2$PD(9(2R8CD1`HB)9&*2$VD(=(2Z8CT-G$:7FV%
M7]'P6NTV_$B65L/OB#4UG;UWIZ:-$:F-A\Q?9]XV.=J),'_%.V^09$=L(Z^T
M=&=DB\[<*F4[$;SSG3=(L2.VD5=:N3.R15YIU4X$[WKG#=+LB&WDE=;NC&R1
MMW!W.Q&\^YVW(DZ'4$O**SJ$5KL=8B1VAR"R,<3-_L+-1[03H<XQ&25$TEV4
MW1Q+USK;B6"=DU%!I-Q%!:RKG0C6-1DU1-I=E&U]Y=:ZVXE@W=M&3A+UX8"3
M16M->_E^?_?[S:,:=^H^;&*>/5.WM>9F5[NXV1V,/Q[;Z66T`1I.F`:OB%$,
M)'-'PB@%4AM@:ZKP;A8R4:%Q<B"Q+QB50*Z]=TM?B0KV-9#8-XQ:(&F)CE$/
M-'BYB=3WRO:YQ43"U'G6+F/CK;7:QJ.>-Z<C6JBMJ-5^_E81*K7GL53>7+,1
M%>PC1C&C1%#`/A45[#-&.:-"4,"^%!7L*T8UHT90P+X5%>P[1KV#W%3KN_!7
MI'J\:7=2/:*%VF5)$I=>$M?ZO%"/:M4O1$4+M*AP-1&CF%$B*&"?B@KV&:.<
M42$H8%^*"O85HYI1(RA@WXH*]AVCWD%NJO7=O)WJMTW/YDS`'NPC6JCMGN1V
MZ>VKUOK@5_4`?0XN*NX!4ZJEOTK#ZVHX#+V^//=6K1@"M5;M+RR!*EBE=%+E
M5RDS*GU0)24NO0U8#J_KW519``4K44ZJ_$I4LRI1PTLJT0`%*]%.JOQ*=%#M
M2TX/P;[DN+U6GV;8O?;`6F0./^SN.:(S63/7ISMD)8O[HE$M=LF*$"@H!A+[
M1%#`/H5*O#)&.9#8%X("]B548E\QJH'$OA$4L&^A$ON.40\TV+MY55W-R>O;
M9B/MXFT61^2M1]YF?*T/*_5LI*8;&:[<`XR]M$YD`L_TAO7/3U-3CXE1"]Y^
MYV16^:E1J5434WZ&\E7?%'N>9W:50&`QJ\222ZQFE5@C4/I#,ZO$%H%RC1U*
MW-?&/6+VM;';T_3YSRMFD/&XR-GBC,B907;(2@/W'Z.21HF4K^YX9X)B(&F!
M1%#`/H5*O#)&.9#8%X("]B548E\QJH'$OA$4L&^A$ON.40\TV+MYU<=+K\BK
M.8VR5X81G:G!8HTE[RYOK9\CZXRIQ(F*4SVJU/8&(RXR@1:*&26S[%,.S!CE
MC(I9]B4'5HQJ1LTL^Y8#.T:]@]Q4ZX,C.]5ZL5A<Z-<XCEYQLC`>/ZD>A13=
MZ(?R.K<J>9+;I7<COC:J0XN%L9>!$,%^G,C.%^>7WAE9;!1ZURX5\#M7,JL"
M*;RD`ADJL!Q6JX5W83DB@J47LTHOX26E5U*Z=7'^6E4C4.:!9E:)+0*EQ`XE
MHL$OWGL[\!Y!^R[9[7?ZK,ON=P<VG^/1F-/!1N0L'3MDM8J?\LVI44FK1(QB
M(&F"1%#`/H5*[#-&.9#8%X("]B548E\QJH'$OA$4L&^A$ON.40\TV#MY7?Q'
M3BH'%W?S:9"WHOB;3ZC"*XI16<M'!#3>6DW-)U"HWA.83V95((67+&D9`M]/
MSR>(")9>P"1X^26\I/0*@<%[[!J!UNTM`H,EM@B4$CL@-#C/)U#LNV2WW[WN
M8'7!!ZL&V?.)H$#*-U#)D(D8Q4`R(A-!`?L4*K'/&.5`8E\("MB74(E]Q:@&
M$OM&4,"^A4KL.T8]T,1\HE839YUXT_YDH5V\^61$9VIK(<-YZ6TBUB;PP/X$
M]LX1K']Z$QF5N;^]6)R=>?OA&#[[5M#AT4LRJTXIO()URE"G/;L8F`0K5,RJ
M4`FO8(4JJ9"=%F^K4<-+>E4SJQ(M`H.5Z%")<:^C,G7A';GV\-G7,.[<I$]>
M[;V.?R#SK\=?JG-./KU3:Q0>!NE.Z'?B$3ESU@Y9#4A[(.-U)C-YQ"@&DE&?
M"`K8IU")?<8H!Q+[0E#`OH1*["M&-9#8-X("]BU48M\QZH$FYBQ]NFGG.[RW
MU8_R_+R.R'W(M_2.XM<F\,#MLU$YFQUC+\MQS*IDEGW*@1FCG%$QR[[DP(I1
MS:B99=]R8,>H=Y`[M/5IX"M2;0X/K?MD?:.MLN\=JOH/^:!2@UM6*Q[5QEYZ
M?&0"K7/.F%$RRS[EP(Q1SJB895]R8,6H9M3,LF\YL&/4.\A-M=KB.JD>=B+G
M[U2;'QC?.M#;?(S(>Z[GG2&L=9]0@8?&M_%2]9"NP9L/HQJWVXOK:V^G$YO"
M%OMVVV;O,:=**;R"5<IP><%[CAQ>,AD7"%1UD2OV!T.)P&`E*G@%*U'#2RK1
M(#!8B1:!P4IT4.U+3@_!ON2X'56?E]ISDK_=F/6RD.Z;?J\=D7>DYVV-UB90
M+X_[L[.!O3U5&?MQUW5Z?G7FO=42(VC?KLOTT=$G7($47E*!S*`SM3I*S?U#
MM1R!LO<L#`J76")02JQFE5@C4$IL9I78(E!*[%#BWD;N$;2OD=V^ID]F[;YV
M8"HT![GV^C<B9PN[0U8>_/&]61B5M$K$*`:2)D@$!>Q3J,0^8Y0#B7TA*&!?
M0B7V%:,:2.P;00'[%BJQ[QCU0(.]FU<UTSAY?=L<HEV\E6]$AX[QC"HXN6[T
M6J7LU9*-IPX1T#B3GEY=^?^:+X9"Q<H@]SM78E3AI3>%EU0@0V!P/<D1*.M)
M@<#@)9<(E!(K!`9+K!$H)38(#);8(E!*[(#V-G(/Q;Y&=OJ:?K''Z6OA.620
MNYW*('L.$11(\P8J&281HQA(1F$B*&"?0B7V&:,<2.P+00'[$BJQKQC50&+?
M"`K8MU")?<>H!^(Y1*7C57G5<B^O(]*['QFK2^_4;#V4<_"%$Z.R;H0B1C&C
M9)9]RH$9HYQ1,<N^Y,"*4<VHF67?<F#'J'>0.X359L$9PL.]T6N?(JLW-Z@'
MC$CO2:P>X-\HF<#P;+TQ*GNY`!IGLO/ETG^.&T.Q;R8;MYRS*I#"2Z;2#(%[
MGOH@(EAZ`1-GF/A+6@DO*;U"8'CI0*"U="`P6&*+0"FQ`]HU^+GW`FH/Q;Y+
M=ON=/NR<O_U41^_4P4:DNC;V$&NCTKU=^IS?G!NH9':,&,5`8I\("MBG4(E]
MQB@'$OM"4,"^A$KL*T8UD-@W@@+V+51BWS'J@09[-Z_Z@-+.ZYNVG_I&SE]1
MS,FGTW&7_E-D$QB^G]O`7EHG,DA=F'Z%<7(^,77:=W=EYA-3S>`]=,H5R%"!
M/<]S$!$LO3"J\.67\)++KZ1TJW/X-]`U`J5S-+-*;!$H)78H<=?@/)\<:'"W
MWZES&J??'=B*:KFW91F1,Y_LD-4J/)\8E;1*I&^2E+V:$3$WQ4#2!(F@@'T*
ME7AEC'(@L2\$!>Q+J,2^8E0#B7TC*&#?0B7V':,>:+!W\ZK&NY/7M^U/M(N7
M[A$MW174.UM=ZXV)3J3Z([2BC"I]`BTJ.L@U7NK674\QEV>+"V\%C:'8MX*:
M*69.G5)X!>N4&96Z%1B^H.-MSW*8!"M4P"382"6\@A6JX.6FQ7^*#"][8S.G
M55H$!BO10;7+U)7W`*^'8E_#N'U8'VN&UL1Y3Y'UZ:W?B4?DS%D[9/5%GK.,
M2AHP,O;6@^482$9](BA@GT(E]AFC'$CL"T$!^Q(JL:\8U4!BWP@*V+=0B7W'
MJ`>:F+/T^2;G^]5?@M%ON(P)E]HNSKRN>`.5W:7I1MLXR7Y^(V%8HB)&,:.$
M4<HH8Y0S*AB5C"I&-:.&4<NH8]0[R!VX:GA3(A?#@\-7?M1'C2H:NP8Y4\BY
M-P.O$2A]<<,H8A0S2ABEC#)&.:."4<FH8E0S:ABUC#I&O8.<S.EEG3)W>C[C
M4S)#I+M5,,C^F`RC#:.(4<PH890RRACEC`I&):.*4<VH8=0RZACU#G+3\KJ#
M1?5Q`W_4`,FDOF:T810QBADEC%)&&:.<4<&H9%0QJADUC%I&':/>06XN]`&=
MO4J%[YB6XWF>_1Z_0:H(+"%K0;)DG=+N`RKG9O;<VWM'HH)]S"AAE#+*&.6,
M"D8EHXI1S:AAU#+J&/5`O*]8^F=F;SI;&5R\"6X\2G,226AC`O4?<I?C_ROS
M2%22->,EG]Y(6)4RRACEC`I&):.*4<VH8=0RZACU0!-9T\<8]CA[6];,88CU
M_'VY.VI"2Z\%62GBX3<&:K$DTC]*BXR7^@/VL=@#)8(L+[_$5+PLU;GWDD@F
M*MCG8@]4"+*\_!)+\;)4%][+>96H8%^+/5`CR/+R2VS%RU+YKQ]WHH)]+_8*
MN5.TVM,[7>?`%*WEWL@>D5Z1)=7^N<-:[6QTH'M^X5_@1E2H>L0H9I0(LBKA
MVZ>B@GW&*&=4"`K8EZ*"?<6H9M0("MBWHH)]QZAWD)MJ?7QASQ('4CV>=CBK
M\8B\1ZY>CU\O36#X$8FH<#41HYA1(BC06*FH8)\QRAD5@@+VI:A@7S&J&36"
M`O:MJ&#?,>H=Y*9:G[W8J7[;@C">X#@]8$3>(U?_+;^E4:DQ+U."/QHWDRHZ
MTH1J/"B;^/`#!,Y-KE]8`E6P2NFDRJ]2!M6^*N40!*M40!6L4CFI\JM4&95^
MWT):G!ZNP$ON]!N@8"7:295?B6Y6)7IX#95P>ZU_J'5@@MJ=76&0W"Q'9!]6
M"K):QN\>&ZCD&4+$*`:2NY%$4,`^A4KL,T8YD-@7@@+V)51B7S&J@<2^$12P
M;Z$2^XY1#S2Q/=7'4/9L=""O6N[M,4;D+3S^D]FE43EW#YQJ8R_-$)E`\V1V
M:HXQ,<[=I.^<S"H_-2KK7:/L4/DY8H+E%[/*+^$EUU^A?'>W[C\10:!T@V96
MB2T"I<1N5HD]`H<2G:GBW#]\"W>I0>YV*8/T8T%KQO1/M:%26QI1^8G?&)7]
M\A"CF%$RRS[EP(Q1SJB895]R8,6H9M3,LF\YL&/4.\A-M7^@]Z;'L^=\SF>0
M?L@BN:6/D!A5^'V'#>REBT>P-V\?+.C?L,<("H[J9%8%4GA)!3)4(#BJ<P3*
MJ"YFE5@B4$JL4.+>2ZX1%+SD9E8%6GA)!3I4('C)/0(GIA55KU>L5.=:[DTK
M([)W($:ED-7/>`XQ@9*'"(&"8B"YYD10P#Z%2KPR1CF0V!>"`O8E5&)?,:J!
MQ+X1%+!OH1+[CE$/--B[<X@^'K1W(&^Z'SH?#QGM^R&#O%7$WYA`=6`5&>V=
M5<2@\4[C?&H.,0JU09%)S.]<R:P*I$9E52!#8/"^(D>@W%<4"`Q><HE`>6A<
M`>V]Y!J*X"4WLRK0PDLJT"$P>,D]`ODNYEQ-/DY?.[`UT7)O#AF1,X?L4"#-
MFZ%HYYVPB%$,)*,P$12P3Z&249@QRH'$OA`4L"^A$ON*40TD]HV@@'T+E=AW
MC'J@B3E$[12=O+YM'Z)=O'2/2+\C($.8/C9R/JH.[4.,O;/6^#?JD?$R]SL3
MG["(C>+`]]%FU2F%5[!.F5LGO@?+8:/626DF?Z8K9E6IA%>P2I5;I8G9MX9/
ML$[-K#JU\`K6J4.=U'P@K>`?]/3P&OJZNQ+JP]G02CCO1;%S;>-UXQ$YL]8.
M697U4[8Q7NI-"YSC1(QB(!GWB:"`?0J5V&>,<B"Q+P0%[$NHQ+YB5`.)?2,H
M8-]")?8=HQYH8M;21[%VO@^L1N/)K;/%,4BJOCXW2"JU810QBADEC%)&&:.<
M4<&H9%0QJADUC%I&':/>0>[8>]WYYCF?;QID/T47%.A&&ZB<B>K".^&)1(61
M&#-*&*6,,D8YHX)1R:AB5#-J&+6,.D8]T,3HT>=^]NAYVWV#.3VT'JR?C\A)
M)*$-5&J/+Y,]O0XA*LF:\;)>AV!5RBACE#,J&)6,*D8UHX91RZACU`-QUB[\
MP\$W96UP<9<X@]0>#"V]%F2EB)8XH]*/X261]#J$J&`?BSU0(LCR\DM,Q<M2
MT>L0HH)]+O9`A2#+RR^Q%"]+1:]#B`KVM=@#-8(L+[_$5KPL%;T.(2K8]V*O
MD#-%7ZC=ES/@P\OE(/?ZB'90_Z=)SNTCO0YA`@^\#B$J5#UB%#-*!%DMX[=?
M*BK89XQR1H6@@'TI*MA7C&I&C:"`?2LJV'>,>@>YJ=8';O;<?B#56NZE>D3>
M4RG_=8@+$^CLZ_U<;$2%JXD8Q8P208'&2D4%^XQ1SJ@0%+`O107[BE'-J!$4
ML&]%!?N.4>\@-]7ZD,Q.]7#K/N/K7!?CZ9J]'3;(>P/"?Z<>*G4[+A,^)]T<
MWCDJNEN'UW@B-O%U+@C4HK^_L`0JIS"_2NFDRJ]29E3AUPUR>,EM0@$4K$0Y
MJ?(K44&UKUUJ"(+MTD`5K%([J?*KU!E5N%UZ>`WMXG94?<SG=U3S;PKF?W#_
M8CPL='KMB+QG7?Y[.P@\,%49>[DAC$R@.5":^CH7K-5D&.JC.^N`*H675"`[
M6($<0<$*%%`%6Z`4%>:C"A50%R#7YY_+U`B4,\@&*%AB*RJ4V,TJL4<@GP1=
MJ`[O]+4#ZY^6>^O?B.P3G\%4G4`'KV8#E31#Q"@&DC0G@JQ6YCG,U$OL,P0*
MRH'$OA`4L"^A$J^*40TD]HV@@'T+E=AWC'J@P=Z=0_P3O@-YY9.\"W-LIYK1
MZLO^0RVHE%A4?BXV1F4]4XJ`QGE[ZC-<4`0G[F16!5)XR1.>#,A4@+\EF$,1
MK$`QJP(EO*0"%=#^E6O,@/Y2UOZV;6:5WZ(P*;]#H'./XD]6/0(GEJG7'2I>
M\*&B0=[6V7_[!BKG_(.[&!U01BA1!E_,*)EEGW)@QBAG5,RR+SFP8E0S:F;9
MMQS8,>H=Y,XF_IGEFYYZ7?!1ID&']M%CH/ZW\/L'P@9>TL4CH'&(J8^M^-_^
MB*$(CK'$J,(52.$E%<@0&!QC.0+M+?*<2RX1*"560'LON88B>,F-484ON867
M5*!#8/"2>P1.3"NJ7J_9D6BYMR,9D;,CV:%@#S(J672C"T(QD$PKB:"`?0J5
MV&>,<B"Q+P0%[$NHQ+YB5`.)?2,H8-]")?8=HQYHL'?FD$O5(9R\OND\=G!Q
MTVV0MXKX&Q6HPJL([*5U(H/D@TTTAR`H>%.1S*I`"B^I0(8*!&\J<@1*>HI9
M)98(E!(KE+CWDTDU@H*7W,RJ0`LOJ4"'"@0ON4?@<,EN7U-W'DY?"^]^+[7<
MZU0CLN<0HSIP5P.5Y"%B%`/)-2>"`J,PA4KL,T8YD-@7@@+V)51B7S&J@<2^
M$12P;Z$2^XY1#S38NWE5_<W)ZYOV(9?:Q4OWB-SS>GK[Q@2&U\2-4;FG^OXA
M4035N$ZKCS3YG_Z)H5`KT/Y=3S*K3BF\W)LY[[-0&51CG28.<'(H@G4J9M6I
MA%>P3A549C]SN5QZ_YJWAB)8IV96G5IX!>O4P2N\Q8$7;W$N]8EOZ(!OWNLW
M@XW7C\>S9&?:VJ%`-]H8+_OU&T8QD`S\1%#`/H5*=K@9HQQ([`M!`?L2*K&O
M&-5`8M\("MBW4(E]QZ@'LJ:MD^?OV^W+YO;E]M.'A^W3M^UZ^^/'\]'=XQ\_
MU9!6;RI;^.AI^_7C\<WYJA\VTSNYX1>K?GASP..?SZY6GU7)ZD#0^T5]KVFE
M/SDT]<NU^F6X&#]F^7ZEOZK",9N+]ZM(/3'E7]1#YE4V^8MZ&+RJ)G]1#VU7
MW>0OGT]7GX?5P:_9Z:H?&M;GBU4_J3]3ESA1V\_+U6=U_LV7<;-45S[!-\OE
M2G^B@"/4QP96^E,"_(OZ*,!*_Y-__D7]X_V5_J?Y_(MZG4IE?K)FYU>K&_6>
MPU3,U6H]^8MZU6>E7W+A&/4ZB?IERDV]`:-J,/F+^N%T*O<WR\7J1GV1@HM1
M'VA9K2=_V:A?].=(.$9]^$/],N6FOE6BLC/U2WFUJJ8NL[Q>55.74IZJ/CEY
M+?75JI[\H;E:-9,_M*J-I\IN50M/E=VJLKM)I^1JE4S^D%ZMLJDBTNM5-E5$
MJHK()IWRJU4^^4-QM2HF?[A1W6[RA[7J=9,_;*Y6T51M-]>K:*JV&U7;:-(I
MOEK%XP\GNP'__.G#K]MOV^KVZ=O]S^>C']NO:@Y]/WQIZ^G^F]X)CG]Y,?]7
M>;\]OKP\/JCU\?CH^_;VR_9)"]3"_O7Q\05_49WPY*_'I]^'>?K3_PL```#_
M_P,`4$L#!!0`!@`(````(0`>#[MX,`@``+0E```9````>&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;*Q:VV[;1A!]+]!_$/0>221UL03;@41NV@`M4!2]/-,2
M;1.11(&DX^3O>X;<V^QN94O(2Q2?G1F>,S/<68JZ_?CML!]\+>JFK(YWPV@T
M&0Z*X[;:E<>GN^'??WWZ<#,<-&U^W.7[ZEC<#;\7S?#C_<\_W;Y6]9?FN2C:
M`2(<F[OA<]N>5N-QLWTN#GDSJD[%$2N/57W(6_Q9/XV;4UWDN\[IL!_'D\E\
M?,C+X["/L*K?$Z-Z?"RW159M7P[%L>V#U,4^;\&_>2Y/C8IVV+XGW"&OO[R<
M/FRKPPDA'LI]V7[O@@X'A^WJ\].QJO.'/71_BZ;Y5L7N_O#"'\IM73758SM"
MN'%/U->\'"_'B'1_NRNA@-(^J(O'N^$Z6HGI9#B^O^T2]$]9O#;6_P?-<_7Z
M2UWN?BN/!;*-.E$%'JKJ"YE^WA$$Y['G_:FKP!_U8%<\YB_[]L_J]=>B?'IN
M4>X9%)&PU>Y[5C1;9!1A1O&,(FVK/0C@W\&AI-9`1O)OW>=KN6N?[X;)?#1;
M3)((YH.'HFD_E11R.-B^-&UU^+<WBF2H/D@L@^!3!HGFHYO9;#J_62#*&<]$
M>N)3>L:C1319)F_X3:4?/B^\(OAT@O$I/=\O>-PGKZM%EK?Y_6U=O0[0X$A/
M<\KI=HE6"*R*T`O79?F_JJ`<%&1-4>Z&B^$`"6_02E_OXV1Z._Z*\F^ES<:W
MB;A%JBRHUA0V<P%A`6,(T"I0OA^@@J*0"G7]C0(L60YE9:%<,A<0%L`HHV]^
M`&6*@L:W$A]-W,3W-G1KZ>K,'!G:1.OP$&$C3`DZ^0<HH2AHPKG%,IK,.<^-
M-#HG19MH*1XB;(1)06!;2G@K4DU/QAUC=:6-1#"A=*8]#:DV4FZ9AP@;8021
M'IM@=[LN;D:PO_".I4"<O$26C/R"%R#51IJ\AP@;8>2Q/WCD+V=.4;Q&N>$\
M-]((T74EW)[7)EJ*AP@;85+H$&)MF^<;A8QYKB7"&\71D&HC3=!#A(TP@BBC
M3;!KE'AQ1:-0($Y>(KQ1EKP`J3;2Y#U$V`@C'^$PX;&_O%.Z,&ZK1!/.=*.L
MSO6*L=%R?$@PB`NBP?7N?HGZ,8>]4%UMHR#6,:Z4U%@IQ\R'!(,X31I6%DWJ
MFILE';\NW5ZB?NPQ"1)B?1-Y9P!M921XD%#AEY0A+H'&E",ANFJ'C.3`LZO0
M0S':4V\K413SADJE(ZR,!.VH(,&LN`0:3XZ$>';%K1O).6<KZ"%'0>(JT%:*
M;B9C6:($@[@"-(RMX/SV2"<39XN14-P?UNDLF/I0YD."09P3C24GJ_-D1*?U
M-^C)>69G44(V/0FAT%9K.$>QC(XW)'6J6T,HB#N:8<5%T$"R1+S!7(XOFWD/
ML<1Z4!9YD&`0YT0SR.+4C9IH^I[,RNEE\Y.0G5D)\01YF956=F:#CN9(R570
M,+)4O)%9.;ILYCW$,NM!6>1!@D&,$]VE-B?*[`RSX3RWSHM/;`596570^:PJ
M*RNK"N*.YIS(%5PT]Y`[=R.04!SK&R;UH<R'!(,X)QHG5J6[?IT`O/`$#4X>
M6SVI[$W`/=<IQVYX]0^Z/B08Q`4@]:X`N9-=*H$B.:TB(?2IM8^YI[M86^D!
MX4."05Q"8,0M\.W-Y47P1UPL(:8@=DY]J;$R"K2C@@2SX@J<$:?NS4LKX,\^
M.FU143A_]YQDK!39S(<$@SA_FD3N77!%_N5`PX=IE]@Y$6UB:87XVLI,N.X6
M2(V-$:3=%"28%1=$,\L2],8FV4\X^WP:2PA30Y.,7"FIL5*<,A\2#.(T:2A9
M-*EOKCMBQW*\63-(0;QUW-.=L3(29"RS)0EFQ24@O"N!SEV7MCZ%Z38?.]]F
MD'1ML8FEU=G6T39&D`<)$PE63%#BS-GSK=-9\TU30;QU'"FIL=(T?4@PB--T
MAFDWN&;8B2],?.*/604A:U;ONX/+6!D!,I;5.,R*"PA-WLL;)]&#UR([<S;X
MC;(ZUSC&Q@B2P?LW#O3D(9@5%T1CT+J9WV@<.32M&S:1$&L<5TIJK`Q-[:@@
MP:PXS<"TO>[`D/CC5D&L=6;NN#)6BF_F0X)!7`+*:&>:>O^J9^*$`CEWKX2X
M`F>&I<K1='KF0X)!7`$-,ZM7KE<@IZ+=1A+B"MQ]/]%6I@8>))@55^!,V.L5
M^,,WD1!7X#SDI<;**-"."A+,BBN@,>?4()K/ND?52S=1.3'M*DB(:W#/.8FV
M4H0S'Q(,XAH0WM.`#KZ4/X5QIF^<.&0WB;1"?#T7')O4V!A!VDU!@EDQ07C'
M[`FBI]P+!75A^(VM(+#1[*.Y.Y:-E2*;^1"]"9>G<ECU_/LWV_W;U$-1/Q5I
ML=\W@VWU0F^MIS.\!]5P_TI]DRQ6U)X(X:W<8.4FL+).EJLUKA[R6<*GVX_<
M:-.)>G?OK*QC1,.$#D3#"IV1`BL)HN%8$EK!;P2"T=9)C.N$]&`PPZ=[GG>X
M;9($*TGP.E.L=%]">#XSK'3#VEN98Z6[/=V5&-'P9!?0$R,:GIG\E74\7ZUQ
M)/97\'`#G_!U4&T\"81\4.UPM`@,<)@.^$2(AF_A0BNH'!X7`RLQZH-O0D(K
MJ`*^8@BMH`IX<O=7UHO5.G@5$`OR@LA@QD`W%&<=39#CL'9T(-ZN^)SP8@0K
M0841%.(]0<@'"O'U>V@%G=%_.>OT#'X,LP['@D,H$J4WA%.+!_#U=+4.]A`(
M!3L5;1+,%)JQBS/6`O";F5/^5/R>UT_EL1GLBT?L3I-NYM7]KV[Z/]KJA.T3
MOYRI6OQ:IOOO,WX=5>`(/*%O9AZKJE5_('5C_7NK^_\```#__P,`4$L#!!0`
M!@`(````(0`.*&RW?`(``#,&```9````>&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;)1476^;,!1]G[3_8/F]&,A7BT*J=%6W2ILT3?MX=LP%K&",;*=I__VN
M<4+3)M+8"V!S?,X]]\/+VV?5D"<P5NHVITD44P*MT(5LJYS^^OEP=4V)=;PM
M>*-;R.D+6'J[^OAAN==F:VL`1Y"AM3FMG>LRQJRH07$;Z0Y:_%-JH[C#I:F8
M[0SPHC^D&I;&\9PI+EL:&#(SAD.7I11PK\5.0>L"B8&&.XS?UK*S1S8EQM`I
M;K:[[DIHU2'%1C;2O?2DE"B1/5:M-GS3H._G9,K%D;M?G-$K*8RVNG01TK$0
MZ+GG&W;#D&FU+"0Z\&DG!LJ<KI/L;D[9:MGGY[>$O3WY)K;6^\]&%E]E"YAL
M+),OP$;KK8<^%GX+#[.STP]]`;X;4D#)=XW[H?=?0%:UPVK/T)#WE14O]V`%
M)A1IHG3FF81N,`!\$B5]9V!"^'/_WLO"U3F=Q-$TG2VN$\23#5CW(#TG)6)G
MG59_`BHY<`66],""[R/+/)HMXLD($A8BZ@W><\=72Z/W!)L&)6W'?0LF&1)?
M=H16/';MP3E=4(*Q6JS"TRI-DB5[PM2)`^8N8/`Y8%X1#$4'950;K^S!7MGG
MUH=R%S9.9=(AD#<RD_^1\6`LSDGP:?+*&Y0#9GJ"F5U61LAX@QZ,-9B?T)[G
M-H!&2&-3C9?VX%YZ2.YA!^=D*&*:3"Z[Q(A/I?QHI->)GX-_-),_^%;VL/.F
MJ,GTG6P8TM##"DP%GZ!I+!%ZYP<PQ:X<=H>[89WZQGF_/\W6_9W!AA\XLQVO
MX!LWE6PM::!$RCA:H!<3ICXLG.XP<AQ<[7!8^\\:+V?`QHPC!)=:N^,"A=EP
MW:_^`@``__\#`%!+`P04``8`"````"$`0`8S,Q\$``!I#@``&0```'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6RL5]N.HT80?8^4?T"\K[GYBFROQH9)5DJD
M*,KEF8&VC09H1./QS-_G-$WW=@.9\4KS8LQQU>'4A>KR]NMK65@OI&$YK7:V
M-W-MBU0IS?+JO+/__NOQR]JV6)M465+0BNSL-\+LK_N??]K>://,+H2T%A@J
MMK,O;5N'CL/2"RD3-J,UJ?#+B39ETN*V.3NL;DB2=4YEX?BNNW3*)*]LP1`V
M]W#0TRE/2433:TFJ5I`TI$A:Z&>7O&:2K4SOH2N3YOE:?TEI68/B*2_R]JTC
MM:TR#;^=*]HD3P7B?O7F22JYNYL1?9FG#67TU,Y`YPBAXY@WSL8!TWZ;Y8B`
MI]UJR&EG/WAA[`6VL]]V"?HG)S>F?;?8A=Y^:?+LM[PBR#;JQ"OP1.DS-_V6
M<0C.SLC[L:O`'XV5D5-R+=H_Z>U7DI\O+<J]0$0\L#![BPA+D5'0S/P%9TII
M`0'XM,J<MP8RDKQVUUN>M9>=[:]FBY4;>#"WG@AK'W-.:5OIE;6T_%<8>3V5
M(/%[$EQ[$F\Y6R\6\^5Z!99W/(/>$U?Y^-G*<S?!!W[SW@_7'WPB]'0!X]I[
M!LM[`W9$\KI:1$F;[+<-O5EH<*2'U0E_7;P0Q+(((G!5EO^K"LK!21XXR\Y>
MV182SM!*+WO?7VR=%Y0_[6T.8QO/M#A*"UYK3AL-@5@#'`2@HD#Y/B$*SL*C
MD,\_2$`+:R!96DB7:`C$&F!(1M]\@F3.LK/QJ25^:6H\"!O^:BFC06V.RD3%
M,4)B'3$B02=_0B2<!4VXU%2.>Z@W>B\49:)"&2&QCABA@%@/97H4R:;GQIUB
M^:1#CYCOP<HLQU$92;=HA,0Z8@A$>NX7R(U-@3UB"EP/!"HC)7"$Q#IB"`2U
M+K";)_-N@O?#].Z9PIE,]3VR,5ID,U"OC)3Z$1+KB*&>[Q;#:<A/%7D2W"V>
M$YGB>\00'[@#\<I(B1\AL8X8XD&MBW^_>;FQ*5`@OC@?^?@]CI!HA,0Z8JCQ
ML!#H<L3)@B'ROJ[.S10F(4V9A$"G9IKGS<UL1M)JKB9Z+"'=T0^^'T1F"/RX
MT=KA`^7B<,($D\4[>`+2<SJ&HC$4&Y"IB9\GFJ8NK2[`#\2)8\@0UT-Z6GM(
MS\Y$6GLK/:T3CG[@JWJ8(8!^,H0?73HXSZ!5>@A=J?K"#P*EHULKCMAJ.\>-
MJE0TAOCN^]U*!"!V6;$_E:0YDR,I"F:E],KW5#CLMPH62_1A$^(504,,<8]O
MUUWJ1[\$<N\>_(*%_,&?Y(+#%.Z'V#XFGHT'='O]D'\>/B"&"8=YB"-S`E^$
M.*DF\&6(`V("7X48O1/X.L14`^XH15CTZ^1,?D^:<UXQJR`G)-B=\=VZ$7\5
MQ$U+:R0>ZSYML>)W7R_X2T<POEP^MD^4MO*&/T#]2=S_!P``__\#`%!+`P04
M``8`"````"$`\2>S37D"```R!@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6R45%MOVR`4?I^T_X!XKXF=2ULK3I6NRE9IE:9IEV>"CVU48RP@MW^_
M@W'<M*G4[`7#\<?WG2OSN[VJR1:,E;K):!R-*(%&Z%PV949__UI=W5!B'6]R
M7NL&,GH`2^\6GS_-=]H\VPK`$61H;$8KY]J4,2LJ4-Q&NH4&_Q3:*.[P:$IF
M6P,\[RZIFB6CT8PI+AL:&%)S"8<N"BG@08N-@L8%$@,U=^B_K61KCVQ*7$*G
MN'G>M%="JQ8IUK*6[M"14J)$^E@VVO!UC7'OXPD71^[N<$:OI##:ZL)%2,>"
MH^<QW[);ADR+>2XQ`I]V8J#(Z#).[V>4+>9=?OY(V-F3/;&5WGTU,O\N&\!D
M8YE\`=9:/WOH8^Y->)F=W5YU!?AA2`X%W]3NI]Y]`UE6#JL]Q8!\7&E^>``K
M,*%($R53SR1TC0[@2I3TG8$)X?ONNY.YJW!W&R4WTW@Z0SQ9@W4KZ3DI$1OK
MM/K;HWJNP)+T+/CM6<:S:'H]&L<?D[#@41?@`W=\,3=Z1[!I4-*VW+=@G"+Q
M^Q%A*!Z[].",7E."OEJLPG:1)/&<;3%UHL?<!PRN`^8%P5!T4$:URY4]V"O[
MW'I7[H/A5"89''DE,_X?&0_.**Z#\TGRPAN4`V9R@IF^KXR0RP/T8*S![(3V
M/+<!=($T-M7ETA[<20_)[2TX)R=Y&+\?)7I\*M6-Q@S[\J->\O=>J_:65S5-
M)F]4PXR&%E9@2O@"=6V)T!L_?PDVY6`=GH9EXOOFK7V2+KLG@PT_<&1;7L(3
M-Z5L+*FA0,I1=(VQF##TX>!TBY[CW&J'L]IM*WR;`?MRY`,OM';'`PJSX;5?
M_`,``/__`P!02P,$%``&``@````A`%C)*T>D`@``(`@``!``"`%D;V-0<F]P
M<R]A<'`N>&UL(*($`2B@``$`````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````G%7?3]LP$'Z?M/\ARCND%+1-R`V"4D0EV"JEL$?+)!?BD=C!YU1E?_W.
MR=JFS$1:W_SCN[OO/I_OV,6Z*H,5&)1:3<*3XU$8@$IU)M7S)'Q8WAQ]"P.T
M0F6BU`HFX1M@>!%__L061M=@K`0,R(7"25A86Y]'$:8%5`*/Z5K13:Y-)2QM
MS7.D\URF<*W3I@)EH_%H]"6"M0650794;QV&G<?SE3W4::93QP\?EV\U$8[9
M95V7,A66LHSO96HTZMP&LW4*)8OZEXS8)9`V1MJW>,2B_I8EJ2AA2H[C7)0(
M+-H=L%L03K2%D`9CMK+G*TBM-@'*WR3;.`R>!(*C,PE7PDBA+-%RL&[3KLL:
MK8E_:O."!8!%%A&@.VR7?6Q_+<_B\=<60:M]I//0,:&+?8Y+:4O`'_E"&.NC
M_+7/N671,>X(;5Z14VWPF;*D%Y^K[K6E[C/?YC#5]-`*(>.T0EW*3%C:7(E2
MJ)34W`*=+EV489.3_[%)+$6K/@RSX_,7J"QRG1/5ZH`H?F97`F7K=&$`Z0>T
M]=@*F#25/\Q<K0"M^R[8`F^HOOBC*!O@]R"\S%R4M`5?R[)Q"G\'R^\T(E^`
M\9K<BU_:\&F#5E?4"[@K"46+0M84UFLRIRY1`5^*->S5Z?;I$JO3%^+2/G=%
MS0#;=+W.6FRAR\P%G[TV5$Q^7/.$\-J0&GRV<IIX4<,R^Y]F6&>_S;!J?IL/
M5"$=G^@S>M,9IC8^P.;T`)LSK\UPK?DE&);-G\^PC3^?CZ3NSKWI>.J07V:9
M='-#T*38%O>N0R7O2[)GP.=]D[U6_*[YWDGU@@_U4E]3D]I,E_U#EA3"0$9]
M=W._.V"W-%A,Z9Q,"Z&>(=M@_KUPL_"Q&_CQR=GQZ'1$8ZYWQJ+=:(__````
M__\#`%!+`P04``8`"````"$`W3/X(C$!``!``@``$0`(`61O8U!R;W!S+V-O
M<F4N>&UL(*($`2B@``$`````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
MG)'12L,P%(;O!=^AY+Y-LTV1T&:@LBL'@A/%NYB<;<$F#3G1;F]O5KLZT2LO
MP__GRW=.JOG.-MD'!#2MJPDK2I*!4ZTV;E.3Q]4BOR(91NFT;%H'-=D#DKDX
M/ZN4YZH-<!]:#R$:P"R1''+E:[*-T7-*46W!2BQ2PZ5PW08K8SJ&#?52O<D-
MT$E97E(+46H9)3T`<S\2R8#4:D3Z]]#T`*TH-&#!1:2L8/2[&R%8_/-"GYPT
MK8E[GV8:=$_96GV%8WN'9BQV75=TTUXC^3/ZO+Q[Z$?-C3OL2@$1A_TT$N,R
MK7)M0%_OQ>XU-!GBMJ*_LTJKWHZK`#*"SM)[_,ONF#Q-;VY7"R(F)9OFC.7E
M;#5A_()Q-GNIZ+$UW!<CT`X"_R8>`:+W_OGGXA,``/__`P!02P$"+0`4``8`
M"````"$`EP_^XL0!``!R$@``$P``````````````````````6T-O;G1E;G1?
M5'EP97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C]0```$P"```+````````
M`````````/T#``!?<F5L<R\N<F5L<U!+`0(M`!0`!@`(````(0!3=PU[K0$`
M`#,1```:`````````````````",'``!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+`0(M`!0`!@`(````(0#[D@GT"@,``$<)```/````````````````
M`!`*``!X;"]W;W)K8F]O:RYX;6Q02P$"+0`4``8`"````"$`G1M8MXP$``!*
M$```&`````````````````!'#0``>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L!`BT`%``&``@````A`.)K*B)\!```RA$``!D`````````````````"1(`
M`'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"+0`4``8`"````"$`'3@A
M>T8>```$)`$`&0````````````````"\%@``>&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+`0(M`!0`!@`(````(0`&LIF8B0(``.D%```9````````````
M`````#DU``!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L!`BT`%``&``@`
M```A`."D?!40"```SS(``!D`````````````````^3<``'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"+0`4``8`"````"$`FEP"/XL%``!N&@``&0``
M``````````````!`0```>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+`0(M
M`!0`!@`(````(0!$I#OC=P,``#,,```9``````````````````)&``!X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L!`BT`%``&``@````A`'`Q(NW+`@``
MFP@``!D`````````````````L$D``'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"+0`4``8`"````"$`M%MWCF4"```3!@``&0````````````````"R
M3```>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+`0(M`!0`!@`(````(0#9
MPIXC004``/@4```8`````````````````$Y/``!X;"]W;W)K<VAE971S+W-H
M965T,BYX;6Q02P$"+0`4``8`"````"$`Y^SI=8D"``#;!@``&```````````
M``````#%5```>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!`BT`%``&``@`
M```A`*%ZE_M7/0``?KX``!0`````````````````A%<``'AL+W-H87)E9%-T
M<FEN9W,N>&UL4$L!`BT`%``&``@````A`/Z8&K(0"P``$&````T`````````
M````````#94``'AL+W-T>6QE<RYX;6Q02P$"+0`4``8`"````"$`^V*E;90&
M``"G&P``$P````````````````!(H```>&PO=&AE;64O=&AE;64Q+GAM;%!+
M`0(M`!0`!@`(````(0"JW%W6@`,``+,+```8``````````````````VG``!X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"+0`4``8`"````"$`AMS)M!,#
M``#W"@``&0````````````````##J@``>&PO=V]R:W-H965T<R]S:&5E=#$Y
M+GAM;%!+`0(M`!0`!@`(````(0#.;?)Z]@P``,)#```9````````````````
M``VN``!X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L!`BT`%``&``@````A
M`-LS<ZV/`@``L@8``!@`````````````````.KL``'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+`0(M`!0`!@`(````(0`W"J-*IQT``!:S```8````````
M`````````/^]``!X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"+0`4``8`
M"````"$`2]CU*/H%``#O&```&`````````````````#<VP``>&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L!`BT`%``&``@````A`)$/K]]#!0``KA0``!@`
M````````````````#.(``'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+`0(M
M`!0`!@`(````(0`L_.(-"0,``*P(```8`````````````````(7G``!X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"+0`4``8`"````"$`45!'[=,'``!^
M(P``&0````````````````#$Z@``>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM
M;%!+`0(M`!0`!@`(````(0"/I!^631,``"!S```9`````````````````,[R
M``!X;"]W;W)K<VAE971S+W-H965T,3`N>&UL4$L!`BT`%``&``@````A`(9G
M<EQY"```.R<``!D`````````````````4@8!`'AL+W=O<FMS:&5E=',O<VAE
M970Q,BYX;6Q02P$"+0`4``8`"````"$`.![.W$0;``"NG@``&0``````````
M```````"#P$`>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+`0(M`!0`!@`(
M````(0`>#[MX,`@``+0E```9`````````````````'TJ`0!X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L!`BT`%``&``@````A``XH;+=\`@``,P8``!D`
M````````````````Y#(!`'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M+0`4``8`"````"$`0`8S,Q\$``!I#@``&0````````````````"7-0$`>&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+`0(M`!0`!@`(````(0#Q)[-->0(`
M`#(&```9`````````````````.TY`0!X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L!`BT`%``&``@````A`%C)*T>D`@``(`@``!``````````````````
MG3P!`&1O8U!R;W!S+V%P<"YX;6Q02P$"+0`4``8`"````"$`W3/X(C$!``!`
M`@``$0````````````````!W0`$`9&]C4')O<',O8V]R92YX;6Q02P4&````
/`"0`)`"N"0``WT(!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EFZAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreements', window );">Collaboration agreements</a></td>
        <td class="nump">$ 4,825<span></span></td>
        <td class="nump">$ 4,190<span></span></td>
        <td class="nump">$ 15,065<span></span></td>
        <td class="nump">$ 9,665<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Research grants</a></td>
        <td class="nump">882<span></span></td>
        <td class="nump">717<span></span></td>
        <td class="nump">2,199<span></span></td>
        <td class="nump">3,058<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="nump">5,707<span></span></td>
        <td class="nump">4,907<span></span></td>
        <td class="nump">17,264<span></span></td>
        <td class="nump">12,723<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">8,703<span></span></td>
        <td class="nump">7,570<span></span></td>
        <td class="nump">26,201<span></span></td>
        <td class="nump">22,427<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">3,163<span></span></td>
        <td class="nump">3,139<span></span></td>
        <td class="nump">9,595<span></span></td>
        <td class="nump">9,125<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">11,866<span></span></td>
        <td class="nump">10,709<span></span></td>
        <td class="nump">35,796<span></span></td>
        <td class="nump">31,552<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(6,159)<span></span></td>
        <td class="num">(5,802)<span></span></td>
        <td class="num">(18,532)<span></span></td>
        <td class="num">(18,829)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest and other income, net</a></td>
        <td class="nump">14<span></span></td>
        <td class="nump">12<span></span></td>
        <td class="nump">52<span></span></td>
        <td class="nump">43<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (6,145)<span></span></td>
        <td class="num">$ (5,790)<span></span></td>
        <td class="num">$ (18,480)<span></span></td>
        <td class="num">$ (18,786)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
        <td class="num">$ (0.11)<span></span></td>
        <td class="num">$ (0.11)<span></span></td>
        <td class="num">$ (0.34)<span></span></td>
        <td class="num">$ (0.36)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing basic and diluted net loss per share</a></td>
        <td class="nump">54,786<span></span></td>
        <td class="nump">52,768<span></span></td>
        <td class="nump">54,013<span></span></td>
        <td class="nump">52,664<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in collaboration agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_CollaborationAgreements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueFromGrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Major Customers, Partnerships and Strategic Alliances</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>NOTE 4&#x2014;MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC
 ALLIANCES</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Collaboration Agreements</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Collaboration and License Agreement with Shire AG in Human
 Therapeutics and Diagnostics</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In January 2012, the Company entered into a collaboration and
 license agreement (the Agreement) with Shire AG (Shire), pursuant
 to which the Company and Shire collaborate to research, develop and
 commercialize human therapeutics and diagnostics for monogenic
 diseases based on Sangamo&#x2019;s novel zinc finger DNA-binding
 proteins (ZFP) technology. Under the Agreement, the Company and
 Shire may develop potential human therapeutic or diagnostic
 products for seven gene targets. The initial four gene targets
 selected were blood clotting Factors VII, VIII, IX and X, and
 products developed for such initial gene targets will be used for
 treating or diagnosing hemophilia. In June 2012, Shire selected a
 fifth gene target for the development of a ZFP therapeutic for
 Huntington&#x2019;s disease, an inherited neurodegenerative disease
 for which there are currently no therapies available to slow the
 disease progression. Shire has the right, subject to certain
 limitations, to designate two additional gene targets. Pursuant to
 the Agreement, the Company granted Shire an exclusive, world-wide,
 royalty-bearing license, with the right to grant sublicenses, to
 use Sangamo&#x2019;s ZFP technology for the purpose of developing
 and commercializing human therapeutic and diagnostic products for
 the gene targets. The initial research term of the Agreement is six
 years and is subject to extensions upon mutual agreement and under
 other specified circumstances.</p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Under the terms of the Agreement, the Company is responsible for
 all research activities through the submission of an Investigative
 New Drug Application (IND) or European Clinical Trial Application
 (CTA), while Shire is responsible for clinical development and
 commercialization of products generated from the research program
 from and after the acceptance of an IND or CTA for the product.
 Shire reimburses Sangamo for its internal and external research
 program-related costs.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company received an upfront license fee of $13.0 million. The
 Company will also be eligible to receive up to $213.5 million of
 contingent payments for each gene target if specified research,
 regulatory, clinical development, commercialization and sales
 milestone events occur, including payments for each gene target
 through the acceptance of an IND or CTA submission totaling $8.5
 million. The Company will also be eligible to receive royalty
 payments that are a tiered double-digit percentage of net sales of
 licensed product sold by Shire or its sublicensees developed under
 the collaboration, if any. To date, no products have been approved
 and therefore no royalty fees have been earned under the Agreement
 with Shire.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 All contingent payments under the Agreement, when earned, will be
 non-refundable and non-creditable. The Company has evaluated the
 contingent payments under the Agreement with Shire based on the
 authoritative guidance for research and development milestones and
 determined that certain of these payments meet the definition of a
 milestone and that all such milestones are evaluated to determine
 if they are considered substantive milestones. Milestones are
 considered substantive if they are related to events (i)&#xA0;that
 can be achieved based in whole or in part on either the
 Company&#x2019;s performance or on the occurrence of a specific
 outcome resulting from the Company&#x2019;s performance,
 (ii)&#xA0;for which there was substantive uncertainty at the date
 the agreement was entered into that the event would be achieved and
 (iii)&#xA0;that would result in additional payments being due to
 the Company. Accordingly, revenue for the achievement of milestones
 that are determined to be substantive will be recognized in its
 entirety in the period when the milestone is achieved and
 collectability is reasonably assured. Revenue for the achievement
 of milestones that are not substantive will be recognized over the
 remaining period of the Agreement.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company has identified the deliverables within the arrangement
 as a license to the technology and on-going research services
 activities. The Company has concluded that the license is not a
 separate unit of accounting as it does not have stand-alone value
 to Shire apart from the research services to be performed pursuant
 to the Agreement. As a result, the Company will recognize revenue
 from the upfront payment on a straight-line basis over a six-year
 initial research term during which the Company will perform
 research services. As of September&#xA0;30, 2013, the Company has
 deferred revenue of $9.5 million related to this Agreement.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Revenues recognized under the agreement with Shire for the three
 and nine months ended September&#xA0;30, 2013 and
 September&#xA0;30, 2012, were as follows (in thousands):</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;months&#xA0;ended<br />
 September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine months ended<br />
 September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Revenue related to Shire Collaboration:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Amortization of upfront fee</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">542</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">542</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,625</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,444</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Research services</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,968</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,675</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,340</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,747</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,510</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,217</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,965</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,191</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Related costs and expenses incurred under the Shire agreement were
 $3.5 million and $2.2 million during the three months ended
 September&#xA0;30, 2013 and September&#xA0;30, 2012, respectively
 and $10.3 million and $3.8 million during the nine months ended
 September&#xA0;30, 2013 and September&#xA0;30, 2012,
 respectively.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Agreement with Sigma-Aldrich Corporation in Laboratory
 Research Reagents, Transgenic Animal and Commercial Protein
 Production Cell-line Engineering</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In July 2007, Sangamo entered into a license agreement (the
 Agreement) with Sigma-Aldrich Corporation (Sigma). Under the
 Agreement, Sangamo agreed to provide Sigma with access to our
 proprietary ZFP technology and the exclusive right to use the
 technology to develop and commercialize research reagent products
 and services in the research field, excluding certain agricultural
 research uses that Sangamo previously licensed to Dow AgroSciences
 LLC (DAS), a wholly-owned subsidiary of Dow Chemical Corporation.
 Under the Agreement, Sangamo and Sigma agreed to conduct a
 three-year research program to develop laboratory research reagents
 using Sangamo&#x2019;s ZFP technology during which time Sangamo
 agreed to assist Sigma in connection with its efforts to market and
 sell services employing the Company&#x2019;s ZFP technology in the
 research field. Sangamo has transferred the ZFP manufacturing
 technology to Sigma.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In October 2009, Sangamo expanded its Agreement with Sigma. In
 addition to the original terms of the Agreement, Sigma received
 exclusive rights to develop and distribute ZFP-modified cell lines
 for commercial production of protein pharmaceuticals and certain
 ZFP-engineered transgenic animals for commercial applications.
 Under the terms of the Agreement, Sigma made upfront cash payment
 of $20.0 million consisting of a $4.9 million purchase of 636,133
 shares of Sangamo common stock, valued at $4.9 million, and a $15.1
 million upfront license fee. The upfront license fee was recognized
 on a straight-line basis from the effective date of the expanded
 license through July 2010, which represents the period over which
 Sangamo was obligated to perform research services for Sigma.
 Sangamo is also eligible to receive commercial license fees of $5.0
 million based upon a percentage of net sales and sublicensing
 revenue and thereafter a reduced royalty rate of 10.5% of net sales
 and sublicensing revenue. In addition, upon the achievement of
 certain cumulative commercial milestones Sigma will make milestone
 payments to Sangamo up to an aggregate of $25.0 million. In April
 2013, the Company recognized $1.3 million in sublicense revenues
 under the agreement with Sigma.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Revenues recognized under the agreement with Sigma for the three
 and nine months ended September&#xA0;30, 2013 and
 September&#xA0;30, 2012, were as follows (in thousands):</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;months&#xA0;ended<br />
 September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;months&#xA0;ended<br />
 September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Revenue related to Sigma Collaboration<b>:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Royalty revenues</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">201</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">428</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">711</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,035</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 License fee and milestone revenues</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">101</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,351</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">302</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">428</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,062</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,035</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Related costs and expenses incurred under the Sigma agreement were
 $0.1 million during both the three months ended September&#xA0;30,
 2013 and 2012. Related costs and expenses incurred under the Sigma
 agreement were $0.1 million and $0.3 million during the nine months
 ended September&#xA0;30, 2013 and 2012, respectively.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Agreement with Dow AgroSciences in Plant
 Agriculture</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In October 2005, Sangamo entered into an exclusive commercial
 license agreement (the Agreement) with DAS. Under the Agreement,
 Sangamo provides DAS with access to its proprietary ZFP technology
 and the exclusive right to use the technology to modify the genomes
 or alter the nucleic acid or protein expression of plant cells,
 plants, or plant cell cultures. Sangamo has retained rights to use
 plants or plant-derived products to deliver ZFP transcription
 factors (ZFP TFs) or ZFP nucleases (ZFNs) into humans or animals
 for diagnostic, therapeutic, or prophylactic purposes. The
 Agreement with DAS provided for an initial three-year research
 term. In June 2008, DAS exercised its option under the agreement to
 obtain a commercial license to sell products incorporating or
 derived from plant cells generated using the Company&#x2019;s ZFP
 technology, including agricultural crops, industrial products and
 plant-derived biopharmaceuticals. The exercise of the option
 triggered a one-time commercial license fee of $6.0 million,
 payment of the remaining $2.3 million of the previously agreed $4.0
 million in research milestones, development and commercialization
 milestone payments for each product, and royalties on sales of
 products. Furthermore, DAS has the right to sublicense
 Sangamo&#x2019;s ZFP technology to third parties for use in plant
 cells, plants, or plant cell cultures. Sangamo will be entitled to
 25% of any cash consideration received by DAS under such
 sublicenses. In December 2010, the Company amended the Agreement
 with DAS to extend the period of reagent manufacturing services and
 research services through December&#xA0;31, 2012.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Agreement also provides for minimum sublicense fees each year
 due to Sangamo every October, provided the Agreement is not
 terminated by DAS. Annual fees range from $250,000 to $3.0 million
 and total $25.3 million over 11 years. The Company does not have
 any performance obligations with respect to the sublicensing
 activities to be conducted by DAS. DAS has the right to terminate
 the Agreement at any time; accordingly, the Company&#x2019;s actual
 sublicense fees over the term of the Agreement could be lower than
 $25.3 million. In addition, each party may terminate the Agreement
 upon an uncured material breach by the other party. In the event of
 any termination of the Agreement, all rights to use the
 Company&#x2019;s ZFP technology will revert to Sangamo, and DAS will
 no longer be permitted access to Sangamo&#x2019;s ZFP technology or
 to develop or, except in limited circumstances, commercialize any
 products derived from the Company&#x2019;s ZFP technology.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Revenues under the agreement were $0.4 million during the three
 months ended September&#xA0;30, 2012, and $1.3 million during the
 nine months ended September&#xA0;30, 2012. Related costs and
 expenses incurred under the agreement were $0.1 million during the
 three months ended September&#xA0;30, 2012, and $0.4 million during
 the nine months ended September&#xA0;30, 2012. There were no such
 revenues or related expenses during the three and nine months ended
 September&#xA0;30, 2013.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Funding from Research Foundations</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>California Institute for Regenerative Medicine</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In October 2009, the California Institute for Regenerative Medicine
 (CIRM), a State of California entity, granted a $14.5 million
 Disease Team Research Award to develop an AIDS-related lymphoma
 therapy based on the application of ZFN gene editing technology in
 stem cells. The four year grant supports an innovative research
 project conducted by a multidisciplinary team of investigators,
 including investigators from the University of Southern California,
 City of Hope National Medical Center and Sangamo BioSciences.
 Sangamo expects to receive funding up to $5.2 million from the
 total amount awarded based on expenses incurred for research and
 development efforts by Sangamo as prescribed in the agreement, and
 subject to its terms and conditions. The award is intended to
 substantially fund Sangamo&#x2019;s research and development efforts
 related to the agreement. The State of California has the right to
 receive, subject to the terms and conditions of the agreement
 between Sangamo and CIRM, payments from Sangamo resulting from
 sales of a commercial product resulting from research and
 development efforts supported by the grant, not to exceed two times
 the amount Sangamo receives in funding under the agreement with
 CIRM.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Revenues attributable to research and development performed under
 the CIRM grant agreement were $0.5 million and $0.3 million during
 the three months ended September&#xA0;30, 2013 and 2012,
 respectively and $ 1.2&#xA0;million and $0.9 million during the
 nine months ended September&#xA0;30, 2013 and 2012, respectively.
 Related costs and expenses incurred under the CIRM agreement were
 $0.5 million and $0.3 million during the three months ended
 September&#xA0;30, 2013 and 2012, respectively, and $1.4 million
 and $0.9 million during the nine months ended September&#xA0;30,
 2013 and 2012, respectively.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>CHDI Foundation, Inc.</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In April 2011, Sangamo entered into an agreement with the CHDI
 Foundation, Inc. (CHDI) to develop a novel therapeutic for
 Huntington&#x2019;s disease based on Sangamo&#x2019;s proprietary ZFP
 technology. Under the agreement with CHDI, and subject to its terms
 and conditions, CHDI paid the Company $1.3 million, the total funds
 due under the agreement, over a period of one year which is
 intended to substantially fund the Company&#x2019;s research efforts
 related to the agreement. During 2012, the agreement was amended to
 extend the project through August 2012 and to increase total
 potential funding from $1.3 million to $2.1 million, plus
 reimbursement for certain direct expenses related to the project.
 The research grant from CHDI was completed in August 2012.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Revenues attributable to research and development performed under
 the CHDI collaboration agreement were $0.3 million and $1.1 million
 during the three and nine months ended September&#xA0;30, 2012,
 respectively. Related costs and expenses incurred under the CHDI
 agreement were $0.3 million and $1.1 million during the three and
 nine months ended September&#xA0;30, 2012, respectively. There were
 no revenues or related expenses during the three and nine months
 ended September&#xA0;30, 2013.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>The Juvenile Diabetes Research Foundation
 International</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In October 2006, Sangamo entered into an agreement with the
 Juvenile Diabetes Research Foundation International (JDRF) to
 provide financial support for one of Sangamo&#x2019;s Phase 2 human
 clinical studies of the Company&#x2019;s product candidate SB-509, a
 ZFP Therapeutic that was in development for the treatment of
 diabetic neuropathy. In January 2010, JDRF and Sangamo amended the
 agreement and, subject to its terms and conditions, JDRF agreed to
 provide additional funding of up to $3.0 million for a Phase 2b
 trial in diabetic neuropathy.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In October 2011, the Company announced of the termination of its
 SB-509 program. In March 2012, the Company received a final payment
 of $0.8 million for work performed under the JDRF agreements. The
 Company does not expect to receive additional funding under these
 agreements.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Revenues attributable to research and development activities
 performed under the JDRF agreements were $0 for the three months
 ended September&#xA0;30, 2012 and $0.8 million during the nine
 months ended September&#xA0;30, 2012. There were no such revenues
 during the three and nine months ended September&#xA0;30, 2013.</p>
 <!-- xbrl,n -->

 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 808<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CollaborativeArrangementDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EVDAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Shire AG [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Shire Collaboration:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DeferredUpfrontContractFeeRevenue', window );">Amortization of upfront fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 542<span></span></td>
        <td class="nump">$ 542<span></span></td>
        <td class="nump">$ 1,625<span></span></td>
        <td class="nump">$ 1,444<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchServiceRevenueUnderCollaborationAgreement', window );">Research services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,968<span></span></td>
        <td class="nump">2,675<span></span></td>
        <td class="nump">11,340<span></span></td>
        <td class="nump">4,747<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Total</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,510<span></span></td>
        <td class="nump">3,217<span></span></td>
        <td class="nump">12,965<span></span></td>
        <td class="nump">6,191<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Revenue related to Sigma Collaboration:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Sigma-Aldrich Corporation [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNetAbstract', window );"><strong>Revenue related to Sigma Collaboration:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">201<span></span></td>
        <td class="nump">428<span></span></td>
        <td class="nump">711<span></span></td>
        <td class="nump">1,035<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License fee and milestone revenues</a></td>
        <td class="nump">1,300<span></span></td>
        <td class="nump">101<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,351<span></span></td>
        <td class="nump">1,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Total</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 302<span></span></td>
        <td class="nump">$ 428<span></span></td>
        <td class="nump">$ 2,062<span></span></td>
        <td class="nump">$ 2,035<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DeferredUpfrontContractFeeRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred upfront contract fee revenue.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_DeferredUpfrontContractFeeRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ResearchServiceRevenueUnderCollaborationAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research service revenue under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ResearchServiceRevenueUnderCollaborationAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ContractsRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicensesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Related Parties<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16382449<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.6-07.1(c))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 07<br><br> -Paragraph b<br><br> -Subparagraph 1<br><br> -Article 6<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueFromRelatedParties</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RoyaltyRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueServicesNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueServicesNetAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Stock-Based Compensation Expense</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following table shows total stock-based compensation expense
 included in the condensed consolidated statement of operations for
 the three month and nine months ended September&#xA0;30, 2013 and
 2012 (in thousands):</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;months&#xA0;ended<br />
 September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;months&#xA0;ended<br />
 September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Costs and expenses:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">732</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">774</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,140</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,195</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">659</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">630</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,958</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,816</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 Total stock-based compensation expense</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,391</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,404</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,098</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,011</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) (Subsequent Event [Member], USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Oct. 01, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Subsequent Event [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares acquired from acquisition</a></td>
        <td class="nump">100,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Market value of shares issued</a></td>
        <td class="nump">$ 1.2<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of equity interests issued or issuable to acquire entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EIPAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) (IPO [Member], USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 23, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from the sale of shares, after offering expenses</a></td>
        <td class="nump">$ 69.5<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
        <td class="nump">7,015,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
        <td class="nump">$ 10.58<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Underwriters [Member] | Common stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
        <td class="nump">915,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received on stock transaction after deduction of issuance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockConsiderationReceivedOnTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsidiarySaleOfStockLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZOAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpenseAbstract', window );"><strong>Costs and expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
        <td class="nump">$ 1,391<span></span></td>
        <td class="nump">$ 1,404<span></span></td>
        <td class="nump">$ 4,098<span></span></td>
        <td class="nump">$ 4,011<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and development [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpenseAbstract', window );"><strong>Costs and expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
        <td class="nump">732<span></span></td>
        <td class="nump">774<span></span></td>
        <td class="nump">2,140<span></span></td>
        <td class="nump">2,195<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">General and administrative [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpenseAbstract', window );"><strong>Costs and expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
        <td class="nump">$ 659<span></span></td>
        <td class="nump">$ 630<span></span></td>
        <td class="nump">$ 1,958<span></span></td>
        <td class="nump">$ 1,816<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LaborAndRelatedExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EB6AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (18,480)<span></span></td>
        <td class="num">$ (18,786)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">445<span></span></td>
        <td class="nump">500<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of premium / discount on marketable securities</a></td>
        <td class="nump">625<span></span></td>
        <td class="nump">692<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump">4,098<span></span></td>
        <td class="nump">4,011<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivable</a></td>
        <td class="num">(18)<span></span></td>
        <td class="nump">20<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="num">(696)<span></span></td>
        <td class="num">(2,585)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
        <td class="num">(387)<span></span></td>
        <td class="num">(364)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
        <td class="num">(1,348)<span></span></td>
        <td class="num">(3,770)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
        <td class="num">(434)<span></span></td>
        <td class="nump">159<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenues</a></td>
        <td class="num">(1,630)<span></span></td>
        <td class="nump">11,818<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(17,825)<span></span></td>
        <td class="num">(8,305)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
        <td class="num">(37,161)<span></span></td>
        <td class="num">(70,570)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments', window );">Maturities of investments</a></td>
        <td class="nump">38,384<span></span></td>
        <td class="nump">75,155<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num">(395)<span></span></td>
        <td class="num">(363)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
        <td class="nump">828<span></span></td>
        <td class="nump">4,222<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from public offering, net of issuance costs</a></td>
        <td class="nump">69,492<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
        <td class="nump">6,135<span></span></td>
        <td class="nump">1,041<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">75,627<span></span></td>
        <td class="nump">1,041<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase / (decrease) in cash and cash equivalents</a></td>
        <td class="nump">58,630<span></span></td>
        <td class="num">(3,042)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
        <td class="nump">21,679<span></span></td>
        <td class="nump">16,766<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
        <td class="nump">$ 80,309<span></span></td>
        <td class="nump">$ 13,724<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceInitialPublicOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Investments and Fair Value Measurement<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments All Other Investments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Investments and Fair Value Measurement</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>NOTE 2&#x2014;INVESTMENTS AND FAIR VALUE MEASUREMENT</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt">
 <b><i>Investments</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Sangamo classifies its marketable securities as available-for-sale
 and records its investments at fair value. Available-for-sale
 securities are carried at estimated fair value based on quoted
 market prices, with the unrealized holding gains and losses
 included in accumulated other comprehensive income. Marketable
 securities which have maturities beyond one year as of the end of
 the reporting period are classified as non-current. The
 Company&#x2019;s investments are subject to a periodic impairment
 review and the Company recognizes an impairment charge when a
 decline in the fair value of its investments below the cost basis
 is judged to be other-than-temporary. The Company considers various
 factors in determining whether to recognize an impairment charge,
 including the length of time and extent to which the fair value has
 been less than the Company&#x2019;s cost basis, the financial
 condition and near-term prospects of the investee, and the
 Company&#x2019;s intent and ability to hold the investment for a
 period of time sufficient to allow for any anticipated recovery in
 the market value.</p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The table below summarizes the Company&#x2019;s available-for-sale
 securities (in thousands):</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Amortized<br />
 Cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross<br />
 Unrealized<br />
 Gains</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross<br />
 Unrealized<br />
 (Losses)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Estimated<br />
 Fair&#xA0;Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 <b>September&#xA0;30, 2013</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Cash equivalents:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,758</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,758</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,758</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,758</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Available-for-sale securities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52,577</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52,603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52,577</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52,603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total cash equivalents and available-for-sale securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">62,335</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">62,361</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 <b>December&#xA0;31, 2012</b></p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Cash equivalents:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,997</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,997</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 Money market funds</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,836</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,836</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Available-for-sale securities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,426</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,426</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total cash equivalents and available-for-sale securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">73,262</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">73,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 As of September&#xA0;30, 2013, none of the available-for-sale
 securities held by the Company had material unrealized losses and
 there were no realized losses for the three and nine months ended
 September&#xA0;30, 2013. The Company had no other-than-temporary
 impairments of available-for-sale securities for the three and nine
 months ended September&#xA0;30, 2013 or the twelve months ended
 December&#xA0;31, 2012.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt">
 <b><i>Fair Value Measurement</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company measures certain financial assets at fair value on a
 recurring basis, including cash equivalents and available-for
 sale-securities.&#xA0;The fair value of these assets was determined
 based on a three-tier hierarchy under the authoritative guidance
 for fair value measurements and disclosures that prioritizes the
 inputs used in measuring fair value as follows:</p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt">
 Level 1: Unadjusted quoted prices in active markets that are
 accessible at the measurement date for identical, unrestricted
 assets or liabilities;</p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt">
 Level 2: Quoted prices in markets that are not active or inputs
 which are observable, either directly or indirectly, for
 substantially the full term of the asset or liability;</p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt">
 Level 3: Prices or valuation techniques that require inputs that
 are both significant to the fair value measurement and unobservable
 (i.e., supported by little or no market activity).</p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt">
 The Company generally classifies its available-for-sale debt
 instruments as Level 2. Instruments can be classified as Level 2
 when observable market prices for identical securities that are
 traded in less active markets are used. When observable market
 prices for identical securities are not available, such instruments
 are priced using benchmark curves, benchmarking of like securities,
 sector groupings, and matrix pricing as well as model processes.
 These models are proprietary to the pricing providers or brokers.
 These valuation models incorporate a number of inputs, including,
 listed in approximate order of priority: benchmark yields, reported
 trades, broker/dealer quotes, issuer spreads, two-sided markets,
 benchmark securities, bids, offers and reference data including
 market research publications. For certain security types,
 additional inputs may be used, or some of the standard inputs may
 not be applicable. Evaluators may prioritize inputs differently on
 any given day for any security based on market conditions, and not
 all inputs listed are available for use in the evaluation process
 for each security evaluation on any given day.</p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt">
 The fair value measurements of our cash equivalents and
 available-for-sale marketable securities are identified at the
 following levels within the fair value hierarchy (in
 thousands):</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>September&#xA0;30,&#xA0;2013<br />
 Fair&#xA0;Value&#xA0;Measurements</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Cash equivalents:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,758</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,758</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,758</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,758</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Available-for-sale securities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52,603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52,603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52,603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52,603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total cash equivalents and available-for-sale securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">62,361</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,758</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52,603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>December&#xA0;31,&#xA0;2012<br />
 Fair&#xA0;Value&#xA0;Measurements</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Cash equivalents:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,997</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,997</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,836</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,997</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Available-for-sale securities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total cash equivalents and available-for-sale securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">73,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">57,449</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 &#xA0;</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FinancialInstrumentsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsAllOtherInvestmentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>NOTE 5&#x2014;INCOME TAXES</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company maintains deferred tax assets that reflect the net tax
 effects of temporary differences between the carrying amounts of
 assets and liabilities for financial reporting purposes and the
 amounts used for income tax purposes. These deferred tax assets
 include net operating loss carryforwards, research credits and
 capitalized research and development. Realization of deferred tax
 assets is dependent upon future earnings, if any, the timing and
 amount of which are uncertain based on the Company&#x2019;s history
 of losses. Accordingly, the net deferred tax assets have been fully
 offset by a valuation allowance. Utilization of operating losses
 and credits may be subject to substantial annual limitation due to
 ownership change provisions of the Internal Revenue Code of 1986,
 as amended and similar state provisions. The annual limitation may
 result in the expiration of net operating losses and credits before
 utilization.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Basic and Diluted Net Loss Per Share</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>NOTE 3&#x2014;BASIC AND DILUTED NET LOSS PER SHARE</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Basic net loss per share has been computed by dividing the net loss
 by the weighted-average number of shares of common stock
 outstanding during the period. Diluted net loss per share is
 calculated by dividing net loss by the weighted average number of
 shares of common stock and potential dilutive securities
 outstanding during the period.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Because Sangamo is in a net loss position, diluted net loss per
 share excludes the effects of common stock equivalents consisting
 of options, which are anti-dilutive. The total stock options
 outstanding excluded from consideration in the calculation of
 diluted net loss per share for the nine months ended
 September&#xA0;30, 2013 and 2012 were 7,853,936 and 8,075,898,
 respectively.</p>
 <!-- xbrl,n -->

 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>29
<FILENAME>0001193125-13-425338-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-13-425338-xbrl.zip
M4$L#!!0````(`%.&9$-:QYIUH8X``!F[!@`1`!P`<V=M;RTR,#$S,#DS,"YX
M;6Q55`D``ZX6>%*N%GA2=7@+``$$)0X```0Y`0``[%WK<^,VDO]^5?L_<+67
M5%(UL`D0?'DRL\5GSK4SMM=6]I+]XJ)%V&:%(A62FK'NK[\&*-NB)-K4@Q2]
MF=14+)(`V+]&=Z,;C^9/?W\8Q](7EN51FGP8X"-Y(+%DE(91<O=A,,U1D(^B
M:"#E19"$09PF[,-@QO+!WS_^Y;]^^BM"TN6EY*9)PN*8S:1?1RQF65`PZ33A
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M?_W\Z6ITS\8!6D8`DG(7!).GFK=!?B/JS1\<BWZ0,5+P8Y60/;](4)2ST=%=
M^N48'JPIGM^-TZ?R>9#<!>-42`HO*IN*O$!*,9NP?"TMXLF:UCD!85&E9PY;
M/2X?5HI&:XMJ9='HB>9BDJW'R)]P,G"5C!'(<Y'-UM>9/UQ#_6B:9:"U=?7F
M3WE%4JW('D;WZROQ)VO>%"5?6%ZLKU(^6U,IF8[7RU]89,>\1XZA!,NBT5,%
M4+S7ZZ0)6JHW+;):03>/X>D`5%22A)+&)[D0Y4MV*PF-.>&M?ACDT7@2<[D6
M]X)LE*4Q:Z:;HL9]QFZA%9!6]"B91P]YN(7J-K<*QR4L_M*3\X0-HS'[%(U8
MDC.?,2_($C"\HS0IV$-QR:EC:7Q]X>F$$`4AA!4LHW_*T.3UU="]EJ^YT&-9
MP?#35!29J`]8-BG%YD":)E'9Q-QJ7/]RY0ZDD(VB<1"#RB%U($4A/`ZOL6D0
MK"C7IFDYNHQ]Y"KP.JH:!)FV:2'-(JKFRJX&CZ\5,"_7\N"C)HO_?CI^"<L"
M6NLN8XR/+RX?=3;#J#UB)"K1=<!(J6F2%?H5&2C$MH$4CSJ(RJJ%#,<QD.5K
M%O8US_`-C3<GZ.?-(GB5@N<0*@3NB7!SB7"LZ"JF*X3;OJ?)1%.1JJH&HI9A
M(L-V;*2:GB/+#C4]%Y>$*X)PLQ'AWL.$C0H66F-NCH:IS2[9B$4P!/IIQD=#
M4)E[*PE=]H7%Z82WL"=X6\A><Q:0P4>5+,K>%C@7N'29SH*XF%W"PV3*\L?&
M%IO9FBL:490'DQB:KCSJ)\#53&4K%EFNJ]N8>,@T=!E1'\3;LAP%J;I/'5>F
M)DC_DWBK%?5L`')1XL,PXHY9$'^.8A@HP)>\"&:<;[\D(<N>Y&U;OG3#"3P7
M%E)E15-P)3_`PSGQDB(J9N!1CM/DJDA'OU_=!QG+SZ>%\+7!_]Z,$?P69\0"
M]%RTN(CZ],Q?@4ULXF&/$J0JMHJH[E%D6)Z,/$\Q7-,E%/L@`-<"KPH6&NNF
M3F3RTW$S%/NQ>1BLLR(O&FML8GVU#W6'$NKZ)OC[,BB\9_G(T%4*?2A;JJK(
M*E7=4IHQMWDB,$"*_(K-\R'*R-TIVT50:Q%L(:G-48+.@@^R(*CKH918Y[[Z
MB1/DW++Q/]X?T^A+$$.1W"J<(,MFT*7_"N+IIOU'N"-4D<XZN,H*7,TQJ:I2
M&X&.NV#%7159IF8BS;!47]4T:J@:5TQR352.5R=4`-X(3Y4%5U#F_%9(]`4X
MF.R"94*R-]5)V21*:;1-57L`%FB4&VVLRSJ8<*!<7\^1ZPG+KE?U=]4[`5$R
MP`?QP%3I-G@GFH),5?$1-BW9M%775>2Y=P4"C^4CU7CF2QW()6G8HXE:$8)F
M)LI2H3%#DY&O>@#2<,`%HS:$&&">;6RZBJGKUV"6=6Z>*)$U55WH_5>-4VW)
MTSR?;CI0MPY2:P2R)/T5?-:TN$^SZ/]ZAQ'4V)`?!]@&Y-?BO`BR\^RJ`',>
M"BW?7H_KK5>-KNZ"GPX^RD<R7HN]#E*5!\\.R440A:>)$TRB(HCWB?L5J]T4
MJS'X"*$E-:N=74-_%>2G*+B)8BC'<D=,<FPZ)G>`#P,^79:K(](JX4N]-QI-
MQ].8]_%Y<<\R/O&8L7N(@L&I/DU&*03%:9Z?L>+\=A@\]`^UPF-AK=JCFV%:
M&H^YY-^G,3@M.1_#BUD/,?,1EH!MQA7<JZ2O]'4&IMH;3^)TQIC-$G8;%3T6
M:(U[SHJYW+DO@%@!S$/J'`*DX"9FX)G-:[\)=5:Y8&OJ,OJFB*JLN&1%$"7`
MMR!+P!W)%W3$!0:.HAYR@)B#CXB8BFE41>!U+%7L<),!2\+Y]$%_>QR\2J(L
M^2+KB:]U0[:)F+KH2D7XDG5>UIJX:$&@0<K?A%4F8)6IK&A:W0B\%D@M[/XA
M)#S(IX2H=0!?U+NS-!GU5O7`U``)^"75>Z9_5?NB8BPB?8C]`1H8)9:,]MZ%
M#WETDD3QAT$!%G_K/L1/JSB/`#X'V>]@4F$\N6*`L-_#(A@2Q33%5--S3[V`
M8,DCR'/68X_'F/MU5705HI?P?`FBF./VTXQ/LCS#M\9I5O"(U4GS+I$2S;:H
MIIC(`A2(FH:#;*SZ"&NV*UNVYAN&<JWR.2*^NK#DW31#\[KT]MG4F**/EX+0
MET%4`5]D;`*1*E\$2?+^>C-\BLRHCOAK*5^GH/U#@]</[B6YZR#X090)M\:-
M\E&<YM/]3@6]-I%M.9:N6`9R7`4CJA,7&<1VD8E55W4<!SLN8+JF0@LUO`;3
M&OK;G[OOPH?A$W[PGEWG[1\CL7+]D6ON&2MZJXP02U+#6)KX>@%!TU&F?P/+
M>I&N!5`%*J:+>FN",'=]*K@6Z*T%TEN9U+A%K<6S5A!/`4+&\N)99'N+CO*Y
M*Z."KI;ZY?$]G;"LF%W$05*`5>(62>SZ`/7L'TXL8D)S>:"OA["PVGTJ]O&)
MR.ES4'"-G/'U\'S_]F8)F^=KMJF8&,FJ1Q!5J8\LWS:0Z\B&B4W'(KI:;L``
M=!?XM_F2]N;T+NY)J"WT<Y;F^2])QH*8N[A\;GIA2NLT67AMEP%E0X.K5'<%
M-H;Y<Q`E'>'<Q[A"GI89]@BS5<?QFN_<(L:#2:ALFG!EZJ8,5ZJN:->F0F3*
MKW09QI6MY*.9CRDV2ZQ,.70%U5!Q,ZA[\*8Y86)SGR:OB]]?=:@[XHEI*`UY
MLI_NI^NZO\UIBV7@.W=_(PNA\"D-%91+WWU*HV5)Z$P?\&[ZL&<OX%!R0=?R
MH.<NPS;,VH,[H?3)G3B4P+QA5T,ABEKG:BA$YX<>VK(WA'L:X*Z;NFKT:?A=
M9LFB2_(B2_8P_/+3.]PM[LC[6H):\30Z@$K70>W$TY@#WUG0&QD(L<%V5<K[
MY&CLBQ]->Q[OI/AM^1D=2P7=2"IZYF9LP*L]N!FXEVY&USSH(BQ?<`1:M`#K
M9?]0X_XAYED4[OTHW79H5P:><FQKQ[Q#]S#X<NW!KHL<>P"ZJSD$A9.B])X+
M;?NVE-.RNF^K-7#<<6\3#@AVIUBZM,*T2RO<:81%.;@U4MANA-7-I`OM\^QM
M9[86[V9K]QY'==7W;W2&=G>C9IFN9WB:C:`-"U%;H<@B'N$91X@GVQ1362_7
M<.0^Q4M=R447$[&=6,^6YQYJO/,^&<_V0Y2::;D#V\[6>_YMSCIU-,="^C7/
MU!GJU9FE?9[!>\K``PZPNEVJ,/B?KEFVC"S;IHA2WX9?AHUDU:8:-BW3P.[3
M!C!3W>),GCW-HX1QR?UC&N7BA'EYWNMQ%V"9-^$\XW^Y1`C[`.8BNMLXB1J_
M)9>IB8@J4^AAK)HU^3Y>RV.E89NOI"'']#5$?0HL<G4+*3HV=(AZ=5U5RTT]
MX@SR$F-V`]W^_G*,R5+FHCWGABDS?(%-Q)J^=%1@BSWF>TR(0E:0[S&/!!$)
M47@Z(`-BJ,,E1&D;I-8(9+L)4=K&V+>$**MX6TR(0OJ3$.5%W/O8NDU$0A1%
M,0VZY+UUDA"E`WP\(8JA+YVT.VQ"E`Y0]RXA2A>8^7%2:IA5V)WF0^E"GGD^
M%*HKRWW;@WPH7:#G9]ADO(*^)_E0NK#7(A\*..!R#_*A=-'C93X4NG'LM6,^
ME"ZZDD^T*[C.R6H_'TH71ID?M26JHM2-OZVF0^FB$_G1-UU3]#J`[:1#Z4+S
MP-(8!M5?TKSVTZ&\`G0/Z5!(N^E0NE`RGM/0T*H>?"?I4#H`9_`4$LIR"K2N
MLZ'L`K393CRQ=*`K1".[+Z#L-1U*!WTLTJ&H2XE"NDZ'T@%.[LLLQ2=MI4/I
M8H!8.[:WF0UE%U"VZAFF[Q*D6X1G,<<Z,OA,+M5\R^2[/CP=ETDR0`F-K1;P
M6LEDWH$+`U*)-;U/V5`Z0,TC24Q6\HIVG0VEBX&%KI7IUM.A=&&",._%"J[V
MTJ%T@*=,=EN'I]5T*!V@XTMB2S.QW:=#Z4(J>4RH+B7P:Y@.Y1`[(G:*L9H:
MH3YL@NC"V+:X7TPT>`'>O@4W0_Y@+Y^*F7.ELT_%B"09/#42GJ\P-L75JE/9
M=J:49OYGNR=X-H&ZPP:A1E#G1[4/!74_!UB:=FIY@(52E6P35QR")]OO&6S:
M^XKX@J%IZCUFR;X.CC25DS8/CFP"M0/E[^Z@?@WP;C:0F^)0":7+J_&'W!?=
M%D.:2CG>S1KN.?0^E%S0M3SHZZ[I'9BUA_C![%/X<"B!>;,G45[F6\NG$S3Q
M[<T5-Z._]K=]SPOOY'EU8WY;EPJZD53TVOJV?99#>P/6MWT>M)<I91E9.PG4
M&ED'Y?%4AVHL?W/ML(%92QG4FC*ES=0+KT#M-#!3NCS?7P.\FQ%`KQ'S/CD&
M^V)(TZ['NZE^6YY!QW)!-Y.+GKD&W280TWOI&G3-@RY<@UV3J#4+#OBVB!Z-
M_8=8@Q&9QMI+3O0RN)9MO%IFXN]C%V^;1JW9V,;E6M4I[1_HKN9=Z7S5M4>K
M4`=8=U+G'VCHS[K3SNG6FO4^*$!G%JW353.1D:Q#<]UI.*9V^>F,)ZC=3&AC
MN<]+8YT99;R;4=Y[S-59Y[_1]:^.5KR`0;V*K#H3B[>_RM7-/(4AYFK@5X^M
M9_O.G-AON88+![:>K?<]W:SO>V8\VYZ1,7II.]M'_>PIABPZ\9(B*F:7["[*
MBRQ(BK-@O(%"$UUYZ>N9Q"8>]BA!JF*KB.H>18;ER<CS%,,U74*Q[UP+!P>4
M=/#QRCK[V?I\+MFGYU?.J7?F>%?2Z9GSTW$=H<\PGC<%Q\$&&:]>H=_QB4<<
M,"M@3<#`."Y&MB-K<.G)JNX8!M;D\BLKMZ"JK"2T0LHRH_TH9ID#0G.79AN<
MQ-\CG\$H@.@R((.+KB0(6N1PA<)G\MT4Q)V#`BL9Q+^Q(//AS@;2OA]6*_SL
M"U9*@FMH6B5Z.)OL3Z@;4LJ/=T"K54HY(:OD7;`L2D,O"?DW8KNFDY0<1;*)
M%+E*;86N94EVH$`6Q*=)R![^P0XCRT`[MQSPCRC*HA`O$?=,^_S@T+/$[)OK
MFY`/P@S-$Z3@DO8ZXNJTL.R?@^@A6)%_KM7"!9J6DEH\N5?GMSRM%$OR@"</
MNV1B#.7^9BYRI-E!SL*+8"9&TR%@LN-T]/O>`)J:C3U3TY&NJ1ZBAFTA6]$U
MY,/X*'L&C)/BDS>@OM_'Q?LP^O+]7?$>D/"KB907LYA]&'RV+G\^/4/#\XL3
M29X4[R7__&R(?.OSZ:??3J1A-`;G\(Q]E2[3<9"\E^;%[?/A\/SS8HVKTW][
M)Q*&&X.%U]SPWV?G0T_2O@_&D_=_>P`\]/W5\-SY![*M*\^5G///%][9E34\
M/3_C58Y%'?%KLM#27Q&2'FZR^-U-&LXDA%[#HG'*AMZO0W1ZYGIGPQ.)?K='
M<,-[)MVF<9Q^Y7DIQ;%]*;]/O^92D?+$=SE/\H)NN`!`?S_+B,3*D^_01)2,
MXFD(SZ-$*NZ%WH;\D<B.F*=Q%(IA+>>Y]\0QI_16XF?J1#LYO#V#1GC%XCYC
M3!J#5-U+01)*293,+W,)!G!HXXI-H(T;ELT[P9+?*_([B<L6KP'M</]-^D%0
MDDYSN)?_>++2!_5"\QKGR()8/)&PTOZ<C>4[[/-+U[M$SOFG3];%%30R`G8'
MDYR]UHO+/2;=I%G(L@\#T"#P%N)\$HR@TYZN)T$8/EY_C<+B_L/`)-\-)/"0
M[Y(/@Q'C9S8'CT+)Y=`&URV1AH+:_V%!6!7'(EN\"!_;U*'-)\DNPFJ9+_.7
MW:1%D8Z?Z%#JJ^SK_K=7+[X:[^_5=:^H%8/CJN!DCXK06-J-JNU=)4&\MZI^
MKQ"]5./ENE7%?;0%?Q.G'F4)3PI)6+7!"F=`LT$IX896IW5B3!AR._=,0VGA
MGJ^%J1.%,^EX3MEZP[<TS&S&@[?&M3,8#?K'M&_"/B`O=AL?F__#Y/15P.3/
M!OA;#^_3BG#7#.+,5<=LG=]FKX016QBAN7]Y!PQ(P<'\F^-XGN_7V*4BG2P^
M>7*F*T$*PFS<,$SYY/E0X;G\:I`B(E$1$LRCCGS5I]^K!*VK>ZARWVC^1O/N
M;L;RA$;K^JR\H,^7+&=!-BJC_)!]87$J4NITKM3_W2C@F5]FT=U]"4%72*.*
M2?HU"R8?!N7?W<7L`$AU^B=!2MYA*O]YL)IJNUCW8[`.ZY*\9,)^9@G+@EA8
ML"`<1XE8`RVB+ZQ[SV2C&JO2H*GF6Y/[G2$K;T[5=X6,WYFJ\><#;6#M@(9N
M;C<F#PVF>#I@Y[)YG$?(8OGC.3Q^F(?':SI@4[/6Z@LW%Y!O_/O&OV_\>RO\
M>WLQK_J"PSALM)R^G?,(3V[3I%@S]#RN+M1*':^WR?"S9<2!WRDF/HCW\19X
M0^7#1-G]YPU])YN'\5K?!&]PRSKUG^;<*C!6A>GT)F9=C8[;O[&?[L4W#G[C
MX#<.MN7D'HN=@_,;Y3]Q>[[G=>%[;KMMW:WN`P9W=OX%E2BYN\C2!'Z.Q%;-
M_`(<^]&L_/_^-_YB1W5U:KO(=JF.J$8PLFS?18:J:CYV'!5[>*.-O]C8;N=O
MQ8LGW[V^%9C_B/@/_@$,\!*>^2=5&"AZ+WH:`I\W#+RZ';7E?;^GB>2SFVP:
M9#.Q??:=V('K6U>V%)6?;[>N?I'.TJ-GX2W/))!W?^$+\@L?(9;*KQ!+/PS3
M2322")%_/)$NV80?6P1^I+>2-1:?YX&;HSC(\^@V8GRO[OE4[`5>.+8EB:^F
MU#3/"9K3\..1-+R/<F@C85_CV2/)P7,OB$_5!UDH9>R/:90QOGU`8N(D@E2D
MTB1+OT1AN7OY-LW&91`6W*1`$F=$,*<X6Z!82DMZ@P5Z4TXOM#*J4!R5%-_,
MQ/TT@?>6!`NFPA]V>\M&?+%@OOLY>^+61&S6SZ4;OL6#?Q%6"FX+8(D+<E;=
MRH95L?&9'$G_RW$$83KA%!7\-4_HYUNR;Z,L+Z0_H+=Y6X#A<<=T"997!?S0
M"CRJ-A!&(;B/A70?`+'`PF@\"4;`A@2XD4&[29",(@AL)VD>/;:1`9Y\&@/[
M*CN]CU:-Y8I=V]04-3T7NG_;Y;N^ZGG80:[K8K!=FH5,3&5$/-EW;5\SJ.EL
M?FBAW8W^Y;[T&Q:G7Z5\.AX'6?3_[+UK;^-&TBC\/8#_`Q\C`68`T2M>=$LV
M`71-O&=F[!U[\ISS?C%HL65Q0Y$*+_9H?_U;5=TDFY3D^X62&]C-6!+9W55=
M]ZZJ_B\,B#2`+.<$*T%>`'?O%V"9#)\ZD*D>`T9AH+@HME5Y]B^89]]N/CS/
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M3M\>M"S#GEP8\.)O"**`L+H-PO2F;3!`Y][35!^<G)^??/Y9:^(;)?/=_.GN
M/EWXAX=_(-(TPIHFH8UVQ,L56OY*B0(V0M#&Y93<#_NGQT"TS?V8,VT8+I9.
ML-(6?+VQ-F51XGB!-O,")YAZX)\X<<S0*TFT&<)W3?"%@>;`$!'24>0%5]JE
M$WMQ0_."J9^Z^,7=;@V\CXZ-7C@V1P71X^+D^69:,F<QRU9SX\2:RQ(6+;R`
MN3`2S,]<6A8\&#&FPWB1-H?_.-%TOM+2P(7/,(;FI,D\A/F<Q+MFVE7JN0`H
M@R%@2?*4BV(+^>)=+Y[Z(4=3,@=\+",/!_+^2U_@$%ZP3.'I%-<"2.1#(#:D
M<6'EL]#WPYL-R8HO2@8EPK:W$_8G=LU\S?A9^Q8X[G_2.`%@_DY#_`<@GL)$
M`)HS)?3Q:GV!#R="'#A3>"3V8).19A#C$B8UUTD88=IS,0-JZO@-V!M`:0)#
M)[258HOA&=]S+CV?2..56>9AN#)_UOY=15`5,V!/)QG6$'RB%!CA9NY-Y_1`
M>!FSZ!JYHZ$Q#Q`7`<D!AR7^BK^1?6IH@GO2RSAQ`(N.#X\@IF>I[VO(%8)A
M."YE5*YJC4CK9^V48S#D[`),"CR=L.D\\/Y.,\:+4*X`Q@2[X7=(-_`-J.BY
M%H.V]F9`6T!O2<@1LY&OB:W3H$`\C/+!.V)'#<#M<AE&N*67*T!>DOBT;4&8
M-:B@K01\?CRJ)T)EZ7[%`I"#2"13'R@"<(,TBF)M/<R$"8DDR8`C4R'\XHS.
MC[1CZ7M`L';)BC%=Z4FB;!9(1)TA3K!(209(P2U9E"21XW))ZH-(J<H<W&^4
MM$?:_VZ<"0:X:ZZ<+S,\X,8#.TK0"\*BD8!88E)V+)C.<1(-1KIFH/?R;_!G
MX#W?^TN.V#606X%W81U749@NX2EX":EOX8#@^T[#XZN`P!OFH]+5%J$+B%Q&
M(8I3T(U\3T$%T@^Q6%4(;[+$B589I6<CP4_7`'-$K'09A7_!G\48!6^)T4!Q
MAQ%0/(IG1PM2;#R*@'`6DQ0[@N)[I!10#2QAGN_>`E\+(Y>_(_3BZF<)42N/
M^2Z,$S'.5MGN(NYH<?]P&9!?Q#4-3AC'*7R,EQ%S\,7D)M1C#\E![#\NI!A?
MPK5VZ>$+X6R&T".2(P9_PJ,,U8]3P`(C"*($!<304-"68*\#E2!JXB,-S.7<
M(A(S`*)72[ZCCNMZ^"#0E)!$"V>%'(%4V4"\Q^$BLUTT%-6N$[G2LS`&4A^\
M`7C$:8$"C[0QWYPPXN,55D;VINO-"!Y2#`$N!'D<6",`^%9$[?A-ON#<-A+`
M@LG.%RYH$-:`@_@Y&&)_D<)RSJ!A`3#<=02'%20D:%284,P!-.9S2X^A<28O
M=%UPKCLN]_9#RN[+5Q!"0<J^LFD(J@!G?RFW961;1G<\'NOCIM74[7ZOHP_,
MMJD/)M:P9=O#<=.HN]LBD*5)V*JMSR+6"B(]"A<%UPIEC")]`4)%6/L@PT$N
M77E3;>E$":A`SO+.%?@'A5D_!6/<N43)AQQ!1!]Q3/R7:S1B7E`MI$JX8A+"
MU>4Z#DTUX(M86X+`2<$1ND;V0(4#$H>K,R#]*'*"*YH7!F#?@<6`_4#VPM,@
MO><P43A%;PI%1R;(:=29]QW9-\H='E)4Q/9\]:!8A'&'CX.\C$-\9H76'_`,
M*,ALB[DA@+R-^",'+L,@C`4<P@)2<!**0-JAUH31N-@$'*1+>)O`($L+-5XD
M7@8QP5`$3\,8A:JWN$RCF(_4*";+L(E``#S>(EV@,5L>8N&!TD_"`##AK(KM
MBL*5X]-.@SR9I4E*&R)>9<5A0.^7&+?)3:<)N9GQ/>TTPWQ9"L[9[G,*8"Q!
ML(Y];HSV"PJ)N=3/=+KCADLN0F=:_^P;C/(EE'QEL]GL@=AJ:)LX63H=R6<<
M<:H3%F_V5FG^#S"/)@;^6(@#KA(C\89$TRC]X1\6D5T`Z[YDH`R8]B\G2,$Z
M*1;+6Y@;#<X8@J:TA5@:C.(6BXLY)S!?+`K`)_,L)T\PEF`.D*J>*^8E0PO8
M'0V2-/#X2^"2ABE8?T"I'E?&\B3@$229EH?7IZ"W0%0X<C`#V)S\L6135"(;
M#%>0L`5B`J;S7=3K18R"B%<:!]:-08Q<3L!8I9'10)IS258:'4WPW/+@^`%=
MAI81EV`T*O!K.'6$.[T(`0(NQ&Y!3&XDP).>'`B),U%#E)C;*3D11`6QY;@C
M*9HMBU:1S>VO"B,A,XQN6=81^H/$"`(?%5;0<MI/)']'DM]!&(#U!U@4Q"XD
M5B.75^34!3K[#GM-DEN,CT((I7\&)DIZ%)AXE!8C8Z(MA),"U3&2P:E#YCHH
M@027X).<%1R<S8;T6M"XH`HL#^,B'W`7NF1"LPC0M'"(,D`P7@GMQ,D71LA`
MG3LNV3)>D)+5O_F](]D=1$Z-$[+9W6S:_"6Q!!&Y`0Y@.;KYQ!+/"]M:F'A$
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MJL5SU&WD>^>2V^5^9/:V_'A9-_&7X57N;W(=E<G(7`]DLS_\Y$O1]![2=!;M
M!4(41=-`,!GU5#12F=S@.=)'F6R4#HEB0"P/DWET^%.<%-V0;<8)4GI&A%7R
ML<#3RH:#UT'FNAA!!9V%D6?0O?\1VBLW\#X4IOCPES_/3L;%Y]$O'\':1),O
M#[?\`BOP(E='SW6U99#ST_4QBA&$U88SX6)+8<Y?T.Q!$"]!"^>:F.SK"EY*
M$X[/3M<G#,19!4T4P+BP+)Q0F@S6H5A9L7+R"YB]&+](.'^A!2U\@(@!VX(!
MC<H)M%3H"MOR%L[?SO<P"(_3\Y%]?M);YF8^R]'SD"58G=\WT.7W,H%(.6_;
MZ7([V;^<45MRZ8O(SPWP];I]*=N5XK3$B8L(##\IQS.@<,F?SP=LE`,$:!-'
MW%*&UV^+$Q2.7;;WA5LF1#Q%T@.=>T)7..^:S+^%&(`(Q2#B+7&DA-[NZEZ$
MU*BX9;G?'V_1)*27I"@$IU@8@<1H51!K0JQ6OS_2C@L!S&.*PD_.%@(\%FL@
MMVE2"KE(DQ:!P<(8\\0(@>Q%9V%.\L6F,%8:W>K_BT,S#*SDP.:H/:>0A11T
ME8*/$@%6`TI$CF=SE`?]W[4/]-='-%`%Z=#->"*F(AQ2%`19W@<.+5RK36Y5
M3?S+?GZDA,?\\D:*HR62@SXWF@'S#`FRB%UMB)D6^042<Z3+$/<7MH60P*T6
MPE=NN/"8`1XW;HC#KL7(,V*@55`6`DV!$\`OQ(A"TA?#\5@&CYSGJ0S7C#9-
M@`027T0BW$QIR%(?7BR1B$@$*&``HH&EX/D:7PA7*R(&*"].LN;*G%P)*!>1
MDIH0S&<1/G>"`.-/E2@Z/\+SX_"V[9(B3UX@Z(7D>CZ"FZ*HH,#[*GLW.PHI
M<@NJ\H(Y41;WK)Q2Y$K?%UP:B;$%A6T[QCC?%..+Z;"!SC*DXX8<1"X`)'ES
M75)RXGQ'6HI\(B(K,IR%IQ+(AT'P?$`QSB-MA*?,D1@DDXU+'(]",(AEC(KQ
M6%`^C71TDO$7#4"L[8KMF#O73!P5YXBM"0&>`3<ZB[#,)SET5\"L0F`4!TED
M4^@K>$+:">&N9`&,F7!0RIL*B/L;R)PGF[#O2T1;%A';NG&4*CBC&'R1!8CJ
M.<X(D58IGPP6BI&_00_(9$,$NJ8>:14\[ELL,U]7OEZ'4I?X6=]]#L'O/,TN
M'WX/95J7PI*C/'_Q^8_!)^V.-6H/3;TU[@UUNV>9>L^T)_IP8-G==J\U;@[&
MKW(,?M>I]Y>3\[%FET[%^O\Z^:H-OYW!(..O9PWMM/_U_`O\]<?QZ9G6_S+2
MSLZ_]L_'OQ\/44%_^G3<_S(<G]UR,/X_NJY]OXS\QF7HKC1=O]>9^?.#.BS9
M6/V<>!]UI/_\R\M#Z<,U6_"3$(C]XIRO9/R!FOHCA8D/*)TI<I8L3;PI/Q\>
M><Y5`*(:/M<VB^&X;+26#;V21>.L6\JRKY7CYP..D*/KXV9CN:$M4TQ0(%F'
M%C7IEI)_!0CD;Q73,FYJ<B'6R"2K6,DT7"Q8A'GBF)\TQTTAHZZT)6ZQ)237
M%V$0@MG@3?$DS(.!42CFYM=&A1*$F%7X7Y":F)E^!2)Y]*6O7V).+'E-H#82
MY@6Q]N'_FYQ^Y`FCH1]>K8ZT;[G,S_'3J`*->HS`1BL[@W`)0U)R[3I<E(V1
M0\7GQTR#S#[`#"<TC+3$B:Y8(L[?/!3>,!RY3_+/=#Z*!A+J$K2(+_T0K#&0
MU@EY*1-G2NE@?QX?-_`_\-_C_TNH_;\-L?Q\`6+UF.*!2^'9C'Q>><K<,J9<
M=:Y!$["Y$I'.(:##3W.V")=SL-P<.GO^5PJC<++E.,N7CF[?S)L!Y4DSY9I<
M5LEXQJO!3I5PRA?Q!_?,$CEU`2E`$`K""P#!:QY.&;`4`&<BKP5M._'<`4]&
MRTD<[6`D:U2ZE#@7A&)RR@/-L]R`UF.?GV,4U(G8!=J)8V#!(P'U/+,<\4`8
M`R'D=.#[A3N&T:[$$9EV\(O+\/B96.HFE-,'R[1R*KBT./7>0KEDEK",93%*
MEIUB-[2;,/)=_09LJ49A8.N7P,6XIT*"-+B@R.'`17);IW`D:.D44F.;>9/V
M,6>X?+]!UBQ#'N$36R_2K\@?*,0&D=@:@Y7E1HF_!$ZV\U=N<<F9\(4N07?3
M^PZCH`7*)13W0+,-!(,(\Z#PO)V\V$5*9_N%M.5IXRX%KD**O>0NM#;UHFFZ
M0&=V^I"<HUV.'W[;;%5O(5HRG:D/KB?22OEAX,9LOF0>A>D5IU#8H85'/$CR
M(P!A=(U'%U>."!O@ZD=1>J7U>98*:<P/`/)'E&CC%',SX+6A#X2"B>#G$5*+
M]#">=PS/^Z`H06[`VCA?K2\8)+,8HN1GK&E$)_/V<O(M)^!EH6^1>HQ"QL&L
M//J-ZJ6*/((I9F(X(E,(@0?#%%8"RRTXCL]RE&NSW'F*,\[EJ?!TL`LCH^C!
M:9#@Z4.V%JY0<#5ZYM"0^UL3G[,2!^">,N!$)";*N8B(K1\-ZZB)@2>?Y/=Y
M*5)+>I!")!A=\[TK3ZB!++J6+O'3C^#F'+6R07A^EA10RT-C>;A35H'>3!(0
MN2E%WN)5ZF.J]ZJQD:8:&\@)-XP2&DOQ/C0Y$I%"*F>NW;HPDJ0%@]U&8Q+S
M)=BV!,?^L7O4XHO($7M_M`J-A)26+3$OE7(TK-X#7/'R6=V%UQ.,4<&V)LX5
M+2]@(J^3[X78<K?(^0Q]JMWAG""HOM!J3+:4,EF>5"/3_$0U`"OR/*009`/M
MAIR;*2Q#(1FJ@[CF^78\52[B^8_P>!;<HG!:\8H(CZ7KYBD,4MCO-6&Y/FSG
M)GK?L/R&'/YK9(:F.*$IDO%$Z4&@3V&GO82?1\@D-)=#^<(@N^<29/^G$M?=
M7/Y)[+$U@I2S62R$O)36242;96/E9:KYXA:,B0`VAJ"\3"$X)>;E)(/$[_O<
M9)=GC)B,AK"8',;@H>Q5)=]2#J=+0QUIGTO#<GQN>D<>5LID%$+F@_>QL$!$
MS%W4@N5Q=HYUBB>'OJAXI#1\W`EQ8'6_0#N^*X[O1()\)J`RH8H.6)@F4RRV
M@3W$Z"*6W&8*]JX)4!!_\&28JIX#'BK)Z-ER/B$DB)2=[&PXH!#5,_1[EB8L
M'T_PU511+)[EX%%:5N$]Y,1VR1!PEXY%R^>`1UI_BOF5\#L>+&7QZ<QRJ)S3
M%"1#HPBI+!,]B749)9D[*45%89%>EA<.C(C5"8%\V)`?*DI'0G$5%0^K;]@`
M#]*&#)%6*LB]`X0L,Y=4]0(VO,AI7;-R:R*HJQ*4USV2Y;&6^(Y24NQ)N3P%
M4\AS*TJDYTDN'B4M!_I5B.A8J^K`]W,+?EVD@\BAG'^WX(9LIBQ-Z:"2Q%])
M54>H$K`-&'^<5"H=Y.J.CU1$:>L\Q"4\8Q(\ZQ9W?I##Z5G(!#0B2G&R\C9K
M?40.9\2R9T,$E%-/QF29/4\9+\)`S<ZY>"I:$CGH?.M@5(EL9TYX#OJI=$Z"
MDGZC<^OR]@+KD3Q:BP!(/AS)0"8P`*UG8/$Q+/8LQ(W5I-2+2D[]G+(\7''&
ME4L0-*][DF%<RGL'0.K&'GD!F<3E4F^(309$)E2HKX0P\`+<J@5LY1PE/!+S
M+8C,(HQ;GS`;/.Q7M(8`%8!\&:8QO!M_?,;L;43P+N7']:3\M2DIT[PY&)ZS
M#-@58.J<5OL'<]SR<<N69+I.ELIV6P);U@=-O&-M?^6YOE=3RU/?LD?/-86Y
M;8HG=Q[ME@^\GJ.[=>6-V]\M,VXF"XJ.K8GHV+J&&>!L8$KXHKV-Z^@8[1QE
M8;$&+@F+SR02Z>%(^T>6*+!1_%5.YIZ])WBML/:EJC7>`$6*M`_-6S<)-?:>
M4>6=`)OO#6"UP\\I1=`0&X-5O&:&;;+2!FM),?O7V?MKGO^7>T/<ERCENCSR
MLMHGMG-^D^?4FM6:GZF?_VOR^*WW4"\PF[<XX\UB.S,PC%^;KQ_9#;QEOTVW
M?07IRT%J--IFZ]W`:MOVR\*Z#W>0W";%OE8#PZ]ODSSLIH8U(K`:O?8+WVA0
M/Z#-1KNS<US^5*`-HV'9S?<&M=WHV)TW%'([>&/'_ER!I?"G\*?PM[OXVSV7
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MP-NGO/8+!QXRW^<YV^/@"OZA^R4(.W7M.9'ZV'"BV6GDY:"59A.;&TO`VVNM
M);:B^P/]]%'JNR"_7LQ,4U!F1-;RAU[DP_,[Y/#',,7D=_F>HTJY>=:9OFC@
MGE>RBP[M\+[T/!50Y2TL*@TL\C3YB--&7NHGN#`O&/""<B7!#*\W:O!%\.L/
M1448@.E-4S])(VINF;]`??FH`")#R#)BUUZ8QOZJ*&:$Q8["&T1?>#;UL/`)
M5_+ITU#[,.J??6S`EF%]E;_2PYM`U'!YKH=H"F?TZG#.%E15*NT1%@AO[(J1
M[PV*!-J-8I?PTB"LJ\3B#'[#(C5PJE8OR_CU<[9;0RR"P7MTWJ>E0+G*`9@@
M>^O@!VF%>`M9G(B%`^IAQ0'CK$I$A06@;#8+(]Z_/[O'+>#7$V#E7;:[;+'T
MP[SQX\;ZL<H*O:+_DTP11SE*J5T$BAE1/X$#XQC`QNG,F2:IN)RF3*D$2TTJ
M)T"`G$R3$.\%PU[UD@SY#NBA^S>2>*T$DP"`=P^*Z[*RDIH0&-7#^K5M70/X
M3F8%W@<_5'D\KC*SZ^$UDI=I0KC5%Z$K>C+@[J*DSNZH*K@^X_"B4!\%O;:<
M.]'"F5(O"L<7%P7E?3UP<"9D/NYEH3X<4A]Q=1*GZ#$0E[GO=MCY948BL81N
M5!650P=4U?:CV2P*VWDM9YR(&^@<[4?[J)?_N$R!*!W>CJ-M@5MN64CV`";C
M=4!B,W'1V*@]":=_-7@E%=T&(0_&N[W#!$;KR#C("\`WE=_S\J]-=?DWCER#
M@_!LJX7*JZ>`>453;5=TJ^:"GY/?0=$7*2MJ%PK/:#:$[*CVXQ.5?%AL10\<
MY/WL:'WB!@VAIG@QU8;J,=QL3NC2^UC*B.7OFVK?)<HH=6O$+6T=-264\C):
MWDMS:P$\:::LLIV+D;R=;U:,SCM)(#<!M3,W+TJ/!";!O&S]5!HV4WG2P-FP
ME3MH:'GK9:0'Q2T5TW21BNZY$NQ246:F^X%/%\Y?4DGH@=P?(,RQRYLRX-4$
M5\`S5P*('\V6W.@!%MD'LP'U[GH]FU3_]:,AF=9XTU_11#-K=GGPPRU58C42
MT@\K;R.DJ_*VO2MO:SZ\O,U^NT*O]SGUUMJS5YA"U0"I\K87*F^K'](4L:MR
MJ#6`5<';O@.L"MY>,S-H4\$;>1>E@K=\?WZ^)3B^^W5.:LUJS>^C!JYZ)\BK
M,_,CTY)`/]SKQ1J5$3PVJ]'<N=J81T+:,=[+GAJ-IO7""8?[7O;V23J)P(!G
MT8+PS439DZNC=D^F/17DXDC6?O0Z]@D?1L-JO3LB`&G8?.&\_7U+,=Z?^AJ%
M/X4_A;_=Q=_NN</OMC[.:KY-"Y7Z8^:M?.SZ8\9L--N*:K;BYDV]^!VT6_>I
MJ$9A4&%087#7,;COI7%%$4BI-*YY9%1+SV!+YEO*X;:D^1S\4!2@X8']T6,6
M=_!#97GEQ5&AG%PYM[E0[N"'^Z6Y;JC/JVD]7+5L"/.:3WU^I4D_KTGBG2IK
M6JXF59NTME6L25>>2IGE!_>^(GG4/]M\0_#!#U)A%M6GQ?APM3P-2UZV%Z<=
M_'"/\K1*R0\5K:RR&T[#!>6>AQ'8C]E5D$$Z]1G6FDP]%W_):E:`5\0=M53)
M@IO-LY`1&/H8-^CY_!=-4$%<KE.*&";M8Y%`7F63THVZ?)!\#!W01E<OYA?B
M43T.73#$,8&%,=/(6XK+-6?B'F.\I%D[G\1T+R?^32#1-=#PTQ?XGG:7;H6E
MZ419S0&OWBGNA6W(=\8V!#*6\Y6/%Q!-LRMHX^S.QRJ/P'Z*S>6W)=/5POR:
MG0TE;@<_4+6.?`ERL]N@4=AW)+Q8U$"%!._&O'NZERN\Y*6!F^I`\/YAW)D<
MI2#XLLH]NIGY`"_AX6BGPAAIGZ7;17EMW6W5:P=RK9E\8Z1<L:A-`9TQ_NJF
M6%KE2`L3]TZ7".'2"RN54[P`*,-/5K,39A0!8UY=$3\[6A@PG8K[-I?'4(%'
MNZCO(*K.[E&:B7+,[(ZN'TU)YHM?I0)+433XHUTJMO&"HKBGJ$UI5"]Y7;^3
M\T"^S&_]QDV!,EXVQ0MO\&Y;++,J+K#,\'JD3=((J7H11HQ35^FJ::*0O$"E
M$%-K&UR1*\G<BURZ@<\3)4LH?[#436@%+BKN+2BRV]+P=K'$IY0O5.B\B`@+
M;*A<+;M?D-<&YW>U7JX(,,XA>.$AO"K=.$TL-H*'%US^8P%7Z<;V!=?6&V_-
MQ(&S2YS=4IG7+"_K+55=%H5<G*0W7`\FZLFR)4G&@<$K7&I2_G->N@23ZL]R
M[85;O@#N6*0+N<*)"L^(3,5%8_SZP$+?@C!?9;JX4<C+M3NU@S`1$M(+2`;Q
M33[2^D&`UV?31'3)'!=</YJM)A[=T>VZT@6]F=+$6"I5=$F,C(K%,/C%W>6;
MY4JWP=$0J_(EDKR4CR[U)C(1-EQ6C%JIGY.OH*:[X43YLP361L[,P3^H7-R.
M-92X)A1PO]!E=OEEC%NE-!(H&3/5[<JN)=QRP?DTNU;2#V_H00>16D)EI8*/
MBRF0#2M@C54!Q1J'\4I$U&U3O'D1GH9G45!?1C3&);=<^*7H-"#-5%QY2;*.
M$"'FD`2T5/Y*]X'+UL=MEX56A)VXA@]PE$B$S*4O-^%\1&H0`GZ`&B-Q]=_"
M2W!["]ON/H*5WT9?5"&'$34!`"\"1:OOP:#5.^$;E9X#`(XD_LO*_9[EYS61
M/GGQX<:*0^&;V5M;J*`6O5_)H=D0/5$V.G:XMP^H7]SD=Z(_>(OG>9O'65K'
MO7UA&:IU'`EA\D"HSOG=M8S?0BVT;);>I-%]QQSL'-2UIC8;:T$/;NTG\\;^
M\`1V*;_]-V_U,@GQTFF2_H_R<U_0;Q^"%``M%7@."$KP:1+L7H"Z^BL3YCPZ
MC9^9ZTVQO&HW_/6>T&H/@@U&^3`\_OJ9VIJ<):*F6QJ#3$U0F%=@19"H!@E@
M%TV:X/T1^!C8Y."<.=+N]V^<R"WWBM#ZQZ,S/6,`?[58SL,%;VV"_N2J=&NX
MW+X!EP0N*KE:&MY;3@PC-P)!?0W,P>UI;J3,PC0BHX4O'7AQN:0V).1P!N$U
M1X3D:((Z^`]:)R6SP]$6>+>UZ\53#Q848,`A04AA35YP#?X'FCC@8*-K5#AT
MI9\*O?(M0#\]QEN5L?]#F"+H@81O'&4H?OXC7#+MBR,NG*8=PYXR%(SA[6*$
MN3CP\I"3W`T!18P($&1-$&:"4WDI_X\MJ;E6MD;2K6@&PA`IVE"XD?GEXF&P
M04A7[W$G=[EPW[+^+X#-O-D-1G`8ABDN^:75)0G?R!K$I)?_$>8BNOB\;0=W
M!@-N18F]IC6B/>P%B?!20OX^OV@:+)L5P;[9OMAZ![U8.8EPZ8I=::E\_DV,
M4S53:1#:A88,6-&/I`Q89I\YDB%XR9(;QH)2RR!DWH;D_^(N9K^7[V5'A`C7
MMQP&$690]1KW>^RHX"G.*10]0U9KD$]`[N"4V@3=A&2"QT*E"L(J5DE8H6AI
M3I];VB<@=P#`=;.]G(2WP''RGB-;"*JX[9H@%`A!D(246K=R6G?%U<4@#S)[
MI,#Z0;G5')]%,X[,XJ7*`GI/M_^V!O8??%I"N-MT6'(GWA[?1W!]W;EM;%<\
MZBWHNC>RJN<U]3P'&?XQ.I;LO098'M.C.IM-U*(&$6IL/^2H-&XA8@,X88`J
MI&!"P0\?2]8.R$#X2PZ5HYJ$E_\`V0=4D(1!60FYPHS*]>Q&554Y]R@%E.5#
ME<KB<7V-K+70FDX5M%HHGP:]`%K%<TLQ0-GYX]8F-Q50;,<BC+5!=#=X\,21
M@H(8M"7CC/>(\F*RGG+EO4EU;_7+<VE['W4]XCS(>:F"*=#8>90S)'>T"&<*
MVS"+2O;3JS1.:!@1.4/A%-$.$D[0G@P31A#D:HW'X&0/&JTPL_!D,12<<@"\
MQ64:Q7QEU-E,M'5RO0@7DLO$"JABH4<B,)GCAJL76@#M+0(+-L#29PFWP"2(
M]DV](KQ3N29Z@YJM]'DUBCTANKZ/C_Z@CJX/57-<\CQDW1M7_=`X347?2/$-
M'LU[4FCC/AD`=5%QR$S_2@%8#VAPY#E@B\/H&X(=I&!`K`;"<:NS&I2B!^V'
M*$)X^UZX*&-"^_"OT=?)1RY;LP:T,W"I`W)#A#-!P@[50]$@L2SN3ZFEHLE/
MJO$,#;QR\HSC!'QOEGM.&W5%YNM,@10]ZFAX-M!;&#O!0`0=D4L:FWK%HJ1$
MN2O)F;Q]&PC\I.B\YQ(JX+V`I:"GG63.(_'_<H(4%38_5$,DE-QWZ62MQ.+P
M3.,^/G`V9-:45<)N=MH@Z2"Z-;5Z_L-/XC/47O)#8GB)],TZ4/70#R4"1DNN
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M9^>C"[-C72`(S9[5O&@>:I[[ZZ'G7AB]KFE8\%.GW^I9?5OO#$<]W>X.QGIO
MU&_JO;8U;(_:]G`XZEP8\.)O")J`[`7.$$IU1^9/#[`0"AS%M=7Y><=A'QMW
MSU!;HE;A;;EY>TX&MB<_A$=WZ-KQ?/Q>!_[2,7PH?$5L=1JY_&VO`!Q/W&>.
M%_$FQD=:?]/[\A3`*%,GBCS>\!A#Y@NR(8M!"H?X[Q0<*K1@11=Q<(3I:#=W
MS],`]+%/_5?GH4\"\@I<)JXO@;YC%N=!>N[T.%/1)1=GH/-S](DB-L>DA&M&
MB6`+@.-SCJ#R^KGWBND/>"J??7O)5J"<"Q_7R6T2="?)5."94VCOX"J%7TS8
MR';&Q=>",-#)%Q"1YFVG\:4MB)AL-61>-VAP#][T(J&T,#$+:,@I>]9%#UM^
M4)*_H4WG3G0%L@U00[:2RZ;4+UH$[Z4-X]JUM*9+$/`W]!RZ.[S'-&Y%K/TG
M=:^X]WHI4AATS)W000)B`EZT*J><9+E-,<P586+909'A2$8:5_.\<SVC'>4:
ME`.U$:;RR0TNTF?!%=`4;AKFQG'G+.&YA%E'_#+,8#A1@!Z0XU,J`\"PW0HM
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M+""A@(F!<F9"\'/JY8VJD0E]-`EYTMBZ?)E[X*&!\;C"CM9$:*JG]8OTM&ZW
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M:LV['7Q5'4+4FM6:7Y*;Z]LAY'4R])^PQ8\,YYJ-7J]SKU=53XUG3`Q2&[UO
M&[U[YDS-&R(]-57+:#6Z5F_7*%Y!O2L,K[!PI]C;P:/9_4EN4OA3^%/XVUW\
M[8-'K4IVC"[88^TWL<=V"4MO9[7N$);>SH7?(235S@BNI>^O^B2]R',*1@7C
M6Z]]_ZS(MS^7V2']U[(;=LM45D+]K(3=QYJBK;K2E@K#UC6,H_"G\*?PM[OX
MVR_?_GT$796=4E<[9?>QIFBKKK2E;."ZZE"%/X4_A;_=Q=\^!)%5YZ3[:^^.
MU3"[JCO0>\Y5>&SKI$[#MA5RE%'\4DIUGYJN*`PJ#"H,[CH&RQ+V'PD:B^(+
M_C_ZVO6N\<M__B.-]2O'6?Z,W7K^Q!X]O/M#/W`_><ZEYY-A*;KUN"?!5S0V
M(R^X@@>^A$&4?1PXL1>?XUSG['LR\,/I7[_!7-H_L_%/HBLG\/[K)%X8##$G
M`OP"^@`#G48L!@N7/I[,)E[@!%//\<_@&]XA:.3%4S_$)<#39X!O;^9-G2#I
M3Z=A&B0P_RF,-X65YK-K4U"B\.$KF_UZR$+_XG3<,4W3TG7=L(RF_F_8!>OB
M['QT87:L"]"!5K-G-2^:AYKG_GKHN1=&KVL:EG4QG#2[W<&HKP\Z\+;=;4WT
M0=^`OP9&LSFQ6OV)W;\PX,7?$+$"KU42$*8_D8!A+I-[N@I99Y1F_L;F&/XE
M_OWEY'RL&;)2'_3/CL^TDXEV^G5\!FY*__SXY(O6_S+2SKY]ABG^'_YV=OS[
ME^/)\;#_Y1Q&ZP^')]^^G!]_^5T[/?ET/#P>GQ&]7.9*5Z;-_]%U[?MEY#<N
M0W>EZ?I=H+<?!WG)<3)_NAL5^(>'?Q!9:N%,DTF,P/!R@#:#MGW]);_/_ND9
MM_)\SC0'2'JQ=((5$+66!D[J>@ESD9I=%L3\+\$\\&&6\0J\'>?L@@"?.<&5
MLPBU@1>>`6,$4Q8WM.-@>J1]*$AD^(MXK/AJ](L61C!:`FN1'QSR5<D/?M3F
MSC73+AD+M&7$E@ZF.7D!@1"YL"ZFW7C)_"#+BF(!BQS?7^$#;(G+=W+^A0$\
M`&3I`_+`LX5A$A9YBQ*`7@"_+&@+R1=>IE&<@A30DI"6&Z7X-OX2L:O4IP<)
M%_`CO'Z6^\GTS/C[=`[`,PT@6WAQC*.643,>EJ`]0O8@T&"]_JJ!PZY`B(,)
MG,#:IG[JPO;YOIBQNEQX>Q:&"3P,"XC0KT=T7:X>A!<8!,G#9PDK4"/M_!%L
M,4T>+KT`)X:U`!4Z5_1S`Y<'0SCN?](XX:3R`>G)BVDN>#C`)?M:+M?E9S\2
M[7DN@X7#*`$#FHJ=:$4;YF@ST"!(!SF?2>0AT.,>:2=+`!9G@Q'@V=1/^(;C
MHI-YQ!AM3N`%3%N`!)_'&@/*=V'W`#.5!G3-AH:"&R&*&&U#MB8/L.D%+BB)
MQ(,UB!W)YDOF3@)H6<':-/9]R:8)X]O#E[%B3H2S(O@;V][1K$?$KCE?TLY(
MG'GI^,0!\9RQ1(/O'`TFW3J<J=T`6F$0P"ZL&#@["A>T&DD";.![F>LS)!.K
M:&N<W?LEUB:PO2!R]/^S!BP,NG%Q,!@N#T@']LGSX3'D:7H5&(20$&^F10`]
M3'W`!*.M=D@V`!3_28,ID4<^T,:WD0QRAN$"*6+`Z?==N%AVAA3X`V7`K4C9
M!N3]E(/1?6WM]BTFTAX#]X*<$7)MZ#L@S&9$^D`RM59V7&MP80&`;*%J)!H4
MI9@^*Q3*O66F$+2Q)`5!7<`("^<O8/X2Y@!OZ6+)M0:)"&<V`]G`N7"!@^-X
MRS!*,G*ZE7B3JC8G2@8)B.I`"X.KD$O!2[11&O("&3@5*2W+@['R16;$C&--
M49--22W*@`LK&%2X!%O$?!(:P#P1NV9!BI)P&H(5C;`BAT]]T!8PFI9$"`B,
M&*6.#Q,B''$"YK0.JR0AM%B"N*,=.RH(3TA@_@P*?E`H840CHGR-R/Z@P>#'
M:Q#/80IK1(X6/1W0?`$YC&3+'Z/?8.&`"D#(VLX@;H5%`O+%]P`LDA$ABG20
M-7$8H"\"!A3(4WIZZD73=`%;Q"TA61T`Y=W,O>D<1<M"["IM"LD:(!1$[7]2
M]TKL[668\A5,G2BBG<7]8C200]X3X@.@\`L/2A"44%,H#5%%.4LTF@!`DO8<
MZ#A,(U@BMS:2E)0Q7^>4Q*GK`55&F7X(8XF*:RNHO@JR^UJ076WEDEAKS#&,
MYHP3`6TXH+.N^58N'#>CK#@!Z<6N@&IA(Q.029REG2LP9`I),`U]'Z@F$A8I
M4H%@P/^BX(J)F&(677M31C_#$,LHO/90;]W,6<"5GP84"<P$-F^,1@W#WY&O
M.&F!5(DB-&AQ7AB`?0<F!$IW@3VN&5AI<Y@HG*)=QUS.`"`GIS3JS/N.C!O!
MPV!V+SQBGH:@8EP]B$%.RBM\/&>P%7%FA'9=ML5<,B?"@N%&GL`@<<04Q`?9
ME06*DM421069;*2L8RU=PML$1HS>/MJFD7@9)"Y##IZ&,3*2M[@$-X"/U"@F
MR[")0``\WB)=:'%Z61YB`:H>!!68FDMG56Q7%*X<GW8:I-4L35+:$/$J*]L.
ML$UN"CH"3^+NS7_FRU)PSG:?06R@&M3&/E<L_8)"<.D>FE+<=W+<<)FIX?[9
M-QCE2WA4V%-FL]G3#:NA;>)D*>*0SSCB5(=T5/!4>?X/,(\F!OY8B(,CM,=R
M1271-$I5ZO5*VI=$/<AGIOW+"5+P0HK%<MO/:'#&R#RSA5@:V=CYXH0J8'[A
M.<<I$FM&GF27@]#ES(CS(E%RLP6E@,=?DI2PQYT->1)M`3[`E$6)0V8#*F\0
M%8ZLT('-2?R328&>%.F4S',1@^$*P,2(R=G@MG7.LBA)`E<>!]9]`SR?RPFT
ML.21A:I#258:G9Q(QW6Y><`UG7#\N*F&HP*_AE.'.TY@'`$$7(C=@IC</(`G
M81G%6N),U!`E+I?`:J2]-U@K.>Y(BI;\T6QNGSNDS(%M%.B[;5E'VJE@!(&/
M"BMH.>W+1H<DOP,,@V)/*D'L0F(U<GD%@\,S.OL.>TV26XR/0@BE?P8F2GH4
MF'A`%R-CIC$3D02`"F4P6@,@<4`))"O9K,.'LMER/S+;4[*GK@5IH3$6N@@:
M_$7Q":(,$(Q70CMY6;PD`W7ND/,)N$K)QMS\'G>'Q3O(J<(H<;-I\Y?$$H05
M!QS`<G3SB26>%]&<S"!&`N4;R^UPL1X8[D@;4C0GSO=1-HPX$^.>12XG00?Q
MB"8GQ0?(VMLMZ>W,$K&EZZ);4.Q1(51E0@9VY6YSYJ`(]D3;V'4B-P\T<7F5
M"\Y,2&Z4S8#V]5+LC?B33<EM^&A+Z-A^,D)'&Y5#EN')IT_]TS,8@XRN9<SN
MVIKUM"`DDNC7P^8AH,#'?N-30$_^>8F247R^\=QD_NNAT6S^5#JRKMQ7(1YK
M_?207%9,.\K>-'_*C^]]-JN<WIOF_0<R'KZ$ZKS",`43C8>BKE*/QWI1,7#E
M@S97A6AB;H\VM'EX4]:X7E"Q747<"#WC0G*[W!?-WI8?+^LF.>B4ZZA,1N9Z
M()O]8>=GBJ;WE*9%E`@)491I`\%DU%/12&5R@^=('V6R,;=Q'"`VWQ?1J"D.
M,O?@)?!-5L@F$1,$*3W#X^A!/A9X6MEP\#K(7!=3_K(P27CY'Z&]<@.O='SQ
MY]G)N'1^`=8FFGQY!N$OL`(O<G7T7%=;!CD_71^C&$%8;3@3+A8C&]+H(DY[
M"5HXU\1D7U?P4IIP?':Z/F'`/+)I::(`QH5EX8329+`.Q<J*E9-?P.S%^$7"
M^2N-Y<,?STTI8@K>V#QTA6UY"^=OYWL8)*4P!A_9Y\=,96[FLQP]#UF"U?E]
M`UU^+Q.(E#FWG2ZWD_W+&;4EE[Z(_-`IRYI]*=N5#>&.QT4$AO;-Q1M>PB5_
M/A^P40X0H$T<<4L97K\M3E`X=MG>%VZ9$/%XX@E>'/>$KBA,7Y7YMQ`#$*$8
M1+QUI/TO!O;0VUW=BY`:%;<L]_OC+9J$])(4A>`4"R.0&*T*8DV(U>KW1]IQ
M(8!Y3%'XR=E"@,=B#>2V.)D#OTZ:M`@,%L:8)T8(9"\Z"W.2+S:%L=+H5O]?
M'#E@8"4'-D<M/YF5@JY2\%$BP&I`B<CQ;([RH/^[]H'^^H@&JB`=<5!+,17A
MD*(@R,X8<&CA6FURJVKB7_9%8`<#KF72ST[$40[ZV7G1E"%!%K&K#3%3?G@B
MXC$9<Z3+$/<7MH60P*T6PE=NN,39Z?&F..Q:C#PC!EK%+/5]/@5.`+\0(PI)
M7PS'8QD\<AZGE[@5.#%MF@`))+Z(1+B9TI"EOA>7203INP0#$`TLY9)E"^%J
M1<0`Y<5)UER9DRL!Y2)24A."^2S"YTX08/RI$D6GG7+\.+QMNZ3(DQ<(>B&Y
MGH_@IB@J*/"^RM[-CD**P]ZJO&!.E,4]*Z<4N=+W!9=&8FQ!8=N.,<XWQ?AB
M.FR@LPSIN"$'D0L`2=Y<EY2<.-^1EB*?B,B*#&?AAX[R81`\'U",\T@;L1F+
M(C%()AM%R@V?A:)B/!:43R,=G63\10,0:[MB.RA7!RUXRM?AB*T)`6Y,VLBA
MNP)F%0*C.$@BFT*G%)%B)X2[D@4PLD22\J8"XOX&,B=A18?709RG7FW=.-AB
ME\TH!E^<.*-ZSM+/^"KED\%",?(WZ`&9;(A`U]0CK8+'?8MEYNO*UXO8\`)^
MUE?C4^$IA34+77D:A4&(HAE14-L3XN-`F[#+*+,(Q,G`I'\V@$V+4]@0C+96
MSL\,2V^:#2'U(S;'8U#@N.-@&B[`Z3X/@70UTVQ^_!D((XMM8T17))X`LD1B
M#['_24JD"KA+%RFGAQ,RT38/S\._M(:/*.3(!`O8#9ZY\B5OL%B*Y)F2=R3X
MYZ"2D)EG112I,L6*M9"OUY'6&XI0X;2T8H^O^')%WX,2Y_8<<`/"@.J8DG+P
MT8PIRR<!H&;9E1?0H3$/DJ^GAQDMGAX&1C@%,3""3@%QM!,RZ+U`Y/=$<8+,
M%N%8``/BL3BM$L%WM`EFE0%<SR6)2J(54.B!6IDFY)6`<5OD#2W#V,O&B.2L
ME'`IW,T-MF.>>AT4>=>91[F6W/_:R??EU/__I:N8F=M'G^"*?4EQ,TYF9W.0
M4D#'A"]10C"%*4:>GXJ$Q\<E\.,A'[T5XPSQ(<CFJ;<`&^770]U:R^^WS>%H
MW&IV='O2&^EVNS76>VUCJ#>;W<X0ANX/!_T+Z\(P#W]KV3A+LUD@]G&@E=%S
MAOE5\]`'+1"/@>&2U9<P80767Z"D8=09#.QV7Q^U)V/='K1-O==K#N%CI]\:
MMP<6(.!A)0V/U!WW*FGHR`D&9^<GP__SQ\FGT?CKF6P0:.-_?SL^_W_/6*OP
MTE;-2;`II]FT&D*G9`G\6;XWFKG<5K@!%SBAH^(EV>(@*F:4>80RPZ-$L<4"
MCT*0L!J%Q2W[>B`"<$"R2,#FN!*QV4ZC";(1"Y0X[VP;460MP.L]\;Q0(^*@
MY5NV3J#I4IZ^HUE-W77PA!C/I#$HD'"[:\FS#3"5:0VN/(;RH]$\:G51TN-!
M.RZ1F^P!2U`O31ESZ>0\0UZ>14V5\AC;X&"1;"<EF,W1$,H"O/=TFO#B"P$#
M?G"!';E:X\Y&5C*0&94\=Z\X],Z7GIED#7X&[2QAF=_I(="]/[9[1RWN5/N8
M4?DT*7]O05*1/],YP.RSD]E0RNX<@B\R"2.29`/T6T^YZR`?0O=Y2(<41_%@
M=91XL#KUG:!<'/9LLLP8FT:O8P_T7JO=`QG>ZND#LVGJ5MML=B?&N-GM-A\D
MRUXA[7D&KF)X0U$_?D8P#V^0;!-*(MZ<;9L1$IE=>4I[EIRSJ38H3T<NFQ+"
M;"KJ+:C,XN%5%Z*FA4)B'V@E81K#=_''9TP$0"&\2T<M/>DHI'(Q.;+R`"U3
MC3A!^P,K(DIJ:,NY3,?\Z=XE[]D[UO97GNM[-;4\M?%\4V^;8BL9/+D=3K=L
M>CU'"[;*&[>_6V;<3!84;802T49H#3/`V<"4\$5[&]>1+7B.<JY8`Y=PQ6<2
M=?1PI/TCBSEM%'P5\_+9&]?5"FM?0!O4#VF*V`_-6[<-=?.>T>F=`)OO#6"U
MP\\I1=`T&X/]NV:8;;+;!FOA@_UK0$=N&[D$F?OZR'N6GMA`ZTV>4VM6:WZF
M%I.OR<^WM5G_NN7@\M69^M$-(-^FP_4;0-JQWPFD9L.PF^\'UE[K96'=AYZX
MMXFPWWD2$&_4X&))+]5>>]?L]2V3AW7(7*.&=NMM.I*^)<C6SK'Z4T$V&KW6
MV_0L?E.@N\8+WRZ];QUD]Z<MN\*?PI_"W^[B;_=\WMMNXCV_UW'ZXXQ'O_:]
MW8V&U3/>Q/K8!=S8S;?QLNN/&[O1[*F;-K;BQGAAGKJC-'1#SM=;)&^5\\>^
ML&3HQ/-3T;!LL/H&XQP'>:/7?M$Y[>DIO5X<VJ;1N?AV-KHCK[<][-FM%B:&
M6=9(M_NCEM[OM7MZN]MO35KMMMUMM2^,"\,Z_$TW.EVS54KLO3]0962,G0@S
MS^-3EF/_F9.:)0Q<P&HNUI.<S4?G.!N`B^:191=XN`.>2B9A>AFSOU.@KO$U
MDMCS9_L!#*VFU6GJ9L?HZ[9I]W7<.=WJ&%VS:XU,LVO7)W.Y6\I<_C8X&__[
M&Q@ZVOA/^&\-^JK?!41_^G?J\=H$S"$<LHAA+=XM"W^+C,J30.NG5VF<W)9%
M34695*L:^OY*#V^P5@M+0CW7PSJ>X>\'V&^S@!=HF?=+;V@.=K-S;GB!:[3,
M2HI+?2L^L^B*DI+AO4H#BU+]J`.+S5O+X:)0NB)R^0#:!U[CM3YT\5II>%ZS
MG.V,6/%!I:E&OG&E-RF2R@UDD31<2JC/"PLIR(KM2$\K_=:K"ZL4TD]%BW/>
M<SPLJB&DW/)BX=B0R[OF:=%SAAU\O#!ATWD0^N$5IHN+1KK:+)RF4KV]7(:'
M!48N"T+=B>-PZE$6[+47I7$5(?W^GV5<X!JH5-A9>J(N60*`>KK*+=X/?BCQ
M0ZDPD8_"T@2;@D;A5>0L2IU[A^.O8]TPF@V>?@]+T:[9-*'FFZ)39[R*$[8H
MVJ)'S$DR`/O^?^<,N"4JS0H#N5[,G%AT`_5`UV+Q7Y!05TW`[ND<?S0KK7X;
M4F7WEBYSO!L=;TV`&<M\[X%)TYD#SV9U!P!'WC!4-`Y+PN_>E+:/]Q%V9@P&
MI%;HE)>_&7_S=$&(*2\T)LZ0.?0CWR699[$R'W/=LY8Y)X#6<MV72%VFL8;P
M)+5X!SKY6)-2UQ-.U/+2&AF?@631%OBGZ$Y.(@UE2L%$HCMV]H7<MB_K,IM&
MUV"X8`?IC$])#,AR$4;():/'\A)6P=A'FQ=)#1B(L7EGR<V;FQ4;!FY)($R!
M[7)O7;#_"N4U+D424`@0<(C4T8O(4^Y4X,@ET%R8+CC^RHV;,N:2Z*<AZF3$
MC0C(\?`]UA-S?O_@?91(J=FLU,E(!3MYK8S8J:++==[5LU((8AR9615()MG*
M^.79]A\\>0V\TA)'H[LBB??*ET;*8DIJ/""-K/DLCG.6E3M6R^D_I9:@O,4B
MU>\+#&U$<4-SN73(BJ$S0LIUY1;-X4GW8\#.4J=VN>T*F*0Z4`\,D+>+((:6
M)3S:K3H6R0K/)R[+^ZP?G$1;99E.-P%0F<:&U"?5.(J[O7O5..JX).7RM@)R
MD[2#H@<1$)"P//*",!9AW:SW7[9%]F6*7R[`N5NSYWH=Y!4?P6QFP@M'D4<X
M!2GC!;'<DED:@6X%^(-7[":59R3[X196XKVNXXI]6V;=@Q]*S`L<"CCD-YW!
M%%=>@L5[F.3I7'$YB!V$>+=O(>,V=(.I=-YEU'B%^F2@$!)[@JVBJ"W+`5T$
MD(FTB!?T8>53WG\E[Y.0]4A`=5."(^M:4C$O\:LU?*CN<TJ(;!8B);&`&A5%
M2)5^T,YA_NQ6'0B<T,C[7&T8HY'UM]%]#^\U@9^QXT+13@DE68GQ#GZ@HEGJ
M6\]]!@H-9C6%H/A*7(L-3I;B3B3JNR1:-><62#Y8SH;;F'!5;G_T?`WR7K9M
M%K8XVFB92=O6D.P'R1'B1=156[8:%_`"ERT";++!XFD$^'<*\R@KH>:B333<
MJEBZ^-"4O#Q>+GU#76FHN82XERT0(Q_DE\;D9O`EK'GF)15;'R?#6'`\6Q7+
M0T-)ZA>>M5B702N:X%1C!$?:B%KJ"?&:=;P#$SB>`S1:`EM45&V7#%4QD62P
M<VSP$E@JDI>0L>4>/7&OW$'EMJY-E_@TJ@VR,UP)HQ?MSS+&G3RDC@QW`_(0
M_RUX0/!SG"Z7O%,=#>+F!=JB(2+\L13\4P&XW*7IH+@,KM+DY^"V*O%M0=IR
M+)=WCCEWOK]D(XIVUS:&XVY?MWIC0[>'@Z;>'?;'>L<PK5YW,FF->Y/ZA'-;
M<CCW^,OPY/-8.^__W^>_(?-EJ\^+=G_`#/!_ZEU%;<6TQ/F>1;NX2F`S/[L!
M"P4\_`Z#\`X\G//9`N.AT4I<2T3W3`)Q)C=,M'/,[TC*V@*1ZA&35"])0@XK
M6%'J[)-&(,=8?J]6KGEBC6*!_,9(:AR$(&2/9_T%-\!WD)?1$V!A=JX#B@_=
M85PT#'J#?1NE6V6F,(C'UXW,QZ,6U)]K6VLP;/.%C^1WG,EK*1#A9?HU;YW(
M[YTA38[G+[SQ<B`Z-B;8X_9*+*/0P44CQKR]8;DYZ<:.@_RR+A'C0/`1<=6+
M+@E+F^BDN.,1>S+R46;P"^IY1^-M,DD@HB]-70VU;XDG8Z2,>Y9UU,AP+;I2
M2D9%WLF1TH&I*2$V_1673KJ9?L%85A3/O:4F+OJDQE6QK+2.41L$\'[6BVT8
MNJ1H0$"U*9P9%RT],80)T_A.Q)6$-)X(&*^M94&-3GA'I\RR`M_#*ZZ\6R<^
M0>49^/R2&Q@E+;!V?V%_FQ0ORWNZ*?=D5FGJM.+_?7[);YNCX7ADM/4)G<Z.
MQJ8^Z%AM?6#;P\G(-HU!N_WPMAWJ:F%UM;"Z6EA=+:RN%I:&4U<+[]+5PNLZ
M_'Z:^?8TI!?H(=@:-@>&U='[D^%0M]OPGYXY[.@=J]49M$?-7GMLU<=ULV37
M;=`_.QYJ_2\C;73\Z=OY>*1]&9]KGT[.SK33\5?M[(_^U_'NN'24D45V)+DN
M2[R5E(YA\;Y/DI`HUBGY['+%+S+,#N6REV`4$?^^$?TL=8<WM-0"ZF@I=<[#
MPT;I@/.@G-DAG?AE][)EF6\;5DBG!5/'GXJ.L/+Z\L<K*]/65G;PPY:U<4T.
M/,Y=!1<7PF]7R+3UG:NO1U;`@$T=O,DD,[P\?FN6A-(P.\%V-V`[0Y!&-Q"Z
MXL((R8LO(:TX/(ZU0H%S[Y`W:8P;DJ>)?IB>H98K+JF17?9&!=%B(4(5E0_F
MLZ9V@BRXI4%ALJUTE,GM-=5^L*TG4='$-U>06J?1;5F-GM6F[[N-9J?5Z/:Z
M#6Y-B*L"_=43FS1NE<QE`=X'M&98+:S+L<#;!-`V)*X6";S547G7Z!=IH7O\
M9;*F#)HCTQQT^GU]/!FW=;O;-/6>U1GK`V,P&(YZDZ9M=KDRZ`".`<4%/IX%
MT#+NOL4,'LSO?GPNC=?LV\WF<-C7A_9HHMO]\43OC\<=O6N-K9;5LB<C\W6Z
MYC[>9_W&KT,:EZZ]'XHNW3QR'=?:A>6^8!X]V6*KXI:C@X1G*<)-O+<GE/<\
M+WP;'DZB-!16PMS:M?0.R=1*%W0,8F9&XJTFZ=JQ!=FGE&^%.:+!5<@%,=U6
MVI`7F%U'$U..:[Y(.>T0[\W!=+KB[(<`%YV[,36@@$VZ67;#%3PH$,O)>3AB
ME()TX)<T;JNY.BH(3_A5>7"2QR!I1/2:(HHJ\#2Q0+L&IRM,8]%C-T^ERF_"
M*_KOPL(!%70A0V5GY$.M2^;CK2PQ/SZZ9,5%($PZN9IZT31=H,J:9K=$2ZW9
MN0)$(A.[2IM"F@@(!5'[G]2]$GN;M\;/@^&4!L8O(L["T=58."<HX7RBCX..
MI[/$4`B>VZ'BY$#'81K!$GD,@9(WLW7R.Z)Y9#[S^D+Y7MS[N!]E:7J[F_%2
MT<)1=VAW^U97;X_;MFX/NFV]:W0F^K#7Z8Z[EFF-Q@]+^U<V^1[9Y'<;6;?Z
MROF5!\=!G$1IY<Z#YR=FR[9;W4G/U+L3HZO;K7Y+[]OCICXVVD#&(\-NMAX6
M^GY1S]DL'WK^.3X[_XS5*^0_3_K'7[4_^Y^^C;7/X_[9MZ]C_.WM"UL>;R$=
M!Z`8>$RRMH90GFB<7:_"U3Y7C#SM2XI'2]>DZC.\0-;)+V[E%Z+SM[T"<(PF
M4L25M-21UM_TOCQ%Q#4;WO/B)%(3_&*00M/_G88\),J7RS,GXD81%4N#B(E#
M54PG0>:_HE-J4I#9":'<`WWM4IF-5\H<:9]S!)77+UV`!>O.OKUDJY#L#Q$/
M=/)30X9?S_(,EO+U,QP;Q<4W3LROC>35&.0@'VRY^JVT!5'IR-,1HX-6P5MD
MO$A<7PCFF0<TE%F/&VXN$_?.\#?P)#0".4VW23D4$D9++L_ZDC9,7/P@KPGL
M)G']-EY4QBT>W(J8;!UN+X(U15N@@_D2Z'EZ0/EBM<SACS/3#B/D#M;`D/6>
MW6R)2!4WBHL,?P[41I@:.5%DZL)GP170%&X:)A7Q=/:$V_/2C1@2S'.Z9I3T
M,V7%(PS;S\T+)#3*=CV/UXM<>3IR`/K1*0-^&84428B+DQS$+^,)_N7$N"IQ
M)%G)6';''8"!'"*-0_B@(Q-,3N+TF,$?I[,9VOKB'@X\CA<73J\HB`/^#W$0
MHIFJD'*'17`JEP;WC(AU=_JZ6HIBD23E-`_.!""!^&DK.6R4LI*447<DO.`=
M">WFP^](:+_=;0'O<^IGO)[AP5.HMO%W]-CN+]",^>]:3W]L`E&Q?Y^]CURM
M$/$[J.BX@H1ON4U:^>%WM$P5>K:AY\,GLM<_OBL,9;&R*C(F8&@62_L3K:GG
MQ8MJ:G]K4_M\@VXY$KS%T]_]GN9JS6K-[Z/?_;!<!:]NKU!K?E=KWH=F\+?U
M]OP<!FR5Q:5F:>#&K\[@C^PAV&MT=J\K^"-AE4^.'CO]'6A0P-<2^%>@<M4&
M_JTF?'TJ5/A3^%/X4VW@'^,*4AOXQUF'_NMUI'Z@75`CLW*'D%0CDTQA;<^Q
MIBS@=ZQ!%?X4_A3^=A=_^Q`^O<TF7D_HE1+5'GE6\IJZ^0V?4S`J&-]Z[;ON
MKM]VLL/;^6`"<D#)S/$2>Y-@.QNL&,+K`]AE(DFK^@NK)SH2+;/1ZG1>UI/8
M?2R9+WSI[.YC2+GQC^2^=M-Z6=I2?GQ=_0"%/X4_A;_=Q=^^^_'OXVQ+6<#*
M`E86L+*`E06L+!"%/X4_A;_7MH!?T]Z]K8*/[-WJ%9>B%=]M1UJU-Y$?F6;=
M-AN6U=IWN^^1R-E_@WCW*Q/JCRQDL;:AS-^':#,+M!F_._"U].?C9ZRG`:(P
MJ#"H,%@W,W@'6EMLOZZ$T'"9JXDZ6\-O^9R"4<'XUFO?=1?^%3IS[-4.*Q@5
MC+L"XSY84N\J__2QT;-&K[?W9^XJ@*:052MDO0+7[9XY^1J-H%Y31S\Q(<-H
M-;I6;]]%LTKV45C;%:R]!D?NVQG1_J18*/PI_"G\[2[^]B&BH8H$C"[HX+W/
M^%'VG<+:KF#M-3A26<5UU:H*?PI_"G^[B[_="Q.KAE?JZ%K!^`Y@W`>'_5VE
M(#S5DVC9#7O_JWF>BB6%(>7'OQ3WM<R7I2WEQ]?5#U#X4_A3^-M=_.V7'_\^
MSK*4O:OL767O*GM7V;O*WE#X4_A3^'MM>[>^E?ZJ!5996W>LAME^86V]L\C9
M?Q-9%:6]#HMUU5V&#])O^]0\1V%085!A<-<Q6):P_Z/KVAALQG.T%[5!Z*XT
M72\$*'Z[:<G"3*4E&^8R^44K6;KV3_>T<P<GY^<GGW_6FCC$MIRM6`MGVAE;
M)M6.5DWJ:&4U0-T$#!]*YFR#]0MC%/:O-F>^JUVNZ-EAN%@ZP4J;.ZZV<!(6
M>6!3IT'$8-/^RUS-#^.8D5$-8\`+$=-N\#]!J%6?@<EHR&0>,49F>.#!HA:@
MFN>QQ@*7X1BW0'&DG5=6!+.$.*F>S)U`A_>68>1$*QC&@X>\:$$6/X!]J\&_
M964PBKRVVU:F90/<,/]Z#:3MG<:.UFAU,_UT\\U_$+F47"7SI[M[HN$?'OXQ
M`>1I?SI^RK3/S(G3B"$J:;5>3OOY*W=#T'Y9!I#I8L'7&VM3%B6.%V@S+W""
M*=*M`W2('F"BS1"^:X(O##0'AHB0'"(ON-(NG=B+&YH73/W4Q2_N=B&1?^`W
MO:"IHV*S<7'R?,2$,<M6<^/$FLN`LQ9`<T@N,#]0&RZ+$Z0.XT7:'/[C1-/Y
M"KC/99S<G#29AS"?DWA`=5>IYP*@2+=(T-*4BV(+^>)=+YX"5Q*:@'42;1EY
M.!"P*WZ!0WC!,H6G4UP+()$/@=B0QG60=7P_O-F0&/JB9%`B;'L[87]BU\S7
MC)^U;X'C_B>-$P#F[S3$?P#B*4P$H#E30A_OC"#PX42(`V<*C\0>RGWX#C$N
M85)S01P2ICT7L\VFCM\@R1@G,'1"6RFV&)[Q/>?2\XDT7IEE'H8K\V?MWU4$
M53$#8C?)L(;@$Z7`"#=S;SJG!\++F$77R!T-C7DHH8'D@,,2?\7?R#XU-,$]
MZ66<.(!%Q_>YXIFEOJ\A5^1:"W$IHW)5:T1:/VNG'(,A9Q=@4N#IA$WG@?=W
MFC%>A'(%,";8#;]#NH%OP!R::S%81MX,:`OH+0DY8C;R-;%U&A2(AU$^>$?L
MJ`&X78):Q"T%G0YX2WS:-M"=HAD(;27@\^,]U=%K(U26[E<L`#F(1#+U@2(`
M-TBC*-;6-3PF?Y(D`XY,A?"+,SH_THZE[P'!VB4KQG2E)XFR62`1=88XP2(E
M&2#;%9(H22+'Y9+4!Y%2E3FXWRAIC[3_W3@3#'#77#E?9GC`C0=VE*`7A$4C
M`;'$I.Q8,)WC)!J,=,U`[^7?X,_`>[[WEVPL-;BMF,`ZKJ(P7<)3\!)2'YB'
MD?>=AL=7`8%@#:'2!7O(!40NHQ#%*>A&OJ<QXS_$8E4AO,D2,-\R2L]&@I^N
M`>:(6.DR"O^"/XLQ"MX2HX'B#B,T!$$\.UJ0HNF%@'`6DQ0[@N)[I!10#2QA
MGN\>&KDPC\O?$7IQ];.$J)4']C&,$S'.5MGN(NYH<?]PP?*%]TG3X(1QG,+'
M>`D6,;Z8W(1Z["$YB/W'A13C2[C6+CU\(9S-$'I$<L3@3WB4H?IQ"EC06.5$
M"0J(H:&@+<$W`BI!U,1'V@1PEUE$8@9`]&K)=]1Q70\?!)H2DFCAK)`CD"H;
MB/<X7.0.!(IJUXE<Z5D8`ZD/W@`\XK1`@4?:F&].&/'Q"BLC>]/U9@0/*88`
M%X(\#JP1`'PKHG;\)E]P;AL)8*=AP!<N:!#6@(/X.1AB?Y'"<LZ@80$PW'4$
MAQ4D)&A4F%#,`33F<TN/H7$F+_2^=KRY_+Y!%'XO2SXI>+?=I]TX?O,-!/,V
M,Q-()4RCC;8S[M"ZM.8[2OM3$6M<WG&IG`CSE-N=*!U\E-(@:\#,$/LI+:FP
MFC]X`7FH81K#$N*/][1897QL]41,R97:OF4"ME)$8WCRZ5/_]`P&F0)`SC)F
M=^W7^OD;":M?#YN'P-^^'R\=%)KYYR6RMOA\X[G)_-?#GOE3'KN>`FI9E`>$
M,=@Q8%>`2![N^`,DE@AWY`'G<O1&C-EN_W3OJ'+VCKW]E>?Z7DTM3VT^W]0/
MGN+)I\W=K<F5C\YH>E!@M,RXF2PH3ND3<4J_AAG@;&!*^,*PM[$=15(VQY>*
M#QAHHH<C[1]B:1BF*1Z@>$WQ40K<Q)5XS1-SP]1>'IJW;F61?/ML.*\YQ.0K
M%6LPWA_P6O7>B'<`LR2I7E+"E(]@))MDD\DBG=`\7D#5/+6I3W'%1U;C/S%?
MY4V>4VM6:]ZS`IUGNMZCUCNFUJS6_%Y[4SQ7O_4G;.(CLQA[C4[KA9,8%:QO
M`&N-4GG?!_#[EJJ[/[4O"G\*?PI_NXN__7(%WT>OAK<SM122]@M)-3)D%=9>
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M3TU7%`85!A4&=QV#90G[/[JNC<%N/$>;41N$[DK3]4*`XK>;EBQ,55JR`?KJ
MGJ9MULFCF;^Q(>9\"ZBN=XT?__F/--:O'&?Y\\0+G&#J.?YQ$"=12NV"1EX\
M]4/L'G3.OB<#/YS^]1L,H/TS>^DKNV9!"@N<@AZ%1[ZRV:^'+/0O3L<=TS0M
M7=<-RVCJ_X:-L"[.SD<79L>Z`#5H-7M6\Z)YJ*6!Q]_RXM`VC<[%M[/1H>:R
MJ;=P_/C70]TZU#P7?G8OC%[7-"SKPC:'HW&KV='M26^DV^W66.^UC:'>;'8[
M0QB_/QST+ZP+Z_`WHV.V;9BZ@#);<!F,XV`:,2=F(\;_/0Y.([9T/'?$9BR*
MF#O^OF1!S/J!>Y+,6<3;=KPJT.UASVZU[('>LRP`NC]JZ?U>NZ>WN_W6I-5N
MV]U6^\*XZ!W^9G4[)9`?!UP90<-PL8S8'![SKF&`:;A@7UAR,CMWOK\J%EK-
M4<<8=6R]U1T,8?_'';TW[C?U_J37'0W-IMT9C6#KS</?=*-K=YLE1-P"1)4<
MKEF<(`?PIXZQ[0U\4T<JAPUOF97]WKSZC9P[B<+%[Y$3O#(UWQ,XV$?3Z/4V
M<7"Q\#)<)TL6.8D77''@/X5Q+2'K$H6VK/+6;5A\&;I39T6"^3SL3_].O8@5
MFUU+<62T0!YUC+91`O,V*.X2S/WI-$J9FQ'U5S9EWC7J5F#E.F*@`UJH>X<\
MO@VF>^`C3`%OQ4MUQ`*0>[O7OAL-%5#*P`,VZLW41G.CWBFM^PY^/HU"D`')
MZM0'T08:>0S?+BF]M8:[:@!Q6[W6[;R]%:**W$;38X.&_A8`=?C>?YG[1^B[
M(!I_=[P`$7D2G.71V'[DQ?#3"#X&5Z<L\D+WI<R3[['W<^#YOQZ"C<P>:Y\8
MA]H_[F+L\6+IARO&OC+?29C[R7,N/9^@K24I&$#ZMF7?P>+;@2JCXW<6@";T
M@5SZ[L(+//!(0"]>,V&JUI'YVX>_]5H59K@#C#7QAJW$@%^N/9>Y@]6W&'6"
M\,N"J_X47JTM`9A@JW5:;;-3%7WWA.DN=LB<%6'^U1$%!KD=;:MY!Q-40+D+
M<NZ4"=T(XA45(U(4-QKJ+A=()5KV72;0O8$L8^ML[D1L`".XJ#J`IX"]PJ".
MB`!#V&[VRFC8O/J*YPWL`XC`?\;%`277<54TUA%NTP('M5MEBH=`5;&8HG#*
MF!NC_W<<QRG($78R`_PMPN`L":=_U1()H!W;AE6QE.Z"Y%[J@;M.M5</!G@`
M7;-['^6P`:*[2>`85NXY_FEZZ7O3DQD(6!B@CH@PF^@*V3WS3EK8"%(UB!,S
M)YHB*XVP#W-(AG6-C220@F8;IJI$=&Z!8OO6?W828?Y3/).['214?#\^F7T*
M@ROPIQ=UCY"T,6)K=>VM]/!P.,LX&S'PJ:8>Z1;XVV?X!^K611@EWG]KJS%!
M<=AV663>!Y0R\'W?#Z?H:FS6M6_!*JV!,;8'UE`W^A;PR]ANZ[W)J*>/VOUV
MNSGN]=KVB!]?K!D,]X-F2T!4_%K+R`D&$EJ=2H1H;>65K94V_60V8I<)'E>A
M`0E\LO#211V)V@;I;Y:)^DXX.-CQU2+\>1CZOG,91O1P_RIB[/4%VWV#88>_
M&:UFF\-ZV^(E\$[#!&NW'?]KN'+\9%4$D\:\I/O1<%9@Z!O=KM7I`P]VS)9N
M=[N&/K"ML=X=3CJ]P60R&L(X!KSXV_E-J"5T!@L>BN8L<%\T[<P)KN!O+:)0
M)?SH!=0K$XT.^(=%_.D,1H&`N\"3,)'I1#KB>*+/>]$S6V:G\]UH&CVCT[K'
MIK?6$-;I=B;FL#O6QYTA(JPYT+M6R]!'W8$Y,4=VT^HTP=EKVKCOV89O`J)$
MS$$2.=,D=?R<&LY!DWD!%_`@Z)X-Y"HX0]NT1Y.>WK2;79#!_8G>[;1LO=5I
M]ELMJ]FR6R,$QT0QC!?NZ/"851#RG0N_DV=%!&P8QJ3,GRJ<7W>/F\4>/PBZ
M%R=PV^[US$<!WQJWAQUST-:'2`=VIV_IW9XUT<=FO]MNFV.0">TUX.\D\-?<
M></JM/!FJ4<`W^N!1]*V>WIO.)CHMMD"Y34P^OJ@VS+ZJ+S:[1X"SZ6ZW6S>
M)=3?:/\Y"N!CV[2L[SVSV^Y8+X<0$U<#U&"8,D)J0A,2!B[`)&F:K>\`6[OW
M2'QT#;/=Z;3T<7?8TVVK/=8'`V`6X!"[TYT,^OU6DQ,(XN.)]/$ZMCO@J-,T
M`"MFJVO=1V8\TI(GK)B`E5[KZ<;\:Z&DVVO?AU`>B1)32!*3BY(G^C<8.3Z?
M.\$Y6RR!SJ+5\6+I>!&2&9X3LECRC/,&9[,PPHJ.X@CQ\3BS3#`BOA/JC$?A
MK-\;C;OC]D"'(?HZ8,_6^^;8U/L3T#O-@0U8ZG!CQ"35\\R05R@L>VX21F>E
MYWZ/8,ROXC"6C[\32#-*2'L0?&74?/*F)*6>K*VX.#::/=LV>H^2QV;+&MGH
M;?:'(Q.A;^K=[K`+ULJ@:UNF`:IK*%LK6T!X?;WTFJ`;3[)2\T.:Z9RYJ<].
M9@)I9V$:35G\!U!*,A^"G#J)KIQ`./"4_)LGRSX53YG&KAKJK<G$:G4F>@MX
M`-WPCM[K3T:@G+L]^`DPT>MR[Q53?46F[ZUYQR9F$9>J[.R?GC$1.4\3!G\Y
MO`J0P3:YR=J-E\RU,^]JX6@@INC'9`X_PA!8D1=X`=,6@-)YK#%XW=7.V#*I
MWI7:;&B(27P#WMO^A-G0;E@$T\<P&2B>FUC[`&Y\,@_3&-Z-/ZXWO-R(/`+\
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MW<AN$UPB/*_-&*.`Y\+S69R$`7L[4?;4=J#&[LFT'>B`NE/X,!I6Z]T1`4C#
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M2_<V'I[N;;U=XO/[G/J6/7JN*52ZMTKW?DVL?:EJC3=`D2)ME?J[!K!*[MYW
M@%5R]VL>:VU*[B9?HI3<O6[5[WZVKEJS6O/[R.0N]:@,9UJZG$5X?C8#P_BU
M^?JQ]V+:;W/4J"!].4B-1MM\X4/2&L%JV_;+PKKO:=U92S`M9M&U-]W!+&ZK
MT6OO7,7&4X$V&^W.SG'YD_.6C89EOW#B<OV@MAL=N_.&0FX'LU[V)]M3X4_A
M3^%O=_&W>R[ON\W6MALMXVV,B_KCQFJ8Q@O;(#N+&\,$!^1M;/'Z(Z?=,'HO
M7%^Y;\;K/B5[*@PJ#"H,[CH&WS!E.[O.Y-E2ET4:ZR/2>KO]EM7N3MJZT6F/
M=;LUGNC]R;"K6Y9AF*-QI]=LM?),;</LM<M7*54A>='DY?M"N=["&E8];@_[
M0[W9-B>ZW6F.]5YW#%":8P#2[G;L,4%I5'J7;\I;IO;6XJK`+,Z,=]&<S/(V
MUR^5ECPT)J8U-O5!VQCIM@D`]-OCL=ZR>F;?&/0ZX[[)H6@>_G;:_G^B%??M
M:]UP0\@9#YH+J+]A'O'F=MX[0;>8<F]8XMZ#Q\$IX2B[2O@;/Q?-Z'_"V"[Q
M,EXJD]V*=C^PWJIQ_1.8WFQ:D\'0,G1C.#%UNPOLWS>-'G"^W>P/)P.S-[2D
M*U3HPMRG7K+3OX)GK^"AONMZ^"[R'2'P*\_,Q^\^9TV&/K-D'F:W4I^'@^PA
M3-]_.[P-;=MHC;LCW>BV0,S8K;[>FW3:>K?3;K>L<:?3MZW\H@>37[*;(^[9
M$/`22#T)^M,I6R;\XM_^<NE[TR?=QOFJV`9!UGT97&_%RU:N#UQ1M53<*O@E
MQ1S?D]EI%+HI6`0P3!1>@TA!N?IR*D-,5\)R^PD&P-:;UAX-<MDF^E^&803F
M]J]9Y%RQ;`BZ?^<D36+8!"P6&3BQ-\7[>3T_31XF#FQ$F[EVWV2,,\3/<=6D
M?6$`+;;,=KM\A^[C0+O7I=OYS:2/NW1["TJ>^;)1$(A@).M=JUDVDN\/4QD7
M8R<*X&>\I3V[GNF9:4)"P`6LYF*=1LQ'DP@H![UY9+4+/-P!3^5:I"#Q7/S!
MNY:N#!I_G_HIX!!K0_&BJC01M[A6Q^[S>T-?@FV.OTS6D-(<F>:@T^_KX\FX
MC3<YFD`IG;$^,`:#X:@W:=IF%^@#A$NWV6EU>UWI?J3G`'1C2?#KLL@]Z8+<
MR(YI;:KXK=#_<3"-F!.S$>/_'@=T'[?G9M:J,,"`A.AFKGX<LX==S?M:<J%W
M^)M5$9:/`ZX:1U@L(S:'QX!V8,!PP4#6G,S.G>^OBH56<]0Q1AU;;W4'0]C_
M<4?OC?M-\#YZW='0;-J=T0BV'I0&6#F=KE4)(6P%HDH.V=UJ_*EC+`F`;^I(
MY;#AME79[\VKWUK,3]=9UI*%81]!Q74W<7"Q\"UWHG/@\;*W.D+6)0KMFKWF
MQFO1B\67H2NNE>Y/_TZ]B$G7`-91'!FMP]\ZS5:G60+S-BCN$LS@/T0I&C6<
MJ+_2+=T8`056KB,&.K#19O,.@7P;4/=`".KEN'BICF@`>C=;W=;=>*C`LF:S
MUYNMC:;0/.VJ77YOC@;C':1`LCKU0;AA[`>^73[4H7TU_NZ@O6'=SMU;(=IP
MV^L&'?TMB,3-G7^$/KIUOSM>@(@\"0HKMA]Y,?PT@H_!%5BL7NC6V4`Q4+$U
MJQ>^O@#P=TF/\6+IARL,OE+`\9/G7'I^?;U>#">W>G=(D>TPE;'Q.PM`W?I`
MD7UWX05>G*#RO6:/N&KYM>1+^_"WGF&6Q>@=8-PKZC'Q`B>8UC[J8>(12],V
MJL+UGB#=Q0R90_2(`Y97XP`Z9.H:W3MXH`+*79!SQT]H7Q#@J'J1H+A=4G>I
M@$K7ZG3NLK+N#62E;=3&"\OKB`@PMNUFI2'6YM57O'M@'T`$_H.Z^=KQ47]S
M15)%8QWA-C$8:C7M<G.WAT!5L<FB<,J8&Z./>1S'*3^M`/PMPN`L>6`WL%=#
M@K%!-MX)R;VT`W?/:J\=#'`R;%C$?;3#!I"J\1%^=(]18Y"A?D@6:XU-`V!^
MT[3-3B58<@L4VXG^LY,(TY)"A=R>)U[R_?AD]BD,KL!37=0]^`#64J=EM%I;
M6>+A<)9Q-F)@KT\]$JGPM\_$^5VIMKV&F`%YF9WO/@24RKF)[X=3-+`WJYBW
M8)76P!C;`VNH&WT+^&5LM_7>9-331^U^N]T<]WIM>\1/!M;TY/V@V1)K?$P.
MRFO)!?30@0?*4G%MY96ME3;]9#9BE\G(B\EN`CY9>.FBCD1M'_[6[I7!O!..
M.Y.-:KFEH.E[[;:45+5E[1LR[BAD_D3_YJ)GMLQ.Y[O1-'I&I_6H9)1.MS,Q
MA]VQ/NX,6WB,.="[5LO01]V!.3%'=M/J-//4'V+5M:0Z&9372!I[.Q0TJRAX
M;-+8RU"!;?=ZYJ-0T!JWAQUST-:'G9:MVYV^I7=[UD0?F_UNNVV.)Y-1.T=!
MM[9$8%A@9MB/PD"OU[-!*_7TWG`PT6VS!;)M8/3U0;=E]%&VM=L]Q`!G^MK2
M`,<`?&R;EO6]9W;;G?LT?WXD/DS$1[."CYI0A(2`!_?"WH".KF&V.YV6/NX.
M>[IMM<?Z8`#\`DQB=[J30;_?:G+R:/*(\E/(XW4,.\!1IVD`5LQ6U[J/V'BD
MF4=8P6A9UV@_V=)[+91T>^W'-4V_%TI,(4=,H]=Z,DJ>T!2_##MG$J/9LVWC
MD?G7+6MDHX'8'XY,'=#0U+O=81?4R*!K6_]_>]?6Y":.A?_*5-Y)2R!N4YE4
M@2^SV9U<:KIGM_8I16S28=.&'K"3[G^_1P)?P-B-;22$4=4\3-HV]CG?)^G<
MI6/83T;;DW2]3(Y.Q1>Y9XA4`*:N3SO;1"O70=1I0L#=`22_#L(H+P/^UT%T
M)BY+G#0A_N4=59W)R`*@54B/W`=Q27-<K9#\&VH8;RWP.2J%;76]<?P[K3I3
M`K"9V,3>-_XZ;[3J3"64_(20K4JD:+2Z2!WG-UKEYK!SX4%7M+X4;[U+\JJD
M$^@`4NLTSDAJ0P;5<,"(Z&0\=35$D`,6G#?5'.H5FS;R3--`)C''>>,(L/\3
M_N^F-:?Z^UHZK/(?;ZQ__,6N#.S5MH]UV@YC(XU,34_SO)$!\DW):(S`Z_-&
MV_[?YD;:NOF#ED'<!>G]2879N9`ZLHX2M'CL2Z7YCF]B=S3%FFV"<&3DPTF%
M1W!FC;T)LKT)'D^<38.56>!7\_-KA-OV7?5)3&IC5<2L%:3,6'^517&89:QZ
M+&/OIOG;Y?.Z/#*CF<QP_C%E&4U:);G;_U.\>C+1\YXL4(YN(O+D&MAT[9.[
M,WP+^^!EZ=K(A4V;3`G2O+'M:8:-'1L<7G#EM]U?N,+Q=@1OQXPS,/463;"G
M\*&PQB4.B^MZ(W!YI]K8@&\GIJ-KKN]ZFN7IIC5&X+6.[,UF1ZJ&Z\%F>2^.
M5\$#''%9L;'?)6<8-GNR$\,&V0U,6G'6QK!"_`G1-</"(#ML[)J'\5@;$8/`
MB>[#5[NTF(,)O8[J;#HQCT@H2!$&;!NGDP"?IP?\F11Z8%5OZ'5S1;2\!`21
M7B]F0^C5$_`@Z=]'<;18+6Y77QZ*MM&-:FX?X?=\C69@&7Q/XDUQ:%LZ.`=0
MXS.-QB%,;9B-$7.Z"!PF9)PDJ^5/=&<\-C1GXA.*)5BBI@LVJ4%5@.&@M=WM
MA`SCY`D9(/JX4[*>`J9.5V<I^IS__!UY`#5ZLTIP3X?:,"9'85;TAE.CE;4?
M;O`'F%L7_7&5AL?[39NO3S!LT&M];<*=+!LW\MK(WE7"VEJORCE%EFF#$:XC
MWP:S;>QH_MBWM,D$>Q-]-/;&CGT)=UD&9KIB+=BG=L?F<KB;(^?B!)L_G5A(
MMTS--$UPJSS'U1Q_Y&NF.QDA-"+N9(RW%ADIC3W8%Z0MQ_"HE&=+0#=5\I)C
MR%XL@@*%5P6K]?S?SBQ#^'K;!;?[<C?1!Y_$-DRD39WI6"/VB$ZI`+D-WQDC
M<PI.I&'DTE(WT2REQ?>DJA3RTH+'W$C>;97(C></X4_VTBE>55D3!T1OZ#@T
M$5LO#&*+[LG&3HUO(\$:*>/?P<,JY*:+EFFPMI6(6[&5&@G'93D(%)S:Q`@U
MX'\1(9VO9N%\;46"Q=RVC-4#MB:4WS`$Q-)4Z#5&YB:\6_WQ1X^;]\$3-2?S
MX2@+=E/DN4<JW6E*F_0%U2X&`OFP#UA.R(B:5)[FC$:.YDTM#T^MB3-UK(WX
M9;?O-!GK)AI=%B;#>?P(EPC`.7[$&&Y7)Q`=CY==NI!?E+']<4MX)RG=9"&O
M%5"88WW"DV[5E7C@OA2[3D-1JKVQHY/T/TGZ'3;SKTFZ.'_@TUI\HZV5[9()
M<7P7;#+/\V%C`V6XX"-I%O'Q5/=UY/G;>8FEM,1I(E:.\("."&5G75T@\%U\
M![M&%LQ.JT+/E6,@5S=R^\Y"]I,+?IYET'^YIO7DPDY&:`@(V_0UW2+.Z:%2
MT+D#>]X$C@`;=`:/UUS3F&K8]9#KF^!;(WM3M.'B<EKW%-$[49IP->6[)>*A
MIU$"7NL\S%-G:Z)^;$51!U1S0D:PB7HV=K-;[7HX2<J:=O6[;T%\%RX>DS1(
MG]\M'H,HI>N4-FB#CK=M(]Z/('J@$7M8U1E\Y[9W^P3561;;MK!>[-HZ(NB)
ME8[A\RHK7-B9)Y:OP2,\6C5$-$^?Z-0>T2?()YCDU&*33:N]ZI=++G9:G:OS
M'E:G%\/J;*O<G-O&L+K6!K0=4@.W^6SZ>CX;QF?.9SM]QE@#(=L!W&"^9[7E
MKF["6"L#M"Z7J]%X"I:?!J>LPF.!X[.$`>C2&7$E*;E/SQ(F&X!HXUIN<IF=
M)4PN.CK+=-"!AK9#<W;.'!TD3"HVQ,"TW;)]<F1P4/?C<H1M1S0=6H%;R+B<
MU@;$"&.119L]C?*`G)/FP[34]BY,8#I?KCI>[H2F][;[.EI8$HT:.5CR@Z#R
MH$_!+<S",+9IJ92-#HQ*K*G9O+B55]RN#P8D=E\L4VVO?Z\DF<@N5KP-:G?:
ML->A`EIHT>/'`/Y-O*6)]S*!+Z!]5]]COTS@"^_>U??6@AQ\Z*9Y5]\M!I:M
M>;>J(E&]NWI>Z(`NMG`$*81[YR[;0FS[<I/O[(Z0BN3BVE;9R;%N6^VL;;=#
M\7%[^T,+7;NUBA#0X9G'6_6#X^"/]>R>6P3>G:RX1E8NS:SU(O+O661P`LW+
M(<IN>EF[TP&MG;9L<]\2ZKB5M3N-`/'-8I2G+(VLERGC_#Y69AGJ>DM;OY@4
MJ\$QQ8KS%"NISM>7,,6ZKP9N*5;<68KUJ)#M`$Y'5=JB4ZR7R-4HI\'*430+
MXXY3K`(`=%FDNH,4JP#9Z$69CG[('N648A4@E\/(:9YX.=%%*58!4K$4JY7W
M^/0JQ2I@.Z(IUO(FV\L4JP`6L11KY<J;[E*L`@0V89.S4?4:Q8Y3K!<MB48A
MR'P,26724B<I5@$8V^Q6$<NJW_#YI5A%[/JOWA)'%S@LN229R`RCP=JF)$BH
M="+[P>NTQ>;6]F3GGU@U9$FL5F47D%AEZ[O4M"T3^,(3JRQ34E*'''SH)K&*
MY4^L&L(3JWDG3,6WDR>QNJ<0[HE5MH78AGZYH2>Z(ZBB,6$-05A$0]#F?=,D
MO2V][_<4GOEGX83FS^^#SG!)9R>)UVH"WQ"?P5Y;*!WG[CN1'%]DE[:>MC>$
MI[*9)VV@@V%2+J.VNQ.63=HN1PVX#-KN3D(:*ZQ(R+,RH2HB_QPT8RS)9PO)
M49G0A0Z`R(9;]`#*5YG0A4:DK4PX5QGG5R;DU>R7.MZ%F.Q'G"TF>Q0\#+XL
M6CX7_X)_1W/ZEZ]1F/Z2S;[!C_GMU;?E\O'7FYN?/W^^SL+9Z_ODQ\WHW;_@
M@$9LT(].AVIM/[9]5!;>,SZ_>?J2/LRC7\.GQX=H%BW?A[30X)=YM*`9DB3^
M[=5VLUC1K.8C'&K/'X)%Z#U%V:NW3$^WWZ(T].[SS[ZYJ7WD6]!I\9V%=#<E
M\=X\;J=@YK]P"=\TIH.1J)XT9&L(PS,V?]V\,8SG.V]S-0/11\]WWO3F9N?A
M;VX*C%H!+#^=>@=8=+\(O(=Y&LV^C9+TL:#X``%<6\Q]0W"<_(0-*;F=16$\
M"[-A(;?KX4H)W#8X</?\6,"VYR;O10L&!6(I&"8IB+0XX'8)>LC#/K/<#BBA
M>31M/$A`6;BWOX"^4/@P+$@/)SFD!+AUBZ?Q-]=O`UZ:!O$](]O:D[I+BD%X
MTR1E0>;,?]X_(XKPRG;@<9@N!G8\'$DW2LD];\9NX<X^),LP^R,)8NH;3J,X
MB&=1?)]/7Z.G/N#]1W@?/$S8C__X=9>S6R+D[F?P$`%5XBAX%V?P[M62AM;_
M#._9%D4WI??A''Y5_-*NI&@L!8T5<4\E[E62H:B?&0H9_KGZ$<;10SB.@B_A
MDJ8,\CUF"A^9LT.85<O'07Z)UB`9D5>3#841HV_S:!?]V8`PYPYR/[53WX@H
MY8+H-`ZN-P-,%P[8D+S":P10Q<'[AYP*H5XIH"J$>CV0JA#J,&)/$E)/A5!5
M"/7*:*R(*S*$*BT95`BUHQ"JO(Q0(=2A8"Y7"%4"[1R]1DO*%2%=?1S`@QNA
M"/\9F`^*1^Z1DQ+$V]67+)I'0?J\<^=<&<MWGS[RS>TXFDX:92]T0P1H1VY)
ME!+":1"E[`II_]G+LG`Y>@BRK`SA*%DLDIAAVY:+I(AS_IVDBD8[GO:FR_)Y
MYTY+L*)V7]DQFEA?UT\X2\#75EQNF\L'+A^6DK#7[J,9S2Q2@Z\MH]?>QBTE
M(;I.ZC<S/N%M7`%#:\#4$NYV":-FC$"\&8%<C$I+>$B9JPL`A+.6@?,"@/G;
MQ`"8IW]`Y[:+R"#Q%)W"R6W.O)&^2.-,0YY1#!E9IY(W'25OY"$#>*_J##D#
M0+M19#E_&U<`S;(1H$H%7T+.;+;T3.Y+S]R>_L2PGUP#/#!C6#@V/_7IZ5Z.
MW+R/XFBQ6@R1*;J!R<!6_$5,"9X&R)3]TD;%E"LJ!I."<XCE2?+Y7#2U;2("
MYQ@V74ES(30A$/Z]@@]-?M3FMRMOX)L:<#6DOYP:*%#F!I^.+-7=U2P0;#4+
M!%O<:DGR]8:(ZNXZ;\619OV4A"^`>`V@*H_C71Z'FV&..6*NVT0UT?+(MW$K
MV3N`F-IG>X[@,/R?*X-.]=%>*Z*JD?:*,%6=M(.(.DG)/=5*JUIIKXW'BKF"
M>VDE98.J\NRN4%M62JAPX6!`EZZ=MGOU&.IJGI-R'DT0XSE#\@!B0W(.KQ)!
M%4WM(W1J^L`5H*ABXM>*J(J)7Q&F*B8^C%BBC-Q3,7$5$[\V'BOF"KZB1U(V
MJ)AX=W?TR$H)%1,?#.ARQ<0E4`^J&S!IZ+:L>^2Q$,\HR+Y-_E[!BGB`UUNV
M=B(X30-X]^ZPR/7?>..A0F[R0:.[MDNA<1WX=P\6SLXHO\W__@.>2:T!.#O`
MXRB#MWG3N_AQM<S8.XRVG)UAK>):JDB\IGM#E<%L,,/E29^0,AUS,$>!KHZ"
MUJARY4>!$*H,XBB@K!DN3WJ%E&U80SD*L#H*6J/*E1\%0J@RC*,`6#-<GO0"
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M,!3-Q_QAD-[YD*%`63@>$AO+DE4!BX-&Y=*D\-I[2Q6)UW1OJ#*8#6:X/.D3
M4BH7IXZ"<ZARY4>!W&FMOK%FN#SI%5(JEZ>.@C.H<N5'@=QIL;ZQ9K@\Z052
MJOFXOVU#7=%$116EL!\4@R]FL`J&*`;WG,'*AU,,[A>#5=_H59<U=L4GE<"4
M+52AJ,Z9ZBI!HZ@^%*JK`+2B^G517:;*=A$RZT9^8ZEK6N"J(HO0&TNQC6Q8
MT!9Q)*USWUG07I:%R]%#D%5X.TH6BR2^72:S[VVM'5H\'\VC('V^A;7Y\2M[
M>/E;WWWZR'<)Z`;'AA;YEH#.>PE@1-1]<B+:L;"&"-_-#"/96I-8%PS'UB3D
MYC(/\I+ILZD(.XHH6-1-X$V_N7\W*'=#*'4MLL!KD45";%4@5G<=B[OK>`=G
MBS?.9OG(QL@E!/>O<W6<_(3--;F=16$\X^?W(_-T/%9QE(,190G1L?WYK]OQ
M1K^+,,A6:?BV>.U7>.W-S?J/^</HYRM/RKX%:9CM/23_<X//[_R2S_##/U>>
M-X]^`&!;^>GG/JP6=&]+M@`V^?6Y;NH_SQX[#N-D`2OUP(/K)-H^<__#;VYV
M?GNMZ)_29+Z:+?=U1UE4O-A`@W=!>A\N:R"@CRE>;/"81WAU[QGTCP<^FS,:
M_N?_4$L#!!0````(`%.&9$-0?^;0L`L``)69```5`!P`<V=M;RTR,#$S,#DS
M,%]C86PN>&UL550)``.N%GA2KA9X4G5X"P`!!"4.```$.0$``.U=7V_J.!9_
M'VF^0Y:15K/24J"=.[.M;F=$:7L7J;U%T(ZN]N7*30SU7B=F[(26_?1['!)"
M(`X.A#IAYJ64<&R?W_&Q??[8SL??WEQJS3`7A'F7C<Y)NV%ASV8.\2:7C:=1
MLSOJ]?N-WW[]_KN/?VLVK>'0NF:>ARG%<^N+C2GFR,?6(WIC'G/G5@]1.Z#(
MA]JL.^)]>T8"_].2?QT+'GVY&MY9IR<=RWKQ_>E%J_7Z^GK"N1-7>6(SMV4U
MFW%SOR\8N[!^/CD%WE9^&;+`<RZL#RN/>APO&G:`I0OKM-TY:W8ZS?9/CZ?M
MB]-?+MKG_UFE9M,Y)Y,7W_K1_@<0MS\T90EK>#(\6<'X=VO$/`'4[A1Y<ZM+
MJ364I80UQ`+S&79.HDII!-<"B7KBLK&"\.V9TQ/&)RUHYJP5$S:^_\Y:$%^\
M"9(J\'H6DW=:7^[O1O8+=E&3>,)'GITJ*"O+*MHY/S]OA;\NJ`6Y$&$M=\P.
MI:3!H*6DD-^:,5E3/FIV3IMGG9,WX31^E0U^Y(SB(1Y;(0\7_GR*+QN"N%.*
M&]&S%X['\&SBLE#R[?.SMBS_PS6S`Q=[`-6Y\7SBS_O>F'$WY+IAR7J?AOTE
M^P)Y$^2R4'/\2`U;DJB56T]K7RZ'4/+KR`=5DVT\C&^)!WU#$!TP0603/8J$
M(&."G2),:];XGNP/$,>%!%^@6O\%^\1&M'Q`?9C%7+PCVU'ATIEZ`+Q<SB4<
MOV!/D!G>BTUE=:4SWD/BY9:R5]'W',*Q[>_(\68]>[-Z381-F0@X@)]AX<N&
M1-=S;A'AOR,:X'N,Y*_R>==Q0BU$=-<Y9>_&WA6O7#B<@&*IT4O:0^'-;NQ]
M\0:NB_@<YIV,'\5"_6[^",@,T:B6[@P1BIXIAAX:P=,1M@,.W88/)Z8R>2Q1
MNE=($!M:NR8T\+'S&?MW3(@!YJ,7F*E+'#F[-%0BSGOT7\9[@?!AHN0"5B'?
M@\\7,I6B'OG2GIT`?Y02:6N)$H&7TK(Y20SQ#'N!_+39Q"/_P\Z3YV#>G7`<
MZNZ["&4K$R7*9^0S^]N5]%WD&@L+;-@#V4]OWN2_A1;R_1HJ&^<+HR!'(6<>
M?UZBTNM67B:>X%G@/P+0AIM9.(66B$:KZG+,K\_,Q^*1+4WHI1DE'O@$@>Z'
MC?7`/664..$7&#(##GXI.#WRZXK]G11.P,@!1F`0C<$"!W/%ML&G]L'Q'T!]
M-JPNC_C-OZ+0?45D52&NCZT;X@?U[(XE]X?NEN6COB=\'JSQ6[)2ZS96$="/
MTHPL28&*-7EH`=P@[H':+>W(DOM97?VA@?48!>.?@2$$_GV7<V`^_.%@*EVD
MP0J!+U.UBS=[:$$L`CN/Z.U@W9[;PJ'A)6V"`[QB[0XQ!1(P@(4OPG$7VL,#
M-`]+E2R!?9FHN)#*'"#EL')H@6WZ'I+V8"-(O[F#`U]S4\H&JJP^`F8G:4"9
M!4P!!%H,+KL30Y1M[9O-6;3:6FOV8+QH)FG"]H$#D$RJ52I3<(RG^SAJ-,RS
MC9%X#I-M@6A.$)JV9-^W,/5%_"34AF:[$^7<?H@>?XWL;P$C3@XQ&3RT;1Y@
MYXZ@9T+#H&$OX#P,URR:AX4.T\O&+C6T#"(<8AN3F63Q,_;U(&46,81!2O0&
M1CJ;8WR%/3PF_O:.R2MD"$?@!N&,KTI%R=`N2/MA#(:%&EBA6HP@7<9Y!H@X
M?:^'IL1'5(5(06V$<R&PS/ED,[KXT1Q?6U0^16."2YF,@2EP/2?C]Q#G<_`'
MP_R-@GN]LD90,=>-XLNY`-;)3/!ZC<<8^M^)`O_Y"J,@K@#?GYEG%V%]A=X$
M]WW/QQP+/UDR\P6OIC?!_8JIHN!WE<(PAV&::]UQV,YV=C'#6/*5I"(6Y#WB
MW[`O=31)I.<SGE>B*@BV3C!;"IG`$9I[N0;**H5A#O-5)(/0!+\#CJ=@<D9)
MXGR6LVG-<,VFF/OS`94I)'#P83*;2O\:;'XE\SE%3&`8PM@B'OAG4:)@Q:N!
MI9W81(5$HZ`)/-IK4MXJM!)[Z?(TZXC;<87P;RKPLKG?.*)H";EW2M;6)#YV
MX_)CSMP-GR9NC*G<"8MQ8#G<\_Y+N]VP7K'<UQU^AV]33AC,D?/+QFG#"@0P
MQZ8+EZZJZ+8M"@G<?QT#W/PY(P%[?@Q@4POE$ENG73=L:PO2*D1-3SOIV,X1
M@<\U21/(IT<$.<?#3`"?'1'@_,!U@OFG(\*<93XG2#\<$5*%X9V`_;D^8#/"
M)ZM0L_S]9$VJD?INP9D3P4O@UDB'=6-.BKY>15U/9=9&G46U!']:(\-#'9K+
M6IFTDL:)$ARC''+3L@GT&AEB>M!5698$<HU,,;U!OID$2\#6*""@!U:9OTXP
MUR@JH(=9)R*7P*]1G$"SRXMNSDA6N%WB"E7;?94^7FZ.Q>A$=J$([N9^/_GD
MZ\JN9-"V^,3;>NHDE]1$)/D3K*,<46E6."[QB/`7^ZJ71^8RP\K;2IG)BL>'
M>Q>]&L<PE$EQ!;D)WF&<)X->P7":QDB^;2HOE('9.NIF95YP@\XHMULEFT5I
M)DLE,"PU,M)Z#:8>96'(/'\DYI<Q@R*T4F]A5?S$T>84J*8SR.T6)H59FR)S
M>DB%\K)TO98IM*U0U=-\+7-HRCDU;2SG3@RU#$]K`=]JG=0R7IVS,J5[/9Z:
M:IEST429H0>*N'RSVGC75Q(),M\SJ&6Z-`MFSM*_7W[4B%.HO+C+S&;P=3:V
M'-C(*_&7:Y.[E3!#=$\>QXC*FVS^S:B\=_,3(I[D\L%+-@-T.1'PTS5\]28#
M#$KM;.FD@S5G=&K04-;5V6)-,VHY&Q:$?#@UJ^$\NWG=H(F33B[C?G31RL/X
M&C^'UPC(C-N`8Y<$KF($;R]7G1-1"UT!30,E$_@:+SY5ZT>1*LR<W8'18Y-0
M\O`_Q=&U.*L]HL"F5=1,[#(MV+ZWN2%)&<?4*%H93#*%N[FY3+V3O&`EU<"Y
MEJ_5AK9>KAIHXHQ[='O$]N-;A:JH!L;%5CB-G1;:D/5KK(8$HBURL0I&SCAP
MO/T8T(Z5&7)&Y,(VX&Q&P':YFC\).95$F4IOTK5],LOKZ`(55`C?(F:Z![ZL
M"BJ$;QE#VA5?5@5_.<O*$V'QC4&L:X.)F+I76<%T;I%*8%`>6=%%I*[`T*D]
M&V-'R%A<7XA`WL_;]T"S$1T$SY38#V.8G$'C5?"TRU<%77C75;QIK`"J=#G3
M:.Z1'[G[X2(ZCR\K[R%*Q</XCGD3,'Q=C1&W7Z5&3C4N[R1;O;5,@4]!;#8:
MM(/[O181TU[>:KG5]T`"RK1O:GD,X$`"RC1P:[F[M+@%OW8N57=5K.5YBO*E
ML[:JUG(7=G&O*"657&M7<>R@XKGJ/26RI[U2RW,+)2M1CKNA.*Y73Y7*<<V/
M+1>XGP3TTAJU/&Z^GV`T,G2UW!^UGU14OE(M]P+N)XJBB2;%GL&CGE_U$HSU
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M*5*,#RJ/,)]!_5'=H6IEGX+,DFKQ2@Q?<Q`Y\W+0J1T1-;T1[MD<47^>KR)K
M1(8/6F5/#DMK0F,`U]+PW`I\AS%72\MRZX!+G41>T^]:9H@*(=Z8]??+!)FP
M8<(])ALYK>RG\0T09IE-W?-6,8MP_3V@E6"O.F^\__,BCQ]41P*:+ZNO'</1
MFY0KPW9\V6;L@5=0LD7>;U]'IJNF$KDOEJ\,E_N^_/U8@%1->_1?JEX=EI6O
M1U>R^+$EFWZ&'H$O_P=02P,$%`````@`4X9D0UV@\=V=%```:T0!`!4`'`!S
M9VUO+3(P,3,P.3,P7V1E9BYX;6Q55`D``ZX6>%*N%GA2=7@+``$$)0X```0Y
M`0``[1UK<]NX\7MG^A]4=:;3SE26'Y>V\5S:\2/)J6/''EEI;_KEAB9AB0U%
MZ`#2L?KKNP`I@I1($*1`@91T'RX)A<?N8K'8%Q8__N-M[O5>$:$N]C_TSTY.
M^SWDV]AQ_>F'_M>GP=73S6C4_\???_N;'W\W&/3&X]XM]GWD>6C9^]E&'B)6
M@'H3ZPW[>+[LW:(7UW<#&*QWY_K?GBV*_MQC_W=Z\.GGZ_%=[_SDK->;!<'B
M<CC\_OW["2'.:L03&\^'O<%@-=N_(K@N>W\Y.0?04K^,<>@[E[UWJ4\W!%E\
M8@<@NNR=GYY=#,[.!J<_3,Y/+\__>GGZ_C_IUGBQ).YT%O3^:/\)&I^^&[`>
MO?')^"2%XA]Z3]BGT'J^L/QE[\KS>F/6B_;&B"+RBIR3>%`O1K<'!/7IAWX*
MP[=GXIU@,AW"-!?#5</^;W_3BQI?OE$WT^'[Q:KYV?#G^[LG>X;FUL#U:6#Y
M=J8C&RROZ]G[]^^'_-=T:X##"9+F:;#>#:,?H];4O:1\SCML<YHJH-,K;,'^
M-5@U&[!/@[/SP<79R1MU^G]G$_Y(L(?&Z*7'(;X,E@OTH4_=^<)#_?C;C*`7
M^#:=8[Y.I^\O3EG_W]]B.YPC'PCC?/0#-UB._!=,YASJ?H^-^W4\2L"GEC^U
MYICS61#S[)`U&DK'&6X+Y1AZ_O(4`&.R.1Y>/KD^K*1K>8^8\MURXUF4NB\N
M<JH`K3CB+L%_M`BJ1/@*PP8S%+BVY>E':`0B;XYJ@AUWU@[4`^!+F.0A:(9\
MZKZBK<`L'$X[X#<6G7WR\'<Z\AV7(#NH"?'F.%N#>NM2V\,T)(#\*Z(!FXA>
M^<XGRR7_LKP0W2.+_<J^7SD.YT++JRM3MIYLI_BR8\8)/<0X.FG;%+[YD^T6
MWW`^M\@2Y$[.CS1BOX^_ANZKY<6C7+U:KF<]>PA6Z`F^/B$[)+!LJ#DRZ811
M(W6O+>K:,-NMZX4!<KZ@X`Y3^HC(TPPDM<:=4V<BC7C>6__%Y":D`0A*0N$4
M"GSX<^8N&*F?`J;\3@$^SW.99D8U(JYE9G.4&*-7Y(?L3QM/??=_R/GJ.XA<
M30GBO+L3HI0"H9$^3P&VOUTS2X>=L7#`\A7(__KQC?VUTD&^W42Z\9QA#^A(
MF>0)EAJ97G5PG?B$SQ3]&@(W?'SE(E0C-DI#ZU&_ON``T0E.5.A$C:(/9&H!
M[_/);L"8Q9[K\'_`EGDD8,6"T</^F=*_16>!#-M@+FRB%]#`05VQ;;#``]>?
M/L)X-IPN$_067'NP?%5HU2*H]VT95A^ZN1P)]$TO2_)IY-.`A&OP:F9JU<E:
M@O2$J9&:&*C:E$T3X*-%?&"[1(_4O,[%PS>-V`WV0/G'H`B!?7]%"`#/?VB,
MI:M,V"+D=;)V]6F;)D3DV)E8;XTMNW2&IM$3<X(!G-)VQ\B#)J``TX#R?<?U
MX4=KR7MIIL"V0+2<2#HWB!Y0FB;8INW!VC:V@]2G:QSQ-3-%-Z*%P\>(6<16
MQ:T@QK2*7K'@TCN.LN5Y_5X\<!J!I)?K!T/'G0_C-D/6H4%X8"KF<\?^P$$O
M5N@%U:#;[+X;6/'<<OW:H$:]FX24SS"8H_DS(A7!S'1M$,89#$'L\!D-$LI4
M@S1O@!A>)XFVLV![!F;89,AW6#@Q^LJ&VC8,&DTZS,[:%"2*L<T6PI2-59H"
M,`[NF9J^,-IH"J#-8.).(=D^%L@A`]C@Z,P`Y+$<#4QRQ1,7*B\6?>:2):2#
MJ64MADPY&"(OH*LO7%T8G)[%21F_CS__DL22/JW'DCX33.D861YSJK.(#-,5
M(P"@`_(^].N-,:R$Y::JP[Z43?G5)ZE)KVR0>"%71$=^)O"904?CP-5PU+R2
MP$\T`_E]?'C*%Z^HFY;U2A'GW@K8!,M;(!LM)G?>XM08Q<1*"#`G,-75FUNT
M<7(:FH?WAD78,(D]P5+>4>BX9_C\<FX$(W[43F:6/T'S!28668[F"SA6&*B1
M6$T?.84[N@!M7:.;H(Q(,BD6`G#`HQ$H"47X5QNCK5AR'\H6&$;]$^R$?G1%
MLGB"U;*:)C9@ZEBW\0@O!,^E`G$U-:XD=GJ8.(CP;&?XK]];$!>SX^)#_[S?
M"RE`C!>1_K4#C&,3NTF$02ZU`.6LK5Z.KTPTI_$O5VT$[N_,X,Z]47D8UQ)0
M:>0K[/T5%4Y/8QZ(/!67S"Q!SH=^0$(D/F(_`$OGH\<-$M"PT#3*VFDEX]0F
M8VWU4[#466NWTW94T61$"4*=[Q^A:MK)@B87^TL3;5JIH-8/9JB5Z\&M2[.,
M(E9\C$>'?=5#NXW.K/Q$[U8YLRI[KLRZ<#;`N9IC$C`!PR*IE9')]MZM`^XS
MB*%F/'#RD8]NQGUV,^K!9>UJA12!_+;FW5M']^*N\>$W%!A$].'E%CT'<"I&
MV1TI@5N\**J]6XK9;<:941VWVW3&P)YB9\A)?(]]M+RWR#<4?`I]1R[."AJW
MU;EY=.'6<.'N$+NO3Y_Q*R(^-P<6[/8`02R]!!&P:,`09/M%45.H-=1>.''W
MV85;H&H9]]NVPF?]%^,A"EE0IJ*^DR9"A2/7/.LK[?5=$*,KP9S*"E6&&@7:
MBD#\K_N)>+VC4I#E;\<`US'`52E"L>8\/`:V5)V3>QW9:B8$N,?A+K5@\5Y'
ML)2U'^/JB_&(WGFG(WHZ:Q*9"%)0B@*:`"]0+XI.%+8_AE@.,<22<,+U,OGK
M3RXB(%UFRSOTBCR)AU^QLU&\1OXB#"@'YDRZ)K(>;<'@O#(&YRW#X*(R!A=M
MP"!]*&RRNC284FV,@\#24-CH&$X^AI,['G`]AEN/X=9CN'6OPJVR@%0U[3QM
MKU<\TXU[,=1B4CNB1U?"4K44MURJY%E)7?">-T*!\TT*M-<KW@@%+C8I8,K=
M?<Q+T92F<<Q+:75>BN%,C&YPOM%TA#W-TBA/3SGF81SS,'(%;''LZ4"BQ*KV
MB''9VLZ@N7+DN*/TD`3-+]H;-*_S2HTA4+6\*V,B[AT]%D!YH=D[;/D\/2&J
MPNA/Q\A&H*:S0L'7($6FEA>5KV0%AT.NKP"BRY(8AM8I]%PQ3:A_[\*\`>@=
M<7GD]==T,@A5ZZL'TBF,-P7F$=/&K^_$C^]PPV,%R#T*9MB)&TSP-1(O].2B
MHFWP=N'ZX`/+H05_U1.DY6+AN7;\WDR#1"B>52]UOH1,D7IX^8Q\-+'(%!7<
M=I:UUP11S.JLK$L^".D&>N><X$APR"<6K?3,[ONAY7U"[.DKGI(YP7)9(6NO
M!:(;RW/A_/!=BST`X@9P3()2,$936.SHY81[Y+@@9U%N0*+>&'H@GSGN)_;<
M,-\C(]^6`%C05`\<XID)4.A6JY.NH<]TQ^C!K]R-5FV`!F#VG3O79J,GD]/5
MGG\DV`EM@&"Q(/AU\[&X,FSJ#ZT)3Q\T)SN`322V-")ST!T8>$5R1Z6;D;R\
ME$+SQ9K+=*;<IB9@OD4OB!"T.O)N0D(V.:>DL19>N,7?83'QD^TBID`72XO\
MAEI@8+O8AEU]-6?+$Q__['AQN,"DB%G;S%YA]C9>%.VQ.L-H@1].HMLP=\O$
MO^B9A?GN8+1R85/04@L4GXGE<S<BV!@1H?,@R&G5T.SWUIL[#^<1JG-N;$II
M4W$$316C0=ME^F_$@DQF@B8K@[*DAQ:H_AF"-`$%_-:%B0.F2T63I54"D)61
M<`>SK%`RU!O(A-1-V<',\LW:PM+\+96>>X>1H2S.==V(<;\\\4?6PR`&JQ=]
MY5`GK<SD-7+A)T_XR[0Q`J7KET.9::-%0L9#/H7/7LQ@B>'Y!*H&>Q<4-(QO
MF+V>^(B(BW/=035&T0+]RJ(0#I@2UX:\@U:8%"%I;/[X?%4$(Z>U%F@>8#QW
MCF(Y``S!7N+,]RD6-=4"!W`=#!M84S@%QGAI>3SFD=:?"1;\"VR:!V'U0?3`
MCFG`M38F]]559)5NFN`+8"RFRW&:+)/W`G%T]N8#5])'#V0$VP@Y-&4D_1N3
M;[".+'*BXM2H.(*)DV/,GC>5.`3$[\:@DYYJZ1:MA["ROEC`F6/DA#9R8NX?
M%[BC<EH9H1!:A&#L6"GU<]W+)-7#U?OO-7:&;(U\MU#J6>25TW."8[$&0HX7
M"Z?790%:/6-WC"IW)==MM`S=,9JPM2S9)3K&/E(E9VQ]9U($#/<?YMOUQ>V,
MK$Q\+DI=$&N-]%`J,R9=>>73ID`NX12ZF;U]MPT_*EW/VWH"+>OW-',)G-;%
M_MYL`SUSNM.Y=>4YQ+5G-Y@LXD"I!`9I!R-\PEY('U$:(N<V)(DOAZ?4T2_H
M._^I\!*J6N<6X<4S86NBM=97"P=]7;P0V!W"09+'-9N-FIE;$D8M;&OV'FH3
M^8KI1%FE.(7Q)&JUVSHMH%4[[J^JL98L/2.-=@53LTVH2QA%.^;M6/;RBR<5
MHI))^<;J*7<))2X,W5]JBA)%*7P)PC^T][9R'81K9B((<ABZ@J0H`#=\T)F]
MGW:PFM_;2G)-%:&NB*L<)W?FTE,V^BS$3GOOBY9AE(WZBXW4WCH0E1W1B719
MLV?%\K7W.OP6R,H-:8'\^SU$OB"75;"W^1(7TG-"9RPBJU]J<=*:%^5JIU.K
MR=B*,['PXKW.P$_^??SMG:A[?&%?-_D5;KAUH094(V21I8)UH2Q4HT0IH$9[
M7T1HE!H%&93&2V"8HDO9?88N5)QJA#`Y00CS%:A,'SO;7['O0H6F=M-0<G7?
M>!4H4\35=MM74+#-1G4SBOUZEDE"B[,6N_L:HD71G5Y!DP-3L2O6`!!T.ARM
MNV*6A2#1X:CB51-L!(T.3"U72KP3U#DPW3SO4H$@QJ$IY\J5N@2)#D?W+KS&
M*XAQ8+IRX4U%09'#T7WKWIE,:'5^.+JQ0GTO098#4X_K7"\7Q#H<'3E38T<0
MX'`TX,+".X(8!Z;JYM4K%,0X,,VV5ODL0:U#4WVSY34%'0Y'OU4L3"!(<V#:
M;OY=/T&.`U-UBZIJB&2R`]-GE>IG"NH<F%JK5)%%4.?`]-BJ%0P%H0Y,WZU:
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MZ(W<\&]U/G[3-_Q-)>`?[Q:WE>,:N@&RH?P<XG4M9;6E&]>M\O5946BCW*+O
MQKWR$CQK6&#=N#I>C'>QEZL+U\`5K0:E&VPMOM5=`\WB7/867]*NLYS%G@3C
M5[%;$C#0$_/;?>R`7P"[!I79N<%S=FF0R][\K_&M0A/Q@2N/#XZBFVF%D.7;
M\HJ=3?@Q/LX7'EZBU4;,!S"&'_[&>'<5M(FRU_F-SS+WJ^Y93%#J,R]9ZL&>
MO7+FL!V8M&(%3./5DSZGH];7!%8C'S8G;$+@3B9X[N(5D(249#U:A($T#B+O
MLQ=8F'KFDZG/P.?Q,1TS>(F#MZ13>V)1*GM=I:=9C[4>::SFO-8YUZY]6PV=
MC?EN+JV+LL<>KQTL2ID,,^\%42L]JG"VI]$N.8+,1QN4XBPZD6Y%64^%/:&D
M/)2G0*Z=;EUP>E7&7%&+[X);3$W5RJ1J*AJQQKUE-7PJ#2@U"G*B4UZ6&?8`
M3OKQUQ"`$\5"1C[S,$6%XXQD,\[GL<-'JE=OMC.A17^R7,+K-UU1B@)ZCRQ&
M7N?!!W8*"2M@!$SGTJ\^?J;`B8R=1OXB#!BW^;;KN9S.UTO>_<:S*)6:>(U-
M=Z1=[>D,6=8).FF()'Z:XO9&_!N/#]+=+7XW8^TG086EE*=R&G8,7F-/,@M`
M)L2"\]AFNXM>+]._2-]=5A[`5&;CPPL_G6X`*M=!41!Y=='QP4\!+<ES5!_#
M,)8LQO3PD@)(RH<*'?<,'T/[+`U87.DVJJ48U5@<56/#\B$,X_A(0-<'_9T#
M6(Y/MKD1V,-GV-BN198/)%+$HP+/(_\5T0#,%P'L]7*S\:J9U/FJ<PJS-$J!
M*CD:BMNW!OJR`&E))ST/VK(,I^]@F((-*'G*=K.5.1='TQ9#-H%BPPXU[@=1
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MGC"J2P^UP5M"ES*GI[2+%I=GS@QYGG-Y6U-.Y)08D(;.\]NV`&I1U4\%[J1U
M2R"7Q_\*VW<:^G30<D<JM(K<2%R-Q?MYCS5A50KI/J&ZH"%KITV)%F-<BRYU
MT2B=>^L6::[0-FYV5_"T2$Z=$EP[Z%[9%ME6^%04S4'IL2;!MFXB_ZXL/EXM
M>8+C.LF6EV26TP<RM7SW?]S08S8M]EQG]9KU(X@H:!-GL.=T%H8DJ[P+0HN]
M-V;Y05RDF;TY!N/9[%4[`/P:=))O_0/%>_6A+?@GGT8^!6UE#:W6+9<BN/S8
M:0V-V0.7P`MTY19K'553!8A>4:H@2(L9H0+(:6;8YY+9QV+/U0JH1J6`,$"+
MZ$_(\H+9#6S.]('`.4>P?H%9N\V0QR*I!OU&R;6ZLC3)S89&X96FX68;'8O/
M[F,]UA8'TQJHO&OH+G1Q^+U0;F0LP[7=NL>N0D6";'7T&G<+JF<IY8KI[A;-
M*];!H]OI$^NMQ7:"`(V]_23NY,?)@OSZO;BUGSQ<NV=HM,L>WBP+P-JVF(G6
MTR/*`?QQR&9^AL6`?_P?4$L#!!0````(`%.&9$,G^;-Z>4```/Q,`P`5`!P`
M<V=M;RTR,#$S,#DS,%]L86(N>&UL550)``.N%GA2KA9X4G5X"P`!!"4.```$
M.0$``-1=^V_C.)+^?8']'^JRA\,,$">6_.Z;WH7SF@LNW0F2]&+N&H>&(M&.
M=F3)0\GI>/[Z(RE1+^M!V3*I!F:ZW39555^ION*;_.4?[RL'WA#V;<_]>**=
M]4\`N:9GV>[RX\F7I][\Z?+V]N0??__K7W[YMUX/'A_ARG-=Y#AH"[^9R$'8
M"!`\&^^>ZZVV<&>\(,>'.]O]_<7PT2G0/RWP7/CMXO$.]#,-X#4(UA_.S[]_
M_WZ&L<6EG9G>ZAQZ/:[IGZ%-'V!\IA.S4K\\>AO7^@"CU%>7&!D!*0T6L>8#
MZ'UMT-.T7G_XK/<_Z),/_=G_IDM[ZRVVEZ\!_&3^3`KW1SWZ!#R>/9ZEX/T'
M/'FN3TJOUH:[A;GCP"-]RH='Y"/\AJRS2*@3P07B3-?_>))"^/Z"G3,/+\^)
MFL$Y+WCRU[]`6/C#NV]G'O@^X,6U\]\^W3V9KVAE]&S7#PS7S#Q(A14]JLUF
MLW/V:UC:MS_X3,J=9S(O"1@(I27HOWJ\6(]^U=/TWD`[>_>MD[]3A;]@ST&/
M:`',A@_!=HT^GOCV:NV@D^B[5XP6Q58X&)_3Y\]=M"3OTJ(:9E2#-J8:_A9]
MS>+L!&C)+X^WI8!F&5GA0^>AD0[]!XW3C)GH/4"NA2QN*'V\PEU,.O,T$TK%
M>F9&H$-][N%"X$S6PO!?F,"-WUL:QOJ<AN(Y<@*??\."L]?7(B?_+?KZV]PT
M"1,"PM0'S[%-&_GS%S_`AAEP;0SCQQ.!!\YC^^DC&008^=X&FZB12\+7T]"*
M;\X+?6CED$=H^D%N[\O3"=C6QQ/;^J;-IKHV&'R;Z=/99/I-^Z:=_#V1!5P8
M?.7B_N^7T(YVH04D+Z&[X^/3]\,WQ]GX,[#)[20?:P!&)<Y-CZ2:==#+O,8%
M]E9"L<3U>\(^.5?''O^S%R#_SC-<?^Y:-[9+LBPQ\Q&9R'XS7ASD7VSO2/IP
MKHGYP?9^<4F?0GAMX&#[3(R<O]M^=22THT(^0UNQ6S3F1_IDDN&T#TP],/U`
M#(#8`DB9`!>DT4&-@-`*N%]`V@Z@AA#.$%/4Y@/YWF09).,;+^N;TSKG2$XF
MK7*Q(/VT]PI4)JP'8TMM)0C(-WA#FC6V\6([=D"RZN4&8^36U/]"$A2D&P&S
M!.-_,-)G^6P226>9))(/*040:5";(]IV@9YQP3IR@4%<8$0N<!(%7<@`#8*[
MB."B_E/)WR3=?$:!&&$+'U'`T"([1.-Q.NGW<Y1,Q`&1UPT&'@PQ2SD<B^L"
MNZI"KXA.I<Y0Q!_*Z.O5VO&V"%T@%RWLH+[*JWI(+H<J+!$-L>%DI,4L8@F<
M"P0N43F/VH*IIV&:WFJ-7#\<Y:,5&.*X7R(5B@DF$)LYBM7Y21')-JN-0T?+
M[H-7A.G@)T:OQ//V&[IUR5M`=Y[ODW1POW@VWLN#H)$4N31L8IIPP.KZ(.8E
M5P!,`V140*@#J!)6ZY'^*M&CC*Q'<X:>=X;'G&%FG&$S'8J9NT_`YZC<V(O-
MN.TO5QYC;'\VZ#.^TF^^S2W+IOG0<#[9I/,:>"XB#>`5R1]?7`OA^1(CM-JM
M&YL]VS(W+8\XB\AEB?P0PP2#<3(9ZOUO`Q:,L618<=&T3T2EP88*!X-+/SL*
M(8L2T_%`:SG0L6B(9`,3#K%TN4GH>,!9ZKDA;Y2.%1IOANVP/D;XB@E#P5BQ
M29[D=:O(0'M1F.:=YHY3TI*(#7PP;.O6O336=F"4UD0EI66V#(I-$*WT!I.X
M!9!0CDHB-3Y$LA35\BT`TW/`UD12SW;!+`<FK0:O#K1,35WA"34<^=?&#RA-
M_6>/=+8)6)OUM9-6P[-W:?BO#]A[LTG&NMA^\1$Q_'Y-UUV0]#8W`_N-#6_5
MS?T>0Y54=K9OO^ALRDP?\OGFQ`IX]B"V@[7DTRU[\B,U!K@U=)J*VD.306P1
M)":IG[56[5\][]_`HZ-GD7]=XE^'.I9\2S^;U+D;ZE"2A+S8H49LPP>U*>EX
MO,[FLR.]M':Z)TO2"*$+;Y*T^XC>D+M!U-2ER[Z+6R^?4/#J65&!9^^"%_HS
M68R3:3BV)EQZ!Z<MR\7HI1'3)@/>!>*ZP4CJ<AP*9VR+U*<Z2"MF0%R(\.\E
M+DJ,D-U14N,\+>N\5$,H$@XI]:F.5FA`7(C4"A=Q46*$B@Z7&@>R[/[@!808
M-O&:L:+S"U$P+3:L,[;P,)@(!P;)Z$^O-D9)$"H9VSU.#DLZ<*V^B&XE['MW
M;E*WTA6K]XOY>NW8YO'S8;G6'S;%ET)JPC[M6+F?+NLV8OOHZB(CL?!'K1A:
M<OF1:@RX=R&QCTX>I"S\D:N3EMS.ZIG;SU=`*I/+YSGXFY>5[?MLTI#5.3]^
M35*;7-NO8JI?3KMUS^?-Z@7A^\6OR$7/!EZB(+^\MKZ\LGQ?8(SHR+4V'.\T
MTETFCB;6)1$(02A1568]%%PN)8;B:`JC`B&2J#*''0I0%WE[ZA-0!<-V4T>9
M3UHB?31+<44T%;^:=`'YM$YI%ZR'^IH^GHXXD:/GV;8TZ;3=VW@M:SP5H(26
M>P/0=[VOD'8%,9[B61YDN\1BPX+(?JMF5U)*&<5B$T3?]&BFC;4\S\(Q8RI&
M%=OVQ)&C7#BW0,6H)-Z>6/2R=Z*>@SMTV"5B%K2264&'"4?6TZN!T07=0'V9
M6OUX_4X_Y@G=\&&9,W="%@DVM(9]?<I;DEPN,,'`)$-:-$2R%<VHM8^;,>O9
M"PP'2)?-_+T7[J[/K(U%Y9BE37\U"N#,A):XS_9GIH_,LZ7W=FXA.R0E^9#G
M(OGJVYRN$J(IX<8QEKF7O/N[!$;M*!6=8-5F0[X=BC\.]'FYQ#C,?%W,_&/'
M>&E@T#`N1JBD#EEY.+#_9*RY7URAE^#*]MFFC@>,5O9F59:T:I^367/4&2.<
M/"?#,8__1"0=>J!"@4N%2*RB^J)5M/H.6F\!ZU`0G(/%(=/Q?@/_C@*V1)*D
MQ@U6OQE0-'@S58>0^]KI7;GNQG!N$/(?$5OV_>Q5K[6N*B^]QU5AC&`[7QMH
MX_$PZGLQ<;`@\D@S/USI3UK\RA92MX9.2Z&C\B`22/MF2E=,MX90S[T_==TS
M`3XE';4Z_$JJ6S>P+=O9!*3?^!3GT.MWT]E8R+HA4&DS=A-$V>G:P*[M+OT'
MA%E#=\ZFILKJA59DRZRVVS!8='4RB62^-C.E%A*]P!4#U0PIU;3^Y\J!:(_Z
MD?/2>4();0#IKF-)X(EV)L%;4ZD^>)N`'C;&=D\@[CQ*5[9WPC0<DVYVBIH4
MS%KR>[Q`<TT<Z5-CE+8@VN1CII71V@M2DJ9\?W<Z-?>CS$3!-`KOKM>FO!'/
MGCL.0^G@2B5#F]L\3D9MC%++I3$C$P*9T$Z0J8O-NET,V4+28[7Q26[#43\=
ML^J7^>\/0Z^FGMP`KEP5OXM174#7'$^1*2,]G!N>RC#1<M%\U),FQ#+Q/A!2
M"=D,'^],8JXZ,6('K_*H%LK6^;*JHKQITAMKPU%1M'<DAQ^"BJ7RRTSHJ]TO
M5154I1SH2(:_,6S\3\/9(#K>2+I`&UPZ-UM:7CHG"HP0;]/.AAE>4%G`A$$B
M324U#@67FF9E^PS1'QO[S7#8KD1V=AX_4J"W\'#/-[HS<%X7D+M<*O.5$CYQ
MO]YX^(EX->E@E[WN\@=D,JK4"M&HF^EQ51.?5D&$`966&LI2U,YJ!QYK=%W[
M@;UBH^A)TE!*F-J(RS"FVA/=HDPT'T874/BE#33!ISM!IHQ)PNU]?2S"+(B%
M`Y6NJ/(Z`O3T-'`%./5\*PQ7,?+M>J=;3/P5>[[_B`R'VDCWY.]1GQ7)Z`0K
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MBR8K*M%*[VK6A&AA[[+*3]T:!GI&[\$%T?Q[X[&%Y,E.#/G$YH@&XV`T$:IO
MOU+)P$2KIE]+H,/5M>8KLC8..R"KIK6@?G1G)TK%QG2R[E%!O`O#M_W[1>ZF
MT6WX9QWW!!^62#\QBT2'&/M]?OX.D\O.#<M=+;OE?ZEGX1&PZPEVPL('8C;O
MPZFD8;.833.Q@8N4D''CVRZBS>$_-K;/SAF[)I^"[2V]3Y-DP%O?WR#K'M._
M:4)A,\%SW[>7[LYYORT)E4G>@RP5ON%QQ)=C<GV04@BA1N`J(=0)]QBXUFC1
M#M>KB.SR?,62P">VVQ7>&'22"]A>%1]LID5I,FB%,YDD<;AK.YD\_+S=_)`R
MML<F^G7?<!,3WJ5D(F2Q^%+__E0\J?A%624YV"\T("K3T?32OO?"1G\(W:!J
M,=\_9R1&=#K3-")8HXPC[NV.9)X[\L5M@%9E2S8J'U&;)6([1"M)?3"M:E!\
MI0*!2535,6@+I+XW2(4<W0G%&N9E7=/*7%^!EF?*XJ*)B=*RLF?DR@P1/=5.
MUR?C:3C)5APR3-IQ*%$Z8]8.J`JR'Q%4]?*!=I!5,+P<F919JCH.Q1-/E8Y0
M63U>>JL7VV5\J]NP6_F(@NJQR`[AFF,TS3,F+4[YOK#6,.K[8I1=.58%8E'E
M6.J95BK'2\.Q%QYV;>/6]0,[V`1TG/P1T=._Z6U;;^@3LFS3ID?M%TR][B=#
M=F7:U$#A(XDF(RTZ4BI1`3;7P1:UX)066$5J)*]4.2Y^+8<_UL'FR]):@*M1
M-&$MP1EZJ3,6>SE#2NV^;Q*(:_V]?*JB-4#O%9R[%OWK.MD@.0\N#8RWMKMD
M@XDE5978LQ+;!T(&"6\BU:<#3F7_%8C<\#+0E&28!\!EEV^#.QCR&F';LZ[=
MPN5CQ\,^C+'3[;+Y/;2G@,BW]#A*9MT1@3\%!@[D0A_50']!2]NE9T(=V0&U
MK<7VH>N5T%6V%QNEJG3#4=Q)W<G`#RRH;ET3(\-'5RC\NU$4E(A0GH^+[1(.
MTG&_7Y>60PW`50#7H6;K]=&\P#9CTSNK;0[T''ZR(DD_`[O8_8?A<77`U].Y
MPI^J6)VRKG*9;G%9R3S=,4!XL&$RTU.$3/-0[2K<PU$E=2$21"630Z7AE2=+
ML1/:&2UYM>P;;^-:;*B!L*]B4*2DJ/2QCV([A.^FFFF3Z&:PR_^ZNH5$U"FM
M<&0/9+0!)B0OD90"0[$H'91H`YA>^I8Z,,10S9QD)*'"$>U0V'.(C1YF\N-#
MN*-CN>EA##ZI;*,[6PIW^#43()WN3:P3'=K2QI,^3P)I^<F)^?$Q^B95P=I@
MT9T^LG?E'=$!VJX#DAO#^$G[3`5KIW,E*M+)\9R@BSO!J'&"G,2S#]^3=-38
MD4=,4@W245<2C^@*E]%,&T;+%?@MXLC`+@DE:X/IP!,]Q3T<>0I7I;F>V\-H
M;6S#*V`V*SHTM?)<M`7CNX&MZ$8/%X@1=/$?^8=)QS_H0?%@@+]&IKVP35AO
M\-HC74G#AS7VWFPKW%5L%J>Y;B2S9DZMREK=R4W-,!4D(:,2D\)4(YI4CI8^
M7.O.-FF"2E3Q!8P/V+,V)DEB:QK\R/KB6@A77@O4EFBUZ6EONP7K2F+89*`7
MMIA(G>B$NE,AF[IV>QWI!R,R`#;4`F67$REQ7%'.(HZ+=*?R5VK=-M</W`!@
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MOQ:-3"84AE$^_G>!*XYZ4HO?XZ>`CC&RQ3K\)K[ZEU?ZI!IFE)DC?-OC9*@5
M<(6(I9MW0\'1@0#Q79C*"=0*Z!U*G<*:H'Y3??E`@R@MH5FE>Q03+]S0.]\$
MKQZFI^/5O^R=)]00+6^&>/J>C`L(%FT$3^0I)]5!``O(%)V@850B5$"JL@@L
M(5.A6SI!HLH#+<I*JR1/LT,31I-Q42NN`X='M`&LG##JCYRIB;1*HB@^JF''
MGOODUFK1MYE^1"5=4G:(GRXXG99S)B6P(\39%V(Y>[QJC,HH5!"'E3S*>T8Q
MF2IW;>6+J2%-HYTIH_%T5$"4XVVY:L*-YD@*^/#O_;.^EO1H_A.F_=-^G_V_
MVS0[A;%V.M3[I^/1B`VVC0:G_='T=*2/LM42^S'%,3`">")<8!U[&/1/@<82
M*W6%S.A;C7VKGP*1LT8F'5EVMAUA9_D>GZ+WH8B%:XQ>D>L3O]VZIK="GU%P
MOW@VWLM#J?0)N=PL,T,TN`>#U$A>(@Q":4"WJMPO@`A4M!&G)83C783T(@;%
M%*F+NAQ;*CVAAC@N.\K!C]:[E;[$7#&I%,GJ%H\:?G!O+`$B$:J8<`"0Y.)U
MM1%?'"[9,"^`V=*"LE#RQG#BY1+/"*^B<TFNC*#P-"V1Q^0O!*NU2737Q;0_
MZ/?Y(J]8:FI1?)#(!8L(EKYTJV6H6AYJLO([)1>H8"6+K5J&JXN_685KJH29
MF5HO)>8H-=7BAIZZ27H&P?:SL4+S=[M\V41!4:G5XZY^X9JEK\<]O$0*4#'P
ME0I2-@]\(":]*29Y%6AY8&4KT1(/[,\&'YEG2^_MW$)V2`3R(1__Y*MOEQN,
M"15O;-\TG/]!!KYVK8*JM;*HA/BOTB\Z3D8T\(5"H20(10&5!=>T@RZ]$FD-
ME[X/KF/S0"3`*`]JO:"B5KA""T1,LJ*&;61?20XK*2RQ9BBV0'C,;,B[3UP.
M[SU!)$E-W=`"*CV#"A^Q3_B&\(MW=#Q:(2"E0R/55$G7=!7X.\#QSP1J$YJG
MRJMC>F*$\(I2$D@E9$^$=8+O>V(K9L@IV\!9`4\177:CKH(Q.8^T,M+"57Q9
M$SO=@'?5;A`J'B<4?$CV*$NM1:(]\?&T/XF.6(V#:!,*96NNJ518(,0C2_(0
M2\LXLXD@$@I<*A"QQQU(K1Q?:1EK>-'GRL.!_6<XD.(MXE=+WJBR(15A"L8#
M*F*>45.IKC$R[7!<!ZT=%&V12_N]-/T+/"JUJJVW1[1FFDUF&B=;(A5BL6S+
M2EJPJAJX9<CZ#F0Z%V[4`)57%XL':[9:%G23$@;&6]/N%W0>$KD^,RA]A@A;
M5/-B^,AZ,+;A7ISJ&PH.%"J3M0=9*K[*5YM$?$[V?MXO(*TQ=SA-HA2X5N67
M(4ATEIYSEE?EK-/06[U&[I*6-5HA6":?'/X:.IUI+M)FUVTM/U1J%W--L:G"
M:SRU\7B?9`,7.?HHWYLNTV'A!8-TP5HO]$-:X0^1/ZIILU<"J?!K.Z,)43^=
M'E+&SL&Z=1<>7H4'910W,<2?DSZF(&"4Z"E2FMZ?1*,*D=3PR+[PL+"4X&.W
M"<I'%MI&JW4`;<T`0]N0]<,ARQEQ:$#39-!!U%O'G[CFIH03AN'1Y#?DN_S*
MC>JRDJ:N2PT0G^/59CDV19.\T4'\3)K\N>MV@.G[`),Q>5T;9'SVNMH/LME`
MI\_%N)"45,*$6+UHN&BS>,0Z%RYLL4,G6+`?J$(.5(.2SX"=P"J._ZP'Y$7_
M`[_%J60%4W$YR9&?42X>(M-\_H_RH[IU2X<#TIL"DAGQA<&4C_==[/*B_9F(
MK7@M[&?)L4UU-HB`?"JGCZN+X\;&ZT+&RXS9=$CD0S6&UU(O__M\B;TGTT;T
M?+_R.TF*"\KOQQ=8(3IW/!L.22,UZKE_A[0@V5/_A\/0TC"`2U)Y#TD+H/2B
M=Z/^`I)*DJ0ZU67X58SH7QN8WKKH\R.2:F8%2XM+'(,OLT$TF<^F6K0Q@DM*
M3O92/C_7"CA]+W"R1L/K0BX]S%WICB[PY<+P;7-.&H2VLPE*#R.J>THA>W*F
M",>9/M!*2<1DLL'02&HWN'0(5$:I$!==SV*%(L!%`=NI3B\."0^*Z!*S2H*S
MBF!%/NH"SQX\QS:W=3/)=4\IY%G.%.&3&J>S22G/0ID=F.5M$ZS.[V"]X[QB
M(D]AS81VB5\E05G%KR+/=(%?39G5"4XU#K#^>%A>:W6/1OOARU5542:'F%*5
MQ]BJHE(C$G6`/JNUXVT1>D+XS391LM(BO19C[C`+R*?[Q2,RO:5+CYH*QQ#9
M`HT[VT6W`5J5;3]O6XM,JK9KNO`EPS-^V"PW`"(+,@ND,NNH$BOH$JO$#CY"
M':ZO^DIM`6:,JNR@T*5ZN4NC)9MI(T[3/O7V]ZFT9'0<-F=2V!%>WO'G'L)5
M'Y>(;C9Q;ET+O?\WVA:,J1>7DS0;4:A<?&0_;E^'ZW8B.<`$`9$D?X;B<$!Z
M4T`R9BTJ@XE/7Y1CEQ;MXB?H"CXDEP<M'#&K]X=ZEA1=.DSW"%CU$JRG@F`E
MTD?P7-T&3I)%K!O;0?B27A7FX?)*)%M**G4RJL7S[6B4X0J3`ER,*FKLCT5O
MA$5>Y!>&3S;4=T'+BNU'M+3IS(0;T`.=2M]*KIC4Z,[J%@^)0;9]E(AAQVZI
MBN\#T.C-T,B+\.(@RH9X`6XEXQ]_;(@Q=9/%V4(R1Q\RFH5[NH,QCW7VO/K)
MX/UAZ,(PI'6R"T,FTT?>A=O*XJ7K=WKH.J*;M3=N\.Q=(-*Y1O8;LFX\_(A\
M1%"\_G]UU]+=-HZL_PIVLTGF2-1[=HZ=].2>=.03.W<6LZ(ER.9MB?20DKL]
MO_[B28(/@"!%HI!-=VR3]6)]A5>ABIYYX3=\3%YU?<G[D'&=^-1#1MO4F\5\
M'BQY6I3D0J_U7VBIT@0]T?(HG!,Z)"FM=,]X\=/2@IOC#*K1[3$MV8.S08\)
M^D3+J`A[$%9(\N*GX@4W@`2LT6T27.DC8`E<5P2*/+VKKW4A1O$O892RW@XW
M6899=]9O4?@4':-S1!/30GJ]=+^-B0*7-"7+1?+`]R1.Y8_TC"E[#)^.K:>'
M(S!R.)L87GK;^>IR*>^_4!E$&THN!0LDBAQ("H*V]&JXX,V>4H5AN3D98N)X
M<.();%I^8_QR.H7I.SVH4*PLF/-[]+1T19B](#I#>0N/6+9DOGD+HR-E_Y'$
MLX\/Y"_H@<K&Q(><;(V';'7"-M+7\R`4-@C/I/T9)T\93M^HT%_CU\N9'M/$
M.Z(RFY)]>F>OWQ[#++M+3F&DJWPU&CNXL#B8#M;KG-4BT`7'YF#(8Y\J$&(2
MH;)(Z-,[IX.85.C?7"X_0B2,F7DE/4N;``6YP3%K"'7#?@70@*?*9&B%H'\>
M(N14A;`>]3>+92UF5.$.V!QA&`7K:`7OC=#J;HU@:[0",%KR?_XSPBE=S+U_
MHTLY.^B87H;!D4$BZP3YU6;2!"KEIYPX8M1]P=A0R@=EY3\H^GH%/0O?U>"P
MS5*@H"R*8;55M32^`@'`!CFLDWW7DW4-=@H]\..+P90,>BOI'&,&5VQ$ELXT
MH'AB,]>,`7S:>-7;Y@T(--7%L.])/ZM/##DY,61-@2Y-#ZTD`Y.-2LZQHW>[
M1NAH[.`+<H+.R`G\0$[0T:G6BZD9.8&'R.FCI((<LTJ0R`FZ(2?P$#FSSLB9
M^8&<63>GVJQG+<B9>8B</DHJR#&K!(F<63?DS'Q!CG)2Q6^7VMV5MG\?`E5M
M0MFZWWRRF-4PIA"7=ZB]N4H]C@6J*RB%N!<PM/7A1E!:6<H7B&;UG12[DT(K
M&L!0U0IFO=R?;>I[&J6C^,9-14].Z`:W1!6V=AI#HK?5O=L0;#;<(/F@7S"^
M:^YR)_[B.FN3L[5,LIM.R+\F/!&3=FO;.^](UT?<J13W#J2Q7!^1`\7"8"F)
M95_-LPP5?4`&MB@.XUU$;VAFYY0Y=U;L9+;./"W?=CF8V8EDG3.QEJ47<\)(
MH:QL8/LPXQQ!=X:=K_$;SLZG/%O.P_EG-S\NC5T=K#;,J'6)]QD!_<]XC].;
MYQ1CW44%S9/.1[5&,6QC\&RS6LW$*$<)T2B,+I04"B4MU^/>``I-"X4()<1(
MH9P6Q,@X@%*!\2O!C9U&Q!1CJ=X"$&/K;S@F\]XC;2ZY/T4QN^UWCMXPO5@0
M9]5IJ^U;#L?2%E%LQY'57!YO"X*\8VJ))!(T80;.(14-5$59Q]022<A!TM(A
MU<'1QC(>8LMX[F#WKC\XZWK`-0MLT09\*#&\WBW@\^+$HI/K=L!B[U,,S33U
M-WHWG0ZI]+X'NP/7-.MH>,KU]+0N@J7/S(/92NR_,!KHP(F(FXZ.)Z57JC$M
MU!!$Q"56@*GHE:HTSD+/+]B#F:@>%/DL5*/\2)C\/?PK.EU.?,I+3+/'>^.2
MLB,%>"R;Q+/TJO5F/@GT.$<GSD(N=S@3L,7IB";0Q@@D6,AEK#`!Y')V1#,$
M?3W!H[!C@WM#2&JU)<2D_FN\2T[X@40')D=+!KCN:8<3=XT(ME/6U7HAQFU.
M".64P#.^A]`LZ*&9JTEXBZNITVZ3*3Q`R3=1:-9P;<GT!AQ:5#&L_6HB._[4
M_$J2`[V1-)2*S="Q4!$(/TU.:,!0S2X>X<B8PV-^!QY+W3)3IIO)M!5-H`DY
MPZG9AB@/LG"L'-("5<#WT;E4C^%?Q2&JU4RN^0WGF&H4P[YB7Q"4$$6HE7($
MO)C67:]BT%=%MU@R.F$=27J[>(*CMGP<XRNP2.J<[;Q9K19&*(&GVPRF905-
ML`6G;-RN!3KP^=I$J!2'&;[#_/]?XYO=CNY[9+R&'ZWJHO^J[:^ZQ5*K/+:Q
M>S%?S'-,,6I(DD5?8R0)HX+RL,C:<'5C_$RF+/L6;`VL]9R54I$:ID8-'6+-
MVDTKF+.SCC?82R]X_S4F(15GYT+&[]@P)>Q"!!J/6LFL?72V#,S(I"R0Y*$@
ME+:#\PJE`]EBSHTA]/48KZVNW8I<L\7\P/`=/N`TQ?L?^`W'M3L7]N^!(K4B
MC*U#KJ?3E0&<DBH29,%FHP-JRZ:DN6(IIP`]+[5S23/<FHSB!\)D8[D?^,CB
M;E&`U?J+&TB`XDXOEW5JY6R]-D`P;V@H.*CUE'V!XT!&",0\ELT'=FK[2YKO
MAJ4AGG",#]'9,\BV^[@9O2TV]`/(VU=,$_/BY]OP-3J'Q_;=3UL"H"#6265]
M?7TQGQD@G)-'@KX/FZ5CF(`!^/:%/(@S%,4HR14/><ECBN-CX=G_\`O";=YM
M!K#1@I[`]_R"4[F>O@_?Z5R<YMSRD-MG6+:G"`MP6S&M9Y(SX[R9\2LVG01'
MGJXNQC</A_%QK!24=J=>A2E8!KLPQ=%L"L"`T!4O+1&BDWW]"!GW*7X-H[U<
M6XB$?"(U5X:%=6L'LR(&&BAL)+3U_EDP71IBA&!5K+'ES14:)40`8?S\V0(;
MWCIL*TQ:`G-Z?)J0,`N$6@O`184ND#`'!&M[#I)A_S4FP24\ROY.CS@];0_&
MC/J6-UQGT)O%L>W_-5D'JRE/F1<$BR9?9-`\T48Z4`GR0VHX537,6[M1DFA[
M`,U_'U)+-KO(M7M-D^<T/-%&;J)7&R*,DY1BY+WXS`1^S[06`EC2NQT4\R1W
M"X/!S!:J&_NW%Q+':K&D_7FG8[Y&"-M[7)/U-$]MKQ]9"6)04_HA=`N\/)YJ
M<;7R0&LR`PQ29)49GE,B)=1^1\WC3G'2+(/M_&X^G^<PD920R`22M*!0,H!F
M99`4$]:(D?R`XN:C:W=X,3M<&2X&>\"BQ:Y*K/YY$+STK(&ZV&R"&F"\*?DZ
MC'K5DEM^0,2BCJM9?5B09#?'(ULPJK]J.YBQ>AD$/B:);)UM/2FV7HKZ;H2P
MV%A1?PM_%C.XYE68?>BENGL@VGAR,RI;33?0#DI._/?P3%OHOM^%9YSE+7:_
M)"EML%OTUVU>_G:FXGZGI:N(MJOVY6(QR7=?"D\\"2YH3]F@4/)A/=@SVK,X
MRUDYWY,9UQ:U,"6Y(,:FZ-^,""-DT;]Y]-V;<>U1*\N9^\8K3J-D#[AITQ?]
MRD9.+]O!SB\>"2OC%>S:@R#S!LG=^K;7I&&!2HD`7[.^2I^@FS[NA_BJ,S4/
MYR7=X;W_EF#T.4FC_[(!TUB!S^)%,'0T26/M7<O)IADM9:K`=?<&5K@V%OEQ
MF=K6-_7@TEH&!&SW6S.F\K^[A(YD:MW5>KZ6*4'H'FVA@=!+?.[O]V;AG?EY
MU2U*[ES2;Y#5W?]<WG`<'?%=1&0BDS)YW/8EN<1[AA.V,QJS?X;'1I>]@I#K
M-5XO*6VG\O,YW>YCR[S'%XS^3_!">\&L.(L]Y.Q0I/)SO,IS8`T6&R0?)!D5
M1_,%*U3B!11)7)DE&,,L3A:$5P6,?$W8W\008_4WFDYQ$^_%-069LF3>;FYY
MR>&H;I;$>I-UO1!7=A@]EK$GK^?D]:>!MY4'U)2G]2>92."7:7J@V?MV?JC.
M&"P,`@(H_!P>/\?GZ/Q.)^;;PRU-#\;I:YB>S5WW;-YT":UV<:S+6BUENV9&
M%'&J?+FY/2"5,'`5KZ&5#IJ53CHH[0R!]HY;@J&EQ4"PV'H#!NA&2X^[%\MI
M(#9L1K]IDIS#HQ$D/:5?LN4#I>[+%9&6*Q\^7.%09""#W<,YV?WQDASW))!]
M_L^%@*[]&S6_!N/MC;)85]M8K=8U"+#)FDH3<:+@T+A>U6:\L#E;IE#^&\):
MC0&`9/12#;KTMO(1<FVK(]O7/8)@Y^O!>9$#"RC"KYW&T#ZH:O\KXM*XP.IB
M-6"<FB\J-#P(@[UNZ?NS>2#S250_&_5*0H<!KH\RRI"VXZ][.!4T7$70J.^'
M]]N/2]470-'0-?IN5O)@K@$5/HTUU^C']^CJ$('=I&MU.3-6/!@Q=FR34%ZU
MHS?O,N-9M>D-IZC1BF&]];N4K8`%L>+.*+M%F@&?<`^E8J"JF%_\95>!S2JZ
M0U&K$Y9A9+8+((XR<XG%ZE/N\9)U+"@XG\VG)8QDL)42KU&CA(,#YB5:3M$1
MDS5*C(V%$J]6[`VG3\EXJDW%+7'V)@K/YS1ZNIQ93O4Y*5(1J,+BVCA42[06
MP#3@/(,N]_A[^'])2K?RL^WA#C^=R=J/K_>*)&9#]K#MVPYC@:5(]H-,(+8^
M&&%VH)/18RQ*FVV!B%V/@CQH!O(8Z@=5]1.A?MA1?5?XZ^C4*BZ[V,]3O!J/
MG>W?]PNSG4YC:>+#LC-J08^BQS%!5^1Z<##=V<$[HA?XD/KW,/T#L\E+(9)Y
M.]/TAE.,:L6P/A;>+%<2E9*8ZGZ@U5>&TB^HZ)<9;_NY0U6KVY5Q9#:&+\CY
M3C3O#![E)6#\%))85]I>3C<F"!44_4%13RWU0/J`XB3^:-`3$E5UEVP#5L4^
M,-AB7;>->Z/E9YPB1V%L._V93>7]4-E!'G:_L[\2@:T2[KR^P5G*3E[5%<2G
MH[C=ITO/N/1IE;'UI<;-0NSIB]>A?;JW$H&M$LY\NLE92CY=TW606VN"[,/E
MZ2@V_N/X$AZ_8)P]O.)==(AV/_#NCR2.XN=[5D"A\BWZ4G%]7ZV[B)8.M9QM
MYN*NFG2H+&="UKF4"]T0SU`F^-"BB)R1J$GA^++:R*8H!8B"">)<$&6#)!^4
M,T+WVO(<XP42%^8(KO$,L,MI_>-"?C.MIUU!ANHDQN]\:OSE$N_-9_2:AUT.
MWHT2V/>I7L@E'*6#."'$*$$/Z-<K%A2*G;ABAU;%G`WR1C<KC?9Z0T#@XSL^
MWX;9RWV:O$5[O/_T_C.CC1F_1'$8[PA\;W;GZ,UT\:4#`8<XLI?*>N-@+F?(
MA#:BQ)&DCCZ](TJ?-F_(.:""!4R"Y4@F6$H3[*@)7J4)GM[1(5<]-*KN"I/=
M75O%:4?S^8W=EH3.'H2\Q'+G]/OE9-(3T^#IH2-;A0VV38J#YHWV]_A^T`;/
M,]6(RFLV73$\-Q&`AW2#5+9CTR:0A52,4,XY^#H\7VL"_?`<Y:I[/3P;7-L"
MPSKS^8W=?L.SB9"76.X\$,V#14],^SH\#V45I?Z@_\.SA<?W@[:OPW/>\;7O
M\-Q$`![2#5+9IXS-;(;GHB&RI\/SM28H#\\7JG:Y';+/0[/!K2WPJS.=W[CM
M-S2;"'F)XXZ#T&RRD55_.^/9UZ%Y**NPH;E)<1^'9@N/[P=M'X9FWK7J6Y(9
M1E_E&;?`+!A;EW)9SI8%YD3'-$H`#$8]=0BD#L?1A+<8WGL*OVP3WB&BZPY>
M`6M%1Q@<_BDZF]/#X#2)R3]W[/YIQCMFV;5RZTS&*9J[R6:=H[<(\DGSGZA@
M@<H\9"\X;UK"C6H/<6-S1Z]BZTP""\M^_EY&;@\##I(T]OU"3Z.WAYO]/N)E
MA7_#,7X,TV>E=[F:8F-^P74JF%$:R^K3T\EB,IOSM"].CS7^SBFB9T(2G3E-
MQ_E=`^HW5?2C;;\+_2A))&@")&T-J&-@]0W!,K&LP)8G7;7;9=`(8(E[']#>
MW3\F9*6V7E<Q[@&P>ZM2@;,G&.ZM3J#_,N!PM0'IJ-#\&I,`8#TR-SP-!=2Z
M*+;Q?#9=3X(J7B-.S@?<7JM9!;Z"G"\POE:[H/V[@:-:#ZH:N#7F&`3C6T(S
M(DMVGE?]!>//81KCQJL9ND==HULCAZV+3#>;]8I#>TO]@9!"1Z7:$&;4'.-Z
M$)VF4B=*"LD*2H08XM0`$#V(7H'0ZZ/F6Z$D1O@OG.ZBC'4H2%ZIZX`AO`52
M.;Q-MH'8.<MWU45'$MTN=OTYAWM?->:6FSGSR7(M\JF+LQ))`V9/^#I5E(*T
MQ7$N-BCD:D-*ZT;JCE.S[EYX?<L)K/YY2!1T3>I9Y>>I=32`'Y@.HUWE7-2+
M9E&MSF;$"/@99RY1ZTEGTY,0^.A^Z#;/ZVT5OC/ZV:?U4-%3'S98T+<0]4<Y
M8"2Q'P.%^5A1ISL(`-+G,!:]BF^)^9)CQ#LCWL3[>UJ^4RQ;M@>1W!\>'\AO
M^%%*V\`R"&V7(!M"8.N0OI:YN2I;5.++JN&IG.G61LX;%<SA1SCGI@NJIOM0
ML5U8M5W2RW;.@L>02"R%F\$^S2\7H.ZB;'=,LDN*:=N4Z#FF%^O#^*R<#=-S
MX`AG;=D3SL7X5<)>#]VL83Y9S(>+D(6@O#E2(6HI"T((ZT$2B->?A47?3V$6
ML;*EI0]`X^[#Y70*TW?ZMQ9#_[(A]XK8,EAT[ON500+Y^06G-UE6/VQK>L)E
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MM8`VUL<""XN/Y,,_XM-KDI+ESM?3:QBE=&9.Y<<9OW#-]U&D"Q`/H`Y0J&;R
M[0&HNPYZUXML7]%_4XIQE#/*6:."-^+,D<(=5=DKP0XPECDV7C$]^G@FG#^>
M<^-%.6^VOO<[@`V'P5J\&NB#0(2G^_"=B?:8W.S^<XE2K(BK\4'C*PX#B4D.
MZZN&P4SDCTEJZ#%!@IX:"H:%^X9K%^/G\(SW)L`/I^2<:4E$?`DSWD8H,JOG
M"ITV+JA"KM4D7N#H/J6GS>?W^R/=:>--C%A70]L/K2<`B3&M5-9#RF(ZUR-.
MDD>,?M[F2]L.$@2"`]F@#LA7J3W=',<FO<&PV>K61J2:+3=(8C>9]M,[J^$S
MWAY^)._AD0ZOC\DG3.^RDN7$_@M1,*^H3=8)3>F[W8FX3@;O+*'U38+E;")N
M;!4\J'.FD@MMV?I$^]%R1CRU)E-8.<XA']D4TXHIM@>4<Z&AZQ-&DA&BG)#*
M"B#U?&1S!-=X!EAN>N^HD&>M]S/K,"$MR<XW)!KL:41@Q<SO+OAGO,=IWF.\
MT1$L7G,>MMIELKW`&"Q7*W%]G%)%H20KRM7O+QA=*.6BI[SKP#2TLM-<V9RL
M:#I`""-&&>6D(4+/T`KSZLBZSXG"C#;Y*+X\7'BQ1V@14"R--5`(.1-Z47CD
MH>N]F)E])K\^OS=_S99WW`</LT"6OD4XKF9YY!`DQ9A.%A[*JH23=1TTAE1R
M"JID6[084M.\7DWT1G?81,8WVX0,G\,H)D'S_(+1<QJ*$8+,3\AT!3-6RL-\
M&;:_[""CB1U8E5!B84F079$4OX;17ESD,"=$-#_K<J^C20#KGAVKB=Q(Y&3D
MM2+8S(CK=0I4G7RX9V?TJ=+N@U9W&"@D.XSW&5TF?,VR2T@4%1?<[]FJ87LX
MX+2^']']?:>0L13*.A]GMII(&''2?$TMB><5&SAY).E#H6L,]8.2^FQD>N7:
M)H+<!Q3C,]O!EV;9D<DD,"H[NG<9J5WLZ`MZMX?;Y'1*XH>S_D)`^WO`:"T)
M8^NFZ\UF;D3I]H`X6<3H^H/._NHVH#)''T'BCJN;Z=2%Q&&CH[;AKVXI:-S]
M'I[%:3D;V?D4]R;>WX;'8[8]?$OB9^(3)XL#[.N(`B&VNZ36H\Y2WC$LP[G@
MB!26[%".,:4PEVS'.ROO`_>1;27ZN>?6\>@L?1"\Z&)#3[,.LX,EY,BWVY/T
M7TGZQSU.#TEZPGN+_?!N%)SO;G42SW8?=;T@/BOVNB2XB_.9)$5_$AYT%Y4S
M@=XQ']$&Y0!7'-D1&U`>*&?BPT;ZB'90-LJL7`!N&ZP7XHM-L>XV!)KA-*=$
M?,?ZG3+#*VYG)UHYK&LZK9?3')K:U!]ZAP!L5C&,CD%)QU*"#UO.`\\:6GVP
M,B<P&P4"2#_HW8J;OR+=K+_XNT.(Y$QMKTTOYS(AE;V*_DU?!KI:WD_XP$9X
M5YY=<PK5C<OZ@?ELN8=]TS<03[CV6\[6NBG3>KHN>2Y_'=)W>RB@>N]=<@JC
M&-Y_RPY2\V!%RT%66C_P_K+#>W&6^",\XXJ-=4^Y7C'51;"=":\FJX7(`!!$
M1!+;.TH)&<>KGFOUF*IZR"-^2@9@Y7*M+H'NFX`M0_1PR)<:&J5!1A1\I/GL
M]R&9GO'XI0N0]0==CB\U[K91.IC*9DV"!F)$C-':P7!SG3Y!-WV<C3Y:9RH-
M0LVZ0WO_8QK&&>WSFL39IW?U+Z9%@CT!(+28I;*>J2]ENDK9ZU3JM,%HQ2<A
M%R/CV*`)>?"KELYNK,.CA:5@</HJ[CWE&W"WM!053E^I;-_#$VX9O&S?=XI2
M2Z&L.]!/YAL)4DFZV)9&*G%$J8./@6/HSPMG=%+5'4P[>G$9I5VL!0/2#!-K
MO-S$^SO\AH\)V^)KJ>;;\I)3.)HDL?;!8)X/E)P>VYE6*((7U1U0T:"D:-A)
M47>HLW'+,M1:#>01OM*4;NKP>!`S"1\3<6CU)4E9O0DRE#\2Z8SSV"%HPZ.U
MF\#6,[]@-FL!M<(92=;TMH1@SHZ-.7LZ3:8"`,^.79O/'"H4SA\*^YT+^QUR
M^WUHLQYP8.F'1XOXT^/C_&)AZEL4XZ]G?!HA2A6D?XT@E<MKO2^T7$V'BU'_
MIOP1$^#7BU#];#=8@&HUWB\0H&I('"@^E3_-+Q:>:&AMV688@O:O$:`*@>U7
M#,O-<!&*3P*`-S!<6V_P2907NR(#`G*@,%7Y//[$*7$YL9-#RG?`XXH0Q#IU
M?CYIVTH1%'V"?Q\EZ[#>%P3]PV;%"=LQI]K$.RR9TZDLWO0%5YVREX+U9MFV
MIR%OI`-G9@VLLQ%L1EV]0)TAN<O24`,E?7%FO]'Z&#\(N_BB2?MJ>,Y]XE==
M"$N?64\7RX7,_!(^PVN"I)R.\]RO*U4I0YZ108(.2/K7E>H(-+,7,V^NHIC0
MH62!:70?%*`/.'V+=EC09Y=8;I,C$3SAK4V-5^"Z$X&"MK6$MNF%<_*/>07X
M&6<BH2_<;:?R`;L*-[(ARF%#,)&!0]R`*_$!O0\WLC&")J\`N<=['=1KH:B;
MO6"F\F>R*L?[SV$:1_%S=K,C`>+"TI3N\"':1?I$@]87G4[DVZ2Q+M8^7^3[
M_IPFDD210A4)LE!S^$'59?A3E=OKE7,W:;=US/*<W<HP,$AC08#>XV<S%/VA
M7/4YISBJ,+=O]SZ3MX_$&,9*6'`B4""Y1I>@OD0!K2RA=9^R^S>I#.SM2M:K
MOI&2_GD8[R\+8>LYL^5BUH`"-;]YM-9%R3D\6L+A"N665+E'RLL3,#1[EP84
M#8H#@N,'WB7/M,Q:$K,&P.]M[<W;WW,/%KTP]B=QBTT9-`I-WH'ZW8-&W\/J
M&VCT]0!5[6[9@*X6LP"BK&7$@1A@[$/N=%J&!NS8T4WN8JB0&SP^3*!,0P3X
MB)"U9O=7'@/PW:Z)[23@E>=$F0<9^U>H4HK<J9C9G1/T\$(;:)6V=_XQBGIO
M.'U*1E1P6CH#:-3!-6;-MPL:=`7!L+A^WGAXIWG()7Y+G*U;I4T6HB!T7M@`
MXG!K`"4"58ET1"5L\'G%MVC2`W9@;?3[$D3KZ@YS)E>BF]&C^1V)QFI7J,;3
M#(O7G)^[M<MDVR=LNEPO)^*DK>(FK('`3@Q82J<PUV=K0RO;%*`R).E6NL1!
MG)\-K7!C$-!]7;B#-'M\%D=GEJ:"&.$?PB/>'EA%[MLDSJ(]YO,\*=@V5N[[
M:T)_-QH.YP>=!+-.QUS(6S24/"U8S1B@$H>B&.PV5BM@P$PQQK,#`^UW?*8-
MCI0R]K0MDFQ]E+V$1*D/*#P0.?-^$U[T?>GE_.HLH+MA@3%.:P!L#XI0QLLJ
M%B_"H%DCC:WK3A>;21.$61D(\I-"&/C^R,`Z![G.B=#Y`U<ZL5<:`)PM7JM!
MI,E@T#"\T%1;\@.+C;0_!MY_[3;2MI,`@F:;7-8.2]9%C2!E#-C/C`7B/-!7
MOP;:8>U0`F[&@1MS0^1#+&L>0PP1Q>AL-@0$A&T]7@=F*W,"P_H^C7;X'J=,
MR'87*3\.`]>2#-:7H2?R#*<,34:,7B7DT`3'8'_EFO#VRK2CW8$SG78`P&KT
M.0V(ZO:``DPF%L,BFS0C2XB6<Z*VMQS#QR"*[<G$:CH)"A1E>::T)$D[%("?
M*PVIJ_:8*7H^A1;'3"[19>&@59"UF0D$:[L7O+_0`'#S%D9'VL;X2Y)2:1_P
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M0%AICL"NOR5L-/]\>CTF[UBN!)L54%44J>;_);;`:93LF7)V\[8A>8%$XP$5
ML(7Q8IGOO"C15@J27UW71LYR@"WD05P@$5D]F4%"V;<VVVRV[\>GFGT_J`9.
M>AG8?:@=`?/-H73H[PD;*J^IP&<5'Z]F`!(4KY7:^G!Q,F^8=PY2'MB/Z.?4
MD+60-TRM8)_"W%!X;8YM@WPMZ(#&#P&84V?_Q.'Q_')+0O0V?0Y)$&8QN>."
MO`=)H*#554[K[:O9?-$4IL2!&6>(.$=$62*5IX=KVY%-52YYILR?>#DJ8]TE
MB)C2%S*Z*-++N"!QHW'VIG.?YH==8KU1`MLQ<CW/,Z<U*RL@6%ZOE;(GQ-<S
MNQ:MG*',Z&`E_.BM,,C-)G:9].:YL99NPP.N;RN5N%M^>Q)M%QM^+8E?E;WY
M;=Q*N$W8O%+ZJ2+],U`=WRM5"*P_@),K0HV.GE\&JJLY#+IH#LW-<9]&NY?;
M)'T5>30&M!E?<(X^DS2VU5Z#Y68FT$C)?13T2"S."3J^%3B<6M-<+2354@B"
MXG8P'8/ZI[/5T0VP;3!6`+W5+B`33H)!-O6O);]4)T7U!UU.-&O<K9.6%BMY
M;4#2\"$_ZSI]@F[Z.)M<:IVI-+%LUAW4^[>'VS![^7),_FRK3V-\!0(1#7)8
MI[:O%LLJ-FB:`:&'&$'X=..AM*P@)NF@I7/T&)RQ$4<ZVP`CZDL4A_$N"H_W
M2<:JIMDC2_\J#,*T\E@7Q"OF;"K2<KI($O8)<<-H74=>9ZT!$-CJO!HDFFT&
MC,BO\2XYX9N8[>BD^`7'6?2&Q6^MP6E%!0:G-J)9#QNS1=``64Z,G826F,@_
M>(3?P:W1,(AV-P$`F+OXO0;7UK8$A;@Q!:+\$`1`.R4-+5?YZ4"QT`%-(NBO
M1G6]YL$)?J/+-#H_\$DZ/41Y28Y[\GD^_^<2G=^UGZ?VH%,?KW*W+L6_7.?C
M3$$#<2(PM7"O5$:IBILIE/Z&L%8G=VZO\Z:RZS?J[X?[MT[4M"^`PJ'KVF$Q
M72^UL/!@EC6(?D%5/XD1V/O.K3YG!HL'\Z&J2-^3,[Z+LMTQR2YI>ZJ5]?N@
MD-((97\'/UCI$4:)HX*Z#]E2HQB@`8+ZH1<.@2T.;`:DR4Y@^.0U>^XNM/H?
M3T3GM7R^XS_9G_0'458ONT9FJT36*^WU:J;`4I:SXI3EA0=1ZHH0YW\'ZC\U
M@N8,C_>7IV.TRXM#?J#I4Z<DYM/)<GDK<)A:^W$-HW:&\PB@_QL>+[@G/BOO
MPL.S+)!U@?+%-&A%)R/M*SBOT)MA\U:!X@?T1JGY",)F7[7`8(-]0"!X><K(
M6H"V8W\C_VE,W#(_ZQ)B30)TJ$0JYZ$Y&<3H`*4Q#:=5T%DK9Z@QN5<))5HC
M>("*UF0-W>-PV.C<L&:QRA.8*H[D07K&$+HU@L2;I(P6AS-`Q8-DC(I`K?L>
MVN<!\=+]QM,BKT9:=RKX78Q!U&O&C$]`,6]1&(W@`50>";^;OR+M&D?S-!Q,
MI`C6:^W%9*Z9=%%2)/H28GY`I)=JS3.O%M6`L%)U-@-22K;P!"?FEA':YV&Q
MTJE90K`I]N2:70JV*<0@ZID0XT/[AS;':T$-=+,'(E&TC\+T?9OR3?G?\?DE
MV7^-WW!VQEBIROWIO?ZP?,R8X#,D"\?H'$IN^W0V=8[(":)M*@^_N`!(DD;E
MLO:?WE'C6_GCL&E*4.8,*N9,=.;\@$HM9]!3R9Y))WNZ##]#X[<:L0;]:K!!
M3A&W91K=_#Q(^*D(8;W3MYJL:K&D'#&@9]/7ZU<!=Q7"?LRIC;[7C+8FFW@#
MG6]M=S+-+T&#Z%O'NXVSR2I8MB'I&_C5S>%4;0-5BZZ@T*KY9BN^OEUQW5-3
MY>`G+5_T9QK1CZ8O;=#PE.MZ!G41+!UE.9DL11$#E09069$KU9BZ5<-<I^!*
M78).NCBI1Z!'0UZ$0*/T,&!\);+06]T[6O#Z"ZZN4S4/.8=B50++MM23Y6*R
M%-5]!`UTY$30`6/'E42NU&*J:B&(($(%`H?7:1)HO@<<"G4P*$#8J/$X&#0-
MB[IGP1'9*1Y/)Y/59C+7`C.#1F8O;70`A1TR!U%-AU@/!M`6].@1W'\P'6;Y
M^#.CE<"S<W0*S]K,S,I##I>'9<[6&P_KA:CR2MYG%?DE!9B5WQ5:!%*+1-&"
M58&^/899%ATB7IT=]`B_V8G4=5V#!4"\_>&WY`VG,1U5'EZ)U9(4[S_'Y`.^
MIE&&LSO\="YZ.AE3)WN1<HF<'O)9E^>8;.1,$#V@@@_*&2&%$Z*L2OW`0),S
M1S<,A^S?'_Z.G@O+9+EER$_TC&)/C9+9&<49CJ^`1PGM?4T,$1/^A:/GES/>
MWQ")PV=<Z@^^O9RS,PFV4?S\*<RB'2TG'QTOY&F-<_4DYC`N]).P0WM>,065
M?)!@A#BGHI&8P@PQ;KQ)!.<'$QH<V";(JU9GZ$+K.T<Q*_%\.5,[/#$[T-%]
MSVFC&).I;I)E?K0+OPXK:HBXPM0<+,(,WPAA\C/YB?R#5LPF/_P_4$L#!!0`
M```(`%.&9$.\=5XUK!\``!T\`@`5`!P`<V=M;RTR,#$S,#DS,%]P<F4N>&UL
M550)``.N%GA2KA9X4G5X"P`!!"4.```$.0$``.U=6W/;.)9^GZKY#UI/U=9L
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M^.T/CV=O/YS]]</;]_]7;ATM5MB?/<>C/[O_`8W?_GA,>XSNW]R_*3'Y[Z.'
M*"30>KYPPM7H/`A&][07&=T#JWB)O#?YH$'.[@@@#<G'HQ*'+T\X>!/AV0E\
MYMW)NN'1'_\PRAI_>"%^I</W=^OFIR?_NOGRX#ZCN7/LAR1V0K?2D0Y6U_7T
M_?OW)^E?L];$_T#24;Y$;HJ2!($C9@OZ?\?K9L?TI^/3L^-WIV]>B'?T-_K!
MGW`4H'LT':4T?(A7"_3QB/CS18".\M^>,9K";[-YE"+_]OV[M[3_GZXB-YG3
M511ZG\+8CU?C<!KA>4KUT8B.^_5^O"&?..',F4?IRHGS=7A"&YUPQSEI2^4]
M]/SE`98ZHM^83*_]$.;&=X*[B/CT$Y>!0X@_]9&G0K3DB/LD_\[!2`EXA6'C
M9Q3[KA/H9V@,Q]@<-20[[ZR=J`GPB^E9@M$S"HF_1*W(9`ZGG?!+ASQ?!]%W
M,@X]'R,W;DCQ[CBM2;WRB1M$),'`_!*1F'Z(G(?>M>/C?SA!@FZ00_]*?S_W
MO'05.D'3,Z7UQ_;*+[TXO"1`=$5OVG;%;_W']LMO,I\[>`7G3LT?2;;\/OV6
M^$LGR$<Y7SI^X#P%"&;H`7Y]0&Z"8=I0=S#II%$CNA<.\5WXVI4?)#'R;E'\
M)2+D#N&'9SBI->Z<)A_2R.>-\VN$+Q,2PT&)"=Q"<0C_?O87%.J'F`JT,Z`O
M"'PJ:Q&-C&OYLCDD[M$2A0G]MQO-0O]WY'T-/83/9QBE:W<OH`B)T(C/0QRY
MWRZH[D+O6+A@TQFH__73"_U/I8N\W8=T\_D<!8`CH2=/O-*XZ&4'U\E/\D30
M;PFLAD_+]`C5R(W4T'K$K]LH1N0QVHC0&S&*3/#,@;6??NP2U-,H\+WT?V#+
ME%7PDOQ=="Z8H1O,ATTT!0D<Q!77!9TZ!LW_#L9SX79Y1"_Q10#3IX)5CZBV
M;1K6/[S.Z=A0W_6T;'X:AR3&R1:]FA>U[,=ZPO0C%2,U+2"U3W8-P"<'A[#L
M-G*DYGEF#]\U8Y=1`,)_!((0Z/?G&`/QZ1\Z6](J'^P1\SJ7MOIGNP8B,^P\
M.B^=33OW"UVS5WP3%."2M'N/`F@"`C")2;KO4GGXSEFEO30CT):(GH.D<X/H
M(:5KP'9U#]JVLQTD_[G.&=]24W0SRAP^9VQ1DA^I&[#"(31&H+-[:Q[IQ]JZ
M<]+/PH>!B,JW`NKMBG`5SOQ3J4N+(/?-+%J>>,@_H0C3_TBA/GY[FCNT_@0_
M_7(.G_;HYZ\#9[8>#NX(%'P\VOW[2>?T7":8ND^N87$YP?\B!W\*O2N8GQK2
MF$W5J-Q=A/277];3<EXS+>=/(!@ZU%E0(4J^7_<XKLG(T`'ISH^\:_B-U`#)
M;KMO.NDLRE%9M-P?C1DR[`59WVY_]#W"L!RRTC]W3TVVZB_A@YBJ4!YZ^1^T
MJB&KOMW>Z(OF\]P4F=[G9)+$-`J!1HBPB>5UVA?EUWZ`\"4U'T>8C6NUU;YH
MNT<SGQYQ87SKS.O68FVS#77EZ_4<5REUL+L>#_ZS<K?NQG'D+4X6J2_^V'WV
M@\VU/,717.6L7E,1U>RF481!*$H#C$[?OCT:`0-3!+>2]R5CF4E@2ET,\A1*
M6]*>?H2!@H]'9T>CA`!ST2(SP+XN>+;DB0*?LP$?SEU2X/1NP(DK%Q1(_3`@
M)9#T"JQ^'+!BWU(%3'\98.*(<`5.?QUPXBNK!53_-4#%E%T+E-X/*,GJ)AO0
M0.+L%K2?3K;M7=U9P23C@QOK,5.'/*58).1XYCB+3)E!04S6OVQK-?G/O^2N
M7W+GK*AUE\:MN2Y.`'#?>?*#-%XM/PBV%)XF(S37U-IS>(]<Y"\IB;<HEF.I
MMHLA'BBBG^:+(%HA=(%"-/5C\<3P.AGB(YDGJ;.!%05-HPH![<GTT7EA,Z8T
MBA%.-R%&=X[OC<-+9^''</8P.&*T-D(Y(2C>-E%N_=$<70SC-*.1.3H%6[/2
MQCB54J!NMS5!-8VRA@MF.]@ZOG0P7H'\D`9F,[B0ZVN$*Y"(_$WT^6641F*A
M,`L:J^>%T\,4![E,QYV"[68F:+W*)<H\)IF_41F->T#W;12Z*J27VIN@?AR"
M<(Y(7(A4?.#9[4U07Q)E&?266QBF,(W`WXYI$)-=WZV/O`BN*^GNAGGC;X">
M:$^[9,BCWP>)X<;!WU!,SX\B_XH//*]'7S@0'OZ"3B;X2%4UKG)1;F&80OX2
MJ6EH@MX[C!:@+N:Y17R2Z]N:H3I:(!RO[@(G,Q_"H;R@HBSHZTSB.5U,\'`/
M>\L/D;>.+R]9)$#L\EV?Q8E$1Q/\\.R3@O->JJL9GB1EH)Y(/<IRCHQDLT>W
M`-].0WT``MO#QO1_9I<_5QX8T55?(&27*U<>(?[E4>!CEPM7'I^*D%7`89>;
M5O6D*2/1Q!4;Q4[P&I!@*&AE0"0-J/OSPO8<+Z[Z6*!D5WBD,DH<XUZ!D5TA
MDLH8\=W0!4QV14@JPU2G@Q?@V!44J0P.0^$O\+%9<);98ZQUTT1<[O^MKVHG
M+T/%L^L6N-DI1K?!C>.%*V"S4]S6M-S*0-DIC;<!BAL+4*@Q=HKE;8#CM2YP
MLU-0U[0S&8[C`KTF(ORKVJX*<KQ4P*RM"72-H>-&L=J:3M<,+5:<4JMDNB7"
M3Y%=./'W71.-L?]'EHJ_;E=!JKL8[30[-,5)_D(M$+33-J$NO5;C0&U-TFR&
M#S,KP-8DS68PR817V)JNV7!AJ2;6V)K"V0P^KMK3*'U318;H7R9B]94/LPD%
M0,L$IV1[Z9VRKN4ISC%@]C2<(I&EO9XG\3.LB]^+*61SLM.C%QR,"4GDJ<];
M]X)R=CDDJ2Y6A^B](C%=ZI2PW0:C`;S=`\EV4XPVT-9GH*TECK0#5E_MH?-R
M1X9DK/QE+QTE.TO5K0'R]<LIV[D4W*8F[JWM$NQ;[P@QKBQ1+Q.<?$8APDY`
M+?[>W`_3(DNTTOCF$9E:3D2]S"1CTE6Y6:8"\8'5V@SEZX>Z,JK6D6=,TAG-
M3=`.RG>AB3,(KK8QD@2UH*_#PM[+%R@S66NG72^H%:QE=GNCU`O715U+,XE/
M!('00&.(K]`2!5$:?,\_`?E]S'"1NM2N0<+Y3`OEL5#?;6>06@&19FD3;+N=
M9B9H_2>B3T`C[WP)>VF&;I/Y$\*3:2I?E*12.0&EX6`F17C!K5\UP&]/:RM)
M_55XG17@X=PZMON[FJ!4OMW:.;KZ[YE7P(<MR]KNVU(`:4MH;N>VLFKY"!5K
M6^N/-L"JZ=5O>QZ<4'VJ"@5<V=_V;#@EK(2V(MOSXI30JK$YM$N(Z_]!SU*<
M*"Q\<Z_M_BP>,AP%WG:/E0(LI*T[ZA4$K["BG`P%JVR3(:A@S.LQF*:Y];EJ
MH/L:8N0$U'']<Q10.>ZSXX>4RDE89.V?8Y_`GZ[@?\-9]HZ(8)(Z^YSA\)&,
MBS2[;(<W^4@2J5%ZXK%6X5A*^;3SYM6`6'=;U/;[70/XW'O(>HF`UK2Y#J+O
M9`RZ/$8`D9&R_[\FF4V//$;WR(U"UT\K?13GR&-$*;W#T=('?B]67PGRQN%&
M!3IW04_,MH.@*GL7GS)2BGX>X=C_/5T7D^D5>DH?;*=)EG<8S?UDS@)`V&\H
M4?]JN/KEK$=\97</[".XM`BZ0MF_E=AC#&&F<#R<O*Z?[A/X[P"EMUKHE?</
M@S>IKH8BF"K`CL/=^DKL<"9QU][P1!.F=\MKL4OE*@[2#SZW4IVE6=ONUP]N
MUOGM]RC-QQ*_':`T1#]XW,@0>0:C.(10=H">\)>6(9,H]2#/L/2(_4`@KS6V
MWF*Y91XH%M=Q;SB8(<-7G8B<A[B7162V54QV@'[S)]C!#0;J$;]9J$6+^:P;
MH-_\-9M/WD`]XK=&A57CLVZ`?O/7;#[[INN_#D<#7,^Y7>7<!94.HR)4BT4T
MMTLO>&"63I?EB#V`H6=$7(0\0GW`-`D/KB'`'%:X$]PE3X'O3J8@;+`3?.7[
M]X6[R;243*?`5;6?:6YNG#@W]Z="X6I3ZM`)`C*9?HG"&2BJ<XD=UVY0(TZX
M/$X/I99]$(%YMA=&8\/.PXV57=Y3N-O%:#'A#BWTU?)M,E8WV\/%]X6VA`_!
M]A)+^X*:=8@=0-"ZHA&L&NRO9MQM%A_Z/D,S1+/4;'AH>.XX`)I%D1XRBG)F
MOV8O,APRK@H&9=N?<]`-+<_?TNX)B,/#<L<39_M;$,T-Y%O/TLD:(VQ_):([
M0+?L'^U>D3@4(%4<7.V>E^A_SDUSYTEE:7*-P\T25%^39*0)Q98F0=N36SM:
MJQPG0+-<U\-;N2HNYG8YL:_V1%6T*!U8FH4>T+HQ]]F>9:$'>Q6MR_;"H-J.
M`.DXCP-ZW(7I;6N&W>&\B*8)0ZYHT.Y=M(/!D*NP'M`#1%(8JN6CM'M\R+Z3
M4/5U^[,&!O9%.A=`&8X/$+Q?SLKP-;"I9_!]"J55Q7UFD]*8@2`B2<6F`YA<
M.SY.V;^!?0=_3<M-;9YR&H?3",\S+[B)],FEXP?4G70=X0>8M"*?^C,&)>`^
MS[NF"@$S2E9M#+40)$8Y<\$GBX1Q^M'2\T;K2YE9_%S/P$828=>4PWHB%<IO
M$"U8)IH\5C<3O&RV3+&G1"%CW"Y:UEQI@G.;X^H*IIZPETS=`FLPBME2Z8_P
MJ?,7GYVNL]/0/+V7@.B,OD:2GJO<]2_1T5BUFL=G)WQ$\T6$';P:SQ>PQ"FA
MV4%:OF28>YC!M*[1C823NL_(2P(TF;*W#%SI:`SR"XM_M3'ZRN4C)T]9OK])
M*5/FG*]$#\JC4MAY["R^R3Z@ZZL$LX_%PT**=S54+.1"<<KVZ.M&!^VF`F43
M:<EVWTT[1#7I/,V<-*_)4]L8YH9*L>U.FM9X:A-F]_?B6W^1KDA][+L^DPC6
M@+VU]7)OA9CBPMZ`N0<T^VJX+"`K7RJ],EPJ6RG-FNMVR,FST6B&%/-I.MG>
M^S6VTK*<W5A;^2,/)N7!I"Q3JZ_DF>(R4-_V\`SA@RG9!E/RC?-KA"E%),MM
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MP01#,(&RW%U6\A7O<]N]<$-41GOH5"3#VJ58IZ#8[BSJ!+VS7?3L=`)U@MZ[
M7?3LS+P;XJF&>*K>@#7$4PWQ5*\^-&B(MMI=FL(0M2&>JCYP@NV3&Q+5.>YK
M69UX")O0&GUB[8726?3)V8#8$'TBCCZY<(COPO:[\H,D1MXM2HN:W"&</G;:
MGU*O8>Q[E$1_69JI3R]ND`#W]"D=^B1K$N?/X'YR<.B'LX*/.7U]D!6IH65L
M$\;I'5+XP0/,YB:WLXB'BM"B9Q7LS^IG9D^GM^ME0N)H#L3>.3@.X=_/_H*&
MACT`NJ`SPZ8/`I\^+D?ZL\GS1T)OHQA.X<@)TX"X=1']XG5;<@&2ULP)0'4"
M\.GC>$FJ1`&C*X%G7>LG])3NV*!_X\-W8U!H\K>KOL(BP.<SC%#V3%6%(;6^
M>BB=P7@TJ+SX;/Y8)GV$9Q:FOVT(N4'Q<[1^3?,QNE@W^KU8V!56M`W>+UXG
M]'5FM(BS9QS/%XO`=_-GPSL$@?U5O>C<)E3=GDP_HQ`].GB&&%5D>.TU490O
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M"[LZ4VKRZY]>+UYZ8!)$+9)4L:<VR6C!VF--AM%"/]Q$5TGMELG_HN<KU"D`
MHXD/&T9++51\QDZ8^B?H6V!UI@A6JXZ^?N.\^/-DGK$Z3Y5-+C:*(VAZL<2G
MC\BOER`],T&2Y5$IZ*&%JO].X#0!`?S*AP_'5);*/E86">"LS`YW4,N8)T.S
M@4R<NB4]F&J^55V8&U4LT],(1UMR!%TI_-!-7@^#')#\<N-3O6EE)C(]/2CX
M(=N5-D:H]$,QE94V6DZ3?,B'Y"G(%]A&27N`:]F?^B[<QM\B:L7,7D*L.TH:
MC**%^K7T71@K!&8`?@>M-$E2TMGW\[M(DHR:UEJHF<!X_ASEYP`L"&H1K[>_
ML9IJH0-6G4O-W3.X`^ZCE1.D/KJRK(FC8OW",JVC4'T0/;2#UIQ*./3<EQ<G
M9;IIHB^&L:C<DV*RR@W`@$QV\]83)^BCAS(<N0AYI*10_#/"WV`>J9=!Q@"@
M.(*)F^/>"6<\Y;GXNS'JN+=:N8666;]'7N*"VIVMK'N&6:2FE1%\T"(!H=LI
MB7;;U@ZNA"O?WPQW=>J[P$DLZ-0C/C"F:S?#/#.R/4;YT0`'1?IN"[D0.03U
MC/W*4/DB2#K4,O0KPX3.I6"OZQA;TQF;D9+:9>IU0'8[(_.2G_-<=76KD1ZD
M*F.2M;6S+#;6`B?1S6RN;9O5*)6,V_H#6N;OX=G'<+>R[6C5!GJ^Z<_FSGG@
M8=]]OHSP(G=`<6C@=C"R3N+(_38F)$'>58(W>G\:!45NT??T3\R4<[G./>(K
MC<)NR-967RTKZ.MBBF%W%,ITW:K9;=3-MSGN*69;DP&!742!E8,(I>S9MN<Q
M\=R_9;`4%"3;(5/P@VP*P:J'Q&Q0?&=GXE(C%%GA.1NP?K`S`;T)6`T]E`64
M=B9][=CI*J=<V4QF^SE68Q.LI&9576'%>61G]JD(C:K[LM@E=M8+4;:';HZ=
M+46M6#9V5B%H`11?NRR`>S\`5P&.$717;$D[RZC(&?'K<QS;&XFLOPQUNA:J
MBI,62_2`O[P3HWA^@YN>8GO-KTX@Y<6UV%X&K%-`&4@>U%VF!TE&&)KMU4PZ
MP504?&U[D;%.0*WQ"MA>=*S;Z[U]'K+MM;7ZC3\G-]KV^EV=3(RV5,P"?5N-
M$'K19X6Y;'`\';0W%1Q9B9X%GH/JUO!4$":5%Q@/VIS*FI4,32G@'50\#?#N
M1#05^`[JGO01(14E62`[Z'SRR-9D0Q1`#DJ?O-(A72:K@'?0Z51.V)V<X@+(
M!CK8$N&GZ-"@Y"==%G@.6I4TF@U21S<XGPU:E_SYRBTG5D`Z*%[2D#;)[B^`
M'K0O::#7I80*\`;=2AJ\NMI$!9"#$J5@%M\M!UD`.>A,TD`VJFQ6(#TH5>I+
M]JJJF)X-FI.\@"JLOU'`.OBR%`PG=2G.!92#"B4O'C&*UA2AQH.>I.!-D2@#
M6R`[J$L*!ZE$H:4"V4$_:B'B\PN`%B`/>I3\\E6L=E6`/.A8PE(L[!BZW3R0
M=X,"((6G5#74(KO&3AE!?T&5RA.]M5GV!_0T8!>@:DK9.:"7!;N8!;U5.@[H
MT<).MD21W+Y&\MV`Y)X/EY)H:/^SD8I/S*TCBXK8[RUQV,@+*-E,"HJH[S2S
M_[46UJLG^1K.9?`U,""$<TH0BCL-]?.'"K4'7*%VQZ)@OA:KH.KH`\)+V!GY
MKD@/\OH8\[KS0'T0,_.9DD5CB_)P&'K%^<S:@NSV!JDGPGVTU<S.RK":*D\Z
MP>8BR-<NN46BHTK4:Z@A.]205:HA.Y2*?`TZJOXR6M8F8G9=1NNP,B^'JE"F
M?2VU#D*V8#84(&B8#B@2Q^PO(%`OXQ?E\L36&OLK80DP:J#1VE_LBHT9VW+:
MKG!5%#M!OU&1U/ZD:D$TJ4/U*K+I&H#$SCFTM+!4DX7$MD6U*Q_U"K;=$)WQ
MVD`='*AR#M2TGL4%*+[>932GM5?2[]3_FA=G,>$D/0_2P5%6:(-)6;TA4+*S
M"2-H,1$T)*6@J5P6)Z7ZB5*]SND06'M;#FH"AT_S11"MT/HNJI^H?![AO^B9
ML?;@9RFK*5,B'Y;NKYA`ZG/Z9$L`Y]JY-_=#GTX:?<`E7\7<1U;E^IK@:AS"
M(06'$:Q/NAB_Y#/`B2_@]>@1!URG.+^/D8`$JFO"^LB/BGQA",X;0:?^.,)E
M]HA,3[/N,CVGF)SG3.>W3`J;>N[9>CNVUOFPW:3=T45?4>8%9YCMYD:)N[0,
ME^#BLGU!2MW;8LURZVJQW3RKC)JDV&K[RP-R\E4EP4%2\[7]?8%.Y1^)\_#@
MK'(=PZQ=$#@06]US%`"?Y--O"1!85*,<A]2&F56M-Y(8,)_G9D.N=K7;SHBU
M*0./K]5N-3)!Y[7CX[1P\SDA*"8WR*'+P)N`VN(FF%8?AAWCDZ]A]$1@&]&M
M-@X724RW2NCZ@9^NAXM5VOTR<`CAFB,Z^YQ1[,KT<.Q)[/9&K$EW$^X^*OYN
MQKJR\?^M!%D?.PU-T_N(';A<7+I2R<6J_!?.XE`8P%10^&2:GJJ70)7O(9Q;
M-[(:$).P1#0G1%Q^#,-<4C?I9%HBB+L*)3J:YB=_$"4K(Y^5EQ^K39IX",,\
MWF$0\T!T2PD4\U-M;H3VY`FV@>_@U01GPD#VAM`X7"(2@^1:$'NQVFV\;L8U
MM.K\A%F,2J1R#E)V^]Y0+W(B"CII2=M(0_^^@PH"DCX[5Z.FE5'3;JU47;&9
M:]U1MELFNY;^JS%(._J;[08EH8)0QJ>[N;!]%;-UA:*85LUI9_^+E*HJ2=4'
ML0NJ[0M)7ORO6',+1=KZF-X.Y%76HA,M6?OMY!V#S1&L[:\8UC&VG)O?_@)@
M)M:M(2^-:809*O%V_J#H4K/^8I?2PEFHB2UGML?[M,)ORRIG>]Q**ZQD;.O[
M"V`QY(,&`-%O"8UX6J8ADGWQ0%\D!*81[G$7+BJ2TK2^L@!6N+2RLV&"Z;_I
M[;56Y_U96."Q9>MK.:@)FZ:09+)-<]T1VA0/N<%[@HO(TLOMHL7.6_.%.G<!
MOZU)-"^C^5/^Y(0H*XG;Q93UOW24<?WM]6U[0'51NUB&[DWKGE#.=]LRVYN4
M(&3.D;+\H.L\MEV*U8ZKX+ZW5=*5NE>V-?;:`\5:&YXR1/RU:;])0^:VWWAS
MV,`>@B&#<S4+-MTAF7NX8@`'I_VGB>Q3RT[?L'B,\M<KG&"3@T`F>.:$_N_I
MUZ@5(@I\+YNST+LK43*9UG0NE'=:$Q^N/_KBLQ/&^=,9]-5G&,^E[YD#X1<@
M`7XS4N)AAQR!0L'I8$*\W?L<U:.R=S),GB7B-5,^3/8_0_L3V@_SG%K_,)Q7
M#4PX-&!I,MVB:I7]4W3*2'8VDMSCX!`((FNGAAQ#HEY&4UCR<#.Z2U0F2;Z_
MF8(IU)5<T"3BAMW>!/6WZ'MI\6,X'9/0S<XQE2E2'L;@.PYY`B8]O^68$_<S
MP<U70I-;2>S/X>)AV4VW&KT>&4?V5+?=G*B&VO::L-4XV`P=B?UO>]T&-<#4
M+P?;@^W5\..(!K8'\:H!I2`AVAY0KP:<4$G8WX,(_=#<-S^-0T`MV5+(C1H&
M94EC*$&2O<VJ0.0\"-+JP^6?^.8$R<YFJT2I\%<YV&3G_-`L;)+`I!XW,V:Q
MI>,'].O7$::QDP\T0<Z/)2S7,CU[4(7E//2^^,Z3'Z2DU60"0H/;*,25Q,!T
M/J3M-?H^-)QJ?3K5I/:&[9IYBTNA@XVX/TV_'_?'MN!K5++;)D94D8O5O`]N
M!E4'0S\<J*(9X.E,!RR%E5[E6J+2HR(]T9A4R*M?K2HCO+I@"\$QHV=LD[M:
M*SK5,B$*"VLX%)C@F%//>*\H[YP!-4V'S<[=['OURBJ^6;SCG97M;_IU^.R5
MN@BH1>1GY`3Q\R4<@>69DU*O6PTYO`!O,.5I4XM;5)IMMZ%1>KFE_ZJ-3(H+
MO#NAZ@>6/G%L#V+O3,+:7CNV`ZE\BVWR3`0'F^TA'"V`J]Y"MH=NL&^/^N><
MFL@;MMMLZV\T^4=L;3V]Q+C4K3Y;7ZI@J\;9FRJ/SDM/#&0U]`C]4NP>YIZ;
M9"`JS4(_C-`2L['[0`^+]4.S.DF_;'A1?MG0Z.X;'CU6))DQ=2V!8(QJUS.=
MK3$>SA,EP,Q9MH=395N3*1-,*:51)]LS5_)3D/)K:_7OL:7\7JSN`D?5Y+I/
M6NPZP0S-YZ&=>[N/Z]&V/=%77LN#=?(@LHSBLOU[_M")/`X'M\^V"H@:W5<[
MU4SY.XS9O`?E](1Z`;M]CZH!\6]"-L>&=]%/)Y18>J7#__P_4$L#!!0````(
M`%.&9$,]JM?(90P``%AP```1`!P`<V=M;RTR,#$S,#DS,"YX<V155`D``ZX6
M>%*N%GA2=7@+``$$)0X```0Y`0``[1Q=;^,V\KU`_P//#W=;H([CI+N]!$D+
M)]DL4B2;P,[V%O=2T!)M\U8BO13EQ/WU-T-]F+9H1;*=71OP2R*+,\/YXG!F
M*.GL]^<P(!.F(B[%>:-]<-@@3'C2YV)XWOC4:W9ZES<WC=]_^_&'LW\TFZ3;
M)5=2"!8$;$H^>RQ@BFI&'NFS%#*<DIXW8B']F?1IQ'PB!?E\T;TE1P=M0D9:
MCT];K:>GIP.E_(S(@2?#%FDVLPG^3%@Y)>\.CH`;:Z0K8^&?DK?6K4O%J`9H
MX@,3I^3HL'W<;+>;A[\\'AV>'OUZ>GCR7QM:CJ>*#T>:O/%^`N##MTW$(-V#
M[H$EU3])3XH(H,,Q%5/2"0+21:R(=%G$U(3Y!RG1R`A+0(,B.F]8\CT='T@U
M;,$4[=;GN]M$*8T??R`)[.ES7P5\#@/O9#C'+2XB387'+)2`BR\E&#B,.K<G
M*:"D;+5/3DY:9M2"CJ/FD-)Q#C^@4=]`IP,MH]S#=O.X/8^EIV,6.=',B!LO
M&H8RQXFH&-)0&D]`Z,.3XT,+5H!EXM`MNZ]5"Z=I`5`3H)CBGHWZ,EX!!V%\
MG:/9:G[;2@8M:`^<4JOI/'C$O(.AG+320;<*O%@I6&G+4--1Q#TJX/J,N]%@
MP#T;>_9&;A0<<>-P,6&1=F,E8TN,J\?*C84CB-.V<#150Z8_TI!%8^JQE[T"
M8D[(A+Z6*KQB`QH'P.+7F`9\P)G?(%1KQ?NQ9G,`L9B!_(94SJ@04IOH87[C
MG?&8BX%,?\(-7"*G2@;L$5R%X,6G[HV309W&OQ8"M:ZD%R.+5/COA>9Z>@-D
M56@F:Q#NGS=*(7(&,A9\-N""&U;;AVW2)!FZ?0FD2$*+6,3.6HL4%HG'$*CO
MQ6_FVJ.!%P<&\19^I\@I1!GB6$%H%'H%S!EGR_'2NYDEUC=0#S@U3G0_N.8"
M(BVGP8.,#!N7`8VBU)?05%U`^*LB0KGECL%<.2&"^Y'PF<!]$JXB&7#<Q7QR
M00.,_:0W8DQ'>P.N;L`'"C%4CYCFH)?:UC38+YCTEU5,2M[,,?;3WL0OF/@&
M$M*0N0V8CI6;Z6TU,^4@$9$#<C_&W!8([-?@2P:Z!U]6F#`K-@*]\@DK,]E2
MZ'(COBL:<9GIYHB36QGM3?B2"2]I-+H.Y%-T(WRNF*?=MBN"E1OMUU56'DY"
MS"Q[L[G,]E%J%CW*?.^::>]>#:G@?QM!9@J&'QWA/UA"6AO?#/F*1UX@HU@Q
M@.[QH8!MT*-"=SQ3R'`Q?`!Z'H>YV;.^"*3WQ7*2+6*JW"7_C5ES3A5^7-"(
M&[^SF3'Y="\.0ZJF.&9-369SDVSRO:/6<]3\UHV(M(H73%W/OZK2*G>+DT6W
MN#$E;A*4T!FN*5?D3QK$C-PQBD`XMC=\/<._ITK`PHD>F.J-:%U3+\<N-6[[
MT+7F/6/6*Q[$N`5]9-ID"@1H$T-\;]IZIKV404#[$I/F">LH!23,P*KKN@Z]
M<O.W%\U_1_\G%;F,(PUYIXI^)E"1:0%7(SY.5GM/8V-["$[2"0*.U=L^QM?T
MAR2K?Z3/JSI`*8%RBQ\5HSG2PH.*O2'K&G*F2"@`H+2"!-X(U64!9N^7,M*1
MB9@7>.KS0*<&JYZMUYVCW!V.%]VAIP&I:6@1>[J]:]1S#:/'D0Q\B)WOO\9<
M3Q%VU05?G5JYN7]QFCLE_"^2D-Z;NJ:IXW[$OL9P^7Y2?WTOQRXWY=N"*7-"
M)*&TM^-V]PBR&UO9*\B9*_?"=Z_1,R!OLJO]$<#KM`\>:3^HZ'CU*)9[RZ^K
MM1+(FX3ZWAM>K_"LX1'UJ99[1:'ON%(1NG>2[U/$U'"<S<Q4[DR%;N6R@F;O
M+^6/ZN0ZM&(T9`\8H4V`MN)SQ_<->[A'+#[/LS:94G,?%?J7%7>4)IG-9C\6
M1-Y<,4WY_MF#];T"'^[TXX#AHP@Y;'VO<),I]XI"6[.R5V2S899J(^W=8F-N
MD90!4*<X!J/D(!W[$!,:I%0Z$]`\QFI8I3VXVV->K$!$MHHW;7+V<B=T=%JK
M.N&L4G+#S!X&L'@U-'-NF\!N$_DE,X;W7ES1B\TA&-@^/0+[R#0>@&5G:Y6V
MNU5(E/M3H55;Y:ANO]&MZPNF&,EK$;L2P5Y*5H?D94@EY]@(S7)O*71Z5RNJ
M]N[S;=VGRR9,Q/C?DT/!_V;^)^$SU1DJ9B+_FI[T(OERIRKTG%=UJHP/,F.$
MQ,@)R5G9>UA%#S,%KJEO[?+6???],UZR12]:A42YIQ3ZPDO+\)*A=*J])]3Q
MA+E3PDJ[456T<HL7>KNNH\7]?K*VC1>."ZM9N!)2N7T+7=K">>/>N'`;_^#[
MIETV(.95TE-\G?*\$?%P'$#@3>Y1Y2%^^4NHK;&28Z:P<FME9#,"!>SYMUZ-
MTRSH+^4JHS!2;`!L#4/9S-XB_`LP#I[#(`/17.,LES,Z!`G!-D^#H-':7LGG
MS5A!<$!P"'Z5D]D1N:'R9T%%D0'6(?(M4M@1:1>7>06A`<4A]-Q1M4/VLY;]
M!BS\FG]#]@Q$ETH347A5M^0%=I*\(W\K/4.H!`5_-3.\)MYJMH^:Q^V#Y\A/
M6:S#P4S3]3C(\.IRX'Q/O.K<&0).^K;2=*7OV2^;UDSI?+&_Q0(=Y;2:,UKU
MM5]XM;Z2$A:Q4!,GJ/[VNW58L+X*4),-*3ZNQDG9AQ/6,`S>J6N7ESY&4,J.
M"R_[L1XCCD\;5./$1LQ_-6=DZO.R\+V$2FQD.'BQEB(6O[Q0:?8<R5RM-7_Q
M&PZ5.+#0TNNUN%C\)D0E'G(D<]6<H=OSIQ^*,`R<-V8Y^QT/@&DI6'KT[FH]
MX7[Z5W64)#DPGW4Y#0%,4S6]T2S$S+E!:#_2BGKZO#&@@=G\#2`D!5SZCP8U
MV?AT-M1/7A@_;_BLS^&NX($Y[CAO:!7CG@9%">SJ,7+W0<EXG$W.8=(E\@^!
MW2'55E,^;4^ES2F\E\MYQ_1(^BG`H[Q@LPZ6K:#-T5Q;@WZLTJ)P086>8OZV
MZ?!>=#R/C4VN<S_HC,<!]ZR2=K/*+9ELM[0..W*?J?O!!R;8H_EL3.32EQ/,
MEI0+S89,K2CH1B1*(\<5L#LGPMQ]FV=\3WJUB+))?A\EN!7C$R?3UN`<YZGF
MOJ.ZA8AI<,WP0,`\@O4HG>&^%.SUELH&8WQV+'Z]>(@/!*+HDU",!A@2/E!P
M#X@*<1@;26]$X>&51"4;(K@+^V-54?'D>9.J*Z?W:IK;8("^B",N&$KQ->;)
M9W3,0X>6-I:#V`*",%P,7>(EO&T@3OCZ=`28RHO[)IZZ);K$;X5))3C%Q\&1
M"IJQ"[N&8,D#P7>@/8_COHN;C25I?=1$`\EG[DY]&<)2>E45E)GR<N3S:_S0
M8A*RA5>4;QG$5HDQ>W9;BCR(VP_@=H2?GKO9B[8FWB[L"6Z17A;Z5<7;8/"9
MYU[XM]Q#Z\SDR-+!!R7]V`,+CL=*3MQ/'#CTL0;%K<HY+Z4P\T&*,\O8F`JY
M,',L9**5H-?*3S<JW!4;,`4^]6D\4,!YQCWD<FE%9(E6`78G'#_[\F/'\0W)
M3LJB+78E\&^\&Y?+]P2N)WL>9_@X36$C6C*^3=L0[A0>[!R=$/NF:56.%9)O
M4H*(4>6-\.E)<+Q`CA?BT$K8.Y!IPTJ[FEN1V8U=V$ZO(?.)@-NEN\<R@!TP
MS`<%])%_6/:)TUERN09WP6!%ON_H,P_C,#$00/JPQ!R&K(NX$YO&#;8-L9&8
M1`_<TN\'+NE?`MRN#H]5,M]1C77V%%.4:'D1/B=J?>2UQ=]D>^Z/&/(6'K`K
M3OM,8_LJ,9I=IFFFDM2-!H6==$7\;=II[[C`I=F+^T&:K>?-O![LHO@6/FR>
M7R1^/>S!,&')OPKR=OE_5I',C@K</?(7X+:J8"GO]F]_DS_C,(VDY6*X@+9*
MFGM@C(<LK85A:>"G^.8.`Y="[$#F`ZO:PT>CANQ^T)53&F"4G\NXE9S%!P@#
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M2P$"'@,4````"`!3AF1#6L>:=:&.```9NP8`$0`8```````!````I($`````
M<V=M;RTR,#$S,#DS,"YX;6Q55`4``ZX6>%)U>`L``00E#@``!#D!``!02P$"
M'@,4````"`!3AF1#4'_FT+`+``"5F0``%0`8```````!````I('LC@``<V=M
M;RTR,#$S,#DS,%]C86PN>&UL550%``.N%GA2=7@+``$$)0X```0Y`0``4$L!
M`AX#%`````@`4X9D0UV@\=V=%```:T0!`!4`&````````0```*2!ZYH``'-G
M;6\M,C`Q,S`Y,S!?9&5F+GAM;%54!0`#KA9X4G5X"P`!!"4.```$.0$``%!+
M`0(>`Q0````(`%.&9$,G^;-Z>4```/Q,`P`5`!@```````$```"D@=>O``!S
M9VUO+3(P,3,P.3,P7VQA8BYX;6Q55`4``ZX6>%)U>`L``00E#@``!#D!``!0
M2P$"'@,4````"`!3AF1#O'5>-:P?```=/`(`%0`8```````!````I(&?\```
M<V=M;RTR,#$S,#DS,%]P<F4N>&UL550%``.N%GA2=7@+``$$)0X```0Y`0``
M4$L!`AX#%`````@`4X9D0SVJU\AE#```6'```!$`&````````0```*2!FA`!
M`'-G;6\M,C`Q,S`Y,S`N>'-D550%``.N%GA2=7@+``$$)0X```0Y`0``4$L%
3!@`````&``8`&@(``$H=`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>30
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]E8V9F9C<Y9E]A,3`P7S0S-65?86,P.5\Y-3-B
M9F$T83(U,CDB#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]E8V9F9C<Y9E]A,3`P7S0S-65?86,P.5\Y
M-3-B9F$T83(U,CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO96-F
M9F8W.69?83$P,%\T,S5E7V%C,#E?.34S8F9A-&$R-3(Y+U=O<FMB;V]K+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P@>&UL;G,Z=CTS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M
M8V]M.G9M;"(@>&UL;G,Z;STS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M8V]M
M.F]F9FEC93IO9F9I8V4B('AM;&YS.G@],T0B=7)N.G-C:&5M87,M;6EC<F]S
M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O
M;G-O;&ED871E9%]"86QA;F-E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O;G-O;&ED871E9%]"86QA;F-E,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E
M9%]#;VYS;VQI9&%T961?4W1A=&5M93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-O
M;3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;F1E
M;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M93$\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y"87-I<U]O9E]0<F5S96YT871I;VY?86YD
M7U-U;6T\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,#<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y)
M;G9E<W1M96YT<U]A;F1?1F%I<E]686QU95]-96$\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#@N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"87-I8U]A;F1?1&EL=71E9%].971?
M3&]S<U]097(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,#DN:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y-86IO<E]#=7-T;VUE<G-?4&%R=&YE<G-H:7!S7V$\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,3`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);F-O;65?5&%X97,\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D7T-O
M;7!E;G-A=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,BYH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E-T;V-K:&]L9&5R<U]%<75I='D\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3,N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y3=6)S97%U96YT7T5V96YT<SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970Q-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D)A<VES7V]F7U!R97-E;G1A
M=&EO;E]A;F1?4W5M;3$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,34N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y);G9E<W1M96YT<U]A;F1?1F%I<E]686QU95]-96$Q/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#$V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^36%J;W)?0W5S=&]M
M97)S7U!A<G1N97)S:&EP<U]A,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/E-T;V-K0F%S961?0V]M<&5N<V%T:6]N7U1A8FQE<SPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970Q."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN=F5S=&UE
M;G1S7V%N9%]&86ER7U9A;'5E7TUE83(\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y);G9E<W1M96YT<U]A;F1?1F%I<E]686QU95]-
M96$S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#(P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YV
M97-T;65N='-?86YD7T9A:7)?5F%L=65?365A-#PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/D)A<VEC7V%N9%]$:6QU=&5D7TYE=%],
M;W-S7U!E<C$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,C(N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y-86IO<E]#=7-T;VUE<G-?4&%R=&YE<G-H:7!S7V$R/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#(S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^36%J;W)?0W5S=&]M97)S7U!A
M<G1N97)S:&EP<U]A,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-"YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-T;V-K0F%S961?0V]M<&5N<V%T:6]N7U-T;V-K0CPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970R-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%
M<75I='E?061D:71I;VYA;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-BYH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E-U8G-E<75E;G1?179E;G1S7T%D9&ET:6]N86Q?23PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970R-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M(#PO>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T>6QE<VAE970@2%)E9CTS
M1")7;W)K<VAE971S+W)E<&]R="YC<W,B+SX-"B`@/'@Z06-T:79E4VAE970^
M,#PO>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T<G5C='5R93Y&86QS
M93PO>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0<F]T96-T5VEN9&]W<SY&
M86QS93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z17AC96Q7;W)K8F]O:SX-
M"CPO>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP
M/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC<F]S;V9T($5X
M8V5L(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V5C9F9F-SEF7V$Q,#!?-#,U95]A8S`Y7SDU,V)F
M831A,C4R.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E8V9F9C<Y
M9E]A,3`P7S0S-65?86,P.5\Y-3-B9F$T83(U,CDO5V]R:W-H965T<R]3:&5E
M=#`Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%,4%!13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY$;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T:6]N/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`S,2P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$;V-U;65N="!!
M;F0@16YT:71Y($EN9F]R;6%T:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4>7!E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,3`M43QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD
M;65N="!&;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG9F%L
M<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$;V-U;65N="!097)I;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/E-E<"`S,"P-"@D),C`Q,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I
M<V-A;"!996%R($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG,C`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!097)I;V0@1F]C=7,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=1,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R
M86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=304Y'
M04U/($))3U-#245.0T53($E.0SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT<F%L($EN9&5X($ME
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S`P,#$P,#$R,S,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#=7)R96YT($9I<V-A;"!996%R($5N9"!$871E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG+2TQ,BTS,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!&:6QE<B!#871E
M9V]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)T%C8V5L97)A
M=&5D($9I;&5R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T
M86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$L-SDW
M+#(P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M96-F9F8W.69?83$P,%\T,S5E7V%C,#E?.34S8F9A-&$R-3(Y#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5C9F9F-SEF7V$Q,#!?-#,U95]A8S`Y
M7SDU,V)F831A,C4R.2]7;W)K<VAE971S+U-H965T,#(N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$510T%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;F1E;G-E9"!#;VYS
M;VQI9&%T960@0F%L86YC92!3:&5E=',@*%531"`D*3QB<CY);B!4:&]U<V%N
M9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E
M;G0@87-S971S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#`L,S`Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,2PV-SD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA<FME
M=&%B;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,SDL.3$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#$L.#8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!R96-E:79A8FQE/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.3`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S(')E8V5I
M=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.#@P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PQ
M,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8X-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@
M87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C8L,30S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-C@L,S8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y-87)K971A8FQE('-E8W5R:71I97,L(&YO;BUC=7)R96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPV.3`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPU.#0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PT.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#4T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@87-S971S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#`L,S8V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#(L-3,S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-U<G)E;G0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L92!A
M;F0@86-C<G5E9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPV-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT+#`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!C;VUP96YS871I;VX@86YD
M(&5M<&QO>65E(&)E;F5F:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#`S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L-#<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPS,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,P-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E
M;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<L,#`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^."PW.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=65S+"!N;VXM8W5R<F5N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPR,C$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#@T-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-"PR,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-RPV,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UI=&UE;G1S(&%N9"!C;VYT:6YG96YC:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G(&5Q=6ET>3H\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VLL("0P+C`Q('!A<B!V86QU93L@.#`L,#`P+#`P,"!S:&%R
M97,@875T:&]R:7IE9"P@-C$L-#(P+#8U-2!A;F0@-3,L,#4X+#4R-2!S:&%R
M97,@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!A="!397!T96UB97(@,S`L(#(P
M,3,@86YD($1E8V5M8F5R(#,Q+"`R,#$R+"!R97-P96-T:79E;'D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Q-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4S,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!P
M86ED+6EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0Q.2PT.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,SDL.#0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!D969I8VET/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R.3,L.3@Y*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(W-2PU,#DI/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U
M;75L871E9"!O=&AE<B!C;VUP<F5H96YS:79E(&EN8V]M93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L('-T;V-K:&]L9&5R
M<R<@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C8L
M,30Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C0L.#DV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&]T86P@;&EA8FEL:71I97,@86YD('-T;V-K:&]L9&5R
M<R<@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$T
M,"PS-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#@R+#4S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?96-F9F8W.69?83$P,%\T,S5E7V%C,#E?.34S8F9A-&$R-3(Y
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5C9F9F-SEF7V$Q,#!?
M-#,U95]A8S`Y7SDU,V)F831A,C4R.2]7;W)K<VAE971S+U-H965T,#,N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$4V1D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;F1E
M;G-E9"!#;VYS;VQI9&%T960@0F%L86YC92!3:&5E=',@*%!A<F5N=&AE=&EC
M86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T871E;65N="!/9B!&:6YA;F-I
M86P@4&]S:71I;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<&%R('9A;'5E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C@P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,"PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@<W1O8VLL('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8Q+#0R,"PV-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU,RPP-3@L-3(U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL
M('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C$L-#(P+#8U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4S+#`U."PU,C4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V5C9F9F-SEF7V$Q,#!?-#,U95]A8S`Y
M7SDU,V)F831A,C4R.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E
M8V9F9C<Y9E]A,3`P7S0S-65?86,P.5\Y-3-B9F$T83(U,CDO5V]R:W-H965T
M<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%1EI!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@
M3W!E<F%T:6]N<R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%!E
M<B!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY2979E;G5E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;&QA8F]R871I;VX@86=R965M96YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#@R-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PQ
M.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$U+#`V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@.2PV-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&=R86YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.#@R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S$W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ.3D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`U.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L
M(')E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#<P
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0L.3`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3<L,C8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3(L-S(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!E>'!E;G-E
M<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^."PW,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW+#4W,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V+#(P,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R+#0R-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A
M;"!A;F0@861M:6YI<W1R871I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L,38S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPQ,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY+#4Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,3(U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;W!E<F%T:6YG
M(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PX
M-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,"PW,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS-2PW.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,2PU-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&9R;VT@;W!E<F%T:6]N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPQ-3DI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PX,#(I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3@L
M-3,R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$X+#@R.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DEN=&5R97-T(&%N9"!O=&AE<B!I;F-O;64L(&YE=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@V+#$T-2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#4L-SDP*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,3@L-#@P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,3@L-S@V*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,@86YD(&1I;'5T960@
M;F5T(&QO<W,@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#`N,3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@P+C$Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,"XS-"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,S8I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@=7-E
M9"!I;B!C;VUP=71I;F<@8F%S:6,@86YD(&1I;'5T960@;F5T(&QO<W,@<&5R
M('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-"PW.#8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M,BPW-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU-"PP,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU,BPV-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V5C9F9F-SEF7V$Q,#!?-#,U95]A8S`Y7SDU,V)F831A
M,C4R.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E8V9F9C<Y9E]A
M,3`P7S0S-65?86,P.5\Y-3-B9F$T83(U,CDO5V]R:W-H965T<R]3:&5E=#`U
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%3$M!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#
M;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!#;VUP<F5H96YS:79E($QO<W,@
M*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E
M8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T871E;65N="!/9B!);F-O;64@06YD
M($-O;7!R96AE;G-I=F4@26YC;VUE(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#8L,30U*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-2PW.3`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@Q."PT.#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@Q."PW.#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V5S(&EN('5N<F5A;&EZ960@;&]S
M<R!O;B!A=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M<')E:&5N<VEV92!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#8L,3$X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H-2PW-C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@Q."PT.#`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q."PW.#,I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E8V9F9C<Y9E]A,3`P
M7S0S-65?86,P.5\Y-3-B9F$T83(U,CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO96-F9F8W.69?83$P,%\T,S5E7V%C,#E?.34S8F9A-&$R-3(Y
M+U=O<FMS:&5E=',O4VAE970P-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14(V044^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^0V]N9&5N<V5D($-O;G-O;&ED871E9"!3=&%T
M96UE;G1S(&]F($-A<V@@1FQO=W,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L
M('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!!8W1I=FET
M:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#$X+#0X,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#$X+#<X-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@=&\@<F5C
M;VYC:6QE(&YE="!L;W-S('1O(&YE="!C87-H('5S960@:6X@;W!E<F%T:6YG
M(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T
M:6]N(&]F('!R96UI=6T@+R!D:7-C;W5N="!O;B!M87)K971A8FQE('-E8W5R
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8R-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Y,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT+#`Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0L,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-H86YG97,@:6X@;W!E
M<F%T:6YG(&%S<V5T<R!A;F0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@<F5C96EV
M86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3@I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C
M8V]U;G1S(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#8Y-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R+#4X-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&%S
M<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S@W*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,V-"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@;&EA8FEL:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,S0X*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-S<P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M<G5E9"!C;VUP96YS871I;VX@86YD(&5M<&QO>65E(&)E;F5F:71S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,S0I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R
M979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PV,S`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3$L.#$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<L.#(U*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@L,S`U
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY);G9E<W1I;F<@06-T:79I=&EE<SH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S97,@;V8@
M:6YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,W
M+#$V,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@W,"PU-S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y-871U<FET:65S(&]F(&EN=F5S=&UE;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS."PS.#0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-2PQ-34\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H
M87-E<R!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@S.34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,S8S*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('!R;W9I9&5D
M(&)Y(&EN=F5S=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT+#(R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&:6YA;F-I;F<@06-T:79I
M=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]C965D<R!F<F]M('!U8FQI8R!O9F9E<FEN9RP@;F5T(&]F(&ES
M<W5A;F-E(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M.2PT.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F(&-O;6UO;B!S=&]C
M:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPQ,S4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`T,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!C87-H('!R;W9I9&5D(&)Y(&9I;F%N8VEN9R!A8W1I=FET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-2PV,C<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`T,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!I;F-R96%S92`O("AD96-R96%S92D@:6X@8V%S:"!A;F0@8V%S:"!E<75I
M=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3@L-C,P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,RPP-#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S+"!B96=I;FYI;F<@
M;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PV
M-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-BPW-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',L(&5N9"!O9B!P
M97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#`L,S`Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q,RPW,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V5C9F9F-SEF7V$Q,#!?-#,U95]A8S`Y7SDU,V)F831A,C4R.0T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E8V9F9C<Y9E]A,3`P7S0S-65?
M86,P.5\Y-3-B9F$T83(U,CDO5V]R:W-H965T<R]3:&5E=#`W+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0F%S:7,@;V8@4')E
M<V5N=&%T:6]N(&%N9"!3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I
M;F<@4&]L:6-I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A
M<VES(&]F(%!R97-E;G1A=&EO;B!A;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N
M="!!8V-O=6YT:6YG(%!O;&EC:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^3D]412`Q)B-X,C`Q-#M"
M05-)4R!/1B!04D5314Y4051)3TX@04Y$(%-534U!4ED@3T8@4TE'3DE&24-!
M3E0-"B!!0T-/54Y424Y'(%!/3$E#2453/"]B/CPO<#X-"B`\(2TM('AB<FPL
M8F]D>2`M+3X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@
M34%21TE.+4Q%1E0Z(#(E.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/CQI/D)A
M<VES(&]F(%!R97-E;G1A=&EO;CPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
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M<FEM(&9I;F%N8VEA;`T*(&EN9F]R;6%T:6]N(&%N9"!P=7)S=6%N="!T;R!T
M:&4@<G5L97,@86YD(')E9W5L871I;VYS(&]F('1H90T*(%-E8W5R:71I97,@
M86YD($5X8VAA;F=E($-O;6UI<W-I;VX@*"8C>#(P,4,[4T5#)B-X,C`Q1#LI
M+@T*($%C8V]R9&EN9VQY+"!T:&5Y(&1O(&YO="!I;F-L=61E(&%L;"!O9B!T
M:&4@:6YF;W)M871I;VX@86YD#0H@9F]O=&YO=&5S(')E<75I<F5D(&)Y(&=E
M;F5R86QL>2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@9F]R#0H@
M8V]M<&QE=&4@9FEN86YC:6%L('-T871E;65N=',N($EN('1H92!O<&EN:6]N
M(&]F(&UA;F%G96UE;G0L(&%L;`T*(&%D:G5S=&UE;G1S("AC;VYS:7-T:6YG
M(&]F(&YO<FUA;"!R96-U<G)I;F<@861J=7-T;65N=',I(&-O;G-I9&5R960-
M"B!N96-E<W-A<GD@9F]R(&$@9F%I<B!P<F5S96YT871I;VX@:&%V92!B965N
M(&EN8VQU9&5D+B!/<&5R871I;F<-"B!R97-U;'1S(&9O<B!T:&4@=&AR964@
M86YD(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S
M#0H@87)E(&YO="!N96-E<W-A<FEL>2!I;F1I8V%T:79E(&]F('1H92!R97-U
M;'1S('1H870@;6%Y(&)E(&5X<&5C=&5D#0H@9F]R('1H92!Y96%R(&5N9&EN
M9R!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S+B!4:&4@8V]N9&5N<V5D#0H@8V]N
M<V]L:61A=&5D(&)A;&%N8V4@<VAE970@9&%T82!A="!$96-E;6)E<B8C>$$P
M.S,Q+"`R,#$R('=E<F4-"B!D97)I=F5D(&9R;VT@=&AE(&%U9&ET960@8V]N
M<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN8VQU9&5D#0H@:6X@
M4V%N9V%M;R8C>#(P,3D[<R!&;W)M(#$P+4L@9F]R('1H92!Y96%R(&5N9&5D
M($1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q,BP@87,@9FEL960@=VET:"!T:&4@
M4T5#+B!4:&5S92!F:6YA;F-I86P@<W1A=&5M96YT<R!S:&]U;&0@8F4-"B!R
M96%D(&EN(&-O;FIU;F-T:6]N('=I=&@@=&AE(&9I;F%N8VEA;"!S=&%T96UE
M;G1S(&%N9"!F;V]T;F]T97,-"B!T:&5R971O(&9O<B!T:&4@>65A<B!E;F1E
M9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$R+"!I;F-L=61E9"!I;@T*(%-A;F=A
M;6\F(W@R,#$Y.W,@1F]R;2`Q,"U++"!A<R!F:6QE9"!W:71H('1H92!314,N
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@34%2
M1TE.+4Q%1E0Z(#(E.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/CQI/E5S92!O
M9B!%<W1I;6%T97,@86YD($-L87-S:69I8V%T:6]N<SPO:3X\+V(^/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE('!R97!A<F%T:6]N(&]F
M(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN(&-O;F9O<FUI='D@=VET:`T*(&=E
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M4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU"3U143TTZ(#!P=#L@34%21TE.+4Q%1E0Z(#(E.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*(#QB/CQI/E)E=F5N=64@4F5C;V=N:71I;VX\+VD^/"]B
M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$
M14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
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M>7!I8V%L;'D@:6YC;'5D97,@=7!F<F]N=`T*('-I9VYI;F<@;W(@;&EC96YS
M92!F965S+"!C;W-T(')E:6UB=7)S96UE;G1S+"!R97-E87)C:"!S97)V:6-E
M<RP-"B!M:6YI;75M('-U8FQI8V5N<V4@9F5E<RP@;6EL97-T;VYE('!A>6UE
M;G1S(&%N9"!R;WEA;'1I97,@;VX@9G5T=7)E#0H@;&EC96YS964F(W@R,#$Y
M.W,@<')O9'5C="!S86QE<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
M4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
M="<^#0H@/&D^375L=&EP;&4@16QE;65N="!!<G)A;F=E;65N=',@<')I;W(@
M=&\@=&AE(&%D;W!T:6]N(&]F($%350T*($YO+B8C>$$P.S(P,#DM,3,L(%)E
M=F5N=64@4F5C;V=N:71I;VXF(W@R,#$T.TUU;'1I<&QE($1E;&EV97)A8FQE
M#0H@4F5V96YU92!!<G)A;F=E;65N=',@*$%352`R,#`Y+3$S*3PO:3XN($9O
M<B!R979E;G5E(&%R<F%N9V5M96YT<PT*(&5N=&5R960@:6YT;R!B969O<F4@
M2F%N=6%R>28C>$$P.S$L(#(P,3$L('1H870@:6YC;'5D92!M=6QT:7!L90T*
M(&1E;&EV97)A8FQE<RP@=&AE(&5L96UE;G1S(&]F('-U8V@@86=R965M96YT
M('=E<F4@9&EV:61E9"!I;G1O#0H@<V5P87)A=&4@=6YI=',@;V8@86-C;W5N
M=&EN9R!I9B!T:&4@9&5L:79E<F%B;&5S(&UE="!C97)T86EN#0H@8W)I=&5R
M:6$L(&EN8VQU9&EN9R!W:&5T:&5R('1H92!F86ER('9A;'5E(&]F('1H92!D
M96QI=F5R960@:71E;7,-"B!C;W5L9"!B92!D971E<FUI;F5D(&%N9"!W:&5T
M:&5R('1H97)E('=A<R!E=FED96YC92!O9B!F86ER('9A;'5E(&]F#0H@=&AE
M('5N9&5L:79E<F5D(&ET96US+B!);B!A9&1I=&EO;BP@=&AE(&-O;G-I9&5R
M871I;VX@=V%S(&%L;&]C871E9`T*(&%M;VYG('1H92!S97!A<F%T92!U;FET
M<R!O9B!A8V-O=6YT:6YG(&)A<V5D(&]N('1H96ER(&9A:7(@=F%L=65S+`T*
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M96-T:79E(&)A<VES+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q
M,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-
M"B`\:3Y-=6QT:7!L92!%;&5M96YT($%R<F%N9V5M96YT<R!A9G1E<B!T:&4@
M861O<'1I;VX@;V8@05-5#0H@,C`P.2TQ,RX\+VD^($%352`R,#`Y+3$S(&%M
M96YD960@=&AE(&%C8V]U;G1I;F<@<W1A;F1A<F1S(&9O<@T*(&-E<G1A:6X@
M;75L=&EP;&4@96QE;65N="!R979E;G5E(&%R<F%N9V5M96YT<R!T;SH\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@-G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE
M('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R
M/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M,3`P)3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-24^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,B4@86QI9VX],T1L969T/B8C>#(P
M,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#YP<F]V:61E
M('5P9&%T960@9W5I9&%N8V4@;VX@=VAE=&AE<@T*(&UU;'1I<&QE(&5L96UE
M;G1S(&5X:7-T+"!H;W<@=&AE(&5L96UE;G1S(&EN(&%N(&%R<F%N9V5M96YT
M('-H;W5L9`T*(&)E('-E<&%R871E9"P@86YD(&AO=R!T:&4@87)R86YG96UE
M;G0@8V]N<VED97)A=&EO;B!S:&]U;&0@8F4-"B!A;&QO8V%T960@=&\@=&AE
M('-E<&%R871E(&5L96UE;G1S.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#9P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S
M='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS
M1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P
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M8FQE.R!T:&ER9"UP87)T>2!E=FED96YC92`H)B-X,C`Q0SM44$4F(W@R,#%$
M.RDL(&EF(&%V86EL86)L90T*(&%N9"!64T]%(&ES(&YO="!A=F%I;&%B;&4[
M(&]R('1H92!B97-T(&5S=&EM871E(&]F('-E;&QI;F<@<')I8V4-"B`H)B-X
M,C`Q0SM%4U`F(W@R,#%$.RDL(&EF(&YE:71H97(@5E-/12!N;W(@5%!%(&ES
M(&%V86EL86)L93L@86YD/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@-G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE
M/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-
M"B`\='(^#0H@/'1D('=I9'1H/3-$-24^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,B4@86QI9VX],T1L969T/B8C>#(P,C([/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#YE;&EM:6YA=&4@=&AE
M('5S92!O9B!T:&4@<F5S:61U86P-"B!M971H;V0@86YD(')E<75I<F4@86X@
M96YT:71Y('1O(&%L;&]C871E(&%R<F%N9V5M96YT(&-O;G-I9&5R871I;VX-
M"B!U<VEN9R!T:&4@<F5L871I=F4@<V5L;&EN9R!P<FEC92!M971H;V0N/"]T
M9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
M4#H@,3)P>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#%P>"<^
M#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@
M5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@1F]R
M(')E=F5N=64@86=R965M96YT<R!W:71H(&UU;'1I<&QE(&5L96UE;G0@87)R
M86YG96UE;G1S+"!S=6-H(&%S#0H@;&EC96YS92!A;F0@9&5V96QO<&UE;G0@
M86=R965M96YT<RP@96YT97)E9"!I;G1O(&]N(&]R(&%F=&5R#0H@2F%N=6%R
M>28C>$$P.S$L(#(P,3$L('1H92!#;VUP86YY(&%L;&]C871E<R!R979E;G5E
M('1O(&5A8V@-"B!N;VXM8V]N=&EN9V5N="!E;&5M96YT(&)A<V5D(&]N('1H
M92!R96QA=&EV92!S96QL:6YG('!R:6-E(&]F(&5A8V@-"B!E;&5M96YT+B!7
M:&5N(&%P<&QY:6YG('1H92!R96QA=&EV92!S96QL:6YG('!R:6-E(&UE=&AO
M9"P@=&AE#0H@0V]M<&%N>2!D971E<FUI;F5S('1H92!S96QL:6YG('!R:6-E
M(&9O<B!E86-H(&1E;&EV97)A8FQE('5S:6YG#0H@5E-/12!O9B!S96QL:6YG
M('!R:6-E(&]R(%1012!O9B!S96QL:6YG('!R:6-E+B!)9B!N96ET:&5R(&5X
M:7-T<PT*('1H92!#;VUP86YY('5S97,@15-0(&9O<B!T:&%T(&1E;&EV97)A
M8FQE+B!2979E;G5E(&%L;&]C871E9"!I<PT*('1H96X@<F5C;V=N:7IE9"!W
M:&5N('1H92!B87-I8R!F;W5R(')E=F5N=64@<F5C;V=N:71I;VX@8W)I=&5R
M:6$-"B!A<F4@;65T(&9O<B!E86-H(&5L96UE;G0N(%1H92!C;VQL86)O<F%T
M:6]N(&%N9"!L:6-E;G-E(&%G<F5E;65N=`T*(&5N=&5R960@:6YT;R!W:71H
M(%-H:7)E($%'("A3:&ER92D@:6X@2F%N=6%R>2`R,#$R('=A<R!E=F%L=6%T
M960-"B!U;F1E<B!T:&5S92!A;65N9&5D(&%C8V]U;G1I;F<@<W1A;F1A<F1S
M+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.
M1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!!9&1I=&EO;F%L
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M;W)M86YC92X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@
M5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@36EN
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M<R!A<R!T:&4@<F5L871E9`T*(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!C
M;W-T<R!F;W(@<V5R=FEC97,@87)E(')E;F1E<F5D+B!$969E<G)E9`T*(')E
M=F5N=64@<F5P<F5S96YT<R!T:&4@<&]R=&EO;B!O9B!R97-E87)C:"!O<B!L
M:6-E;G-E('!A>6UE;G1S#0H@<F5C96EV960@=VAI8V@@:&%V92!N;W0@8F5E
M;B!E87)N960N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[
M(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%-A
M;F=A;6\F(W@R,#$Y.W,@<F5S96%R8V@@9W)A;G1S(&%R92!T>7!I8V%L;'D@
M;75L=&DM>65A<B!A9W)E96UE;G1S#0H@86YD('!R;W9I9&4@9F]R('1H92!R
M96EM8G5R<V5M96YT(&]F('%U86QI9FEE9"!E>'!E;G-E<R!F;W(-"B!R97-E
M87)C:"!A;F0@9&5V96QO<&UE;G0@87,@9&5F:6YE9"!U;F1E<B!T:&4@=&5R
M;7,@;V8@=&AE(&=R86YT#0H@86=R965M96YT+B!2979E;G5E('5N9&5R(&=R
M86YT(&%G<F5E;65N=',@:7,@<F5C;V=N:7IE9"!W:&5N('1H90T*(')E;&%T
M960@<75A;&EF:65D(')E<V5A<F-H(&5X<&5N<V5S(&%R92!I;F-U<G)E9"X\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3AP=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!-05)'
M24XM3$5&5#H@,B4[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^/&D^4F5C96YT
M($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=#PO:3X\+V(^/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P="<^#0H@26X@1F5B<G5A<GD@,C`Q,RP@=&AE($9!
M4T(@:7-S=65D($%352!.;RXF(WA!,#LR,#$S+3`R+`T*($-O;7!R96AE;G-I
M=F4@26YC;VUE("A4;W!I8R`R,C`I.B!297!O<G1I;F<@;V8@06UO=6YT<R!2
M96-L87-S:69I960-"B!/=70@;V8@06-C=6UU;&%T960@3W1H97(@0V]M<')E
M:&5N<VEV92!);F-O;64@*$%352`R,#$S+3`R*2X@5&AI<PT*(&YE=VQY(&ES
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M96-E;6)E<B8C>$$P.S$U+"`R,#$R+B!790T*(&%D;W!T960@=&AI<R!S=&%N
M9&%R9"!I;B!T:&4@9FER<W0@<75A<G1E<B!O9B`R,#$S(&%N9"!T:&4@861O
M<'1I;VX-"B!O9B!T:&ES('-T86YD87)D(&1I9"!N;W0@:&%V92!A;B!I;7!A
M8W0@;VX@;W5R(&9I;F%N8VEA;"!P;W-I=&EO;@T*(&]R(')E<W5L=',@;V8@
M;W!E<F%T:6]N<RX\+W`^#0H@/"$M+2!X8G)L+&X@+2T^#0H@#0H@/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E8V9F
M9C<Y9E]A,3`P7S0S-65?86,P.5\Y-3-B9F$T83(U,CD-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO96-F9F8W.69?83$P,%\T,S5E7V%C,#E?.34S
M8F9A-&$R-3(Y+U=O<FMS:&5E=',O4VAE970P."YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN=F5S=&UE;G1S(&%N9"!&86ER
M(%9A;'5E($UE87-U<F5M96YT/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^26YV97-T;65N=',@06QL($]T:&5R($EN
M=F5S=&UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5S=&UE;G1S(&%N9"!&86ER(%9A;'5E
M($UE87-U<F5M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P="<^#0H@/&(^3D]412`R)B-X,C`Q-#M)3E9%4U1-14Y4
M4R!!3D0@1D%)4B!604Q512!-14%355)%345.5#PO8CX\+W`^#0H@/"$M+2!X
M8G)L+&)O9'D@+2T^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P
M<'0[($U!4D=)3BU,1494.B`R)3L@1D].5"U325I%.B`Q,'!T)SX-"B`\8CX\
M:3Y);G9E<W1M96YT<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
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M('9A;'5E(&AA<PT*(&)E96X@;&5S<R!T:&%N('1H92!#;VUP86YY)B-X,C`Q
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M3BU43U`Z(#$X<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q
M<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P
M<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M(%1H92!T86)L92!B96QO=R!S=6UM87)I>F5S('1H92!#;VUP86YY)B-X,C`Q
M.3MS(&%V86EL86)L92UF;W(M<V%L90T*('-E8W5R:71I97,@*&EN('1H;W5S
M86YD<RDZ/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G/@T*("8C>$$P.SPO
M<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(^/"$M+2!"96=I;B!486)L
M92!(96%D("TM/@T*(#QT<CX-"B`\=&0@=VED=&@],T0V,"4^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,R4^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY!;6]R=&EZ960\8G(@+SX-"B!#;W-T
M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY'
M<F]S<SQB<B`O/@T*(%5N<F5A;&EZ960\8G(@+SX-"B!'86EN<SPO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^1W)O<W,\8G(@
M+SX-"B!5;G)E86QI>F5D/&)R("\^#0H@*$QO<W-E<RD\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D5S=&EM871E9#QB<B`O
M/@T*($9A:7(F(WA!,#M686QU93PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE
M860@+2T^/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*(#QT<B!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@
M,3!P="<^#0H@/&(^4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,\+V(^/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@
M1D].5"U325I%.B`Q,'!T)SX-"B!#87-H(&5Q=6EV86QE;G1S.CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`U96T[($9/3E0M4TE:13H@,3!P="<^#0H@36]N97D@;6%R
M:V5T(&9U;F1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDL-S4X/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDL-S4X/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E
M;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!4;W1A;#PO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^.2PW-3@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M.2PW-3@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*($%V86EL86)L92UF;W(M<V%L92!S96-U<FET:65S.CPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#5E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!5+E,N
M(&=O=F5R;FUE;G0@<W!O;G-O<F5D(&5N=&ET>2!D96)T('-E8W5R:71I97,\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4R+#4W-SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C(V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XU,BPV,#,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XU,BPU-S<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3(L-C`S/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M1D].5"U325I%.B`Q,'!T)SX-"B!4;W1A;"!C87-H(&5Q=6EV86QE;G1S(&%N
M9"!A=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C8R+#,S-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XV,BPS-C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^1&5C96UB
M97(F(WA!,#LS,2P@,C`Q,CPO8CX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[($9/
M3E0M4TE:13H@,3!P="<^#0H@0V%S:"!E<75I=F%L96YT<SH\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`U96T[($9/3E0M4TE:13H@,3!P
M="<^#0H@52Y3+B!G;W9E<FYM96YT('-P;VYS;W)E9"!E;G1I='D@9&5B="!S
M96-U<FET:65S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPY.3<\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,BPY.3<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@-65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($UO;F5Y(&UA
M<FME="!F=6YD<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,34L.#,Y/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$U+#@S.3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C
M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`S96T[($9/3E0M4TE:13H@,3!P="<^#0H@5&]T86P\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X+#@S-CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XQ."PX,S8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*($%V86EL86)L92UF;W(M<V%L92!S96-U<FET:65S.CPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#5E;3L@1D].5"U325I%
M.B`Q,'!T)SX-"B!5+E,N(&=O=F5R;FUE;G0@<W!O;G-O<F5D(&5N=&ET>2!D
M96)T('-E8W5R:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4T+#0R
M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(V/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XU-"PT-3(\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU
M-"PT,C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^-30L-#4R/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!4;W1A;"!C87-H
M(&5Q=6EV86QE;G1S(&%N9"!A=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE
M<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C<S+#(V,CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XR-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW,RPR.#@\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE
M($)O9'D@+2T^/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q
M,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-
M"B!!<R!O9B!397!T96UB97(F(WA!,#LS,"P@,C`Q,RP@;F]N92!O9B!T:&4@
M879A:6QA8FQE+69O<BUS86QE#0H@<V5C=7)I=&EE<R!H96QD(&)Y('1H92!#
M;VUP86YY(&AA9"!M871E<FEA;"!U;G)E86QI>F5D(&QO<W-E<R!A;F0-"B!T
M:&5R92!W97)E(&YO(')E86QI>F5D(&QO<W-E<R!F;W(@=&AE('1H<F5E(&%N
M9"!N:6YE(&UO;G1H<R!E;F1E9`T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S
M+B!4:&4@0V]M<&%N>2!H860@;F\@;W1H97(M=&AA;BUT96UP;W)A<GD-"B!I
M;7!A:7)M96YT<R!O9B!A=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<R!F
M;W(@=&AE('1H<F5E(&%N9"!N:6YE#0H@;6]N=&AS(&5N9&5D(%-E<'1E;6)E
M<B8C>$$P.S,P+"`R,#$S(&]R('1H92!T=V5L=F4@;6]N=&AS(&5N9&5D#0H@
M1&5C96UB97(F(WA!,#LS,2P@,C`Q,BX\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4)/5%1/33H@,'!T.R!-05)'24XM3$5&5#H@,B4[($9/3E0M4TE:
M13H@,3!P="<^#0H@/&(^/&D^1F%I<B!686QU92!-96%S=7)E;65N=#PO:3X\
M+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)
M3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A
M;GD@;65A<W5R97,@8V5R=&%I;B!F:6YA;F-I86P@87-S971S(&%T(&9A:7(@
M=F%L=64@;VX@80T*(')E8W5R<FEN9R!B87-I<RP@:6YC;'5D:6YG(&-A<V@@
M97%U:79A;&5N=',@86YD(&%V86EL86)L92UF;W(-"B!S86QE+7-E8W5R:71I
M97,N)B-X03`[5&AE(&9A:7(@=F%L=64@;V8@=&AE<V4@87-S971S('=A<R!D
M971E<FUI;F5D#0H@8F%S960@;VX@82!T:')E92UT:65R(&AI97)A<F-H>2!U
M;F1E<B!T:&4@875T:&]R:71A=&EV92!G=6ED86YC90T*(&9O<B!F86ER('9A
M;'5E(&UE87-U<F5M96YT<R!A;F0@9&ES8VQO<W5R97,@=&AA="!P<FEO<FET
M:7IE<R!T:&4-"B!I;G!U=',@=7-E9"!I;B!M96%S=7)I;F<@9F%I<B!V86QU
M92!A<R!F;VQL;W=S.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V
M<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!-05)'24XM3$5&5#H@-"4[($9/
M3E0M4TE:13H@,3!P="<^#0H@3&5V96P@,3H@56YA9&IU<W1E9"!Q=6]T960@
M<')I8V5S(&EN(&%C=&EV92!M87)K971S('1H870@87)E#0H@86-C97-S:6)L
M92!A="!T:&4@;65A<W5R96UE;G0@9&%T92!F;W(@:61E;G1I8V%L+"!U;G)E
M<W1R:6-T960-"B!A<W-E=',@;W(@;&EA8FEL:71I97,[/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[
M($U!4D=)3BU,1494.B`T)3L@1D].5"U325I%.B`Q,'!T)SX-"B!,979E;"`R
M.B!1=6]T960@<')I8V5S(&EN(&UA<FME=',@=&AA="!A<F4@;F]T(&%C=&EV
M92!O<B!I;G!U=',-"B!W:&EC:"!A<F4@;V)S97)V86)L92P@96ET:&5R(&1I
M<F5C=&QY(&]R(&EN9&ER96-T;'DL(&9O<@T*('-U8G-T86YT:6%L;'D@=&AE
M(&9U;&P@=&5R;2!O9B!T:&4@87-S970@;W(@;&EA8FEL:71Y.SPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@
M,'!T.R!-05)'24XM3$5&5#H@-"4[($9/3E0M4TE:13H@,3!P="<^#0H@3&5V
M96P@,SH@4')I8V5S(&]R('9A;'5A=&EO;B!T96-H;FEQ=65S('1H870@<F5Q
M=6ER92!I;G!U=',@=&AA=`T*(&%R92!B;W1H('-I9VYI9FEC86YT('1O('1H
M92!F86ER('9A;'5E(&UE87-U<F5M96YT(&%N9"!U;F]B<V5R=F%B;&4-"B`H
M:2YE+BP@<W5P<&]R=&5D(&)Y(&QI='1L92!O<B!N;R!M87)K970@86-T:79I
M='DI+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[(%1%6%0M
M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
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M8F5R(&]F(&EN<'5T<RP@:6YC;'5D:6YG+`T*(&QI<W1E9"!I;B!A<'!R;WAI
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M86QU871I;VX@;VX@86YY(&=I=F5N(&1A>2X\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,3)P>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)
M6D4Z(#%P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#!P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($U!4D=)3BU,1494.B`T
M)3L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@9F%I<B!V86QU92!M96%S=7)E
M;65N=',@;V8@;W5R(&-A<V@@97%U:79A;&5N=',@86YD#0H@879A:6QA8FQE
M+69O<BUS86QE(&UA<FME=&%B;&4@<V5C=7)I=&EE<R!A<F4@:61E;G1I9FEE
M9"!A="!T:&4-"B!F;VQL;W=I;F<@;&5V96QS('=I=&AI;B!T:&4@9F%I<B!V
M86QU92!H:65R87)C:'D@*&EN#0H@=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3)P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS
M1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L
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M3E0M4TE:13H@.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1E
M<CX\8CY397!T96UB97(F(WA!,#LS,"PF(WA!,#LR,#$S/&)R("\^#0H@1F%I
M<B8C>$$P.U9A;'5E)B-X03`[365A<W5R96UE;G1S/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E1O
M=&%L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\
M8CY,979E;"8C>$$P.S$\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N
M/3-$8V5N=&5R/CQB/DQE=F5L(#(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L)B-X03`[,SPO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@
M16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*
M(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M($9/3E0M4TE:13H@,3!P="<^#0H@07-S971S.CPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[($9/3E0M4TE:13H@
M,3!P="<^#0H@0V%S:"!E<75I=F%L96YT<SH\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M-65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($UO;F5Y(&UA<FME="!F=6YD<SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY+#<U.#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^.2PW-3@\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[($9/3E0M
M4TE:13H@,3!P="<^#0H@5&]T86P\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CDL-S4X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.2PW-3@\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!!=F%I
M;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<SH\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`U
M96T[($9/3E0M4TE:13H@,3!P="<^#0H@52Y3+B!G;W9E<FYM96YT('-P;VYS
M;W)E9"!E;G1I='D@9&5B="!S96-U<FET:65S/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XU,BPV,#,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF
M(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4R
M+#8P,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%
M.B`Q,'!T)SX-"B!4;W1A;#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3(L
M-C`S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU,BPV,#,\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@5&]T86P@8V%S:"!E<75I=F%L
M96YT<R!A;F0@879A:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XV,BPS-C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M.2PW-3@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3(L-C`S/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D/CPO=&0^#0H@
M/'1D(&-O;'-P86X],T0Q-CX\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1E<CX\8CY$96-E;6)E
M<B8C>$$P.S,Q+"8C>$$P.S(P,3(\8G(@+SX-"B!&86ER)B-X03`[5F%L=64F
M(WA!,#M-96%S=7)E;65N=',\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0G/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^5&]T86P\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L)B-X03`[
M,3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^
M3&5V96P@,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^3&5V96PF(WA!,#LS/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-
M"B!!<W-E=',Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!#87-H(&5Q=6EV
M86QE;G1S.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`U96T[($9/3E0M4TE:13H@,3!P
M="<^#0H@52Y3+B!G;W9E<FYM96YT('-P;VYS;W)E9"!E;G1I='D@9&5B="!S
M96-U<FET:65S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.3DW/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPY.3<\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#5E;3L@
M1D].5"U325I%.B`Q,'!T)SX-"B!-;VYE>2!M87)K970@9G5N9',\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-2PX,SD\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,34L.#,Y/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T
M)SX-"B!4;W1A;#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3@L.#,V/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,34L.#,Y/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,BPY.3<\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[($9/3E0M4TE:13H@,3!P
M="<^#0H@079A:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,Z/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@-65M.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*(%4N4RX@9V]V97)N;65N="!S<&]N<V]R960@96YT:71Y(&1E8G0@
M<V5C=7)I=&EE<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-30L-#4R/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU-"PT-3(\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[
M($9/3E0M4TE:13H@,3!P="<^#0H@5&]T86P\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C4T+#0U,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C
M>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-30L
M-#4R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*(%1O=&%L(&-A<V@@97%U:79A;&5N=',@86YD(&%V86EL86)L
M92UF;W(M<V%L92!S96-U<FET:65S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S,L
M,C@X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$U+#@S.3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XU-RPT-#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^/"]T86)L93X-"B`\
M<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P="<^#0H@)B-X03`[/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96-F9F8W.69?83$P,%\T,S5E7V%C
M,#E?.34S8F9A-&$R-3(Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V5C9F9F-SEF7V$Q,#!?-#,U95]A8S`Y7SDU,V)F831A,C4R.2]7;W)K<VAE
M971S+U-H965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY"87-I8R!A;F0@1&EL=71E9"!.970@3&]S<R!097(@4VAA<F4\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY%87)N:6YG<R!097(@4VAA<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,@86YD($1I;'5T
M960@3F5T($QO<W,@4&5R(%-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^3D]412`S)B-X,C`Q-#M"
M05-)0R!!3D0@1$E,551%1"!.150@3$]34R!015(@4TA!4D4\+V(^/"]P/@T*
M(#PA+2T@>&)R;"QB;V1Y("TM/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^
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M=&EE<PT*(&]U='-T86YD:6YG(&1U<FEN9R!T:&4@<&5R:6]D+CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!"96-A=7-E(%-A;F=A;6\@:7,@
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M;W(@=&AE(&YI;F4@;6]N=&AS(&5N9&5D#0H@4V5P=&5M8F5R)B-X03`[,S`L
M(#(P,3,@86YD(#(P,3(@=V5R92`W+#@U,RPY,S8@86YD(#@L,#<U+#@Y."P-
M"B!R97-P96-T:79E;'DN/"]P/@T*(#PA+2T@>&)R;"QN("TM/@T*(`T*(#PO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M96-F9F8W.69?83$P,%\T,S5E7V%C,#E?.34S8F9A-&$R-3(Y#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5C9F9F-SEF7V$Q,#!?-#,U95]A8S`Y
M7SDU,V)F831A,C4R.2]7;W)K<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY-86IO<B!#=7-T;VUE<G,L
M(%!A<G1N97)S:&EP<R!A;F0@4W1R871E9VEC($%L;&EA;F-E<SQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N
M:7IA=&EO;B!#;VYS;VQI9&%T:6]N($%N9"!0<F5S96YT871I;VX@3V8@1FEN
M86YC:6%L(%-T871E;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%J;W(@0W5S=&]M97)S+"!0
M87)T;F5R<VAI<',@86YD(%-T<F%T96=I8R!!;&QI86YC97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B`\8CY.
M3U1%(#0F(W@R,#$T.TU!2D]2($-54U1/34524RP@4$%25$Y%4E-(25!3($%.
M1"!35%)!5$5'24,-"B!!3$Q)04Y#15,\+V(^/"]P/@T*(#PA+2T@>&)R;"QB
M;V1Y("TM/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/D-O;&QA8F]R871I;VX@06=R965M96YT
M<SPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P="<^#0H@/&(^/&D^0V]L;&%B;W)A=&EO;B!A;F0@
M3&EC96YS92!!9W)E96UE;G0@=VET:"!3:&ER92!!1R!I;B!(=6UA;@T*(%1H
M97)A<&5U=&EC<R!A;F0@1&EA9VYO<W1I8W,\+VD^/"]B/CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($EN($IA;G5A<GD@,C`Q,BP@=&AE($-O
M;7!A;GD@96YT97)E9"!I;G1O(&$@8V]L;&%B;W)A=&EO;B!A;F0-"B!L:6-E
M;G-E(&%G<F5E;65N="`H=&AE($%G<F5E;65N="D@=VET:"!3:&ER92!!1R`H
M4VAI<F4I+"!P=7)S=6%N=`T*('1O('=H:6-H('1H92!#;VUP86YY(&%N9"!3
M:&ER92!C;VQL86)O<F%T92!T;R!R97-E87)C:"P@9&5V96QO<"!A;F0-"B!C
M;VUM97)C:6%L:7IE(&AU;6%N('1H97)A<&5U=&EC<R!A;F0@9&EA9VYO<W1I
M8W,@9F]R(&UO;F]G96YI8PT*(&1I<V5A<V5S(&)A<V5D(&]N(%-A;F=A;6\F
M(W@R,#$Y.W,@;F]V96P@>FEN8R!F:6YG97(@1$Y!+6)I;F1I;F<-"B!P<F]T
M96EN<R`H6D90*2!T96-H;F]L;V=Y+B!5;F1E<B!T:&4@06=R965M96YT+"!T
M:&4@0V]M<&%N>2!A;F0-"B!3:&ER92!M87D@9&5V96QO<"!P;W1E;G1I86P@
M:'5M86X@=&AE<F%P975T:6,@;W(@9&EA9VYO<W1I8PT*('!R;V1U8W1S(&9O
M<B!S979E;B!G96YE('1A<F=E=',N(%1H92!I;FET:6%L(&9O=7(@9V5N92!T
M87)G971S#0H@<V5L96-T960@=V5R92!B;&]O9"!C;&]T=&EN9R!&86-T;W)S
M(%9)22P@5DE)22P@25@@86YD(%@L(&%N9`T*('!R;V1U8W1S(&1E=F5L;W!E
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M;PT*('5S92!386YG86UO)B-X,C`Q.3MS(%I&4"!T96-H;F]L;V=Y(&9O<B!T
M:&4@<'5R<&]S92!O9B!D979E;&]P:6YG#0H@86YD(&-O;6UE<F-I86QI>FEN
M9R!H=6UA;B!T:&5R87!E=71I8R!A;F0@9&EA9VYO<W1I8R!P<F]D=6-T<R!F
M;W(-"B!T:&4@9V5N92!T87)G971S+B!4:&4@:6YI=&EA;"!R97-E87)C:"!T
M97)M(&]F('1H92!!9W)E96UE;G0@:7,@<VEX#0H@>65A<G,@86YD(&ES('-U
M8FIE8W0@=&\@97AT96YS:6]N<R!U<&]N(&UU='5A;"!A9W)E96UE;G0@86YD
M('5N9&5R#0H@;W1H97(@<W!E8VEF:65D(&-I<F-U;7-T86YC97,N/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[($U!4D=)3BU"3U143TTZ
M(#!P>#L@1D].5"U325I%.B`Q<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*(%5N9&5R('1H92!T97)M<R!O9B!T:&4@06=R
M965M96YT+"!T:&4@0V]M<&%N>2!I<R!R97-P;VYS:6)L92!F;W(-"B!A;&P@
M<F5S96%R8V@@86-T:79I=&EE<R!T:')O=6=H('1H92!S=6)M:7-S:6]N(&]F
M(&%N($EN=F5S=&EG871I=F4-"B!.97<@1')U9R!!<'!L:6-A=&EO;B`H24Y$
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M+7)E;&%T960@8V]S=',N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(%1H92!#;VUP86YY(')E8V5I=F5D(&%N('5P9G)O;G0@;&EC96YS92!F
M964@;V8@)#$S+C`@;6EL;&EO;BX@5&AE#0H@0V]M<&%N>2!W:6QL(&%L<V\@
M8F4@96QI9VEB;&4@=&\@<F5C96EV92!U<"!T;R`D,C$S+C4@;6EL;&EO;B!O
M9@T*(&-O;G1I;F=E;G0@<&%Y;65N=',@9F]R(&5A8V@@9V5N92!T87)G970@
M:68@<W!E8VEF:65D(')E<V5A<F-H+`T*(')E9W5L871O<GDL(&-L:6YI8V%L
M(&1E=F5L;W!M96YT+"!C;VUM97)C:6%L:7IA=&EO;B!A;F0@<V%L97,-"B!M
M:6QE<W1O;F4@979E;G1S(&]C8W5R+"!I;F-L=61I;F<@<&%Y;65N=',@9F]R
M(&5A8V@@9V5N92!T87)G970-"B!T:')O=6=H('1H92!A8V-E<'1A;F-E(&]F
M(&%N($E.1"!O<B!#5$$@<W5B;6ES<VEO;B!T;W1A;&EN9R`D."XU#0H@;6EL
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M(%1O(&1A=&4L(&YO('!R;V1U8W1S(&AA=F4@8F5E;B!A<'!R;W9E9`T*(&%N
M9"!T:&5R969O<F4@;F\@<F]Y86QT>2!F965S(&AA=F4@8F5E;B!E87)N960@
M=6YD97(@=&AE($%G<F5E;65N=`T*('=I=&@@4VAI<F4N/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($%L;"!C;VYT:6YG96YT('!A>6UE;G1S
M('5N9&5R('1H92!!9W)E96UE;G0L('=H96X@96%R;F5D+"!W:6QL(&)E#0H@
M;F]N+7)E9G5N9&%B;&4@86YD(&YO;BUC<F5D:71A8FQE+B!4:&4@0V]M<&%N
M>2!H87,@979A;'5A=&5D('1H90T*(&-O;G1I;F=E;G0@<&%Y;65N=',@=6YD
M97(@=&AE($%G<F5E;65N="!W:71H(%-H:7)E(&)A<V5D(&]N('1H90T*(&%U
M=&AO<FET871I=F4@9W5I9&%N8V4@9F]R(')E<V5A<F-H(&%N9"!D979E;&]P
M;65N="!M:6QE<W1O;F5S(&%N9`T*(&1E=&5R;6EN960@=&AA="!C97)T86EN
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M=F5N=',@*&DI)B-X03`[=&AA=`T*(&-A;B!B92!A8VAI979E9"!B87-E9"!I
M;B!W:&]L92!O<B!I;B!P87)T(&]N(&5I=&AE<B!T:&4-"B!#;VUP86YY)B-X
M,C`Q.3MS('!E<F9O<FUA;F-E(&]R(&]N('1H92!O8V-U<G)E;F-E(&]F(&$@
M<W!E8VEF:6,-"B!O=71C;VUE(')E<W5L=&EN9R!F<F]M('1H92!#;VUP86YY
M)B-X,C`Q.3MS('!E<F9O<FUA;F-E+`T*("AI:2DF(WA!,#MF;W(@=VAI8V@@
M=&AE<F4@=V%S('-U8G-T86YT:79E('5N8V5R=&%I;G1Y(&%T('1H92!D871E
M#0H@=&AE(&%G<F5E;65N="!W87,@96YT97)E9"!I;G1O('1H870@=&AE(&5V
M96YT('=O=6QD(&)E(&%C:&EE=F5D(&%N9`T*("AI:6DI)B-X03`[=&AA="!W
M;W5L9"!R97-U;'0@:6X@861D:71I;VYA;"!P87EM96YT<R!B96EN9R!D=64@
M=&\-"B!T:&4@0V]M<&%N>2X@06-C;W)D:6YG;'DL(')E=F5N=64@9F]R('1H
M92!A8VAI979E;65N="!O9B!M:6QE<W1O;F5S#0H@=&AA="!A<F4@9&5T97)M
M:6YE9"!T;R!B92!S=6)S=&%N=&EV92!W:6QL(&)E(')E8V]G;FEZ960@:6X@
M:71S#0H@96YT:7)E='D@:6X@=&AE('!E<FEO9"!W:&5N('1H92!M:6QE<W1O
M;F4@:7,@86-H:65V960@86YD#0H@8V]L;&5C=&%B:6QI='D@:7,@<F5A<V]N
M86)L>2!A<W-U<F5D+B!2979E;G5E(&9O<B!T:&4@86-H:65V96UE;G0-"B!O
M9B!M:6QE<W1O;F5S('1H870@87)E(&YO="!S=6)S=&%N=&EV92!W:6QL(&)E
M(')E8V]G;FEZ960@;W9E<B!T:&4-"B!R96UA:6YI;F<@<&5R:6]D(&]F('1H
M92!!9W)E96UE;G0N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R
M<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M(%1H92!#;VUP86YY(&AA<R!I9&5N=&EF:65D('1H92!D96QI=F5R86)L97,@
M=VET:&EN('1H92!A<G)A;F=E;65N=`T*(&%S(&$@;&EC96YS92!T;R!T:&4@
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M('!E<F9O<FUE9"!P=7)S=6%N=`T*('1O('1H92!!9W)E96UE;G0N($%S(&$@
M<F5S=6QT+"!T:&4@0V]M<&%N>2!W:6QL(')E8V]G;FEZ92!R979E;G5E#0H@
M9G)O;2!T:&4@=7!F<F]N="!P87EM96YT(&]N(&$@<W1R86EG:'0M;&EN92!B
M87-I<R!O=F5R(&$@<VEX+7EE87(-"B!I;FET:6%L(')E<V5A<F-H('1E<FT@
M9'5R:6YG('=H:6-H('1H92!#;VUP86YY('=I;&P@<&5R9F]R;0T*(')E<V5A
M<F-H('-E<G9I8V5S+B!!<R!O9B!397!T96UB97(F(WA!,#LS,"P@,C`Q,RP@
M=&AE($-O;7!A;GD@:&%S#0H@9&5F97)R960@<F5V96YU92!O9B`D.2XU(&UI
M;&QI;VX@<F5L871E9"!T;R!T:&ES($%G<F5E;65N="X\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P="<^#0H@4F5V96YU97,@<F5C;V=N:7IE9"!U;F1E
M<B!T:&4@86=R965M96YT('=I=&@@4VAI<F4@9F]R('1H92!T:')E90T*(&%N
M9"!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(F(WA!,#LS,"P@,C`Q,R!A
M;F0-"B!397!T96UB97(F(WA!,#LS,"P@,C`Q,BP@=V5R92!A<R!F;VQL;W=S
M("AI;B!T:&]U<V%N9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0
M.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T)SX-
M"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!3
M13H@8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R/CPA+2T@
M0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S$E
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0G/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^/&(^5&AR964F(WA!,#MM
M;VYT:',F(WA!,#ME;F1E9#QB<B`O/@T*(%-E<'1E;6)E<B8C>$$P.S,P+#PO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^/&(^3FEN
M92!M;VYT:',@96YD960\8G(@+SX-"B!397!T96UB97(F(WA!,#LS,"P\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@
M86QI9VX],T1C96YT97(^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE
M($AE860@+2T^/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*(#QT<B!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:
M13H@,3!P="<^#0H@4F5V96YU92!R96QA=&5D('1O(%-H:7)E($-O;&QA8F]R
M871I;VXZ/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!!;6]R=&EZ871I;VX@
M;V8@=7!F<F]N="!F964\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-30R
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU-#(\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-C(U/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XQ+#0T-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[
M($9/3E0M4TE:13H@,3!P="<^#0H@4F5S96%R8V@@<V5R=FEC97,\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#DV.#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#8W-3PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XQ,2PS-#`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-"PW-#<\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PU,3`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPR,3<\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,3(L.38U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L,3DQ
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM
M($5N9"!486)L92!";V1Y("TM/CPO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P="<^#0H@4F5L871E9"!C;W-T<R!A;F0@97AP96YS97,@:6YC=7)R
M960@=6YD97(@=&AE(%-H:7)E(&%G<F5E;65N="!W97)E#0H@)#,N-2!M:6QL
M:6]N(&%N9"`D,BXR(&UI;&QI;VX@9'5R:6YG('1H92!T:')E92!M;VYT:',@
M96YD960-"B!397!T96UB97(F(WA!,#LS,"P@,C`Q,R!A;F0@4V5P=&5M8F5R
M)B-X03`[,S`L(#(P,3(L(')E<W!E8W1I=F5L>0T*(&%N9"`D,3`N,R!M:6QL
M:6]N(&%N9"`D,RXX(&UI;&QI;VX@9'5R:6YG('1H92!N:6YE(&UO;G1H<R!E
M;F1E9`T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S(&%N9"!397!T96UB97(F
M(WA!,#LS,"P@,C`Q,BP-"B!R97-P96-T:79E;'DN/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-
M"B`\8CX\:3Y!9W)E96UE;G0@=VET:"!3:6=M82U!;&1R:6-H($-O<G!O<F%T
M:6]N(&EN($QA8F]R871O<GD-"B!297-E87)C:"!296%G96YT<RP@5')A;G-G
M96YI8R!!;FEM86P@86YD($-O;6UE<F-I86P@4')O=&5I;@T*(%!R;V1U8W1I
M;VX@0V5L;"UL:6YE($5N9VEN965R:6YG/"]I/CPO8CX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T)SX-"B!);B!*=6QY(#(P,#<L(%-A;F=A;6\@96YT
M97)E9"!I;G1O(&$@;&EC96YS92!A9W)E96UE;G0@*'1H90T*($%G<F5E;65N
M="D@=VET:"!3:6=M82U!;&1R:6-H($-O<G!O<F%T:6]N("A3:6=M82DN(%5N
M9&5R('1H90T*($%G<F5E;65N="P@4V%N9V%M;R!A9W)E960@=&\@<')O=FED
M92!3:6=M82!W:71H(&%C8V5S<R!T;R!O=7(-"B!P<F]P<FEE=&%R>2!:1E`@
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M#0H@=7-I;F<@4V%N9V%M;R8C>#(P,3D[<R!:1E`@=&5C:&YO;&]G>2!D=7)I
M;F<@=VAI8V@@=&EM92!386YG86UO#0H@86=R965D('1O(&%S<VES="!3:6=M
M82!I;B!C;VYN96-T:6]N('=I=&@@:71S(&5F9F]R=',@=&\@;6%R:V5T(&%N
M9`T*('-E;&P@<V5R=FEC97,@96UP;&]Y:6YG('1H92!#;VUP86YY)B-X,C`Q
M.3MS(%I&4"!T96-H;F]L;V=Y(&EN('1H90T*(')E<V5A<F-H(&9I96QD+B!3
M86YG86UO(&AA<R!T<F%N<V9E<G)E9"!T:&4@6D90(&UA;G5F86-T=7)I;F<-
M"B!T96-H;F]L;V=Y('1O(%-I9VUA+CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T)SX-"B!);B!/8W1O8F5R(#(P,#DL(%-A;F=A;6\@97AP86YD960@
M:71S($%G<F5E;65N="!W:71H(%-I9VUA+B!);@T*(&%D9&ET:6]N('1O('1H
M92!O<FEG:6YA;"!T97)M<R!O9B!T:&4@06=R965M96YT+"!3:6=M82!R96-E
M:79E9`T*(&5X8VQU<VEV92!R:6=H=',@=&\@9&5V96QO<"!A;F0@9&ES=')I
M8G5T92!:1E`M;6]D:69I960@8V5L;"!L:6YE<PT*(&9O<B!C;VUM97)C:6%L
M('!R;V1U8W1I;VX@;V8@<')O=&5I;B!P:&%R;6%C975T:6-A;',@86YD(&-E
M<G1A:6X-"B!:1E`M96YG:6YE97)E9"!T<F%N<V=E;FEC(&%N:6UA;',@9F]R
M(&-O;6UE<F-I86P@87!P;&EC871I;VYS+@T*(%5N9&5R('1H92!T97)M<R!O
M9B!T:&4@06=R965M96YT+"!3:6=M82!M861E('5P9G)O;G0@8V%S:"!P87EM
M96YT#0H@;V8@)#(P+C`@;6EL;&EO;B!C;VYS:7-T:6YG(&]F(&$@)#0N.2!M
M:6QL:6]N('!U<F-H87-E(&]F(#8S-BPQ,S,-"B!S:&%R97,@;V8@4V%N9V%M
M;R!C;VUM;VX@<W1O8VLL('9A;'5E9"!A="`D-"XY(&UI;&QI;VXL(&%N9"!A
M("0Q-2XQ#0H@;6EL;&EO;B!U<&9R;VYT(&QI8V5N<V4@9F5E+B!4:&4@=7!F
M<F]N="!L:6-E;G-E(&9E92!W87,@<F5C;V=N:7IE9`T*(&]N(&$@<W1R86EG
M:'0M;&EN92!B87-I<R!F<F]M('1H92!E9F9E8W1I=F4@9&%T92!O9B!T:&4@
M97AP86YD960-"B!L:6-E;G-E('1H<F]U9V@@2G5L>2`R,#$P+"!W:&EC:"!R
M97!R97-E;G1S('1H92!P97)I;V0@;W9E<B!W:&EC:`T*(%-A;F=A;6\@=V%S
M(&]B;&EG871E9"!T;R!P97)F;W)M(')E<V5A<F-H('-E<G9I8V5S(&9O<B!3
M:6=M82X-"B!386YG86UO(&ES(&%L<V\@96QI9VEB;&4@=&\@<F5C96EV92!C
M;VUM97)C:6%L(&QI8V5N<V4@9F5E<R!O9B`D-2XP#0H@;6EL;&EO;B!B87-E
M9"!U<&]N(&$@<&5R8V5N=&%G92!O9B!N970@<V%L97,@86YD('-U8FQI8V5N
M<VEN9PT*(')E=F5N=64@86YD('1H97)E869T97(@82!R961U8V5D(')O>6%L
M='D@<F%T92!O9B`Q,"XU)2!O9B!N970@<V%L97,-"B!A;F0@<W5B;&EC96YS
M:6YG(')E=F5N=64N($EN(&%D9&ET:6]N+"!U<&]N('1H92!A8VAI979E;65N
M="!O9@T*(&-E<G1A:6X@8W5M=6QA=&EV92!C;VUM97)C:6%L(&UI;&5S=&]N
M97,@4VEG;6$@=VEL;"!M86ME(&UI;&5S=&]N90T*('!A>6UE;G1S('1O(%-A
M;F=A;6\@=7`@=&\@86X@86=G<F5G871E(&]F("0R-2XP(&UI;&QI;VXN($EN
M($%P<FEL#0H@,C`Q,RP@=&AE($-O;7!A;GD@<F5C;V=N:7IE9"`D,2XS(&UI
M;&QI;VX@:6X@<W5B;&EC96YS92!R979E;G5E<PT*('5N9&5R('1H92!A9W)E
M96UE;G0@=VET:"!3:6=M82X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
M4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
M="<^#0H@4F5V96YU97,@<F5C;V=N:7IE9"!U;F1E<B!T:&4@86=R965M96YT
M('=I=&@@4VEG;6$@9F]R('1H92!T:')E90T*(&%N9"!N:6YE(&UO;G1H<R!E
M;F1E9"!397!T96UB97(F(WA!,#LS,"P@,C`Q,R!A;F0-"B!397!T96UB97(F
M(WA!,#LS,"P@,C`Q,BP@=V5R92!A<R!F;VQL;W=S("AI;B!T:&]U<V%N9',I
M.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T)SX-"B`F(WA!,#L\+W`^#0H@
M/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@
M8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R/CPA+2T@0F5G:6X@5&%B;&4@2&5A
M9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S`E/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/CPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@
M86QI9VX],T1C96YT97(^/&(^5&AR964F(WA!,#MM;VYT:',F(WA!,#ME;F1E
M9#QB<B`O/@T*(%-E<'1E;6)E<B8C>$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#8@86QI9VX],T1C96YT97(^/&(^3FEN928C>$$P.VUO;G1H<R8C
M>$$P.V5N9&5D/&)R("\^#0H@4V5P=&5M8F5R)B-X03`[,S`L/"]B/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N
M/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!(96%D
M("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*(%)E=F5N=64@<F5L871E9"!T;R!3:6=M82!#;VQL86)O<F%T:6]N
M/&(^.CPO8CX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%)O>6%L='D@<F5V
M96YU97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C`Q/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
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M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,2PP,S4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*($QI8V5N<V4@9F5E(&%N9"!M:6QE<W1O;F4@<F5V96YU97,\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,#$\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PS-3$\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PP,#`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1O=&%L/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,S`R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0R.#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#`V,CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XR+#`S-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%)E;&%T960@8V]S=',@86YD(&5X
M<&5N<V5S(&EN8W5R<F5D('5N9&5R('1H92!3:6=M82!A9W)E96UE;G0@=V5R
M90T*("0P+C$@;6EL;&EO;B!D=7)I;F<@8F]T:"!T:&4@=&AR964@;6]N=&AS
M(&5N9&5D(%-E<'1E;6)E<B8C>$$P.S,P+`T*(#(P,3,@86YD(#(P,3(N(%)E
M;&%T960@8V]S=',@86YD(&5X<&5N<V5S(&EN8W5R<F5D('5N9&5R('1H92!3
M:6=M80T*(&%G<F5E;65N="!W97)E("0P+C$@;6EL;&EO;B!A;F0@)#`N,R!M
M:6QL:6]N(&1U<FEN9R!T:&4@;FEN92!M;VYT:',-"B!E;F1E9"!397!T96UB
M97(F(WA!,#LS,"P@,C`Q,R!A;F0@,C`Q,BP@<F5S<&5C=&EV96QY+CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P="<^#0H@/&(^/&D^06=R965M96YT('=I=&@@1&]W($%G<F]38VEE
M;F-E<R!I;B!0;&%N=`T*($%G<FEC=6QT=7)E/"]I/CPO8CX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T)SX-"B!);B!/8W1O8F5R(#(P,#4L(%-A;F=A
M;6\@96YT97)E9"!I;G1O(&%N(&5X8VQU<VEV92!C;VUM97)C:6%L#0H@;&EC
M96YS92!A9W)E96UE;G0@*'1H92!!9W)E96UE;G0I('=I=&@@1$%3+B!5;F1E
M<B!T:&4@06=R965M96YT+`T*(%-A;F=A;6\@<')O=FED97,@1$%3('=I=&@@
M86-C97-S('1O(&ET<R!P<F]P<FEE=&%R>2!:1E`@=&5C:&YO;&]G>0T*(&%N
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M=&]R<R`H6D90(%1&<RD@;W(@6D90(&YU8VQE87-E<R`H6D9.<RD@:6YT;R!H
M=6UA;G,@;W(@86YI;6%L<PT*(&9O<B!D:6%G;F]S=&EC+"!T:&5R87!E=71I
M8RP@;W(@<')O<&AY;&%C=&EC('!U<G!O<V5S+B!4:&4-"B!!9W)E96UE;G0@
M=VET:"!$05,@<')O=FED960@9F]R(&%N(&EN:71I86P@=&AR964M>65A<B!R
M97-E87)C:`T*('1E<FTN($EN($IU;F4@,C`P."P@1$%3(&5X97)C:7-E9"!I
M=',@;W!T:6]N('5N9&5R('1H92!A9W)E96UE;G0@=&\-"B!O8G1A:6X@82!C
M;VUM97)C:6%L(&QI8V5N<V4@=&\@<V5L;"!P<F]D=6-T<R!I;F-O<G!O<F%T
M:6YG(&]R#0H@9&5R:79E9"!F<F]M('!L86YT(&-E;&QS(&=E;F5R871E9"!U
M<VEN9R!T:&4@0V]M<&%N>28C>#(P,3D[<R!:1E`-"B!T96-H;F]L;V=Y+"!I
M;F-L=61I;F<@86=R:6-U;'1U<F%L(&-R;W!S+"!I;F1U<W1R:6%L('!R;V1U
M8W1S(&%N9`T*('!L86YT+61E<FEV960@8FEO<&AA<FUA8V5U=&EC86QS+B!4
M:&4@97AE<F-I<V4@;V8@=&AE(&]P=&EO;@T*('1R:6=G97)E9"!A(&]N92UT
M:6UE(&-O;6UE<F-I86P@;&EC96YS92!F964@;V8@)#8N,"!M:6QL:6]N+`T*
M('!A>6UE;G0@;V8@=&AE(')E;6%I;FEN9R`D,BXS(&UI;&QI;VX@;V8@=&AE
M('!R979I;W5S;'D@86=R965D("0T+C`-"B!M:6QL:6]N(&EN(')E<V5A<F-H
M(&UI;&5S=&]N97,L(&1E=F5L;W!M96YT(&%N9"!C;VUM97)C:6%L:7IA=&EO
M;@T*(&UI;&5S=&]N92!P87EM96YT<R!F;W(@96%C:"!P<F]D=6-T+"!A;F0@
M<F]Y86QT:65S(&]N('-A;&5S(&]F#0H@<')O9'5C=',N($9U<G1H97)M;W)E
M+"!$05,@:&%S('1H92!R:6=H="!T;R!S=6)L:6-E;G-E#0H@4V%N9V%M;R8C
M>#(P,3D[<R!:1E`@=&5C:&YO;&]G>2!T;R!T:&ER9"!P87)T:65S(&9O<B!U
M<V4@:6X@<&QA;G0-"B!C96QL<RP@<&QA;G1S+"!O<B!P;&%N="!C96QL(&-U
M;'1U<F5S+B!386YG86UO('=I;&P@8F4@96YT:71L960@=&\-"B`R-24@;V8@
M86YY(&-A<V@@8V]N<VED97)A=&EO;B!R96-E:79E9"!B>2!$05,@=6YD97(@
M<W5C:`T*('-U8FQI8V5N<V5S+B!);B!$96-E;6)E<B`R,#$P+"!T:&4@0V]M
M<&%N>2!A;65N9&5D('1H92!!9W)E96UE;G0-"B!W:71H($1!4R!T;R!E>'1E
M;F0@=&AE('!E<FEO9"!O9B!R96%G96YT(&UA;G5F86-T=7)I;F<@<V5R=FEC
M97,@86YD#0H@<F5S96%R8V@@<V5R=FEC97,@=&AR;W5G:"!$96-E;6)E<B8C
M>$$P.S,Q+"`R,#$R+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q
M,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-
M"B!4:&4@06=R965M96YT(&%L<V\@<')O=FED97,@9F]R(&UI;FEM=6T@<W5B
M;&EC96YS92!F965S(&5A8V@@>65A<@T*(&1U92!T;R!386YG86UO(&5V97)Y
M($]C=&]B97(L('!R;W9I9&5D('1H92!!9W)E96UE;G0@:7,@;F]T#0H@=&5R
M;6EN871E9"!B>2!$05,N($%N;G5A;"!F965S(')A;F=E(&9R;VT@)#(U,"PP
M,#`@=&\@)#,N,"!M:6QL:6]N#0H@86YD('1O=&%L("0R-2XS(&UI;&QI;VX@
M;W9E<B`Q,2!Y96%R<RX@5&AE($-O;7!A;GD@9&]E<R!N;W0@:&%V90T*(&%N
M>2!P97)F;W)M86YC92!O8FQI9V%T:6]N<R!W:71H(')E<W!E8W0@=&\@=&AE
M('-U8FQI8V5N<VEN9PT*(&%C=&EV:71I97,@=&\@8F4@8V]N9'5C=&5D(&)Y
M($1!4RX@1$%3(&AA<R!T:&4@<FEG:'0@=&\@=&5R;6EN871E#0H@=&AE($%G
M<F5E;65N="!A="!A;GD@=&EM93L@86-C;W)D:6YG;'DL('1H92!#;VUP86YY
M)B-X,C`Q.3MS(&%C='5A;`T*('-U8FQI8V5N<V4@9F5E<R!O=F5R('1H92!T
M97)M(&]F('1H92!!9W)E96UE;G0@8V]U;&0@8F4@;&]W97(@=&AA;@T*("0R
M-2XS(&UI;&QI;VXN($EN(&%D9&ET:6]N+"!E86-H('!A<G1Y(&UA>2!T97)M
M:6YA=&4@=&AE($%G<F5E;65N=`T*('5P;VX@86X@=6YC=7)E9"!M871E<FEA
M;"!B<F5A8V@@8GD@=&AE(&]T:&5R('!A<G1Y+B!);B!T:&4@979E;G0@;V8-
M"B!A;GD@=&5R;6EN871I;VX@;V8@=&AE($%G<F5E;65N="P@86QL(')I9VAT
M<R!T;R!U<V4@=&AE#0H@0V]M<&%N>28C>#(P,3D[<R!:1E`@=&5C:&YO;&]G
M>2!W:6QL(')E=F5R="!T;R!386YG86UO+"!A;F0@1$%3('=I;&P-"B!N;R!L
M;VYG97(@8F4@<&5R;6ET=&5D(&%C8V5S<R!T;R!386YG86UO)B-X,C`Q.3MS
M(%I&4"!T96-H;F]L;V=Y(&]R#0H@=&\@9&5V96QO<"!O<BP@97AC97!T(&EN
M(&QI;6ET960@8VER8W5M<W1A;F-E<RP@8V]M;65R8VEA;&EZ92!A;GD-"B!P
M<F]D=6-T<R!D97)I=F5D(&9R;VT@=&AE($-O;7!A;GDF(W@R,#$Y.W,@6D90
M('1E8VAN;VQO9WDN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R
M<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M(%)E=F5N=65S('5N9&5R('1H92!A9W)E96UE;G0@=V5R92`D,"XT(&UI;&QI
M;VX@9'5R:6YG('1H92!T:')E90T*(&UO;G1H<R!E;F1E9"!397!T96UB97(F
M(WA!,#LS,"P@,C`Q,BP@86YD("0Q+C,@;6EL;&EO;B!D=7)I;F<@=&AE#0H@
M;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3(N(%)E
M;&%T960@8V]S=',@86YD#0H@97AP96YS97,@:6YC=7)R960@=6YD97(@=&AE
M(&%G<F5E;65N="!W97)E("0P+C$@;6EL;&EO;B!D=7)I;F<@=&AE#0H@=&AR
M964@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$R+"!A;F0@
M)#`N-"!M:6QL:6]N(&1U<FEN9PT*('1H92!N:6YE(&UO;G1H<R!E;F1E9"!3
M97!T96UB97(F(WA!,#LS,"P@,C`Q,BX@5&AE<F4@=V5R92!N;R!S=6-H#0H@
M<F5V96YU97,@;W(@<F5L871E9"!E>'!E;G-E<R!D=7)I;F<@=&AE('1H<F5E
M(&%N9"!N:6YE(&UO;G1H<R!E;F1E9`T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R
M,#$S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P="<^#0H@/&(^1G5N9&EN9R!F<F]M(%)E<V5A<F-H
M($9O=6YD871I;VYS/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0
M.B`V<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B`\8CX\:3Y#86QI9F]R
M;FEA($EN<W1I='5T92!F;W(@4F5G96YE<F%T:79E($UE9&EC:6YE/"]I/CPO
M8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!415A4+4E.
M1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!);B!/8W1O8F5R
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M97-E87)C:`T*('!R;VIE8W0@8V]N9'5C=&5D(&)Y(&$@;75L=&ED:7-C:7!L
M:6YA<GD@=&5A;2!O9B!I;G9E<W1I9V%T;W)S+`T*(&EN8VQU9&EN9R!I;G9E
M<W1I9V%T;W)S(&9R;VT@=&AE(%5N:79E<G-I='D@;V8@4V]U=&AE<FX@0V%L
M:69O<FYI82P-"B!#:71Y(&]F($AO<&4@3F%T:6]N86P@365D:6-A;"!#96YT
M97(@86YD(%-A;F=A;6\@0FEO4V-I96YC97,N#0H@4V%N9V%M;R!E>'!E8W1S
M('1O(')E8V5I=F4@9G5N9&EN9R!U<"!T;R`D-2XR(&UI;&QI;VX@9G)O;2!T
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M86YG86UO)B-X,C`Q.3MS(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!E9F9O
M<G1S#0H@<F5L871E9"!T;R!T:&4@86=R965M96YT+B!4:&4@4W1A=&4@;V8@
M0V%L:69O<FYI82!H87,@=&AE(')I9VAT('1O#0H@<F5C96EV92P@<W5B:F5C
M="!T;R!T:&4@=&5R;7,@86YD(&-O;F1I=&EO;G,@;V8@=&AE(&%G<F5E;65N
M=`T*(&)E='=E96X@4V%N9V%M;R!A;F0@0TE232P@<&%Y;65N=',@9G)O;2!3
M86YG86UO(')E<W5L=&EN9R!F<F]M#0H@<V%L97,@;V8@82!C;VUM97)C:6%L
M('!R;V1U8W0@<F5S=6QT:6YG(&9R;VT@<F5S96%R8V@@86YD#0H@9&5V96QO
M<&UE;G0@969F;W)T<R!S=7!P;W)T960@8GD@=&AE(&=R86YT+"!N;W0@=&\@
M97AC965D('1W;R!T:6UE<PT*('1H92!A;6]U;G0@4V%N9V%M;R!R96-E:79E
M<R!I;B!F=6YD:6YG('5N9&5R('1H92!A9W)E96UE;G0@=VET:`T*($-)4DTN
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$
M14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%)E=F5N=65S(&%T
M=')I8G5T86)L92!T;R!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@<&5R9F]R
M;65D('5N9&5R#0H@=&AE($-)4DT@9W)A;G0@86=R965M96YT('=E<F4@)#`N
M-2!M:6QL:6]N(&%N9"`D,"XS(&UI;&QI;VX@9'5R:6YG#0H@=&AE('1H<F5E
M(&UO;G1H<R!E;F1E9"!397!T96UB97(F(WA!,#LS,"P@,C`Q,R!A;F0@,C`Q
M,BP-"B!R97-P96-T:79E;'D@86YD("0@,2XR)B-X03`[;6EL;&EO;B!A;F0@
M)#`N.2!M:6QL:6]N(&1U<FEN9R!T:&4-"B!N:6YE(&UO;G1H<R!E;F1E9"!3
M97!T96UB97(F(WA!,#LS,"P@,C`Q,R!A;F0@,C`Q,BP@<F5S<&5C=&EV96QY
M+@T*(%)E;&%T960@8V]S=',@86YD(&5X<&5N<V5S(&EN8W5R<F5D('5N9&5R
M('1H92!#25)-(&%G<F5E;65N="!W97)E#0H@)#`N-2!M:6QL:6]N(&%N9"`D
M,"XS(&UI;&QI;VX@9'5R:6YG('1H92!T:')E92!M;VYT:',@96YD960-"B!3
M97!T96UB97(F(WA!,#LS,"P@,C`Q,R!A;F0@,C`Q,BP@<F5S<&5C=&EV96QY
M+"!A;F0@)#$N-"!M:6QL:6]N#0H@86YD("0P+CD@;6EL;&EO;B!D=7)I;F<@
M=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C>$$P.S,P+`T*(#(P
M,3,@86YD(#(P,3(L(')E<W!E8W1I=F5L>2X\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB
M/CQI/D-(1$D@1F]U;F1A=&EO;BP@26YC+CPO:3X\+V(^/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P="<^#0H@26X@07!R:6P@,C`Q,2P@4V%N9V%M;R!E
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M871E9"!T;R!T:&4@86=R965M96YT+B!$=7)I;F<@,C`Q,BP@=&AE(&%G<F5E
M;65N="!W87,@86UE;F1E9"!T;PT*(&5X=&5N9"!T:&4@<')O:F5C="!T:')O
M=6=H($%U9W5S="`R,#$R(&%N9"!T;R!I;F-R96%S92!T;W1A;`T*('!O=&5N
M=&EA;"!F=6YD:6YG(&9R;VT@)#$N,R!M:6QL:6]N('1O("0R+C$@;6EL;&EO
M;BP@<&QU<PT*(')E:6UB=7)S96UE;G0@9F]R(&-E<G1A:6X@9&ER96-T(&5X
M<&5N<V5S(')E;&%T960@=&\@=&AE('!R;VIE8W0N#0H@5&AE(')E<V5A<F-H
M(&=R86YT(&9R;VT@0TA$22!W87,@8V]M<&QE=&5D(&EN($%U9W5S="`R,#$R
M+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.
M1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!2979E;G5E<R!A
M='1R:6)U=&%B;&4@=&\@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT('!E<F9O
M<FUE9"!U;F1E<@T*('1H92!#2$1)(&-O;&QA8F]R871I;VX@86=R965M96YT
M('=E<F4@)#`N,R!M:6QL:6]N(&%N9"`D,2XQ(&UI;&QI;VX-"B!D=7)I;F<@
M=&AE('1H<F5E(&%N9"!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(F(WA!
M,#LS,"P@,C`Q,BP-"B!R97-P96-T:79E;'DN(%)E;&%T960@8V]S=',@86YD
M(&5X<&5N<V5S(&EN8W5R<F5D('5N9&5R('1H92!#2$1)#0H@86=R965M96YT
M('=E<F4@)#`N,R!M:6QL:6]N(&%N9"`D,2XQ(&UI;&QI;VX@9'5R:6YG('1H
M92!T:')E92!A;F0-"B!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(F(WA!
M,#LS,"P@,C`Q,BP@<F5S<&5C=&EV96QY+B!4:&5R92!W97)E#0H@;F\@<F5V
M96YU97,@;W(@<F5L871E9"!E>'!E;G-E<R!D=7)I;F<@=&AE('1H<F5E(&%N
M9"!N:6YE(&UO;G1H<PT*(&5N9&5D(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S
M+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P="<^#0H@/&(^/&D^5&AE($IU=F5N:6QE($1I86)E=&5S
M(%)E<V5A<F-H($9O=6YD871I;VX-"B!);G1E<FYA=&EO;F%L/"]I/CPO8CX\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.
M5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!);B!/8W1O8F5R(#(P
M,#8L(%-A;F=A;6\@96YT97)E9"!I;G1O(&%N(&%G<F5E;65N="!W:71H('1H
M90T*($IU=F5N:6QE($1I86)E=&5S(%)E<V5A<F-H($9O=6YD871I;VX@26YT
M97)N871I;VYA;"`H2D121BD@=&\-"B!P<F]V:61E(&9I;F%N8VEA;"!S=7!P
M;W)T(&9O<B!O;F4@;V8@4V%N9V%M;R8C>#(P,3D[<R!0:&%S92`R(&AU;6%N
M#0H@8VQI;FEC86P@<W1U9&EE<R!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!P
M<F]D=6-T(&-A;F1I9&%T92!30BTU,#DL(&$-"B!:1E`@5&AE<F%P975T:6,@
M=&AA="!W87,@:6X@9&5V96QO<&UE;G0@9F]R('1H92!T<F5A=&UE;G0@;V8-
M"B!D:6%B971I8R!N975R;W!A=&AY+B!);B!*86YU87)Y(#(P,3`L($I$4D8@
M86YD(%-A;F=A;6\@86UE;F1E9"!T:&4-"B!A9W)E96UE;G0@86YD+"!S=6)J
M96-T('1O(&ET<R!T97)M<R!A;F0@8V]N9&ET:6]N<RP@2D121B!A9W)E960@
M=&\-"B!P<F]V:61E(&%D9&ET:6]N86P@9G5N9&EN9R!O9B!U<"!T;R`D,RXP
M(&UI;&QI;VX@9F]R(&$@4&AA<V4@,F(-"B!T<FEA;"!I;B!D:6%B971I8R!N
M975R;W!A=&AY+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T
M.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!)
M;B!/8W1O8F5R(#(P,3$L('1H92!#;VUP86YY(&%N;F]U;F-E9"!O9B!T:&4@
M=&5R;6EN871I;VX@;V8@:71S#0H@4T(M-3`Y('!R;V=R86TN($EN($UA<F-H
M(#(P,3(L('1H92!#;VUP86YY(')E8V5I=F5D(&$@9FEN86P@<&%Y;65N=`T*
M(&]F("0P+C@@;6EL;&EO;B!F;W(@=V]R:R!P97)F;W)M960@=6YD97(@=&AE
M($I$4D8@86=R965M96YT<RX@5&AE#0H@0V]M<&%N>2!D;V5S(&YO="!E>'!E
M8W0@=&\@<F5C96EV92!A9&1I=&EO;F%L(&9U;F1I;F<@=6YD97(@=&AE<V4-
M"B!A9W)E96UE;G1S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q
M,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-
M"B!2979E;G5E<R!A='1R:6)U=&%B;&4@=&\@<F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT(&%C=&EV:71I97,-"B!P97)F;W)M960@=6YD97(@=&AE($I$4D8@
M86=R965M96YT<R!W97)E("0P(&9O<B!T:&4@=&AR964@;6]N=&AS#0H@96YD
M960@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3(@86YD("0P+C@@;6EL;&EO;B!D
M=7)I;F<@=&AE(&YI;F4-"B!M;VYT:',@96YD960@4V5P=&5M8F5R)B-X03`[
M,S`L(#(P,3(N(%1H97)E('=E<F4@;F\@<W5C:"!R979E;G5E<PT*(&1U<FEN
M9R!T:&4@=&AR964@86YD(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C
M>$$P.S,P+"`R,#$S+CPO<#X-"B`\(2TM('AB<FPL;B`M+3X-"B`-"B`\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5C
M9F9F-SEF7V$Q,#!?-#,U95]A8S`Y7SDU,V)F831A,C4R.0T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]E8V9F9C<Y9E]A,3`P7S0S-65?86,P.5\Y
M-3-B9F$T83(U,CDO5V]R:W-H965T<R]3:&5E=#$Q+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YC;VUE(%1A>&5S/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC
M;VUE(%1A>"!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M92!487AE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M(#QB/DY/5$4@-28C>#(P,30[24Y#3TU%(%1!6$53/"]B/CPO<#X-"B`\(2TM
M('AB<FPL8F]D>2`M+3X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[
M(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1H
M92!#;VUP86YY(&UA:6YT86EN<R!D969E<G)E9"!T87@@87-S971S('1H870@
M<F5F;&5C="!T:&4@;F5T('1A>`T*(&5F9F5C=',@;V8@=&5M<&]R87)Y(&1I
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M:"!C<F5D:71S(&%N9`T*(&-A<&ET86QI>F5D(')E<V5A<F-H(&%N9"!D979E
M;&]P;65N="X@4F5A;&EZ871I;VX@;V8@9&5F97)R960@=&%X#0H@87-S971S
M(&ES(&1E<&5N9&5N="!U<&]N(&9U='5R92!E87)N:6YG<RP@:68@86YY+"!T
M:&4@=&EM:6YG(&%N9`T*(&%M;W5N="!O9B!W:&EC:"!A<F4@=6YC97)T86EN
M(&)A<V5D(&]N('1H92!#;VUP86YY)B-X,C`Q.3MS(&AI<W1O<GD-"B!O9B!L
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M90T*('5T:6QI>F%T:6]N+CPO<#X-"B`-"B`-"B`\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5C9F9F-SEF7V$Q,#!?
M-#,U95]A8S`Y7SDU,V)F831A,C4R.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]E8V9F9C<Y9E]A,3`P7S0S-65?86,P.5\Y-3-B9F$T83(U,CDO
M5V]R:W-H965T<R]3:&5E=#$R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&ES
M8VQO<W5R92!/9B!#;VUP96YS871I;VX@4F5L871E9"!#;W-T<R!3:&%R96)A
M<V5D(%!A>6UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
M="<^#0H@/&(^3D]412`V)B-X,C`Q-#M35$]#2RU"05-%1"!#3TU014Y3051)
M3TX\+V(^/"]P/@T*(#PA+2T@>&)R;"QB;V1Y("TM/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P="<^#0H@5&AE(&9O;&QO=VEN9R!T86)L92!S:&]W<R!T;W1A
M;"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS90T*(&EN8VQU9&5D
M(&EN('1H92!C;VYD96YS960@8V]N<V]L:61A=&5D('-T871E;65N="!O9B!O
M<&5R871I;VYS(&9O<@T*('1H92!T:')E92!M;VYT:"!A;F0@;FEN92!M;VYT
M:',@96YD960@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,@86YD#0H@,C`Q,B`H
M:6X@=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M,'!T.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P="<^#0H@
M)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z
M(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP
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M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/E1H<F5E)B-X03`[;6]N
M=&AS)B-X03`[96YD960\8G(@+SX-"B!397!T96UB97(F(WA!,#LS,"P\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/DYI;F4F
M(WA!,#MM;VYT:',F(WA!,#ME;F1E9#QB<B`O/@T*(%-E<'1E;6)E<B8C>$$P
M.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%
M;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M1D].5"U325I%.B`Q,'!T)SX-"B!#;W-T<R!A;F0@97AP96YS97,Z/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@
M1D].5"U325I%.B`Q,'!T)SX-"B!297-E87)C:"!A;F0@9&5V96QO<&UE;G0\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S,R/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
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M1')I9VAT/C(L,30P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR
M+#$Y-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[($9/3E0M4TE:13H@,3!P
M="<^#0H@1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XV-3D\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^-C,P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C$L.34X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C$L.#$V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#5E;3L@1D].5"U325I%.B`Q,'!T)SX-
M"B!4;W1A;"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$L,SDQ/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C$L-#`T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L,#DX/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C0L,#$Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(`T*(`T*(#PO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96-F9F8W.69?
M83$P,%\T,S5E7V%C,#E?.34S8F9A-&$R-3(Y#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V5C9F9F-SEF7V$Q,#!?-#,U95]A8S`Y7SDU,V)F831A
M,C4R.2]7;W)K<VAE971S+U-H965T,3,N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5Q
M=6ET>2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3=&]C:VAO;&1E<G,G($5Q=6ET>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/DY/
M5$4@-R8C>#(P,30[4U1/0TM(3TQ$15)3)B-X,C`Q.3L@15%52519/"]B/CPO
M<#X-"B`\(2TM('AB<FPL8F]D>2`M+3X-"B`\<"!S='EL93TS1"=-05)'24XM
M5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T)SX-"B!/;B!397!T96UB97(F(WA!,#LR,RP@,C`Q,RP@4V%N9V%M;R!C
M;VUP;&5T960@86X@=6YD97)W<FET=&5N#0H@<'5B;&EC(&]F9F5R:6YG(&]F
M(&ET<R!C;VUM;VX@<W1O8VLL(&EN('=H:6-H('1H92!#;VUP86YY('-O;&0@
M86X-"B!A9V=R96=A=&4@;V8@-RPP,34L,#`P('-H87)E<R!O9B!I=',@8V]M
M;6]N('-T;V-K+"!I;F-L=61I;F<-"B`Y,34L,#`P(&ES<W5E9"!T;R!T:&4@
M56YD97)W<FET97)S('!U<G-U86YT('1O(&$@,S`M9&%Y#0H@;W9E<F%L;&]T
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M;G-E<RP@=V5R92!A<'!R;WAI;6%T96QY("0V.2XU#0H@;6EL;&EO;BX\+W`^
M#0H@/"$M+2!X8G)L+&X@+2T^#0H@#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E8V9F9C<Y9E]A,3`P7S0S-65?
M86,P.5\Y-3-B9F$T83(U,CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO96-F9F8W.69?83$P,%\T,S5E7V%C,#E?.34S8F9A-&$R-3(Y+U=O<FMS
M:&5E=',O4VAE970Q-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-U8G-E<75E;G0@179E;G1S/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N
M=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4W5B<V5Q=65N="!%=F5N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B`\8CY.3U1%(#@F
M(W@R,#$T.U-50E-%455%3E0@159%3E13/"]B/CPO<#X-"B`\(2TM('AB<FPL
M8F]D>2`M+3X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T)SX-"B`\8CY!8W%U:7-I=&EO;B!O9B!#97)E9V5N
M93PO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!415A4
M+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!/;B!!=6=U
M<W0F(WA!,#LR,RP@,C`Q,RP@4V%N9V%M;R!A;F0@:71S('=H;VQL>2UO=VYE
M9"!S=6)S:61I87)Y($-'#0H@06-Q=6ES:71I;VX@4W5B+"!);F,N+"!A($1E
M;&%W87)E(&-O<G!O<F%T:6]N("@F(W@R,#%#.TUE<F=E<@T*(%-U8B8C>#(P
M,40[*2P@96YT97)E9"!I;G1O(&%N($%G<F5E;65N="!A;F0@4&QA;B!O9B!-
M97)G97(@*'1H90T*("8C>#(P,4,[365R9V5R($%G<F5E;65N="8C>#(P,40[
M*2!W:71H($-E<F5G96YE+"!);F,N+`T*("@F(W@R,#%#.T-E<F5G96YE)B-X
M,C`Q1#LI(&%N9"!A('-T;V-K:&]L9&5R<R8C>#(P,3D[(')E<')E<V5N=&%T
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M97)A<&EE<RX@5&AE(&%C<75I<F5D(&%S<V5T<R!I;F-L=61E(&%L;`T*(&]F
M($-E<F5G96YE)B-X,C`Q.3MS('1H97)A<&5U=&EC('!R;V=R86US+"!I;F-L
M=61I;F<@0T5212TQ,3`L(&%N#0H@04%6('9E8W1O<B!D96QI=F5R>2!S>7-T
M96T@9F]R('1H92!T<F5A=&UE;G0@;V8@06QZ:&5I;65R)B-X,C`Q.3MS#0H@
M9&ES96%S92!T:&%T(&ES(&-U<G)E;G1L>2!I;B!A(%!H87-E(#(@8VQI;FEC
M86P@=')I86PL(&-E<G1A:6X-"B!I;G1E;&QE8W1U86P@<')O<&5R='D@<FEG
M:'1S(')E;&%T:6YG('1O('1H92!M86YU9F%C='5R:6YG(&]F($%!5BP-"B!A
M;F0@8V5R=&%I;B!T;WAI8V]L;V=Y(&%N9"!S869E='D@9&%T82!F<F]M($-E
M<F5G96YE)B-X,C`Q.3MS(&AU;6%N#0H@8VQI;FEC86P@=')I86QS("AT:&4@
M06-Q=6ES:71I;VXI+B!4:&4@06-Q=6ES:71I;VX@=V%S(&-L;W-E9"!O;@T*
M($]C=&]B97(F(WA!,#LQ+"`R,#$S("AT:&4@0VQO<VEN9R!$871E*2X\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z
M(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@3VX@=&AE($-L;W-I;F<@
M1&%T92P@365R9V5R(%-U8B!M97)G960@=VET:"!A;F0@:6YT;R!#97)E9V5N
M92P@=VET:`T*($-E<F5G96YE(&-O;G1I;G5I;F<@87,@=&AE('-U<G9I=FEN
M9R!C;VUP86YY(&%N9"!A('=H;VQL>2UO=VYE9`T*('-U8G-I9&EA<FEE<R!O
M9B!T:&4@0V]M<&%N>2X@3VX@=&AE($-L;W-I;F<@1&%T92P@96%C:"!S:&%R
M92!O9@T*($-E<F5G96YE)B-X,C`Q.3MS(&ES<W5E9"!A;F0@;W5T<W1A;F1I
M;F<@8V%P:71A;"!S=&]C:R!H96QD(&)Y(&ET<PT*('-T;V-K:&]L9&5R<R!C
M;VYV97)T960@=&\@=&AE(')I9VAT('1O(')E8V5I=F4@82!P;W)T:6]N(&]F
M('1H90T*(&UE<F=E<B!C;VYS:61E<F%T:6]N(&9O<B!T:&4@06-Q=6ES:71I
M;VXL('=H:6-H(&-O;G-I<W1S(&EN:71I86QL>0T*(&]F("AI*28C>$$P.S$P
M,"PP,#`@<VAA<F5S(&]F(%-A;F=A;6\@8V]M;6]N('-T;V-K('=I=&@@82!M
M87)K970-"B!V86QU92!O9B!A<'!R;WAI;6%T96QY("0Q+C(@;6EL;&EO;B!O
M;B!T:&4@0VQO<VEN9R!$871E+"!A;F0-"B`H:6DI)B-X03`[86UO=6YT(&]F
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M(&-O;G1I;F=E;G0@96%R;BUO=70-"B!P87EM96YT<R`H=&AE("8C>#(P,4,[
M16%R;BU/=70@4&%Y;65N=',F(W@R,#%$.RD@=&\@=&AE('-T;V-K:&]L9&5R
M<PT*(&]F($-E<F5G96YE(&%S(&9O;&QO=W,Z/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#9P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$
M15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I
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M(&$@=&AI<F0M<&%R='D-"B!L:6-E;G-E('1O(&1E=F5L;W`@86YD(&-O;6UE
M<F-I86QI>F4@0V5R96=E;F4F(W@R,#$Y.W,@0T5212TQ,3`@9F]R#0H@=&AE
M('1R96%T;65N="!O9B!!;'IH96EM97(F(W@R,#$Y.W,@9&ES96%S92!O<B!#
M15)%+3$R,"!F;W(@=&AE#0H@=')E871M96YT(&]F(%!A<FMI;G-O;B8C>#(P
M,3D[<R!D:7-E87-E<R!O<B!(=6YT:6YG=&]N)B-X,C`Q.3MS#0H@9&ES96%S
M92`H=&AE("8C>#(P,4,[16%R;BU/=70@4')O9'5C=',F(W@R,#%$.RDL('1H
M92!#;VUP86YY(&ES#0H@<F5Q=6ER960@=&\@<&%Y(&$@9&]U8FQE(&1I9VET
M('!E<F-E;G1A9V4@;V8@86YY('5P9G)O;G0@86YD#0H@;6EL97-T;VYE('!A
M>6UE;G1S('1H92!#;VUP86YY(')E8V5I=F5S(&9O<B!S=6-H(&QI8V5N<V4L
M('-U8FIE8W0-"B!T;R!C97)T86EN(')E9'5C=&EO;G,@8F%S960@;VX@97AP
M96YS97,@:6YC=7)R960@8GD@=&AE($-O;7!A;GD@:6X-"B!T:&4@9&5V96QO
M<&UE;G0@;V8@=&AE($5A<FXM3W5T(%!R;V1U8W1S.R!A;F0\+W1D/@T*(#PO
M='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`V<'0G/@T*("8C>$$P
M.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL
M87!S93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Q,#`E/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U)3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0R)2!A;&EG
M;CTS1&QE9G0^)B-X,C`R,CL\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX]
M,T1L969T/DEF('1H92!#;VUP86YY(&-O;6UE<F-I86QI>F5S(&%N>0T*($5A
M<FXM3W5T(%!R;V1U8W0@:71S96QF+"!T:&4@0V]M<&%N>2!I<R!R97%U:7)E
M9"!T;R!P87DL(&9O<B!E86-H#0H@16%R;BU/=70@4')O9'5C="P@<F]Y86QT
M>2UL:6ME(&5A<FYO=70@<&%Y;65N=',@87,@82!P97)C96YT86=E(&]F#0H@
M;F5T('-A;&5S('1H870@<F%N9V4@:6X@=&AE(&QO=R!D;W5B;&4@9&EG:71S
M(&1E<&5N9&EN9R!U<&]N('1H90T*(&%M;W5N="!O9B!N970@<V%L97,L('-U
M8FIE8W0@=&\@8V5R=&%I;B!R961U8W1I;VYS(&)Y('1H90T*($-O;7!A;GDN
M/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
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M;&5T960N/"]P/@T*(`T*(`T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?96-F9F8W.69?83$P,%\T,S5E7V%C,#E?
M.34S8F9A-&$R-3(Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5C
M9F9F-SEF7V$Q,#!?-#,U95]A8S`Y7SDU,V)F831A,C4R.2]7;W)K<VAE971S
M+U-H965T,34N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5(1D%#/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D)A<VES(&]F(%!R97-E;G1A=&EO;B!A;F0@4W5M;6%R>2!O9B!3
M:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A0;VQI8VEE<RD\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!
M8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VES(&]F(%!R97-E;G1A
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($U!4D=)3BU,1494
M.B`R)3L@1D].5"U325I%.B`Q,'!T)SX-"B`\8CX\:3Y"87-I<R!O9B!0<F5S
M96YT871I;VX\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0
M.B`V<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(%1H92!A8V-O;7!A;GEI;F<@=6YA=61I=&5D(&-O;F1E;G-E9"!C;VYS
M;VQI9&%T960@9FEN86YC:6%L#0H@<W1A=&5M96YT<R!O9B!386YG86UO($)I
M;U-C:65N8V5S+"!);F,N("@F(W@R,#%#.U-A;F=A;6\F(W@R,#%$.R!O<@T*
M('1H92`F(W@R,#%#.T-O;7!A;GDF(W@R,#%$.RD@:&%V92!B965N('!R97!A
M<F5D(&EN(&%C8V]R9&%N8V4@=VET:`T*(%4N4RX@9V5N97)A;&QY(&%C8V5P
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M:6]N(&%N9`T*(&9O;W1N;W1E<R!R97%U:7)E9"!B>2!G96YE<F%L;'D@86-C
M97!T960@86-C;W5N=&EN9R!P<FEN8VEP;&5S(&9O<@T*(&-O;7!L971E(&9I
M;F%N8VEA;"!S=&%T96UE;G1S+B!);B!T:&4@;W!I;FEO;B!O9B!M86YA9V5M
M96YT+"!A;&P-"B!A9&IU<W1M96YT<R`H8V]N<VES=&EN9R!O9B!N;W)M86P@
M<F5C=7)R:6YG(&%D:G5S=&UE;G1S*2!C;VYS:61E<F5D#0H@;F5C97-S87)Y
M(&9O<B!A(&9A:7(@<')E<V5N=&%T:6]N(&AA=F4@8F5E;B!I;F-L=61E9"X@
M3W!E<F%T:6YG#0H@<F5S=6QT<R!F;W(@=&AE('1H<F5E(&%N9"!N:6YE(&UO
M;G1H<R!E;F1E9"!397!T96UB97(F(WA!,#LS,"P@,C`Q,PT*(&%R92!N;W0@
M;F5C97-S87)I;'D@:6YD:6-A=&EV92!O9B!T:&4@<F5S=6QT<R!T:&%T(&UA
M>2!B92!E>'!E8W1E9`T*(&9O<B!T:&4@>65A<B!E;F1I;F<@1&5C96UB97(F
M(WA!,#LS,2P@,C`Q,RX@5&AE(&-O;F1E;G-E9`T*(&-O;G-O;&ED871E9"!B
M86QA;F-E('-H965T(&1A=&$@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q,B!W
M97)E#0H@9&5R:79E9"!F<F]M('1H92!A=61I=&5D(&-O;G-O;&ED871E9"!F
M:6YA;F-I86P@<W1A=&5M96YT<R!I;F-L=61E9`T*(&EN(%-A;F=A;6\F(W@R
M,#$Y.W,@1F]R;2`Q,"U+(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C
M>$$P.S,Q+`T*(#(P,3(L(&%S(&9I;&5D('=I=&@@=&AE(%-%0RX@5&AE<V4@
M9FEN86YC:6%L('-T871E;65N=',@<VAO=6QD(&)E#0H@<F5A9"!I;B!C;VYJ
M=6YC=&EO;B!W:71H('1H92!F:6YA;F-I86P@<W1A=&5M96YT<R!A;F0@9F]O
M=&YO=&5S#0H@=&AE<F5T;R!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(F
M(WA!,#LS,2P@,C`Q,BP@:6YC;'5D960@:6X-"B!386YG86UO)B-X,C`Q.3MS
M($9O<FT@,3`M2RP@87,@9FEL960@=VET:"!T:&4@4T5#+CPO<#X-"B`\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E5S92!O9B!%<W1I;6%T97,@86YD($-L87-S:69I8V%T:6]N<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!-05)'24XM3$5&5#H@,B4[($9/
M3E0M4TE:13H@,3!P="<^#0H@/&(^/&D^57-E(&]F($5S=&EM871E<R!A;F0@
M0VQA<W-I9FEC871I;VYS/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T)SX-"B!4:&4@<')E<&%R871I;VX@;V8@9FEN86YC:6%L('-T871E
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M97,L(&EN8VQU9&EN9R!C<FET:6-A;`T*(&%C8V]U;G1I;F<@<&]L:6-I97,@
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M=&EM871E<RX\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E(%)E8V]G;FET:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL
M93TS1"=-05)'24XM5$]0.B`Q.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($U!4D=)3BU,1494.B`R)3L@
M1D].5"U325I%.B`Q,'!T)SX-"B`\8CX\:3Y2979E;G5E(%)E8V]G;FET:6]N
M/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!4
M15A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!2979E
M;G5E<R!F<F]M(')E<V5A<F-H(&%C=&EV:71I97,@;6%D92!U;F1E<B!S=')A
M=&5G:6,@<&%R=&YE<FEN9PT*(&%G<F5E;65N=',@86YD(&-O;&QA8F]R871I
M;VYS(&%R92!R96-O9VYI>F5D(&%S('1H92!S97)V:6-E<R!A<F4-"B!P<F]V
M:61E9"!W:&5N('1H97)E(&ES('!E<G-U87-I=F4@979I9&5N8V4@=&AA="!A
M;B!A<G)A;F=E;65N=`T*(&5X:7-T<RP@9&5L:79E<GD@:&%S(&]C8W5R<F5D
M+"!T:&4@<')I8V4@:7,@9FEX960@;W(@9&5T97)M:6YA8FQE+`T*(&%N9"!C
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M)B-X,C`Q.3MS('!R;V1U8W0@<V%L97,N/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*(#QI/DUU;'1I<&QE($5L96UE;G0@07)R86YG96UE;G1S
M('!R:6]R('1O('1H92!A9&]P=&EO;B!O9B!!4U4-"B!.;RXF(WA!,#LR,#`Y
M+3$S+"!2979E;G5E(%)E8V]G;FET:6]N)B-X,C`Q-#M-=6QT:7!L92!$96QI
M=F5R86)L90T*(%)E=F5N=64@07)R86YG96UE;G1S("A!4U4@,C`P.2TQ,RD\
M+VD^+B!&;W(@<F5V96YU92!A<G)A;F=E;65N=',-"B!E;G1E<F5D(&EN=&\@
M8F5F;W)E($IA;G5A<GDF(WA!,#LQ+"`R,#$Q+"!T:&%T(&EN8VQU9&4@;75L
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M;B!C<FET97)I82!A<F4@8V]N<VED97)E9`T*('-E<&%R871E;'D@9F]R(&5A
M8V@@;V8@=&AE('-E<&%R871E('5N:71S(&]F(&%C8V]U;G1I;F<N(%!R:6]R
M('1O#0H@=&AE(&%D;W!T:6]N(&]F($%352`R,#`Y+3$S+"!T:&4@0V]M<&%N
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M82!P<F]S<&5C=&EV92!B87-I<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P="<^#0H@/&D^375L=&EP;&4@16QE;65N="!!<G)A;F=E;65N=',@869T
M97(@=&AE(&%D;W!T:6]N(&]F($%350T*(#(P,#DM,3,N/"]I/B!!4U4@,C`P
M.2TQ,R!A;65N9&5D('1H92!A8V-O=6YT:6YG('-T86YD87)D<R!F;W(-"B!C
M97)T86EN(&UU;'1I<&QE(&5L96UE;G0@<F5V96YU92!A<G)A;F=E;65N=',@
M=&\Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#9P="<^#0H@)B-X03`[/"]P/@T*
M(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#$P,"4^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#4E/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#(E(&%L:6=N/3-$;&5F
M=#XF(W@R,#(R.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^
M<')O=FED92!U<&1A=&5D(&=U:61A;F-E(&]N('=H971H97(-"B!M=6QT:7!L
M92!E;&5M96YT<R!E>&ES="P@:&]W('1H92!E;&5M96YT<R!I;B!A;B!A<G)A
M;F=E;65N="!S:&]U;&0-"B!B92!S97!A<F%T960L(&%N9"!H;W<@=&AE(&%R
M<F%N9V5M96YT(&-O;G-I9&5R871I;VX@<VAO=6QD(&)E#0H@86QL;V-A=&5D
M('1O('1H92!S97!A<F%T92!E;&5M96YT<SL\+W1D/@T*(#PO='(^#0H@/"]T
M86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`V<'0G/@T*("8C>$$P.SPO<#X-"B`\
M=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B
M;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED
M=&@],T0Q,#`E/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U)3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0R)2!A;&EG;CTS1&QE9G0^
M)B-X,C`R,CL\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/G)E
M<75I<F4@86X@96YT:71Y('1O(&%L;&]C871E#0H@87)R86YG96UE;G0@8V]N
M<VED97)A=&EO;B!T;R!E86-H(&5L96UE;G0@8F%S960@;VX@82!S96QL:6YG
M('!R:6-E#0H@:&EE<F%R8VAY('=H97)E('1H92!S96QL:6YG('!R:6-E(&9O
M<B!A;B!E;&5M96YT(&ES(&)A<V5D(&]N#0H@=F5N9&]R+7-P96-I9FEC(&]B
M:F5C=&EV92!E=FED96YC92`H)B-X,C`Q0SM64T]%)B-X,C`Q1#LI+"!I9@T*
M(&%V86EL86)L93L@=&AI<F0M<&%R='D@979I9&5N8V4@*"8C>#(P,4,[5%!%
M)B-X,C`Q1#LI+"!I9B!A=F%I;&%B;&4-"B!A;F0@5E-/12!I<R!N;W0@879A
M:6QA8FQE.R!O<B!T:&4@8F5S="!E<W1I;6%T92!O9B!S96QL:6YG('!R:6-E
M#0H@*"8C>#(P,4,[15-0)B-X,C`Q1#LI+"!I9B!N96ET:&5R(%933T4@;F]R
M(%1012!I<R!A=F%I;&%B;&4[(&%N9#PO=&0^#0H@/"]T<CX-"B`\+W1A8FQE
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#9P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L
M92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E
M<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
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M:&]D+CPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#$R<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%
M.B`Q<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0
M.B`P<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*($9O<B!R979E;G5E(&%G<F5E;65N=',@=VET:"!M=6QT:7!L92!E;&5M
M96YT(&%R<F%N9V5M96YT<RP@<W5C:"!A<PT*(&QI8V5N<V4@86YD(&1E=F5L
M;W!M96YT(&%G<F5E;65N=',L(&5N=&5R960@:6YT;R!O;B!O<B!A9G1E<@T*
M($IA;G5A<GDF(WA!,#LQ+"`R,#$Q+"!T:&4@0V]M<&%N>2!A;&QO8V%T97,@
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M=&\@=VET:"!3:&ER92!!1R`H4VAI<F4I(&EN($IA;G5A<GD@,C`Q,B!W87,@
M979A;'5A=&5D#0H@=6YD97(@=&AE<V4@86UE;F1E9"!A8V-O=6YT:6YG('-T
M86YD87)D<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@
M5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@061D
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M=&AA=`T*(&]B:F5C=&EV97,@=VEL;"!B92!A8VAI979E9"!A;F0@:68@=&AE
M(&%C:&EE=F5M96YT(&ES(&)A<V5D(&]N('1H90T*($-O;7!A;GDF(W@R,#$Y
M.W,@<&5R9F]R;6%N8V4N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
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M;&ET>2!O9B!T:&4@<F5L871E9`T*(')O>6%L='D@<&%Y;65N="!I<R!R96%S
M;VYA8FQY(&%S<W5R960N(%1H92!#;VUP86YY(')E8V]G;FEZ97,@8V]S=`T*
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M;F]T(&)E96X@96%R;F5D+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0
M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M)SX-"B!386YG86UO)B-X,C`Q.3MS(')E<V5A<F-H(&=R86YT<R!A<F4@='EP
M:6-A;&QY(&UU;'1I+7EE87(@86=R965M96YT<PT*(&%N9"!P<F]V:61E(&9O
M<B!T:&4@<F5I;6)U<G-E;65N="!O9B!Q=6%L:69I960@97AP96YS97,@9F]R
M#0H@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&%S(&1E9FEN960@=6YD97(@
M=&AE('1E<FUS(&]F('1H92!G<F%N=`T*(&%G<F5E;65N="X@4F5V96YU92!U
M;F1E<B!G<F%N="!A9W)E96UE;G1S(&ES(')E8V]G;FEZ960@=VAE;B!T:&4-
M"B!R96QA=&5D('%U86QI9FEE9"!R97-E87)C:"!E>'!E;G-E<R!A<F4@:6YC
M=7)R960N/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U
M;F-E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3AP=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!-05)'24XM
M3$5&5#H@,B4[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^/&D^4F5C96YT($%C
M8V]U;G1I;F<@4')O;F]U;F-E;65N=#PO:3X\+V(^/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P="<^#0H@26X@1F5B<G5A<GD@,C`Q,RP@=&AE($9!4T(@
M:7-S=65D($%352!.;RXF(WA!,#LR,#$S+3`R+`T*($-O;7!R96AE;G-I=F4@
M26YC;VUE("A4;W!I8R`R,C`I.B!297!O<G1I;F<@;V8@06UO=6YT<R!296-L
M87-S:69I960-"B!/=70@;V8@06-C=6UU;&%T960@3W1H97(@0V]M<')E:&5N
M<VEV92!);F-O;64@*$%352`R,#$S+3`R*2X@5&AI<PT*(&YE=VQY(&ES<W5E
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M;6)E<B8C>$$P.S$U+"`R,#$R+B!790T*(&%D;W!T960@=&AI<R!S=&%N9&%R
M9"!I;B!T:&4@9FER<W0@<75A<G1E<B!O9B`R,#$S(&%N9"!T:&4@861O<'1I
M;VX-"B!O9B!T:&ES('-T86YD87)D(&1I9"!N;W0@:&%V92!A;B!I;7!A8W0@
M;VX@;W5R(&9I;F%N8VEA;"!P;W-I=&EO;@T*(&]R(')E<W5L=',@;V8@;W!E
M<F%T:6]N<RX\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E<W1M96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+51/4#H@-G!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM0D]45$]-.B`P<'0[($U!4D=)3BU,1494.B`R)3L@1D].5"U325I%
M.B`Q,'!T)SX-"B`\8CX\:3Y);G9E<W1M96YT<SPO:3X\+V(^/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P
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M92!#;VUP86YY)B-X,C`Q.3MS(&-O<W0@8F%S:7,L('1H92!F:6YA;F-I86P-
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M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1F%I<B!686QU92!-96%S=7)E;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
M4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4)/5%1/33H@,'!T.R!-05)'24XM3$5&5#H@,B4[($9/3E0M4TE:13H@,3!P
M="<^#0H@/&(^/&D^1F%I<B!686QU92!-96%S=7)E;65N=#PO:3X\+V(^/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z
M(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A;GD@;65A
M<W5R97,@8V5R=&%I;B!F:6YA;F-I86P@87-S971S(&%T(&9A:7(@=F%L=64@
M;VX@80T*(')E8W5R<FEN9R!B87-I<RP@:6YC;'5D:6YG(&-A<V@@97%U:79A
M;&5N=',@86YD(&%V86EL86)L92UF;W(-"B!S86QE+7-E8W5R:71I97,N)B-X
M03`[5&AE(&9A:7(@=F%L=64@;V8@=&AE<V4@87-S971S('=A<R!D971E<FUI
M;F5D#0H@8F%S960@;VX@82!T:')E92UT:65R(&AI97)A<F-H>2!U;F1E<B!T
M:&4@875T:&]R:71A=&EV92!G=6ED86YC90T*(&9O<B!F86ER('9A;'5E(&UE
M87-U<F5M96YT<R!A;F0@9&ES8VQO<W5R97,@=&AA="!P<FEO<FET:7IE<R!T
M:&4-"B!I;G!U=',@=7-E9"!I;B!M96%S=7)I;F<@9F%I<B!V86QU92!A<R!F
M;VQL;W=S.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[(%1%
M6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
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M)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($U!4D=)
M3BU,1494.B`T)3L@1D].5"U325I%.B`Q,'!T)SX-"B!,979E;"`R.B!1=6]T
M960@<')I8V5S(&EN(&UA<FME=',@=&AA="!A<F4@;F]T(&%C=&EV92!O<B!I
M;G!U=',-"B!W:&EC:"!A<F4@;V)S97)V86)L92P@96ET:&5R(&1I<F5C=&QY
M(&]R(&EN9&ER96-T;'DL(&9O<@T*('-U8G-T86YT:6%L;'D@=&AE(&9U;&P@
M=&5R;2!O9B!T:&4@87-S970@;W(@;&EA8FEL:71Y.SPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!-
M05)'24XM3$5&5#H@-"4[($9/3E0M4TE:13H@,3!P="<^#0H@3&5V96P@,SH@
M4')I8V5S(&]R('9A;'5A=&EO;B!T96-H;FEQ=65S('1H870@<F5Q=6ER92!I
M;G!U=',@=&AA=`T*(&%R92!B;W1H('-I9VYI9FEC86YT('1O('1H92!F86ER
M('9A;'5E(&UE87-U<F5M96YT(&%N9"!U;F]B<V5R=F%B;&4-"B`H:2YE+BP@
M<W5P<&]R=&5D(&)Y(&QI='1L92!O<B!N;R!M87)K970@86-T:79I='DI+CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4
M.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/
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M(&EN<'5T<RP@:6YC;'5D:6YG+`T*(&QI<W1E9"!I;B!A<'!R;WAI;6%T92!O
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M;VX@;VX@86YY(&=I=F5N(&1A>2X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@3&]S<R!P
M97(@4VAA<F4L('!O;&EC>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!415A4
M+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!"87-I8R!N
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M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96-F9F8W.69?
M83$P,%\T,S5E7V%C,#E?.34S8F9A-&$R-3(Y#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V5C9F9F-SEF7V$Q,#!?-#,U95]A8S`Y7SDU,V)F831A
M,C4R.2]7;W)K<VAE971S+U-H965T,38N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R1CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY);G9E<W1M96YT<R!A;F0@1F%I<B!686QU
M92!-96%S=7)E;65N="`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN=F5S=&UE;G1S($%L;"!/=&AE
M<B!);G9E<W1M96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!);G9E<W1M96YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5.5#H@-"4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@=&%B;&4@8F5L;W<@<W5M;6%R
M:7IE<R!T:&4@0V]M<&%N>28C>#(P,3D[<R!A=F%I;&%B;&4M9F]R+7-A;&4-
M"B!S96-U<FET:65S("AI;B!T:&]U<V%N9',I.CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/
M4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$
M8V5N=&5R/CPA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D
M('=I9'1H/3-$-C`E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^
M06UO<G1I>F5D/&)R("\^#0H@0V]S=#PO8CX\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#(@86QI9VX],T1C96YT97(^/&(^1W)O<W,\8G(@+SX-"B!5;G)E86QI>F5D
M/&)R("\^#0H@1V%I;G,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N
M/3-$8V5N=&5R/CQB/D=R;W-S/&)R("\^#0H@56YR96%L:7IE9#QB<B`O/@T*
M("A,;W-S97,I/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CY%<W1I;6%T960\8G(@+SX-"B!&86ER)B-X03`[5F%L=64\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@
M0F]D>2`M+3X-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/E-E<'1E;6)E<B8C
M>$$P.S,P+"`R,#$S/"]B/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`S96T[($9/3E0M4TE:13H@,3!P="<^#0H@0V%S
M:"!E<75I=F%L96YT<SH\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@-65M.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*($UO;F5Y(&UA<FME="!F=6YD<SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XY+#<U.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XY+#<U.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[($9/3E0M4TE:13H@,3!P="<^
M#0H@5&]T86P\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDL-S4X/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CDL-S4X/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!!=F%I;&%B;&4M
M9F]R+7-A;&4@<V5C=7)I=&EE<SH\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`U96T[($9/
M3E0M4TE:13H@,3!P="<^#0H@52Y3+B!G;W9E<FYM96YT('-P;VYS;W)E9"!E
M;G1I='D@9&5B="!S96-U<FET:65S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XU,BPU-S<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3(L-C`S/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!4;W1A;#PO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3(L-3<W/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C4R+#8P,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@5&]T
M86P@8V%S:"!E<75I=F%L96YT<R!A;F0@879A:6QA8FQE+69O<BUS86QE('-E
M8W5R:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV,BPS,S4\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X
M,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-C(L,S8Q/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*(#QB/D1E8V5M8F5R)B-X03`[,S$L(#(P,3(\+V(^/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($-A<V@@
M97%U:79A;&5N=',Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@-65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%4N4RX@9V]V97)N;65N="!S
M<&]N<V]R960@96YT:71Y(&1E8G0@<V5C=7)I=&EE<SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C(L.3DW/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.3DW/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#5E;3L@1D].5"U3
M25I%.B`Q,'!T)SX-"B!-;VYE>2!M87)K970@9G5N9',\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C$U+#@S.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XQ-2PX,SD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XQ."PX,S8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3@L.#,V/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!!=F%I;&%B;&4M9F]R
M+7-A;&4@<V5C=7)I=&EE<SH\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`U96T[($9/3E0M4TE:13H@,3!P="<^#0H@52Y3+B!G;W9E<FYM
M96YT('-P;VYS;W)E9"!E;G1I='D@9&5B="!S96-U<FET:65S/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XU-"PT,C8\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XR-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P
M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-30L-#4R
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!4;W1A;#PO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^-30L-#(V/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF
M(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4T
M+#0U,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:
M13H@,3!P="<^#0H@5&]T86P@8V%S:"!E<75I=F%L96YT<R!A;F0@879A:6QA
M8FQE+69O<BUS86QE('-E8W5R:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW
M,RPR-C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C8\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^-S,L,C@X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O9B!&86ER(%9A
M;'5E($UE87-U<F5M96YT<R!O9B!#87-H($5Q=6EV86QE;G1S(&%N9"!!=F%I
M;&%B;&4M9F]R+5-A;&4@4V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
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M(&AI97)A<F-H>2`H:6X-"B!T:&]U<V%N9',I.CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/
M4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$
M8V5N=&5R/CPA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D
M('=I9'1H/3-$-C8E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$T(&%L:6=N/3-$8V5N=&5R/CQB
M/E-E<'1E;6)E<B8C>$$P.S,P+"8C>$$P.S(P,3,\8G(@+SX-"B!&86ER)B-X
M03`[5F%L=64F(WA!,#M-96%S=7)E;65N=',\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X
M<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^5&]T86P\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE
M=F5L)B-X03`[,3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(^/&(^3&5V96P@,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(^/&(^3&5V96PF(WA!,#LS/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@
M5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].
M5"U325I%.B`Q,'!T)SX-"B!!<W-E=',Z/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T
M)SX-"B!#87-H(&5Q=6EV86QE;G1S.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`U96T[
M($9/3E0M4TE:13H@,3!P="<^#0H@36]N97D@;6%R:V5T(&9U;F1S/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CDL-S4X/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XY+#<U.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%
M.B`Q,'!T)SX-"B!4;W1A;#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.2PW
M-3@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY+#<U.#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($%V86EL86)L
M92UF;W(M<V%L92!S96-U<FET:65S.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#5E;3L@
M1D].5"U325I%.B`Q,'!T)SX-"B!5+E,N(&=O=F5R;FUE;G0@<W!O;G-O<F5D
M(&5N=&ET>2!D96)T('-E8W5R:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C4R+#8P,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P
M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3(L-C`S
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU,BPV,#,\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4R+#8P,SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@1D].5"U325I%.B`Q,'!T)SX-"B!4;W1A;"!C87-H(&5Q=6EV86QE;G1S
M(&%N9"!A=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C8R+#,V,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY+#<U
M.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU,BPV,#,\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0^/"]T9#X-"B`\=&0@
M8V]L<W!A;CTS1#$V/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0G/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#$T(&%L:6=N/3-$8V5N=&5R/CQB/D1E8V5M8F5R)B-X
M03`[,S$L)B-X03`[,C`Q,CQB<B`O/@T*($9A:7(F(WA!,#M686QU928C>$$P
M.TUE87-U<F5M96YT<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY4;W1A;#PO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^3&5V96PF(WA!,#LQ/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY,979E
M;"`R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\
M8CY,979E;"8C>$$P.S,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($%S
M<V5T<SH\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($-A<V@@97%U:79A;&5N
M=',Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#5E;3L@1D].5"U325I%.B`Q,'!T)SX-
M"B!5+E,N(&=O=F5R;FUE;G0@<W!O;G-O<F5D(&5N=&ET>2!D96)T('-E8W5R
M:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPY.3<\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#DY-SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@-65M.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*($UO;F5Y(&UA<FME="!F=6YD<SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$U+#@S.3PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XQ-2PX,SD\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ."PX,S8\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-2PX,SD\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XR+#DY-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-
M"B!!=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<SH\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`U96T[($9/3E0M4TE:13H@,3!P="<^
M#0H@52Y3+B!G;W9E<FYM96YT('-P;VYS;W)E9"!E;G1I='D@9&5B="!S96-U
M<FET:65S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU-"PT-3(\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C4T+#0U,CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].
M5"U325I%.B`Q,'!T)SX-"B!4;W1A;#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-30L-#4R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU-"PT-3(\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P
M="<^#0H@5&]T86P@8V%S:"!E<75I=F%L96YT<R!A;F0@879A:6QA8FQE+69O
M<BUS86QE('-E8W5R:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW,RPR.#@\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,34L.#,Y/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C4W+#0T.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R
M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/"]T86)L93X-"B`-"B`-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5C9F9F-SEF7V$Q,#!?-#,U95]A
M8S`Y7SDU,V)F831A,C4R.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]E8V9F9C<Y9E]A,3`P7S0S-65?86,P.5\Y-3-B9F$T83(U,CDO5V]R:W-H
M965T<R]3:&5E=#$W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%34-!0SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY-86IO<B!#=7-T;VUE<G,L(%!A<G1N97)S:&EP<R!A;F0@
M4W1R871E9VEC($%L;&EA;F-E<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:6=M82U!;&1R:6-H($-O<G!O<F%T
M:6]N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y2979E;G5E<R!296-O9VYI>F5D('5N9&5R($%G<F5E;65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P="<^#0H@4F5V96YU97,@<F5C;V=N:7IE9"!U;F1E<B!T:&4@
M86=R965M96YT('=I=&@@4VEG;6$@9F]R('1H92!T:')E90T*(&%N9"!N:6YE
M(&UO;G1H<R!E;F1E9"!397!T96UB97(F(WA!,#LS,"P@,C`Q,R!A;F0-"B!3
M97!T96UB97(F(WA!,#LS,"P@,C`Q,BP@=V5R92!A<R!F;VQL;W=S("AI;B!T
M:&]U<V%N9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T)SX-"B`F(WA!
M,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R/CPA+2T@0F5G:6X@
M5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S`E/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#8@86QI9VX],T1C96YT97(^/&(^5&AR964F(WA!,#MM;VYT:',F
M(WA!,#ME;F1E9#QB<B`O/@T*(%-E<'1E;6)E<B8C>$$P.S,P+#PO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^/&(^3FEN928C>$$P
M.VUO;G1H<R8C>$$P.V5N9&5D/&)R("\^#0H@4V5P=&5M8F5R)B-X03`[,S`L
M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N
M/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!4
M86)L92!(96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*(%)E=F5N=64@<F5L871E9"!T;R!3:6=M82!#;VQL
M86)O<F%T:6]N/&(^.CPO8CX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%)O
M>6%L='D@<F5V96YU97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C`Q
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
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M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,2PP,S4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*($QI8V5N<V4@9F5E(&%N9"!M:6QE<W1O;F4@
M<F5V96YU97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,#$\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,2PS-3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,2PP,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1O=&%L
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,S`R/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C0R.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#`V,CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XR+#`S-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H:7)E($%'
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M979E;G5E<R!296-O9VYI>F5D('5N9&5R($%G<F5E;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P="<^#0H@4F5V96YU97,@<F5C;V=N:7IE9"!U;F1E<B!T:&4@86=R
M965M96YT('=I=&@@4VAI<F4@9F]R('1H92!T:')E90T*(&%N9"!N:6YE(&UO
M;G1H<R!E;F1E9"!397!T96UB97(F(WA!,#LS,"P@,C`Q,R!A;F0-"B!397!T
M96UB97(F(WA!,#LS,"P@,C`Q,BP@=V5R92!A<R!F;VQL;W=S("AI;B!T:&]U
M<V%N9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($U!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T)SX-"B`F(WA!,#L\
M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P
M<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R/CPA+2T@0F5G:6X@5&%B
M;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S$E/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0G/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#8@86QI9VX],T1C96YT97(^/&(^5&AR964F(WA!,#MM;VYT:',F(WA!
M,#ME;F1E9#QB<B`O/@T*(%-E<'1E;6)E<B8C>$$P.S,P+#PO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^/&(^3FEN92!M;VYT:',@
M96YD960\8G(@+SX-"B!397!T96UB97(F(WA!,#LS,"P\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^
M,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^
M/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*(#QT<B!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^
M#0H@4F5V96YU92!R96QA=&5D('1O(%-H:7)E($-O;&QA8F]R871I;VXZ/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E
M;3L@1D].5"U325I%.B`Q,'!T)SX-"B!!;6]R=&EZ871I;VX@;V8@=7!F<F]N
M="!F964\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-30R/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XU-#(\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C$L-C(U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XQ+#0T-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[($9/3E0M4TE:
M13H@,3!P="<^#0H@4F5S96%R8V@@<V5R=FEC97,\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XS+#DV.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XR+#8W-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ,2PS-#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-"PW-#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PU,3`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,RPR,3<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,3(L.38U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L,3DQ/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M96-F9F8W.69?83$P,%\T,S5E7V%C,#E?.34S8F9A-&$R-3(Y#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5C9F9F-SEF7V$Q,#!?-#,U95]A8S`Y
M7SDU,V)F831A,C4R.2]7;W)K<VAE971S+U-H965T,3@N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP
M96YS871I;VX@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY$:7-C;&]S=7)E($]F($-O;7!E;G-A=&EO
M;B!296QA=&5D($-O<W1S(%-H87)E8F%S960@4&%Y;65N=',@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N($5X<&5N<V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P="<^#0H@5&AE(&9O;&QO=VEN9R!T86)L92!S:&]W<R!T;W1A;"!S=&]C
M:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS90T*(&EN8VQU9&5D(&EN('1H
M92!C;VYD96YS960@8V]N<V]L:61A=&5D('-T871E;65N="!O9B!O<&5R871I
M;VYS(&9O<@T*('1H92!T:')E92!M;VYT:"!A;F0@;FEN92!M;VYT:',@96YD
M960@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,@86YD#0H@,C`Q,B`H:6X@=&AO
M=7-A;F1S*3H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P="<^#0H@)B-X03`[
M/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA
M<'-E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
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M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/E1H<F5E)B-X03`[;6]N=&AS)B-X
M03`[96YD960\8G(@+SX-"B!397!T96UB97(F(WA!,#LS,"P\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/DYI;F4F(WA!,#MM
M;VYT:',F(WA!,#ME;F1E9#QB<B`O/@T*(%-E<'1E;6)E<B8C>$$P.S,P+#PO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B
M;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U3
M25I%.B`Q,'!T)SX-"B!#;W-T<R!A;F0@97AP96YS97,Z/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U3
M25I%.B`Q,'!T)SX-"B!297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S,R/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XW-S0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C(L,30P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#$Y-3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`S96T[($9/3E0M4TE:13H@,3!P="<^#0H@
M1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+W`^#0H@/"]T9#X-"B`\=&0@
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M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-C,P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C$L.34X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C$L.#$V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#5E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!4;W1A
M;"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C$L,SDQ/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-#`T
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L,#DX/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C0L,#$Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T
M86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V5C9F9F-SEF7V$Q,#!?-#,U95]A8S`Y7SDU,V)F831A,C4R
M.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E8V9F9C<Y9E]A,3`P
M7S0S-65?86,P.5\Y-3-B9F$T83(U,CDO5V]R:W-H965T<R]3:&5E=#$Y+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%,49!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);G9E
M<W1M96YT<R!A;F0@1F%I<B!686QU92!-96%S=7)E;65N="`M($%D9&ET:6]N
M86P@26YF;W)M871I;VX@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N
M9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY38VAE9'5L92!O9B!!=F%I;&%B;&4M9F]R+7-A;&4@4V5C
M=7)I=&EE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^26YV97-T;65N=',@;6%T=7)I='D@<&5R
M:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,2!Y96%R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$@
M>65A<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D=R;W-S(%5N<F5A;&EZ960@*$QO<W-E<RD\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^079A:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY38VAE9'5L92!O9B!!=F%I;&%B;&4M9F]R+7-A;&4@4V5C=7)I
M=&EE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1W)O<W,@56YR96%L:7IE9"`H3&]S<V5S*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296%L:7IE9"!L;W-S97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(M=&AA;BUT
M96UP;W)A<GD@:6UP86ER;65N=',@;V8@879A:6QA8FQE+69O<BUS86QE('-E
M8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M96-F9F8W.69?83$P,%\T,S5E7V%C,#E?.34S8F9A-&$R-3(Y#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5C9F9F-SEF7V$Q,#!?-#,U95]A8S`Y
M7SDU,V)F831A,C4R.2]7;W)K<VAE971S+U-H965T,C`N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5804)'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/DEN=F5S=&UE;G1S(&%N
M9"!&86ER(%9A;'5E($UE87-U<F5M96YT("T@4V-H961U;&4@;V8@26YV97-T
M;65N=',@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S
M<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($%V
M86EL86)L92UF;W(M<V%L92!396-U<FET:65S(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T
M:7IE9"!#;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8R
M+#,S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-S,L,C8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y'<F]S<R!5;G)E86QI>F5D($=A:6YS/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S<R!5;G)E86QI>F5D
M("A,;W-S97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S=&EM871E9"!&86ER(%9A;'5E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,BPS-C$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,RPR.#@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-A<V@@97%U:79A;&5N=',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($%V86EL86)L
M92UF;W(M<V%L92!396-U<FET:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IE9"!#
M;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#<U.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X+#@S
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1W)O<W,@56YR96%L:7IE9"!'86EN<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S
M(%5N<F5A;&EZ960@*$QO<W-E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17-T:6UA=&5D
M($9A:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL
M-S4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3@L.#,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<R!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4V-H961U;&4@;V8@079A:6QA8FQE+69O<BUS86QE(%-E8W5R:71I97,@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06UO<G1I>F5D($-O<W0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4R+#4W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4T+#0R-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)O<W,@56YR96%L:7IE9"!'
M86EN<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)O
M<W,@56YR96%L:7IE9"`H3&]S<V5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<W1I;6%T
M960@1F%I<B!686QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3(L-C`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-30L-#4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y-;VYE>2!M87)K970@9G5N9',@6TUE;6)E<ET@?"!#
M87-H(&5Q=6EV86QE;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!!=F%I;&%B;&4M
M9F]R+7-A;&4@4V5C=7)I=&EE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ960@0V]S
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PW-3@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PX,SD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=R;W-S(%5N<F5A;&EZ960@1V%I;G,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S<R!5
M;G)E86QI>F5D("A,;W-S97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S=&EM871E9"!&
M86ER(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#<U
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$U+#@S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^52Y3+B!G;W9E<FYM96YT('-P;VYS;W)E9"!E;G1I='D@9&5B
M="!S96-U<FET:65S(%M-96UB97)=('P@0V%S:"!E<75I=F%L96YT<R!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4V-H961U;&4@;V8@079A:6QA8FQE+69O<BUS86QE(%-E8W5R:71I97,@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06UO<G1I>F5D($-O<W0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#DY-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1W)O<W,@56YR96%L:7IE9"!'86EN<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=R;W-S(%5N<F5A;&EZ960@*$QO<W-E<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17-T:6UA=&5D($9A:7(@
M5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DY-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M52Y3+B!G;W9E<FYM96YT('-P;VYS;W)E9"!E;G1I='D@9&5B="!S96-U<FET
M:65S(%M-96UB97)=('P@079A:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-C:&5D=6QE(&]F($%V86EL86)L92UF;W(M<V%L92!396-U<FET
M:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IE9"!#;W-T/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU,BPU-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-"PT,C8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S(%5N<F5A;&EZ
M960@1V%I;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=R;W-S(%5N<F5A;&EZ960@*$QO<W-E<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17-T
M:6UA=&5D($9A:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-3(L-C`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`U-"PT-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V5C9F9F-SEF7V$Q,#!?-#,U95]A8S`Y7SDU,V)F
M831A,C4R.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E8V9F9C<Y
M9E]A,3`P7S0S-65?86,P.5\Y-3-B9F$T83(U,CDO5V]R:W-H965T<R]3:&5E
M=#(Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%44-$23X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N
M9SY);G9E<W1M96YT<R!A;F0@1F%I<B!686QU92!-96%S=7)E;65N="`M(%-U
M;6UA<GD@;V8@1F%I<B!686QU92!-96%S=7)E;65N=',@;V8@0V%S:"!%<75I
M=F%L96YT<R!A;F0@079A:6QA8FQE+69O<BU386QE(%-E8W5R:71I97,@*$1E
M=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I
M<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($%V86EL86)L92UF
M;W(M<V%L92!396-U<FET:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-A<V@@97%U
M:79A;&5N=',@86YD(&%V86EL86)L92UF;W(M<V%L92!S96-U<FET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8R+#,V,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-S,L,C@X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#87-H(&5Q=6EV86QE;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!!=F%I;&%B
M;&4M9F]R+7-A;&4@4V5C=7)I=&EE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C87-H
M(&5Q=6EV86QE;G1S(&%N9"!A=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PW-3@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PX,S8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%V86EL86)L92UF;W(M<V%L92!S96-U<FET:65S(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L
M92!O9B!!=F%I;&%B;&4M9F]R+7-A;&4@4V5C=7)I=&EE<R!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!C87-H(&5Q=6EV86QE;G1S(&%N9"!A=F%I;&%B;&4M9F]R+7-A
M;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3(L-C`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-30L-#4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y5+E,N(&=O=F5R;FUE;G0@<W!O;G-O<F5D(&5N=&ET
M>2!D96)T('-E8W5R:71I97,@6TUE;6)E<ET@?"!#87-H(&5Q=6EV86QE;G1S
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY38VAE9'5L92!O9B!!=F%I;&%B;&4M9F]R+7-A;&4@4V5C=7)I
M=&EE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C87-H(&5Q=6EV86QE;G1S(&%N9"!A
M=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L.3DW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5+E,N(&=O=F5R;FUE;G0@<W!O;G-O
M<F5D(&5N=&ET>2!D96)T('-E8W5R:71I97,@6TUE;6)E<ET@?"!!=F%I;&%B
M;&4M9F]R+7-A;&4@<V5C=7)I=&EE<R!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V-H961U;&4@;V8@079A
M:6QA8FQE+69O<BUS86QE(%-E8W5R:71I97,@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M8V%S:"!E<75I=F%L96YT<R!A;F0@879A:6QA8FQE+69O<BUS86QE('-E8W5R
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4R+#8P,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4T
M+#0U,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^36]N97D@;6%R:V5T(&9U;F1S(%M-96UB97)=('P@0V%S:"!E<75I
M=F%L96YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4V-H961U;&4@;V8@079A:6QA8FQE+69O<BUS86QE
M(%-E8W5R:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V%S:"!E<75I=F%L96YT
M<R!A;F0@879A:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDL-S4X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34L.#,Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,979E;"`Q(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY38VAE9'5L92!O9B!!=F%I;&%B;&4M9F]R+7-A;&4@4V5C=7)I=&EE
M<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!C87-H(&5Q=6EV86QE;G1S(&%N9"!A=F%I
M;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.2PW-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-2PX,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE=F5L(#$@6TUE;6)E<ET@?"!#
M87-H(&5Q=6EV86QE;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!!=F%I;&%B;&4M
M9F]R+7-A;&4@4V5C=7)I=&EE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C87-H(&5Q
M=6EV86QE;G1S(&%N9"!A=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PW-3@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PX,SD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE
M=F5L(#$@6TUE;6)E<ET@?"!!=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE
M<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4V-H961U;&4@;V8@079A:6QA8FQE+69O<BUS86QE(%-E8W5R
M:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V%S:"!E<75I=F%L96YT<R!A;F0@
M879A:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M979E;"`Q(%M-96UB97)=('P@52Y3+B!G;W9E<FYM96YT('-P;VYS;W)E9"!E
M;G1I='D@9&5B="!S96-U<FET:65S(%M-96UB97)=('P@0V%S:"!E<75I=F%L
M96YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4V-H961U;&4@;V8@079A:6QA8FQE+69O<BUS86QE(%-E
M8W5R:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V%S:"!E<75I=F%L96YT<R!A
M;F0@879A:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,979E;"`Q(%M-
M96UB97)=('P@52Y3+B!G;W9E<FYM96YT('-P;VYS;W)E9"!E;G1I='D@9&5B
M="!S96-U<FET:65S(%M-96UB97)=('P@079A:6QA8FQE+69O<BUS86QE('-E
M8W5R:71I97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($%V86EL86)L92UF;W(M<V%L
M92!396-U<FET:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-A<V@@97%U:79A;&5N
M=',@86YD(&%V86EL86)L92UF;W(M<V%L92!S96-U<FET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3&5V96P@,2!;365M8F5R72!\($UO;F5Y(&UA<FME="!F=6YD<R!;
M365M8F5R72!\($-A<V@@97%U:79A;&5N=',@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F
M($%V86EL86)L92UF;W(M<V%L92!396-U<FET:65S(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L(&-A<V@@97%U:79A;&5N=',@86YD(&%V86EL86)L92UF;W(M<V%L92!S
M96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#<U
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$U+#@S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&5V96P@,B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V-H961U;&4@;V8@079A:6QA8FQE
M+69O<BUS86QE(%-E8W5R:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V%S:"!E
M<75I=F%L96YT<R!A;F0@879A:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4R+#8P,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4W+#0T.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3&5V96P@,B!;365M8F5R72!\($-A<V@@97%U:79A;&5N=',@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C
M:&5D=6QE(&]F($%V86EL86)L92UF;W(M<V%L92!396-U<FET:65S(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O=&%L(&-A<V@@97%U:79A;&5N=',@86YD(&%V86EL86)L92UF
M;W(M<V%L92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPY.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE=F5L(#(@6TUE;6)E<ET@?"!!
M=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE<R!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V-H961U;&4@
M;V8@079A:6QA8FQE+69O<BUS86QE(%-E8W5R:71I97,@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@8V%S:"!E<75I=F%L96YT<R!A;F0@879A:6QA8FQE+69O<BUS86QE
M('-E8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4R
M+#8P,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4T+#0U,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3&5V96P@,B!;365M8F5R72!\(%4N4RX@9V]V97)N;65N
M="!S<&]N<V]R960@96YT:71Y(&1E8G0@<V5C=7)I=&EE<R!;365M8F5R72!\
M($-A<V@@97%U:79A;&5N=',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($%V86EL86)L
M92UF;W(M<V%L92!396-U<FET:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-A<V@@
M97%U:79A;&5N=',@86YD(&%V86EL86)L92UF;W(M<V%L92!S96-U<FET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY.3<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE=F5L
M(#(@6TUE;6)E<ET@?"!5+E,N(&=O=F5R;FUE;G0@<W!O;G-O<F5D(&5N=&ET
M>2!D96)T('-E8W5R:71I97,@6TUE;6)E<ET@?"!!=F%I;&%B;&4M9F]R+7-A
M;&4@<V5C=7)I=&EE<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4V-H961U;&4@;V8@079A:6QA8FQE+69O
M<BUS86QE(%-E8W5R:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V%S:"!E<75I
M=F%L96YT<R!A;F0@879A:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4R+#8P,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4T+#0U,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5V
M96P@,B!;365M8F5R72!\($UO;F5Y(&UA<FME="!F=6YD<R!;365M8F5R72!\
M($-A<V@@97%U:79A;&5N=',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($%V86EL86)L
M92UF;W(M<V%L92!396-U<FET:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-A<V@@
M97%U:79A;&5N=',@86YD(&%V86EL86)L92UF;W(M<V%L92!S96-U<FET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&5V96P@,R!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V-H961U;&4@;V8@079A
M:6QA8FQE+69O<BUS86QE(%-E8W5R:71I97,@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M8V%S:"!E<75I=F%L96YT<R!A;F0@879A:6QA8FQE+69O<BUS86QE('-E8W5R
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y,979E;"`S(%M-96UB97)=('P@0V%S:"!E
M<75I=F%L96YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4V-H961U;&4@;V8@079A:6QA8FQE+69O<BUS
M86QE(%-E8W5R:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V%S:"!E<75I=F%L
M96YT<R!A;F0@879A:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,979E;"`S(%M-96UB97)=('P@079A:6QA8FQE+69O<BUS86QE
M('-E8W5R:71I97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($%V86EL86)L92UF;W(M
M<V%L92!396-U<FET:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-A<V@@97%U:79A
M;&5N=',@86YD(&%V86EL86)L92UF;W(M<V%L92!S96-U<FET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&5V96P@,R!;365M8F5R72!\(%4N4RX@9V]V97)N;65N="!S
M<&]N<V]R960@96YT:71Y(&1E8G0@<V5C=7)I=&EE<R!;365M8F5R72!\($-A
M<V@@97%U:79A;&5N=',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($%V86EL86)L92UF
M;W(M<V%L92!396-U<FET:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-A<V@@97%U
M:79A;&5N=',@86YD(&%V86EL86)L92UF;W(M<V%L92!S96-U<FET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3&5V96P@,R!;365M8F5R72!\(%4N4RX@9V]V97)N;65N="!S<&]N<V]R960@
M96YT:71Y(&1E8G0@<V5C=7)I=&EE<R!;365M8F5R72!\($%V86EL86)L92UF
M;W(M<V%L92!S96-U<FET:65S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!!=F%I;&%B
M;&4M9F]R+7-A;&4@4V5C=7)I=&EE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C87-H
M(&5Q=6EV86QE;G1S(&%N9"!A=F%I;&%B;&4M9F]R+7-A;&4@<V5C=7)I=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DQE=F5L(#,@6TUE;6)E<ET@?"!-;VYE>2!M87)K
M970@9G5N9',@6TUE;6)E<ET@?"!#87-H(&5Q=6EV86QE;G1S(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M8VAE9'5L92!O9B!!=F%I;&%B;&4M9F]R+7-A;&4@4V5C=7)I=&EE<R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!C87-H(&5Q=6EV86QE;G1S(&%N9"!A=F%I;&%B;&4M
M9F]R+7-A;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5C9F9F-SEF7V$Q,#!?-#,U
M95]A8S`Y7SDU,V)F831A,C4R.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]E8V9F9C<Y9E]A,3`P7S0S-65?86,P.5\Y-3-B9F$T83(U,CDO5V]R
M:W-H965T<R]3:&5E=#(R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1T@^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^0F%S:6,@86YD($1I;'5T960@3F5T($QO<W,@4&5R(%-H
M87)E("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^16%R
M;FEN9W,@4&5R(%-H87)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!O<'1I;VYS(&]U='-T
M86YD:6YG(&5X8VQU9&5D(&9R;VT@=&AE(&-A;&-U;&%T:6]N(&]F(&1I;'5T
M960@;F5T(&QO<W,@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW+#@U,RPY,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XX+#`W-2PX.3@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V5C9F9F-SEF7V$Q,#!?-#,U95]A8S`Y
M7SDU,V)F831A,C4R.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E
M8V9F9C<Y9E]A,3`P7S0S-65?86,P.5\Y-3-B9F$T83(U,CDO5V]R:W-H965T
M<R]3:&5E=#(S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%6$E#3SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY-86IO<B!#=7-T;VUE<G,L(%!A<G1N97)S:&EP<R!A;F0@4W1R
M871E9VEC($%L;&EA;F-E<R`M($%D9&ET:6]N86P@26YF;W)M871I;VX@*$1E
M=&%I;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,CXQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,SXQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`S,2P@,C`P
M.3QB<CY#86QI9F]R;FEA($EN<W1I='5T92!F;W(@4F5G96YE<F%T:79E($UE
M9&EC:6YE(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3,\8G(^0V%L:69O<FYI82!);G-T:71U=&4@9F]R
M(%)E9V5N97)A=&EV92!-961I8VEN92!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/D-A;&EF;W)N
M:6$@26YS=&ET=71E(&9O<B!296=E;F5R871I=F4@365D:6-I;F4@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CY#86QI9F]R;FEA($EN<W1I='5T92!F;W(@4F5G96YE<F%T:79E
M($UE9&EC:6YE(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^0V%L:69O<FYI82!);G-T:71U=&4@
M9F]R(%)E9V5N97)A=&EV92!-961I8VEN92!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$Q/&)R/D-(1$D@
M1F]U;F1A=&EO;BP@26YC+B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/D-(1$D@1F]U;F1A=&EO
M;BP@26YC+B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$R/&)R/D-(1$D@1F]U;F1A=&EO;BP@26YC+B!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$S/&)R/D-(1$D@1F]U;F1A=&EO;BP@26YC+B!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R
M/&)R/D-(1$D@1F]U;F1A=&EO;BP@26YC+B!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/D-(1$D@
M1F]U;F1A=&EO;BP@26YC+B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/DIU=F5N:6QE($1I86)E
M=&5S(%)E<V5A<F-H($9O=6YD871I;VX@26YT97)N871I;VYA;"!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R
M,#$P/&)R/DIU=F5N:6QE($1I86)E=&5S(%)E<V5A<F-H($9O=6YD871I;VX@
M26YT97)N871I;VYA;"!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/DIU=F5N:6QE($1I86)E=&5S
M(%)E<V5A<F-H($9O=6YD871I;VX@26YT97)N871I;VYA;"!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R
M/&)R/DIU=F5N:6QE($1I86)E=&5S(%)E<V5A<F-H($9O=6YD871I;VX@26YT
M97)N871I;VYA;"!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/DIU=F5N:6QE($1I86)E=&5S(%)E
M<V5A<F-H($9O=6YD871I;VX@26YT97)N871I;VYA;"!;365M8F5R73QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R
M/DIU=F5N:6QE($1I86)E=&5S(%)E<V5A<F-H($9O=6YD871I;VX@26YT97)N
M871I;VYA;"!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y/8W0N(#,Q+"`R,#`V/&)R/DIU=F5N:6QE($1I86)E=&5S(%)E<V5A
M<F-H($9O=6YD871I;VX@26YT97)N871I;VYA;"!;365M8F5R73QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/DQI
M8V5N<V4@86=R965M96YT('1E<FUS(%M-96UB97)=/&)R/D-A;&EF;W)N:6$@
M26YS=&ET=71E(&9O<B!296=E;F5R871I=F4@365D:6-I;F4@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,CQB<CY,:6-E;G-E(&%G<F5E;65N="!T97)M<R!;365M8F5R73QB<CY#86QI
M9F]R;FEA($EN<W1I='5T92!F;W(@4F5G96YE<F%T:79E($UE9&EC:6YE(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^3&EC96YS92!A9W)E96UE;G0@=&5R;7,@6TUE;6)E<ET\
M8G(^0V%L:69O<FYI82!);G-T:71U=&4@9F]R(%)E9V5N97)A=&EV92!-961I
M8VEN92!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$R/&)R/DQI8V5N<V4@86=R965M96YT('1E<FUS(%M-
M96UB97)=/&)R/D-A;&EF;W)N:6$@26YS=&ET=71E(&9O<B!296=E;F5R871I
M=F4@365D:6-I;F4@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2G5N+B`S,"P@,C`Q,CQB<CY3:&ER92!!1R!;365M8F5R73QB
M<CY487)G971S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA
M;BX@,S$L(#(P,3(\8G(^4VAI<F4@04<@6TUE;6)E<ET\8G(^5&%R9V5T<SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S
M/&)R/E-H:7)E($%'(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^4VAI<F4@04<@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CY3:&ER92!!1R!;365M8F5R73QB<CY0<F]D=6-T/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^4VAI<F4@
M04<@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M07!R+B`S,"P@,C`Q,SQB<CY3:6=M82U!;&1R:6-H($-O<G!O<F%T:6]N(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@
M,S$L(#(P,#D\8G(^4VEG;6$M06QD<FEC:"!#;W)P;W)A=&EO;B!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6PN(#,Q+"`R
M,#`W/&)R/E-I9VUA+4%L9')I8V@@0V]R<&]R871I;VX@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB
M<CY3:6=M82U!;&1R:6-H($-O<G!O<F%T:6]N(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^4VEG
M;6$M06QD<FEC:"!#;W)P;W)A=&EO;B!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/E-I9VUA+4%L
M9')I8V@@0V]R<&]R871I;VX@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CY3:6=M82U!;&1R:6-H
M($-O<G!O<F%T:6]N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D]C="X@,S$L(#(P,#D\8G(^4VEG;6$M06QD<FEC:"!#;W)P
M;W)A=&EO;B!;365M8F5R73QB<CY5<&9R;VYT(&QI8V5N<V4@9F5E(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3,\8G(^4VEG;6$M06QD<FEC:"!#;W)P;W)A=&EO;B!;365M8F5R73QB
M<CY,:6-E;G-E(&%G<F5E;65N="!T97)M<R!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/E-I9VUA
M+4%L9')I8V@@0V]R<&]R871I;VX@6TUE;6)E<ET\8G(^3&EC96YS92!A9W)E
M96UE;G0@=&5R;7,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY3:6=M82U!;&1R:6-H($-O<G!O
M<F%T:6]N(%M-96UB97)=/&)R/DQI8V5N<V4@86=R965M96YT('1E<FUS(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3(\8G(^4VEG;6$M06QD<FEC:"!#;W)P;W)A=&EO;B!;365M8F5R
M73QB<CY,:6-E;G-E(&%G<F5E;65N="!T97)M<R!;365M8F5R73QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#,Q+"`R,#`Y/&)R/E-I
M9VUA+4%L9')I8V@@0V]R<&]R871I;VX@6TUE;6)E<ET\8G(^3&EC96YS92!A
M9W)E96UE;G0@=&5R;7,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^3V-T+B`S,2P@,C`P-3QB<CY$;W<@06=R;U-C:65N8V5S
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3,\8G(^1&]W($%G<F]38VEE;F-E<R!;365M8F5R73QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R
M/D1O=R!!9W)O4V-I96YC97,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY$;W<@06=R;U-C:65N
M8V5S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3(\8G(^1&]W($%G<F]38VEE;F-E<R!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#,Q+"`R,#`U
M/&)R/D1O=R!!9W)O4V-I96YC97,@6TUE;6)E<ET\8G(^36EN:6UU;2!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#,Q
M+"`R,#`U/&)R/D1O=R!!9W)O4V-I96YC97,@6TUE;6)E<ET\8G(^36%X:6UU
M;2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/
M8W0N(#,Q+"`R,#`U/&)R/D1O=R!!9W)O4V-I96YC97,@6TUE;6)E<ET\8G(^
M3&EC96YS92!A9W)E96UE;G0@=&5R;7,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5S96%R8V@@86YD
M($1E=F5L;W!M96YT($%R<F%N9V5M96YT+"!#;VYT<F%C="!T;R!097)F;W)M
M(&9O<B!/=&AE<G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!N=6UB97(@
M;V8@9V5N92!T87)G971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYU;6)E<B!O9B!I;FET:6%L(&=E;F4@=&%R9V5T<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@
M9V5N92!T87)G971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYU;6)E<B!O9B!A9&1I=&EO;F%L(&=E;F4@=&%R9V5T<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!P
M<F]G<F%M('1O(&1E=F5L;W`@;&%B;W)A=&]R>2!R97-E87)C:"!R96%G96YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<V('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S,@>65A<G,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)S,@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y5<&9R;VYT(&QI8V5N<V4@9F5E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q,RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(P+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,34L,3`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!O=&5N=&EA;"!A;6]U;G0@=&\@8F4@9G5N
M9&5D(&9O<B!C97)T86EN(%-H:7)E(&UI;&5S=&]N97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR,3,L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DE.1"!O<B!#
M5$$@<W5B;6ES<VEO;B!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#4P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<')O9'5C=',@87!P
M<F]V960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F]Y86QT>2!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#$L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(X
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<Q,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#`S-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L,S`T+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDL-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VQL86)O<F%T:6]N($%G<F5E;65N="!296QA=&5D($-O<W1S(&%N
M9"!%>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#0P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,3`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,RPU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,S`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,L.#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!V86QU960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT+#DP,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0=6)L:6,@;V9F97)I;F<L(&-O;6UO;B!S=&]C:R!S:&%R97,@:7-S=65D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-C,V+#$S,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)O>6%L='D@<F5V96YU97,@97AP96-T960@=&\@8F4@<F5C96EV960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M961U8V5D(')O>6%L='D@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+C4P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D9U;F1I;F<@879A:6QA8FQE('5N9&5R('1H
M92!A;65N9&5D(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E(&%T=')I8G5T86)L92!T
M;R!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#,U,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/;F4M=&EM92!L:6-E;G-E(&9E92!E87)N
M960@;VX@97AE<F-I<V4@;V8@;W!T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-BPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!R;WEA
M;'1I97,@=&\@8F4@<F5C96EV960@9G)O;2!S=6)L:6-E;G-I;F<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2XP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;FYU86P@
M9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DUI;FEM=6T@<W5B;&EC96YS92!A;FYU86P@9F5E<R!S
M<&5C:69I8R!R96-K;VYI;F<@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)S$Q('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F5E(&1U93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(U+#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&=6YD<R!D
M=64@=6YD97(@=&AE(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-"PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9W)E96UE;G0@=&\@<F5C96EV
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-"!Y96%R<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG,2!Y96%R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^17AP96-T960@86UO=6YT('1O(&)E(')E8V5I=F5D(&9O<B!R
M97-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-2PR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9W)E96UE;G0@9&%T93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y/8W0@,S$L#0H)"3(P,#D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^07!R(#,P+`T*"0DR,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y/8W0@,S$L#0H)"3(P,#8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-E:79A8FQE<R!F
M<F]M('-A;&4@86=A:6YS="!T:&4@9W)A;G0@9G5N9&5D('1O(&5N=&ET>2!F
M<F]M('-A;&4@;V8@<')O9'5C=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)U1W;R!T:6UE<R!T:&4@86UO=6YT("!386YG86UO(')E8V5I=F5S
M(&EN(&9U;F1I;F<@=6YD97(@=&AE(&%G<F5E;65N=#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E
M<R!U;F1E<B!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDP,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D9U;F1S(&1U92!U;F1E<B!A9W)E96UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYT
M<F%C='5A;"!A9W)E96UE;G0@=&5R;6EN871I;VX@9&%T93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D%U9R`S,"P-"@D),C`Q
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U
M;F1S(&1U92!U;F1E<B!A9W)E96UE;G0@87,@<&5R(&%M96YD;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R
M86YT(&9U;F1I;F<@86UO=6YT(&UA>&EM=6T@=6YD97(@86UE;F1E9"!A9W)E
M96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y296-E:79E9"!F;W(@=V]R:R!P97)F;W)M960@=6YD97(@86=R
M965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`X,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?96-F9F8W.69?83$P,%\T,S5E7V%C,#E?.34S8F9A-&$R-3(Y#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5C9F9F-SEF7V$Q,#!?-#,U95]A
M8S`Y7SDU,V)F831A,C4R.2]7;W)K<VAE971S+U-H965T,C0N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$561$%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DUA:F]R($-U<W1O
M;65R<RP@4&%R=&YE<G-H:7!S(&%N9"!3=')A=&5G:6,@06QL:6%N8V5S("T@
M4F5V96YU97,@4F5C;V=N:7IE9"!U;F1E<B!!9W)E96UE;G0@*$1E=&%I;"D@
M*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E
M8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D%P<BX@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAI<F4@04<@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E)E=F5N=64@<F5L871E9"!T;R!3:&ER92!#;VQL86)O<F%T:6]N.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M
M;W)T:7IA=&EO;B!O9B!U<&9R;VYT(&9E93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-30R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`U-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-C(U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#0T-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R
M8V@@<V5R=FEC97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#DV.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L-C<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3$L,S0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PW-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0L-3$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR,3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPY-C4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#$Y,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY2979E;G5E(')E;&%T960@=&\@4VEG;6$@0V]L;&%B;W)A=&EO;CH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M;WEA;'1Y(')E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VEG;6$M06QD<FEC:"!#;W)P;W)A=&EO;B!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4F5V96YU92!R96QA=&5D('1O(%-I9VUA($-O;&QA8F]R871I;VXZ/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F]Y
M86QT>2!R979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L,#,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y,:6-E;G-E(&9E92!A;F0@;6EL97-T;VYE(')E
M=F5N=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#,U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#,P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-#(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R+#`V,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPP,S4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5C9F9F-SEF7V$Q,#!?-#,U
M95]A8S`Y7SDU,V)F831A,C4R.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]E8V9F9C<Y9E]A,3`P7S0S-65?86,P.5\Y-3-B9F$T83(U,CDO5V]R
M:W-H965T<R]3:&5E=#(U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%6D]!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP96YS871I;VX@+2!3=&]C
M:RU"87-E9"!#;VUP96YS871I;VX@17AP96YS92`H1&5T86EL*2`H55-$("0I
M/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0V]S=',@86YD(&5X<&5N<V5S.CPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<W1O
M8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2PS.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-#`T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#`Y.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PP,3$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;W-T<R!A;F0@
M97AP96YS97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP
M96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S<T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ
M-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#$Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M0V]S=',@86YD(&5X<&5N<V5S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<W1O8VLM8F%S960@8V]M<&5N
M<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-C4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`V,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$L.34X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#@Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?96-F9F8W.69?83$P,%\T,S5E7V%C,#E?
M.34S8F9A-&$R-3(Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5C
M9F9F-SEF7V$Q,#!?-#,U95]A8S`Y7SDU,V)F831A,C4R.2]7;W)K<VAE971S
M+U-H965T,C8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5)4$%#/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y("T@061D:71I;VYA;"!);F9O
M<FUA=&EO;B`H1&5T86EL*2`H25!/(%M-96UB97)=+"!54T0@)"D\8G(^26X@
M36EL;&EO;G,L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,C,L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4W5B<VED:6%R>2P@4V%L92!O9B!3=&]C:R!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!P<F]C965D<R!F<F]M('1H92!S86QE(&]F('-H87)E<RP@869T97(@
M;V9F97)I;F<@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-CDN-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U8G-I9&EA<GDL(%-A
M;&4@;V8@4W1O8VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE(&]F('-T;V-K+"!N=6UB97(@
M;V8@<VAA<F5S(&ES<W5E9"!I;B!T<F%N<V%C=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-RPP,34L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE(&]F('-T;V-K+"!P
M<FEC92!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,3`N-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E5N9&5R=W)I=&5R<R!;365M8F5R72!\($-O;6UO;B!S=&]C
M:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY3=6)S:61I87)Y+"!386QE(&]F(%-T;V-K(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4V%L92!O9B!S=&]C:RP@;G5M8F5R(&]F('-H87)E<R!I<W-U960@:6X@=')A
M;G-A8W1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDQ-2PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5C
M9F9F-SEF7V$Q,#!?-#,U95]A8S`Y7SDU,V)F831A,C4R.0T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]E8V9F9C<Y9E]A,3`P7S0S-65?86,P.5\Y
M-3-B9F$T83(U,CDO5V]R:W-H965T<R]3:&5E=#(W+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M1$9!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6)S97%U96YT($5V96YT
M<R`M($%D9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@*%-U8G-E<75E
M;G0@179E;G0@6TUE;6)E<ETL(%531"`D*3QB<CY);B!-:6QL:6]N<RP@97AC
M97!T(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`P,2P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5B<V5Q=65N="!%
M=F5N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY"=7-I;F5S<R!!8W%U:7-I=&EO;B!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H
M87)E<R!A8W%U:7)E9"!F<F]M(&%C<75I<VET:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87)K970@=F%L=64@;V8@<VAA
M<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M+C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5C
M9F9F-SEF7V$Q,#!?-#,U95]A8S`Y7SDU,V)F831A,C4R.0T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]E8V9F9C<Y9E]A,3`P7S0S-65?86,P.5\Y
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M;&4@2%)E9CTS1")3:&5E=#`R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970P,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#0N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`U+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970P-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`X+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P.2YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,3`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#$Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,BYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3,N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#$T+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970Q-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,38N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$W+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970Q."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,3DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(P
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,2YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,C(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#(S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R
M-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C4N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(V+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970R-RYH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?3F5X=%!A
K<G1?96-F9F8W.69?83$P,%\T,S5E7V%C,#E?.34S8F9A-&$R-3(Y+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>122</ContextCount>
  <ElementCount>140</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>23</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/StatementOfIncome</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/StatementOfOtherComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Investments and Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock</Role>
      <ShortName>Investments and Fair Value Measurement</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Basic and Diluted Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock</Role>
      <ShortName>Basic and Diluted Net Loss Per Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Major Customers, Partnerships and Strategic Alliances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Investments and Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlockTables</Role>
      <ShortName>Investments and Fair Value Measurement (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Major Customers, Partnerships and Strategic Alliances (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Investments and Fair Value Measurement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementAdditionalInformation</Role>
      <ShortName>Investments and Fair Value Measurement - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Investments and Fair Value Measurement - Schedule of Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementScheduleOfInvestments</Role>
      <ShortName>Investments and Fair Value Measurement - Schedule of Investments (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Investments and Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents and Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureInvestmentsAndFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAndAvailableforSaleSecurities</Role>
      <ShortName>Investments and Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents and Available-for-Sale Securities (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Basic and Diluted Net Loss Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureBasicAndDilutedNetLossPerShareAdditionalInformation</Role>
      <ShortName>Basic and Diluted Net Loss Per Share - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformation</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreement</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sangamo.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element sgmo_AnnualFeesRelatedToAgreement had a mix of decimals attribute values: -5 1.</Log>
    <Log type="Info">Element us-gaap_DeferredRevenueCurrent had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_LicensesRevenue had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_RoyaltyRevenue had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">'Monetary' elements on report '124 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 103 - Statement - Condensed Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 105 - Statement - Condensed Consolidated Statements of Operations</Log>
    <Log type="Info">Process Flow-Through: 106 - Statement - Consolidated Statements of Comprehensive Loss</Log>
    <Log type="Info">Process Flow-Through: 107 - Statement - Condensed Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>sgmo-20130930.xml</File>
    <File>sgmo-20130930.xsd</File>
    <File>sgmo-20130930_cal.xml</File>
    <File>sgmo-20130930_def.xml</File>
    <File>sgmo-20130930_lab.xml</File>
    <File>sgmo-20130930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6FAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">80,000,000<span></span></td>
        <td class="nump">80,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">61,420,655<span></span></td>
        <td class="nump">53,058,525<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">61,420,655<span></span></td>
        <td class="nump">53,058,525<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>NOTE 8&#x2014;SUBSEQUENT EVENTS</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Acquisition of Ceregene</b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On August&#xA0;23, 2013, Sangamo and its wholly-owned subsidiary CG
 Acquisition Sub, Inc., a Delaware corporation (&#x201C;Merger
 Sub&#x201D;), entered into an Agreement and Plan of Merger (the
 &#x201C;Merger Agreement&#x201D;) with Ceregene, Inc.,
 (&#x201C;Ceregene&#x201D;) and a stockholders&#x2019; representative.
 Pursuant to the Merger Agreement, the Company acquired all
 outstanding shares of Ceregene, a privately held biotechnology
 company focused on the development of adeno-associated virus
 (&#x201C;AAV&#x201D;) gene therapies. The acquired assets include all
 of Ceregene&#x2019;s therapeutic programs, including CERE-110, an
 AAV vector delivery system for the treatment of Alzheimer&#x2019;s
 disease that is currently in a Phase 2 clinical trial, certain
 intellectual property rights relating to the manufacturing of AAV,
 and certain toxicology and safety data from Ceregene&#x2019;s human
 clinical trials (the Acquisition). The Acquisition was closed on
 October&#xA0;1, 2013 (the Closing Date).</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On the Closing Date, Merger Sub merged with and into Ceregene, with
 Ceregene continuing as the surviving company and a wholly-owned
 subsidiaries of the Company. On the Closing Date, each share of
 Ceregene&#x2019;s issued and outstanding capital stock held by its
 stockholders converted to the right to receive a portion of the
 merger consideration for the Acquisition, which consists initially
 of (i)&#xA0;100,000 shares of Sangamo common stock with a market
 value of approximately $1.2 million on the Closing Date, and
 (ii)&#xA0;amount of cash and cash equivalent of Ceregene on the
 Closing Date less certain liabilities and expenses. In addition to
 such initial merger consideration, during the term of the Merger
 Agreement, the Company is required to make contingent earn-out
 payments (the &#x201C;Earn-Out Payments&#x201D;) to the stockholders
 of Ceregene as follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">If the Company grants a third-party
 license to develop and commercialize Ceregene&#x2019;s CERE-110 for
 the treatment of Alzheimer&#x2019;s disease or CERE-120 for the
 treatment of Parkinson&#x2019;s diseases or Huntington&#x2019;s
 disease (the &#x201C;Earn-Out Products&#x201D;), the Company is
 required to pay a double digit percentage of any upfront and
 milestone payments the Company receives for such license, subject
 to certain reductions based on expenses incurred by the Company in
 the development of the Earn-Out Products; and</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">If the Company commercializes any
 Earn-Out Product itself, the Company is required to pay, for each
 Earn-Out Product, royalty-like earnout payments as a percentage of
 net sales that range in the low double digits depending upon the
 amount of net sales, subject to certain reductions by the
 Company.</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Also on the Closing Date, the Company, Ceregene and certain of its
 stockholders entered into an indemnity escrow agreement, pursuant
 to which a portion of the purchase price was deposited in an escrow
 account for the benefit of the Company to satisfy indemnity
 obligations of the stockholders under the Merger Agreement. Due to
 the relatively short time from the Closing Date of the Acquisition
 to the completion of the accompanying unaudited interim
 consolidated financial statements, the accounting for the initial
 purchase price allocation as well as certain required supplemental
 disclosures with respect to the Acquisition have not been
 completed.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELKAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (6,145)<span></span></td>
        <td class="num">$ (5,790)<span></span></td>
        <td class="num">$ (18,480)<span></span></td>
        <td class="num">$ (18,786)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Changes in unrealized loss on available-for-sale securities</a></td>
        <td class="nump">27<span></span></td>
        <td class="nump">22<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">3<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num">$ (6,118)<span></span></td>
        <td class="num">$ (5,768)<span></span></td>
        <td class="num">$ (18,480)<span></span></td>
        <td class="num">$ (18,783)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16317811<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=SL7669646-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQCAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 80,309<span></span></td>
        <td class="nump">$ 21,679<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
        <td class="nump">39,913<span></span></td>
        <td class="nump">41,868<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
        <td class="nump">208<span></span></td>
        <td class="nump">190<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
        <td class="nump">4,880<span></span></td>
        <td class="nump">4,129<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
        <td class="nump">149<span></span></td>
        <td class="nump">203<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump">684<span></span></td>
        <td class="nump">296<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">126,143<span></span></td>
        <td class="nump">68,365<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
        <td class="nump">12,690<span></span></td>
        <td class="nump">12,584<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">1,494<span></span></td>
        <td class="nump">1,543<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
        <td class="nump">39<span></span></td>
        <td class="nump">41<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">140,366<span></span></td>
        <td class="nump">82,533<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
        <td class="nump">2,665<span></span></td>
        <td class="nump">4,013<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and employee benefits</a></td>
        <td class="nump">2,039<span></span></td>
        <td class="nump">2,473<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
        <td class="nump">2,300<span></span></td>
        <td class="nump">2,304<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">7,004<span></span></td>
        <td class="nump">8,790<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues, non-current</a></td>
        <td class="nump">7,221<span></span></td>
        <td class="nump">8,847<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">14,225<span></span></td>
        <td class="nump">17,637<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 80,000,000 shares authorized, 61,420,655 and 53,058,525 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively</a></td>
        <td class="nump">614<span></span></td>
        <td class="nump">531<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">419,490<span></span></td>
        <td class="nump">339,848<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(293,989)<span></span></td>
        <td class="num">(275,509)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
        <td class="nump">26<span></span></td>
        <td class="nump">26<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">126,141<span></span></td>
        <td class="nump">64,896<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 140,366<span></span></td>
        <td class="nump">$ 82,533<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedEmployeeBenefitsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=SL7669686-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestReceivableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 2<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (f)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecuritiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total debt and equity financial instruments including: (1) securities held-to-maturity and (2) securities available-for-sale that will be held for the long-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecuritiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate carrying amounts, as of the balance sheet date, of assets not separately disclosed in the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 10<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386993&amp;loc=d3e5879-108316<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EXICO">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="3">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2009

</div>
          <div>California Institute for Regenerative Medicine [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>California Institute for Regenerative Medicine [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>California Institute for Regenerative Medicine [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>California Institute for Regenerative Medicine [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>California Institute for Regenerative Medicine [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011

</div>
          <div>CHDI Foundation, Inc. [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>CHDI Foundation, Inc. [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>CHDI Foundation, Inc. [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>CHDI Foundation, Inc. [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>CHDI Foundation, Inc. [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>CHDI Foundation, Inc. [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012

</div>
          <div>Juvenile Diabetes Research Foundation International [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2010

</div>
          <div>Juvenile Diabetes Research Foundation International [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Juvenile Diabetes Research Foundation International [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Juvenile Diabetes Research Foundation International [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Juvenile Diabetes Research Foundation International [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Juvenile Diabetes Research Foundation International [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2006

</div>
          <div>Juvenile Diabetes Research Foundation International [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>License agreement terms [Member]

</div>
          <div>California Institute for Regenerative Medicine [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>License agreement terms [Member]

</div>
          <div>California Institute for Regenerative Medicine [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>License agreement terms [Member]

</div>
          <div>California Institute for Regenerative Medicine [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>License agreement terms [Member]

</div>
          <div>California Institute for Regenerative Medicine [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Shire AG [Member]

</div>
          <div>Targets</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2012

</div>
          <div>Shire AG [Member]

</div>
          <div>Targets</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Shire AG [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Shire AG [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Shire AG [Member]

</div>
          <div>Product</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Shire AG [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2013

</div>
          <div>Sigma-Aldrich Corporation [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2009

</div>
          <div>Sigma-Aldrich Corporation [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2007

</div>
          <div>Sigma-Aldrich Corporation [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Sigma-Aldrich Corporation [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Sigma-Aldrich Corporation [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Sigma-Aldrich Corporation [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Sigma-Aldrich Corporation [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2009

</div>
          <div>Sigma-Aldrich Corporation [Member]

</div>
          <div>Upfront license fee [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Sigma-Aldrich Corporation [Member]

</div>
          <div>License agreement terms [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Sigma-Aldrich Corporation [Member]

</div>
          <div>License agreement terms [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Sigma-Aldrich Corporation [Member]

</div>
          <div>License agreement terms [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Sigma-Aldrich Corporation [Member]

</div>
          <div>License agreement terms [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2009

</div>
          <div>Sigma-Aldrich Corporation [Member]

</div>
          <div>License agreement terms [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2005

</div>
          <div>Dow AgroSciences [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Dow AgroSciences [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Dow AgroSciences [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Dow AgroSciences [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Dow AgroSciences [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2005

</div>
          <div>Dow AgroSciences [Member]

</div>
          <div>Minimum [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2005

</div>
          <div>Dow AgroSciences [Member]

</div>
          <div>Maximum [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2005

</div>
          <div>Dow AgroSciences [Member]

</div>
          <div>License agreement terms [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateNumberOfGeneTargets', window );">Aggregate number of gene targets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfInitialGeneTargets', window );">Number of initial gene targets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfGeneTargets', window );">Number of gene targets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfAdditionalGeneTargets', window );">Number of additional gene targets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Research program to develop laboratory research reagents</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_UpfrontLicenseFee', window );">Upfront license fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 13,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 20,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 15,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized', window );">Potential amount to be funded for certain Shire milestones</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">213,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication', window );">IND or CTA submission amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">201,000<span></span></td>
        <td class="nump">428,000<span></span></td>
        <td class="nump">711,000<span></span></td>
        <td class="nump">1,035,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="nump">2,300,000<span></span></td>
        <td class="nump">2,304,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses', window );">Collaboration Agreement Related Costs and Expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="nump">1,400,000<span></span></td>
        <td class="nump">900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,500,000<span></span></td>
        <td class="nump">2,200,000<span></span></td>
        <td class="nump">10,300,000<span></span></td>
        <td class="nump">3,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock, valued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering, common stock shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">636,133<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_RoyaltyRevenuesExpectedToBeReceived', window );">Royalty revenues expected to be received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ReducedRoyaltyRate', window );">Reduced royalty rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AdditionalMilestonePaymentUnderAgreement', window );">Funding available under the amended agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Revenue attributable to research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">101,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,351,000<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">400,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OneTimeLicenseFeeEarned', window );">One-time license fee earned on exercise of option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing', window );">Percentage of royalties to be received from sublicensing</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AnnualFeesRelatedToAgreement', window );">Annual fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000.0<span></span></td>
        <td class="nump">3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod', window );">Minimum sublicense annual fees specific reckoning period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">11 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_FeeDue', window );">Fee due</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GrantFundingAmount', window );">Funds due under the agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementToReceive', window );">Agreement to receive</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment', window );">Expected amount to be received for research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementDate', window );">Agreement date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Oct. 31,
				 2009<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Apr. 30,
				 2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Oct. 31,
				 2006<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PotentialRoyaltyPaymentsToEntity', window );">Receivables from sale against the grant funded to entity from sale of product</a></td>
        <td class="text">Two times the amount  Sangamo receives in funding under the agreement<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchGrantRevenue', window );">Revenues under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="nump">1,200,000<span></span></td>
        <td class="nump">900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_FundsDueUnderAgreement', window );">Funds due under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContractualAgreementTerminationDate', window );">Contractual agreement termination date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Aug. 30,
				 2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PostAmendmentFundsDueUnderAgreement', window );">Funds due under agreement as per amendment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GrantFundingAmountMaximumUnderAmendedAgreement', window );">Grant funding amount maximum under amended agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ProceedsReceivedForWorkPerformedUnderAgreement', window );">Received for work performed under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AdditionalMilestonePaymentUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional milestone payment under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AdditionalMilestonePaymentUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate additional revenue recognition milestone method revenue to be recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate additional revenue recognition milestone method revenue to be recognized on acceptance of application.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateNumberOfGeneTargets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of gene targets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AggregateNumberOfGeneTargets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AgreementDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreement date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AgreementDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AgreementToReceive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreement to receive.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AgreementToReceive</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AnnualFeesRelatedToAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Annual fees related to agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AnnualFeesRelatedToAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementRelatedCostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration agreement related costs and expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_CollaborationAgreementRelatedCostsAndExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration and license agreements number of products approved under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContractualAgreementTerminationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual agreement termination date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ContractualAgreementTerminationDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected amount to be received for research and development.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_FeeDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fee due.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_FeeDue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_FundsDueUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Funds due under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_FundsDueUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GrantFundingAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Grant funding amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_GrantFundingAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GrantFundingAmountMaximumUnderAmendedAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Grant funding amount maximum under amended agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_GrantFundingAmountMaximumUnderAmendedAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Initial research term of agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_InitialResearchTermOfAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum sublicense annual fees specific reckoning period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfAdditionalGeneTargets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of additional gene targets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_NumberOfAdditionalGeneTargets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfGeneTargets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of gene targets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_NumberOfGeneTargets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfInitialGeneTargets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of initial gene targets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_NumberOfInitialGeneTargets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OneTimeLicenseFeeEarned">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>One time license fee earned.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_OneTimeLicenseFeeEarned</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of royalties to be received from sublicensing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PostAmendmentFundsDueUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Post amendment funds due under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_PostAmendmentFundsDueUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PotentialRoyaltyPaymentsToEntity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Potential Royalty Payments To Entity</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_PotentialRoyaltyPaymentsToEntity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ProceedsReceivedForWorkPerformedUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds received for work performed under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ProceedsReceivedForWorkPerformedUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ReducedRoyaltyRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reduced royalty rate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ReducedRoyaltyRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ResearchGrantRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research grant revenue.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_ResearchGrantRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RoyaltyRevenuesExpectedToBeReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty revenues expected to be received.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_RoyaltyRevenuesExpectedToBeReceived</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_UpfrontLicenseFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Upfront license fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_UpfrontLicenseFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicensesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RoyaltyRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>NOTE 7&#x2014;STOCKHOLDERS&#x2019; EQUITY</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On September&#xA0;23, 2013, Sangamo completed an underwritten
 public offering of its common stock, in which the Company sold an
 aggregate of 7,015,000 shares of its common stock, including
 915,000 issued to the Underwriters pursuant to a 30-day
 overallotment option, at a public offering price of $10.58 per
 share. The net proceeds to Sangamo from the sale of shares in this
 offering, after deducting underwriting discounts and commissions
 and other estimated offering expenses, were approximately $69.5
 million.</p>
 <!-- xbrl,n -->

 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Investments and Fair Value Measurement (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments All Other Investments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Schedule of Investments</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The table below summarizes the Company&#x2019;s available-for-sale
 securities (in thousands):</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Amortized<br />
 Cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross<br />
 Unrealized<br />
 Gains</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Gross<br />
 Unrealized<br />
 (Losses)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Estimated<br />
 Fair&#xA0;Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 <b>September&#xA0;30, 2013</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Cash equivalents:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,758</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,758</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,758</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,758</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Available-for-sale securities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52,577</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52,603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52,577</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52,603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total cash equivalents and available-for-sale securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">62,335</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">62,361</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 <b>December&#xA0;31, 2012</b></p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Cash equivalents:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,997</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,997</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 Money market funds</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,836</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,836</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Available-for-sale securities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,426</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,426</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total cash equivalents and available-for-sale securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">73,262</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">73,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurements of Cash Equivalents and Available-for-Sale Securities</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt">
 The fair value measurements of our cash equivalents and
 available-for-sale marketable securities are identified at the
 following levels within the fair value hierarchy (in
 thousands):</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>September&#xA0;30,&#xA0;2013<br />
 Fair&#xA0;Value&#xA0;Measurements</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Cash equivalents:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,758</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,758</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,758</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,758</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Available-for-sale securities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52,603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52,603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52,603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52,603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total cash equivalents and available-for-sale securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">62,361</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,758</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52,603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>December&#xA0;31,&#xA0;2012<br />
 Fair&#xA0;Value&#xA0;Measurements</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Cash equivalents:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,997</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,997</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18,836</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,997</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Available-for-sale securities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 U.S. government sponsored entity debt securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">54,452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total cash equivalents and available-for-sale securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">73,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">15,839</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">57,449</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27337-111563<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a,b,bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=SL7498348-110258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19279-110258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsAllOtherInvestmentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>NOTE 6&#x2014;STOCK-BASED COMPENSATION</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following table shows total stock-based compensation expense
 included in the condensed consolidated statement of operations for
 the three month and nine months ended September&#xA0;30, 2013 and
 2012 (in thousands):</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;months&#xA0;ended<br />
 September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine&#xA0;months&#xA0;ended<br />
 September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Costs and expenses:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">732</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">774</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,140</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,195</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">659</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">630</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,958</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,816</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; FONT-SIZE: 10pt">
 Total stock-based compensation expense</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,391</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,404</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,098</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,011</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>NOTE 1&#x2014;BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT
 ACCOUNTING POLICIES</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt">
 <b><i>Basis of Presentation</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The accompanying unaudited condensed consolidated financial
 statements of Sangamo BioSciences, Inc. (&#x201C;Sangamo&#x201D; or
 the &#x201C;Company&#x201D;) have been prepared in accordance with
 U.S. generally accepted accounting principles for interim financial
 information and pursuant to the rules and regulations of the
 Securities and Exchange Commission (&#x201C;SEC&#x201D;).
 Accordingly, they do not include all of the information and
 footnotes required by generally accepted accounting principles for
 complete financial statements. In the opinion of management, all
 adjustments (consisting of normal recurring adjustments) considered
 necessary for a fair presentation have been included. Operating
 results for the three and nine months ended September&#xA0;30, 2013
 are not necessarily indicative of the results that may be expected
 for the year ending December&#xA0;31, 2013. The condensed
 consolidated balance sheet data at December&#xA0;31, 2012 were
 derived from the audited consolidated financial statements included
 in Sangamo&#x2019;s Form 10-K for the year ended December&#xA0;31,
 2012, as filed with the SEC. These financial statements should be
 read in conjunction with the financial statements and footnotes
 thereto for the year ended December&#xA0;31, 2012, included in
 Sangamo&#x2019;s Form 10-K, as filed with the SEC.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt">
 <b><i>Use of Estimates and Classifications</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The preparation of financial statements in conformity with
 generally accepted accounting principles requires management to
 make estimates and assumptions that affect the amounts reported in
 the financial statements and the accompanying notes. On an ongoing
 basis, management evaluates its estimates, including critical
 accounting policies or estimates related to revenue recognition,
 clinical trial accruals, and stock-based compensation. Estimates
 are based on historical experience and on various other market
 specific and other relevant assumptions that the Company believes
 to be reasonable under the circumstances, the results of which form
 the basis for making judgments about the carrying values of assets
 and liabilities that are not readily apparent from other sources.
 Actual results could differ from those estimates.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt">
 <b><i>Revenue Recognition</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Revenues from research activities made under strategic partnering
 agreements and collaborations are recognized as the services are
 provided when there is persuasive evidence that an arrangement
 exists, delivery has occurred, the price is fixed or determinable,
 and collectability is reasonably assured. Revenue generated from
 research and licensing agreements typically includes upfront
 signing or license fees, cost reimbursements, research services,
 minimum sublicense fees, milestone payments and royalties on future
 licensee&#x2019;s product sales.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <i>Multiple Element Arrangements prior to the adoption of ASU
 No.&#xA0;2009-13, Revenue Recognition&#x2014;Multiple Deliverable
 Revenue Arrangements (ASU 2009-13)</i>. For revenue arrangements
 entered into before January&#xA0;1, 2011, that include multiple
 deliverables, the elements of such agreement were divided into
 separate units of accounting if the deliverables met certain
 criteria, including whether the fair value of the delivered items
 could be determined and whether there was evidence of fair value of
 the undelivered items. In addition, the consideration was allocated
 among the separate units of accounting based on their fair values,
 and the applicable revenue recognition criteria are considered
 separately for each of the separate units of accounting. Prior to
 the adoption of ASU 2009-13, the Company recognized nonrefundable
 signing, license or non-exclusive option fees as revenue when
 rights to use the intellectual property related to the license were
 delivered and over the period of performance obligations if the
 Company had continuing performance obligations. The Company
 estimated the performance period at the inception of the
 arrangement and reevaluated it each reporting period. Changes to
 these estimates were recorded on a prospective basis.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <i>Multiple Element Arrangements after the adoption of ASU
 2009-13.</i> ASU 2009-13 amended the accounting standards for
 certain multiple element revenue arrangements to:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">provide updated guidance on whether
 multiple elements exist, how the elements in an arrangement should
 be separated, and how the arrangement consideration should be
 allocated to the separate elements;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">require an entity to allocate
 arrangement consideration to each element based on a selling price
 hierarchy where the selling price for an element is based on
 vendor-specific objective evidence (&#x201C;VSOE&#x201D;), if
 available; third-party evidence (&#x201C;TPE&#x201D;), if available
 and VSOE is not available; or the best estimate of selling price
 (&#x201C;ESP&#x201D;), if neither VSOE nor TPE is available; and</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">eliminate the use of the residual
 method and require an entity to allocate arrangement consideration
 using the relative selling price method.</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 For revenue agreements with multiple element arrangements, such as
 license and development agreements, entered into on or after
 January&#xA0;1, 2011, the Company allocates revenue to each
 non-contingent element based on the relative selling price of each
 element. When applying the relative selling price method, the
 Company determines the selling price for each deliverable using
 VSOE of selling price or TPE of selling price. If neither exists
 the Company uses ESP for that deliverable. Revenue allocated is
 then recognized when the basic four revenue recognition criteria
 are met for each element. The collaboration and license agreement
 entered into with Shire AG (Shire) in January 2012 was evaluated
 under these amended accounting standards.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Additionally, the Company may be entitled to receive certain
 milestone payments which are contingent upon reaching specified
 objectives. These milestone payments are recognized as revenue in
 full upon achievement of the milestone if there is substantive
 uncertainty at the date the arrangement is entered into that
 objectives will be achieved and if the achievement is based on the
 Company&#x2019;s performance.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Minimum annual sublicense fees are also recognized as revenue in
 the period in which such fees are due. Royalty revenues are
 generally recognized when earned and collectability of the related
 royalty payment is reasonably assured. The Company recognizes cost
 reimbursement revenue under collaborative agreements as the related
 research and development costs for services are rendered. Deferred
 revenue represents the portion of research or license payments
 received which have not been earned.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Sangamo&#x2019;s research grants are typically multi-year agreements
 and provide for the reimbursement of qualified expenses for
 research and development as defined under the terms of the grant
 agreement. Revenue under grant agreements is recognized when the
 related qualified research expenses are incurred.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt">
 <b><i>Recent Accounting Pronouncement</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In February 2013, the FASB issued ASU No.&#xA0;2013-02,
 Comprehensive Income (Topic 220): Reporting of Amounts Reclassified
 Out of Accumulated Other Comprehensive Income (ASU 2013-02). This
 newly issued accounting standard requires an entity to provide
 information about the amounts reclassified out of accumulated other
 comprehensive income by component. This ASU is effective for
 reporting periods beginning after December&#xA0;15, 2012. We
 adopted this standard in the first quarter of 2013 and the adoption
 of this standard did not have an impact on our financial position
 or results of operations.</p>
 <!-- xbrl,n -->

 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1FAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Investments and Fair Value Measurement - Additional Information (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities', window );">Investments maturity period</a></td>
        <td class="text">1 year<span></span></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross Unrealized (Losses)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Available-for-sale securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross Unrealized (Losses)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses', window );">Realized losses</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Other-than-temporary impairments of available-for-sale securities</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Available for sale securities gross unrealized loss accumulated in investments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investments maturity dates available for sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt">
 <b><i>Basis of Presentation</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The accompanying unaudited condensed consolidated financial
 statements of Sangamo BioSciences, Inc. (&#x201C;Sangamo&#x201D; or
 the &#x201C;Company&#x201D;) have been prepared in accordance with
 U.S. generally accepted accounting principles for interim financial
 information and pursuant to the rules and regulations of the
 Securities and Exchange Commission (&#x201C;SEC&#x201D;).
 Accordingly, they do not include all of the information and
 footnotes required by generally accepted accounting principles for
 complete financial statements. In the opinion of management, all
 adjustments (consisting of normal recurring adjustments) considered
 necessary for a fair presentation have been included. Operating
 results for the three and nine months ended September&#xA0;30, 2013
 are not necessarily indicative of the results that may be expected
 for the year ending December&#xA0;31, 2013. The condensed
 consolidated balance sheet data at December&#xA0;31, 2012 were
 derived from the audited consolidated financial statements included
 in Sangamo&#x2019;s Form 10-K for the year ended December&#xA0;31,
 2012, as filed with the SEC. These financial statements should be
 read in conjunction with the financial statements and footnotes
 thereto for the year ended December&#xA0;31, 2012, included in
 Sangamo&#x2019;s Form 10-K, as filed with the SEC.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates and Classifications</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt">
 <b><i>Use of Estimates and Classifications</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The preparation of financial statements in conformity with
 generally accepted accounting principles requires management to
 make estimates and assumptions that affect the amounts reported in
 the financial statements and the accompanying notes. On an ongoing
 basis, management evaluates its estimates, including critical
 accounting policies or estimates related to revenue recognition,
 clinical trial accruals, and stock-based compensation. Estimates
 are based on historical experience and on various other market
 specific and other relevant assumptions that the Company believes
 to be reasonable under the circumstances, the results of which form
 the basis for making judgments about the carrying values of assets
 and liabilities that are not readily apparent from other sources.
 Actual results could differ from those estimates.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt">
 <b><i>Revenue Recognition</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Revenues from research activities made under strategic partnering
 agreements and collaborations are recognized as the services are
 provided when there is persuasive evidence that an arrangement
 exists, delivery has occurred, the price is fixed or determinable,
 and collectability is reasonably assured. Revenue generated from
 research and licensing agreements typically includes upfront
 signing or license fees, cost reimbursements, research services,
 minimum sublicense fees, milestone payments and royalties on future
 licensee&#x2019;s product sales.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <i>Multiple Element Arrangements prior to the adoption of ASU
 No.&#xA0;2009-13, Revenue Recognition&#x2014;Multiple Deliverable
 Revenue Arrangements (ASU 2009-13)</i>. For revenue arrangements
 entered into before January&#xA0;1, 2011, that include multiple
 deliverables, the elements of such agreement were divided into
 separate units of accounting if the deliverables met certain
 criteria, including whether the fair value of the delivered items
 could be determined and whether there was evidence of fair value of
 the undelivered items. In addition, the consideration was allocated
 among the separate units of accounting based on their fair values,
 and the applicable revenue recognition criteria are considered
 separately for each of the separate units of accounting. Prior to
 the adoption of ASU 2009-13, the Company recognized nonrefundable
 signing, license or non-exclusive option fees as revenue when
 rights to use the intellectual property related to the license were
 delivered and over the period of performance obligations if the
 Company had continuing performance obligations. The Company
 estimated the performance period at the inception of the
 arrangement and reevaluated it each reporting period. Changes to
 these estimates were recorded on a prospective basis.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <i>Multiple Element Arrangements after the adoption of ASU
 2009-13.</i> ASU 2009-13 amended the accounting standards for
 certain multiple element revenue arrangements to:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">provide updated guidance on whether
 multiple elements exist, how the elements in an arrangement should
 be separated, and how the arrangement consideration should be
 allocated to the separate elements;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">require an entity to allocate
 arrangement consideration to each element based on a selling price
 hierarchy where the selling price for an element is based on
 vendor-specific objective evidence (&#x201C;VSOE&#x201D;), if
 available; third-party evidence (&#x201C;TPE&#x201D;), if available
 and VSOE is not available; or the best estimate of selling price
 (&#x201C;ESP&#x201D;), if neither VSOE nor TPE is available; and</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">eliminate the use of the residual
 method and require an entity to allocate arrangement consideration
 using the relative selling price method.</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 For revenue agreements with multiple element arrangements, such as
 license and development agreements, entered into on or after
 January&#xA0;1, 2011, the Company allocates revenue to each
 non-contingent element based on the relative selling price of each
 element. When applying the relative selling price method, the
 Company determines the selling price for each deliverable using
 VSOE of selling price or TPE of selling price. If neither exists
 the Company uses ESP for that deliverable. Revenue allocated is
 then recognized when the basic four revenue recognition criteria
 are met for each element. The collaboration and license agreement
 entered into with Shire AG (Shire) in January 2012 was evaluated
 under these amended accounting standards.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Additionally, the Company may be entitled to receive certain
 milestone payments which are contingent upon reaching specified
 objectives. These milestone payments are recognized as revenue in
 full upon achievement of the milestone if there is substantive
 uncertainty at the date the arrangement is entered into that
 objectives will be achieved and if the achievement is based on the
 Company&#x2019;s performance.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Minimum annual sublicense fees are also recognized as revenue in
 the period in which such fees are due. Royalty revenues are
 generally recognized when earned and collectability of the related
 royalty payment is reasonably assured. The Company recognizes cost
 reimbursement revenue under collaborative agreements as the related
 research and development costs for services are rendered. Deferred
 revenue represents the portion of research or license payments
 received which have not been earned.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Sangamo&#x2019;s research grants are typically multi-year agreements
 and provide for the reimbursement of qualified expenses for
 research and development as defined under the terms of the grant
 agreement. Revenue under grant agreements is recognized when the
 related qualified research expenses are incurred.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncement</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt">
 <b><i>Recent Accounting Pronouncement</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In February 2013, the FASB issued ASU No.&#xA0;2013-02,
 Comprehensive Income (Topic 220): Reporting of Amounts Reclassified
 Out of Accumulated Other Comprehensive Income (ASU 2013-02). This
 newly issued accounting standard requires an entity to provide
 information about the amounts reclassified out of accumulated other
 comprehensive income by component. This ASU is effective for
 reporting periods beginning after December&#xA0;15, 2012. We
 adopted this standard in the first quarter of 2013 and the adoption
 of this standard did not have an impact on our financial position
 or results of operations.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt">
 <b><i>Investments</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Sangamo classifies its marketable securities as available-for-sale
 and records its investments at fair value. Available-for-sale
 securities are carried at estimated fair value based on quoted
 market prices, with the unrealized holding gains and losses
 included in accumulated other comprehensive income. Marketable
 securities which have maturities beyond one year as of the end of
 the reporting period are classified as non-current. The
 Company&#x2019;s investments are subject to a periodic impairment
 review and the Company recognizes an impairment charge when a
 decline in the fair value of its investments below the cost basis
 is judged to be other-than-temporary. The Company considers various
 factors in determining whether to recognize an impairment charge,
 including the length of time and extent to which the fair value has
 been less than the Company&#x2019;s cost basis, the financial
 condition and near-term prospects of the investee, and the
 Company&#x2019;s intent and ability to hold the investment for a
 period of time sufficient to allow for any anticipated recovery in
 the market value.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt">
 <b><i>Fair Value Measurement</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company measures certain financial assets at fair value on a
 recurring basis, including cash equivalents and available-for
 sale-securities.&#xA0;The fair value of these assets was determined
 based on a three-tier hierarchy under the authoritative guidance
 for fair value measurements and disclosures that prioritizes the
 inputs used in measuring fair value as follows:</p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt">
 Level 1: Unadjusted quoted prices in active markets that are
 accessible at the measurement date for identical, unrestricted
 assets or liabilities;</p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt">
 Level 2: Quoted prices in markets that are not active or inputs
 which are observable, either directly or indirectly, for
 substantially the full term of the asset or liability;</p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt">
 Level 3: Prices or valuation techniques that require inputs that
 are both significant to the fair value measurement and unobservable
 (i.e., supported by little or no market activity).</p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 4%; FONT-SIZE: 10pt">
 The Company generally classifies its available-for-sale debt
 instruments as Level 2. Instruments can be classified as Level 2
 when observable market prices for identical securities that are
 traded in less active markets are used. When observable market
 prices for identical securities are not available, such instruments
 are priced using benchmark curves, benchmarking of like securities,
 sector groupings, and matrix pricing as well as model processes.
 These models are proprietary to the pricing providers or brokers.
 These valuation models incorporate a number of inputs, including,
 listed in approximate order of priority: benchmark yields, reported
 trades, broker/dealer quotes, issuer spreads, two-sided markets,
 benchmark securities, bids, offers and reference data including
 market research publications. For certain security types,
 additional inputs may be used, or some of the standard inputs may
 not be applicable. Evaluators may prioritize inputs differently on
 any given day for any security based on market conditions, and not
 all inputs listed are available for use in the evaluation process
 for each security evaluation on any given day.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share, policy</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Basic net loss per share has been computed by dividing the net loss
 by the weighted-average number of shares of common stock
 outstanding during the period. Diluted net loss per share is
 calculated by dividing net loss by the weighted average number of
 shares of common stock and potential dilutive securities
 outstanding during the period.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872867&amp;loc=d3e40691-111596<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section M<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2,12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 2, 12<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share - Additional Information (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options outstanding excluded from the calculation of diluted net loss per share</a></td>
        <td class="nump">7,853,936<span></span></td>
        <td class="nump">8,075,898<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EXABG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Investments and Fair Value Measurement - Schedule of Investments (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump">$ 62,335<span></span></td>
        <td class="nump">$ 73,262<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments', window );">Gross Unrealized Gains</a></td>
        <td class="nump">26<span></span></td>
        <td class="nump">26<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross Unrealized (Losses)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
        <td class="nump">62,361<span></span></td>
        <td class="nump">73,288<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump">9,758<span></span></td>
        <td class="nump">18,836<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments', window );">Gross Unrealized Gains</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross Unrealized (Losses)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
        <td class="nump">9,758<span></span></td>
        <td class="nump">18,836<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Available-for-sale securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump">52,577<span></span></td>
        <td class="nump">54,426<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments', window );">Gross Unrealized Gains</a></td>
        <td class="nump">26<span></span></td>
        <td class="nump">26<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross Unrealized (Losses)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
        <td class="nump">52,603<span></span></td>
        <td class="nump">54,452<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Money market funds [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump">9,758<span></span></td>
        <td class="nump">15,839<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments', window );">Gross Unrealized Gains</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross Unrealized (Losses)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
        <td class="nump">9,758<span></span></td>
        <td class="nump">15,839<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">U.S. government sponsored entity debt securities [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,997<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments', window );">Gross Unrealized Gains</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross Unrealized (Losses)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,997<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">U.S. government sponsored entity debt securities [Member] | Available-for-sale securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump">52,577<span></span></td>
        <td class="nump">54,426<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments', window );">Gross Unrealized Gains</a></td>
        <td class="nump">26<span></span></td>
        <td class="nump">26<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments', window );">Gross Unrealized (Losses)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
        <td class="nump">$ 52,603<span></span></td>
        <td class="nump">$ 54,452<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Available for sale securities gross unrealized gains accumulated in investments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Available for sale securities gross unrealized loss accumulated in investments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (aa)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26610-111562<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesAmortizedCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1AAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">SANGAMO BIOSCIENCES INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001001233<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">61,797,202<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>sgmo_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>sgmo_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQCDI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Investments and Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents and Available-for-Sale Securities (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="nump">$ 62,361<span></span></td>
        <td class="nump">$ 73,288<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="nump">9,758<span></span></td>
        <td class="nump">18,836<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Available-for-sale securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="nump">52,603<span></span></td>
        <td class="nump">54,452<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">U.S. government sponsored entity debt securities [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,997<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">U.S. government sponsored entity debt securities [Member] | Available-for-sale securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="nump">52,603<span></span></td>
        <td class="nump">54,452<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Money market funds [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="nump">9,758<span></span></td>
        <td class="nump">15,839<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="nump">9,758<span></span></td>
        <td class="nump">15,839<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="nump">9,758<span></span></td>
        <td class="nump">15,839<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member] | Available-for-sale securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member] | U.S. government sponsored entity debt securities [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member] | U.S. government sponsored entity debt securities [Member] | Available-for-sale securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member] | Money market funds [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="nump">9,758<span></span></td>
        <td class="nump">15,839<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="nump">52,603<span></span></td>
        <td class="nump">57,449<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2,997<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member] | Available-for-sale securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="nump">52,603<span></span></td>
        <td class="nump">54,452<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member] | U.S. government sponsored entity debt securities [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,997<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member] | U.S. government sponsored entity debt securities [Member] | Available-for-sale securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="nump">52,603<span></span></td>
        <td class="nump">54,452<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member] | Money market funds [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member] | Available-for-sale securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member] | U.S. government sponsored entity debt securities [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member] | U.S. government sponsored entity debt securities [Member] | Available-for-sale securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member] | Money market funds [Member] | Cash equivalents [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and available-for-sale securities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
